dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Muu lepingAvalik

European Joint Programme on Rare Diseases Annex A

Sotsiaalministeerium · 18. september 2018
Viit
1.8-2/790-1
Registreeritud
18. september 2018
Dokumendi liik
Muu leping
Funktsioon
1.8 Finantsplaneerimine ja raamatupidamisarvestus
Sari
1.8-2 Lepingud (töövõtt ja käsundus juriidiliste isikutega, koostöölepe kulude hüvitamiseks, haldus, liising, üür-rent, kindlustus, müük, litsentsid, ost, varaline vastutus, varakasutus, andmevahetus) koos aktidega
Toimik
1.8-2/2023
Vastutaja
Mari Teesalu (Sotsiaalministeerium, Kantsleri vastutusvaldkond, e-teenuste asekantsleri vastutusvaldkond, Analüüsi ja statistika osakond)

Failid

  • 📎GA Declaration - GAP-825575 - 998429731-SoM.pdf178 KB
  • 📎H2020-SC1-BHC-2018-2020.pdf7187 KB

Sisu (failidest)

Proposal number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD DECLARATION OF HONOUR (To be filled out by the applicant and signed by its legal representative) I, the undersigned: ❑ for natural persons: in my own name or ❑ ✘ for legal persons or ‘legal entities without legal personality’1: representing the following legal person/entity without legal personality: SOTSIAALMINISTEERIUM Suur-Ameerika 1 TALLINN 10122 Estonia hereby certify that (subject to the additional declarations below): 1 — the information provided in the Participant Portal for the grant agreement preparation is correct and complete; 2 — the information concerning the legal status given in the Beneficiary Register is correct; 3 — my organisation commits to comply2 with all the eligibility criteria, as defined in the work programme and the call for proposals; 4 — my organisation: - is committed to participate in the action; - has stable and sufficient sources of funding to maintain its activity throughout its participation in the action and to provide any counterpart funding necessary, and - has or will have the necessary resources as and when needed to carry out its involvement in the abovementioned action; 5 — my organisation is not in one of the situations which would exclude it from receiving EU grants3, i.e. it: 1 See Article 131(2) of the Regulation (EU, Euratom) No 966/2012 of the European Parliament and of the Council of 25 October 2012 on the financial rules applicable to the general budget of the Union and repealing Council Regulation (EC, Euratom) No 1605/2002 (OJ L298, 26.10.2012, p.1) and Article 198 of the Commission Delegated Regulation (EU) No 1268/2012 of 29 October 2012 on the rules of application of Regulation (EU, Euratom) No 966/2012 of the European Parliament and of the Council on the financial rules applicable to the general budget of the Union (OJ L 362, 31.12.2012, p. 1). 2 'commits to comply' means that I comply now and will comply for the duration of the grant agreement concluded with the Commission should a grant be awarded. 3 See Article 131(5) of Regulation (EU, Euratom) No 966/2012. 1 Proposal number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD - is not bankrupt or being wound up, is not having its affairs administered by the courts, has not entered into an arrangement with creditors, has not suspended business activities, is not the subject of proceedings concerning those matters, or is not in any analogous situation arising from a similar procedure provided for in national legislation or regulations; - it (or persons having powers of representation, decision making or control over it) have not been convicted of an offence concerning their professional conduct by a judgment of a competent authority of a Member State which has the force of res judicata; - has not been guilty of grave professional misconduct proven by any means which the Commission can justify including by decisions of the EIB and international organisations; - is in compliance with its obligations relating to the payment of social security contributions and the payment of taxes, in accordance with the legal provisions of the country in which it is established and with those of the country of the authorising officer responsible and those of the country where the action is to be performed; - it (or persons having powers of representation, decision making or control over it) have not been the subject of a judgment which has the force of res judicata for fraud, corruption, involvement in a criminal organisation or any other illegal activity, where such illegal activity is detrimental to the EU’s financial interests; - is not currently subject to an administrative penalty under Article 131(5) of Regulation (EC, Euratom) No 966/2012; - is not subject to a conflict of interest in connection with the grant; - will inform the Commission, without delay, of any situation considered a conflict of interests or which could give rise to a conflict of interests; - has not granted and will not grant, has not sought and will not seek, has not attempted and will not attempt to obtain, and has not accepted and will not accept any advantage, financial or in kind, to or from any party whatsoever, where such advantage constitutes an illegal practice or involves corruption, either directly or indirectly, inasmuch as it is an incentive or reward relating to the award of the grant; - has not made false declarations in supplying the information required by the Commission as a condition of participation in the grant award procedure or does not fail to supply this information. 6 — I will inform the Commission of any other grant applications or grants from the EU or Euratom budget related to this action. 7 — my organisation is aware that the Commission may impose administrative or financial penalties4 on legal entities which: 4 See Article 131(5) of Regulation (EU, Euratom) No 966/2012. 2 Proposal number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD - are guilty of misrepresentation in supplying the information required by the Commission as a condition of participation in the grant award procedure or fail to supply this information; - have been declared to be in serious breach of their obligations under any contract/grant agreement covered by the budget of the Commission. Such penalties will be proportionate to the importance of the contract/grant agreement and the seriousness of the misconduct, and may consist in their exclusion from contracts/grants financed by the EU or Euratom budget and payment of financial penalties. and acknowledge that: 1 — Grants will be signed and managed electronically, through the Commission’s electronic exchange system (in the ‘My Area’ section5 of the Participant Portal). 2 — Access and use of the electronic exchange system is subject to the Terms and conditions of use6 of the Participant Portal). 3 — Personal data submitted or otherwise collected by the Commission will be subject to the privacy statement7. 4 — Any sensitive information or material that qualifies as ‘EU classified information’ under Decision 2001/844/EC8 must comply with specific rules (i.e. it must be indicated in the technical annex of the proposal; a Security Aspect Letter (SAL) will be annexed to the grant agreement; an amendment is necessary if (more or new) sensitive information or material becomes relevant only later on). SIGNATURE For the applicant [--TGSMark#signature-998429731_75_210--] 5 Available at http://ec.europa.eu/research/participants/portal/ 6 Available at http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/lev/h2020-lev-terms-of-use_en.pdf 7 Available at http://ec.europa.eu/geninfo/legal_notices_en.htm 8 See Commission Decision 2001/844/EC, ECSC, Euratom amending the Commission’s internal Rules of Procedure (OJ L 317, 3.12.2001). Available at http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:02001D0844-20130701&rid=1 3 Digitally sealed by the European Commission Date: 2018.08.03 10:15:03 CEST This document is digitally sealed. The digital sealing mechanism uniquely binds the document to the modules of the Participant Portal of the European Commission, to the transaction for which it was generated and ensures its integrity and authenticity. Any attempt to modify the content will lead to a breach of the electronic seal, which can be verified at any time by clicking on the digital seal validation symbol. Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË - Tel. +32 22991111 Proposal Submission Forms Please check our wiki for help on navigating the form. Horizon 2020 Call: H2020-SC1-BHC-2018-2020 (Better Health and care, economic growth and sustainable health systems) Topic: SC1-BHC-04-2018 Type of action: COFUND-EJP Proposal number: SEP-210488440 Proposal acronym: EJP RD Deadline Id: H2020-SC1-2018-Single-Stage-RTD Table of contents Section Title Action 1 General information 2 Participants & contacts 3 Budget 4 Ethics 5 Call-specific questions How to fill in the forms The administrative forms must be filled in for each proposal using the templates available in the submission system. Some data fields in the administrative forms are pre-filled based on the steps in the submission wizard. H2020-CP-2017 ver 1.00 20180221 Page 1 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD 1 - General information Topic SC1-BHC-04-2018 Type of Action COFUND-EJP Call Identifier H2020-SC1-BHC-2018-2020 Deadline Id H2020-SC1-2018-Single-Stage-RTD Acronym EJP RD Proposal title European Joint Programme on Rare Diseases Note that for technical reasons, the following characters are not accepted in the Proposal Title and will be removed: < > " & Duration in 60 months Fixed keyword 1 Health sciences rare diseases, funding, data, omics, shared access, FAIR, patients, training, empowerment, Free keywords translation, public-private partnerships, innovative methodologies for clinical studies Abstract As recognized by the Council Recommendation 2009/C 151/02, rare diseases (RD) are a prime example of a research area that can strongly profit from coordination on a European and international scale. RD research should be improved to overcome fragmentation, leading to efficacious use of data and resources, faster scientific progress and competitiveness, and most importantly to decrease unnecessary hardship and prolonged suffering of RD patients. In the specific context of the massive generation, need for reuse and efficient interpretation of data, introduction of omics into care practice and the structuration of RD care centers in European Reference Networks, it appears crucial and timely to maximize the potential of already funded tools and programmes by supporting them further, scaling up, linking, and most importantly, adapting them to the needs of end-users through implementation tests in real settings. Such a concerted effort is necessary to develop a sustainable ecosystem allowing a virtuous circle between RD care, research and medical innovation. To achieve this goal, the European Joint Programme on RD (EJP RD) has two major objectives: (i) To improve the integration, the efficacy, the production and the social impact of research on RD through the development, demonstration and promotion of Europe/ world-wide sharing of research and clinical data, materials, processes, knowledge and know-how; (ii) To implement and further develop an efficient model of financial support for all types of research on RD (fundamental, clinical, epidemiological, social, economic, health service) coupled with accelerated exploitation of research results for benefit of patients. To this end, the EJP RD actions will be organized within four major Pillars assisted by the central coordination: (P1): Funding of research; (P2): Coordinated access to data and services; (P3) Capacity building; (P4): Accelerated translation of research projects and improvement outcomes of clinical studies. Remaining characters 3 Has this proposal (or a very similar one) been submitted in the past 2 years in response to a call for proposals under Horizon 2020 or any other EU programme(s)? Yes No Please give the proposal reference or contract number. xxxxxx-x H2020-CP-2017 ver 1.00 20180221 Page 2 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Declarations 1) The coordinator declares to have the explicit consent of all applicants on their participation and on the content of this proposal. 2) The information contained in this proposal is correct and complete. 3) This proposal complies with ethical principles (including the highest standards of research integrity — as set out, for instance, in the European Code of Conduct for Research Integrity — and including, in particular, avoiding fabrication, falsification, plagiarism or other research misconduct). 4) The coordinator confirms: - to have carried out the self-check of the financial capacity of the organisation on http://ec.europa.eu/research/participants/portal/desktop/en/organisations/lfv.html or to be covered by a financial viability check in an EU project for the last closed financial year. Where the result was “weak” or “insufficient”, the coordinator confirms being aware of the measures that may be imposed in accordance with the H2020 Grants Manual (Chapter on Financial capacity check); or - is exempt from the financial capacity check being a public body including international organisations, higher or secondary education establishment or a legal entity, whose viability is guaranteed by a Member State or associated country, as defined in the H2020 Grants Manual (Chapter on Financial capacity check); or - as sole participant in the proposal is exempt from the financial capacity check. 5) The coordinator hereby declares that each applicant has confirmed: - they are fully eligible in accordance with the criteria set out in the specific call for proposals; and - they have the financial and operational capacity to carry out the proposed action. The coordinator is only responsible for the correctness of the information relating to his/her own organisation. Each applicant remains responsible for the correctness of the information related to him and declared above. Where the proposal to be retained for EU funding, the coordinator and each beneficiary applicant will be required to present a formal declaration in this respect. According to Article 131 of the Financial Regulation of 25 October 2012 on the financial rules applicable to the general budget of the Union (Official Journal L 298 of 26.10.2012, p. 1) and Article 145 of its Rules of Application (Official Journal L 362, 31.12.2012, p.1) applicants found guilty of misrepresentation may be subject to administrative and financial penalties under certain conditions. Personal data protection The assessment of your grant application will involve the collection and processing of personal data (such as your name, address and CV), which will be performed pursuant to Regulation (EC) No 45/2001 on the protection of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free movement of such data. Unless indicated otherwise, your replies to the questions in this form and any personal data requested are required to assess your grant application in accordance with the specifications of the call for proposals and will be processed solely for that purpose. Details concerning the purposes and means of the processing of your personal data as well as information on how to exercise your rights are available in the privacy statement. Applicants may lodge a complaint about the processing of their personal data with the European Data Protection Supervisor at any time. Your personal data may be registered in the Early Detection and Exclusion system of the European Commission (EDES), the new system established by the Commission to reinforce the protection of the Union's financial interests and to ensure sound financial management, in accordance with the provisions of articles 105a and 108 of the revised EU Financial Regulation (FR) (Regulation (EU, EURATOM) 2015/1929 of the European Parliament and of the Council of 28 October 2015 amending Regulation (EU, EURATOM) No 966/2012) and articles 143 - 144 of the corresponding Rules of Application (RAP) (COMMISSION DELEGATED REGULATION (EU) 2015/2462 of 30 October 2015 amending Delegated Regulation (EU) No 1268/2012) for more information see the Privacy statement for the EDES Database. H2020-CP-2017 ver 1.00 20180221 Page 3 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD 2 - Participants & contacts # Participant Legal Name Country Action 1 INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE France 2 FONDS ZUR FÖRDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG AT 3 AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH AT 4 LUDWIG BOLTZMANN GESELLSCHAFT GMBH AT 5 FONDS NATIONAL DE LA RECHERCHE SCIENTIFIQUE BE 6 FONDS VOOR WETENSCHAPPELIJK ONDERZOEK-VLAANDEREN BE 7 KATHOLIEKE UNIVERSITEIT LEUVEN BE 8 MINISTRY OF EDUCATION YOUTH AND SPORTS CZ 9 SOTSIAALMINISTEERIUM EE 10 SUOMEN AKATEMIA FI 11 AGENCE NATIONALE DE LA RECHERCHE FR 12 FONDATION MALADIES RARES FR 13 Association Française contre les Myopathies FR 14 IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES FONDATION FR 15 DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV DE 16 UNIVERSITAETSKLINIKUM AACHEN DE 17 CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE 18 UNIVERSITAETSKLINIKUM FREIBURG DE 19 NEMZETI KUTATASI FEJLESZTESI ES INNOVACIOS HIVATAL HU 20 THE HEALTH RESEARCH BOARD IE 21 MINISTERO DELLA SALUTE IT H2020-CP-2017 ver 1.00 20180221 Page 4 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD 22 REGIONE TOSCANA IT 23 FONDAZIONE REGIONALE PER LA RICERCA BIOMEDICA IT 24 FONDAZIONE PER LA RICERCA FARMACOLOGICA GIANNI BENZI ONLUS IT 25 FONDAZIONE TELETHON IT 26 ISTITUTO SUPERIORE DI SANITA IT 27 CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE IT 28 TEDDY - EUROPEAN NETWORK OF EXCELLENCE FOR PAEDIATRIC CLINICAL RESEARCH IT 29 MINISTERO DELL'ISTRUZIONE, DELL'UNIVERSITA' E DELLA RICERCA IT 30 VALSTS IZGLITIBAS ATTISTIBAS AGENTURA LV 31 Lietuvos mokslo taryba LT 32 VIESOJI ISTAIGA VILNIAUS UNIVERSITETO LIGONINE SANTAROS KLINIKOS LT 33 FONDS NATIONAL DE LA RECHERCHE LU 34 ZORGONDERZOEK NEDERLAND ZON NL 35 ACADEMISCH ZIEKENHUIS GRONINGEN NL 36 UNIVERSITEIT MAASTRICHT NL 37 NARODOWE CENTRUM BADAN I ROZWOJU PL 38 WARSZAWSKI UNIWERSYTET MEDYCZNY PL 39 GDANSKI UNIWERSYTET MEDYCZNY PL 40 INSTYTUT POMNIK CENTRUM ZDROWIA DZIECKA PL 41 FUNDACAO PARA A CIENCIA E A TECNOLOGIA PT 42 INSTITUTO NACIONAL DE SAUDE DR. RICARDO JORGE PT 43 SLOVENSKA AKADEMIA VIED SK 44 INSTITUTO DE SALUD CARLOS III ES 45 FUNDACIO CENTRE DE REGULACIO GENOMICA ES H2020-CP-2017 ver 1.00 20180221 Page 5 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD 46 UNIVERSIDAD POLITECNICA DE MADRID ES 47 CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. ES 48 VETENSKAPSRADET - SWEDISH RESEARCH COUNCIL SE 49 VERKET FÖR INNOVATIONSSYSTEM SE 50 UNIVERSITY OF LEICESTER UK 51 THE UNIVERSITY OF LIVERPOOL UK 52 UNIVERSITY OF NEWCASTLE UPON TYNE UK 53 ST. ANNA KINDERKREBSFORSCHUNG AT 54 ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS FR 55 HOPITAUX UNIVERSITAIRES DE STRASBOURG FR 56 CENTRE ANTICANCEREUX LEON BERARD FR 57 UNIVERSITAETSKLINIKUM HEIDELBERG DE 58 EBERHARD KARLS UNIVERSITAET TUEBINGEN DE 59 JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN DE 60 HELIOS DR. HORST SCHMIDT KLINIKEN WIESBADEN GMBH DE 61 ISTITUTO ORTOPEDICO RIZZOLI IT 62 AZIENDA OSPEDALIERO UNIVERSITARIA PISANA IT 63 AZIENDA OSPEDALIERA UNIVERSITARIA SENESE IT 64 ACADEMISCH ZIEKENHUIS LEIDEN NL 65 STICHTING KATHOLIEKE UNIVERSITEIT NL 66 Academisch Medisch Centrum bij de Universiteit van Amsterdam NL 67 ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL 68 SERVICIO MADRILENO DE SALUD ES 69 THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST UK H2020-CP-2017 ver 1.00 20180221 Page 6 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD 70 GREAT ORMOND STREET HOSPITAL FOR CHILDREN NATIONAL HEALTH SERVICE TRUST UK 71 EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL BE 72 INFRAFRONTIER GMBH DE BIOBANKS AND BIOMOLECULAR RESOURCESRESEARCH INFRASTRUCTURE 73 AT CONSORTIUM(BBMRI-ERIC) 74 ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK FR 75 EATRIS ERIC NL 76 EUROPEAN MOLECULAR BIOLOGY LABORATORY DE 77 EURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION FR 78 MINISTRY OF HEALTH IL SCHWEIZERISCHER NATIONALFONDS ZUR FORDERUNG DER WISSENSCHAFTLICHEN 79 CH FORSCHUNG 80 BLACKSWAN Foundation CH 81 TURKIYE BILIMSEL VE TEKNOLOJIK ARASTIRMA KURUMU TR 82 ACIBADEM MEHMET ALI AYDINLAR UNIVERSITESI TR 83 HACETTEPE UNIVERSITESI TR 84 CANADIAN INSTITUTES OF HEALTH RESEARCH CA 85 FONDS DE RECHERCHE DU QUEBEC - SANTE CA H2020-CP-2017 ver 1.00 20180221 Page 7 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name INSERM 2 - Administrative data of participating organisations PIC Legal name 999997833 INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Short name: INSERM Address of the organisation Street RUE DE TOLBIAC 101 Town PARIS Postcode 75654 Country France Webpage www.inserm.fr Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................20/05/2016 - no SME self-assessment ............................................... unknown SME validation sme...................................................18/07/1964 - no Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 8 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name INSERM Department(s) carrying out the proposed work Department 1 Department name INSERM - IT GGB not applicable Same as proposing organisation's address Street 8 rue de la Croix Jarry Town Paris Postcode 75013 Country France Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 9 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name INSERM Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Daria Last name JULKOWSKA E-Mail [email protected] Position in org. EJP RD Coordinator Same as Department INSERM - IT GGB organisation name Same as proposing organisation's address Street 8 rue de la Croix Jarry Town Paris Post code 75013 Country France Website www.inserm.fr Phone 06 20 14 13 81 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Kristina Fiedler [email protected] +xxx xxxxxxxxx Dahlia TSAKIROPOULOS [email protected] +xxx xxxxxxxxx Wahida Giry [email protected] +xxx xxxxxxxxx Catherine Nguyen [email protected] +xxx xxxxxxxxx Thien-Ly Pham [email protected] +xxx xxxxxxxxx Florian Cordonnier [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 10 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FWF PIC Legal name 998735960 FONDS ZUR FÖRDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG Short name: FWF Address of the organisation Street SENSENGASSE 1 Town WIEN Postcode 1090 Country Austria Webpage www.fwf.ac.at Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status...........................................01/01/1900 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 11 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FWF Department(s) carrying out the proposed work Department 1 Department name Biology and Medical Sciences not applicable Same as proposing organisation's address Street SENSENGASSE 1 Town WIEN Postcode 1090 Country Austria Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 12 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FWF Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Stephanie Last name Resch E-Mail [email protected] Position in org. Head of Department Biology and Medical Sciences Same as Department Department Biology and Medical Sciences organisation name Same as proposing organisation's address Street SENSENGASSE 1 Town WIEN Post code 1090 Country Austria Website www.fwf.ac.at Phone +4315056740-8210 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 13 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AIT PIC Legal name 999584128 AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH Short name: AIT Address of the organisation Street GIEFINGGASSE 4 Town WIEN Postcode 1210 Country Austria Webpage http://www.ait.ac.at/ Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................11/05/2016 - no SME self-assessment ............................................... unknown SME validation sme...................................................14/01/2009 - no Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 14 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AIT Department(s) carrying out the proposed work Department 1 Department name Center for Health & Bioresources not applicable Same as proposing organisation's address Street GIEFINGGASSE 4 Town WIEN Postcode 1210 Country Austria Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 15 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AIT Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Guenter Last name Schreier E-Mail [email protected] Position in org. Thematic Coordinator Same as Department Center for Health & Bioresources organisation name Same as proposing organisation's address Street GIEFINGGASSE 4 Town WIEN Post code 1210 Country Austria Website http://www.ait.ac.at Phone +43 664 6207679 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Michael Parik [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 16 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name LBG (LBI-RUD) PIC Legal name 998399079 LUDWIG BOLTZMANN GESELLSCHAFT GMBH Short name: LBG (LBI-RUD) Address of the organisation Street NUSSDORFER STRASSE 64 6 STOCK Town WIEN Postcode 1090 Country Austria Webpage www.lbg.ac.at Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................unknown International organisation of European interest ........unknown Industry (private for profit)..................no Secondary or Higher education establishment .........unknown Research organisation ..............................................yes Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 17 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name LBG (LBI-RUD) Department(s) carrying out the proposed work Department 1 Department name Bock Lab not applicable Same as proposing organisation's address Street Lazarettgasse 14 AKH BT 25.3 Town Vienna Postcode 1090 Country Austria Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 18 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name LBG (LBI-RUD) Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Kaan Last name Boztug E-Mail [email protected] Position in org. Institute Director Same as Department Ludwig Boltzmann Institute for Rare and Undiagnosed Disease organisation name Same as proposing organisation's address Street Lazarettgasse 14 AKH BT 25.3 Town Vienna Post code 1090 Country Austria Website www.rare-diseases.at Phone +43 1 40160 70069 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Christopher Bock [email protected] +xxx xxxxxxxxx David Medgyesi [email protected] +43 1 40160 70096 H2020-CP-2017 ver 1.00 20180221 Page 19 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FNRS PIC Legal name 999540381 FONDS NATIONAL DE LA RECHERCHE SCIENTIFIQUE Short name: FNRS Address of the organisation Street Rue d'Egmont 5 Town BRUXELLES Postcode 1050 Country Belgium Webpage Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 20 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FNRS Department(s) carrying out the proposed work Department 1 Department name European and International Affairs not applicable Same as proposing organisation's address Street Rue d'Egmont 5 Town BRUXELLES Postcode 1050 Country Belgium Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 21 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FNRS Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Quist Last name Florence E-Mail [email protected] Position in org. Scientific Officer Same as Department European and International Affairs organisation name Same as proposing organisation's address Street Rue d'Egmont 5 Town BRUXELLES Post code 1050 Country Belgium Website http://www.frs-fnrs.be/ Phone +3225049351 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Xavier Hellebaut [email protected] +3225049250 H2020-CP-2017 ver 1.00 20180221 Page 22 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FWO PIC Legal name 997949484 FONDS VOOR WETENSCHAPPELIJK ONDERZOEK-VLAANDEREN Short name: FWO Address of the organisation Street EGMONTSTRAAT 5 Town BRUSSEL Postcode 1000 Country Belgium Webpage www.fwo.be Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 23 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FWO Department(s) carrying out the proposed work Department 1 Department name Strategic Research Programmes not applicable Same as proposing organisation's address Street EGMONTSTRAAT 5 Town BRUSSEL Postcode 1000 Country Belgium Department 2 Department name Fundamental research department not applicable Same as proposing organisation's address Street EGMONTSTRAAT 5 Town BRUSSEL Postcode 1000 Country Belgium Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 24 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FWO Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Alain Last name Deleener E-Mail [email protected] Position in org. Science Policy Advisor Strategic Research Programmes Same as Department Strategic Research Programmes and Fundamental Research department organisation name Same as proposing organisation's address Street EGMONTSTRAAT 5 Town BRUSSEL Post code 1000 Country Belgium Website www.fwo.be Phone +32 2 550 15 95 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 25 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name KU Leuven PIC Legal name 999991334 KATHOLIEKE UNIVERSITEIT LEUVEN Short name: KU Leuven Address of the organisation Street Oude Markt 13 Town LEUVEN Postcode 3000 Country Belgium Webpage www.kuleuven.be Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................12/08/1911 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 26 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name KU Leuven Department(s) carrying out the proposed work Department 1 Department name Center for Human Genetics not applicable Same as proposing organisation's address Street Herestraat 49, ON1, PB 606 Town Leuven Postcode 3000 Country Belgium Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 27 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name KU Leuven Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Gert Last name Matthijs E-Mail [email protected] Position in org. Head of Laboratory for Molecular Diagnosis Same as Department Center for Human Genetics organisation name Same as proposing organisation's address Street Herestraat 49, ON1, PB 606 Town Leuven Post code 3000 Country Belgium Website https://gbiomed.kuleuven.be/apps/cme/ Phone +32 16 34 60 70 Phone 2 +xxx xxxxxxxxx Fax +32 16 32 06 23 Other contact persons First Name Last Name E-mail Phone Myriam Witvrouw [email protected] +32 16 320623 Liliane Geyskens [email protected] +32 16 346053 H2020-CP-2017 ver 1.00 20180221 Page 28 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name MEYS PIC Legal name 938834192 MINISTRY OF EDUCATION YOUTH AND SPORTS Short name: MEYS Address of the organisation Street Karmelitska 7 Town Prague Postcode 118 12 Country Czech Republic Webpage www.msmt.cz Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 29 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name MEYS Department(s) carrying out the proposed work Department 1 Department name Department of Research and Development not applicable Same as proposing organisation's address Street Karmelitská 529/5 Town Prague Postcode 11812 Country Czech Republic Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 30 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name MEYS Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Mrs Sex Male Female First name Renata Last name Hruba E-Mail [email protected] Position in org. Administration officer Same as Department Department of Research and Development organisation name Same as proposing organisation's address Street Karmelitská 529/5 Town Prague Post code 11812 Country Czech Republic Website www.msmt.cz Phone +420234811504 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Lukas Levak [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 31 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name MOSAE PIC Legal name 998429731 SOTSIAALMINISTEERIUM Short name: MOSAE Address of the organisation Street Suur-Ameerika 1 Town TALLINN Postcode 10122 Country Estonia Webpage http://www.sm.ee/ Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................unknown International organisation of European interest ........unknown Industry (private for profit)..................no Secondary or Higher education establishment .........unknown Research organisation ..............................................unknown Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 32 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name MOSAE Department(s) carrying out the proposed work Department 1 Department name Head of Healthcare Policy not applicable Same as proposing organisation's address Street Suur-Ameerika 1 Town TALLINN Postcode 10122 Country Estonia Department 2 Department name Analysis and Statistics Department not applicable Same as proposing organisation's address Street Suur-Ameerika 1 Town TALLINN Postcode 10122 Country Estonia Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 33 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name MOSAE Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Heli Last name Paluste E-Mail [email protected] Position in org. Head of Healthcare Policy Same as Department Health System Development Department organisation name Same as proposing organisation's address Street Suur-Ameerika 1 Town TALLINN Post code 10122 Country Estonia Website www.sm.ee Phone (+372) 626 9127 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Angela Ivask [email protected] (+372) 626 9301 H2020-CP-2017 ver 1.00 20180221 Page 34 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AKA PIC Legal name 999517586 SUOMEN AKATEMIA Short name: AKA Address of the organisation Street HAKANIEMENRANTA 6 Town HELSINKI Postcode 00531 Country Finland Webpage www.aka.fi Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status...........................................19/05/2016 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 35 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AKA Department(s) carrying out the proposed work Department 1 Department name Heath Research Unit not applicable Same as proposing organisation's address Street HAKANIEMENRANTA 6 Town HELSINKI Postcode 00531 Country Finland Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 36 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AKA Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Heikki Last name Vilen E-Mail [email protected] Position in org. Science Adviser Same as Department Heath Research Unit organisation name Same as proposing organisation's address Street HAKANIEMENRANTA 6 Town HELSINKI Post code 00531 Country Finland Website Phone +358 533 5135 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Paula Pesola [email protected] +358 533 5089 H2020-CP-2017 ver 1.00 20180221 Page 37 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ANR PIC Legal name 998711613 AGENCE NATIONALE DE LA RECHERCHE Short name: ANR Address of the organisation Street 50 avenue Daumesnil Town PARIS Postcode 75012 Country France Webpage www.agence-nationale-recherche.fr Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 38 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ANR Department(s) carrying out the proposed work Department 1 Department name Biology and Health Dpt. not applicable Same as proposing organisation's address Street 50 avenue Daumesnil Town PARIS Postcode 75012 Country France Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 39 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ANR Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Dominique Last name DUNON-BLUTEAU E-Mail [email protected] Position in org. Head of the Biology and Health Department Same as Department Biology and Health Dpt. organisation name Same as proposing organisation's address Street 50 avenue Daumesnil Town PARIS Post code 75012 Country France Website Phone +33178098021 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Blandine Castrillo [email protected] +33 (0)1 80 48 83 85 H2020-CP-2017 ver 1.00 20180221 Page 40 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FFRD PIC Legal name 954438485 FONDATION MALADIES RARES Short name: FFRD Address of the organisation Street RUE DIDOT 96 Town PARIS Postcode 75014 Country France Webpage Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status...........................................07/02/2012 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 41 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FFRD Department(s) carrying out the proposed work Department 1 Department name French Foundation for rare diseases not applicable Same as proposing organisation's address Street RUE DIDOT 96 Town PARIS Postcode 75014 Country France Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 42 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FFRD Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Mrs Sex Male Female First name Roseline Last name Favresse E-Mail [email protected] Position in org. Regional coordinator, in charge of EU Affairs Same as Department French Foundation for rare diseases organisation name Same as proposing organisation's address Street RUE DIDOT 96 Town PARIS Post code 75014 Country France Website http://fondation-maladiesrares.org/ Phone +33676222780 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 43 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AFM PIC Legal name 959828387 Association Française contre les Myopathies Short name: AFM Address of the organisation Street rue de l'Internationale 1 Town EVRY Postcode 91002 Country France Webpage http://www.afm-telethon.fr Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 44 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AFM Department(s) carrying out the proposed work Department 1 Department name French Foundation for rare diseases not applicable Same as proposing organisation's address Street rue de l'Internationale 1 Town EVRY Postcode 91002 Country France Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 45 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AFM Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Alexandre Last name Mejat E-Mail [email protected] Position in org. Scientific department Same as Department International Scientific Affairs Manager organisation name Same as proposing organisation's address Street rue de l'Internationale 1 Town EVRY Post code 91002 Country France Website http://www.afm-telethon.fr Phone +33169132234 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 46 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name IMAGINE PIC Legal name 955276177 IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES FONDATION Short name: IMAGINE Address of the organisation Street RUE DE VAUGIRARD 156 Town PARIS Postcode 75015 Country France Webpage www.fondationimagine.org Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 47 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name IMAGINE Department(s) carrying out the proposed work Department 1 Department name Imagine Institute not applicable Same as proposing organisation's address Street 24 Boulevard du Montparnasse Town Paris Postcode 75015 Country France Department 2 Department name Innovation and Technology Transfer Department not applicable Same as proposing organisation's address Street 24 Boulevard du Montparnasse Town Paris Postcode 75015 Country France Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 48 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name IMAGINE Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Stanislas Last name Lyonnet E-Mail [email protected] Position in org. Director Same as Department IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS M organisation name Same as proposing organisation's address Street 24 boulevard du Montparnasse Town Paris Post code 75015 Country France Website www.institutimagine.org Phone 00(33)142754200 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Laure Boquet [email protected] +33 1 42 75 42 60 H2020-CP-2017 ver 1.00 20180221 Page 49 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name DLR PIC Legal name 999981731 DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV Short name: DLR Address of the organisation Street Linder Hoehe Town KOELN Postcode 51147 Country Germany Webpage www.dlr.de Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................28/10/2008 - no SME self-assessment ............................................... unknown SME validation sme...................................................28/10/2008 - no Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 50 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name DLR Department(s) carrying out the proposed work Department 1 Department name DLR Project Management Agency not applicable Same as proposing organisation's address Street Heinrich-Konen-Str. 1 Town Bonn Postcode 53227 Country Germany Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 51 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name DLR Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Ralph Last name Schuster E-Mail [email protected] Position in org. Scientific officer Same as Department DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV organisation name Same as proposing organisation's address Street Heinrich-Konen-Str. 1 Town Bonn Post code 53227 Country Germany Website http://DLR-PT.de Phone +49 -228-38211233 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Johana Vogt [email protected] +49-228-38212025 H2020-CP-2017 ver 1.00 20180221 Page 52 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UKA PIC Legal name 999897632 UNIVERSITAETSKLINIKUM AACHEN Short name: UKA Address of the organisation Street Pauwelsstrasse 30 Town AACHEN Postcode 52074 Country Germany Webpage www.ukaachen.de Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................unknown International organisation of European interest ........unknown Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................unknown Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 53 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UKA Department(s) carrying out the proposed work Department 1 Department name Department of Medical Statistics not applicable Same as proposing organisation's address Street Pauwelsstrasse 19 Town Aachen Postcode 52074 Country Germany Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 54 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UKA Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Ralf-Dieter Last name Hilgers E-Mail [email protected] Position in org. Department Chair Same as Department Department of Medical Statistics organisation name Same as proposing organisation's address Street Pauwelsstrasse 19 Town Aachen Post code 52074 Country Germany Website https://www.ukaachen.de/kliniken-institute/institut-fuer-medizini Phone +49-241-8082501 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Herman Jennessen [email protected] +49 241 8080717 H2020-CP-2017 ver 1.00 20180221 Page 55 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CHARITE PIC Legal name 999992692 CHARITE - UNIVERSITAETSMEDIZIN BERLIN Short name: CHARITE Address of the organisation Street Chariteplatz 1 Town BERLIN Postcode 10117 Country Germany Webpage www.charite.de Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................unknown International organisation of European interest ........unknown Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................01/01/1710 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 56 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CHARITE Department(s) carrying out the proposed work Department 1 Department name Neurocure Cluster not applicable Same as proposing organisation's address Street Chariteplatz 1 Town BERLIN Postcode 10117 Country Germany Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 57 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CHARITE Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Sebastian Last name Köhler E-Mail [email protected] Position in org. PI Same as Department Neurocure Cluster organisation name Same as proposing organisation's address Street Chariteplatz 1 Town BERLIN Post code 10117 Country Germany Website www.charite.de Phone +4930450576024 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Eveline Fraessdorf [email protected] +4930450576024 H2020-CP-2017 ver 1.00 20180221 Page 58 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UKL-FR PIC Legal name 999881918 UNIVERSITAETSKLINIKUM FREIBURG Short name: UKL-FR Address of the organisation Street HUGSTETTER STRASSE 49 Town FREIBURG Postcode 79106 Country Germany Webpage http://www.uniklinik-freiburg.de/ip/splash/start.html Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................12/09/1457 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 59 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UKL-FR Department(s) carrying out the proposed work Department 1 Department name Department of Neuropediatrics and Muscle Disorders not applicable Same as proposing organisation's address Street Mathildenstr. 1 Town Freiburg Postcode 79106 Country Germany Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 60 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UKL-FR Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Janbernd Last name Kirschner E-Mail [email protected] Position in org. Acting Medical Director Same as Department Department of Neuropediatrics and Muscle Disorders organisation name Same as proposing organisation's address Street Mathildenstr. 1 Town Freiburg Post code 79106 Country Germany Website Phone +4976127043150 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Gerhard Henninger [email protected] +4976127019200 H2020-CP-2017 ver 1.00 20180221 Page 61 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name NKFIH PIC Legal name 999578696 NEMZETI KUTATASI FEJLESZTESI ES INNOVACIOS HIVATAL Short name: NKFIH Address of the organisation Street KETHLY ANNA TER 1 Town BUDAPEST Postcode 1077 Country Hungary Webpage www.nkfih.gov.hu Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status...........................................06/03/2009 - no SME self-assessment ............................................... unknown SME validation sme...................................................06/03/2009 - no Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 62 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name NKFIH Department(s) carrying out the proposed work Department 1 Department name Department for Research and Development not applicable Same as proposing organisation's address Street KETHLY ANNA TER 1 Town BUDAPEST Postcode 1077 Country Hungary Department 2 Department name Department for International Affairs not applicable Same as proposing organisation's address Street KETHLY ANNA TER 1 Town BUDAPEST Postcode 1077 Country Hungary Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 63 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name NKFIH Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Gábor Last name Tóth E-Mail [email protected] Position in org. head of department Same as Department Department for Research and Development organisation name Same as proposing organisation's address Street KETHLY ANNA TER 1 Town BUDAPEST Post code 1077 Country Hungary Website http://nkfih.gov.hu/english Phone +36 1 8961727 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Elod Nemerkenyi [email protected] +36 1 8963987 Klara Horvath [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 64 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name HRB PIC Legal name 999546686 THE HEALTH RESEARCH BOARD Short name: HRB Address of the organisation Street LOWER BAGGOT STREET 73 Town DUBLIN Postcode 2 Country Ireland Webpage www.hrb.ie Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 65 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name HRB Department(s) carrying out the proposed work Department 1 Department name Research Strategy and Funding not applicable Same as proposing organisation's address Street 67-72 Lower Mount Street Town Dublin Postcode D02 H638 Country Ireland Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 66 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name HRB Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Annalisa Last name Montesanti E-Mail [email protected] Position in org. Programme Manager Same as Department Research Strategy and Funding organisation name Same as proposing organisation's address Street 67-72 Lower Mount Street Town Dublin Post code D02 H638 Country Ireland Website www.hrb.ie Phone +363-1-2345208 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 67 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name IT-MOH PIC Legal name 999531942 MINISTERO DELLA SALUTE Short name: IT-MOH Address of the organisation Street Via Giorgio Ribotta 5 Town ROMA Postcode 00144 Country Italy Webpage www.salute.gov.it Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status...........................................01/01/1900 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 68 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name IT-MOH Department(s) carrying out the proposed work Department 1 Department name General Directorate of Research and Innovation in Healthcare not applicable Same as proposing organisation's address Street Via Giorgio Ribotta 5 Town ROMA Postcode 00144 Country Italy Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 69 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name IT-MOH Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Giselda Last name Scalera E-Mail [email protected] Position in org. General Directorate of Research and Innovation in Healthcare Same as Department Head Office organisation name Same as proposing organisation's address Street Via Giorgio Ribotta 5 Town ROMA Post code 00144 Country Italy Website Phone +390659942596 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Gaetano Guglielmi [email protected] +390659942197 H2020-CP-2017 ver 1.00 20180221 Page 70 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name TuscReg PIC Legal name 998823842 REGIONE TOSCANA Short name: TuscReg Address of the organisation Street Palazzo Strozzi Sacrati - Piazza del Duomo 10 Town FIRENZE Postcode 50122 Country Italy Webpage www.regione.toscana.it Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................unknown International organisation of European interest ........unknown Industry (private for profit)..................no Secondary or Higher education establishment .........unknown Research organisation ..............................................unknown Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 71 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name TuscReg Department(s) carrying out the proposed work Department 1 Department name Direction Citizenship rights and Programmes Management Department not applicable Same as proposing organisation's address Street via Taddeo Alderotti n. 26 N Town Florence Postcode 50139 Country Italy Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 72 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name TuscReg Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Mrs Sex Male Female First name Katia Last name Belvedere E-Mail [email protected] Position in org. Head of Sector Same as Department Direction Citizenship rights and social cohesion organisation name Same as proposing organisation's address Street via Taddeo Alderotti n. 29 N Town Florence Post code 50139 Country Italy Website http://www.regione.toscana.it/ Phone +390554383386 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Donatella Tanini [email protected] +39 055 4383256 H2020-CP-2017 ver 1.00 20180221 Page 73 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FRRB PIC Legal name 929009450 FONDAZIONE REGIONALE PER LA RICERCA BIOMEDICA Short name: FRRB Address of the organisation Street PIAZZA CITTA DI LOMBARDIA 1 Town MILANO Postcode 20124 Country Italy Webpage www.frrb.it Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................31/12/2015 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 74 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FRRB Department(s) carrying out the proposed work Department 1 Department name Main premises not applicable Same as proposing organisation's address Street Via Torquato Taramelli 12 Town Milano Postcode 20124 Country Italy Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 75 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FRRB Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Mr. Sex Male Female First name Gianni Last name D'Errico E-Mail [email protected] Position in org. European Funding Officer Same as Department FONDAZIONE REGIONALE PER LA RICERCA BIOMEDICA organisation name Same as proposing organisation's address Street Via Torquato Taramelli 12 Town Milano Post code 20124 Country Italy Website www.frrb.it Phone +39267650174 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Marina Gerini [email protected] +39267650555 H2020-CP-2017 ver 1.00 20180221 Page 76 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FGB PIC Legal name 962478330 FONDAZIONE PER LA RICERCA FARMACOLOGICA GIANNI BENZI ONLUS Short name: FGB Address of the organisation Street VIA ABATE EUSTASIO 30 Town VALENZANO BARI Postcode 70010 Country Italy Webpage www.benzifoundation.org Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................19/11/2008 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 77 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FGB Department(s) carrying out the proposed work Department 1 Department name Research department not applicable Same as proposing organisation's address Street via Putignani, 133 Town Bari Postcode 70122 Country Italy Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 78 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FGB Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Viviana Last name Giannuzzi E-Mail [email protected] Position in org. Coordinator of Research Department Same as Department Research Department organisation name Same as proposing organisation's address Street via Putignani, 133 Town Bari Post code 70122 Country Italy Website www.benzifoundation.org Phone +390802052499 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Fedele Bonifazi [email protected] +390802052499 Serena Ottomano [email protected] +390802052499 H2020-CP-2017 ver 1.00 20180221 Page 79 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FTELE PIC Legal name 999448716 FONDAZIONE TELETHON Short name: FTELE Address of the organisation Street VIA VARESE 16/B Town ROMA Postcode 00185 Country Italy Webpage www.telethon.it Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................01/01/1970 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 80 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FTELE Department(s) carrying out the proposed work Department 1 Department name Research & Development Department not applicable Same as proposing organisation's address Street VIA VARESE 16/B Town ROMA Postcode 00185 Country Italy Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 81 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FTELE Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Lucia Last name Faccio E-Mail [email protected] Position in org. Director of Research & Development Same as Department Research & Development Department organisation name Same as proposing organisation's address Street VIA VARESE 16/B Town ROMA Post code 00185 Country Italy Website www.telethon.it Phone +39 02 202217213 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Rafaella Pettorruso [email protected] +390644015360 H2020-CP-2017 ver 1.00 20180221 Page 82 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ISS PIC Legal name 999978821 ISTITUTO SUPERIORE DI SANITA Short name: ISS Address of the organisation Street Viale Regina Elena 299 Town ROMA Postcode 00161 Country Italy Webpage http://www.iss.it Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 83 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ISS Department(s) carrying out the proposed work Department 1 Department name National Center for Rare Diseases not applicable Same as proposing organisation's address Street Viale Regina Elena 299 Town ROMA Postcode 00161 Country Italy Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 84 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ISS Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Domenica Last name Taruscio E-Mail [email protected] Position in org. Director Same as Department National Center for Rare Diseases organisation name Same as proposing organisation's address Street Viale Regina Elena 299 Town ROMA Post code 00161 Country Italy Website www.iss.it/cnmr Phone +390649904016 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Rosa Maria Martoccia [email protected] +390649901 H2020-CP-2017 ver 1.00 20180221 Page 85 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CVBF PIC Legal name 999717018 CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE Short name: CVBF Address of the organisation Street VIA NICOLO PUTIGNANI 178 Town BARI Postcode 70122 Country Italy Webpage www.cvbf.net Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................07/02/2001 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 86 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CVBF Department(s) carrying out the proposed work Department 1 Department name Consorzio per Valutazioni Biologiche e Farmacologiche not applicable Same as proposing organisation's address Street VIA NICOLO PUTIGNANI 178 Town BARI Postcode 70122 Country Italy Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 87 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CVBF Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Mr. Sex Male Female First name Donato Last name Bonifazi E-Mail [email protected] Position in org. Chief Executive Officer Same as Department Consorzio per Valutazioni Biologiche e Farmacologiche organisation name Same as proposing organisation's address Street VIA NICOLO PUTIGNANI 178 Town BARI Post code 70122 Country Italy Website www.cvbf.net Phone +390809751974 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Marina Montanaro [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 88 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name TEDDY PIC Legal name 910591963 TEDDY - EUROPEAN NETWORK OF EXCELLENCE FOR PAEDIATRIC CLINICAL RESEARCH Short name: TEDDY Address of the organisation Street VIA LUIGI PORTA 14 Town PAVIA Postcode 231261 Country Italy Webpage www.teddynetwork.net Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 89 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name TEDDY Department(s) carrying out the proposed work Department 1 Department name TEDDY- European Network of Excellence for Paediatric Clinic not applicable Same as proposing organisation's address Street VIA LUIGI PORTA 14 Town PAVIA Postcode 231261 Country Italy Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 90 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name TEDDY Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Mrs Sex Male Female First name Lupo Last name Mariangela E-Mail [email protected] Position in org. Communication manager Same as Department TEDDY - EUROPEAN NETWORK OF EXCELLENCE FOR PAEDIATRIC CL organisation name Same as proposing organisation's address Street VIA LUIGI PORTA 14 Town PAVIA Post code 231261 Country Italy Website www.teddynetwork.net Phone +393493524360 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Antonella Minervini [email protected] +xxx xxxxxxxxx Joana Claverol [email protected] +xxx xxxxxxxxx Begonya Nafría [email protected] +xxx xxxxxxxxx Leonor Norton [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 91 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name MIUR PIC Legal name 999641358 MINISTERO DELL'ISTRUZIONE, DELL'UNIVERSITA' E DELLA RICERCA Short name: MIUR Address of the organisation Street Via Michele Carcani 61 Town ROMA Postcode 00153 Country Italy Webpage www.istruzione.it Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status...........................................01/01/1900 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 92 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name MIUR Department(s) carrying out the proposed work Department 1 Department name Department for higher education and research not applicable Same as proposing organisation's address Street Via Michele Carcani 61 Town ROMA Postcode 00153 Country Italy Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 93 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name MIUR Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Gianluigi Last name Consoli E-Mail [email protected] Position in org. Head of Office Same as Department Department for higher education and research organisation name Same as proposing organisation's address Street Via Michele Carcani 61 Town ROMA Post code 00153 Country Italy Website http://www.miur.gov.it/ Phone +371 67358451 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 94 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name VIAA PIC Legal name 948820730 VALSTS IZGLITIBAS ATTISTIBAS AGENTURA Short name: VIAA Address of the organisation Street VALNU IELA 1 Town RIGA Postcode 1050 Country Latvia Webpage www.viaa.gov.lv Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status...........................................26/08/2004 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 95 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name VIAA Department(s) carrying out the proposed work Department 1 Department name Science, Research and Innovation Policy Support Department not applicable Same as proposing organisation's address Street VALNU IELA 1 Town RIGA Postcode 1050 Country Latvia Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 96 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name VIAA Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Janis Last name Ancans E-Mail [email protected] Position in org. Science, Research and Innovation Policy Support Department Same as Department Senior Expert organisation name Same as proposing organisation's address Street VALNU IELA 1 Town RIGA Post code 1050 Country Latvia Website www.viaa.gov.lv Phone +371 67358451 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Kristine Fortina [email protected] +371 67814333 H2020-CP-2017 ver 1.00 20180221 Page 97 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name LMT PIC Legal name 997808446 Lietuvos mokslo taryba Short name: LMT Address of the organisation Street Gedimino 3 Town Vilnius Postcode LT01103 Country Lithuania Webpage http://www.lmt.lt/ Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 98 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name LMT Department(s) carrying out the proposed work Department 1 Department name Research Foundation/International programmes unit not applicable Same as proposing organisation's address Street Gedimino 3 Town Vilnius Postcode LT01103 Country Lithuania Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 99 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name LMT Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Saulius Last name Marcinkonis E-Mail [email protected] Position in org. Chief Officer Same as Department Research Foundation/International programmes unit organisation name Same as proposing organisation's address Street Gedimino 3 Town Vilnius Post code LT01103 Country Lithuania Website http://www.lmt.lt/en/ Phone +370 676 17256 Phone 2 +370 670 32435 Fax +370 5 261 8535 Other contact persons First Name Last Name E-mail Phone Ausra Vilutiene [email protected] +370 676 16715 H2020-CP-2017 ver 1.00 20180221 Page 100 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name VUHSK PIC Legal name 991636530 VIESOJI ISTAIGA VILNIAUS UNIVERSITETO LIGONINE SANTAROS KLINIKOS Short name: VUHSK Address of the organisation Street SANTARISKIU G 2 Town VILNIUS Postcode 08661 Country Lithuania Webpage www.santa.lt Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status...........................................23/03/1998 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 101 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name VUHSK Department(s) carrying out the proposed work Department 1 Department name Joint Center for Competences and Biomedical Research not applicable Same as proposing organisation's address Street SANTARISKIU G 2 Town VILNIUS Postcode 08661 Country Lithuania Department 2 Department name Centre of Hematology, Oncology and Transfusion Medicine not applicable Same as proposing organisation's address Street SANTARISKIU G 2 Town VILNIUS Postcode 08661 Country Lithuania H2020-CP-2017 ver 1.00 20180221 Page 102 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name VUHSK Department 3 Department name Centre of Medical Genetics not applicable Same as proposing organisation's address Street SANTARISKIU G 2 Town VILNIUS Postcode 08661 Country Lithuania Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 103 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name VUHSK Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Birute Last name Tumiene E-Mail [email protected] Position in org. Coordinator of competence centers Same as Department Joint Center for Competences and Biomedical Research organisation name Same as proposing organisation's address Street SANTARISKIU G 2 Town VILNIUS Post code 08661 Country Lithuania Website www.santa.lt Phone +37061445026 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Laimonas Griskevicius [email protected] +xxx xxxxxxxxx Algirdas Utkus [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 104 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FNR PIC Legal name 998597153 FONDS NATIONAL DE LA RECHERCHE Short name: FNR Address of the organisation Street 2 AVENUE DE L'UNIVERSITE Town ESCH-SUR-ALZETTE Postcode 4365 Country Luxembourg Webpage www.fnr.lu Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status...........................................18/02/2009 - no SME self-assessment ............................................... unknown SME validation sme...................................................18/02/2009 - no Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 105 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FNR Department(s) carrying out the proposed work Department 1 Department name FONDS NATIONAL DE LA RECHERCHE not applicable Same as proposing organisation's address Street 2 AVENUE DE L'UNIVERSITE Town ESCH-SUR-ALZETTE Postcode 4365 Country Luxembourg Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 106 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FNR Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Sean Last name Sapcariu E-Mail [email protected] Position in org. Programme Manager Same as Department FONDS NATIONAL DE LA RECHERCHE organisation name Same as proposing organisation's address Street 2 AVENUE DE L'UNIVERSITE Town ESCH-SUR-ALZETTE Post code 4365 Country Luxembourg Website Phone +35226192547 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 107 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ZonMw PIC Legal name 999544164 ZORGONDERZOEK NEDERLAND ZON Short name: ZonMw Address of the organisation Street Laan Van Nieuw Oost Indie 334 Town DEN HAAG Postcode 2593CE Country Netherlands Webpage WWW.ZONMW.NL Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................01/01/2009 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 108 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ZonMw Department(s) carrying out the proposed work Department 1 Department name ZON not applicable Same as proposing organisation's address Street Laan Van Nieuw Oost Indie 334 Town DEN HAAG Postcode 2593CE Country Netherlands Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 109 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ZonMw Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Van Weely Last name Sonja E-Mail [email protected] Position in org. Programme Officer Same as Department ZON organisation name Same as proposing organisation's address Street Laan Van Nieuw Oost Indie 334 Town DEN HAAG Post code 2593CE Country Netherlands Website www.zonmw.nl Phone +31 70 349 5111 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Richard van Beekum [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 110 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UMCG PIC Legal name 999914801 ACADEMISCH ZIEKENHUIS GRONINGEN Short name: UMCG Address of the organisation Street HANZEPLEIN 1 Town GRONINGEN Postcode 9713 GZ Country Netherlands Webpage www.umcg.nl Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................11/11/1797 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 111 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UMCG Department(s) carrying out the proposed work Department 1 Department name Department of Genetics not applicable Same as proposing organisation's address Street HANZEPLEIN 1 Town GRONINGEN Postcode 9713 GZ Country Netherlands Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 112 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UMCG Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Morris Last name Swertz E-Mail [email protected] Position in org. Head of Genomics Coordination Center Same as Department Department of Genetics organisation name Same as proposing organisation's address Street HANZEPLEIN 1 Town GRONINGEN Post code 9713 GZ Country Netherlands Website http://umcg.nl Phone +31 50 36171000 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Tineke Spel [email protected] +31 50 361 6999 H2020-CP-2017 ver 1.00 20180221 Page 113 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UM PIC Legal name 999975911 UNIVERSITEIT MAASTRICHT Short name: UM Address of the organisation Street Minderbroedersberg 4-6 Town MAASTRICHT Postcode 6200 MD Country Netherlands Webpage http://www.maastrichtuniversity.nl Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................no Enterprise Data SME self-declared status...........................................01/01/1976 - no SME self-assessment ...............................................01/01/1976 - no SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 114 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UM Department(s) carrying out the proposed work Department 1 Department name BIGCAT / Faculty of Health Medicine and Life sciences / NUTRIM not applicable Same as proposing organisation's address Street Universiteitssingel 50 Town Maastricht Postcode 6229 ER Country Netherlands Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 115 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UM Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Chris Last name Evelo E-Mail [email protected] Position in org. PI and head of the department BIGCAT Same as Department BIGCAT / Faculty of Health Medicine and Life sciences / NUTRIM organisation name Same as proposing organisation's address Street Universiteitssingel 50 Town Maastricht Post code 6229ER Country Netherlands Website https://www.bigcat.unimaas.nl/ Phone +390649904016 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Pascal Stevens [email protected] +31 43 3881961 H2020-CP-2017 ver 1.00 20180221 Page 116 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name NCBR PIC Legal name 999519720 NARODOWE CENTRUM BADAN I ROZWOJU Short name: NCBR Address of the organisation Street UL. NOWOGRODZKA 47A Town WARSZAWA Postcode 00 695 Country Poland Webpage www.ncbr.gov.pl Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................no International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status...........................................17/08/2007 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 117 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name NCBR Department(s) carrying out the proposed work Department 1 Department name Programmes Management Department not applicable Same as proposing organisation's address Street UL. NOWOGRODZKA 47A Town WARSZAWA Postcode 00 695 Country Poland Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 118 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name NCBR Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Marcin Last name Chmielewski E-Mail [email protected] Position in org. Chief Specialist Same as Department Programmes Management Department organisation name Same as proposing organisation's address Street UL. NOWOGRODZKA 47A Town WARSZAWA Post code 00 695 Country Poland Website http://www.ncbr.gov.pl/ Phone +48222019408 Phone 2 +48223907109 Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Matylda Marczak [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 119 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name MUW PIC Legal name 999878329 WARSZAWSKI UNIWERSYTET MEDYCZNY Short name: MUW Address of the organisation Street UL. ZWIRKI I WIGURY 61 Town WARSZAWA Postcode 02 091 Country Poland Webpage www.wum.edu.pl Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................no Enterprise Data SME self-declared status...........................................11/07/2008 - no SME self-assessment ............................................... unknown SME validation sme...................................................11/07/2008 - no Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 120 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name MUW Department(s) carrying out the proposed work Department 1 Department name Department of General and Transplantation Surgery not applicable Same as proposing organisation's address Street 59 Nowogrodzka St. Town Warsaw Postcode 02-006 Country Poland Department 2 Department name Department of Dermatology and Immunodermatology not applicable Same as proposing organisation's address Street 59 Nowogrodzka St. Town Warsaw Postcode 02-006 Country Poland H2020-CP-2017 ver 1.00 20180221 Page 121 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name MUW Department 3 Department name Department of Neurology not applicable Same as proposing organisation's address Street 59 Nowogrodzka St. Town Warsaw Postcode 02-006 Country Poland Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 122 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name MUW Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Piotr Last name Fiedor E-Mail [email protected] Position in org. Clinical Professor Same as Department Department of General and Transplantation Surgery organisation name Same as proposing organisation's address Street 59 Nowogrodzka St. Town Warsaw Post code 02-006 Country Poland Website http://www.chirurgia-transplantacyjna.wum.edu.pl/ Phone +48 571 33 55 56 Phone 2 +48 606 74 10 77 Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Cezary Kowalewski [email protected] +xxx xxxxxxxxx Anna Kostera-Pruszczyk [email protected] +xxx xxxxxxxxx Krzysztof Zieniewicz [email protected] +xxx xxxxxxxxx Wieslaw Jedrzejczak [email protected] +xxx xxxxxxxxx Karolina Nowak [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 123 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name MUG PIC Legal name 999880754 GDANSKI UNIWERSYTET MEDYCZNY Short name: MUG Address of the organisation Street ULICA M SKLODOWSKIEJ CURIE 3A Town GDANSK Postcode 80210 Country Poland Webpage www.gumed.edu.pl Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................08/10/1945 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 124 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name MUG Department(s) carrying out the proposed work Department 1 Department name Rare Disease Centre not applicable Same as proposing organisation's address Street ULICA M SKLODOWSKIEJ CURIE 3A Town GDANSK Postcode 80210 Country Poland Department 2 Department name Department Pediatrics, Nephrology & Hypertension not applicable Same as proposing organisation's address Street ULICA M SKLODOWSKIEJ CURIE 3A Town GDANSK Postcode 80210 Country Poland H2020-CP-2017 ver 1.00 20180221 Page 125 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name MUG Department 3 Department name Pediatrics, Oncology & Hematology & Pediatric Surgery & Urology not applicable Same as proposing organisation's address Street ULICA M SKLODOWSKIEJ CURIE 3A Town GDANSK Postcode 80210 Country Poland Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 126 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name MUG Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Aleksandra Last name Zurowska E-Mail [email protected] Position in org. Head Department and Coordinator of Centre Same as Department Rare Disease Centre organisation name Same as proposing organisation's address Street ULICA M SKLODOWSKIEJ CURIE 3A Town GDANSK Post code 80210 Country Poland Website gumed.edu.pl Phone +48583492850 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Malgorzata Szydlowska-Czyzak [email protected] +48583491207 H2020-CP-2017 ver 1.00 20180221 Page 127 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name IPCZD PIC Legal name 999516228 INSTYTUT POMNIK CENTRUM ZDROWIA DZIECKA Short name: IPCZD Address of the organisation Street Aleja Dzieci Polskich 20 Town WARSZAWA Postcode 04730 Country Poland Webpage www.czd.pl Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................15/02/2002 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 128 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name IPCZD Department(s) carrying out the proposed work Department 1 Department name Medical Genetics Unit not applicable Same as proposing organisation's address Street Aleja Dzieci Polskich 20 Town WARSZAWA Postcode 04730 Country Poland Department 2 Department name Gastroenterology,Paediatric not applicable Same as proposing organisation's address Street Aleja Dzieci Polskich 20 Town WARSZAWA Postcode 04730 Country Poland H2020-CP-2017 ver 1.00 20180221 Page 129 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name IPCZD Department 3 Department name Hepatology Nutrition Disorders not applicable Same as proposing organisation's address Street Aleja Dzieci Polskich 20 Town WARSZAWA Postcode 04730 Country Poland Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 130 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name IPCZD Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Krystyna Last name Chrzanowska E-Mail [email protected] Position in org. Head of Medical Genetics Unit Same as Department Medical Genetics Unit organisation name Same as proposing organisation's address Street Aleja Dzieci Polskich 20 Town WARSZAWA Post code 04730 Country Poland Website www.czd.pl Phone +48 22 8157452 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Piotr Socha [email protected] +xxx xxxxxxxxx Paulina Glowacka [email protected] +48 22 8151124 H2020-CP-2017 ver 1.00 20180221 Page 131 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FCT PIC Legal name 999543970 FUNDACAO PARA A CIENCIA E A TECNOLOGIA Short name: FCT Address of the organisation Street AVENIDA D CARLOS I 126 Town LISBOA Postcode 1249 074 Country Portugal Webpage www.fct.pt Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 132 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FCT Department(s) carrying out the proposed work Department 1 Department name Department for International Relations not applicable Same as proposing organisation's address Street AVENIDA D CARLOS I 126 Town LISBOA Postcode 1249 074 Country Portugal Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 133 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FCT Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Anabela Last name Isidro E-Mail [email protected] Position in org. Science Officer Same as Department Department for International Relations organisation name Same as proposing organisation's address Street AVENIDA D CARLOS I 126 Town LISBOA Post code 1249 074 Country Portugal Website www.fct.pt Phone +351213911552 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Ana Quartin [email protected] +351 213911542 H2020-CP-2017 ver 1.00 20180221 Page 134 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name INSA PIC Legal name 998308190 INSTITUTO NACIONAL DE SAUDE DR. RICARDO JORGE Short name: INSA Address of the organisation Street AVENIDA PADRE CRUZ Town LISBOA Postcode 1600 560 Country Portugal Webpage http://www.insa.pt Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 135 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name INSA Department(s) carrying out the proposed work Department 1 Department name Human Genetics Department not applicable Same as proposing organisation's address Street Rua Alexandre Herculano, 321 Town Porto Postcode 4000-055 Country Portugal Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 136 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name INSA Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Sandra Last name Alves E-Mail [email protected] Position in org. Researcher Same as Department Human Genetics Department organisation name Same as proposing organisation's address Street Rua Alexandre Herculano, 321 Town Porto Post code 4000-055 Country Portugal Website http://www.insa.min-saude.pt/ Phone (+351) 223 401 100 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Isabel Carvalho Oliveira [email protected] +351 217519200 H2020-CP-2017 ver 1.00 20180221 Page 137 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name SAS PIC Legal name 999530390 SLOVENSKA AKADEMIA VIED Short name: SAS Address of the organisation Street STEFANIKOVA 49 Town BRATISLAVA Postcode 814 38 Country Slovakia Webpage www.sav.sk Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................26/05/2008 - no SME self-assessment ............................................... unknown SME validation sme...................................................26/05/2008 - no Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 138 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name SAS Department(s) carrying out the proposed work Department 1 Department name International Cooperation not applicable Same as proposing organisation's address Street STEFANIKOVA 49 Town BRATISLAVA Postcode 814 38 Country Slovakia Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 139 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name SAS Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Jan Last name Barancik E-Mail [email protected] Position in org. Head Same as Department Internatiom Cooperation organisation name Same as proposing organisation's address Street STEFANIKOVA 49 Town BRATISLAVA Post code 814 38 Country Slovakia Website www.sav.sk Phone +421 2 57510137 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 140 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ISCIII PIC Legal name 999507886 INSTITUTO DE SALUD CARLOS III Short name: ISCIII Address of the organisation Street MONFORTE DE LEMOS 5 Town MADRID Postcode 28029 Country Spain Webpage http://www.isciii.es Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................22/04/2014 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 141 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ISCIII Department(s) carrying out the proposed work Department 1 Department name Institute of Rare Diseases Research not applicable Same as proposing organisation's address Street MONFORTE DE LEMOS 5 Town MADRID Postcode 28029 Country Spain Department 2 Department name SGPIRI Sub-Directorate General for International Research not applicable Same as proposing organisation's address Street MONFORTE DE LEMOS 5 Town MADRID Postcode 28029 Country Spain Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 142 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ISCIII Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Eva Last name Bermejo-Sanchez E-Mail [email protected] Position in org. Tenured Scientist, Chief of Area Same as Department Institute of Rare Diseases Research organisation name Same as proposing organisation's address Street MONFORTE DE LEMOS 5 Town MADRID Post code 28029 Country Spain Website www.isciii.es Phone +34913877541 Phone 2 +xxx xxxxxxxxx Fax +34913877541 Other contact persons First Name Last Name E-mail Phone Maria Ortiz [email protected] +34918223673 Ignacio Baanante-Balastegui [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 143 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CNAG-CRG PIC Legal name 999544455 FUNDACIO CENTRE DE REGULACIO GENOMICA Short name: CNAG-CRG Address of the organisation Street CARRER DOCTOR AIGUADER 88 Town BARCELONA Postcode 08003 Country Spain Webpage www.crg.es Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................01/08/2008 - no SME self-assessment ............................................... unknown SME validation sme...................................................01/08/2008 - no Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 144 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CNAG-CRG Department(s) carrying out the proposed work Department 1 Department name Parc Cientific de Barcelona not applicable Same as proposing organisation's address Street C/ Baldiri Reixac 4 Town Barcelona Postcode 08028 Country Spain Department 2 Department name CNAG-CRG Bioinformatics Unit not applicable Same as proposing organisation's address Street Baldiri Reixac 4, Town Barcelona Postcode 08028 Country Spain H2020-CP-2017 ver 1.00 20180221 Page 145 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CNAG-CRG Department 3 Department name European Genome-phenome Archive EGA not applicable Same as proposing organisation's address Street C/ Dr. Aiguader, 88 Town Barcelona Postcode 08003 Country Spain Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 146 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CNAG-CRG Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Ivo Last name Gut E-Mail [email protected] Position in org. Director and Head of Biomedical Genomics Group Same as Department Parc Cientific de Barcelona organisation name Same as proposing organisation's address Street C/ Baldiri Reixac 4 Town Barcelona Post code 08028 Country Spain Website http://www.cnag.cat/ivo-glynne-gut Phone +34 93 4020542 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Anne-Laure Aslanian [email protected] +34 93 316 0234 Sergi Beltran [email protected] +xxx xxxxxxxxx Jordi Rambla [email protected] +xxx xxxxxxxxx Gabriele Picarella [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 147 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UPM PIC Legal name 999974844 UNIVERSIDAD POLITECNICA DE MADRID Short name: UPM Address of the organisation Street CALLE RAMIRO DE MAEZTU 7 EDIFICIO REC Town MADRID Postcode 28040 Country Spain Webpage www.upm.es Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................04/11/2008 - no SME self-assessment ............................................... unknown SME validation sme...................................................04/11/2008 - no Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 148 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UPM Department(s) carrying out the proposed work Department 1 Department name Center for Plant Biotechnology and Genomics not applicable Same as proposing organisation's address Street Parque Científico y Tecnológico UPM Town Pozuelo de Alarcón (Madrid) Postcode 28023 Country Spain Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 149 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UPM Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Mark Denis Last name Wilkinson E-Mail [email protected] Position in org. Isaac Peral Distinguished Researcher Same as Department Center for Plant Biotechnology and Genomics organisation name Same as proposing organisation's address Street Parque Científico y Tecnológico de la U.P.M. Town Pozuelo de Alarcón (Madrid) Post code 28023 Country Spain Website Phone +34 913364592 Phone 2 34 91 336 6048 Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Asuncion Gómez Pérez [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 150 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CIBER PIC Legal name 997154957 CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. Short name: CIBER Address of the organisation Street CALLE MONFORTE DE LEMOS 5 Town MADRID Postcode 28029 Country Spain Webpage www.ciberisciii.es Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................26/11/2007 - no SME self-assessment ...............................................26/11/2007 - no SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 151 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CIBER Department(s) carrying out the proposed work Department 1 Department name Thematic Area of Rare Diseases (CIBERER) not applicable Same as proposing organisation's address Street Monforte de Lemos, 3-5 Town Madrid Postcode 28029 Country Spain Department 2 Department name Orphanet Spain not applicable Same as proposing organisation's address Street Monforte de Lemos, 3-5 Town Madrid Postcode 28029 Country Spain Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 152 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CIBER Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Pablo Last name Lapunzina E-Mail [email protected] Position in org. Scientific Director of Rare Diseases Area Same as Department Thematic Area of Rare Diseases (CIBERER) organisation name Same as proposing organisation's address Street Monforte de Lemos, 3-5 Town Madrid Post code 28029 Country Spain Website http://www.ciberisciii.es/ Phone +34671481675 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Raquel Campo [email protected] +34911718114 H2020-CP-2017 ver 1.00 20180221 Page 153 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name SRC PIC Legal name 999586165 VETENSKAPSRADET - SWEDISH RESEARCH COUNCIL Short name: SRC Address of the organisation Street VASTRA JARNVAGSGATAN 3 Town STOCKHOLM Postcode 111 64 Country Sweden Webpage www.vr.se Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status...........................................01/01/1900 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 154 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name SRC Department(s) carrying out the proposed work Department 1 Department name Department of Research Policy not applicable Same as proposing organisation's address Street Västra Järnvägsgatan 3 Town Stockholm Postcode 10138 Country Sweden Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 155 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name SRC Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Malin Last name Eklund E-Mail [email protected] Position in org. Senior Research Officer Same as Department Department of Research Policy organisation name Same as proposing organisation's address Street Västra Järnvägsgatan 3 Town Stockholm Post code 10138 Country Sweden Website vr.se Phone +46(0)765267256 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Frederik Gunnarsson [email protected] +46 8 546 44 209 H2020-CP-2017 ver 1.00 20180221 Page 156 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name VINNOVA PIC Legal name 999618757 VERKET FÖR INNOVATIONSSYSTEM Short name: VINNOVA Address of the organisation Street Mäster Samuelsgatan 56 Town STOCKHOLM Postcode 10158 Country Sweden Webpage www.vinnova.se Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................unknown International organisation of European interest ........unknown Industry (private for profit)..................no Secondary or Higher education establishment .........unknown Research organisation ..............................................no Enterprise Data SME self-declared status...........................................18/11/2008 - no SME self-assessment ............................................... unknown SME validation sme...................................................18/11/2008 - no Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 157 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name VINNOVA Department(s) carrying out the proposed work Department 1 Department name Health Department not applicable Same as proposing organisation's address Street Mäster Samuelsgatan 56 Town STOCKHOLM Postcode 10158 Country Sweden Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 158 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name VINNOVA Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Frida Last name Lundmark E-Mail [email protected] Position in org. Programme director Same as Department Health Department organisation name Same as proposing organisation's address Street Mäster Samuelsgatan 56 Town STOCKHOLM Post code 10158 Country Sweden Website [email protected] Phone +46-76 527 12 97 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 159 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ULEIC PIC Legal name 999985514 UNIVERSITY OF LEICESTER Short name: ULEIC Address of the organisation Street UNIVERSITY ROAD Town LEICESTER Postcode LE1 7RH Country United Kingdom Webpage www.le.ac.uk Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................01/05/1957 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 160 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ULEIC Department(s) carrying out the proposed work Department 1 Department name Department of Genetics and Genome Biology not applicable Same as proposing organisation's address Street UNIVERSITY ROAD Town LEICESTER Postcode LE1 7RH Country United Kingdom Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 161 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ULEIC Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Anthony Last name Brookes E-Mail [email protected] Position in org. Professor of Genetics Same as Department Department of Genetics and Genome Biology organisation name Same as proposing organisation's address Street UNIVERSITY ROAD Town LEICESTER Post code LE1 7RH Country United Kingdom Website https://le.ac.uk/ Phone +44(0)1162523401 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Janet Harris [email protected] +44(0)116223 1384 H2020-CP-2017 ver 1.00 20180221 Page 162 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ULIV PIC Legal name 999980567 THE UNIVERSITY OF LIVERPOOL Short name: ULIV Address of the organisation Street BROWNLOW HILL 765 FOUNDATION BUILDIN Town LIVERPOOL Postcode L69 7ZX Country United Kingdom Webpage www.liverpool.ac.uk Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................no Enterprise Data SME self-declared status...........................................06/03/2014 - no SME self-assessment ...............................................06/03/2014 - no SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 163 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ULIV Department(s) carrying out the proposed work Department 1 Department name Women’s and Children’s Health not applicable Same as proposing organisation's address Street BROWNLOW HILL 765 FOUNDATION BUILDING Town LIVERPOOL Postcode L69 7ZX Country United Kingdom Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 164 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ULIV Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Mark Last name Turner E-Mail [email protected] Position in org. Senior Lecturer / Consultant in Neonatology Same as Department Women’s and Children’s Health organisation name Same as proposing organisation's address Street BROWNLOW HILL 765 FOUNDATION BUILDING Town LIVERPOOL Post code L69 7ZX Country United Kingdom Website www.liverpool.ac.uk Phone +44 (0)151 795 9558 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Tomasz Rygielst [email protected] +44 (0)151 795 0314 H2020-CP-2017 ver 1.00 20180221 Page 165 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UNEW PIC Legal name 999985417 UNIVERSITY OF NEWCASTLE UPON TYNE Short name: UNEW Address of the organisation Street KINGS GATE Town NEWCASTLE UPON TYNE Postcode NE1 7RU Country United Kingdom Webpage www.newcastle.ac.uk Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................31/03/2014 - no SME self-assessment ...............................................31/03/2014 - no SME validation sme...................................................31/03/2014 - no Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 166 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UNEW Department(s) carrying out the proposed work Department 1 Department name International Centre for Life not applicable Same as proposing organisation's address Street Biosciences West, Town Newcastle Upon Town Postcode NE1 3BZ Country United Kingdom Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 167 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UNEW Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Victoria Last name Hedley E-Mail [email protected] Position in org. Harold Macmillan Professor of Medicine Same as Department International Centre for Life organisation name Same as proposing organisation's address Street University of Newcastle upon Tyne Town Newcastle Upon Tyne Post code NE1 3BZ Country United Kingdom Website https://newcastle-muscle.org/ Phone +1912418762 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 168 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CCRI PIC Legal name 998645362 ST. ANNA KINDERKREBSFORSCHUNG Short name: CCRI Address of the organisation Street ZIMMERMANNPLATZ 10 Town WIEN Postcode 1090 Country Austria Webpage www.ccri.at/science Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................11/09/2008 - no SME self-assessment ............................................... unknown SME validation sme...................................................11/09/2008 - no Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 169 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CCRI Department(s) carrying out the proposed work Department 1 Department name ST. ANNA KINDERKREBSFORSCHUNG not applicable Same as proposing organisation's address Street ZIMMERMANNPLATZ 10 Town WIEN Postcode 1090 Country Austria Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 170 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CCRI Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Ruth Last name Ladenstein E-Mail [email protected] Position in org. Head of the Clinical Trials Unit Same as Department ST. ANNA KINDERKREBSFORSCHUNG organisation name Same as proposing organisation's address Street ZIMMERMANNPLATZ 10 Town WIEN Post code 1090 Country Austria Website http://science.ccri.at/ Phone +431404704750 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Nuno Andrade [email protected] +431404704441 H2020-CP-2017 ver 1.00 20180221 Page 171 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AP-HP PIC Legal name 999645432 ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS Short name: AP-HP Address of the organisation Street 3 Avenue Victoria Town PARIS Postcode 75004 Country France Webpage www.aphp.fr Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................unknown International organisation of European interest ........unknown Industry (private for profit)..................no Secondary or Higher education establishment .........unknown Research organisation ..............................................yes Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 172 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AP-HP Department(s) carrying out the proposed work Department 1 Department name Hôpital Bichat Service Cardiologie (VASCERN) not applicable Same as proposing organisation's address Street 46 rue Henri-Huchard Town Paris Postcode 75018 Country France Department 2 Department name Hôpital Saint Louis Service d'Hématologie Senior (Eurobloodnet) not applicable Same as proposing organisation's address Street 1 Avenue Claude Vellefaux Town Paris Postcode 75010 Country France H2020-CP-2017 ver 1.00 20180221 Page 173 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AP-HP Department 3 Department name Hôpital Necker Service Dermatologie (ERN-Skin) not applicable Same as proposing organisation's address Street 149 rue de Sèvres Town Paris Postcode 75015 Country France Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 174 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AP-HP Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Mrs Sex Male Female First name Florence Last name Favrel Feuillade E-Mail [email protected] Position in org. LEAR and director of DRCI (AP-HP) Same as Department Délégation à la Recherche Clinique et à l'Innovation (DRCI) organisation name Same as proposing organisation's address Street Carré historique de l'Hôpital Saint Loui Town Paris Post code 75475 Country France Website https://aphp.fr/ Phone 0144841787 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Guillaume Jondeau [email protected] +xxx xxxxxxxxx Pierre Fenaux [email protected] +xxx xxxxxxxxx Christine Bodemer [email protected] +xxx xxxxxxxxx Jerome Bertherat [email protected] +xxx xxxxxxxxx Marc Humbert [email protected] +xxx xxxxxxxxx Rima Nabbout [email protected] +xxx xxxxxxxxx Catherine Tostain [email protected] +33144841783 H2020-CP-2017 ver 1.00 20180221 Page 175 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name HUS PIC Legal name 951206930 HOPITAUX UNIVERSITAIRES DE STRASBOURG Short name: HUS Address of the organisation Street PLACE DE L HOPITAL 1 Town STRASBOURG CEDEX Postcode 67091 Country France Webpage www.chru-strasbourg.fr Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 176 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name HUS Department(s) carrying out the proposed work Department 1 Department name CARGO (Centre des Affections Rares en Génétique Ophtalmologique) not applicable Same as proposing organisation's address Street PLACE DE L HOPITAL 1 Town STRASBOURG CEDEX Postcode 67091 Country France Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 177 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name HUS Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Helene Last name Dolfus E-Mail [email protected] Position in org. Chief of department Same as Department CARGO (Centre des Affections Rares en Génétique Ophtalmologique) organisation name Same as proposing organisation's address Street PLACE DE L HOPITAL 1 Town STRASBOURG CEDEX Post code 67091 Country France Website http://www.chru-strasbourg.fr/Les-centres-de-reference/Affections Phone +33 3 88 11 67 55 Phone 2 +33 3 88 11 64 81 Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Dorothe Leroux [email protected] +33388116997 Christophe Masutti [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 178 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CLB PIC Legal name 998171032 CENTRE ANTICANCEREUX LEON BERARD Short name: CLB Address of the organisation Street RUE LAENNEC 28 Town LYON Postcode 69373 Country France Webpage www.centreleonberard.fr Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................01/01/1998 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 179 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CLB Department(s) carrying out the proposed work Department 1 Department name Oncology not applicable Same as proposing organisation's address Street RUE LAENNEC 28 Town LYON Postcode 69373 Country France Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 180 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CLB Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Jean-Yves Last name Blay E-Mail [email protected] Position in org. Prof of Medical oncology & General director Same as Department Oncology organisation name Same as proposing organisation's address Street RUE LAENNEC 28 Town LYON Post code 69373 Country France Website www.centreleonberard.fr Phone +33478785126 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Cecile Marini [email protected] +33478782603 H2020-CP-2017 ver 1.00 20180221 Page 181 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UKL-HD PIC Legal name 999841081 UNIVERSITAETSKLINIKUM HEIDELBERG Short name: UKL-HD Address of the organisation Street IM NEUENHEIMER FELD 672 Town HEIDELBERG Postcode 69120 Country Germany Webpage Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................unknown International organisation of European interest ........unknown Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................unknown Enterprise Data SME self-declared status...........................................24/03/2016 - no SME self-assessment ...............................................24/03/2016 - no SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 182 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UKL-HD Department(s) carrying out the proposed work Department 1 Department name Center for Pediatrics and Adolescent Medicine not applicable Same as proposing organisation's address Street Im Neuenheimer Feld 430 Town Heidelberg Postcode 69120 Country Germany Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 183 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name UKL-HD Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Franz Last name Schaefer E-Mail [email protected] Position in org. Head of Division of Pediatric Nephrology Same as Department Center for Pediatrics and Adolescent Medicine organisation name Same as proposing organisation's address Street Im Neuenheimer Feld 430 Town Heidelberg Post code 69120 Country Germany Website https://www.klinikum.uni-heidelberg.de/Schaefer.3888.0.html Phone +4915254582519 Phone 2 +49 6221 5632396 Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Martina Manns [email protected] +49 6221 56-8438 H2020-CP-2017 ver 1.00 20180221 Page 184 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name EKUT PIC Legal name 999991916 EBERHARD KARLS UNIVERSITAET TUEBINGEN Short name: EKUT Address of the organisation Street GESCHWISTER-SCHOLL-PLATZ Town TUEBINGEN Postcode 72074 Country Germany Webpage www.uni-tuebingen.de Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................23/12/1476 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 185 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name EKUT Department(s) carrying out the proposed work Department 1 Department name Institute for Medicial Genetics and Applied Genomics not applicable Same as proposing organisation's address Street Calwerstr. 7 Town Tübingen Postcode 72076 Country Germany Department 2 Department name Rare Disease Centre not applicable Same as proposing organisation's address Street Calwerstr. 7 Town Tübingen Postcode 72076 Country Germany Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 186 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name EKUT Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Olaf Last name Riess E-Mail [email protected] Position in org. Head of Institute Same as Department Institute for Medicial Genetics and Applied Genomics organisation name Same as proposing organisation's address Street GESCHWISTER-SCHOLL-PLATZ Town TUEBINGEN Post code 72074 Country Germany Website [email protected] Phone +4970712976458 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Holm Graessner [email protected] +4970712985944 H2020-CP-2017 ver 1.00 20180221 Page 187 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name GUF PIC Legal name 999978724 JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN Short name: GUF Address of the organisation Street THEODOR W ADORNO PLATZ 1 Town FRANKFURT AM MAIN Postcode 60629 Country Germany Webpage www.uni-frankfurt.de Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................05/11/2007 - no SME self-assessment ...............................................05/11/2007 - no SME validation sme...................................................05/11/2007 - no Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 188 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name GUF Department(s) carrying out the proposed work Department 1 Department name Medical Informatics Group not applicable Same as proposing organisation's address Street Theodor Stern Kai 7 Town Frankfurt am Main Postcode 60596 Country Germany Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 189 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name GUF Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Thomas Last name Wagner E-Mail [email protected] Position in org. Head of FRZSE Same as Department FRZSE organisation name Same as proposing organisation's address Street Theodor Stern Kai 7 Town Frankfurt am Main Post code 60596 Country Germany Website www.frzse.de Phone +49 69 6301 87899 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Holger Storf [email protected] +xxx xxxxxxxxx Sabine Monz [email protected] +49 69 798 17264 H2020-CP-2017 ver 1.00 20180221 Page 190 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name HSK PIC Legal name 918199964 HELIOS DR. HORST SCHMIDT KLINIKEN WIESBADEN GMBH Short name: HSK Address of the organisation Street LUDWIG ERHARD STRASSE 100 Town WIESBADEN Postcode 65199 Country Germany Webpage Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................no International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................yes Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 191 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name HSK Department(s) carrying out the proposed work Department 1 Department name Center for Rare Diseases not applicable Same as proposing organisation's address Street LUDWIG ERHARD STRASSE 100 Town WIESBADEN Postcode 65199 Country Germany Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 192 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name HSK Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Maurizio Last name Scarpa E-Mail [email protected] Position in org. Director Center for Rare Diseases, Coordinator MetabERN Same as Department HELIOS DR. HORST SCHMIDT KLINIKEN WIESBADEN GMBH organisation name Same as proposing organisation's address Street LUDWIG ERHARD STRASSE 100 Town WIESBADEN Post code 65199 Country Germany Website Phone +393480330390 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Beate Paschen [email protected] +393480330390 H2020-CP-2017 ver 1.00 20180221 Page 193 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name IOR PIC Legal name 999445709 ISTITUTO ORTOPEDICO RIZZOLI Short name: IOR Address of the organisation Street VIA DI BARBIANO 1/10 Town BOLOGNA Postcode 40136 Country Italy Webpage www.ior.it Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................01/01/1900 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 194 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name IOR Department(s) carrying out the proposed work Department 1 Department name Department of Medical Genetics anProgrammes Management Departmen not applicable Same as proposing organisation's address Street VIA DI BARBIANO 1/10 Town BOLOGNA Postcode 40136 Country Italy Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 195 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name IOR Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Luca Last name Sangiorgi E-Mail [email protected] Position in org. Head of Department Same as Department Department of Medical Genetics and Rare Orthopaedic Diseases organisation name Same as proposing organisation's address Street VIA DI BARBIANO 1/10 Town BOLOGNA Post code 40136 Country Italy Website http://www.ior.it/en/curarsi-al-rizzoli/medical-genetics-and-rare Phone +390516366519 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Andrea Rizzi [email protected] +390516366923 Luigi Pilolli [email protected] +xxx xxxxxxxxx Matias Ignacio de la Calle [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 196 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AOUP PIC Legal name 988322040 AZIENDA OSPEDALIERO UNIVERSITARIA PISANA Short name: AOUP Address of the organisation Street VIA ROMA 67 Town PISA Postcode 56123 Country Italy Webpage http://www.ao-pisa.toscana.it/ Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 197 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AOUP Department(s) carrying out the proposed work Department 1 Department name Rheumatology Unit not applicable Same as proposing organisation's address Street VIA ROMA 67 Town PISA Postcode 56123 Country Italy Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 198 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AOUP Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Marta Last name Mosca E-Mail [email protected] Position in org. Chief of Rheumatology Unit Same as Department Rheumatology Unit organisation name Same as proposing organisation's address Street VIA ROMA 67 Town PISA Post code 56123 Country Italy Website http://www.ao-pisa.toscana.it/ Phone +390502218289 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Sara Cannizzo [email protected] +393284930483 H2020-CP-2017 ver 1.00 20180221 Page 199 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AOUS PIC Legal name 952725368 AZIENDA OSPEDALIERA UNIVERSITARIA SENESE Short name: AOUS Address of the organisation Street STRADA DELLE SCOTTE 14 Town SIENA Postcode 53100 Country Italy Webpage www.ao-siena.toscana.it Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................12/04/1994 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 200 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AOUS Department(s) carrying out the proposed work Department 1 Department name Medical Genetics Unit not applicable Same as proposing organisation's address Street Viale Bracci 2 Town Siena Postcode 53100 Country Italy Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 201 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AOUS Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Alessandra Last name Renieri E-Mail [email protected] Position in org. Director of Unit Same as Department Medical Genetics Unit organisation name Same as proposing organisation's address Street Viale Bracci 2 Town Siena Post code 53100 Country Italy Website http://www.ao-siena.toscana.it/ Phone +39 0577585316 Phone 2 +xxx xxxxxxxxx Fax +39 0577233325 H2020-CP-2017 ver 1.00 20180221 Page 202 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name LUMC PIC Legal name 999990849 ACADEMISCH ZIEKENHUIS LEIDEN Short name: LUMC Address of the organisation Street ALBINUSDREEF 2 Town LEIDEN Postcode 2333 ZA Country Netherlands Webpage www.lumc.nl Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................yes Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 203 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name LUMC Department(s) carrying out the proposed work Department 1 Department name Human Genetics not applicable Same as proposing organisation's address Street ALBINUSDREEF 2 Town LEIDEN Postcode 2333 ZA Country Netherlands Department 2 Department name Endocrinology not applicable Same as proposing organisation's address Street ALBINUSDREEF 2 Town LEIDEN Postcode 2333 ZA Country Netherlands Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 204 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name LUMC Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Marco Last name Roos E-Mail [email protected] Position in org. Assistant Professor Same as Department Human Genetics organisation name Same as proposing organisation's address Street ALBINUSDREEF 2 Town LEIDEN Post code 2333 ZA Country Netherlands Website https://www.lumc.nl/org/humane-genetica/research/research-line-3/ Phone +31-71-526 8642 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Alberto Pereira Arias [email protected] +xxx xxxxxxxxx Ruth Esveld [email protected] +31 71 5297353 H2020-CP-2017 ver 1.00 20180221 Page 205 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name Radboudumc PIC Legal name 999992110 STICHTING KATHOLIEKE UNIVERSITEIT Short name: Radboudumc Address of the organisation Street GEERT GROOTEPLEIN NOORD 9 Town NIJMEGEN Postcode 6525 EZ Country Netherlands Webpage www.ru.nl Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................31/07/1905 - no SME self-assessment ...............................................31/07/1905 - no SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 206 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name Radboudumc Department(s) carrying out the proposed work Department 1 Department name Department of Genetics not applicable Same as proposing organisation's address Street Geert Grooteplein zuid 10 Town Nijmegen Postcode 6525GA Country Netherlands Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 207 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name Radboudumc Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Nicoline Last name Hoogerbrugge E-Mail [email protected] Position in org. Professor Heriditary Cancers Same as Department Department of Genetics organisation name Same as proposing organisation's address Street Geert Grooteplein zuid 10 Town Nijmegen Post code 6525GA Country Netherlands Website https://www.radboudumc.nl Phone +31243666205 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Martijn Gerretsen [email protected] +31616603224 H2020-CP-2017 ver 1.00 20180221 Page 208 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AMC PIC Legal name 998732274 Academisch Medisch Centrum bij de Universiteit van Amsterdam Short name: AMC Address of the organisation Street MEIBERGDREEF 9 Town AMSTERDAM Postcode 1105AZ Country Netherlands Webpage www.amc.nl Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................unknown International organisation of European interest ........unknown Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................30/10/2008 - no SME self-assessment ............................................... unknown SME validation sme...................................................30/10/2008 - no Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 209 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AMC Department(s) carrying out the proposed work Department 1 Department name Department of Cardiology not applicable Same as proposing organisation's address Street MEIBERGDREEF 9 Town AMSTERDAM Postcode 1105AZ Country Netherlands Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 210 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name AMC Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Arthur A.M. Last name Wilde E-Mail [email protected] Position in org. Head of Department of Cardiology Same as Department Department of Cardiology organisation name Same as proposing organisation's address Street MEIBERGDREEF 9 Town AMSTERDAM Post code 1105AZ Country Netherlands Website www.amc.nl Phone +3120 56 63072 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Franck J.M. Groen [email protected] +31 20 56 63198 Ronald Cornet [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 211 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ERASMUS MC PIC Legal name 999988424 ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM Short name: ERASMUS MC Address of the organisation Street S GRAVENDIJKWAL 230 Town ROTTERDAM Postcode 3015 CE Country Netherlands Webpage www.erasmusmc.nl Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................11/09/2008 - no SME self-assessment ............................................... unknown SME validation sme...................................................11/09/2008 - no Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 212 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ERASMUS MC Department(s) carrying out the proposed work Department 1 Department name Department of Plastic and Reconstructive Surgery not applicable Same as proposing organisation's address Street S GRAVENDIJKWAL 230 Town ROTTERDAM Postcode 3015 CE Country Netherlands Department 2 Department name Department of Pediatric Surgery not applicable Same as proposing organisation's address Street S GRAVENDIJKWAL 230 Town ROTTERDAM Postcode 3015 CE Country Netherlands Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 213 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ERASMUS MC Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Irene Last name Mathijssen E-Mail [email protected] Position in org. Head of Department and plastic surgeon at Erasmus Medical Centre. Profess Same as Department Department of Plastic and Reconstructive Surgery organisation name Same as proposing organisation's address Street S GRAVENDIJKWAL 230 Town ROTTERDAM Post code 3015 CE Country Netherlands Website https://www.erasmusmc.nl/ Phone +31 655758441 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Renee De Ruiter [email protected] +31 10 7031825 René Wijnen [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 214 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name SERMAS PIC Legal name 999481987 SERVICIO MADRILENO DE SALUD Short name: SERMAS Address of the organisation Street PLAZA CARLOS TRIAS BERTRAN 7 Town MADRID Postcode 28020 Country Spain Webpage http://cort.as/10Yf Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status...........................................08/04/2016 - no SME self-assessment ............................................... unknown SME validation sme...................................................13/01/2009 - no Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 215 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name SERMAS Department(s) carrying out the proposed work Department 1 Department name Immunology Department not applicable Same as proposing organisation's address Street Paseo de la Castellana 261 Town Madrid Postcode 28046 Country Spain Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 216 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name SERMAS Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Eduardo Last name Lopez-Granados E-Mail [email protected] Position in org. Head of Immunology Department Same as Department TransplantChild Executive Committee organisation name Same as proposing organisation's address Street Paseo de la Castellana 261 Town Madrid Post code 28046 Country Spain Website http://www.madrid.org/cs/Satellite?language=es&pagename=HospitalL Phone +34917277576 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Marisa Tejedor [email protected] +34917277576 H2020-CP-2017 ver 1.00 20180221 Page 217 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name NUTH PIC Legal name 999600521 THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST Short name: NUTH Address of the organisation Street FREEMAN HOSPITAL, HIGH HEATON Town NEWCASTLE-UPON-TYNE Postcode NE7 7DN Country United Kingdom Webpage Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................unknown International organisation of European interest ........unknown Industry (private for profit)..................no Secondary or Higher education establishment .........unknown Research organisation ..............................................unknown Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 218 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name NUTH Department(s) carrying out the proposed work Department 1 Department name Institute of Cellular Medicine not applicable Same as proposing organisation's address Street Faculty of Medical Sciences Newcastle Town Newcastle upon Tyne Postcode NE2 4HH Country United Kingdom Department 2 Department name Faculty of Medical Sciences not applicable Same as proposing organisation's address Street Faculty of Medical Sciences Newcastle Town Newcastle upon Tyne Postcode NE2 4HH Country United Kingdom H2020-CP-2017 ver 1.00 20180221 Page 219 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name NUTH Department 3 Department name Institute of genetic medicine- ERN EURO-NMD not applicable Same as proposing organisation's address Street Central Parkway Town Newcastle upon Tyne Postcode NE1 3BZ Country United Kingdom Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 220 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name NUTH Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Dave Last name Jones E-Mail [email protected] Position in org. Professor of Liver Immunology Same as Department Institute of Cellular Medicine organisation name Same as proposing organisation's address Street Faculty of Medical Sciences Newcastle Town Newcastle upon Tyne Post code NE2 4HH Country United Kingdom Website [email protected] Phone +44 (0) 191 208 7572 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Evangelista Teresinha [email protected] +xxx xxxxxxxxx Andrew Cant [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 221 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name GOSH PIC Legal name 993285918 GREAT ORMOND STREET HOSPITAL FOR CHILDREN NATIONAL HEALTH SERVICE TRUST Short name: GOSH Address of the organisation Street GREAT ORMOND STREET Town LONDON Postcode WC1N 3JH Country United Kingdom Webpage Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status...........................................21/03/1994 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 222 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name GOSH Department(s) carrying out the proposed work Department 1 Department name Neurology not applicable Same as proposing organisation's address Street GREAT ORMOND STREET Town LONDON Postcode WC1N 3JH Country United Kingdom Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 223 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name GOSH Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name J Helen Last name Cross E-Mail [email protected] Position in org. Honorary Consultant in Paediatric Neurology Same as Department Neurology organisation name Same as proposing organisation's address Street GREAT ORMOND STREET Town LONDON Post code WC1N 3JH Country United Kingdom Website www.gosh.org Phone +442079052981 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Kevin Samuel [email protected] +44 207 4059200 H2020-CP-2017 ver 1.00 20180221 Page 224 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name EORTC PIC Legal name 999524861 EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL Short name: EORTC Address of the organisation Street Avenue E. Mounier 83 Town Brussels Postcode 1200 Country Belgium Webpage www.eortc.be Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................01/01/2006 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 225 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name EORTC Department(s) carrying out the proposed work Department 1 Department name Headquarters not applicable Same as proposing organisation's address Street Avenue E. Mounier 83 Town Brussels Postcode 1200 Country Belgium Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 226 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name EORTC Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Mr. Sex Male Female First name Stephane Last name Lejeune E-Mail [email protected] Position in org. Head EU Program Same as Department Headquarters organisation name Same as proposing organisation's address Street Avenue E. Mounier 83 Town Brussels Post code 1200 Country Belgium Website www.eortc.org Phone +3227741075 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 227 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name INFRAFRONTIER PIC Legal name 949754646 INFRAFRONTIER GMBH Short name: INFRAFRONTIER Address of the organisation Street INGOLSTADTER LANDSTRASSE 1 Town NEUHERBERG Postcode 85764 Country Germany Webpage www.infrafrontier.eu Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status...........................................26/05/2013 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 228 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name INFRAFRONTIER Department(s) carrying out the proposed work Department 1 Department name INFRAFRONTIER GMBH not applicable Same as proposing organisation's address Street INGOLSTADTER LANDSTRASSE 1 Town NEUHERBERG Postcode 85764 Country Germany Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 229 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name INFRAFRONTIER Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Martin Last name Hrabe de Angelis E-Mail [email protected] Position in org. Scientific Director Same as Department INFRAFRONTIER GMBH organisation name Same as proposing organisation's address Street INGOLSTADTER LANDSTRASSE 1 Town NEUHERBERG Post code 85764 Country Germany Website www.infrafrontier.eu Phone +498931873302 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Michael Raess [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 230 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name BBMRI PIC Legal name 946597878 BIOBANKS AND BIOMOLECULAR RESOURCESRESEARCH INFRASTRUCTURE CONSORTIUM(B Short name: BBMRI Address of the organisation Street NEUE STIFTINGTALSTRASSE 2/B/6 Town GRAZ Postcode 8010 Country Austria Webpage www.bbmri-eric.eu Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 231 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name BBMRI Department(s) carrying out the proposed work Department 1 Department name BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRAST not applicable Same as proposing organisation's address Street NEUE STIFTINGTALSTRASSE 2/B/6 Town GRAZ Postcode 8010 Country Austria Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 232 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name BBMRI Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Petr Last name Holub E-Mail [email protected] Position in org. Manager Same as Department BIOBANKS AND BIOMOLECULAR RESOURCESRESEARCH INFRASTRU organisation name Same as proposing organisation's address Street NEUE STIFTINGTALSTRASSE 2/B/6 Town GRAZ Post code 8010 Country Austria Website Phone +43 316 34 99 17-18 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Carmen Cristea [email protected] +43 316 34 99 17- Erik Steinfelder [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 233 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ECRIN PIC Legal name 948646712 ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK Short name: ECRIN Address of the organisation Street 5 RUE WATT Town PARIS Postcode 75013 Country France Webpage www.ecrin.org Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 234 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ECRIN Department(s) carrying out the proposed work Department 1 Department name Management office not applicable Same as proposing organisation's address Street 5 RUE WATT Town PARIS Postcode 75013 Country France Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 235 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ECRIN Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Mr. Sex Male Female First name Jacques Last name Demotes E-Mail [email protected] Position in org. General Director Same as Department Management office organisation name Same as proposing organisation's address Street 5 RUE WATT Town PARIS Post code 75013 Country France Website www.ecrin.org Phone +33180058646 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Alicja Szofer-Araya [email protected] +33180058637 H2020-CP-2017 ver 1.00 20180221 Page 236 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name EATRIS PIC Legal name 941506445 EATRIS ERIC Short name: EATRIS Address of the organisation Street DE BOELELAAN 1118 Town AMSTERDAM Postcode 1081 HZ Country Netherlands Webpage www.eatris.eu Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 237 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name EATRIS Department(s) carrying out the proposed work No department involved Department name Name of the department/institute carrying out the work. not applicable Same as proposing organisation's address Street Please enter street name and number. Town Please enter the name of the town. Postcode Area code. Country Please select a country Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 238 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name EATRIS Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Mr. Sex Male Female First name Anton Last name Ussi E-Mail [email protected] Position in org. Operations & Finance Director Same as Department EATRIS ERIC organisation name Same as proposing organisation's address Street DE BOELELAAN 1118 Town AMSTERDAM Post code 1081 HZ Country Netherlands Website www.eatris.eu Phone +31204442254 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Anne-Charlotte Fauvel [email protected] +31 6 50 12 98 94 H2020-CP-2017 ver 1.00 20180221 Page 239 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ELIXIR PIC Legal name 999988230 EUROPEAN MOLECULAR BIOLOGY LABORATORY Short name: ELIXIR Address of the organisation Street Meyerhofstrasse 1 Town HEIDELBERG Postcode 69117 Country Germany Webpage www.embl.org Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................yes International organisation of European interest ........yes Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................17/05/2016 - no SME self-assessment ...............................................17/05/2016 - no SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 240 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ELIXIR Department(s) carrying out the proposed work Department 1 Department name ELIXIR/EMBL-EBI not applicable Same as proposing organisation's address Street Wellcome Genome Campus Town Hinxton,Cambridgeshire Postcode CB10 1SD Country United Kingdom Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 241 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ELIXIR Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Niklas Last name Blomberg E-Mail [email protected] Position in org. Director Same as Department ELIXIR organisation name Same as proposing organisation's address Street Wellcome Genome Campus Town Hinxton,Cambridgeshire Post code CB10 1SD Country United Kingdom Website https://www.elixir-europe.org/ Phone +xxx xxxxxxxxx Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Juan Arenas Marques [email protected] +447784882460 Juan Arenas [email protected] +447784882460 Hannah Hurst [email protected] +xxx xxxxxxxxx grants ebi [email protected] +xxx xxxxxxxxx Jill Rowe [email protected] +xxx xxxxxxxxx Dimitrios Kontostolis [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 242 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name EURORDIS PIC Legal name 965288323 EURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION Short name: EURORDIS Address of the organisation Street RUE DIDOT 96 Town Paris Postcode 75014 Country France Webpage www.eurordis.org Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status...........................................08/04/2016 - no SME self-assessment ...............................................08/04/2016 - no SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 243 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name EURORDIS Department(s) carrying out the proposed work Department 1 Department name Plateforme Maladies Rares not applicable Same as proposing organisation's address Street RUE DIDOT 96 Town Paris Postcode 75014 Country France Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 244 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name EURORDIS Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Virginie Last name Bros-Facer E-Mail [email protected] Position in org. Scientific Director Same as Department Plateforme Maladies Rares organisation name Same as proposing organisation's address Street RUE DIDOT 96 Town Paris Post code 75014 Country France Website https://www.eurordis.org/ Phone +33 1 56 53 52 13 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Patrice Regnier [email protected] +33 1 56 53 52 14 H2020-CP-2017 ver 1.00 20180221 Page 245 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CSO-MOH PIC Legal name 999596156 MINISTRY OF HEALTH Short name: CSO-MOH Address of the organisation Street YIRMIYAHU 39 Town JERUSALEM Postcode 9101002 Country Israel Webpage www.health.gov.il Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 246 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CSO-MOH Department(s) carrying out the proposed work Department 1 Department name Director of Medical Research Department not applicable Same as proposing organisation's address Street YIRMIYAHU 39 Town JERUSALEM Postcode 9101002 Country Israel Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 247 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CSO-MOH Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Irit Last name Allon E-Mail [email protected] Position in org. Director of Medical Research Department Same as Department Ministry of Health organisation name Same as proposing organisation's address Street YIRMIYAHU 39 Town JERUSALEM Post code 9101002 Country Israel Website https://www.health.gov.il/UnitsOffice/PH/Scientist/Pages/default. Phone +xxx xxxxxxxxx Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Elina Kushnir [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 248 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name SNSF PIC Legal name 999540575 SCHWEIZERISCHER NATIONALFONDS ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSC Short name: SNSF Address of the organisation Street Wildhainweg 3 Town Bern Postcode 3012 Country Switzerland Webpage www.snf.ch Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................31/12/2015 - no SME self-assessment ...............................................31/12/2015 - no SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 249 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name SNSF Department(s) carrying out the proposed work Department 1 Department name Department Biology and Medicine not applicable Same as proposing organisation's address Street Wildhainweg 3 Town Bern Postcode 3012 Country Switzerland Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 250 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name SNSF Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Aysim Last name Yilmaz E-Mail [email protected] Position in org. Head of Department Same as Department Department Biology and Medicine organisation name Same as proposing organisation's address Street Wildhainweg 3 Town Bern Post code 3012 Country Switzerland Website www.snf.ch Phone +41 31 3082 330 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 251 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name Blackswan PIC Legal name 909343088 BLACKSWAN Foundation Short name: Blackswan Address of the organisation Street Chemin de la Riaz 11 Town Vuarrens Postcode 1418 Country Switzerland Webpage https://www.blackswanfoundation.ch/en/ Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................unknown Legal person .....................................yes Non-profit ..................................................................unknown International organisation .........................................unknown International organisation of European interest ........unknown Industry (private for profit)..................unknown Secondary or Higher education establishment .........unknown Research organisation ..............................................unknown Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 252 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name Blackswan Department(s) carrying out the proposed work Department 1 Department name BLACKSWAN Foundation not applicable Same as proposing organisation's address Street Chemin de la Riaz 11 Town Vuarrens Postcode 1418 Country Switzerland Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 253 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name Blackswan Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Menzel Last name Olivier E-Mail [email protected] Position in org. Chairman Same as Department BLACKSWAN Foundation organisation name Same as proposing organisation's address Street Chemin de la Riaz 11 Town Vuarrens Post code 1418 Country Switzerland Website https://www.blackswanfoundation.ch/en/ Phone +41 21 887 64 34 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 254 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name TUBITAK PIC Legal name 999587135 TURKIYE BILIMSEL VE TEKNOLOJIK ARASTIRMA KURUMU Short name: TUBITAK Address of the organisation Street Ataturk Bulvari 221 Town ANKARA Postcode 06100 Country Turkey Webpage www.tubitak.gov.tr Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................yes Enterprise Data SME self-declared status...........................................02/12/2008 - no SME self-assessment ............................................... unknown SME validation sme...................................................02/12/2008 - no Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 255 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name TUBITAK Department(s) carrying out the proposed work Department 1 Department name Directorate for International Cooperation Bilateral and Multilate not applicable Same as proposing organisation's address Street Remzi Oguz Arik Mahallesi Tunus Caddesi Town Ankara Postcode 6100 Country Turkey Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 256 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name TUBITAK Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Jale Last name Sahin E-Mail [email protected] Position in org. Senior Expert Same as Department Directorate for International Cooperation Bilateral and Multilateral Relations organisation name Same as proposing organisation's address Street Remzi Oguz Arik Mahallesi Tunus Caddesi No:80 Town Ankara Post code 6100 Country Turkey Website www.tubitak.gov.tr Phone +903122981796 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 257 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ACURARE PIC Legal name 959704421 ACIBADEM MEHMET ALI AYDINLAR UNIVERSITESI Short name: ACURARE Address of the organisation Street İçerenköy Mahallesi Kayışdağı Caddesi No:32 A Town ISTANBUL Postcode 34752 Country Turkey Webpage www.acibadem.edu.tr Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................yes Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 258 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ACURARE Department(s) carrying out the proposed work Department 1 Department name ACURARE-CENTER OF RARE DISEASES AND ORPHAN DRUGS not applicable Same as proposing organisation's address Street KAYISDAGI CADDESI NO 32, ATASEHIR Town ISTANBUL Postcode 34752 Country Turkey Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 259 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name ACURARE Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name OsmanUgur Last name Sezerman E-Mail [email protected] Position in org. FACULTY MEMBER Same as Department ACURARE-CENTER OF RARE DISEASES AND ORPHAN DRUGS organisation name Same as proposing organisation's address Street KAYISDAGI CADDESI NO 32, ATASEHIR Town ISTANBUL Post code 34752 Country Turkey Website www.acibadem.edu.tr/en Phone +902165004056 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Emrah Yasan [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 260 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name HUGEN PIC Legal name 999900930 HACETTEPE UNIVERSITESI Short name: HUGEN Address of the organisation Street HACETTEPE UNIVERSITESI BEYTEPE KAMP Town CANKAYA ANKARA Postcode 06800 Country Turkey Webpage www.hacettepe.edu.tr Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........yes Research organisation ..............................................yes Enterprise Data SME self-declared status........................................... unknown SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 261 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name HUGEN Department(s) carrying out the proposed work Department 1 Department name Center for Genomics and Rare Diseases/Biobank for rare diseases not applicable Same as proposing organisation's address Street Adnan Saygun Street Town Ankara Postcode 6100 Country Turkey Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 262 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name HUGEN Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Prof. Sex Male Female First name Meral Last name OZGUC E-Mail [email protected] Position in org. Scientific Director Same as Department Center for Genomics and Rare Diseases/Biobank for Rare Diseases organisation name Same as proposing organisation's address Street Adnan Saygun Street Town Ankara Post code 6100 Country Turkey Website www.hacettepe.edu.tr Phone +90 0 532 3922240 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 263 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CIHR PIC Legal name 960368386 CANADIAN INSTITUTES OF HEALTH RESEARCH Short name: CIHR Address of the organisation Street ELGIN STREET 9TH FLOOR ADDRESS LOCA Town OTTAWA ONTARIO Postcode K1T 4H8 Country Canada Webpage www.cihr-irsc.gc.ca Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................yes Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status...........................................13/04/2000 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 264 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CIHR Department(s) carrying out the proposed work Department 1 Department name Institute of Genetics not applicable Same as proposing organisation's address Street 3649 Prm Sir-William Osler Town Montreal Postcode H3G 0B1 Country Canada Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 265 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name CIHR Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Richer Last name Etienne E-Mail [email protected] Position in org. Associate Director Same as Department Institute of Genetics organisation name Same as proposing organisation's address Street 3649 Prm Sir-William Osler Town Montreal Post code H3G 0B1 Country Canada Website http://www.cihr-irsc.gc.ca Phone 514-398-2421 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx Other contact persons First Name Last Name E-mail Phone Danièle St-Jean [email protected] +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 266 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FRQS PIC Legal name 963122410 FONDS DE RECHERCHE DU QUEBEC - SANTE Short name: FRQS Address of the organisation Street RUE SHERBROOKE OUEST 500 Town MONTREAL QUEBEC Postcode H3A3C6 Country Canada Webpage www.frqs.gouv.qc.ca Legal Status of your organisation Research and Innovation legal statuses Public body ...............................................................no Legal person .....................................yes Non-profit ..................................................................yes International organisation .........................................no International organisation of European interest ........no Industry (private for profit)..................no Secondary or Higher education establishment .........no Research organisation ..............................................no Enterprise Data SME self-declared status...........................................23/03/2004 - no SME self-assessment ............................................... unknown SME validation sme................................................... unknown Based on the above details of the Beneficiary Registry the organisation is not an SME (small- and medium-sized enterprise) for the call. H2020-CP-2017 ver 1.00 20180221 Page 267 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FRQS Department(s) carrying out the proposed work Department 1 Department name FRQS not applicable Same as proposing organisation's address Street RUE SHERBROOKE OUEST 500 Town MONTREAL QUEBEC Postcode H3A3C6 Country Canada Dependencies with other proposal participants Character of dependence Participant H2020-CP-2017 ver 1.00 20180221 Page 268 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Short name FRQS Person in charge of the proposal The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes. Title Dr. Sex Male Female First name Anne-Cecile Last name Desfaits E-Mail [email protected] Position in org. Director - Programs and Partnerships Same as Department FONDS DE RECHERCHE DU QUEBEC - SANTE organisation name Same as proposing organisation's address Street RUE SHERBROOKE OUEST 500 Town MONTREAL QUEBEC Post code H3A3C6 Country Canada Website frqs.gouv.qc.ca Phone 001-514-873-0463 Phone 2 +xxx xxxxxxxxx Fax +xxx xxxxxxxxx H2020-CP-2017 ver 1.00 20180221 Page 269 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD 3 - Budget No Participant Country (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) Direct Other direct Direct costs of Direct costs of Costs of inkind Indirect Costs Special unit Total Reimburse- Max.EU Requested personnel costs/€ sub- providing contributions /€ costs covering estimated ment rate (%) Contribution / EU not used on the costs/€ contracting/€ financial direct & eligible costs € Contribution/ beneficiary's support to (=0.25(A+B-E)) indirect costs /€ € premises/€ third parties/€ /€ (=A+B+C+D+F (=H*I) +G) ? ? ? ? ? ? ? ? ? ? ? Institut 1 National De La FR 5805841 6953937 310000 1500000 0 3189944,50 0 17759722,50 70 12431805,75 12431805,00 Sante Et De Fonds Zur 2 Förderung Der AT 27000 18850 0 1200000 0 11462,50 0 1257312,50 70 880118,75 524000,00 Wissenschaftli Ait Austrian 3 Institute Of AT 995042 19600 0 0 0 253660,50 0 1268302,50 70 887811,75 887811,00 Technology Ludwig 4 Boltzmann AT 154140 10900 0 0 0 41260,00 0 206300,00 70 144410,00 144410,00 Gesellschaft Fonds 5 National De La BE 35000 14850 0 480000 0 12462,50 0 542312,50 70 379618,75 248260,00 Recherche Fonds Voor 6 Wetenschapp BE 16500 6000 0 1400000 0 5625,00 0 1428125,00 70 999687,50 575425,00 elijk Katholieke 7 Universiteit BE 80400 16786 0 0 0 24296,50 0 121482,50 70 85037,75 85037,00 Leuven Ministry Of 8 Education CZ 0 0 0 1200000 0 0,00 0 1200000,00 70 840000,00 470400,00 Youth And Sotsiaalminist 9 EE 8100 14610 0 75000 0 5677,50 0 103387,50 70 72371,25 55575,00 eerium Suomen 10 FI 18000 18850 0 1200000 0 9212,50 0 1246062,50 70 872243,75 512750,00 Akatemia H2020-CP-2017 ver 1.00 20180221 Page 270 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Agence 11 Nationale De FR 87000 20850 0 6000000 0 26962,50 0 6134812,50 70 4294368,75 2479350,00 La Recherche Fondation 12 Maladies FR 659250 99516 150000 200000 0 189691,50 0 1298457,50 70 908920,25 908920,00 Rares Association 13 Française FR 0 5900 0 0 0 1475,00 0 7375,00 70 5162,50 5162,00 Contre Les Imagine 14 Institut Des FR 21000 5900 0 0 0 6725,00 0 33625,00 70 23537,50 23537,00 Maladies Deutsches 15 Zentrum Fuer DE 269780 26490 0 6000000 0 74067,50 0 6370337,50 70 4459236,25 2686817,00 Luft - Und Universitaetskl 16 DE 492000 17200 0 0 0 127300,00 0 636500,00 70 445550,00 445550,00 inikum Aachen Charite - 17 Universitaetsm DE 338506 26130 0 0 0 91159,00 0 455795,00 70 319056,50 319056,00 edizin Berlin Universitaetskl 18 inikum DE 133768 10900 0 0 0 36167,00 0 180835,00 70 126584,50 126584,00 Freiburg Nemzeti 19 Kutatasi HU 13500 14850 0 400000 0 7087,50 0 435437,50 70 304806,25 190025,00 Fejlesztesi Es The Health 20 Research IE 18000 18610 0 740000 0 9152,50 0 785762,50 70 550033,75 332130,00 Board Ministero Della 21 IT 44000 18850 0 4000000 0 15712,50 0 4078562,50 70 2854993,75 1635350,00 Salute Regione 22 IT 15000 14610 0 300000 0 7402,50 0 337012,50 70 235908,75 152400,00 Toscana Fondazione 23 Regionale Per IT 15000 18610 0 1300000 0 8402,50 0 1342012,50 70 939408,75 547900,00 La Ricerca Fondazione 24 Per La Ricerca IT 190000 13720 0 0 0 50930,00 0 254650,00 70 178255,00 178255,00 Farmacologica Fondazione 25 IT 1006110 62221 15000 0 0 267082,75 0 1350413,75 70 945289,63 945289,00 Telethon H2020-CP-2017 ver 1.00 20180221 Page 271 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Istituto 26 Superiore Di IT 503950 322773 0 0 0 206680,75 0 1033403,75 70 723382,63 723382,00 Sanita Consorzio Per 27 Valutazioni IT 464000 9900 0 0 0 118475,00 0 592375,00 70 414662,50 414662,00 Biologiche E Teddy - 28 European IT 108000 45844 55000 0 0 38461,00 0 247305,00 70 173113,50 173113,00 Network Of Ministero 29 Dell'istruzione, IT 9789 14610 0 400000 0 6099,75 0 430498,75 70 301349,13 185086,00 Dell'universita' Valsts 30 Izglitibas LV 5500 6140 0 0 0 2910,00 0 14550,00 70 10185,00 10185,00 Attistibas Lietuvos 31 LT 3951 14610 0 200000 0 4640,25 0 223201,25 70 156240,88 99388,00 Mokslo Taryba Viesoji Istaiga 32 Vilniaus LT 79250 73166 0 0 0 38104,00 0 190520,00 70 133364,00 133364,00 Universiteto Fonds 33 National De La LU 25794 14610 0 600000 0 10101,00 0 650505,00 70 455353,50 283492,00 Recherche Zorgonderzoe 34 k Nederland NL 249300 24490 0 3800000 0 68447,50 0 4142237,50 70 2899566,25 2899566,00 Zon Academisch 35 Ziekenhuis NL 1518939 49916 0 0 0 392213,75 0 1961068,75 70 1372748,13 1372748,00 Groningen Universiteit 36 NL 670904 37920 0 0 0 177206,00 0 886030,00 70 620221,00 620221,00 Maastricht Narodowe 37 Centrum PL 7500 18850 0 1200000 0 6587,50 0 1232937,50 70 863056,25 499625,00 Badan I Warszawski 38 Uniwersytet PL 51813 41050 0 0 0 23215,75 0 116078,75 70 81255,13 81255,00 Medyczny Gdanski 39 Uniwersytet PL 18000 32103 0 0 0 12525,75 0 62628,75 70 43840,13 43840,00 Medyczny Instytut 40 Pomnik PL 80000 19606 0 0 0 24901,50 0 124507,50 70 87155,25 87155,00 Centrum H2020-CP-2017 ver 1.00 20180221 Page 272 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Fundacao 41 Para A PT 7500 14850 0 300000 0 5587,50 0 327937,50 70 229556,25 143325,00 Ciencia E A Instituto 42 Nacional De PT 5130 10900 0 0 0 4007,50 0 20037,50 70 14026,25 14026,00 Saude Dr. Slovenska 43 Akademia SK 13500 14610 0 240000 0 7027,50 0 275137,50 70 192596,25 127005,00 Vied Instituto De 44 Salud Carlos ES 359166 42196 0 1000000 0 100340,50 0 1501702,50 70 1051191,75 765898,00 Iii Fundacio 45 Centre De ES 1158344 37920 0 0 0 299066,00 0 1495330,00 70 1046731,00 1046730,00 Regulacio Universidad 46 Politecnica De ES 375467 14900 0 0 0 97591,75 0 487958,75 70 341571,13 341571,00 Madrid Consorcio 47 Centro De ES 59790 10900 0 0 0 17672,50 0 88362,50 70 61853,75 61853,00 Investigacion Vetenskapsra 48 det - Swedish SE 30000 18610 0 1500000 0 12152,50 0 1560762,50 70 1092533,75 645050,00 Research Verket För 49 Innovationssys SE 22200 18610 0 1000000 0 10202,50 0 1051012,50 70 735708,75 439300,00 tem University Of 50 UK 1517560 45520 0 0 0 390770,00 0 1953850,00 70 1367695,00 1367695,00 Leicester The University 51 UK 72000 7670 0 0 0 19917,50 0 99587,50 70 69711,25 69711,00 Of Liverpool University Of 52 Newcastle UK 70000 5900 0 0 0 18975,00 0 94875,00 70 66412,50 66412,00 Upon Tyne St. Anna 53 Kinderkrebsfor AT 114000 15840 0 0 0 32460,00 0 162300,00 70 113610,00 113610,00 schung Assistance 54 Publique - FR 662000 95110 11250 0 0 189277,50 0 957637,50 70 670346,25 670346,00 Hopitaux De Hopitaux 55 Universitaires FR 0 13600 0 0 0 3400,00 0 17000,00 70 11900,00 11900,00 De Strasbourg H2020-CP-2017 ver 1.00 20180221 Page 273 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Centre 56 Anticancereux FR 18000 14070 0 0 0 8017,50 0 40087,50 70 28061,25 28061,00 Leon Berard Universitaetskl 57 inikum DE 300522 434560 0 0 0 183770,50 0 918852,50 70 643196,75 643196,00 Heidelberg Eberhard 58 Karls DE 172778 486092 50000 0 0 164717,50 0 873587,50 70 611511,25 611511,00 Universitaet Johann 59 Wolfgang DE 1118961 41670 0 0 0 290157,75 0 1450788,75 70 1015552,13 1015552,00 Goethe- Helios Dr. 60 Horst Schmidt DE 170080 20900 0 0 0 47745,00 0 238725,00 70 167107,50 167107,00 Kliniken Istituto 61 Ortopedico IT 72916 15840 0 0 0 22189,00 0 110945,00 70 77661,50 77661,00 Rizzoli Azienda 62 Ospedaliero IT 0 14070 0 0 0 3517,50 0 17587,50 70 12311,25 12311,00 Universitaria Azienda 63 Ospedaliera IT 10185 14070 0 0 0 6063,75 0 30318,75 70 21223,13 21223,00 Universitaria Academisch 64 Ziekenhuis NL 1881943 459490 0 0 0 585358,25 0 2926791,25 70 2048753,88 2048753,00 Leiden Stichting 65 Katholieke NL 712907 465540 0 0 0 294611,75 0 1473058,75 70 1031141,13 1031140,00 Universiteit Academisch 66 Medisch NL 620200 46470 0 0 0 166667,50 0 833337,50 70 583336,25 583336,00 Centrum Bij Erasmus 67 Universitair NL 0 28140 0 0 0 7035,00 0 35175,00 70 24622,50 24622,00 Medisch Servicio 68 Madrileno De ES 41250 14070 0 0 0 13830,00 0 69150,00 70 48405,00 48405,00 Salud The Newcastle 69 Upon Tyne UK 5804 42210 0 0 0 12003,50 0 60017,50 70 42012,25 42011,00 Hospitals Nhs Great Ormond 70 Street Hospital UK 71850 15840 0 0 0 21922,50 0 109612,50 70 76728,75 76728,00 For Children H2020-CP-2017 ver 1.00 20180221 Page 274 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD European 71 Organisation BE 0 5900 0 0 0 1475,00 0 7375,00 70 5162,50 5162,00 For Research Infrafrontier 72 DE 197964 10900 0 0 0 52216,00 0 261080,00 70 182756,00 182756,00 Gmbh Biobanks And 73 Biomolecular AT 1776060 75450 0 0 0 462877,50 0 2314387,50 70 1620071,25 1620070,00 Resourcesres Ecrin 74 European FR 468000 10370 0 0 0 119592,50 0 597962,50 70 418573,75 418573,00 Clinical 75 Eatris Eric NL 840000 18830 0 0 0 214707,50 0 1073537,50 70 751476,25 751476,00 European 76 Molecular DE 2070049 101208 0 0 0 542814,25 0 2714071,25 70 1899849,88 1899849,00 Biology Eurordis - 77 European FR 793221 270397 0 0 0 265904,50 0 1329522,50 70 930665,75 930665,00 Organisation Ministry Of 78 IL 175540 21670 0 600000 0 49302,50 0 846512,50 70 592558,75 476942,00 Health Schweizerisch 79 er CH 28500 18850 0 1680000 0 11837,50 0 1739187,50 70 1217431,25 714035,00 Nationalfonds Blackswan 80 CH 0 155900 0 0 0 38975,00 0 194875,00 70 136412,50 136412,00 Foundation Turkiye 81 Bilimsel Ve TR 16250 18850 0 2000000 0 8775,00 0 2043875,00 70 1430712,50 824162,00 Teknolojik Acibadem 82 Mehmet Ali TR 211482 43793 0 0 0 63818,75 0 319093,75 70 223365,63 223365,00 Aydinlar Hacettepe 83 TR 48500 10096 0 0 0 14649,00 0 73245,00 70 51271,50 51271,00 Universitesi Canadian 84 Institutes Of CA 0 0 0 2000000 0 0,00 0 2000000,00 70 1400000,00 0,00 Health Fonds De 85 Recherche Du CA 0 0 0 660000 0 0,00 0 660000,00 70 462000,00 0,00 Quebec - H2020-CP-2017 ver 1.00 20180221 Page 275 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Total 30529246 11416710 591250 43175000 0 10486489,00 0 96198695,00 67339086,57 55089667,00 H2020-CP-2017 ver 1.00 20180221 Page 276 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD 4 - Ethics 1. HUMAN EMBRYOS/FOETUSES Page Does your research involve Human Embryonic Stem Cells (hESCs)? Yes No Does your research involve the use of human embryos? Yes No Does your research involve the use of human foetal tissues / cells? Yes No 2. HUMANS Page Does your research involve human participants? Yes No - Are they volunteers for social or human sciences research? Yes No Are they persons unable to give informed consent? Yes No - Are they vulnerable individuals or groups? Yes No - Are they children/minors? Yes No - Are they patients? Yes No - Are they healthy volunteers for medical studies? Yes No - Does your research involve physical interventions on the study participants? Yes No - Does it involve invasive techniques? Yes No Does it involve collection of biological samples? Yes No If your research involves processing of genetic information, see also section 4. 3. HUMAN CELLS / TISSUES Page Does your research involve human cells or tissues (other than from Human Embryos/ Yes No Foetuses, i.e. section 1)? 4. PERSONAL DATA Page Does your research involve personal data collection and/or processing? Yes No - Does it involve the collection and/or processing of sensitive personal data Yes No (e.g: health, sexual lifestyle, ethnicity, political opinion, religious or philosophical - conviction)? Does it involve processing of genetic information? Yes No - H2020-CP-2017 ver 1.00 20180221 Page 277 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD Does it involve tracking or observation of participants? Yes No - Does your research involve further processing of previously collected personal data Yes No - (secondary use)? 5. ANIMALS Page Does your research involve animals? Yes No 6. THIRD COUNTRIES Page In case non-EU countries are involved, do the research related activities undertaken in Yes No these countries raise potential ethics issues? Do you plan to use local resources (e.g. animal and/or human tissue samples, genetic Yes No material, live animals, human remains, materials of historical value, endangered fauna or flora samples, etc.)? Do you plan to import any material - including personal data - from non-EU countries into Yes No the EU? Do you plan to export any material - including personal data - from the EU to non-EU Yes No countries? In case your research involves low and/or lower middle income countries, are any Yes No benefits-sharing actions planned? Could the situation in the country put the individuals taking part in the research at risk? Yes No 7. ENVIRONMENT & HEALTH and SAFETY Page Does your research involve the use of elements that may cause harm to the Yes No environment, to animals or plants? Does your research deal with endangered fauna and/or flora and/or protected areas? Yes No Does your research involve the use of elements that may cause harm to humans, Yes No including research staff? 8. DUAL USE Page Does your research involve dual-use items in the sense of Regulation 428/2009, Yes No or other items for which an authorisation is required? 9. EXCLUSIVE FOCUS ON CIVIL APPLICATIONS Page Could your research raise concerns regarding the exclusive focus on civil applications? Yes No 10. MISUSE Page Does your research have the potential for misuse of research results? Yes No H2020-CP-2017 ver 1.00 20180221 Page 278 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD 11. OTHER ETHICS ISSUES Page Are there any other ethics issues that should be taken into consideration? Please specify Yes No I confirm that I have taken into account all ethics issues described above and that, if any ethics issues ✖ apply, I will complete the ethics self-assessment and attach the required documents. How to Complete your Ethics Self-Assessment H2020-CP-2017 ver 1.00 20180221 Page 279 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Proposal Submission Forms Proposal ID SEP-210488440 Acronym EJP RD 5 - Call-specific questions Extended Open Research Data Pilot in Horizon 2020 If selected, applicants will by default participate in the Pilot on Open Research Data in Horizon 20201 , which aims to improve and maximise access to and re-use of research data generated by actions. However, participation in the Pilot is flexible in the sense that it does not mean that all research data needs to be open. After the action has started, participants will formulate a Data Management Plan (DMP), which should address the relevant aspects of making data FAIR – findable, accessible, interoperable and re-usable, including what data the project will generate, whether and how it will be made accessible for verification and re-use, and how it will be curated and preserved. Through this DMP projects can define certain datasets to remain closed according to the principle "as open as possible, as closed as necessary". A Data Management Plan does not have to be submitted at the proposal stage. Furthermore, applicants also have the possibility to opt out of this Pilot completely at any stage (before or after the grant signature). In this case, applicants must indicate a reason for this choice (see options below). Please note that participation in this Pilot does not constitute part of the evaluation process. Proposals will not be penalised for opting out. We wish to opt out of the Pilot on Open Research Data in Horizon 2020. Yes No Further guidance on open access and research data management is available on the participant portal: http://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/open-access-dissemination_en.htm and in general annex L of the Work Programme. 1 According to article 43.2 of Regulation (EU) No 1290/2013 of the European Parliament and of the Council, of 11 December 2013, laying down the rules for participation and dissemination in "Horizon 2020 - the Framework Programme for Research and Innovation (2014-2020)" and repealing Regulation (EC) No 1906/2006. H2020-CP-2017 ver 1.00 20180221 Page 280 of 280 Last saved 18/04/2018 17:41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. EUROPEAN JOINT PROGRAMME ON RARE DISEASES 1. EXCELLENCE ......................................................................................................................................................................... 3 1.1 Rare Diseases burden in Europe ...............................................................................................................................................................................3 1.2 Efforts deployed by the European Union and Member States so far............................................................................................................3 1.3 Key policy recommendations ....................................................................................................................................................................................5 1.4 Major challenges to overcome ...................................................................................................................................................................................5 1.5 Objectives of the European Joint Programme on Rare Diseases ...................................................................................................................5 1.6. Relation to the work programme .............................................................................................................................................................................6 1.7. Concept and methodology .........................................................................................................................................................................................7 1.8 Ambition ........................................................................................................................................................................................................................ 11 2. IMPACT ................................................................................................................................................................................... 13 2.1 Expected impacts ........................................................................................................................................................................................................ 13 2.1.1. Barriers / obstacles................................................................................................................................................................................................ 17 2.1.2. Framework conditions .......................................................................................................................................................................................... 18 2.2 Measures to maximize impact ................................................................................................................................................................................ 19 2.2.1 Dissemination and exploitation of results ....................................................................................................................................................... 19 2.2.2 Communication activities ..................................................................................................................................................................................... 19 2.2.3 Data Management Plan ......................................................................................................................................................................................... 19 2.2.4 Dissemination and communication Plan ......................................................................................................................................................... 19 3. IMPLEMENTATION ............................................................................................................................................................. 27 3.1a. List of workpackages ............................................................................................................................................................................................. 31 3.1b: Work packages description .................................................................................................................................................................................. 31 3.1c: List of deliverables .................................................................................................................................................................................................. 76 3.2. Management structure, milestones and procedures ........................................................................................................................................ 81 Table 3.2a: List of milestones ........................................................................................................................................................................................ 85 Table 3.2b: Critical risks for implementation ........................................................................................................................................................... 88 3.3: Consortium as a whole ............................................................................................................................................................................................. 92 3.4: Resources to be committed..................................................................................................................................................................................... 94 Table 3.4a: Summary of staff effort (per participants and per WP) .................................................................................................................. 95 Table 3.4b: ‘Other direct cost’ items (travel, equipment, other goods and services, large research infrastructures) ....................... 98 Partner Countr N° Participant organisation name Acronym y 1 INSERM INSTITUT NATIONAL DE LA SANTE DE DE LA RECHERCHE MEDICALE FR 2 FWF FONDS ZUR FÖRDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG AT 3 AIT AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH AT 4 LBG (LBI-RUD) LUDWIG BOLTZMANN GESELLSCHAFT GMBH AT 5 FNRS FOND DE LA RECHERCHE SCIENTIFIQUE-FNRS BE 6 FWO FONDS VOOR WETENSCHAPPELIJK ONDERZOEK - VLAANDEREN BE 7 KULeuven KU LEUVEN (UNIVERSITY OF LEUVEN) BE 8 MEYS MINISTRY OF EDUCATION YOUTH AND SPORT CZ 9 MoSAE MINISTRY OF SOCIAL AFFAIRS OF ESTONIA EE 10 AKA SUOMEN AKATEMIA FI 11 ANR AGENCE NATIONALE DE LA RECHERCHE FR FONDATION MALADIES RARES - FRENCH FOUNDATION FOR RARE 12 FFRD FR DISEASES 13 AFM ASSOCIATION FRANÇAISE CONTRE LES MYOPATHIES FR IMAGINE - INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS 14 IMAGINE FR MALADES 15 DLR DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV DE 16 UKA UNIVERSITAETSKLINIKUM AACHEN DE 17 CHARITE CHARITE - UNIVERSITÄTSMEDIZIN BERLIN DE UKLFR 18 DE (Freiburg) UNIVERSITAETSKLINIKUM FREIBURG 19 NKFIH NEMZETI, KUTATASI, FEJLESZTESI ES INNOVACIOS HIVATAL HU 20 HRB HEALTH RESEARCH BOARD IE 21 IT MoH MINISTRY OF HEALTH IT 1 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. 22 RT (TuscReg) TUSCANY REGION - REGIONE TOSCANA IT 23 FRRB FONDAZIONE REGIONALE PER LA RICERCA BIOMEDICA IT 24 FGB FONDAZIONE PER LA RICERCA FARMACOLOGICA GIANNI BENZI ONLUS IT 25 FTELE FONDAZIONE TELETHON IT 26 ISS ISTITUTO SUPERIORE DI SANITA IT 27 CVBF CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE IT TEDDY- EUROPEAN NETWORK OF EXCELLENCE FOR PAEDIATRIC CLINICAL 28 TEDDY IT RESEARCH 29 MIUR MINISTERO DELL'ISTRUZIONE, DELL'UNIVERSITA E DELLA RICERCA IT 30 VIAA (SEDA) VALSTS IZGLITIBAS ATTISTIBAS AGENTURA LV 31 LMT (RCL) LIETUVOS MOKSLO TARYBA LT 32 VUHSK VILNIUS UNIVERSITY HOSPITAL SANTAROS KLINIKOS LT 33 FNR FONDS NATIONAL DE LA RECHERCHE LU 34 ZON (ZonMw) ZORGONDERZOEK NEDERLAND NL 35 UMCG ACADEMISCH ZIEKENHUIS GRONINGEN NL 36 UM UNIVERSITEIT MAASTRICHT NL 37 NCBR NATIONAL CENTRE FOR RESEARCH AND DEVELOPMENT PL 38 MUW MEDICAL UNIVERSITY OF WARSAW (POLAND) PL 39 MUG GDANSKI UNIWERSYTET MEDYCZNY (MEDICAL UNIVERSITY GDANSK) PL 40 IPCZD (CMHI) INSTYTUT "POMNIK- CENTRUM ZDROWIA DZIECKA" PL 41 FCT FUNDAÇÃO PARA A CIENCIA E A TECNOLOGIA PT 42 INSA INSTITUTO NACIONAL DE SAUDE DOUTOR RICARDO JORGE, I.P. PT 43 SAS SLOVAK ACADEMY OF SCIENCES SK 44 ISCIII INSTITUTO DE SALUD CARLOS III / INSTITUTE OF HEALTH CARLOS III ES 45 CNAG-CRG FUNDACIO CENTRE DE REGULACIO GENOMICA ES 46 UPM UNIVERSIDAD POLITECNICA DE MADRID ES 47 CIBER CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED, M.P. ES 48 SRC SWEDISH RESEARCH COUNCIL SE 49 Vinnova VINNOVA SE 50 ULEIC UNIVERSITY OF LEICESTER UK 51 ULIV UNIVERSITY OF LIVERPOOL UK 52 UNEW UNIVERSITY OF NEWCASTLE UPON TYNE UK 53 CCRI ST. ANNA KINDERKREBSFORSCHUNG AT 54 APHP ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR 55 HUS HOPITAUX UNIVERSITAIRES DE STRASBOURG FR 56 CLB CENTRE LEON BERARD FR 57 UKL-HD UNIVERSITAETSKLINIKUM HEIDELBERG DE 58 EKUT EBERHARD KARLS UNIVERSITÄT TÜBINGEN DE 59 GUF GOETHE UNIVERSITÄT FRANKFURT DE 60 HSK HELIOS DR. HORST SCHMIDT KLINIK GMBH DE 61 IOR ISTITUTO ORTOPEDICO RIZZOLI - IRCCS IT 62 AOUP AZIENDA OSPEDALIERO UNIVERSITARIA PISANA IT 63 AOUS AZIENDA OSPEDALIERA UNIVERSITARIA SENESE IT ACADEMISCH ZIEKENHUIS LEIDEN / LEIDEN UNIVERSITY MEDICAL 64 LUMC CENTER NL 65 RUMC STICHTING KATHOLIEKE UNIVERSITEIT NL 66 AMC ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL 67 Erasmus MC ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL 68 SERMAS SERVICIO MADRILEÑO DE SALUD ES 69 NUTH THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST UK 70 GOSH GREAT ORMOND STREET HOSPITAL UK 2 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. 71 EORTC EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER EU org INFRAFRONTI EU 72 ER INFRAFRONTIER GMBH Infra EU 73 BBMRI BBMRI-ERIC Infra ECRIN/PedCRI EU 74 N EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK Infra EU 75 EATRIS EATRIS-ERIC Infra EUROPEAN MOLECULAR BIOLOGYLABORATORY (FORELIXIR ANDEMBL- EU 76 ELIXIR EBI) Infra 77 EURORDIS EURORDIS-RARE DISEASES EUROPE EU org 78 CSO/MoH CHIEF SCIENTIST OFFICE - MINISTRY OF HEALTH IL 79 SNSF SWISS NATIONAL SCIENCE FOUNDATION CH 80 BLACKSWAN BLACKSWAN CH 81 TUBITAK TÜBITAK TURKIYE BILIMSEL VE TEKNOLOJIK ARASTIRMA KURUMU TK ACU/ACURAR 82 E ACIBADEM UNIVERSITY TK HUGEN 83 (HACETTEPE) HACETTEPE UNIVERSITY TK 84 CIHR CANADIAN INSTITUTES OF HEALTH RESEARCH CA 85 FRQS FONDS DE RECHERCHE DU QUEBEC - SANTE CA 1. EXCELLENCE 1.1 Rare Diseases burden in Europe Rare Diseases (RDs) are life threatening or chronically debilitating conditions from which fewer than five affected persons per 10,000 citizens in the European Union (EU) suffer. It is estimated that 6,000-8,000 different RDs exist, affecting between 6% and 8% of the population in the course of their lives. Many RDs manifest in childhood, affect patient’s life-long and are not curable with current interventions or medications, resulting in high medical need and immense costs for health care system, society and families. Whereas the rarity of each disease, the extreme variability of the clinical manifestation, the common affection of different organs, and the lack of broad recognition of RDs would call for clustering of expertise, research on RD remains scarce and scattered in different research and care organizations throughout the EU. This translates into delayed diagnosis, few medicinal products and difficult access to care. That is why RDs are a prime example of a research area that can strongly profit from coordination on a European and international scale. This was recognized in the Council Recommendation of June 8, 2009 on an action in the field of RD (2009/C 151/02), which specifically emphasized that the coordination of Community, national and regional programmes for RD research should be improved. 1.2 Efforts deployed by the European Union and Member States so far Between 2007 and 2017 the European Commission (EC) invested over 874 M€1 in research on RD. The European Commission has supported not only key actions to produce data necessary to improve identification and knowledge on RD under the form of large multinational scientific projects but also strategic and coordination initiatives to provide recommendations on specific areas to support and guide Member States policies on RD. In particular, the EC has supported the International RD Research Consortium (IRDiRC2), a global consortium of funders and organizations (including patient organizations) involved in RD research to address RD grand challenges through collaborative actions such as establishing and providing access to harmonized data and samples, performing the molecular and clinical characterization of RDs, boosting translational, preclinical and clinical research, and streamlining ethical and regulatory procedures. The ambitious goal to deliver 200 new therapies for RDs by 2020 has already been met and means for RD diagnosis have greatly improved since IRDiRC was founded. IRDiRCs new vision is to provide diagnosis for most RD patients within a year of first sub-specialty medical consultation and 1000 new therapies by 2027. The EC supports several associated projects like RD-Connect3, a global infrastructure project that links up omics databases, registries, biobanks and clinical bioinformatics data used in RD research into a central resource for 1 Communicated by the EC for FP7 and H2020 2014-2015 2 http://www.irdirc.org 3 rd-connect.eu/ 3 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. researchers worldwide or RareBestPractices4, which is a platform to improve the management of RD patients by disseminating trustworthy guidelines globally, identifying and prioritizing RD research needs and facilitating timely, effective and efficient translation of research results into patient oriented strategy on the clinical as well as the public health level. Finally, the European Rare Diseases Registries Infrastructure (ERDRI) being developed by the DG Joint Research Centre (JRC) in collaboration with DG SANTE will promote and support European-level solutions ensuring interoperability for registries established at the European, national and/or regional level. It will provide a source of information on rare disease patient data with a large transnational coverage. Part of the EC’s comprehensive approach to tackle the RD burden in Europe is to co-finance projects and actions with Member States. An example is the Rare Diseases Joint Action5 (continuation of EUCERD Joint Action initiated in 2011) that has the general objectives to (i) support further development and sustainability of the Orphanet6 database on RD (the biggest repository of information about RD globally co-funded by the EC since 2000), (ii) contribute to solutions to ensure an appropriate codification of RD in health information systems; (iii) continue implementation of the priorities identified in the 2009 Council Recommendation and the 2008 Commission Communication on RD, and (iv) support the work of the Commission Expert Group on Rare Diseases7 by gathering expertise and producing data necessary to its action. An additional important initiative for research on and healthcare for RD is the current development of European Reference Networks8 (ERNs) in which specialists in various disciplines in different countries in Europe join their efforts to treat RD that require highly specialized healthcare and a concentration of knowledge and resources. Although their primary goal is the development of cross-border health care, ERNs have often evolved from European research networks and their outstanding gathering of expertise has the potential, in the future, to support and facilitate translational research in areas such as quality assurance mechanisms for laboratory testing; development of good practice guidelines for diagnosis and care; natural history studies; support to cross-national clinical trials; registries; etc. The landscape cannot be complete without mentioning important efforts of Member States that integrate on one hand direct research funding and on the other support for medical infrastructures providing services to the research community. Since at present, only few European countries fund research on RD through specific dedicated programmes, the funding of transnational collaborative research is the most effective joint activity to enhance the cooperation between scientists working on RD in Europe and beyond, and thus reducing fragmentation of research in this field. The E-Rare, ERA-Net for Research Programmes on Rare Diseases9, was established in 2006 to link responsible funding organizations and ministries that combine the scarce resources for research and thus enable the participation of many researchers to transnational projects via Joint Transnational Calls (JTCs). At the start of E-Rare-1 in 2006 the consortium consisted of eight countries and extended in the following years. Today, E-Rare-3 is a network of twenty-eight partners – public bodies, ministries and research funding organizations – from twenty countries: Member States (Austria, Belgium, Czech Republic, Finland, France, Germany, Greece, Hungary, Italy, Latvia, Poland, Portugal, Romania, Spain, The Netherlands), three Associate States (Switzerland, Israel and Turkey) and two non-European countries (Canada and Japan). In addition E-Rare is member of IRDiRC and strongly contributes to its objectives. RD research also benefits from several biomedical and life sciences European Research Infrastructures such as BBMRI, ELIXIR, EU-Openscreen, Eatris, or Infrafrontier and ECRIN, which were developed in the past years through collaborative efforts of Member States. Although not specific for RDs, these infrastructures aim at development of services facilitating researchers access to resources and knowledge and to contribute to sharing of data and avoiding duplication of efforts. Finally, Rare disease research can take full advantage of cutting-edge data- focused initiatives in current European policy, including the European Open Science Cloud (EOSC)10, which aims to accelerate and support the current transition to more effective Open Science and Open Innovation in the Digital Single Market and to enable trusted access to services, systems and the re-use of shared scientific data across disciplinary, social and geographical borders. The very rarity of RD means that the field has a vast amount to gain from opening up and reuse of research data, and tapping into such major flagship initiatives will help maximize gains for the RD community as early adopters of these cutting edge data stewardship initiatives. 4 www.rarebestpractices.eu/ 5 www.rd-action.eu 6 www.orpha.net/ 7 http://ec.europa.eu/health/rare_diseases/expert_group_en 8 http://ec.europa.eu/health/ern/policy/index_en.htm 9 www.e-rare.eu 10 http://ec.europa.eu/research/openscience/index.cfm?pg=open-science-cloud 4 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. 1.3 Key policy recommendations In 2017 report “Rare Diseases - a major unmet medical need”11 the European Commission pinpoints five key policy recommendations: ● Support integration and networking among EU research, patient and healthcare organisations; ● Adapt implementation of regulatory requirements, especially for clinical trials in rare diseases; ● Develop legally and ethically robust agreements for collecting and exchanging health and genetic data; ● Support health technology assessment, standards and evidence-base for guiding public health policy; ● Collaborate globally through the International Rare Diseases Research Consortium (IRDiRC) to accelerate research on improving the lives of patients with rare diseases. These recommendations, together with identified challenges are the main driving force of the EJP RD. 1.4 Major challenges to overcome Despite significant developments in the RD field over the past years, several challenges still remain. To achieve an integrated strategy for RD research and care there is a need for: ● Sustainable and interoperable organization with established, accepted standards to govern the collection, organisation, sharing and reuse of (health) data and resources that are currently fragmented and/or duplicated (information or samples, omics data, registries and cohorts, national history studies, biobanks, ontologies, inventories, the ethical framework, trial readiness). This includes advanced data sharing and linkage mechanism according to FAIR (Findable, Accessible, Interoperable, Reusable); ● Structured connection of research efforts with European Reference Networks (ERNs). These networks should be well placed to show how standards and tools supported by European infrastructures or developed by the RD community can be efficiently implemented and integrated into healthcare while improving the equity of healthcare provision across the EU on rare diseases, and to improve HTA methodologies so that they can also be fully applied specifically to interventions addressing rare diseases; ● High quality research to identify novel disease mechanisms and to lump diseases based on common pathways; ● Enhanced uptake of research results for translation into tangible outcomes for better health and effective transfer of exploitable results to SMEs and relevant industry sectors, in particular for drug development or repurposing, humanized models, preclinical trials, biomarker development, patient trial readiness and clinical trials; ● Centralized planning and coordination that takes the overall responsibility and disposes necessary means to support the needs of the RD community and reach a greater level of integration, including in EU-13 countries and ensures active and broad participation of European and international research stakeholders in IRDiRC activities and the wide uptake of collaborative results; ● Systematic implication of patient organizations in the design of research and care programming and actions at national and regional levels; ● Effective interaction and training across RD community at all different levels (researchers, practitioners and patients). 1.5 Objectives of the European Joint Programme on Rare Diseases RD research in Europe can be improved to overcome fragmentation, leading to efficacious use of data and resources, faster scientific progress and increase of competitiveness, and most importantly to decrease unnecessary hardship and prolonged suffering of RD patients. In the specific context of the massive generation and need for reuse and efficient interpretation of data, introduction of omics into care practice and the ongoing structuration of RD care centers in European Reference Networks, it appears crucial and timely to maximize the potential of already funded tools, projects and programmes by supporting them further, scaling them up, linking them together, and most importantly, adapting them to the needs of end-users through implementation tests in real settings. Such a concerted effort is necessary to develop a sustainable ecosystem allowing a virtuous circle between RD care, research and medical innovation. To achieve this goal, the European Joint Programme on RD will have two major objectives: • To improve the integration, the efficacy, the production and the social impact of research on RD through the development, demonstration and promotion of Europe-wide and even world-wide sharing of research and clinical data, materials, processes, knowledge and know-how; 11 https://ec.europa.eu/info/sites/info/files/rarediseases_p4p-report_2017.pdf 5 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. • To implement and further develop an efficient model of financial support for all types of research on RD (fundamental, clinical, epidemiological, social, economic, health service) coupled with accelerated exploitation of research results for benefit of patients. Figure 1. The EJP RD concept 1.6. Relation to the work programme The proposed joint programme of activities ranging from research to coordination and networking activities, including training, demonstration and dissemination activities will be structured along five main components ensuring the implementation of a comprehensive and cohesive research and innovation bench to bedside pipeline, fully in line with the Work Programme call SC1-BHC-04-2018 “Rare Disease European Joint Programme Cofund”: ● Pillar 1 “funding collaborative research on RD” will foster joint transnational calls for collaborative research projects resulting in financial support to third parties encompassing various aspects of rare diseases. In addition, the financial support actions will be extended to the Networking Scheme (to encourage sharing of knowledge on rare diseases between clinicians, (biomedical) scientists and patient organizations) and the Rare Disease Research Challenges (innovative funding scheme to foster private-public partnerships and multi- stakeholder collaborations). All calls will be implemented according to standards and good practice of Horizon 2020 including international peer review, Horizon 2020 evaluation criteria, proposal selection following the ranking list etc.; ● Pillar 2 “innovative coordinated access to data and services for transformative RD research” aiming at rationalized, optimized and increased potential of existing resources and services, will develop a FAIR virtual platform for RD information encompassing research data, samples, tools and standards to support and accelerate rare diseases research. The usefulness of the developed tools and their upscaling will be ensured through the direct links with funded research projects (Pillar 1) and new connections across the rare diseases community in particular with European Reference Networks (ERNs). In addition, pilot and proof-of-concept projects will be put in place to enable multidisciplinary, holistic approaches for rare disease diagnostics and therapeutics and fostering creation of complete diseases pathways; ● Pillar 3 “capacity building and empowerment” will be raising the level of knowledge and know-how within the RD research and care community, including through ERNs and RD patient representatives and advocates. To this end, a comprehensive programme of training courses will tackle areas such as research data management, orphan drug development, HTA & regulatory processes, scientific innovation & translational research, best practice guidelines and ERN cross-cutting themes & needs. Activities will involve large groups of stakeholders including adult and paediatric patients. Furthermore, training courses will be developed and adapted to address the specific needs of EU13 countries and to provide capacity building of the different stakeholders on the use of the common platform developed within Pillar 2. Finally, Pillar 3 aims at first-in- Europe online academic course to provide an EU-wide streamlined education programme on RD research to all interested stakeholders; ● Pillar 4 concentrates on“ accelerating the translation of high potential projects and improving outcomes of clinical studies in small populations”. By creating a bridge between basic research and medical innovation, otherwise known as the “bench to bedside” approach, this pillar aims to support the RD community to more 6 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. effectively translate high quality research into high impact interventions for the RD patient community. To demonstrate its efficiency, research projects funded through Pillar 1 and previously by E-Rare will be selected for their translational potential and specifically supported and guided throughout this process. In addition, Pillar 4 will foster the development of innovative methodologies tailored for clinical studies in RDs by specifically supporting ERNs to use the most adapted methodologies improving trial studies in RDs. Demonstration studies will be funded to validate existing and most recently presented innovative methodologies as well as most promising new statistical methodologies; ● Finally, the strategic coordination and management of the EJP RD will constitute the foundation linking all the Pillars together, enabling cross-communication, prioritisation and alignment between different activities. It will encompass annual programming including gap-analysis and identification of research priorities and policy questions in demand for evidence generation, as well as monitoring of the outcome of the EJP RD. Close linkage with IRDiRC will be ensured by integration of the IRDiRC Secretariat in the EJP RD Coordination Office. A specific WP will be dedicated to provide all Pillars with the proper strategy to address ethical, regulatory, legal and Intellectual Property Right (IPR) issues, and will ensure that relevant rules are complied with within the course of the project. Finally, exploitation of EJP RD results, its innovative potential and sustainability will be key aspects, tackled from the start and throughout the course of the programme. 1.7. Concept and methodology The linked approaches and complementary strategic orientation of the four core pillars together with that of the coordination and transversal activities create an overall comprehensive and cohesive structure that will deliver and ensure implementation of the wide range of jointly related activities bridging the gaps and adding value to existing resources and initiatives. The schematic concept of EJP RD is presented in Figure 2. Figure 2. Structure of the EJP RD (coordination, transversal activities and four pillars) COORDINATION AND TRANSVERSAL ACTIVITIES: The EJP RD will be based on the concerted action of 85 beneficiaries and their linked third parties from 23 European (AT, BE, CZ, DE, ES, EE, FI, FR, HU, IE, IT, NL, LT, LV, LU, PL, PT, RO, SE, SK, SV, UK), 4 associated (AM, CH, IL, TK) and 1 non-EU country (CA). In addition institutions from Japan and Australia will participate as “associated partners or “observers”. EJP RD will strive for further inclusion and “openness” at all levels including funding opportunities, Virtual Platform of resources and services, trainings and translation and innovation services. RD stakeholders from all countries involved in the EJP RD will be eligible to profit from offered support and the Virtual Platform will be constructed as fully open source for the benefit of the whole RD community. The EJP RD will be structured around centralised coordination and management, which will focus not only on active and efficient support of the EJP RD partners and planned activities but also will allow necessary overarching governance and implementation of transversal actions that require convergent approach, like communication, EJP RD research and innovation strategy, tackling of ethical, legal and regulatory issues, exploitation of results and IPR and closely related sustainability plan. Furthermore, direct collaboration with Policy 7 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Board of relevant high-level stakeholders (ministries, EC directorates, industry, regulatory agencies and European infrastructures forum) will ensure decisive alignment of national and European strategies and policies. PILLAR 1: COLLABORATIVE RESEARCH FUNDING Notwithstanding the important progress in the Rare Diseases (RD) field, many aspects remain without solutions. The need for fundamental, translational, clinical, social and health services research and most efficient modes of fostering them are therefore still topical. The interdisciplinary cooperative approaches to be addressed through national and EC programmes should be promoted. Since at present, only few European countries fund research on RD through specific dedicated programmes, the funding of transnational collaborative research is the most effective joint activity to enhance the cooperation between scientists working on RD in Europe and beyond, and thus reducing fragmentation of research in this field. Pillar 1 will be based on the strong previous collaboration and reputation of the E-Rare ERA-Net. The activities of E-Rare demonstrated that continuous cooperation of funding organizations, particularly for the implementation of joint transnational calls, influences the alignment of processes, funding procedures and timelines in addition to the gained common knowledge. The high number of proposals received in response to the calls of E-Rare highlights the great potential and diversity of the European RD research community and the need for funding of collaborative projects. The ex-post analysis of projects financed between 2007 and 2011 showed that all of them were able to achieve critical mass of resources necessary to complete their goals. In addition, the consortia demonstrated intensive exchange of samples as well as creation of databases, biobanks, or registries. These “infrastructures” were created either from scratch or by pooling the existing, but disconnected sources. The transnational collaboration within projects translated also through the training and exchange of personnel. Finally, the number of joint publications also confirmed this success: 525 peer review articles were published by 37 consortia with a mean impact factor of 7.32 (range from 0.5 to 59). This confirms that joint research funding and support of RD research is considered as “stimulator” of transnational, enduring partnerships and should be further developed. However, some weaknesses were also pointed out, namely (i) insufficient level of interactions between different types of stakeholders (not only scientists) for the benefit of RD research and (ii) lack of commitment from private investors and industry. Pillar 1 will engage 29 funding bodies from 22 countries and will be open for further integration of new partners. At the moment of submission of this proposal the commitment to two first joint transnational calls reached 37 M€. Further engagement of at least 20 M€ for calls 2021-22 is also planned. Most importantly Pillar 1 takes into account lessons and recommendations learned during previous (E-Rare) years. Therefore, the proposed funding support will be extended beyond joint transnational calls and will encompass the Networking scheme (2 M€) and the Rare Diseases Research Challenges (1.5 M€ of public funding), the latter targeting public-private partnerships. Foreseen funding activities will not only strengthen rare diseases research but also increase its exploitation potential by implementing innovative mechanism of public-private support. Pillar 1 will also expand the collaboration potential beyond the national and EU borders by enabling RD networks and events including partners from and outside EJP RD participating countries. PILLAR 2: INNOVATIVE COORDINATED ACCESS TO DATA AND SERVICES FOR TRANSFORMATIVE RARE DISEASE RESEARCH Despite the significant resources already in place (knowledge bases, databases, registries and infrastructures), the fragmentation and duplication of effort and resources in relation to data, information or samples persist, making efficient and timely use of these resources in RD research challenging. In order to overcome these bottlenecks Pillar 2 will create a sustainable and interoperable ecosystem of resources (the EJP RD virtual platform), coupled to robust standards, tools and procedures that will infuse FAIR principles into advanced and secure forms of data discovery, linkage and sharing. It will allow flexible, real-time access to data (under suitably controlled conditions), with supporting tools and services that serve the ultimate goal of increasing the efficiency and efficacy of RD research. Driven by concrete use-cases and needs arising from the RD clinical and research community, it will provide the means to harmonise and standardise the way RD relevant data, samples and tools are made findable, accessible, interoperable and re-usable, and the means to query the progressively increasing number of resources and repositories connected to the EJP RD virtual platform through a central facility. The EJP RD Pillar 2 will establish a stronger and broader collaboration between the RD community and European Research Infrastructures and global consortia than ever before. This will have major mutual benefit and impact. On one hand RD research, supported by highly motivated patient representatives and ERNs, presents an exemplar challenge and opportunity for research infrastructures to create common solutions and stimulate collaboration. On the other hand, progress in RD research depends on the strongest possible infrastructure to address its needs towards efficient information retrieval and analysis across its distributed data resources. The increased capacity of infrastructures and their seamless integration with RD community will ultimately translate to higher innovation potential and benefit for patients. 8 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. To that point, Pillar 2 will develop three parallel and complementary axes of work, all three governed by consistent quality, regulations and compliance with agreed standards requirements. Moreover, all axes will be driven by research and clinical user community, ensuring that Virtual Platform is built for and adopted by this community. The axes are: • Centralized metadata repository describing pre-existing resources (including catalogs, data repositories, tools and infrastructures12) with RD-specific semantic standards and metadata that conforms to an ontological, machine-readable model that also encompasses consent and data use conditions. This will make resources Findable, and their Accessibility conditions to be known. Furthermore, it will provide guidance and services to produce, store and share phenotype-genotype data for researchers, as well as standards for data processing, generation and deposition of multi-omics data, relevant for RD. More importantly, the involvement of key partner resources to normalise their metadata models, and to harmonise data deposition is already secured; • Federated ecosystem of FAIR-at-the-source resources, in order to enable data discovery, sharing and analysis down to the record level. This axis of work organizes partnering with target resources to make them FAIR compliant, as well as the required interdisciplinary collaboration between RD experts and data experts. Beyond achieving FAIRification of resources in the VP, Pillar 2 will offer to the RD community at large the means and support, including training, to enlarge the scope of the federated ecosystem, by building a sustainable FAIRification service. • Extension of the virtual platform with workflows that allow holistic research based on rare disease data and biological knowledge, by filling gaps in data on disease modifiers such as nutrition and metabolism, aspects of lifestyle and exposure to toxicants with the final aim to improve the understanding of the etiology and progression or rare diseases and to support the discovery of biomarkers and the identification of druggable pathways and targets. This axis of work requires exploitation of previously performed explorative studies and the conduction of proof of principle studies specific for RD. It will be based on important collaboration between European Research Networks and top-level research teams excelling in data mining and interpretation. Relevant connection to Solve-RD project will be also ensured. PILLAR 3: CAPACITY BUILDING & EMPOWERMENT Critical to ensuring equity and optimizing outcomes for people living with rare diseases is integrating RD activities under a common joint education & training programme to raise the level of knowledge and build capacity within the RD community. This is what Pillar 3 of the EJP RD is aiming to achieve by working closely and collaboratively with 45 partners including RD patient representatives (e.g. ePAGs involved in ERNs and young RD patient representatives), several ERNs, academics, researchers, clinical scientists, European Networks (e.g. Orphanet) and European research infrastructures (e.g. BBMRI, ELIXIR). The pooling of existing resources, training initiatives, relevant expertise and experience in RD trainings from the different partners within the central place of the EJP RD will meaningfully facilitate the engagement of the RD community with regulatory bodies, the private sector and the biomedical industry in order to fast-track access and provide diagnosis to unsolved cases as well as facilitate clinical trials and boost drug development of RD therapies. Patient-centered health service is increasingly recognized as a priority in medicines R&D and is a founding principle of the common values in European Union Health Systems, spanning from research to healthcare. In order to build and reinforce partnerships between patients and researchers, current practices need to evolve. This holistic approach will ultimately deliver the improved outcomes for patients and the health system. The key success factor for patient researcher partnerships is building the capability of researchers to engage meaningfully with patients, maintain transparency and build trust thus empowering them to contribute proactively with researchers and help inform research objectives. Consequently, a crucial element for sustainable research and the translation of new knowledge into the health system is to invest in capacity building for effective engagement among all stakeholders. Through this investment, significant opportunities will be created that will enhance the research and innovation capability among all stakeholders, thus enabling effective, patient centered outcomes that address RD patient needs and can be readily adopted within healthcare systems. Pillar 3 will concentrate its activities on developing and delivering a seamless flow of training programmes on key aspects relevant for rare disease research across the RD community. Existing training courses will be expanded further and new ones developed to adequately suit the needs of the RD research community with a specific attention to the needs of ERNs and EU13 countries. Pillar 3 has secured an essential and key asset which is represented by the inclusion of the major players in the European RD landscape as EJP RD partners responsible for developing and updating the training courses according to emerging needs from the community. 12 Catalogs: Orphanet, BBMRI, ERDRI, ELIXIR’s bio.tools; Data repositories: ERNs’ registries, biobanks, RD-Connect’s GPAP; Infrastructures: INFRAFRONTIER, ECRIN, are examples of those. 9 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. The methodology chosen consists of a blended approach of face-to-face courses ranging from short 1 or 2-day workshops to 3 or 5 days residential training and a comprehensive EU-wide online academic RD research training programme. All training courses will be open to all and offered free of charge to interested participants. Researchers funded through Pillar 1 funding schemes and Pillar4- supported researchers and clinicians with specific issues (e.g. IP, regulatory, etc.) will be encouraged to apply and register for the training activities. In addition, 10 to 15% of selected participants will be offered travel and accommodation fellowships enabling a more equitable level of participation among less wealthy EU countries. Successful applicants will be selected using an eligibility matrix including a scoring system based on pre-identified criteria which will be adapted along the course of the EJP RD. Furthermore, several training courses will be changing location each year, hosted by EJP partners based in different countries to ensure wide participation across Europe. The EJP RD represents the unique opportunity to showcase all the relevant education and empowerment activities for RD research under one umbrella. PILLAR 4: ACCELERATING THE TRANSLATION OF HIGH POTENTIAL PROJECTS AND IMPROVING OUTCOMES OF CLINICAL STUDIES IN SMALL POPULATIONS The improvement of outcomes in translational and clinical research by providing on one hand suitable support, mentoring, expertise and improved industrial uptake and on the other hand direct innovative methodologies for RD clinical studies is one of the main goals of the EJP RD. This will be achieved with Pillar 4, which aims to structure a long-term sustainable strategy for improving pipeline productivity and translational research capacities on therapies of RDs working closely with ERNs and other actors in the RD community. There are two main areas in need of urgent attention in the development pathway. Firstly, due to the historical lack of academic incentives, expertise and funding opportunities to perform translational research in all but a handful of RDs combined with large pharmaceutical industry’s retreat from performing early translation (due to the biological complexity and high failure rates), there is a substantial gap that slows or even prevents good science from being efficiently translated into effective interventions for society. Secondly, clinical development of novel interventions for rare diseases is particularly challenging, as they are complex and heterogeneous with lack of suitable patient cohorts, incomplete understanding of outcome measures and natural history. In addition, the small size of many ultra-rare disease populations make pivotal clinical trials difficult and at the same time commercially less viable despite the incentives for the development of therapies for RDs. Improving the development pathway for rare diseases through an integrated development methodology with innovative clinical trial design and statistical analysis methods will help encourage more successful development of life changing drugs for more rare diseases. To achieve these goals Pillar 4 will promulgate three hallmarks of sounds translational research, namely mindset, professional management, and mentoring. This will be achieved through a combination of self-help resources and active in- project support from diverse fields, such as product development, regulatory and commercial. To do so, the expertise of several partners (EATRIS, FTELE, ECRIN, ERNs), will be utilised. An active mentoring programme coordinated by an Innovation Manager assigned to project teams, investigators and funders of Pillar 1 will benefit from active guidance and input into design, development and help in the execution of cutting edge translational and clinical studies. In addition, in close connection with RDR Challenges Pillar 4 will support high potential projects to find resources and expertise of private and for-profit funders and developers, in order to complete the development pathway to the patient. In Europe, several cases show that, despite the limited size of the market, the field of rare diseases is attractive to investors. On the basis of recent examples in Italy, the Netherlands and France, the Pillar 4 will create a roadmap for innovation funding in RD, utilizing blended investment modes that will feed also sustainability strategy. Acceleration of arrival of new therapeutic options to patients passes also by more efficient and reliable clinical studies. Pillar 4 is particularly well armed to tackle this issue as it gathers the capacity and expertise of the European Reference Networks strengthened by know-how of ECRIN and high-level methodologists from IDeAl project. This will be done at three levels: (i) through identification of already existing but not sufficiently used highest methodological standard for clinical trials in RDs and their direct promotion via the powerful network of ERNs and other relevant EJP RD partners; (ii) via demonstrators projects focusing on validation of recently developed methodologies for design and analysis of clinical trials and finally (iii) via design of innovative methodologies in parts of clinical design that were not adequately addressed until now (e.g. more appropriate endpoints allowing better assessment of clinically meaningful responses as PCOMs; validation of composite end points and surrogates; capture in the cohorts of natural history studies efficacy and important safety information through life span; evidence assessment associated with randomization in limited populations; pharmacometric modeling, extrapolation modelling). Pillar 4 will collaborate closely with Pillar 2 to exploit existing data and to deliver validated or new methodological standards to enhance the panel of tools for RD community. Finally, the involvement of funds from the private sector (pharma, SMEs, start ups) and the promotion of rare disease therapies 10 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. as the future of personalized medicine based on particular characteristics of each individual or each small group of individuals will be extensively addressed in this Pillar. Gender/sex aspects: EJP-RD will respect the gender equality and work to keep on a gender balance throughout the project. Sex and gender are captured in the EJP RD project at three levels: In the project management and governance: The gender representation of the partners’ involved at the EJP-RD is well balanced (M/F=52/42). Attention will be taken to keep gender balance in the governance structures (Governing Board and Policy Board) as well as Advisory Ethics, Regulatory & Legal Board. With regards to conduct of research: gender perspective will be integrated in all EJP RD activities in support of gender justice, based on the recognition that a systematic approach to gender in research enhances quality and excellence. All partners, and the consortium as an entity, are committed to recruiting collaborators to the program or training activities without bias of race or gender. Furthermore, gender will be one of the indicators for the assessment of the funded projects in the calls of Pillar 1 and in the pilot projects of Pillar 2 and 4. Special attention will be paid to ensure that extra effort will be performed to try and recruit more women researchers in these projects, and to avoid the loss of women scientists during the transition between junior and higher positions. The equality will be also applied to the trainings offered by Pillar 3. Sex and gender aspects in research activities to be performed: Most rare diseases do not discriminate between males and females. Even for the X-linked diseases that seem to affect mainly males there is more and more evidence that also female carriers may suffer from these conditions. However, sex/gender aspects will be taken into account whenever considered relevant, e.g. (i) in Pillar 1 funded projects; (ii) in Pillar 2 with respect to influence of gender on disease mechanisms being taking into account together with environmental factors in POCs (WP13), as well as gender being represented in metadata describing data collection (WP11&12); (iii) in Pillar 2 for the development of tools of virtual platform that will serve research community; (iv) in Pillar 4 (WP20) demonstration and innovation projects for innovative methodologies to improve outcomes of clinical studies, where sex and gender are crucial elements for natural history registries, PCOMs, etc. 1.8 Ambition The European Joint Programme Cofund is a supreme instrument to grant high-level strategic organization and performance of research activities in an organized and transversal manner. EJP RD will maximize the potential of this European tool, by expanding the panel and potential of involved stakeholders. The commonly involved Programme Owners (ministries) and Programme Managers (Research Performing Organizations) will be accompanied for the first time by funders (Research Funding Organizations), European Research Infrastructures, European Reference Networks, patient organizations, education institutions, and will reach regulatory bodies and private sector. This will ensure the necessary level of integration and unique strategy to efficiently tackle societal challenges specific and relevant for the field of rare diseases. The overarching ambition of the EJP RD is to establish an urgently needed comprehensive strategy covering research, data, tools and clinics leading to optimization and exploitation of results, higher and timely diagnostic rates, faster drug discovery at reduced costs, improved patients’ care, empowering all stakeholders as well as giving Europe a leading role in the field of RD in the coming years. To do so, rare diseases need efficient research paths from patient to “product” (product being standardized diagnostic guidelines, methodological and technology approaches, biomarkers, tools, medicines or devices). Thus, the EJP RD will formalise the development “value chain” for RD in terms of diagnosis and therapies. All stakeholders will have access to a seamless pipeline from patient needs to effective intervention through relevant resources. The current state of the organization of the path from patient to product and respective EJP RD elements are summarised in Figure 3.. In this path, the first step is to identify relevant patients and populations. The second step is to gather information about them. Information gathering involves clinical information, phenotyping and genotyping, but also information beyond the exome (which is integrated through the deployment of multiple –omic technologies). The third step is to extract actionable insights from the information. Then useful insights are harnessed to develop products that are subsequently evaluated. At each step in the value chain there are three key determinants of a success: (i) input (access to facilities); (ii) resources (capability and capacity of staff, equipment and facilities); (iii) outputs and connections to the next step. Currently, for RDs, this value chain is fragmented which leads to gaps, delays, inefficiencies and diseconomies of scale. It also causes significant barriers to entry for the RD patients, researchers and funders. Finally, the challenges are magnified by the dispersed nature of rare diseases patients and expertise. 11 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Figure 3: Current generic value chain for RD “product” development. The EJP RD will develop innovative services through a combination of: (i) improvement of existing components of the value chain (and their adaptation to RD when needed – mainly working with small populations and large effects); (ii) integration through developing a systematic approach to inputs and outputs to each service that improves the accessibility of all services to the RD community. Improvement and integration will be driven by funding projects, pilots and by supporting stakeholders at each step of the value chain. The experience of these projects and pilots will promote changes to the services used during RD products development and the connections between services. The future state is shown in Figure 4. Figure 4: Impact of EJP RD on value chain for RD “product” development. Therefore, the work done by EJP RD will promote consistent links that facilitate collaboration. In addition, these linkages will reduce the risks arising from dispersal and fragmentation providing a robust platform for judgments about funding allocation by research funders and third sector organizations (such as patient organizations funding research). The EJP RD will lead directly to at least 165 projects (transnational, networking, RDR challenges, POCs, demonstrators) that will each push forward the state of the art in their respective topic areas. More fundamentally, these projects will provide proof-of-concept for the joined-up approach that EJP RD will champion. This work will a) reduce barriers to entry for all contributors to the value chain; b) reduce the costs of collaboration; c) increase the benefits gained at each step of the value chain by focusing methodologies on the needs of RD. EJP-RD will increase the value of investment through a combination of shortened timelines, targeted collaborations and optimised methods. This will provide a step change in the value of work on RD product development and increase 12 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. the productivity of existing investment in RD. It will build a comprehensive research environment. It will also attract new funding because of the increased likelihood of good returns on investment. Thus, the EJP RD 360° approach will be a true game changer in a way RD is conducted so as to allow realistic achievement of IRDiRC new ambitious goals. 2. IMPACT 2.1 Expected impacts EJP RD will contribute to: Overall impact: Improved alignment of national/regional activities and policies in RD Rare diseases are capital example where pooling of expertise and resources together with coordination of national and European efforts are game changers. Despite significant efforts employed so far, RD research in Europe can be further improved, to overcome fragmentation, leading to efficacious use of data and resources, faster scientific progress and increase of competitiveness, and most importantly to decrease unnecessary hardship and prolonged suffering of RD patients. To that extent, EJP RD will be the first initiative gathering over ninety partners (and their networks, e.g. only the ERNs by themselves cover 900 healthcare units from near all EU Member States) from 32 countries representing key stakeholders in RD field. The strength of the EJP RD consortium lies not only in the number and diversity of its partners but also in its capacity to exploit the existing elements, detect their weaknesses, improve, innovate and deliver novel more efficient solutions. To efficiently transcribe EJP RD activities and outcomes at regional, national, EU and international levels the EJP RD already involved and will maintain strong connection with relevant policy makers. The governance, research & innovation strategy and prioritization process will be organized around the Policy Board gathering ministries of research & health, relevant EC directorates and other key high-level stakeholders (see section 3.2). In addition, each country will be urged to put in place National Mirror Group (NMG) bringing national partners participating directly in the EJP RD and additional actors of the RD field. The NMDs will be central in identifying, discussing and bringing the national needs to the upper level. Each country will speak with united and single voice. This will be also reflected in the EJP RD Governing Board where each country will possess one vote (in the name of all national stakeholders). The same rule will apply to the EU Research Infrastructures, Patient Organizations, ERNs and charities. Once again EJP RD will capitalize on already existing seminal configurations (e.g. at national level around National Plans for Rare Diseases; for EU research infrastructures within CORBEL project; for ERNs within ERN Board of Coordinators, etc.) and reinforce their (gathering) potential through the EJP RD governance. Such explicit organization fortified by extraordinary commitment of EJP RD partners and RD community in general will be the key to successful alignment of regional/national and EU activities and policies in the field of rare diseases. Specific impact 1: Improve lives of rare disease patients by providing new and optimised treatment options and diagnostic tools for these diseases The contribution of the EJP RD to the improvement of lives of RD patients by providing new and optimised treatment options and diagnostic tools will be achieved as a sum of efforts provided within different pillars and transversal activities strengthened by the central coordination and close linkage with relevant policy stakeholders to translate these efforts at regional, national and EU levels. New and optimised treatment options and diagnostic tools can only emerge from well-organized, coordinated science that includes basic, translational, clinical, social and health economic research. These different types of research will be financed and closely monitored in Pillar 1 thereby accelerating development of diagnostic tools and treatments. Pillar 2 aims at removing obstacles, for both humans and computers, to finding, accessing under well defined conditions, analysing and reusing data across the many resources that are relevant for clinical and biological research on rare diseases. The power of Pillar 2 virtual platform will lie in enabling RD data and tool providers to make their data as usable as possible through FAIR principles. RD researchers and experts will be able to find and exploit most relevant data and tools more rapidly to perform advanced and reproducible analysis allowing better understanding of RD causes, mechanisms and determinants, which will improve ways to diagnose and to treat RD. 13 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. The successful delivery and implementation of Pillar 3 training courses will result in the systematic implication of patient representatives in the design of research, treatment strategies and developments, as well as care programming and actions at European, national and regional levels. By creating an end-to-end pipeline of support and expertise for RD research, Pillar 4’s focus on translating excellent science into effective interventions for RD patients will maximise the patient impact of the EJP RD efforts. By ensuring access to expertise, facilities and funding, the complexities to translation will be ameliorated, while the efforts to develop, demonstrate and disseminate improved clinical study methodologies with a support desk available will substantially improve our ability to develop valuable interventions for small populations and enhance the involvement of ERNs in clinical studies. Specific impact 2: Decrease fragmentation of rare diseases expertise and research resources Through the participation of 85 partners including policy makers, funders, research organizations, ERNs, infrastructures and patients from 32 countries, EJP RD programme is unique in achieving centralised critical mass of expertise and research resources from Europe and beyond. The long standing collaboration (2006 – 2019) of funding agencies in EU member, associated and non-EU states in the ERA-Net E-Rare resulted in ten Joint Transnational Calls funding 117 projects including 556 research teams. Each of these projects proved the capacity to achieve critical mass in pooling resources (data, samples, expertise and patients) to perform high quality research. At least 77% of these projects established long-lasting collaborations, often extended to other research groups and countries. Progressive joining of new countries allowed pooling of national resources and better coordination of research programmes on rare diseases. EJP RD goes beyond E-Rare by integrating of 11 new agencies (total of 29 covering 22 countries) and expanding further the power of international collaboration of funders to support and encourage excellent (national/regional) research groups to collaborate transnationally in the area of rare diseases. Thus, activities of Pillar 1 will be major leverage action to decrease fragmentation and increase potential of expertise and research resources. All Pillar 2 activities focus on centralization and uniform access to resources and expertise. The Virtual Platform of Pillar 2 will provide a single access point to find and query resources through the most important catalogues for RD (e.g. Orphanet, biobank and patient registry catalogues) and tools (customized ELIXIR bio.tools). It will create an ecosystem of RD resources that are FAIR from resource level down to data element level and encompass interoperable solutions for centralised but also decentralised resources. For the first time research resources: data, infrastructures and tools will be accessible in an integrated way. In addition, Pillar 2 will be working through networks of experts from and across different disciplines to address a specific bottleneck (e.g. an interoperability standards, adoption of FAIR principles for particular health data sets). Pillar 3 will provide the training opportunities to a large panel of RD stakeholders: researchers, healthcare providers and patients, thereby contributing to strengthening knowledge and creating new experts. In addition, it will decrease the fragmentation by structuring the organization and access to already available and relevant trainings for the RD community in Europe. Multi-disciplinary, multi-sector collaboration is a hallmark of the Pillar 4 approach, and thus will bring together experts from basic research, product development, ESFRI infrastructures, ERNs, regulatory science, financing and more, and make these available to EJP RD and E-RARE projects to maximise their chance to reach the patient. In so doing, not only European but global level efforts to bring people together RD community will occur. Moreover, P4 brings together clinical and methodological experts from around the world to drive the improvement of clinical study design for small populations and enhance the development of clinical studies for very rare diseases. Specific impact 3: Increase the EU's capacity to innovate in the field of rare diseases 14 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. The EJP RD programme combines massive amount of expertise and capacity not only through its direct partners but also through hundreds of rare disease researchers that will be financed in the joint transnational projects. This increases the opportunities for innovation and for translation into improved diagnostic tools and new or optimized treatments. In addition, the discoveries brought by RD field may serve and be expanded to other medical domains, as the underlying disease mechanisms may also be useful for improved diagnostic and therapeutic solutions for more common diseases. All funding activities of Pillar 1 foster the increase of research and knowledge capacity for rare diseases in Europe. The dedicated Rare Disease Challenge funding scheme will specifically aim at removing general obstacles for innovation in the field of therapeutic research in rare diseases by bringing together public and private stakeholders (academia, SMEs, industry and funders). In addition, the support provided from Pillar 4 to detect exploitation potential in funded projects of Pillar 1 and subsequent accompanying of these projects through translation to clinic steps will contribute to the increase of innovation and competitiveness potential of EU. Pillar 2 will support the increase of EU’s capacity to innovate at different levels: (i) it will maximize the potential of already existing, EU funded facilities and tools, both RD-specific and broader ones (RD-Connect, Orphanet, HPO, ELIXIR, BBMRI, EATRIS, INFRAFRONTIER, etc.) by supporting them further, scaling them up, linking them together and fully tuning them to the needs of end-users; (ii) it will set mechanisms to continuous integration of new data elements, standards and tools so as to provide European research with a unique ecosystem that will efficiently translate research into better care and medical innovation; (iii) by working hand in hand with the European Reference Networks it will bring a unique opportunity to efficiently link healthcare and research opening the road to diagnostics innovation; (iv) furthermore, as omics becomes more prevalent in clinical practice Pillar 2 will develop novel tools and pathways for comprehensive interpretation of data and setting of standards thereby accelerating means to tackle undiagnosed diseases. Providing state-of-the-art education and bringing together different type of stakeholders will enhance the innovation potential of the RD community. In addition, empowering patients and promoting patients’ centered approaches brings attention back to their needs, helps in focusing on relevant priorities and thereby accelerates the process of innovation. In addition, Pillar 3 itself will be source of innovation in training and education field by creating the first EU e-learning academic education programme on RD. EJP RD is structured specifically to improve innovation, and Pillar 4 creates the bridge from basic research to the clinic and back, in the bench-to-bedside-and-back approach. By both supporting the best projects to get to the patient more effectively, and working on some longstanding bottlenecks, such as methodological challenges in design and analysis of clinical studies of small populations, and access to proof-of-concept funding for preclinical projects, this pillar will allow immediate systemic improvement to Europe’s ability to innovate in RD and accelerate the reach for therapies. Specific impact 4: Improve healthcare systems' capacity to take up research results The EJP RD pipeline translated by its interlocked Pillars and transversal activities fosters effective and efficient implementation of research and innovation outcomes in the daily life of rare disease patients. The participation and strong involvement of the European Reference Networks, linking centres of expertise and professionals in different countries, will be the key element to improve the uptake of research results into health care. The funding of socio-economic and health care/health services related projects in Pillar 1 (WP6) will facilitate a better understanding of the real life problems and possible solutions for better uptake of research results in the general practice. In addition, the expected exchange of knowledge facilitated through the Networking schemes (WP7) and close connections between researchers, doctors and patients will also lead to an increased uptake of research results by providing the space to share diagnostic practices and guidelines, put more light on research results and innovative solutions and strengthen the collaborations by different stakeholders. The Pillar 2 strategy is based on giving the European Reference Networks a leading role in driving the way VP is built, with the ultimate aim to accelerate the take up of research results in clinical practice for the benefit of patients. ERNs will ensure the usability and the usefulness of the VP by continuously testing it against real-life use cases, by bringing research questions and establishing, together with Pillar 2 partners, sustainable mechanisms for ensuring a virtuous cycle between care and research. 15 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. The translation from research to healthcare cannot be done without relevant education. Pillar 3 will train on how research results can be exploited in other settings like diagnosis, drug development, etc. It will also provide dedicated trainings developed by and targeted to ERNs, thus closely connecting the needs of healthcare providers and research. Pillar 4 is dedicated to patient-centrism, and in so doing will ensure that all projects traversing the chasm between lab and clinic are designed for optimal patient uptake. This will be achieved by ensuring strong technical, product development, regulatory, HTA and funding support is available, so that projects are structured with patient uptake at their heart, and can benefit from follow-on funding to get them closer to the patient. Moreover, the methodological work being done to improve statistical methods for small populations will allow clinical uptake for interventions designed for rare diseases, thereby also improving ability to implement results into the clinic. The involvement of ERNs and of patients group will be a key factor for this implementation. Specific impact 5: Reinforce the EU's role as a global leader for rare diseases The EJP is exemplary to the world in bringing together the various expertise on research and innovation of rare diseases from so many institutions, clinicians, researchers and patient organisations in one programme to investigate and implement the results into the life of rare disease patients in Europe and beyond. The joint funding activity of Pillar 1 bringing 22 countries and the European Commission is key to speed up rare diseases research in Europe. The joint effort leveraging national funding resources in addition to the EC funding capacity is estimated at more than 60M € for 5 years. The variety of proposed funding schemes fostering transnational research, Networks and Rare Disease Challenges will be essential to enhance excellence and thus European leadership in the field of rare diseases. European Pillar 2 partners are already leading global endeavours (Orphanet, HPO, FAIR data principles and metrics) or are deeply involved in global initiatives (IRDiRC, MME, Beacon, GA4GH). Consolidating their efforts into the Pillar 2 work will maximize their impact and constitute an unprecedented resource that will establish a new paradigm for conducting research in the RD field, and could be a model for other domains. Europe will demonstrate that synergizing efforts by building a structuring long-lasting ecosystem of data and resources across domains (healthcare and research) but also linking national and transnational levels has a direct impact in clinically applicable discovery and innovation. As for the other EJP RD elements, the strength of Pillar 3 is based on bringing together yet fragmented but already existing EU capacities and organizing them in a coherent and efficient RD training and education landscape. Furthermore, the EU potential will be expanded by seizing and creation of novel, first-in-class trainings. The highly multi-disciplinary, outcome-oriented approach to the EJP RD in general, and specifically in Pillar 4, will augment Europe’s world class output in RD research and development. The outstanding outputs to be expected from the efforts in Pillars 1,2 and 3 will create a rich seedbed of knowledge, which will supported by Pillar 4 on the long journey from publication to patient. P4’s combination of active support to today’s projects, combined with a systematic tackling of serious systemic roadblocks to innovation, will cement Europe’s lead in RD research and innovation. Specific impact 6: Follow the policies and contribute to the objectives of the International Rare Diseases Research Consortium (IRDiRC) The organization of the EJP RD consortium reflects well the organization of IRDiRC by bringing under single umbrella funders, research performing institutions, healthcare providers, patients and linking to industry. In addition, the majority of EJP RD partners are also members of IRDiRC. This will not only allow but also accelerate the follow up of IRDiRC policies and contribution to its objectives. Furthermore, constant connection to IRDiRC will be maintained by the integration of IRDiRC chair and vice chair in the EJP RD Policy Board, incorporation of IRDiRC Scientific Secretariat in the EJP RD Coordination Office, implementation of joint Task Forces and participation of rare diseases experts and other EJP RD members in IRDiRC scientific and constituent committees. 16 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. The large part of funders involved in the EJP RD are members of IRDiRC. Funding bodies participate either with “individual” status or through the “E-Rare group of funders” that joined IRDiRC in 2012 and were strongly involved in determining the vision and goals of IRDiRC for the period 2017-2027. The support to IRDiRC policies and objectives is already translated through introduction of IRDiRC recommendations in guidelines for researchers as well as implementation of joint transnational calls targeting topics identified by IRDiRC as of most importance. This will be continued and further expanded within Pillar 1 activities. The Pillar 2 main goal is to provide access to data and services to allow better research towards diagnostics as well as new and more effective therapies for rare diseases. Thus, the overall Pillar 2 was designed towards IRDiRC 2017 – 2027 goals, namely (i) provision of a diagnosis within one year to all patients coming to medical attention with a suspected rare disease if their disorder is known in the medical literature or integrating of all currently undiagnosable individuals into a globally coordinated diagnostic and research pipeline and (ii) to develop 1000 therapies. These new IRDiRC goals can only be achieved with fundamental changes to the way science is conducted, shared, and applied to the care of rare disease patients. By creating an innovative VP and by putting in place mechanisms for constant improvement and continuous integration of new data, standards and resources, Pillar 2 realizes the commitment of Europe to catalyse those qualitative changes. Based on real-life use cases and needs brought by ERNs, Pillar 2 will help generating new knowledge on disease mechanisms towards better diagnosis and identification of druggable targets and disease modifiers to be used in research, by bringing together data and resources (expanding beyond RD), so as to take the best advantage of the most cutting-edge research across domains. Although IRDiRC recommendations do not target specifically education and training activities, its overarching and specific goals will be followed within Pillar 3. This will include for example raising awareness of complexity in diagnostics of unsolved patients with RD in the healthcare system or enhanced uptake of research results for translation into tangible outcomes, diagnosis and therapy development. With a central aim of IRDiRC being therapies and diagnostics, the patient-centric approach to Pillar 4 will directly contribute to its goals. The vast pool of resources, expertise and projects that will be created by EJP RD will be supported by P4 to take the outstanding discoveries and bring them towards the patient in form of a novel product. Further leveraging other funding sources will act as a multiplier to these efforts, and thereby improve Europe’s ability to contribute significantly to the IRDiRC goals. Other substantial impact(s): Contribution to the European Open Science Cloud EJP RD will increase its impact by actively contributing to the European Open Science Cloud (EOSC) by: (i) supporting the EOSC in its stated desire to apply FAIR Principles (in league with the GO FAIR network), given that establishing FAIR Rare Disease data is a cornerstone of the EJP RD (Pillar 2 WP12); (ii) aligning with EOSC on the respective data plus software quality assurance approaches and the data governance principles (Pillar 2 WP10); (iii) developing the EJP RD data Virtual Platform to be a multi-tenant federated architecture able to support a plurality of service providers and service consumers, as needed for EOSC (Pillar 2 WP11); and (iv) exploring cross-fertilising sustainability models for the life science ecosystem with EJP RD being the leader on rare diseases aspects of this ecosystem (Pillar 2 WPs10 & 12, transversal WP3). In particular, this work will begin with EJP RD building on the previous European investments into the EOSC, e.g., by utilizing outcomes of EOSCpilot and EOSC-hub projects. Outcomes of these projects, such as policies for dealing with sensitive data or common metadata models and guidelines, will be adopted and promoted to help their expansion on European scale within the communities relevant to EJP RD. 2.1.1. Barriers / obstacles The key barriers to achieving the expected impacts are the dispersal of patients and fragmentation of expertise. Overcoming dispersal of patients involves interacting with relevant umbrella organisations at national (National Alliances for Rare Diseases existing in most EU countries and members of EURORDIS) and European level (European Federations for specific Rare Diseases, also members of EURORDIS) which can then interact with their members reaching a large number of individuals. However, each interaction could provide an obstacle to the work of the EJP RD because of the need to address specific anxieties, concerns, and institutional processes. Hospitals that provide care for people with RD may derive a number of benefits from working in isolation (tangible revenue streams, intangible reputational benefits). These obstacles will be balanced against the direct benefits of collaboration to patients and hospitals. RD cannot be addressed locally and the European patient advocacy groups 17 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. that participate in the EJP RD will reinforce this message as appropriate. The improved value chain for RD product development developed by EJP RD will provide the trusted environment that allows individual institutions and persons to realise the benefits of collaboration. In the long-term, improved treatments will reduce the overall costs to society of RDs and will promote the reputations of hospitals that provide innovative treatments. Overcoming fragmentation of expertise involves obtaining buy-in, and institutional approval, from researchers and their host organizations. Obtaining buy-in could prove to be an obstacle because of competing opportunities and perceptions about the low value of RD research. The work done by EJP RD to improve the efficiency and effectiveness of RD research will redress the balance in favour of RD research. Institutional approval for research is equally difficult for RD and other types of research: all EJP RD participants are extremely skilled in seeking institutional approvals and will be further supported by dedicated services developed under the EJP RD. These barriers and obstacles are unlikely to have a material effect on the ability of EJP RD to achieve impact because a critical mass of collaborating individuals, advocacy groups, hospitals, and academic organizations already exists. The uncertainty about achievement relates to the scale and breadth of success beyond the groups that are already committed. Direct investment of 25 countries through funded calls in Pillar 1 will promote scale and breadth of involvement. Progress will be monitored in WP1 Task 1.3. The Operating Group and Executive Committee will have sufficient information to identify and address deficiencies. 2.1.2. Framework conditions A number of regulatory frameworks are relevant and will be addressed comprehensively: information governance (WP1, WP4 & Pillar 2); research conduct (WP4, WP19); transfer of biological material (WP4) and data (GDPR); national divergence (WP1). The regulatory context is relatively stable so that direct work on these topics is likely to lead to predictable achievement of the expected impacts. Many relevant standards are missing or incomplete but will be developed as needed, with full participation of EJP RD and its members in all similar initiatives. The standards environment is established and key players are included in the consortium (Orphanet, Human Phenotype Ontology -HPO-, FAIR principles conceivers) so that effort in this domain is highly likely to lead to the anticipated impacts. Public acceptance of the need for research in RD may vary. Past efforts of the RD community have increased the visibility of research and acceptance of the specific features of RD in many European countries. There is a risk that this growing acceptance will stall and that countries without RD programmes do not develop them or that member states with RD programmes will not support continued growth of those programmes. This risk would only be material to the impact of the EJP RD programme if public acceptance is reduced: this is highly unlikely. A subtler risk is the possibility that collaboration about RDs reduces the likelihood of public donations because of less direct emotional impact arising from reduced awareness of individual cases. This risk is already well-managed by umbrella groups such as EURORDIS or Telethon advocacy organizations and this know-how can be further shared. All of these risks to public acceptance of RD research and the specific actions of the EJP RD are actively mitigated by efforts made by EJP RD participants in parallel to EJP RD. Acceptance of research and methods by RD patients and their families will not change. Workforce considerations relate to the number of researchers involved in RD; the skills-mix of those researchers and the lack of support for collaboration in academic settings (that can reduce the drivers and incentives for academics to collaborate in the way proposed by this application). At present, the workforce is not a rate-limiting step in the RD product development value chain. As the current rate-limiting steps of dispersal of patients and fragmentation of expertise are addressed during the EJP RD, the skills-mix will become more important, particularly the adaptation of generic skills to the needs of RD research. The programme is designed to promote appropriate skills through Pillar 3 but also through the dedicated incentives within Pillar 1 joint transnational calls and Networking scheme. The number of researchers and the involvement of academic institutions will be increased by the increased flow of projects prompted by the EJP RD actions and organizational legacy provided by the EJP RD. The clearer relationship between effort and reward provided by improvements in the RD product development value chain is likely to improve the return on investment for individual researchers (as career pathways become more obvious) and for academic institutions (as the number and value of collaborative projects increase). Thus, attention to supply and demand elements of workforce management will promote the success of the EJP RD. The only way that workforce considerations could reduce impact would be a general reduction in the scientific workforce. This possibility is highly unlikely and the effects of a general reduction in the scientific workforce would be mitigated for RDs by the effects on supply and demand outline here. Finance of follow-up steps is directly addressed in Pillar 4, WP19. This will be directly facilitated by work to reduce costs and increase benefits. Finally, cooperation of other links in the value chain is built into the EJP RD through the extensive partnerships that beneficiaries are involved in. The EJP RD value chain starts with diagnosed patients and ends with evaluated 18 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. products. Before the EJP RD value chain starts, patients are diagnosed and given clinical care. The ERNs are positioned to improve diagnosis and clinical management and will embed their work in the EJP RD. Products developed by the EJP RD value chain are fed into health care systems. ERNs will do this at the level of clinical management. EJP RD participants from national funding agencies and policy organizations will provide links to relevant national intersectoral networks. 2.2 Measures to maximize impact 2.2.1 Dissemination and exploitation of results The dissemination of outputs (new knowledge, tools, services, trainings, etc.) and achievements obtained by the EJP RD program is essential for the visibility, outreach, impact and sustainability beyond the five year of the programme. The plan on dissemination and exploitation of results is designed to maximize the impact and serves three goals: (i) increase awareness on the EJP RD in order to involve more partner countries in joining EJP RD activities resulting in a substantial contribution to the overall goals of IRDiRC and inducing changes in the RD landscape at regional/national/EU and international level; (ii) to increase knowledge on and understanding of rare diseases, accelerate diagnosis and therapy development; and, finally (iii) to engage key stakeholders to support a sustainability scenario for EJP RD ecosystem as a whole and for individual “products”. The results of EJP RD will be disseminated at different levels by means specifically tailored to the needs of the targeted audience. On one hand the consortium will take advantage of its extensive network of partners, their powerful outreach and excellent reputation, on the other hand it will develop new instruments that will serve to increase the impact. The dissemination plan is presented in the table below. 2.2.2 Communication activities Strengthening the communication and interactions between different stakeholders is essential to raise awareness on the importance and benefits of rare diseases research. EJP RD communication activities will include such elements as workshops/briefings to stakeholders, webinars, educational sessions with patients, practitioners and/or policy makers or scientific meetings. The communication tools will comprehend portals, newsletters, networking platforms, official reports and strategic publications, videos and social media. In order to multiply the impact special attention will be given to encourage consortia financed through Pillar 1 to organize open events to disseminate their results and knowledge as well a mandatory publication in open access journals. Scientific congresses will be organized [RE(ACT) & IRDiRC] and dedicated RD sessions will be put in place in collaboration with other European or international congresses (ESHG, ECRD, DIA BIO, etc.). 2.2.3 Data Management Plan EJP RD will contribute to the European Open Science Cloud and data management will be dealt with extensively. All data activities will follow Open Research Data principles (which conform to FAIR data principles), and comply with the GDPR and existing ethical and legal expectations for healthcare, research and patient data. Whenever possible, datasets managed by EJP RD will have no access restrictions, though more sensitive data will be provisioned in a responsible and secure manner such that discovery, access and use (analysis and linking) will be controlled based on reasonable regulatory conditions, all of which will be fully transparent. Processes for requesting data will be maximally streamlined and progressively automated. A clear commitment to the above principles will be included in the Consortium Agreement. It is important to underline that the whole of Pillar 2 relates to professional IT and RD data management, emphasizing Open data and FAIR data principles, by means of an advanced Virtual Platform (VP). Pillar 2 will provide the technology, standards, access/analysis capabilities, utility/quality assurance and GDPR guidelines for local, hosted and centralised data management. All of this shall be coordinated by Pillar 2 WP10, with monitoring and strategic guidance provided by the RD research and healthcare community. More details are provided in Pillar 2 description of the Implementation and Annual Work Plan parts. Ongoing data management in the EJP RD will be a shared responsibility. All data-related activities (existing, new and derived data) will exploit and align with the data management systems provided by Pillar 2. In Pillar 1 this pertains to the projects that are financed within joint transnational calls. In Pillar 4 this applies to generated and derived data that supports translational research. In Pillar 3, in close collaboration with Pillar 2, it is relevant to educating data custodians, stewards and users about how to apply best data management practices and how to use the Pillar 2 VP. Finally, the EJP RD extends its data management ambition to long term data support through its sustainability and scaling-up activities (transversal WP3 and Pillar 2). 2.2.4 Dissemination and communication Plan Table 1. Dissemination and communication plan including expected effects of planned activities 19 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. EJP RD planned Expected effects of dissemination Target Audience Means of dissemination and WP Date Activity/Outputs and communication communication tools INTERNAL COMMUNICATION EJP RD internal ● EJP RD partners informed of all ● EJP RD partners ● Monthly internal NL including EJP RD 1 Continuous communication actions on time Action Updates ● Timely delivery of expected ● Regular conference calls outputs by partners ● Consortium assembly meetings EXTERNAL DISSEMINATION & COMMUNICATION Central Helpdesk ● Timely communication between ● All stakeholders ● Website Continuous providers of RD research ● Multimedia marketing campaigns targeted Every year services and consumers of at users of RD research services research services SRIA ● National and EU needs and ● Ministries of Research & Health ● Policy Board meetings 2 Every year recommendations well captured ● Relevant EU directorates (DG RTD, ● Annual SRIA Scoping paper & M33, M57 ● EJP RD annual priorities Santé, Connect) ● State of play of funded research and drug for strategic defined by Transparent ● IRDiRC development, overlaps and trends at workshops decision-making process ● ESFRI representatives international level report ● Alignment and enhancement of ● Regulatory authorities ● SoA of Member States activities related to national, EU and international ● Patient Organisations the EJP RD RD research activities (funding, ● National Mirror Groups ● Strategic workshops targeted to EU13 and support to sharing of data and EU15 needs & interactions resources, training, accelerated exploitation of research results) Medium and long-term ● Joint (with IRDiRC) ● Research and health policy makers ● Publication of outcomes on IRDiRC and 2 Continuous strategy - Task Forces identification of gaps and ● Research funders EJP RD websites bottlenecks in RD research → ● Industry ● Targeted reports or/and publications in peer alignment of strategies ● Patient(s)/Organisations review journals ● Adoption and endorsement of ● RD researchers ● Presentation at relevant workshops and TF recommendations conferences ● Integration of relevant elements in the EJP RD activities (e.g. trainings) 20 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Management of EJP ● Implementation of EJP RD ● EJP RD partners ● Presentation of ethics, regulatory & legal 4 Every year or RD ethics, regulatory activities in line with ethical, ● RD stakeholders at large updates to partners Continuous & legal issues regulatory and legal guidelines ● Regulatory agencies ● Dissemination via dedicated Flash News or ● Establishment of efficient NL dialogue with regulatory ● Short update reports to be published at EJP agencies RD website and redistributed to relevant ● Become an “information stakeholders for further dissemination reference” for legal, ethical and regulatory issues in RD field EJP RD service ● Detection and promotion of ● Researchers on rare diseases ● EJP RD website and Helpdesk 3 M24-M36 then catalogue useful services complying with ● ERNs / care givers ● Dedicated events continuous interoperability objectives in ● Patients’ organizations ● Channeling to ESFRI, funding bodies, RD research activities ● SMEs and industry (pharma, medical governmental bodies ● Increased interest and adhesion devices, ICT) of the research community / end ● Public funders and authorities users, ● Other funders ● Public and private support to ● Learned societies sustain most acclaimed services ● Regulators Sustainability roadmap ● Action in engaging key ● Policy makers ● Business plan 3 From M24 stakeholders ● Ministries ● Reports on innovative sustainability ● Program owners and managers solutions & sustainability models ● European Commission ● EJP-RD service catalogue ● SMEs and industry ● EJP RD dedicated strategic reports ● Foundations and learned societies ● Meetings with Policy Board ● Patients’ organizations Funded research ● Critical mass of ● Clinicians and heads of reference centers ● OA publications 6 Continous projects data/samples/patients achieved ● Researchers on rare diseases ● EJP RD and IRDiRC websites ● Increased knowledge on and ● Technology platforms ● EJP RD and partner organizations understanding of rare diseases ● European infrastructures Newsletter ● Improved diagnosis ● Patients organizations ● Scientific meetings and congresses ● Accelerated therapy ● SMEs and industry (RE(ACT), IRDiRC Congress, ECRD, development ● Program owners and managers ESHG) ● Data sharing and networking ● European Commission ● Targeted workshops (also at national level) ● Input for EJP RD virtual ● All other rare diseases related initiatives ● Pillar 3 trainings platform ● General public ● RE(ACT) platform ● Contribution to the objectives of ● EJP RD public reports and brochures IRDiRC ● EC Cordis & ERA-LEARN Networking projects ● New RD networks ● RD researchers & clinicians ● Networking events publicized on EJP RD 7 Continuous 21 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. ● Increased collaboration of RD ● Patients website, Newsletter and through partner from Y2 researchers, clinicians and ● European Reference Networks organizations channels patients ● Healthcare providers ● Reports from organized events published ● Increased sharing of knowledge on EJP RD website, Newsletter on undiagnosed patients ● OA publications (when relevant) ● Expanded geographical coverage (e.g. networks covering more EU13 countries or new collaboration with Africa, South America, etc.) RDR Challenge ● Effective academia-industry ● Industry/pharmaceutical ● ERTC specific communication 8 Case by case projects collaboration companies/SMEs (EURORDIS) basis (from ● Outputs with patenting, IP ● Venture capitals ● EFPIA website M36) potential ● Academic RD researchers ● IRDiRC website and Newsletter ● New (technology) solutions ● Creation of valuable know-how ● POCs Virtual Platform for ● Increased visibility of resources ● RD researchers and clinicians (including ● EJP RD website and Helpdesk 11 & Starting from federated FAIR data ● Resources and FAIRdata P1 funded projects) ● EJP RD and related partners newsletter 12 M12 and resources (record level) findable at a ● ERNs and national reference ● Scientific OA publications & central point centers/hospitals ● Strategic reports 13 ● Increased interoperability ● Patients ● IRDiRC Recognized resource label between resources ● Policy makers/ministries ● Inclusion in dedicated trainings ● Accelerated access to data and ● Funders ● Congresses and workshops resources ● Industry (EFPIA) ● Recommendations on use in calls for ● Integration in national and EU ● SMEs (EUCOPE) projects of Pillar 1 recommendations (e.g. RD ● EJP RD Sustainability Roadmap national plans) ● EJP RD catalogue of services ● EOSC RD analysis tools and ● Improved usability of ● RD researchers and clinicians (including ● EJP RD website and Helpdesk 11 & Starting from data sharing genomics/phenomics/multi- P1 funded projects) ● EJP RD and related partners newsletter 13 M12 capabilities omics data deposition and ● Systems Biologists and Data scientists ● Scientific OA publications (pathway analysis resources ● ERNs and national reference ● Strategic reports portal will start ● Facilitated and secure centers/hospitals ● Guidelines and recommendations month 1) deposition of data ● Policy makers ● IRDiRC Recognized resource label ● Higher number of submissions ● Funders ● Inclusion in dedicated trainings ● Higher number of accessible ● Industry (including pharma) ● Congresses and workshops datasets for research ● Recommendations on use in calls for ● Faster identification of projects of Pillar 1 causative genes and variants ● EJP RD catalogue of services ● Accelerated diagnosis including ● Presentations and workshops in ELIXIR 22 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. undiagnosed or misinterpreted SME events cases ● Tutorials on pathway creation and multi- ● Increased EU innovation omics workflows(with pillar 3) capacity ● Pathway portal on WikiPathways ● Better disease mechanism ● Network deposition on NDEX descriptions (on pathway portal) ● New ideas for drug targets and drug repositioning Organisation of data ● Good flow of standards, ● RD researchers and clinicians ● EJP RD website and Helpdesk 12 & Starting from stewarding technologies and capabilities ● Research institutes and hospitals ● IRDiRC Recognized resource label 14 M1 collaborations, between infrastructures, data ● Infrastructures ● Guidelines and protocols advocacy, and self-help experts and RD experts ● Funders ● OA publications networks for practical ● Emergence of self-helping data ● Policy makers ● Webinars FAIRification support stewarding networks within the ● Industry ● Trainings RD community ● Tailored service support ● Increased awareness and better ● Collaboration with international expert FAIR data stewardship groups (e.g. organised through IRDiRC, capacity planning by RD ELIXIR, GA4GH, BBMRI-ERIC, EOSC, resource managers GO FAIR, NIH, OHDSI, etc.) ● Model for FAIRification ● Recommendations for FAIR data support as a service by and for stewardship in Data Management plans in the RD community, including calls for projects of Pillar 1 public-private-partnership ● EJP RD Sustainability Roadmap ● Project-based and on-site engagement with exemplar stakeholders to seed FAIRification capacity in RD networks (e.g. ERNs) ● Online communication channels, telephone conferencing, and workshops for FAIR experts and interdisciplinary communication ● Support for advocacy and networking by stakeholder data stewards at EJPRD meetings and international conferences for RD Innovative holistic ● Reduced product attrition ● RD researchers and clinicians ● EJP RD website and Helpdesk 13 From M36 and approaches for rare ● More rapid completion of ● Research institutes and hospitals ● EJP RD and related partners newsletter then continous diseases diagnosis and product development ● Infrastructures ● Scientific OA publications therapeutics ● Funders ● Strategic reports ● Policy makers ● IRDiRC Recognized resource label ● Industry (EFPIA) ● Inclusion in dedicated trainings 23 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. ● SMEs (EUCOPE) ● Congresses and workshops ● Recommendations on use in calls for projects of Pillar 1 ● EJP RD Sustainability Roadmap Training on data ● All potential participants ● Academic researchers and clinicians ● EJP RD website and Helpdesk 14 Every year management and interested in training course(s) ● Biobank managers ● EJP RD and related partners websites & quality informed in time for registration ● Laboratory scientists & technicians newsletter ● Clinical geneticists ● Universities websites, and social media ● Applicants of EJP RD joint transnational ● EU-funded projects’ Newsletters (Solve- calls RD, RD-Connect, Share4Rare, Orphanews, ● ERNs etc.) ● ePAGs (RD patient rep involved in ERNs ● Recommendations on use in calls for for task 14.5) projects of Pillar 1 and Pillar 4 ● ePAGs online communities ● ERN specific Newsletters ● ERN specific websites ● Communication channels of Learned Societies ● Other relevant EU and international networks (UDNI, EuroBioBank website, ESBB etc.) ● Journals listing (e.g Nature Events) Training of patients ● All potential participants ● Rare disease patients and representatives ● EJP RD website and Helpdesk 15 Every year and researches in rare interested in training course(s) ● ePAGs (RD patient rep involved in ● EJP RD and related partners newsletter, diseases research and informed in time for registration ERNs) websites and social media (twitter, processes ● Increase of knowledge and ● YPAGs (young patient advisory groups LinkedIn, facebook) awareness within the targeted representatives) ● ePAGs online communities community ● Academic researchers ● EURORDIS website (Open Academy), e- News, ePAGs Newsletter and EURORDIS working groups/Task Force mailing lists (e.g. DITA, Summer School Alumni, TAG, SWAN Europe etc.) ● TEDDY and, EPTRI and eYPAGnet mailing lists/Newsletters/website ● C4C Website/Newsletter Online academic RD ● Increase awareness of the online ● Academic clinicians and researchers ● EJP RD website and Helpdesk 16 Every year and education course course among several ● Medical & biomedical students ● EJP RD and related partners (e.g. more starting stakeholder groups ● Industry researchers/scientists universities) newsletters M12 ● RD patient representatives and advocates ● Dedicated printed materials (leaflets, ● Industry posters) to be distributed by partner ● Lecturers organizations 24 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. ● University managers ● FutureLearn platform and Newsletter ● Professional organizations ● Communication channels of Learned ● Organizations of academic institutions Societies (like UEMS) ● Scientific meetings and congresses (RE(ACT), IRDiRC Congress, ECRD, ESHG ● Conferences and events dedicated to academic education ERN training & ● All potential participants ● Academic clinicians and researchers ● ERNs specific Newsletters 17 Every year support interested in training involved in ERNs ● ERNs specific websites programme informed in time for ● Mailing list ERN training and education registration working groups Development and ● Needs of RD research ● Ministries of Research & Health ● Policy Board meetings 18 Every year adaptation of training community as a whole and ● National Mirror Groups ● EJP RD website and Helpdesk from year 2 activities relevant groups of stakeholders ● Patient Organizations ● EJP RD and related partners newsletter and (ERN, countries) well captured ● ERNs websites ● Transparent decision-making ● Organizations of academic institutions ● Conferences and events dedicated to process for EJP RD annual academic education priorities Innovation ● Appropriate and timely ● RD research community especially ● ERNs, website and roadshows 19 Continuous Management Toolbox connections between innovators researchers with a potential product ● EJP RD website and Helpdesk and facilitators of innovation ● ERNs ● EJP RD and related partners newsletter & ● Self-help resources openly ● RD research community websites accessible to RD research ● Institutional innovation managers community Real-time mentoring ● Timely design and resource ● Researchers with a potential product ● ERNs, website and roadshows 19 Continuous and technical support identification for researchers ● E-Rare & Pillar 1 funded projects ● EJP RD website and Helpdesk for translational ● EJP RD and related partners newsletters projects Support in exploitation ● Timely match between investors ● Researchers with an evaluated product ● ERNs, website and roadshows 19 Continuous of research results and and product ● Investors (industry, venture capitals, ● EJP RD website and Helpdesk follow-up funding charities, etc.) ● EJP RD and related partners newsletter ● Dedicated meetings and congresses Roadmap for EU ● Shared agenda for research in ● Funders ● Publication of outcomes on EJP RD 19 M36 investment platform RD and clear entry points for ● Clinicians and heads of reference centers websites investors ● Researchers on rare diseases ● Targeted reports or/and publications in peer ● Technology platforms review journals ● European infrastructures ● Presentation at relevant workshops and ● Patients organizations conferences ● SMEs Activity: Support in ● Timely design and resource ● Researchers with a potential product ● ERNs, website and roadshows 20 Continuous 25 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. design and planning of identification for clinical studies ● clinicians with a potential project of a ● EJP RD website and Helpdesk RD clinical studies clinical study ● EJP RD and related partners newsletter ● Demonstration studies ● Increased range of ● Funders ● Publication of outcomes on EJP RD 20 M12 – M48 to validate promising methodologies that have been ● Clinicians and heads of reference centers websites methodologies to validated for use in RD clinical ● Researchers on rare diseases ● Targeted reports or/and publications in peer improve RD clinical trials ● methodologists involved in RDs review journals trials ● Large pharma and SMEs ● Presentation at relevant workshops and ● Regulators conferences ● diffusion through clinical trials help desk Innovative ● Increased range of innovative ● Funders ● Publication of outcomes on EJP RD 20 M15 – M56 methodologies to methodologies and new ● Clinicians and heads of reference centers websites improve RD clinical statistical designs for use in RD ● Researchers on rare diseases ● Targeted reports or/and publications in peer trials in limited clinical studies to fill the urgent ● Methodologists involved in RDs review journals populations gaps ● Large pharma and SMEs ● Presentation at relevant workshops and ● Regulators conferences ● Webinars EJP RD project as a ● Increased use of EJP RD ● RD community at large (researchers, ● Creation of unique, recognizable identity 1 Continuous whole tools and services healthcare providers, patients) ● Annual Progress Report ● More knowledgeable RD ● Policy makers ● EJP RD website, newsletter and printable stakeholders ● Research institutions and infrastructures publicity elements ● Better connected RD ● Funders ● Presentations at national, EU and stakeholders ● Industry and SMEs international congresses ● Improved alignment of ● Patient Organisations ● Targeted videos adapted to different types national, EU and ● General public of stakeholders international strategies ● Scientific and strategic publications 26 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. 3. IMPLEMENTATION A more detailed description of the specific activities to be carried out in the first year will be included in Annex 7 Figure 6. EJP RD implementation structure (interactions being represented in the table below) 27 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Table 2: Description of interactions between different work packages of the EJP RD 28 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. EJP RD Gantt Chart TASK Start End YEAR 1 YEAR 2 YEAR 3 YEAR 4 YEAR 5 WP1. Coordination and management Task 1.1 Implementation and responsibilities of the coordination office (MS 1.1;1.2;1.3) 1 60 M 2 M 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 1.2 Coordination & support within and across pillars 1 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 1.3 Monitoring of the EJP RD activities and achievements 1 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 1.4 Data management plan 1 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # WP2. Integrative research and innovation strategy Task 2.1 Prioritization scheme for EJP RD actions (MS 2.1;2.2) 1 36 1 2 M 4 5 M 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 2.2 Mapping the research and innovation need (MS2.3) 1 48 1 2 3 4 M 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 2.3 Scientific programming of joint transnational calls 1 36 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 2.4 Management of the medium, longer-term research strategy questions and dedicated linkage with Task Forces 1 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # of IRDiRC Task 2.5 Translation/impact of prioritization on national and EU strategies 6 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # WP3. Sustainability strategy and business plan Task 3.1 Service roadmap alignment of the needs, expectations and engagement of the different RD research 1 36 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # stakeholders in Europe with respect to EJP RD sustainability Task 3.2 Preparation of the sustainable EJP-RD services catalogue, supporting the EJP-RD dissemination and 12 36 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # communication activities Task 3.3 Preparation of the EJP-RD sustainability plan with business plan (MS3.1) 1 42 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # M # # # # # # # # # # # # # # # # # # Task 3.4 Sustainability roadmap (MS3.2) 37 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # M # # # # # # WP4. Ethical, regulatory, legal and IPR framework of the EJP RD Task 4.1 Setting up the ‘Advisory Regulatory Ethics Board (MS4.1) 1 60 1 2 3 4 M 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 4.2 Managing ethical and regulatory issues (MS4.2) 1 60 1 2 3 4 5 M 7 8 9 # # # # # # # # M # # # # # # # # # # # M # # # # # # # # # # # M # # # # # # # # # # # # # # # # # # Task 4.3 Managing legal and IPR issues (MS4.3) 1 60 1 2 3 4 5 6 M 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # WP5. Communication & dissemination Task 5.1 EJP RD external communication & dissemination of results (MS5.1) 1 60 1 M 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 5.2 Integrating EJP-RD communication and dissemination strategies with the strategies of involved stakeholders 1 60 1 M 3 M 5 6 7 8 9 # # # # # # # # M # # # # # # # # # # # # # # # # # # # # # # # M # # # # # # # # # # # # # # # # # # (MS5.2;5.3) WP6. Joint Transnational Calls for collaborative research projects Task 6.1 1st co-funded Joint Transnational Call (JTC 2019) 1 12 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 6.2 2nd co-funded Joint Transnational Call (JTC 2020) 4 24 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 6.3 3rd Joint Transnational Call (JTC 2021) not co-funded by the EC 16 36 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 6.4 4th Joint Transnational Call (JTC 2022) not co-funded by the EC 28 48 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # WP7. Networking to share knowledge on rare diseases Task 7.1 Development of the networking scheme (MS7.1) 1 7 1 2 3 4 5 6 M 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 7.2 Application and evaluation of proposals for the Networking Scheme 7 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 7.3 Early assessment of the Networking scheme 21 24 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # WP8. Rare Disease Research Challenges Task 8.1 Development of the scheme (MS8.1) 1 8 1 2 3 4 5 6 7 M 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 8.2 Identification of challenges 9 12 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 8.3 The call for projects, eligibility criteria and evaluation 13 52 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 8.4 Management of the funding resources, establishment of contracts and distribution of funding to selected 17 50 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # projects WP9. Monitoring of funded projects Task 9.1 Monitoring of Joint Transnational Calls for collaborative research projects (MS9.1) 1 60 1 2 3 4 5 6 7 8 M # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 9.2 Monitoring of networking to share knowledge on rare diseases (MS9.2) 1 60 1 2 3 4 5 6 7 8 M # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 9.3 Monitoring of Rare Disease Research Challenge (MS9.3) 17 56 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # M # # # # # # WP10. User-driven strategic planning and transversal activities for Pillar 2 data ecosystem Task 10.1 Convene yearly retreats leading to Pillar 2 annual strategic plans (MS10.1) 1 60 1 2 3 4 5 M 7 8 9 # # # # # # # # M # # # # # # # # # # # M # # # # # # # # # # # M # # # # # # # # # # # M # # # # # # Task 10.2 Coordinating Pillar 2 Work Packages outputs and aligning to RD community needs (MS10.2) 1 60 1 2 3 4 M 6 7 8 9 # # # # # # # M # # # # # # # # # # # M # # # # # # # # # # # M # # # # # # # # # # # M # # # # # # # Task 10.3 Coordination of technical GDPR implementation 1 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 10.4 Quality oversight 1 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 10.5 Sustainability and scaling up (MS10.3;10.4) 1 60 1 2 3 4 5 6 7 8 9 # # # # # # # # M # # # # # # # # # # # # # # # # # # # # # # # # # # # # # M # # # # # # # # # # # # 29 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. WP11. Common virtual platform for discoverable data and resources for RD research Task 11.1 Metadata and ontological model definition for cataloging resources for RD research (MS11.1) 1 60 1 2 3 4 5 6 7 8 M # # # # # # # # # # # M # # # # # # # # # # # M # # # # # # # # # # # M # # # # # # # # # # # M # # # Task 11.2 FAIR-compliant virtual platform for discovery of RD resources 1 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 11.3 Data deposition and access to data infrastructures for RD research (MS11.2;11.3) 1 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # M # # # # # # # # # # # M # # # # # # # # # # # # # # # # # # # # # # # # Task 11.4 Provision of RD analysis and data sharing capabilities through online resources (MS11.4) 1 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # M # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # WP12. Enabling sustainable FAIRness and Federation at the record level for RD data, patients and samples Task 12.1 Compare and align core interoperability standards of relevance (MS12.1) 1 60 1 2 3 4 5 6 7 8 9 # # M # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 12.2 Multi-team software development to enable the FAIR ecosystem (MS12.2) 1 60 1 2 3 4 5 6 7 8 9 # # # # # # # # M # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 12.3 Combining expertise for practical FAIRification support (MS12.3;12.4) 1 60 1 2 3 4 5 M 7 8 9 # # M # # # # # # # # # # # # # # # # # M # # # # # # # # # # # M # # # # # # # # # # # M # # # # # # WP13. Enabling multidisciplinary, holistic approaches for rare disease diagnostics and therapeutics Task 13.1 Fill a number of pre identified gaps to allow integrative systems biology approaches for rare diseases 1 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 13.2 Organise proof of principle studies to identify efficacy of the work done and identify remaining (including 1 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # M # # # # # # # # # # # M new) gaps (MS13.1;13.2) WP14. Training on data management & quality (MS14.2) M Task 14.1 Training on the Orphanet nomenclature and RD ontologies for RD research (MS14.1) 1 60 1 2 3 4 5 6 7 8 9 M # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 14.2 Standards and quality of genetics/genomics data in laboratory and clinical research practice 1 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 14.3 Training on strategies to foster solutions of undiagnosed rare disease cases 12 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 14.4 Training for biobanks and researchers/clinicians on sample data management 1 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 14.5 Training on rare disease registries and FAIRification of data at the source 1 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 14.6 Training on the European Rare Diseases Registry Infrastructure (ERDRI) 1 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # WP15. Capacity building and training of patients and researchers in Rare Disease research and processes Task 15.1 ExPRESS Expert Patients and Researchers EURORDIS Summer School 1 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 15.2 Training for patient advocates on scientific innovation and translational research aspects in rare diseases 12 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 15.3 Training for patient representatives and advocates on leadership and communication skills 1 48 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 15.4 Educational materials and activities for paediatric patients 25 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # WP16. Online Academic education course Task 16.1 Assess the needs, target audience, main topics of the academic education course 1 6 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 16.2 Developing the online course (MS16.1,16.2,16.3,16.4;16.5) 6 48 1 2 3 4 5 6 7 8 M # # # # # # # # M # # # # # M # # # # # # # # # # # # # # # # # # # # # # # M # # # # # # # # # # # # Task 16.3 Follow-up, assessment and monitoring of the e-learning course 18 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # WP17. ERN RD training and support programme Task 17.1 Mapping to collect information on preferences, needs and resources from the ERNs ecosystem (MS17.1) 1 3 M 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 17.2 Development of training programs for the ERN training networks based on the results of survey (MS17.2) 4 6 1 2 3 4 5 M 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 17.3 Deliver training programs through the ERN training networks 7 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 17.4 Accreditation of training activities 7 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # WP18. Development and adaptation of training activities Task 18.1 Evaluation of developing needs according to progress of work in Pillars 2 and 4 and relevant adaptation of 24 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # training activities Task 18.2 Evaluation of strategic priorities and development of existing training activities according to specific needs 24 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # of EU-13 countries Task 18.3 Evaluation of developing ERN training and support needs and adaptation of training activities in WP17 of 24 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Pillar 3 WP19. Facilitating partnerships and accelerating translation for higher patient impact Task 19.1 Accelerating translation (MS19.1) 1 60 1 2 3 4 5 6 7 M 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 19.2 Support in exploitation and follow-on funding 1 60 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 19.3 Evaluation of Innovation Management and exploitation support tasks (MS19.2) 44 48 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # M # # # # # # # # # # # # # # Task 19.4 Roadmap for a European investment platform for RD (MS19.3) 2 36 1 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # M # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # WP20. Accelerating the validation, use and development of innovative methodologies tailored for clinical trials in RDs Task 20.1 Task Force Group (MS20.1) 1 60 M 2 3 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 20.2 Support in design and planning of RD clinical trials (MS20.4) 1 60 1 2 M 4 5 6 7 8 9 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 20.3 Demonstration projects on existing statistical methodologies to improve RD clinical trials (MS20.2) 9 48 1 2 3 4 5 6 7 8 9 # # # # # M # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # Task 20.4 Projects on innovative methodologies to improve RD clinical trials in limited populations (MS20.3) 12 56 1 2 3 4 5 6 7 8 9 # # # # # # # # M # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # 30 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. 3.1a. List of workpackages TITLE LEAD BENEFICIARY COORDINATION & TRANSVERSAL ACTIVITIES INSERM (Coo) WP1. Coordination and management INSERM (Coo) WP2. Integrative research and innovation strategy ISCIII, ISS INSERM (RaDiCo), WP3. Sustainability strategy and business plan EATRIS, ISCIII WP4. Ethical, regulatory, legal and IPR framework of the EJP RD FGB WP5. Communication & dissemination INSERM (Coo) PILLAR 1: RESEARCH COLLABORATIVE FUNDING DLR, ZonMw WP6. Joint Transnational Calls for collaborative research projects DLR WP7. Networking to share knowledge on rare diseases ZonMw WP8. Rare Disease Research Challenges FFRD WP9. Monitoring of funded projects CSO/MOH PILLAR 2: INNOVATIVE COORDINATED ACCESS TO DATA AND INSERM (Orphanet), SERVICES FOR TRANSFORMATIVE RARE DISEASES RESEARCH UKL-HD WP10. User-driven strategic planning and transversal activities for Pillar 2 data INSERM (Orphanet), ecosystem ULEIC INSERM (Orphanet), WP11. Common virtual platform for discoverable data and resources for RD research CNAG WP12. Enabling sustainable FAIRness and Federation at the record level for RD data, patients and samples ULEIC, LUMC WP13. Enabling multidisciplinary, holistic approaches for rare disease diagnostics and therapeutics UM, UKL-HD PILLAR 3: CAPACITY BUILDING AND EMPOWERMENT EURORDIS, VUHSK WP14. Training on data management & quality ISS WP15. Capacity building and training of patients and researchers in Rare Disease research and processes EURORDIS WP16. Online Academic education course FFRD WP17. ERN RD training and support programme EKUT VUHSK, CMHI, WP18. Development and adaptation of training activities EURORDIS PILLAR 4: ACCELERATING THE TRANSLATION OF HIGH POTENTIAL PROJECTS AND IMRPOVING OUTCOMES OF CLINICAL STUDIES IN APHP, EATRIS SMALL POPULATIONS WP19. Facilitating partnerships and accelerating translation for higher patient impact EATRIS, FTELE WP20. Accelerating the validation, use and development of innovative methodologies UKA, APHP, HSK tailored for clinical trials in RDs (MetabERN) 3.1b: Work packages description COORDINATION & TRANSVERSAL ACTIVITIES WP N°1 Coordination and management Lead beneficiary INSERM Start date M1 End date M 60 31 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Participant short (Orphanet) (1a) ZONMW (34) name & (N°) UKL-HD (57) EATRIS (75) VUHSK (32) INSERM (1) ELIXIR (76) EURORDIS CVBF (27) APHP (54) ULIV (51) DLR (15) INSERM (77) P.M 397 6 6 16 6 6 6 6 6 8 6 1 Objectives ● Carry out the overall management of the initiative (capture, guide and lead all work related to the 5-year programme and the annual work plans); ● Oversee and organize project-related meetings, including meetings of the General Assembly, Executive Committee, Policy Board, ad hoc Scientific Board(s) and IRDiRC; ● Execute Scientific Secretariat of IRDiRC; ● Ensure appropriate financial administration (budgeting, planning, accounting); ● Report to the European Commission (including annual reports, annual summary progress reports, annual work plans and deliverables); ● Ensure efficient internal communication (with help of dedicated tools); ● Ensure effective dialogue and coordination with project partners to assess progress and challenges in implementing the annual work plans; ● Develop and implement the EJP RD Helpdesk; ● Ensure efficient decision making and manage conflicts in accordance with the rules set-out in the consortium agreement; ● Implement the risk management strategy; ● Develop and implement the monitoring of the EJP RD activities. Description of work Task 1.1: Implementation and responsibilities of the coordination office (M1-M60) TL: INSERM (Coo) The Coordination Office based at INSERM will consist of the coordinator, two senior and two junior project managers, communication officer, financial officer and assistant. The CO will be central point and carry out the day-to-day operational management by supporting EJP RD partners. It will be the primary contact for the EJP RD partners, Policy Board, IRDiRC, European Commission, and other interested parties. The CO will be responsible for an efficient management of overall contractual obligations. It will ensure compliance by Beneficiaries with their obligations under the Grant Agreement and Consortium Agreement in terms of administrative, legal and financial management. It will monitor timely preparation and submission of the Deliverables to the European Commission, and coordinate preparation and submission to the EC of the periodic Annual Progress Reports, Annual Work Plans, technical and financial reports and Final Report. It will manage and coordinate any legal obligation such as Amendments to the Grant Agreement when required. SubTask 1.1.1: Scientific Secretariat of IRDiRC (M1-M60) STL: INSERM (Coo) The Scientific Secretariat (SciSec) of IRDiRC will be secured by EJP RD Project Managers seconded by the Communication and Financial Officers. The integration of the SciSec in the EJP RD coordination is crucial as it guarantees tight connection between EJP RD and IRDiRC necessary for common strategy, harmonized efforts and critical position of Europe within IRDiRC Consortium. SciSec acts in service of and in response to the needs/requests of the IRDiRC. The SciSec will provide support to the IRDiRC bodies (Consortium Assembly, Constituent Committees, Scientific Committees, Operating Committee), manage the logistics of the meetings and reporting. It will ensure a liaison between the EJP RD and IRDiRC members and Task Forces and other IRDiRC-specific Activities (see also WP2) to optimize the complementarity and the coherence of their specific activities contributing to the common goals. SubTask 1.1.2: Central Helpdesk (M1-M60) STL: INSERM (Coo), Participants: Operating Group (INSERM (Orpha), DLR, UKL-HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS); ULiv The proposed central Helpdesk will be the single-entry point for any inquiry related to the actions and services proposed within the EJP RD. From the start, it will be managed by one of the EJP RD project managers that will be 32 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. responsible for providing of rapid response or re-directing the demand to the expert groups of a specific Pillar or connected projects (in order to avoid duplication of efforts). It will function through the EJP RD website where contact information will be provided. The project managers will be responsible for the registration and analysis of all incoming queries that will be classified based on the “key” agreed with Helpdesk support groups formed by dedicated pillars’ members. The goal is to monitor the incoming demands and adapt the service according to the needs. An analysis of incoming requests will be performed every 3 months in connection to Task 1.3. A directory of people and services available within and outside the EJP RD (via connected partners) will be created for the need of efficient management of demands and in support for the Helpdesk. The Helpdesk will have close working relationships with similar elements of other initiatives like C4C project or involved infrastructures in order to manage cross-referrals between initiatives. Task 1.2: Coordination & support within and across pillars (M1-M60) TL: INSERM (Coo), Participants: Operating Group (INSERM (Orpha), DLR, UKL-HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS) In order to coordinate the support and swift communication within and across pillars, the pillar leaders together with coordinator and project managers will form the Operating Group (OG). The OG is already a functioning body that has gained experience, cohesion and efficacy during the preparation phase. Regular (twice a month) conference calls will ensure close follow up of activities, continuous alignment and adequate reactivity in case of urgent situations and risk management. The OG will participate in the preparation of the Executive Committee meetings and will be the driving force for the elaboration of the Annual Work Plans (see also 1.2.1). The Pillar leaders will coordinate the activities of WPs within their Pillars, will reflect on progress and engage in a collective brainstorming on future directions and visions for the EJP RD. They will identify possible bottlenecks and report them to the CO. While the OG will be the operative body, the Executive Committee (ExCom composed of the Coordinator, project officer, Pillar leaders, patients and ERN representatives and all WP leaders) will be the forum to discuss details of the EJP RD progress, annual work plans and related resource utilization. The ExCom will meet by conference call every month in the first year and every two months in the following years of the project. It will also hold one face-to-face meeting per year: at M6, jointly with the Policy Board (see 3.2) in order to discuss the priorities and work on the development of the Annual Work Plan to be presented at the start of M9 at the Governance Board meeting. SubTask 1.2.1: Development of Annual Progress Report and Annual Work Plans (M1-M60) STL: INSERM (Coo), Participants: Operating Group (INSERM (Orpha), DLR, UK- HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS); ALL WP leaders The development of the Annual Progress Report and Annual Work Plan will follow a structured process managed by the Executive Committee: ● Each pillar will be responsible to capture outcomes and reflect them in the summary progress reports documenting proposals and ideas, including input to the monitoring of EJP RD activities. These annual progress reports will be drafted by each WP leader and compiled by the respective Pillar leaders. The CO jointly with relevant leaders of transversal WPs will follow the same procedure; ● The CO will be responsible for the collation of the single summary progress reports to be complemented by the outcomes of the monitoring and progress against established Key Performance Indicators captured within Task 1.3. The final draft of the full Annual Progress Report will be presented to the Governing Board for validation before sending to the Commission; ● At the same time the ExCom will be asked to propose tasks and deliverables based on the internal consultation of WPs and in line with their implementation status. This will include update of the budgetary plan and proposition of the redistribution of funds and new responsibilities. The collated draft will be discussed at the ExCom face-to-face meeting (M6) and updated based on the inputs from the Policy Board and prioritization procedure. As for the Annual Progress Report, the finalized version of Annual Plan will be presented for validation to the Governing Board (M9) before sending to the Commission; ● The Annual Work Plan and Annual Progress Report will be complementary: the report will show how the activities proposed in the annual work plan for the next year provide continuity with completed and ongoing work. The Commission will thus be informed regarding project progress and compliance with commitments. SubTask 1.2.2: Organization of EJP RD governance meetings (M1-M60) STL: INSERM (Coo) The CO will prepare and organize meetings of the Governing Board (once a year, M9/M21/M33/M45/M57), the highest-decision making body (see also section 3.2), to approve the organization, work programme, the Annual Work Plan of the following year, the structure and information flow and the political outcome of the EJP RD. The Governing Board shall consist of one representative per participating country, one representative of ERNs, one representative of participating EU infrastructures, 1 patient organization representative (EURORDIS), one 33 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. representative of Orphanet and one representative of other non-profit organizations. It will be up to each participating country/type of beneficiary to decide on the nomination procedure for their representative. Back-to- back to GB meeting, the CO will organize meetings of the whole EJP RD Consortium (M9/M21/M33/M45/M57), to present yearly progress, oversee the needs within the pillars (and respective work packages) and to ensure the efficient implementation of recommendations and/or decisions taken by the Governing Board, the Executive Committee and the Policy Board. Finally, INSERM will support WP2 leaders in organization of the Policy Board meetings (once a year, M6/M18/M30/M42/M54). All meetings planned during the project will be held in different countries to raise visibility and encourage commitment. Joint or back-to-back organization of these events with workshops or Task Forces planned in different WP will be privileged in order to reduce the costs. SubTask 1.2.3: EJP RD internal communication (M1-M60) STL: INSERM (Coo) Beside regular conference calls and meetings of the OG and ExCom, the whole EJP RD Consortium will meet at least once a year, while each of the Pillars will follow its specific agenda according to planned activities. Due to the size of the Consortium, direct communication (on regular basis) will be ensured through a dedicated internal monthly newsletter including “EJP RD Actions Updates”. The internal Newsletter will summarize important timelines (conference calls, activity reports, deliverables etc.) as well as specific events outside the consortium of high importance for partners. An Intranet secured platform will be established for the exchange and deposit of project related documents accessible to all partners. Task 1.3: Monitoring of the EJP RD activities and achievements (M1-M60) TL: CVBF, Participants: ELIXIR, ULiv The aim of this task is to evaluate the quality of the EJP RD activities and the achievement of the expected project goals. The identification of KPIs and suitable metrics to monitor the impact of EJP RD activities not otherwise monitored within specific Pillars represents the first step of this task. The monitoring activities will include collecting and analyzing relevant documents (reports from Helpdesk and Pillars) to measure the performance and evaluate if the expected targets are reached. The results of the monitoring activities highlighting strengths and weaknesses of the EJP will be delivered to the coordination bodies for the adaptation of the strategy, integration in the annual reports and work plans, and to support risk management. SubTask 1.3.1: Identification of key performance indicators (M1-M60) STL: ULiv; Participants: Operating Group (INSERM [Coo & Orpha], DLR, UKL-HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS); CVBF, ELIXIR Upon definition of the key processes to be monitored the related KPIs, the metrics and the methodology for the monitoring of the project activities will be defined. The OG will participate to this subtask. To ensure an adequate quality standard, the EJP RD activities will be monitored and evaluated considering three perspectives: (i) internal to the EJP; (ii) the RD community; (iii) interfaces between the EJP and the broader health research community. The KPIs and metrics will be defined (and adapted) on the basis of: (i) overall and yearly objectives of the EJP RD; (ii) timeline of the milestones and deliverables; (iii) list of monitored procedures. Criteria which will be considered for the KPIs definition are: 1) all activities will be directed towards sustainability and 5 years strategy; 2) all performance indicators will be SMART and context specific; 3) limited in number and scope. The deliverable 1.7 “Monitoring activities Handbook” will contain: (i) the list of KPIs used for the monitoring of the EJP RD as a whole; (ii) the list of other performance indicators used within specific Pillars/WPs; (iii) the process to alert EJP to risks and issues (including mechanisms and timelines for escalation from Task to WP to Pillar to Coordination). EJP RD performance will be evaluated in term of compliance with: (i) standards for all monitored activities; (ii) user experience and assessment; (iii) review of “exceptions” when services do not meet standards. A workshop will be organized at month 2 with the ExCom, in order to approve the final list of proposed KPIs and related metrics, handbook of monitored procedures and methodology for the monitoring. The Monitoring Activities Handbook will be available by the end of Month 3. Since it may be necessary to revise and adapt KPIs and metrics during the project, in this workshop the responsible(s) for KPIs and metrics revision will be designated. KPIs and metrics revision and approval will be performed yearly at months 14, 26, 38 and 50 during the annual meeting or the coordinating board ExecCom meeting. A detailed description of the monitoring methods and procedures, together with the specific roles and competencies, i.e., who does what and how, will be included in the Handbook. SubTask 1.3.2: Implementation of the monitoring process (M1-M60) STL: CVBF, Participant: ULiv The monitoring will be performed continuously and reported every 12 months (12-24-36-48-60) in period deliverables called Monitoring Reports. The monitoring reports will serve to: (i) assess the quality and specificity 34 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. of performed activities; (ii) adjust the quality and specificity of planned activities; (iii) integrate the results of the monitoring in the up scaling model and sustainability beyond the EJP RD; (iv) disseminate the EJP RD results. The first Monitoring Report will be produced in the 1st AWP at Month 12 and will be used to monitor and assess the project progresses and to promptly identify issues which need corrective actions. Also, interim internal reports at month will be provided at month 6, 18, 30, 42, and 54 and will be used for drafting the Annual Work Plans at months 9, 21, 33, 45 and 57, respectively. Task 1.4: Data management plan (M1-M60) TL: INSERM, Participants: Operating Group (INSERM [Coo & Orpha], DLR, UKL-HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS); (Pillar 2 WPLs) As stated in the section 2.2.4 data management is one of the major activities of the EJP RD Pillar 2 and thus Pillar 2 can be assimilated as DMP itself. All data activities will follow Open Research Data principles (which conform to FAIR data principles), and comply with the GDPR and existing ethical and legal expectations for healthcare, research and patient data. Nevertheless, it will be important to describe how data management will be extended and tackled under other Pillars. That is why, EJP RD decided to deliver concise DMP at M6 taking the advantage of top-level experts of Pillar 2. This initial DMP will be updated in line with Pillar 2 developments and its revised version will be delivered at M42. Deliverables: D1.1: Report from the Kick-off meeting (M2) D1.2: Helpdesk directory of people and services (M3) D1.3: Report from the face-to-face ExCom and Policy Board meeting (M7, M19, M31, M43, M55) D1.4: Summary Progress Report and Annual Work Plan (M9, 21, 33, 45, 57) D1.5: Technical and Financial Report (M15, 27, 39, 51, 63) D1.6: Monitoring activities handbook (M3) D1.7: EJP RD Monitoring Report (M12, 24, 36, 48, 60) D1.8: Initial Data Management Plan (M6) D1.9: Updated DMP (M42) WP N°2 Integrative research and Lead beneficiary ISCIII, ISS innovation strategy Start date M1 End date M 60 Participant short APHP (54) ISCIII (44) (Orphanet) name & (N°) DLR (15) ZONMW UKL-HD INSERM INSERM EATRIS VUHSK ISS (26) (57) (32) (34) (75) (1a) (1) P.M 12 1 1 1 1 1 1 1 16 18 Participant short IT MoH EURORD ANR (11) name & (N°) ELIXIR Projects FTELE IS (77) CVBF MUW DTL- (LTP (27) (25) (21) (38) NL) P.M 2 1 1 2 4 1 Objectives: This WP focuses on the development of EJP RD research and innovation strategy in connection to all related stakeholders. Specific objectives are: ● To map the needs for RD research and innovation; ● To define the prioritization model for the EJP RD actions as part of the annual planning and in connection to WP3 (Sustainability) and WP4 (Ethical, Regulatory, Legal and IPR framework); ● To prioritize topics for the joint transnational calls (JTCs) to be implemented within Pillar; ● To feed the medium and long-term RD research and innovation strategy in collaboration with IRDiRC; ● To prepare a Scoping Paper to be promoted (and implemented) by the national mirror groups and within the current and forthcoming EC Framework Programme. 35 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Description of work Task 2.1: Prioritization scheme for EJP RD actions (M1-M36) TL: CVBF, FTELE; Participants: ISCIII, ISS The prioritization scheme will be based on a set of criteria and procedure defining the decision-making process, by which to order mapped needs and actions that contribute to the EJP RD objectives or that stand in need of further exploration. The identified criteria will encompass scientific evidence aspects, demands of the RD community, regulatory and societal concerns and take into account financial and technical feasibility. The criteria will be defined based on the input collected (through a survey) from RD stakeholders representing research community, ERNs, patients and policy makers. The ExCom will endorse the prioritization criteria and will submit the prioritization scheme for the input and validation of the Governing Board to be finally adopted by the Policy Board during its first face-to-face meeting. Task 2.2 Mapping the research and innovation needs (M1-M48) TL: ISCIII, ISS, Participants: Operating Group (INSERM [Coo & Orpha], DLR, UKL-HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS); DTL-Projects (ELIXIR-NL); MUW The aim of this task is to identify and regularly update the research and innovation needs that will feed the EJP RD Annual Plans and contribute to the development of the long-term strategy of the EJP RD. This mapping exercise will include inputs from: ● Internal input from the EJP RD (Operating Group); ● National and EU needs represented by the EJP RD Policy Board and in connection to national mirror groups; ● Yearly analysis of the state of play of funded research and drug development, overlaps and trends at international level (based on data collected in Pillar 2, WP11, Task 11.2); ● International research strategy developed by the International Rare Diseases Research Consortium (IRDiRC) and represented by its scientific and constitutive committees. Taking into account the overall objective of the EJP RD is to establish a sustainable structure for support of RD research and innovation, the mapping shall expand beyond mere scientific requisites and encompass other connected domains comprising: (i) Diagnosis & healthcare; (ii) Regulatory & ethics (including the open data & science issues); (iii) EU competitiveness & innovation. The inputs will be collected from all stakeholders on a yearly basis within the first trimester of every year. A summary document will be generated and sent to the Policy Board and ExCom as basis for prioritization exercise. The Policy Board will meet once a year (month 6) to deliberate, prioritize (according to prioritization scheme developed under Task 2.1) and issue recommendations to the EJP RD ExCom on the actions to implement within subsequent Annual Work Plan and the ones that require medium and longer-term investigation. In addition to informing Annual Work Plan, the outcomes of the mapping and prioritization will be reformulated in the form of Scoping Paper (prepared by the Task 2.2 leaders with help of CO) to be transmitted to the leaders of Task 2.3, 2.4 and 2.5 for complementary actions. Task 2.3: Scientific programming of joint transnational calls (M1-M36) TL: ISCIII, ANR, Participants: DLR, FFRD, IT MoH The joint transnational calls (JTCs) to be implemented within Pillar 1 represent important resource of both funding and research capacity. Firstly, because their goal is to integrate national investments into RD research under single, common programme; secondly, because funded research projects not only advance knowledge, diagnosis and therapy development for RDs in general, but also should significantly contribute to the development, improvement and demonstration of the EJP RD infrastructure, tools and methodologies. Thus, programming of research topics for JTCs will be treated with particular attention. The above-mentioned mapping and prioritization exercise will serve as basis to produce JTC topics table that will be submitted for further refinement by the specific ad hoc Scientific Advisory Board called on the demand of Pillar 1 Call Steering Committee(s). As result, a list of maximum 3 detailed topics will be produced. Particular attention will be made to avoid any COI of Research Performing Organizations participating in the EJP RD and that would be eligible to apply to JTCs. That is why, the final decision on topics will be taken independently by the Board of Funders, in agreement with the established call rules and national prerogatives (see Pillar 1 WP6). Task 2.4: Management of the medium, longer-term research strategy questions and dedicated linkage with Task Forces of IRDiRC (M1 – M60) TL: INSERM (Coo), Participants: Operating Group (INSERM (Orpha), DLR, UKL-HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS); ISCIII, ISS At present each of the IRDiRC Scientific (Diagnostics, Interdisciplinary, Therapies) or Constituent (Funders, Patients Advocacy, Companies) Committees has the possibility to seize upon specific RD research need or bottleneck and propose a Task Force aiming at issuing recommendations or concrete actions to overcome the 36 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. identified obstacle. The majority of EJP RD countries and the European Commission are also members of IRDiRC and participate actively in different committees. Furthermore, the Chair and Vice-Chair of IRDiRC will be members of EJP RD Policy Board. Such strong connection is a mutual advantage and will prevent duplication of efforts. Thus, any research strategic question or need identified by the Policy Board as requiring medium or longer- term approach (Task 2.2) will be studied in relation to the ongoing or future Task Forces planned within IRDiRC activities. Whenever an issue recognized by Policy Board either of national or EU-specific nature, a dedicated, IRDiRC-independent Task Force(s) will be proposed. The setting up of a Task Force will follow well-established scheme proposed by IRDiRC, composed of the following steps: (i) Analysis and preparation of background document; (ii) Call for experts to constitute TF working group; (iii) Establishment of TF work plan; (iv) Up to 6 months of work including regular conference calls; (v) Production of final recommendations and/or roadmap to be followed by the engaged stakeholders (enquirers); (vi) Dissemination. Any other issue with identified synergy to IRDiRC TF will be integrated and treated jointly. Finally, needs/questions of international wingspan, not yet treated by IRDiRC will be proposed as subjects for new collective Task Forces. The EJP RD Coordination office (including IRDiRC SciSec) will be responsible for the management of the TF. Task 2.5: Translation/impact of prioritization on national and EU strategies (M6 – M60) TL: ISS, MUW, Participants: EURORDIS, FTELE, ISCIII, IT MoH It is expected that the European dimension of the EJP RD and involvement of the Policy Board should have impact both ways - on the activities of the EJP RD itself but also on the undertakings at national and EU level. Thus, the T2.2 Scoping Paper will be promoted by the national mirror groups and within the current and forthcoming EC Framework Programme. In addition, the Task leaders will be responsible for collection of information from EU Member States (via a survey targeting national mirror groups) on the EJP RD relevant/complementary actions performed at national level. Specific focus will be made on EU-13 countries in respect to their specific needs, obstacles and advancements. A report analyzing national alignment with EJP RD will be produced annually and presented at the occasion of the Policy Board & ExCom meetings. In addition, two Strategic Workshops with relevant policy stakeholders will be organized (M33, M57). Deliverables: D2.1: Final list of prioritization criteria (M5) D2.2: Prioritization scheme including decision-making process (M5) D2.3: Summary document on mapped research and innovation needs (M5, 17, 29, 41, 53) D2.4: Scoping paper (M7, M19, M31, M42, M54) D2.5: List of refined JTC topics (M7, M19, M31) D2.6: List of research and innovation needs requiring medium- or long-term approach and related Task Forces (M7, M18, M30, M42, M54) D2.7: Analysis of national state of play and alignment process with EJP RD (M9, M21, M32, M55) D2.8: Report from strategic workshop with national policy makers (M34, M58) WP N°3 Sustainability strategy and Lead INSERM, EATRIS, ISCIII business plan beneficiary Start date M1 End date M 60 Participant short (ELIXIR NL DTL-Projects EATRIS (75) VUHSK (32) EURORDIS name & (N°) APHP (54) ISCIII (44) (Orphanet) ULIV (51) (RaDiCo) DLR (15) ZONMW UKL-HD INSERM INSERM INSERM (Coo) (1) (1b) (57) (34) (76) (77) (1c) P.M 12 13 1 1 1 1 1 14 1 1 3 3 1 3 Objectives The objective of WP3 is to prepare, and implement the EJP RD sustainability strategy in collaboration with the EJP-RD boards, Pillars and relevant WP/Task leaders. The strategy will identify routes to sustainability and develop relevant action plans. Specific objectives: 37 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. ● Identify elements of the EJP RD that are potentially sustainable by integrating information from the monitoring of EJP activities (WP1) with feedback from targeted end-user groups and key stakeholders including entities that will provide the resources for sustainability (ex. EU Member States); ● Identify potential sustainability models, including both ‘classic’ and innovative approaches to fund-raising activities, business models and legal status of on-going European infrastructures and initiatives; ● Initiate efforts to promote the sustainable activities of the EJP-RD; ● In collaboration with WP4 (Ethical, regulatory & legal framework) formulate recommendations for the governance of the organization(s) that will succeed EJP RD with a particular focus on intellectual property and access issues; ● Develop the sustainability roadmap of the EJP RD. WP3 will ensure liaison with other strategic initiatives working on global sustainability issues (e.g. RDA, EOSC, EC-funded e-Infrastructures, ESFRI Forum and its Health and Food Strategic Working Group, relevant H2020 projects and other international initiatives) in view of aligning strategic sustainability activities and exploiting synergies. Description of work WP Methodology Sustainability strategy encompasses several important aspects that will be addressed in this WP: (i) identification of value propositions that emerge from EJP RD activities, taking into account effective segmentation of capabilities and markets and the needs of resource holders; (ii) developing business plans for the activities of EJP RD that are sustainable, including identification of necessary resources; (iii) scoping legal and governance issues relating to sustainability. The experience and lessons learnt from the performance of E-RARE, RD-Connect, Orphanet, ERNs and other initiatives indicate that long term sustainability is a serious issue necessary to be tackled by the EJP RD as early as possible. Consultation with internal and external stakeholders will be essential to ensure that the approach to sustainability is appropriate and that sustainability is considered throughout the programme. Task 3.1: Service roadmap: alignment of the needs, expectations and engagement of the different RD research stakeholders in Europe with respect to EJP RD sustainability (M1 – M36) TL: INSERM (RaDiCo), ISCIII, Participants: ULiv, DTL-Projects, Operating Group (INSERM [Coo & Orpha], DLR, UKL-HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS) In close collaboration with the OG and transversal WPs 2 & 5, this task aims to integrate and maintain the information collected on needs, expectations and possible contributions of: (i) National Programme Owners (PO) and Programme Managers (PM) (Subtask 3.1.1 led by ISCIII) and (ii) other stakeholders (Subtask 3.1.2 led by INSERM-RaDiCo) to define in a standard format value propositions that can drive sustainability perspectives. In a 360° perspective matrix-based approach, the stakeholders will be segmented into specific subgroups (funders and public authorities, patients, researchers and learned societies, care givers, industry) taking into account their needs, expectations and possible contributions (including long term financial and/or in-kind commitment). This task will develop value propositions for “viable” activities that will be prioritized via Task 3.2 and by stakeholders with resources that can sustain them. Task 3.2: Preparation of the sustainable EJP-RD services catalogue, supporting the EJP-RD dissemination and communication activities (M12 – M36) TL: INSERM (RaDiCo), EATRIS, Participants: ISCIII, ULiv, DTL-Projects Based on the results of Task 3.1 together with subsequent internal monitoring of EJP RD performance (WP1, Task 1.3), inputs from Pillars and Transversal WPs, and clear user demand, a catalogue of services will be compiled by WP3 and disseminated by WP5. The dissemination will include participation at dedicated events or channeling information to the ESFRI infrastructures, funding agencies and governmental bodies about the ‘catalogue’ and EJP RD plans and successes. In addition, WP3 will support EJP RD components seeking resources to develop study cases of innovative sustainability solutions. Task 3.3: Preparation of the EJP-RD sustainability plan with business plan (M1 – M42) TL: EATRIS, ISCIII, Participants: INSERM (RaDiCo), ULiv, DTL-Projects The task will consist of benchmarking of sustainability strategies that exist in the EU research fields, such as European ESFRI landmark research infrastructures and projects in the ESFRI Roadmap, European and national research data hubs (e.g. EOSC / EDI), public and private institutes, foundations across the globe, with strong interconnections and involvements of NGOs, private partners and public bodies. The results will be assessed, with high potential benchmark strategies collated for possible use in the EJP sustainability roadmap. Then, the specific ecosystem in which the EJP RD will operate will be evaluated: current state, target users, relevant unique value within-project take-up, post-project take-up, financial aspects, and competitive analysis. The evaluation of the ecosystem will identify the expectations and requirements of the member states (and other sources of sustainable 38 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. resources) regarding: (i) expected benefits and willingness to pay; (ii) constraints on operational structure, legal model, IP and other governance issues. The potential sustainability models identified will be submitted to a SWOT analysis including their structure and governance differences, budgetary needs, legal and tax-related environments, and the identification of potential financing sources and their possible consequences on competing or synergistic interests. The sustainability cases will be based on a business case with strategy of clients and combination of financial sources, including: national funds for availability of e-Infrastructures, public funds and research grants, regional resource sharing and collaboration via Memorandum of Understanding, public-private partnerships and exploration of pay-per-use and in-kind business models. Sustainability models will be targeted to segments of resource holders. Finally, the most relevant sustainability models will be selected with its business case, taking into account prioritization information from the EJP RD sustainable service catalogue produced by Task 3.2, and presented to the EJP RD Governance and the stakeholders. The models will include the following criteria: (i) open- access versus controlled availability of the EJP RD deliverables and outcomes in line with European Open Science Cloud and European Data Infrastructure, (ii) design of services that enable researchers to make the most of the EJP outcomes (iii) ensuring the possibility for accession of new members/contributors interested in joining, (iv) identification of cash flow between the actors, (v) pricing of services, (vi) financial viability and (vii) buy-in by the stakeholders. The selected sustainability models should include the Beneficiaries having contributed to the considered deliverables and PO, PM and other key stakeholders that are involved in RD research (and beyond). A first list of the relevant models addressing sustainability for key stakeholders will be delivered. This list will be published for a public consultation. Following it, a refined list will be delivered to inform the Task 3.4. Task 3.4: Sustainability roadmap (M36-M60) TL: ISCIII, EATRIS, Participants: INSERM (RaDiCo), ULiv, DTL-Projects This task will build on Tasks 3.1 – 3.3 to define the final sustainability roadmap for the EJP RD with all milestones to be reached in order to roll out and implement the selected model to ensure sustainability of the integrated RD research infrastructure at both EU and national levels. Upon the preferences and requirements expressed by Member States a proposal with SWOT produced in T3.3 and future KPIs will be drafted and presented to Members States for adoption after the EJP RD ends. A first version of the sustainability roadmap will be prepared and defined at M46. The roadmap will be finalized at M54 with final decision after an iterative process taking into account associated deliverable completion and evaluation by other WPs. Deliverables: D3.1: Dynamic catalogue of EJP-RD sustainable resources including Service Roadmap Database (M36) D3.2: Study cases of innovative sustainability solutions for specific EJP RD outcomes (M36) D3.3: Analysis of structures, business models and required complementarity from other relevant initiatives (M42) D3.4: Proposal of structure, governance and financial model and global sustainability roadmap (M46, M54) WP N°4 Ethical, regulatory, legal and IPR Lead beneficiary FGB, FTELE framework of the EJP RD Start date M1 End date M 60 Participant short EATRIS (75) VUHSK (32) ELIXIR (76) BBMRI (73) name & (N°) CVBF (27) APHP (54) (Orphanet) DLR (15) ZONMW UKL-HD INSERM INSERM (Coo) (1) (1b) (57) (34) P.M 12 1 1 1 1 1 1 1 2 1 1 Participant short EURORDIS FTELE (25) ECRIN (74) name & (N°) (RaDiCo) FGB (24) INSERM (77) (1c) P.M 20 16 1 2 1 Objectives 39 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. This WP aims at providing all Pillars with the proper strategy to address ethical, regulatory (including GDPR), legal and Intellectual Property Right (IPR) issues, and at ensuring that relevant rules are complied with within the course of the EJP for RD. The specific objectives include: ● Setting up an ‘Advisory Ethics Board’; ● Advising on the regulatory procedures and ethical provisions to perform regulatory-compliant research and data collection and to protect patient rights; ● Coordinating activities related to IPR issues of the EJP for RD as a whole. This will allow EJP RD to perform not only ethically-sounded but also regulatory-compliant multi-national research. Description of work Task 4.1. Setting up the ‘Advisory Regulatory Ethics Board’ (M1-M4) TL: FGB A project ‘Advisory Regulatory Ethics Board’ (AREB) will be set up. It will be composed of internal EJP RD experts in regulatory and ethical framework, including members with recognised expertise from involved European RIs. AREB will ensure compliance with all relevant rules, including but not limited to patient rights, data management, protection and confidentiality, and will be able to address all the regulatory and ethical needs of the project, as it will comprise the necessary expertise and knowledge. Task 4.2 Managing ethical and regulatory issues (M1-M60) TL: FGB, Participants: BBMRI, ECRIN, ELIXIR , CVBF, INSERM, Operating Group (INSERM [Coo& Orpha], DLR, UKL-HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS) In order to ensure compliance of the project and its activities with ethical and regulatory requirements, the AREB will be in charge of overseeing ethical issues and regulatory procedures envisaged in the EJP RD four Pillars and by assisting partners. Specifically, the AREB will: ● Collaborate with Pillar 1 to ensure that the Joint Transnational Calls for collaborative research projects will include all relevant requirements in the call text and guidelines for applicants; ● Verify that the collaborative research projects funded in Pillar 1 as well as pilot project/proof of concept foreseen in Pillars 2 and 4 activities are regulatory- and ethically-compliant and that they will properly address patient rights and the necessary regulatory procedures, e.g. ethical approval, authorisation from competent authorities, regulatory advice from EMA or national agencies (Scientific Advice/Protocol Assistance, EMA qualification opinion, certification of ATMP quality etc.), Paediatric Investigation Plan (PIP) or waiver, pharmacovigilance obligations; ● Inform and update EJP RD consortium partners on the advancements, changes and news from the regulatory, ethical and legal framework during the yearly EJP RD Consortium meetings; ● Support EJP RD partners with ethical and legal advice whenever requested; ● Provide recommendations in case of detection of possible gap in the regulatory/ethical/legal framework to be applied in multi-national biomedical research in the context of the EJP RD. A dialogue with the EMA and its committees as well as the national competent authorities will be established. Whenever relevant, other regulatory agencies/authorities will be addressed as well, e.g. Food and Drug Administration (FDA, US) and Japanese Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency (PMDA). Task 4.3. Managing legal and IPR issues (M1-M60) TL: FTELE, Participant: FGB, BBMRI Considering the high number of partners in the EJP RD consortium and the variety of planned activities, a one-size- fits-all approach cannot be adopted. The Task Leader (TL) will therefore manage case by case the requests from EJP RD beneficiaries and proactively monitor the IP relevant issues throughout the whole project duration. The IP support report will serve as input to the Monitoring (Task 1.3) of the EJP RD activities and outcomes. Every six months, the TL will interview the ExCom in order to: ● Collect emerging needs on IP issues in every WP; ● Identify the activities more likely to produce results that are expected to be commercially or industrially exploitable and therefore needs IP protection; ● Keep track of the IP generated by each of the WPs, in particular in terms of copyrighted softwares or training materials and patents (if any) and feed the WP3 Sustainability strategy. Moreover, the TL will: ● Collect and archive any new or updated declaration on background IP by EJP-RD beneficiaries; 40 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. ● Upon request, facilitate the contact and the negotiation between the Technology Transfer Offices and/or legal departments of the relevant beneficiaries in case of joint ownership of the results; ● Make available, through the EJP RD website, a set of legal templates for Inter Institutional Agreements, Data Transfer Agreement and Material Transfer Agreement compliant with EU rules, Grant Agreement and Consortium Agreement provisions; ● Upon request, support EJP RD beneficiaries in the use and adaptation to their specific needs of the above mentioned templates. Deliverables: D4.1 First AREB report (M6) D4.2 Periodic AREB report (M19, M31, M43, M55) D4.3 Set of template agreements for EJP RD website (M6) D4.4 Periodic IPR report (based on ExCom inputs) (M6, 12, 18, 24, 30, 36, 42, 48, 54, 60) D4.5 IPR support (monitoring) report (M6, M12, 18, 24, 30, 36, 42, 48, 54, 60). WP N°5 Communication & dissemination Lead INSERM beneficiary Start date M1 End date M 60 Participant short ZONMW (34) UKL-HD (57) BLACKSWA EATRIS (75) name & (N°) VUHSK (32) TEDDY (28) (Orphanet & EURORDIS APHP (54) ULIV (51) LTP) (1b) DLR (15) INSERM INSERM (Coo) (1) N (80) (77) P.M 62 1 1 1 1 1 1 12* 1 1 1 6 * Participation in kind Objectives ● Prepare and support the communication and dissemination strategy for the EJP RD as a whole and taking into account the needs of each Pillar and transversal WPs ● Effectively communicate on activities of each Pillar/WP to a wide range of stakeholders and potential users in a coherent, targeted and timely manner; ● Actively disseminate outputs from all work packages through a wide range of channels and tailored activities to target audiences; ● Promote the initiative and ensure awareness by establishing dialogues with key stakeholders and potential partners at national and EU level. Description of work Task 5.1: EJP RD external communication & dissemination of results (M1-M60) TL: INSERM (Coo), Participants: Operating Group (INSERM (Orpha), EURORDIS, DLR, UKL-HD, APHP, VUHSK, EATRIS, ZonMw), BLACKSWAN Subtask 5.1.1: Implementation of the EJP RD communication strategy (M1-M60) STL: INSERM (Coo), Participants: Operating Group (INSERM (Orpha), EURORDIS, DLR, UKL-HD, APHP, VUHSK, EATRIS, ZonMw) The operational day-to-day management of the communication & dissemination will be ensured by the Communication Manager (CM) who will be part of the Coordination Office. The CM will collaborate closely with the Operating Group to provide the interface between the partners participating in different pillars/WPs, collect their needs and provide suitable communication and dissemination means to design communication actions targeted for the different audiences. The CM will be responsible for the timely aggregation of items requiring communication/dissemination actions and propose implementation, in line with the communication and dissemination plan provided in the proposal, and taking advantage of the centrally provided tools (website, broadcast media, scientific support from project managers) coupled with the extensive capacity and international coverage of the EJP RD partners (see also Task 5.2). The strategy will be adapted to the type of stakeholders: general public, patients, policy makers and research community. The initially proposed frequency and formats will 41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. be agreed and validated by the Executive Committee with the possibility of revision whenever deemed necessary. Impact of communication and dissemination activities will be assessed during the course of the project via the Task 1.3 (Monitoring). Dissemination activities will be tracked and evaluated regularly based on the criteria determined in the Communication and Dissemination Plan to ensure an efficient impact and European-added value. Subtask 5.1.2: Communication and dissemination tools (M1-M60) STL: INSERM (Coo), Participants: BLACKSWAN EJP RD website: the website will be established at the start of the project (M2). It will be a central tool to communicate, disseminate the results but also serve as a single entry point for the EJP RD Helpdesk (see Subtask 1.1.2). The website will be developed and maintained by INSERM under the responsibility of Coordination Unit and Communication Manager in particular. The website will constantly updated and will feature individual pages dedicated to specific activities developed within each Pillar and transversal WPs as well as sections focusing on promotion of relevant news and activities of other EJP RD related initiatives. It will also encompass user-friendly interface for the EJP RD Helpdesk. Newsletters: Project newsletters and flash news will be produced and disseminated through various listing of stakeholders. The service used will be MailChimp, which has several reporting features such as download/access statistics and breaking down the subscribers by country, age and gender etc. The newsletters will also be published on the website. Social media pack: The social media like Facebook, Twitter or LinkedIn are now part of the regular communication and dissemination panoply. They will be also included in the EJP RD communication strategy. Special attention will be given to the regular follow up and appropriate management (including privacy policy) of these tools to be subsumed under duties of the CM. Printed communication materials: leaflets, brochures presenting the goals and activities of the EJP RD for the distribution during meetings and workshops; generic posters with the intention to reflect the status of the project and to support the presentations at events and meetings. Whenever possible these communication materials will be translated into the national languages of the EJP RD partner in order to facilitate and increase awareness. Broadcast media: The audio and video support will be available to cover EJP RD events, interviews and preparation of dedicated content (ex. general public, young patients, to feature new tools, etc.). EJP RD will pro- actively engage with EC specific (e.g., Horizon Magazine, Cordis) and international media. Scientific writing support: The experience gathered by the SciSec of IRDiRC (see also Task 1.1.1) showed that centralized support for writing of reports, drafting of papers and preparation of scientific contents increases the efficiency of the communication and dissemination of outputs produced by numerous Task Forces, workshops and working groups. This model will be also implemented in the EJP RD. The scientific writing support will be provided by the CM and EJP RD project managers. This core group may be reinforced on an ad hoc basis by experts mobilized from among EJP RD partners. Scientific Congresses: The EJP RD intends to continue the collaboration initiated by E-Rare and IRDiRC with BlackSwan Foundation to support and further expand RE(ACT) Congress. In addition, collaboration with other relevant events like ECRD, ICORD, UDNI or ESHG congresses will be used to strengthen the dissemination capacity and exploit the potential of these events to promote excellent research financed by Pillar 1 (and previously by E-Rare), outcomes of other Pillars and provide stimulating environment for RD community. Joint targeted workshops fostering promotion and collaboration with relevant stakeholders (regulatory bodies, patients or private investors) will be also organized at these occasions. Subtask 5.1.3: Support of communication and dissemination activities of IRDiRC (M1-M60) STL: INSERM At present the communication and dissemination support of IRDiRC is ensured by its Scientific Secretariat. It includes the maintenance and regular updates of the IRDiRC website, the development of a monthly newsletter, updates on social media and development of suitable written content and organization of IRDiRC Congress. Since IRDiRC SciSec will be integrative part of the EJP RD Coordination office, these activities and dedicated to IRDiRC communication tools will be maintained (along with other responsibilities of the SciSec) and supported by Communication and project Managers. Yearly communication and dissemination plan specific to IRDiRC will be presented at the IRDiRC Consortium Assembly. Task 5.2: Integrating EJP-RD communication and dissemination strategies with the strategies of involved stakeholders (M1-M60) TL: INSERM(Orphanet LTPs), Participants: EURORDIS, TEDDY, ULiv The EJP RD gathers 85 partners from 32 EU, associated and non-European countries. Many involved beneficiaries represent networks or projects that cover multitude of stakeholders like research communities (alliances, learned societies), healthcare providers, patients (including young patients) or policy-makers (ministries, ethics and data 42 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. protection authorities, HTA). Thus, the internal potential of EJP RD partners should not be neglected, as it will serve to vehicle unified information and multiply the communication and dissemination capacity of the EJP RD at regional and national level. For this Task the Orphanet and EURORDIS networks already implemented in all of the EJP RD countries will be used to link with national RD stakeholders and support EJP RD communication & dissemination efforts. The TEDDY and C4C networks (ULiv), specifically dedicated to pediatric clinical research and having large experience in communication to young patients will second EURORDIS and Orphanet. Finally, national networks of collaborators (including voluntary helpers) will assist in adapting and translating the EJP RD newsletter, specific reports or publication in national languages to reach wider public. Deliverables: D5.1: EJP RD website (M2) D5.2: EJP RD Newsletter (M2) D5.3: RE(ACT) Congress report (M16, M30, M54) PILLAR 1: RESEARCH COLLABORATIVE FUNDING WP N°6 Joint Transnational Calls for Lead beneficiary DLR collaborative research projects Start date M1 End date M 60 Participant IT MoH (21) MEYS** (8) NKFIH (19) FRQS* (85) CIHR* (84) short name & MoSAE (9) MIUR (29) FFRD (12) AKA (10) ANR (11) HRB (20) FNRS (5) DLR (15) FWO (6) (N°) FWF (2) P.M 3 3 3 0 0 0 3 3 12.4 15.4 21. 3 3 3 3 4 Participant VINNOVA (49) TUBITAK (81) CSO/MoH (78) short name & TuscReg (22) ZonMw (34) (N°) EURORDIS NCBR (37) FRRB (23) ISCIII (44) SNSF (79) LMT (31) FNR (33) SRC (48) FCT (41) SAS (43) (77) P.M 3 3 3 3 3 3 3 3 12.4 3 3 3 3 3 3 * Full beneficiary not receiving EC funding; **Full beneficiary contributing with in kind PMs Objectives The funding of transnational collaborative research is critical to enhance the cooperation between scientists working on rare diseases across Europe and beyond, and thus reduce the fragmentation of research in this field. Therefore, the central Pillar 1 activity is providing financial support to third parties. WP1 will foster the implementation of four joint transnational calls for research projects combining national/regional funding and EC co-funding. Transnational calls including basic, translational, clinical, social and health economic research topics will be included in the overall research agenda for the five years of the EJP RD. The first two calls should have broad topics to enable the widest participation of funding organizations. It is expected that at least 60 Mio € will be spent to research projects in the four calls. Specific objectives are: Implementation of four joint transnational calls for research projects combining national/regional funding and EC co-funding which include the tasks: ● Topic selection ● Preparation of the call and establishment of the joint call secretariat ● Evaluation of the joint call and funding decision ● Quality management of call procedures Description of work 43 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. The Joint Transnational Calls (JTCs) will be implemented using the “virtual common pot” funding mode. This means that national/regional funding will be made available through national/regional funding organisations according to their own regulations. In addition, in two Joint Transnational Calls the EC will also provide funding that will maximize the number of selected projects that can be funded. Each country/region will fund only their own national/regional component of the transnational research project. Funding from the EC will be distributed through the national/regional funding agencies. The participation in each call will be negotiated between the EJP Pillar 1 funding agency partners on the basis of their possible funding commitments, taking into account the principle of variable geometry (i.e. that each partner decides to join one, several or all planned calls on the basis of their political and financial possibilities and commitments). Moreover, funding bodies (agencies, patient organizations, charities) not belonging to the EJP RD will also have the possibility to support the calls and provide additional funding. The representatives of the participating funding agencies in a joint call will constitute the call steering committee (CSC), which is in charge of deciding on the final topic (based on inputs from Task 2.3) selection and the specific design of the joint call. The CSC will also be the monitoring body for all actions taken by the acting joint call secretariat (JCS). The implementation of transnational research funding will be streamlined according to the lessons learned in the previous E-Rare JTCs and will be built on the established procedures and underlying documents. Due to the yearly overlapping of the joint calls the JCS responsibility will be shared between four partners (DLR-PT, Germany; ANR, France; FFRD, France; ISCIII, Spain) in order to distribute the workload and ensure good practice. Three partners have experience in managing joint transnational calls in several ERA-Nets, including E-Rare, or other transnational initiatives. Most importantly, the incorporation of the joint transnational calls within the broader EJP RD ecosystem provides a unique opportunity for synergies between the individual research projects (Pillar 1) and the supporting resources and tools (Pillars 2-4) since successful research projects will be supported by and will make use of the methodologies, tools and resources made available through Pillars 2-4 (strong recommendations on Data Management Plan, use of Pillar 2 Virtual Platform and links to other relevant activities of the EJP RD will be explicit). Task 6.1 1st co-funded Joint Transnational Call (JTC 2019) (M1-M12) TL: DLR; Participants: all participants in the call Subtask 6.1.1 Topic selection and eligibility criteria (M1) TL: DLR; Participants: all partners joining the call As indicated above the topics of co-funded calls will be broad topics to enable the widest participation of funding organizations. The call will focus on implementing IRDiRC objectives. Special consideration will be given to avoid duplication with Horizon 2020 calls in the area of rare diseases. Examples of research areas to be supported include but will not be limited to: ● Cutting-edge basic science research into pathomechanisms and molecular pathways ● Dedicated models that efficiently mimic human conditions ● Natural history studies with improved, scalable and participants-centered registries ● Development of new therapies in preclinical setting and improvement of existing highly specialized treatment procedures ● Discovery and validation of robust biomarkers ● New schemes for finding diagnosis for undiagnosed patients ● Improved annotation and interpretation of variants and development of diagnostic tests for the more prevalent variants ● Functional analysis of candidate variants through cell and animal studies. The final validation of the topics will be taken by the CSC in close collaboration with the EC. General eligibility criteria: Only transnational projects will be funded. Usually each consortium submitting a proposal will have to involve a minimum of three eligible and a maximum of six eligible partners from at least three different countries participating to the call. Not more than two eligible partners from the same country participating in the call will be accepted in one consortium. The consortium coordinator must always be eligible to receive funding from the funding organisations participating in the call. Whilst applications will be submitted jointly by research partners from several countries, individual groups will be funded by the individual funding organisation of their country/region that is participating in the call. The applications are therefore subjected to eligibility criteria of individual funding organisations. Joint research proposals may be submitted by applicants belonging to one of the following categories (according to country/regional regulations): ● Academia (research teams working in universities, other higher education institutions or research institutes) 44 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. ● Clinical/public health sector (research teams working in hospitals/public health and/or other health care settings and health organisations) ● Enterprise (all sizes of private companies). Participation of small and medium-size enterprises (SMEs) is encouraged when allowed by national/regional regulations. Although no limit will be set for maximum grant amount, is expected that consortia will apply for budgets aligned with the proposed research activities planned for maximum of 36 months. Moreover, national budget limitations may apply. Subtask 6.1.2 Preparation of the call and establishment of the joint call secretariat (M1-M2) STL: DLR; Participants: all partners joining the call The task leader will be responsible for drafting and finalizing all necessary documents: Memorandum of Understanding, Call text, Governance and evaluation procedures, Guidelines for applicants and Proposal templates. Previous versions of these documents already established within E-Rare-3 ERA-Net and validated by the Commission, will efficiently be used as templates. In addition, the task leader will set up the JCS. The JCS will act as central support to the applicants regarding all aspects of proposal drafting and submission. Finally, each participating funding organization will establish its national contact point. Potential applicants will be strongly encouraged to contact their national representative for advice on national rules and regulations, including eligibility and financial budget regulations. The call for proposals will be published on the EJP RD website and by the national funding organizations via their national publishing routines such as websites, newsletters, press announcements. The publishing instruments of the EC like the Participant Portal and ERA-LEARN will be used as well. If feasible and necessary, a call pre- announcement will be published to maximize the early mobilization of the rare diseases research community. The EC will be duly notified of the call and its content at least 30 days before the expected date of publication. The call will be opened for the submission of proposals for at least 60 days. Subtask 6.1.3 Evaluation of the joint call (M1-M10) STL: DLR; Participants: all partners joining the call The evaluation will be implemented in a two-step procedure according to the Horizon 2020 rules. In the first step, applicants are invited to submit pre-proposals, which describe a short outline of the proposed work. The eligible applications will first undergo national eligibility check and then be submitted to the transnational peer review Scientific Evaluation Committee (SEC) composed of independent expert scientists chosen for their scientific, technical and/or disease-specific expertise, as well as patient representatives. The Committee will be as far as possible gender and geographically balanced, including experts from countries participating and not participating in the call, experienced (i.e. previous SEC members) as well as new members. Reviewers will be carefully selected with regard to any potential conflict of interest. Each pre-proposal will be reviewed by two SEC members with expertise in line with the research proposal. The evaluation of proposals will be aligned on the scoring system and criteria (‘excellence’, ‘impact’ and ‘quality and efficiency of the implementation’) given in Annex H of the General Annexes of the Horizon 2020. The SEC will select the most promising applications for submission of a full proposal. The tentative number of proposals retained for the second step will be about 2-3 times the number of possibly funded projects and will depend on where a break is perceptible in the quality of proposals. In the second step of the evaluation the JCS will check the submitted full proposals to ensure that they meet the call formal criteria and have not changed substantially from the respective pre-proposals. Subsequently, the submitted full proposals will be reviewed by at least five independent experts: two (remote) external specialists of the disease and/or approach described in the research proposal and three members of the previously established peer review SEC. As the diseases and research approaches vary widely within the large field of rare disease research, addition of external (remote) evaluators is seen as beneficial to support the final decision of the SEC by providing supplementary expertise. The anonymized reports of external (remote) reviewers will be sent to the project coordinators to allow them to respond to the evaluators’ comments in a so-called “rebuttal step”. These external evaluations and the rebuttal letter will serve as additional information to the SEC members. In a second meeting, taking into account all this information, the SEC will agree on a final ranking list of excellent proposals recommended for funding. The consortium will take all lawful steps to ensure confidentiality of information and documents obtained during the evaluation and selection procedures of the joint call. In addition, an independent expert will be invited as official observer to the second SEC meeting to assess the conformity of the general implementation of the joint call and specifically the proper implementation of the international peer review and establishment of the ranking list of transnational projects. The assessment of the observer will be provided in a report to the European Commission. Subtask 6.1.4: Funding decision (M10-M12) STL: DLR; Participants: all partners joining the call 45 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. The CSC will take its final funding decision based strictly on the scientific recommendation of the SEC (ranking list). As many full proposals as possible with a clear funding recommendation will be funded, taking into account the available budget. Each eligible applicant will be funded by the organization of the country from which the applicants have applied and according to the national administrative regulations (virtual common pot model). The final distribution of the EC contribution will be discussed and agreed by the CSC in order to maximize the number of high quality proposals to be funded by filling funding gaps and/or topping up the national contributions (mixed model). This will be done in accordance to the general criteria fixed in advance to the launch of the call to avoid the underestimation of national budgets and to permit a balanced distribution of the EC contribution in line with the national funding. If proposals have identical scores, the proposals coming from participating Member States or associated countries with still available funding will be given precedence, in order to further maximize the number of selected projects. The joint selection list of projects to be funded will be communicated to the EC. The applicants will be informed about the final funding decision and the national negotiations will commence. The final funding list will be prepared by the JCS and provided to WP5 for publication on the EJP RD website and Newsletter, the relevant EC portals as well as the IRDiRC webpage. Subtask 6.1.5 Quality management of call procedures (M1-M12) STL: DLR; Participants: all partners joining the call The practicability of administrative and operational mechanisms used for implementation of calls, peer review, funding of projects and scientific follow up will be monitored by the JCS with feedback from all participating stakeholders. The lessons learned will feed the call design and implementation of the next joint calls. Thus, the evolution of robust and functional administrative and operational practices will be facilitated and continual process improvement will be implemented. Results of this quality management process will be incorporated in the lessons learned reports for individual calls and presented to the CSC. In addition, detailed statistics and information of the submitted, pre-selected, recommended and funded proposals will be collected and made available on the demand of the European Commission. Task 6.2 – 6.4 Joint Transnational Calls 2020-22 TL: DLR In general, the description of work for the other calls is analogous to the first call described above. Lessons learned from the first call and strategic input from the other work packages will be taken into account for all the steps included in these calls. Identification of topics for subsequent calls (2020 – 2022) will be based on the procedure described in the transversal strategy WP and will include multi-stakeholder input from the rare disease community inside and outside the EJP as well as IRDiRC and lessons learned from previous E-Rare calls. Each time the topics and call procedures will be submitted in advance to the EC for validation. Task 6.2 2nd co-funded Joint Transnational Call (JTC 2020) (M4-M24) TL: ANR; Participants: all participants in the call Task 6.3 3rd Joint Transnational Call (JTC 2021) not co-funded by the EC (M16-M36) TL: FFRD; Participants: all partners joining the call Task 6.4 4th Joint Transnational Call (JTC 2022) not co-funded by the EC (M28-M48) TL: ISCIII; Participants: all partners joining the call Deliverables: D6.1: Confidential Call documents: memorandum of understanding, governance of the call and evaluation document JTC2019-2022 (M1, M11, M23, M35) D6.2: Public Call documents JTC2019-2022: call text, guidelines for applicants, proposal templates (M1, M11, M23, M35) D6.3: Joint selection list of the projects to be funded JTC2019-2022 (M10, M22, M24, M46) WP N°7 Networking to share knowledge on rare diseases Lead beneficiary ZonMw Start date M1 End date M 60 Participan CSO/MoH ZonMw VIAA CIHR* SRC (48) TUBITAK (81) EURORDIS t short (78) (34) (30) (84) (77) name & (N°) 46 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. P.M 3.2 13.2 1 0 1 2 1 * Full beneficiary not receiving EC funding Objectives The main objective of this work package is to encourage sharing of knowledge on rare diseases of clinicians, (biomedical) scientists and patient (organization[s]) by implementing a Networking support scheme. The scheme will provide financial support to third parties for fostering organization of workshops or conferences to support new research networks or strengthening existing research networks, to enable exchange of knowledge. It is expected that these new or improved networks may lead to future collaborative research efforts, e.g. by applying to research funding within the EJP RD (e.g. Joint Transnational Calls), to COST actions or Marie Skłodowska-Curie Actions (mobility and training calls). A budget of 2 M€ is foreseen to finance about 70 networking grants. Specific objectives are: ● Establishment of the Networking scheme ● Early assessment of the Networking scheme and further improvement Description of work Task 7.1: Development of the Networking scheme (M1-M7) TL: CSO-MoH, ZonMw, Participants: CIHR, TUBITAK The experience of several countries (e.g. Netherlands or France) shows that networking schemes developed at national scale are of added value and generate positive results13. Taking the example of these initiatives, the EJP RD proposes to implement the support for networking at European/international level. Financial support will be provided through competitive calls to foster networking of rare disease stakeholders to (list not exhaustive): • Share existing knowledge on a specific (group of) rare disease(s) or on cohorts of undiagnosed patients that are suspected of suffering from a rare disease/rare diseases; • Improve the knowledge on rare disease(s); • Encourage further innovation and research, e.g. by preparing an application for another networking grant, training grant or research grant in an EC or other international programme; • Share knowledge and best practices on data sharing (Pillar 2) and /or to promote novel/validated methodological approaches for clinical research (including clinical trials) (Pillar 4). It is expected that networks of researchers/clinicians and patient organizations from countries involved in the EJP RD will be eligible to apply. The consortia should include beneficiaries from at least three different eligible countries at the time of application. Additional partners, from countries not involved in the EJP RD, may be also part of the consortium, depending on the scope of the networking event. However, they will not be eligible to directly receive funds. There will be no limitation in the number of participants. Nonetheless, the maximum grant amount will be limited to 30 000 € for each funded networking event. Documents for the application and evaluation procedure will be developed within the first semester of the EJP RD and will be submitted for validation of the EC before opening of the call. The call will be published widely through the same channels as the Joint Transnational Calls (WP6). Task 7.2: Application and evaluation of proposals for the Networking Scheme (M7-M60) TL: ZonMw, Participants: CSO-MOH, EURORDIS, VIAA, SRC, TUBITAK An existing electronic submission system provided by one of the involved participants will be chosen and modified to the needs of the Networking scheme. The application system will be open permanently, but the proposals will be collected every three months for evaluation by a Committee of independent experts issued from funding agencies and EURORDIS. The dates of collection of the proposals for each evaluation session as well as changes will be clearly communicated to interested applicants. Applicants may apply for a budget for a networking event more than once. The principal investigator will receive the funding on behalf of the consortium and will be the responsible person for the internal management of the consortium. The budget has to be spent within a year after receiving the grant. Funded applicants will be bound to communicate the dates and information on the organized event at least two months in advance for the dissemination purposes by the EJP RD (WP5). In addition, the funded applicants will have to deliver a final (public) report after the meeting. These reports will be monitored and assessed (Pillar 1 Task WP9.2) and used for dissemination and communication purposes (WP5). The evaluation procedure will respect Horizon 2020 rules and evaluation criteria (excellence, impact & quality and efficiency of implementation). Proposals will be ranked according to the evaluation results. It is expected that about 13https://www.zonmw.nl/fileadmin/zonmw/documenten/Geneesmiddelen/Subsidieoproepen/Experiences_of_national_networking_schemes_VF.pdf 47 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. 15 projects will be granted per year. An independent expert will be invited as official observer to the evaluation session after the first subsidy round and after the fifth subsidy round (see Task 7.3) to assess the conformity of the general implementation of the Networking scheme and establishment of the ranking list of transnational networks. The assessments of the observer will be provided in a report to the European Commission. The management of grants will be ensured by ZonMw that will be responsible for collection of the applications at each deadline, supporting the Evaluation Committee and communication with the applicants, including sending the budget for the meetings to the granted applicants. The ZonMw grant terms and conditions will be applied for the management of the grants. Task 7.3 Early assessment of the Networking scheme (M21-M24) TL: CSO-MOH, ZonMw; Participants: CIHR, TUBITAK After four subsidy rounds the Networking scheme will be assessed to analyze whether it meets its objectives. This will be done in collaboration with WP1 Task 1.3 (Monitoring). In addition, “lessons learned” from the quarterly implementation and evaluation process will serve for improvement of next rounds. Deliverables: D7.1: Confidential Call documents for Evaluation Committee for Networking scheme, including set of criteria for evaluation (M7) D7.2: Public Call document for Networking scheme (M7) D7.3: List of funded networks in Networking scheme (M21, M54) D7.4: Confidential Observers’ report on the evaluation of sets of applications for the Networking scheme (M12, M30) WP N°8 Rare Disease Research Challenges Lead beneficiary FFRD Start date M1 End date M 60 Participan FFRD (12) EURORDIS DLR ZonMw EATRIS AFM* (13) t short (77) (15) (34) (75) name & (N°) P.M 16.5 4 1.5 1.5 1.5 4 * Participation in kind Objectives Main objectives: ● To solve specific Rare Disease Research (RDR) Challenges in the field of therapeutic development. ● To facilitate collaboration between academia and industry. Description of work Task 8.1: Development of the scheme (M1-M8) TL: EURORDIS; Participants: FFRD, DLR, ZonMw, EATRIS, AFM The RDR Challenges will be created based on the successful examples of other funding opportunities such as the challenge-driven innovation scheme of Vinnova (https://www.vinnova.se/en/m/challenge-driven-innovation/) and UK Crack-IT scheme (https://crackit.org.uk/crack-it-challenges) The goal is to set up an innovative, rapid and efficient call for projects involving both industry and academia and with strong incentive for all participants: facilitated pathway for academics to exploit their research and access to scientific and technological innovations emerging from academic research for industry. The concept of the RDR Challenge will need to be fit for the rare diseases field. This will be addressed in 2 multi-stakeholder workshops gathering experienced/interested funders, experts in public-private partnerships from Pillar 4, industry representatives and independent scientific experts. Industry representatives will be drawn from the EURORDIS Round Table of Companies (ERTC; http://www.eurordis.org/ertc consisting of about 70 private companies), the companies that are members of IRDiRC and/or EFPIA. Special attention will be given to alleviate risks of lengthy negotiations about intellectual property rights, economical use of the results and safeguarding utilization, for 48 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. example by developing a model cooperation agreement. IP developed within the project will be the property of the contractor (Challenge winner) and its sub-contractors. This WP will be closely connected to the Pillar 4 efforts aiming at public-private collaborations. It is expected that industry will provide input by co-funding and/or in-kind contributions to the projects. Task 8.2: Identification of challenges (M9-M12) TL: FFRD; Participants: EURORDIS, DLR, ZonMw, EATRIS, AFM A multidisciplinary stakeholder committee including industry participants will be established to propose the Challenges solvable in a short time period of 18 months with a possible 12-month extension.The final choice of challenges will be based on predefined criteria e.g. viability, impact and time to impact, commercial potential/potential for uptake of the technology, alignment with external activities, risk of Challenge not being solved, added value for RD community. The Challenges that meet the criteria will be approved by the multidisciplinary stakeholder committee for use in the call. The final chosen challenge(s) will be used to develop call documents. Task 8.3: The call for projects, eligibility criteria and evaluation (M13-M56) TL: FFRD; Participants: EURORDIS, DLR, ZonMw, EATRIS, AFM The opening of the RDR Challenges is foreseen for Year 2. As specified above the scheme will be refined and proposed for validation of the Commission within Annual Work Plan for Y2. However, general principles and eligibility criteria are presented below: The RDR Challenges scheme foresees selection and funding of projects in a 4-stage process: (i) selection of most promising proofs of concept (POCs) responding to the proposed challenge(s); (ii) funding of POCs for maximum of 18 months; (iii) evaluation of results of funded POCs and selection of projects passing to the second stage; (iv) funding of selected projects for additional 12 months to finalize the challenge. All projects should involve the sponsor as co-investor from the start. The expected co-funding from sponsors should be of at least 30%. Financial support to third parties will be provided to academia and SMEs from countries participating in the EJP RD. Since each application will have to involve the sponsor, EJP RD will organize a face-to-face networking meeting for academia, SMEs and industry to initiate formation of future consortia in advance of the opening of the call. The evaluation process will follow Horizon 2020 rules and criteria (Excellence, Impact, Quality and efficiency of implementation). Projects will be assessed by a multidisciplinary Review Panel composed of independent experts. Special attention will be given that the expertise of the review panel matches the challenges that will be addressed. The two-stage selection process will be done by the same Review Panel.The projects will be financed based on the established ranking list. Task 8.4: Management of the funding resources, establishment of contracts and distribution of funding to selected projects (M17-M50) TL: FFRD The maximum grant amount for the phase 1 POCs will be of 150 000 € and for the 2nd phase of 100 000 € The administrative and legal action necessary for the distribution of the funding to the successful applicants of the call will be performed by FFRD. The contractual obligations applied will be the ones of Horizon 2020 and will take into account the necessary regulations including the required ethical, legal and data protection approvals. Deliverables: D8.1: Report on multi-stakeholder workshops for RDR Challenges (M8) D8.2: Call documents for RDR Challenge scheme for validation (M13) D8.3: List of first phase challenge projects financed (M21) D8.4: List of second phase challenge projects financed (M43) WP N°9 Monitoring of funded projects Lead beneficiary CSO/MoH Start date M1 End date M 60 Participant EATRIS (75) short name ZonMw (34) EURORDIS ISCIII (44) FFRD (12) VIAA (30) TUBITAK CSO/MoH & (N°) ANR (11) FNRS (5) DLR (15) SRC (48) FCT (41) (78) (81) (77) P.M 20 0 4 0 1 0 0 0 0 0 0 0 0 49 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. *Funding agencies and stakeholders involved in different funding schemes as WPL or call secretariats, contributing in kind for the monitoring work. Objectives The proposed subsidy schemes, granted projects and granted networks in Pillar 1 and the previous E-Rare projects have to be monitored for progress and results of Pillar 1 funding schemes. Monitoring of the results of the different granted projects is necessary to measure their outcomes and ensure an adequate use of resources. The results of the monitoring will be communicated to the coordination and communication office for further dissemination in the transversal activities within the EJP and for dissemination outside the EJP. In addition, there will be a close collaboration with Pillar 4 to enhance the translational development of the funded project results from WP1. Description of work Task 9.1 Monitoring of Joint Transnational Calls for collaborative research projects (M1-M60) TL: CSO-MoH, DLR; Participants: FNRS, FCT, FFRD, ANR, ISCIII, EATRIS, and all partners participating in the monitored calls participate with 100% in kind personnel contribution for this activity) All funded projects of WP6 will be required to complete an on-line questionnaire for monitoring annual progress and a final report at the end of the funding period. The results of the projects follow-up and assessment will be presented to the EJP RD funding partners every year. In addition, the coordinators and/or national/regional group leaders will be asked to present the results of their projects at a mid-term monitoring meeting. In this midterm meeting, experts will be invited to evaluate the progress of the funded projects. Representatives of the funding agencies will participate in the meetings as well. Subtask 9.1.1 Definition/Update of the indicators for ex-post evaluation of funded projects in each call (M1- M60) STL: CSO-MoH, Participants: FNRS; DLR, FCT, FFRD, ANR, ISCIII, EATRIS, and all partners participating in the monitored calls participate with 100% in kind personnel contribution for this activity Within the frame of E-Rare-3 a list of indicators was developed and applied to design the template for periodic and final reports of funded projects. This set indicators will serve to establish and refine indicators for the EJP funded projects and will need to be adapted to the specificities of the different call topics. The selected indicators will be embedded in the design of the online reporting forms to be used in the follow-up and monitoring activities. Some examples include: number of project-related publications, patents, new employees, established collaborations, etc. Subtask 9.1.2 Adaptation of the monitoring tool for follow-up and assessment of funded projects (M1-M60) STL: FNRS The aim of this task is to adapt the online tool for reporting, monitoring, and assessment of all funded projects that was developed in E-Rare-3. It will enable an easy collection and management of the reports of funded projects. Subtask 9.1.3 Follow-up, monitoring and assessment of funded projects in WP6, including organization of mid-term monitoring meetings for each Call (M1-M60) STL: CSO-MoH, Participants: FCT, DLR, ANR, FFRD, ISCIII and all partners participating in the monitored calls participate with 100% in kind personnel contribution for this activity This task aims at both evaluating the progress and assessing the outputs of granted projects. It will be carried out in close collaboration with the co-funded call secretariats (WP6). The funded projects will be followed up and monitored through brief online annual progress reports and a final report at the end of the funding period. The results of the WP6 projects follow up and assessment will be analyzed by the STL and the summary of this analysis will be presented to the WP6 partners every year. These results will also be available for analysis in the P4 innovation support activities. Relevant outputs (e.g. publications, patents etc.) will be communicated through the central dissemination activities. In addition, mid-term monitoring meetings will be set up for each call. Subtask 9.1.4 Assessment of E-Rare 3 Joint Call Funding programme (M1-M48) STL: CSO-MoH, Participants: FCT, ANR, ISCIII, ZonMw and all partners participating in the monitored calls participate with 100% in kind personnel contribution for this activity Analogous to subtask 9.1.3, the monitoring of projects funded in the E-Rare calls of 2017 and 2018 will be continued and completed in this task. Task 9.2 Monitoring of networking grants to share knowledge on rare diseases (M1-M60) TL: CSO-MoH, ZonMw; Participants: FNRS, SRC, TUBITAK, VIAA, EURORDIS. The granted applicants of all funded networking grants in P1WP7 will have to complete a short, standardized report after the meeting has taken place. These reports will be monitored and also used for dissemination purposes (WP5 - Communication and Dissemination). The report format will be customized using indicators (developed in Subtask 9.2.1) and a specific on-line reporting form on an existing monitoring tool (adapted in subtask 9.2.2). The 50 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. monitoring team (consisting of the Task 9.2 leaders) will contact the granted applicant directly for information delivery and reporting requests. Subtask 9.2.1 Definition of indicators for ex-post evaluation of funded networking events (M1-M7) STL: CSO-MoH, ZonMw; Participants: FNR,. SRC, TUBITAK, VIAA, EURORDIS The monitoring team will define indicators for the ex-post evaluation of funded networking grants with help of the Evaluation Committee that evaluates the applications of the networking scheme (Task 7.2). Subtask 9.2.2 Adaptation of monitoring tool for follow-up and assessment of funded networking events (M1- M7) STL: FNRS For each call, a reporting template will be developed to be implemented within online existing monitoring tool. These templates will facilitate the collection of the reports of the funded projects, their analysis and subsequent reporting. Subtask 9.2.3 Assessment of the funded networking events (M13-M60) STL: CSO-MoH, ZonMw Follow-up, analysis and assessments of results of the networking grants and communication of the results to the EJP RD management for dissemination. This monitoring of the results of the networking grants will regularly take place: a report on the assessment of the first set of funded meetings will be written after four subsidy rounds for the early assessment of the networking scheme (Task 7.3). Subsequently, two midterm monitoring reports will be written on the assessment of the results of the second and third set of funded meetings and a final monitoring report. Task 9.3. Monitoring of Rare Disease Research Challenge (M17-M56) TL: CSO-MoH, FFRD; Participants: FNRS, EURORDIS, DLR, ZonMw, EATRIS, AFM participate with 100% in kind personnel contribution for this activity The granted applicants of the Rare Disease Challenges in WP8 will have to complete a report after finalizing the two stages of the project. The report format will be customized using relevant indicators (to be established). In addition, the achievement of defined milestones will be closely monitored. The monitoring team will contact directly the granted applicants for information delivery and reporting request. The reports will be used to facilitate the uptake, implementation or further development of the solutions by industry or other stakeholders. Deliverables: D9.1: Refined list of indicators for monitoring of JTC funded project (M5) D9.2: Yearly reports on progress assessment of JTC 2019, 2020 and 2021 projects (M28, M40, M52) D9.3: Final assessment report of E-Rare-3 JTC 2016, JTC 2017, JTC 2018 projects and the EJP RD JTC 2019 projects (M35, M47, M59) D9.4: List of indicators for monitoring of Networking grants (M7) D9.5: Reports on the assessment of results of a 1st, 2nd and 3rd set of funded Networking events and a final general report on all funded Networking events (M24, M39, M54, M59) D9.6: List of indicators for RD funded Challenges (M21) D9.7: Report on the assessment of 1st phase results of the RD challenges (M41) D9.8: Report on the assessment of 2nd phase results of the RD challenges (M57) PILLAR 2: INNOVATIVE COORDINATED ACCESS TO DATA AND SERVICES FOR TRANSFORMATIVE RARE DISEASE RESEARCH WP N°10 User-driven strategic planning and transversal activities for Lead INSERM, Pillar 2 data ecosystem beneficiary ULEIC Start date M1 End date M 60 51 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Participant (Orphanet) (RaDiCo) short name & (N°) CNAG-CRG (45) UKL-HD (57) ELIXIR (76) BBMRI (73) FTELE (25) ULEIC (50) LUMC (64) INSA (42) All ERNs INSERM INSERM UM (36) ISS (26) (1b) (1c) P.M * 23.1 5.7 23.9 25.1 1.1 9.8 3.6 6 5.2 13.5 1.1 0.5 * All ERNs will participate in annual retreats Objectives: The overall objective of this WP is to provide a unifying coordination effort that places users, not least ERNs, in a central strategic position in Pillar 2. Research Infrastructures (RIs) will be key in addressing quality and sustainability/upscaling challenges. WP10 will have special importance in optimising the activities and the quality of work conducted by WP11 (about metadata and centralised data resources), WP12 (about record level and federated solutions), and WP13 (about filling gaps in data and analysis methods regarding heterogeneous RD data). This WP will thus help Pillar 2 to build and iteratively test the desired Virtual Platform (VP) for efficient deposition, discoverability, access, and advanced use of RD data, samples, patients, tools and resources. EJP RD will thereby progressively reduce fragmentation of effort, accelerate scientific progress, shorten the diagnostic odyssey, and expand treatment possibilities. Specific objectives include: ● Continuously track the utility of Pillar 2 outputs compared to RD community needs ● Iteratively refine a strategic plan guiding Pillar 2 activities to meet real-world needs ● Establish and apply quality management and GDPR compliance by design for WP11/12/13 operations ● Evaluate models to sustain and scale-up the use of the virtual platform and FAIRification support services Description of work WP Methodology WP10 will base its work on methodologies that consult and empower the relevant RD communities, in particular ERNs. Actions will be ongoing, but based around annual cycles of tracking progress and needs in parallel (via TCs, surveys, interviews, virtual platform impact and quality assessments, etc), with a final bringing together of all these aspects in an large community retreat, to produce guidance on prioritizations and adjustments for the following year. Annual retreats will also entail field-testing of developed systems, by working on specific use-cases proposed by ERNs and by Pillar 4 partners. Hence listening, distilling and strategic planning are core elements of this WP. Task 10.1: Convene yearly retreats leading to Pillar 2 annual strategic plans (M1-M60) TL:INSERM (Orph) [STLs: ISS, INSERM (Orph), ULEIC] Other: [contribute to annual retreat, design and draft annual strategic plan] All ERNs, CNAG-CRG, LUMC, UM, UKL-HD This Task will ensure that the direction of developments in WP11 and WP12 are iteratively adjusted to meet the needs of the RD community. Additionally, and critically, in the first two years of the project, the goal will also be to identify and ensure prioritisation of work towards proof of principle demonstrators to validate the core functionalities that Pillar 2 seeks to create, and to prioritize proof-of-concept studies to be performed in WP13 allowing for integrative systems biology approaches for rare diseases. Based on the lessons learned during the continuous monitoring of pillar 2 WPs, and on the feedback from the community provided in Task 10.2, as well as on the needs and expectations of the ERNs community, back-and- forth discussions will be organized between the users and builders of Pillar 2, so that gaps, risks and opportunities can be agreed and specific actions triggered. This will occur via a transparent and inclusive process, with ERNs in the driving seat for making these decisions (as main users of the data and resource ecosystem created in Pillar 2). The mechanism will involve two activities, both occurring once per year: Subtask 10.1.1 (“Whole-RD-community annual retreat”) will take place over approximately 3 days each May, involve 24 ERNs plus Pillar 2 WPs contributors and Pillar 4 representatives, and be open to others who wish to attend (space allowing); and Subtask 10.1.2 (“Annual strategic plan for Pillar 2”) whereby a multi-stakeholder strategy board will refine the Pillar 2 workplan, guided by recommendations from the annual retreat, to be put into action by WP leaders. The updated Pillar 2 workplan will itself contribute to the EJP RD Annual workplan (Coordination WP2). In addition, annual 52 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. retreats will include field-testing exercises, by organizing use case based, end-users live tests of the virtual platform functionalities in order to adjust developments and to monitor usefulness. Task 10.2: Coordinating Pillar 2 Work Packages outputs and aligning to RD community needs (M1-M60) TL: ULEIC [STL: FTELE, CNAG-CRG] Other: [conduct surveys/interviews, contribute to TCs and surveys/interviews] All ERNs, INSERM (Orph), LUMC, UM, INSA, UKL-HD This Task will gather and summarize the information needed to simultaneously assess Pillar 2 WPs outputs against RD community needs. Specifically, we will undertake Subtask 10.2.1 (”Bi-monthly TCs and reports with WPs leaders”), leading to regular progress reports that are properly documented and made promptly available to the EJP consortium. In parallel, to expose and track the evolving needs of the RD community, we will undertake Subtask 10.2.2 (”Community surveys and structured interviews”) on a continual basis throughout the project, focused on technical, scientific and strategic requirements and how the outputs of Pillar 2 are or are not serving the community. ERNs will be centrally involved in advising, designing and responding to these activities, as well as Pillar 4 partners, in order to ensure Pillar 2 activities are optimised to enable innovation. Task 10.3: Coordination of technical GDPR implementation (M1-M60) TL: BBMRI, ELIXI;, Other: [explore and advise re GDPR] INSERM (RaDiCo), CNAG-CRG, LUMC, ULEIC In collaboration with all the Pillar 2 contributors and according to the EJP policy established in Transversal WP4, this task will identify and document personal data processing, including legal basis and technical and organizational safeguards implemented. Methodology will be developed for risk assessment, including assistance with DPIA to the extent needed. The task will provide technical guidance to WP11, WP12 and WP13 to ensure consistent implementation of security and privacy by design in the software and services delivered by Pillar 2. Task 10.4: Quality oversight (M1-M60) TL: BBMRI, ELIXIR; Other: [establish & deploy formalised quality policy] All ERNs, INSERM (RaDiCo), INSERM (Orph), CNAG-CRG, LUMC, ULEIC This task will analyze processes and services delivered within Pillar 2 and propose a quality management system (QMS) to assist with complying with user requirements and to ensure quality of services delivered. Specific aspects include documenting user requirements, software design and development (including software development best practice14), operation of services. The FitSM lightweight IT service management standard15 will be assessed for this purpose, as it has been already used in EOSCpilot and EOSC-hub projects. The QMS will define performance indicators and monitor them in regular improvement cycles. The code developed within the project will undergo peer review in order to provide feedback to developers. Task 10.5: Sustainability and scaling up (M1-M60) TL: DTL-Projects (ELIXIR-NL), Other: [design sustainability options] ELIXIR, FTELE, INSERM (RaDiCo), INSERM (Orph), BBMRI, CNAG-CRG, LUMC, ISS, ULEIC This task will investigate financing models to sustain and scale up the development and use of the virtual platform (VP) and its support services, in close collaboration with sustainability experts in the EJP RD transversal WP3, the RIs, the European Open Science Cloud project (EOSC), experts associated with RDA, and the international GO FAIR offices (currently in the Netherlands, Germany, and France, with an RD implementation network starting in 2018). This task will explore needs, opportunities and methods for sustaining and scaling up each VP component and service judged to be useful by the EJP RD community, and map this to a financing model matrix developed by Transversal WP3. By eliciting real costs of the VP activities, selected models will be simulated and evaluated with sustainability experts, potential payers (e.g. funders, ERN HCPs, patient organizations), and suppliers (e.g. SMEs). Deliverables: D10.1: Annual strategic report and Action plan for Pillar 2, including: Systematic surveys reports, QMS of Pillar 2 description, GDPR compliance report and sustainability planning reporting (M9, updates M21,M33, 45) WP N°11 Common virtual platform for discoverable data and Lead beneficiary INSERM resources for RD research (Orphanet), CNAG-CRG Start date M1 End date M 60 14 Jiménez RC, Kuzak M, Alhamdoosh M, et al. Four simple recommendations to encourage best practices in research software. F1000Research. 2017;6:ELIXIR-876. doi:10.12688/f1000research.11407.1. 15 http://fitsm.itemo.org/) 53 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Participant (PaedCan) ACU/ACURARE CNAG-CRG (45) short name CHARITE (17) & (N°) ELIXIR (76) BBMRI (73) CIBER (47) FTELE (25) AMC (66) GUF (59) AIT (3) CCRI (82) (53) P.M 9.4 26.8 5.7 5 65.8 31.3 14.7 181.7 194.1 9.9 73.5 Participant (ERN-LUNG) (Metab-ERN) (Endo-ERN) (RaDiCo) INSERM (Orphanet & INFRAFRONTIER (77) INSERM(AMU) (1d) short name LBG (LBI-RUD) (4) IPCZD (CMHI) (40) & (N°) RUMC (65) LUMC (64) ISCIII (44) LTPs) (1) INSERM ISS (26) LUMC GUF HSK (57) (60) (64) (1c) P.M 3.3 3.9 39 21.2 30.9 379.3 10 9.9 6.8 22.3 35.4 6.7 10.7 Participant EORTC (71)** (ChemBioNet)* short name (ERKnet) (57) VUHSK (32) UKLFR (18) UMCG (35) ULEIC (50) & (N°) JRC-EC** UPM (46) UKL-HD MPI-CBG UM (36) WTSI* P.M 17.4 2.8 12.6 11 74 10.6 5 0 2 0 0 *Associated partner; **Participation in kind Objectives: The overall objectives of this WP are i) to build a comprehensive, FAIR-compliant virtual platform describing resources (including registries, biobanks, research infrastructures, genome-phenome repositories, methods, standards, etc) allowing for these resources to be findable online via a central access point and ii) to provide researchers the means to deposit, share and analyse phenotypic, genomic and multi-omics data building on and scaling up existing resources. The specific objectives of this WP are: ● To produce an ontological model to represent fine-grained metadata describing existing and future resources relevant for RD research. ● To build a comprehensive suite of catalogs based on this ontological model to allow queries through a central facility. ● To facilitate data generated from RD research to be deposited in existing repositories by improving their capacity, interoperability, privacy protection, and security compliance. ● To facilitate user access to resources by adopting a common Authentication and Authorization Interface (AAI) ● To improve and scale up genomic, phenomic and multi-omics analysis, integration and sharing capabilities Description of work Methodology WP11 will build on and scale up existing catalogs (Orphanet, BBMRI, RD-Connect Biobank and Registry Finder, JRC’s ERDRI and ELIXIR bio.tools) to develop a comprehensive suite of catalogs using standardized metadata and utilizing existing recommended ontologies (i.e. Orphanet rare disease ontology (ORDO), Human Phenotype Ontology (HPO). It will allow registries, biobanks, data repositories, and other resources and tools to be findable by queries in terms of disease, genes, phenotypes, sample types, and other data element types. Queries may expand to federated queries at data record-level through the FAIRIfication process of WP12. This centralized metadata system will be FAIR compliant. Furthermore, WP11 will improve, adapt, scale up and document existing RD data 54 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. deposition and analysis resources (such as the RD-Connect GPAP and Sample Catalogue, DECIPHER, INFRAFRONTIER, hPSCreg, Cellosaurus, EGA, Metabolights or Pride), and make them findable through the EJP virtual platform, to serve researchers’ deposition and analysis needs (i.e. for the projects funded in Pillar 1, Solve- RD and others). Access will be simplified by adopting a common Authentication and Authorization Infrastructure (AAI), and a system to link anonymised data from the same patient in different projects will be deployed via Privacy Preserving Record Linkage (PPRL). Functionality of resources will be expanded by improving their usability. Additional experimental data issued from WP4 will be included. Task 11.1: Metadata and ontological model definition for cataloging resources for RD research (M1-M60) TL: EMBL-EBI, GUF [STL: SIB (ELIXIR-CH), GUF, AMC] Other: [metadata definition and modelisation] JRC, INSERM(Orph), BBMRI, UMCG, UPM, LUMC, ULEIC, Charité, ACU/ACURARE, UM, ISCIII, CIBER Subtask 11.1.1: A set of metadata will be defined to describe each RD resource to be included in the virtual platform following prioritization provided by WP10. This set of metadata will be based on, and expand, metadata already developed by Orphanet, BBMR-ERIC (for biobanks), RD-Connect (for registries and biobanks), and JRC’s ERDRI (European Rare Disease Registry Infrastructure, including the registries Central Metadata Repository and the European Directory of Registries). Schemas such as MIABIS (biobanks), and Bioschema.org, and standard ontologies (Orphanet Rare Disease Ontology ORDO, Human Phenotype Ontology HPO, OBIB) and standard nomenclatures (HGNC, Uniprot/neXtProt, Cellosaurus etc) will be used to improve interoperability. This will provide a unified way to describe a range of includable resources in the centralized suite of catalogs built in Task 11.2. Accessibility metadata will be included based on ADA-M tool as well as provenance information about the metadata itself. These metadata will serve as a starting point for metadata description at record level in WP12. Metadata will be organized as application ontology integrated with other standard ontologies (Subtask 11.1.2). Resources to be included will be prioritized following WP10 strategic decisions, and the model will be updated and extended every year in order to include new resources (subtask 11.1.3). Prioritized resources will be financially supported to provide their metadata. Task 11.2: FAIR-compliant virtual platform for discovery of RD resources (M1-M60) TL: INSERM(Orph) [STL: INSERM(Orph), UMCG, DTU (ELIXIR-DK), BSC (ELIXIR-ES), GUF] Other: [integration and extension of catalogs and development of central query point] JRC, BBMRI, CNAG-CRG, UPM, LUMC, UM, CIBER, VUHSK, IPCZD (CMHI), ULEIC A database of RD-specific expert resources is already maintained by Orphanet by the collection, manual curation and quality control of expert centres (including ERNs), diagnostic tests, patient organizations, infrastructures, registries and databases and RD research projects and clinical trials and orphan drugs in 35 countries. These are described with a set of metadata and organized around the elements of ORDO, which allows these resources to be findable by disease and by gene. Task 11.2 aims at building a virtual platform using and expanding this catalog based on the metadata model developed in Task 11.1, integrating it with catalogs already developed by BBMRI- ERIC and RD-Connect for biobanks and registries (using MOLGENIS) and JRC’s ERDRI (for registries), and ensuring manual curation, quality and updates (subtask 11.2.1). In order to provide analytical data to inform the research strategic agenda elaborated by Transversal WP2, an international RD specific database of research projects, clinical trials and developing therapies will be enriched by national data and by IRDiRC members (subtask 11.2.2). To make relevant RD analysis tools and methods discoverable, the ELIXIR's bio.tools catalogue will continue its adaptation for the RD community initiated in EXCELERATE (subtask 11.2.3). The virtual platform built in Task 11.2 will be optimized to allow queries using the underlying ontological model. Query facilities will provided online and to the EJP-RD helpdesk (Subtask 11.2.4). Task 11.3: Data deposition and access to data infrastructures for RD research (M1-M60) TL: EMBL-EBI [STL: CSC (ELIXIR-FI), MU-CERIT-SC (ELIXIR-CZ), ELIXIR, BSC (ELIXIR-ES), UU (ELIXIR-SE), INSERM (RaDiCo), AIT] Other: [develop and document secure linked data deposition and access capabilities] INFRAFRONTIER, UKL-HD (ERKnet), APHP (PaedCan), LUMC(Endo-ERN), GUF(ERN-Lung), HSK (MetabERN), FTELE, UMCG, BBMRI, CNAG-CRG, GUF, Charité, INSERM (AMU), ISCIII, ISS, UKLFR, CIBER, ULEIC, WTSI (Associated partner) Task 11.3 aims to serve the needs for depositing, integrating and storing quality controlled (meta)data produced by the EJP and the overall RD community building on existing resources including registries (JRC-ERDRI, RD- Connect Registry and Biobank Finder, known also as IDcards), patient cohorts (RadiCo, BBMRI-ERIC Directory), biobanks (RD-Connect Sample Catalogue, RD-Connect Registry and Biobank Finder, BBMRI-ERIC Directory), cell lines (hPSCreg, Cellosaurus), mouse models (INFRAFRONTIER), raw omics data (EGA, Pride, MetaboLights) and genome-phenome platforms (DECIPHER, RD-Connect GPAP). Subtask 11.3.1 will support resources by improving and/or expanding their deposition and access mechanisms (Application Programming Interfaces, APIs, and Graphical User Interfaces, GUIs) and deploying mechanisms to ensure quality of datasets, evaluating GDPR compliance and implementing transparency measures and means to monitor data re-usability 55 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. following Pillar 2 Task 10.3 guidance. BBMRI-ERIC Negotiator, used for implementing access pipeline for biobanks and registries will be extended to support resources integrated in WP12. The LifeScience AAI (converging from ELIXIR and BBMRI-ERIC Authorization and Authentication Infrastructure), enabling users to access several resources using the same credential while controlling access permissions, will be implemented (subtask 11.3.2). To overcome issues associated with patient identification and duplication, subtask 11.3.3. will deploy a GDPR compliant PPRL (Privacy Preserving Record Linkage) solution based on EUPID, aligned with the proposals from the joint GA4GH/IRDiRC PPRL working group. General and resource specific documentation and guidelines including user registration, data deposition, data access, data security, policies, transparency, incentives for data submitters and usage of ontologies and standards will be published online via EJP RD website (subtask 11.3.4). Task 11.4: Provision of RD analysis and data sharing capabilities through online resources (M1-M60) TL: CNAG-CRG [STL: UMCG, CNAG-CRG, BSC (ELIXIR-ES), SIB (ELIXIR-CH), EMBL-EBI, CSC (ELIXIR-FI), UU (ELIXIR-SE), LBG (LBI-RUD)] Other: [phenotype, genotype and multi-omics integrated analysis facilities ] LUMC (Endo-ERN), FTELE, INSERM (RaDiCo), BBMRI, RUMC, LUMC, INSERM (AMU), ISS, UM, ACU/ACURARE, ISCIII, CIBER, UKLFR, WTSI, (Associated partner) To contribute to the achievement of the IRDiRC diagnostics goals and provide analysis and data sharing capabilities to the EJP platform, task 11.4 will support and upscale user friendly software and tools for the analysis of omics data together with rich standardised clinical and phenotypic data. To create a comprehensive suite of online analysis tools, they will be made compatible with the models developed in T11.1, included in T11.2 and linked to key resources from T11.3. The capacity to identify causative genetic variants and discover new pathogenic genes will be provided by building on the online RD-Connect genome-phenome analysis platform (GPAP) (subtask 11.4.1). The GPAP is a recognised IRDiRC resource that provides secure user-friendly deposition, access, analysis and interpretation of/to integrated genotype (whole genomes, exomes and panels) and standardised phenotype information. The GPAP will play a central role in the Solve-RD project. In subtask 11.4.2, methods and tools for integrative bioinformatics analysis will be developed and implemented in alignment with WP13, including user-friendly interfaces for easy access and interactive analysis. This collaborative, integrated analysis of multi-omics data will be provided to projects funded in Pillar 1 generating multi-omics datasets and to WP13 selected use cases, being leveraging also on the multi-omics datasets generated within Solve-RD. Furthermore, a pilot cloud computing capability will be piloted for custom analyses from funded projects in Pillar 1 (subtask 11.4.3). Main raw omics data resources such as the EGA or MetaboLights will be connected building on the developments from Solve-RD. Newly developed analysis methods and tools will be integrated or linked to in the analysis systems following a user-driven prioritisation, and improvements on the usability of the resources will be made according to the EJP and ERN needs (subtask 11.4.4). Deliverables: D11.1: Ontological model of resources metadata (M12, 24, 36, 48, 60) D11.2: Virtual platform of RD resources annotated with EJP ontological model and updated regularly (M12, 24, 36, 48, 60) D11.3: Additional facilities integrated to resources regarding data deposition and access, including User guidelines and documentation for data deposition and access (M12, M24, M36, M48, M60) D11.4: Report on processed genome-phenome datasets and multi-omics use cases analysed, including Description of new cloud and online analysis functionalities and tools (M12, M24, M36, M48, M60) WP N°12 Enabling sustainable FAIRness and Federation at the Lead ULEIC, record level for RD data, patients and samples beneficiary LUMC Start date M1 End date M 60 Participant ACU/ACURA (RaDiCo) (1c) (ELIXIR) (76) BBMRI (73) short name CNAG-CRG (AMU) (1d) FTELE (25) CIBER (47) EMBL-EBI (Orphanet) ISCIII (44) CHARITE & N° AMC (66) GUF (59) INSERM INSERM INSERM AIT (3) RE (82) (1b) (17) (45) P.M 2.9 10 94.3 180. 9 2.9 11 25.9 36.6 121. 16.8 11 20 2.5I 6.5 8 5 .1 56 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Participant UPM (46) JRC-EC* UKL-HD ISS* (26) short name UM (36) UMCG RUMC ULEIC LUMC MUW & (N°) (64) (38) (65) (57) (50) (35) P.M 151.6 11.7 32.9 2.8 193. 2.5 162.4 54.8 0 0 9 *Participation in kind Objectives: This WP will ensure the availability of standards, inter-operable tools, and networks of expert support for biological, clinical and preclinical data, samples, and patient information, to create maximal utility as per the FAIR paradigm. Specific objectives of this WP are: ● To identify, refine and expose core standards for dataset interoperability, asset (data, sample, subject) discovery, and responsible data sharing (via Task 12.1), concentrating on data level rather than resource level information, guided by the needs of EJPRD stakeholders from pillar 1 and 4, including ERNs towards the overall EJPRD objectives. ● To improve and deploy open-source tools, by multi-site teams, made maximally interoperable and compliant with EJPRD agreed standards, to enable RD data to be made FAIR in practice (via Task 12.2). ● To coordinate and deploy broad expertise and practical support for data ‘FAIRification’, including options for data hosting and brokering (via Task 12.3), with a path towards a self-propagating and self-sustaining ecosystem for provisioning of FAIR data stewardship. Description of work Methodology: To progressively ‘FAIRify’ RD resources at the record-level to support innovative basic, translational and clinical research, our efforts will synergise with and extend those of WP11 (which has a resource level focus) and WP13 (which has a data integration focus) – with guidance from WP10. The approach assumes that RD research data, samples and clinical information gathered from patients will typically be distributed, heterogeneous and sensitive. By joint research, development, services and sharing of expertise we will enhance and apply extant capabilities to support RD data custodians, biobanks, and registries. Relevant standards will be identified and refined for WP12 by a community wide effort (Task 12.1), existing software will be improved to stress interoperability and functionalities needed by WP12 (Task 12.2), and expertise for practical FAIRification support and FAIR data hosting services for EJP RD projects will be leveraged via user workshops and engagement (Task 12.3) – whilst reflecting users’ needs back to Tasks 12.1 & 12.2, and maturing everything towards a sustainable model. Task 12.1: Compare and align core interoperability standards of relevance (M1-M60) TL: ULEIC [STLs: BBMRI, UMCG, LUMC, AMC, ULEIC] Other: [TC/Workshop attendance, info gathering, design/testing] UKL-HD (ERK-net), JRC, INSERM (Orph), EMBL-EBI, CSC (ELIXIR-FI), SIB (ELIXIR-CH), UPM, UM, ACU/ACURARE, INSERM (RaDiCo), GUF, AIT, FTELE, Charité, ISCIII, MUW, CIBER This task will underpin the Virtual Platform by defining the standards required to maximise interoperability and federation potential. This will span RD genotype-phenotype databases, RD biobanks, RD patient registries, ERN networks, and ultimately (as guided by WP13) extend to clinical and digital health data, PROM information, natural history and environmental data. The aim is not to invent new standards. Instead, we will engage a broad community of stakeholders to jointly survey the standards that already exist, establish how/where they are being used, and thereby define overlaps, conflicts and gaps that exist. We will then establish what is needed to map and translate between alternatives, and devise refinements and extensions as necessary. Undertaking this work along with the existing producers and users of today’s most relevant standards, and publishing our results (along with Transversal WP5), will ensure they are accepted and employed by the field’s practitioners (who will have been involved in their creation). To this end, we will arrange regular teleconferences and workshops between teams that presently develop or use standards in this space, and encourage external groups to join in. Key external partners would be IRDiRC, ELIXIR, BBMRI, Solve-RD and GA4GH, which have overlapping membership with EJP. Topic priorities will be guided by WP12 tool developments (Task 12.2) and FAIRification activities (Task 12.3), and by WPs 10, 11 and 13. Task 12.1 will be adaptive, but organised around five domains, each having its own expert leadership team coordinating subgroups on specific standards: “Metadata and data models” (Subtask 12.1.1) to provide syntactic and semantic targets that FAIRification procedures would target to improve Findability and Interoperability, beyond the resource-level models of WP11; “Federation architectures and network registers” 57 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. (Subtask 12.1.2) to underpin a growing federated arrangement of RD resources; “Automated Accessibility and Reusability elements” (Subtask 12.1.3), not least machine-readable consent & use conditions, governance policies, patient/sample/data identifiers, and anonymization methods; “Query languages and data exchange formats” (Subtask 12.1.4) to provide a 'lingua franca' for databases and data discovery platforms to translate from and to, so that they can (with suitable permissions) interpret and respond to mutual queries and promote Findability and Interoperability; and “Ontologies & semantics for record-level clinical and preclinical information” (Subtask 12.1.5), to steadily improve our ability to feed complex medical data into the research world. Task 12.2: Multi-team software development to enable the FAIR ecosystem (M1-M60) TL: AIT [STL: BBMRI, GUF, AIT, ULEIC] Other: [developers and service providers] JRC, INSERM (Orph), UMCG, CNAG-CRG, UPM, LUMC, AMC, MUW, FTELE, INSERM (AMU), RUMC A wide array of technologies and capabilities are needed to make RD datasets and resources FAIR, and so in Task 12.2 we will work with RD communities to improve existing Open Source software. The goal will be to enhance their utility, their interoperability and their compatibility with standards defined by Task 12.1, driven by priorities defined in WP10. We will use these tools in Task 12.3, assist the community in adopting them, and thereby validate them and inform iteratively cycles of further optimisation. Task 12.2 activities will be guided by tool users and by feedback at annual retreats organised by WP10. More specifically, we will start each cycle of tool development by first defining an unmet need, and assess the effectiveness of the developed software by evaluating its ability to address the targeted need - all in conjunction with real-world users. The work will also be undertaken by multi- team efforts, addressing four key topics, namely: “Semantic and syntactic harmonisation of data records” (Subtask 12.2.1) which is a core need when making datasets, samples and patients precisely Findable and maximally Interoperable; “Data extraction, obfuscation, anonymisation and disclosure control” (Subtask 12.2.2) to appropriately manage the confidentiality of sensitive patient-level data; “Metadata-level, data-level and sample- level discovery support” (Subtask 12.2.3) which extends the resource level Findability work of WP11 and includes new approaches to RD patient matchmaking that give the person making the query more influence over what constitutes a real match; and “Management of consent and data use conditions, plus automated access control (Subtask 12.2.4) to ensure data discovery and sharing are made more efficient and more responsibly conducted. Awareness of and access to these tools will be facilitates in conjunction with the main EJP RD Helpdesk. Task 12.3: Combining expertise for practical FAIRification support (M1-M60) TL: LUMC [STLs: UMCG, LUMC, AMC, ULEIC] Other: [TC/Expertise gathering, hosting services, FAIR Services] INSERM (Orph), CNAG-CRG, INSERM (RaDiCo), BBMRI, EMBL-EBI, SIB (ELIXIR-CH), INSERM (AMU), Charité, UPM, RUMC, ISS Widespread implementation of FAIR data principles requires interdisciplinary collaboration and practical support to ensure a good flow of standards, technologies and capabilities out to the community. Developing guidelines, protocols, and support services to aid the RD community with practical implementation of FAIR data principles is the goal of Task 12.3. Specifically, Subtask 12.3.1 (“Coordinating teams of experts”) will organise online and face- to-face meetings to engage dispersed experts and integrate RD infrastructural activities with bodies such as IRDiRC, GA4GH, ELIXIR and BBMRI. A liaison program will involve early-career representatives of EJPRD stakeholders in developing FAIR infrastructure and best data stewardship practices. Subtask 12.3.2 (“Brokered hosting service”) will establish a data hosting service to support data discovery in FAIRification efforts. This will include new forms of RD patient matchmaking for use within networks of authorised users, and place the queryer in full control of the matching criteria. Subtask 12.3.3 (“FAIR data stewardship service”) entails practical FAIRification activities. Dedicated FAIR data stewards, engaged via Subtask 12.3.1 will work with stakeholders to implement standards (Task 12.1) and tools (Task 12.2) to make selected data more FAIR compliant, in order to solve real-world problems from pillars 1 and 4 and external users. Formalised, objective FAIR metrics will be used to monitor progress. Each FAIRification undertaking will address a different set of challenges and different cross- resource questions to ensure that FAIRification guidelines, standards and tools cover a sufficient range of practical applications of the EJPRD. The FAIRification process and reusable artefacts, such as an application ontology, will be documented and shared with the wider RD community, and fed into the training program of Pillar 3. The actual total costs of FAIRification in practice will be analysed as input for developing financial models for a sustainable FAIRification service for the RD community (Task 10.5). Deliverables: D12.1: Report on core set of unified FAIR data standards (M18) D12.2: Report on core set of FAIR software tools and on extended set of unified FAIR data standards, applied in EJP RD, available (M30, M48) D12.3: Report on extended set of FAIR software tools, applied in EJP RD, including overview of FAIRification guidelines for RD data managers (M60) 58 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Enabling multidisciplinary, holistic approaches for rare UM WP N°13 Lead beneficiary disease diagnostics and therapeutics UKL-HD Start date M1 End date M 60 UMCG (35) (AMU) (1d) RUMC (65) LUMC (64) RARE (82) EKUT (58) ACU/ACU ISCIII (44) Participant LBG/LBI- CRG (45) UKL-HD INSERM RUD (4) UM (36) ISS (26) UKLFR ELIXIR short name CNAG- & N° (76) (18) (57) P.M 28.5 6.6 3.1 2.8 17.3 5 12.2 0.7 63.7 54.8 5.6 5.6 88.4 3.6 Objectives: Extend the virtual platform with workflows that allow holistic research based on rare disease data and biological knowledge. Fill gaps in technologies identified in previously performed explorative studies and perform proof of principle studies to evaluate the results and improve and optimise the approach. Thereby, improve the understanding of the etiology and progression or rare diseases and support the discovery of biomarkers and the identification of druggable pathways and targets, and allow the study of disease modifiers such as nutrition, and metabolism (exercise) aspects of lifestyle and exposure to toxicants. Provide content for training in pillar 3 to make these new workflows available for the community. Description of work Methodology: The approach will include the following steps: (i) Knowledge structuring based on text and data mining and expert curation; (ii) creation of technical links for integration (database ID linksets, FAIR format conversions from repository data to tool ready data, links between biological entities (e.g. gene variants and their effects); (iii) create disease specific pathways and networks with flexible data representations based on i and ii; (iv) Allow extension of these networks with relevant regulatory information (e.g. transcription factors and miRNAs) and evaluation for intrinsic lifestyle factors (e.g. micronutrient targets) and epigenetic factors and allow extension with external environmental factors like chemical exposure (toxicology) and allow subsequent active node analysis to evaluate these; (v) Create complete workflows. As part of the whole process continuously perform small proof of principle studies that help to drive the work forward, help show the relevance of what is done and help identify problems with the effectiveness of what is being done and to adapt that to the next level. Basically implementing an agile approach as known in software development for this WP. Some of the outcomes of WP13 will be applied and tested within the collaborative analyses of multi-omics datasets performed in WP11 task 11.4.2 on existing data, data provided by the ERNs and data generated from Pillar 1 funded projects and the Solve-RD project. Work with Pillar 3 to develop training, especially on creating pathways, using the pathways, networks and complete workflows for discovery of diagnostic and therapeutic activities and for inference of lifestyle and environmental factors. Task 13.1: Fill a number of pre identified gaps to allow integrative systems biology approaches for rare diseases (M1-M60) TL: UM, LUMC, [STLs: LUMC, RUMC, UM, INSERM (AMU), ISS Other: EKUT, ACU/ACURARE, EMBL-EBI, SIB (ELIXIR-CH), UMCG, CNAG-CRG, UK-LFR, ISCIII, LBG/LBI-RUD (mentioned at the end of subtasks they are involved in, subtask leaders in bold) Subtask 13.1.1: Pathways created and expert curated. Build a knowledge base of relevant rare diseases biological pathways for the existing pathway portal available on WikiPathways. Select relevant diseases in collaboration with ERNs (via WP10) and Solve-RD. For diseases where pathways that can be used by analytical tools are not yet available, use literature review including FAIR text-mining predictive methods, data mining and expert input from ERNs and FAIR to identify disease-relevant genes and use the knowledge available in neXtProt and other resources, e.g. protein-protein interactions, co-expression, co-localisation, etc. to create a network structure. Annotate those network structures and make them available for integrated omics analysis in pathway and network tools and in BioPax ontology based pathway RDF format contributed to the Open PHACTS platform and WikiData. (UM, LUMC, ACU/ACURARE; M1-36) Subtask 13.1.2 Mapping to genes: Allow gene directed mapping of rare disease gene variants to genes (and then to pathways) based on mappings available in external resources. Update mapping databases and allow access to a 59 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. location-based gene mapping service. Work with WP11/12 to get interoperable gene variant descriptions (correct identifiers including genome locations) that allow these mappings to be used, use genomics platform annotation pipeline from RD-connect. (UM, LUMC; M1-36; develop, updates 1-60) Subtask 13.1.3 Mapping (combinations) of variants to function: Mapping of (combinations of) variants to functional gene regulatory sequences and protein domains operationalized for the rare disease community and allow use of that to evaluate edges (interactions and reactions in pathways), linking this to the edgetic concept. (RUMC, LUMC, CNAG-CRG, EMBL-EBI, SIB(ELIXIR-CH); M1-60) Subtask 13.1.4 Link to external FAIR data: Leverage on the data generated by Solve-RD and the funded projects in Pillar 1 and work with WP11/12 to allow integration, and thereby analysis, of FAIRified experimental multi- omics data with knowledge based pathways and networks derived from FAIRified external data sources (e.g. using ELIXIR core repositories and resources respectively), and using the fact that it was already linked to FAIR genotype and phenotype data within the RD-Connect platform, provide specific scripts/tools. (RUMC, LUMC, CNAG-CRG, UMCG, UM, EKUT; M13-60) Subtask 13.1.5 Network repository: For a limited number of diseases create evaluated and documented networks and deposit in the network repository NDEX (for analysis in Cytoscape). (UM, LUMC; M37-60) Subtask 13.1.6 Environmental lifestyle: Allow network analysis to discover identify possibly relevant environmental factors (such as exercise and nutrition including factors affecting epigenetics) from multi-omics networks. (INSERM-AMU, RUMC, UM; M19-60) Subtask 13.1.7 Treatment drugs: Allow and describe network analysis and single pathway approaches to compare rare diseases with to known treatable diseases and to add drugs to networks and explore sub paths using network directionality for target selection using methods that will be developed in collaboration with external EFPIA partners. (LUMC, UM, UK-LFR, M1-36) Subtask 13.1.8 Environmental toxicology: Allow and describe network enrichment analysis and single pathway approaches and connect environmental (toxicology based) data via the OpenRiskNet and eNanomapper APIs, thereby allowing links between (epi)genetics and exposure. (ISS, UM, ISCIII; M1-48) Subtask 13.1.9 Workflow leading to understanding of disease mechanisms and diagnosis: Describe workflow for (multi)omics data analysis finding (sub)pathways, building networks and describing basic network analysis (up to finding affected sub pathways and active nodes and thereby diagnostic biomarker (Subtasks 1 to 4) and extended workflows for Subtasks 6, 7 and 8. (UM, INSERM-AMU, LBG/LBI-RUD, LUMC, RUMC; M25-60) Subtask 13.1.10 Link to Adverse Outcome Pathway approach: Harmonize the rare disease pathways (from 1) to be linked with events that occur in Adverse Outcome Pathways (AOPs) created by the EUToxRisk flagship project as made available on the OECD AOPWiki. (LUMC, ISS, UM; M13-36) Task 13.2: Organise proof of principle studies to identify efficacy of the work done and identify remaining (including new) gaps (M1-M60) TL: RUMC Other: LUMC (data linking), UM (integrating 4,1 tasks, network building, extension and evaluation), ACU/ACURARE (active sub-paths and effects thereon for MS2) The proof of principle studies form an essential element in the agile approach for the pathway and workflow development in task 13.1. They steer the pathway selection in task 13.1.1 and set targets for the other 13.1 tasks. The developed elements are continually tested in these studies and where possible improved. The topics for the studies will be selected based on the strategic annual plan established in WP10 together with ERNs and with the participation of Solve-RD and EuRenOmics. With their input we will identify relevant resources and select the pathways that need to be developed. We expect to carry out 5 rare disease related proof of principle studies for relevant parts of the WP work plan. The first study will help select and create datasets to link and analyse and pathways to be developed and in the second study we will use these pathways to analyse omics data. In a third study we will evaluate advanced omics analysis: evaluate genetics mappings and protein structure effects. These will contribute to MS1.The final two studies will evaluate nutritional lifestyle effects in disease networks and links between disease network and toxicology data and will contribute to MS2. A second group of studies, possibly for different diseases, will aim at research questions relevant for multi-omics linkage to known drug targets, lifestyle nutrition and metabolism (exercise) relations and to environmental toxicology resources for MS13.2. All studies will combine data FAIRified in WP12, in part selected for this purpose, with the pathways from task 13.1.1 leading to the selection of enriched pathways which are then combined in networks, we will then use the 13.1 subtasks to define the workflow to answer research questions and we will identify gaps in available technology. The operational, tested, workflows, tools and pathway- and mapping data that result after the pilot studies will be integrated in the Pillar 2 virtual platform and will form the basis for tutorial development with pillar 3. After having conducted these studies, the remaining gaps will be reported to the strategic research agenda transversal activity, for possible implementation in research calls through Pillar 1. 60 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Deliverables: D13.1: Collection of 20 curated pathways in (sub)portal on WikiPathways (M36) D13.2: Completed pathway analysis workflow (data analysis including both types of genetic variant linking and network creation) (M48) D13.3: Completed network analysis workflow (active node detection, lifestyle factor network evaluation and extended network analysis for drugs and toxic compounds) (M54) PILLAR 3: CAPACITY BUILDING & EMPOWERMENT WP N°14 Training on data management & Lead beneficiary ISS quality Start date M1 End date M 60 Participant LUMC (+for Endo- ACU/ACURARE (82) IOR (Bond-ERN) (61) short name & LBG (LBI-RUD) (4) IPCZD (CMHI) (40) HSK (MetabERN) (N°) CNAG-CRG (45) EURORDIS (77) EKUT (58) IMAGINE (14) MUW* (38) UMCG (35) FTELE (25) ISCIII (44) ERN) (64) ISS (26) (60) P.M 43 1 2 2 3 2 6 7 10 4 7 2 5 1 27 Participant (ELIXIR-IT) (RaDiCo) INSERM (AMU) (1d) Projects(ELIXIR-NL) (HACETTEPE) (83) short name & (Orphanet + LTPs) (N°) CHARITE (17) KULeuven (7) VUHSK (32) BBMRI (73) INSERM** MUG (39) AMC (66) INSERM HUGEN DTL- CNR (76) (76) (1b) (1c) P.M 5 8 1 1 1 12 3 4 2 2 24 1 Participant short name & (N°) JRC-EC* AIT* P.M 0 0 * Participation in kind; ** 41 PM provided in kind Objectives The main objectives of WP14 are to decrease RD data fragmentation and increase data quality through training activities on data management & quality which will raise the level of capacities and help data sharing and networking within the RD community. The training activities of WP14 will focus on (i) Standardization of rare disease data; (ii) Standards and quality in genetic testing; (iii) Strategies to foster solutions of undiagnosed rare disease cases; (iv) Biological rare disease sample data management, and sharing; (v) Establishment and long term sustainability of International, FAIR and high quality rare disease registries and (vi) Learn components and interoperability tools of the European Rare Diseases Registry Infrastructure. Description of work Methodology 61 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. WP14 will achieve the objectives through (i) the integration and implementation of existing and successful training activities and (ii) development of new specific trainings to address all objectives. This will ensure appropriate coverage of relevant aspects on data management & quality under a joint programme for meaningful interaction and comprehensive training across RD community in Europe. Task 14.1: Training on the Orphanet nomenclature and RD ontologies for RD research (M1-M60) TL: INSERM (Orph), Participants: LUMC, LBG (LBI-RUD), MUW An Orphanet nominated training manager will develop a novel training module on the Orphanet nomenclature and RD ontologies for RD research for clinicians and scientists. This work will be done in collaboration with a scientific committee. The novel course will be translated and adapted to country-specific needs by the Orphanet Network teams, in order to organise ‘National trainings’ in their national languages (free for participants). The training manager will also organise a 'Training for Trainers' which will be dispensed to the Orphanet Network teams, enabling them to acquire efficient training techniques and thus in turn dispense effective ‘National trainings’ in their country. Participation in this training will help clinicians and researchers to exploit the full potential of the Orphanet database integrated data through ORDO and Orphanet nomenclature use thus enabling them to generate additional knowledge in their field. Task 14.2: Standards and quality of genetics/genomics data in laboratory and clinical research practice (M1-M60) TL: KULeuven, Participants: EKUT, ACU/ACURARE, ISS, IPCZD (CMHI), CNAG-CRG, INSERM (AMU), UMCG ‘Next generation sequencing’ (NGS) generates overwhelming amounts of data. Clinical and basic researchers are increasingly confronted with the complexity of genomic data. It is of importance to provide training on the interpretation of genetic variants and quality standards. Courses for scientists, bio-informaticians and clinicians with an interest in genomic technologies and applications will be developed. The aim is to teach participants about the evaluation of the pathogenic nature and clinical significance of genetic variants, on the criteria that have to be set to the NGS analysis pipelines and on the use of international databases. The course will build on expertise gained by EuroGentest and help in the translation of research tools to diagnostic applications (in line with the IRDiRC objectives). The impact is on the quality and reliability of NGS results, obtained through rare disease research. Over the years, the course content will shift to total genome interpretation, which will entail novel disease molecular mechanisms. Annual 3-day residential training courses typically host 20 participants and will travel across Europe (KULeuven, EKUT, ACU/ACURARE, ISS and IPCZD (CHMI)). Task 14.3: Training on strategies to foster solutions of undiagnosed rare disease cases (M12-M60) TL: ISS, Participants: EKUT, LBG (LBI-RUD), ACU/ACURARE, ISCIII, INSERM (AMU), FTELE, UMCG, IMAGINE, CNAG-CRG, IPCZD (CMHI) This task will implement a new 3-day residential training course that will provide newly-developed strategies and tools based on phenotypic and molecular analysis to foster solutions for undiagnosed rare disease cases for researchers and clinicians. The course will be organised and hosted in ISS in close collaboration with task partners, “Solve-RD”, and the Undiagnosed Network International (UDNI). The course will guide participants on novel molecular strategies, functional analysis, integrative multi-omics interpretation and clinical utility (EKUT, linked with Pillar 3 Task 14.1, and with Pillar 2 WP13). In particular, a selected number of cases will be presented (in rotation by the following partners LBG (LBI-RUD), EKUT, ACU/ACURARE, ISCIII, IMAGINE, UMCG, FTELE, INSERM (AMU). Moreover participants during the course will learn how to use tools such as the RD- Connect genome-phenome analysis platform (CNAG-CRG and linked with Pillar 2 WP11) and other bio- informatic resources (INSERM-AMU). Participants at the end of the course will be better equipped with specific knowledge enabling them to solve undiagnosed cases. Task 14.4: Training for biobanks and researchers/clinicians on sample data management (M1-M60) TL: FTELE; Participants: UMCG, BBMRI, CHARITE, ISCIII, MUG, HUGEN (HACETTEPE), VUHSK Biological samples from RD patients are precious resources for research. Due to their intrinsic rarity, these samples are often dispersed in multiple biobanks and are difficult to locate. Moreover, samples collected by researchers within projects are often not available for reuse or processed with adequate standards. Such practices do not facilitate research reproducibility and are not in the best interest of the patients. Biobanks have begun to share RD datasets to centralised sample catalogues (e.g. RD-Connect, EuroBioBank) to facilitate access, and support the change towards best practice with their special position interfacing patients, clinicians and researchers. However, RD samples and associated data pose particular management challenges for their high variety of data types (e.g. disease names, genetic variants, phenotypes, clinical data), as well as balancing the need to share while preserving privacy and rights of patients. The goals of this task are to train (subtask 14.4.1) researchers/clinicians on how to use biobanks to support their projects for sample management, and (subtask 14.4.2) to train biobank staff how to share and link individual RD samples and data, using existing platforms and standards developed by Pillar 2. The 62 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. latest ethical and legal requirements including privacy/data protection provisions will be covered (linked with Transversal activities in WP4). Two annual workshops (developed by FTELE, BBMRI, UMCG, CHARITE), rotating in different locations including EU-13 countries, will be organised (ISCIII, MUG, HUGEN (HACETTEPE), VUHSK). Task 14.5: Training on rare disease registries and FAIRification of data at the source (M1-M60) TL: ISS; Participants: LUMC (also for Endo-ERN); Bond-ERN (IOR), Metab-ERN (HK) EURORDIS, ISCIII, LUMC, INSERM (RaDiCo); UMCG, DTL-Projects (ELIXIR-NL), CNR (ELIXIR -IT), AMC Since 2013 this course has been organised and hosted in ISS with the collaboration and support of key partners including RD-Connect, ELIXIR, LUMC, and EURORDIS. The enhanced and expanded course provided by this task will be an annual residential training course for the establishment of Findable, Accessible, Interoperable, and Reusable, for humans and computers, (FAIR) Rare Disease (RD) registries. The course, organised and hosted in ISS in close collaboration with task partners, is open to the international researcher community, patients, registry curators, database managers, healthcare professionals and students and takes place over 5 days split into two main parts. In the first 3 days, participants learn (a) what resources are needed for the establishment / maintenance of a high-quality registry; (b) the features of successful strategies to ensure (i) long-time sustainability of the registry, (ii) including quality, (iii) legal and ethical issues in compliance with the EU General Data Protection Regulation, and (iv) FAIR principles (most of the speakers from task partners). The final two days of the course are a hands-on tutorial (Bring Your Own Data, BYOD) where the attendees work with IT-Trainers and use a set of light-weight tools to make use cases FAIR (mainly from LUMC, and ELIXIR, link with Pillar 2 WP12 in particular task 12.3). Use cases are brought by task partners (ENDO-ERN, BOND-ERN and METAB-ERN) and in part by participants. Task 14.6: Training on the European Rare Diseases Registry Infrastructure (ERDRI) (M1-M60) TL: JRC; Participants: INSERM (Orph), AIT; Other (external collaborators for JRC) UMC Frankfurt, University of Mainz The task will be in accordance to the JRC's contribution to Pillar 2 WP11 and WP12. Accordingly, the JRC and its partners for this task will provide trainings to all interested stakeholders on the ERDRI components and other interoperability tools including the Central Metadata Repository: structure, functioning, access by registries, implementation (JRC and UMC Frankfurt); the European Directory of Registries: structure, functioning, access by registries, implementation (JRC and University of Mainz); the implementation of the Set of Common Data Elements for Rare Disease Registration (JRC) and linked element sources (codification, ontologies - Orphanet) and the EUPID Pseudonymisation tool for RD registries : functioning, access, implementation (JRC and AIT). Deliverables: D14.1: Reports of Orphanet nomenclature training for trainers and national trainings (M14 and M60) D14.2: Report on course on interpretation of genetic variants and quality standards (M12 and M60) D14.3: Report on International course on undiagnosed diseases (M24 and M60) D14.4: Report on sample data management training workshops (M12 and M60) D14.5: Report on International course on Rare Disease Registries and FAIRification of data at source (M12 and M60) WP N°15 Capacity building and training of patients and researchers Lead beneficiary EURORDIS in Rare Disease research and processes Start date M1 End date M 60 Participan EURORDIS LUMC* ISS (26) ACU/A MUG TEDDY IMAGINE t short (77) (64) CU (39) + LTP: (14) name & RARE FSJD (N°) (32) (28) P.M 89 0 2 2 2 22 0.4 *Contribution in kind Objectives The overall objective of this WP is to address one key component of the EJP on RD that is to improve RD research and innovation and to enhance the uptake of research results by building the capacity of the patient community and other key stakeholders. The specific objectives of this WP include: 63 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. ● Gaining an understanding of therapeutic development and regulatory processes for medicinal products in the field of rare diseases for patients and researchers; ● Providing the knowledge and skills required for patients to become legitimate collaborators in RD scientific & translational research hence enabling the implementation of the strategy supported by the EJP on education of patients; ● Empowering the patient community and specifically patient representatives in their roles as equal, valued, and efficient partners in research and scientific project / ERNs governance bodies; ● Applying appropriate methods in the empowerment process of the paediatric patients to provide them with knowledge, skills and educational comprehensive tools covering some of the main knowledge gaps related to the paediatric developmental specificities. Description of work Methodology This WP will apply a blended approach to deliver the existing and new training activities (e-learning and face to face for T15.1, T15.2 and T15.3) open and free to all participants that will be integrated within the EURORDIS Open Academy16. The T15.4 will develop gamified training material adapted to the paediatric target audience and deliver its course via short workshops in year 4 and 5 organised in synergy with the TEDDY Network, FSJD and the IMI2-funded project C4C (i.e. Conect4Children). Task 15.1: ExPRESS Expert Patients and Researchers EURORDIS Summer School (M1-M60) TL: EURORDIS, Participant: LUMC One of the ultimate aims of research is to bring innovative, life-transforming therapeutic options to patients who are also taking on ever increasing roles in advocating for medicines development, equal access to treatments across Europe and ensuring that medical information is clear, accurate and comprehensible. ExPRESS Expert Patients and Researchers EURORDIS Summer School (ExPRESS) is an annual training programme organised by EURORDIS. The face-to-face course trains 45 expert patients and 15 researchers annually as part of an intensive 4.5-day course held in Barcelona. It was demonstrated that joint training of patients and researchers is of great benefit for both type of stakeholders helping to raise awareness and sharpen advocacy skills and gain an understanding of therapeutic development and regulatory processes for medicinal products in the field of rare diseases. Joint training enable both stakeholders to become more active in this ecosystem. This task will support the human resources necessary to organize, develop and carry out all activities as well as the operational support needed to ensure participation of researchers. The EJP for RD’s contribution is being requested pro-rata thus leveraging on complementary and diverse sources of funding raised by EURORDIS. Task 15.2: Training for patient advocates on scientific innovation and translational research aspects in rare diseases (M12-M60) TL: EURORDIS; Participant: IMAGINE This task will enable further development of a new 5-day annual residential training workshop for 30 patient representatives, focused on scientific innovation and translational research organised by EURORDIS since 2018. The programme will introduce trainees to translational research, genetics, the latest advances in diagnostic tools and pathways including those developed within the large European project called Solve-RD, disease model systems, data (collection, sharing, and protection), patient-reported outcomes and the use of novel technologies in the context of rare diseases research. Training will be delivered by experts in research coming from academia and industry, along with patient groups who will provide case studies in successful research engagement. The course will also provide information on research funding in the EU, research funding strategies for patient groups and corporate collaborations. The course will take place at the Imagine Institute for Genetic Diseases in Paris which will enable daily on site visits to relevant laboratories and interactive discussion between research teams and participants. This task will support the development of the programme in line with scientific breakthrough in RD research and implementation of the course from Y2 (2020) to Y5 (2023) of the EJP (the 2018 and 2019 editions are funded through Solve-RD). Task 15.3: Training for patient representatives and advocates on leadership and communication skills (M1- M48) TL: EURORDIS; Participants: ISS, ACU/ACURARE and MUG This task uses a unique strategy of engagement and integration of patients at all levels of leadership, design, training, coaching and communication. The brand new Leadership Programme aims to provide patient representatives including but not limited to members of the European Patient Advocacy Groups (ePAGs) involved 16 https://openacademy.eurordis.org/ 64 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. in the 24 European Reference Networks with a comprehensive overview of working processes involved in various advisory, management and steering research committees, governance processes and terminology, fostering meaningful communication, cooperation, and coordination strategies and helping patient representatives carefully consider strategic health and research advocacy processes, roles, and responsibilities. The EURORDIS leadership programme will be developed and implemented for the first time within the course of the EJP and will combine 4 modules (Personal Impact, Building Partnerships, Leadership Style and Knowledge Generation) that will help nurture individual personal authority to better act on behalf of others, influence decisions and set the strategic direction within ERNs and European-wide disease specific and infrastructure research initiatives and projects. This task will support the development of the annual face-to-face 2 days training programme for 30 participants. The location will be rotating each year between France (EURORDIS), Italy (ISS), Turkey (ACU/ACURARE) and Poland (MUG). Task 15.4: Educational materials and activities for paediatric patients (M25-M60) TL: TEDDY & LTP (FSJD); Participant: EURORDIS Due to the paediatric specific developmental characteristics, specifically tailored methods should be applied to the training and empowerment process of paediatric patients. The activities undertaken in this task will be conducted based on the experience carried out within the FP6 TEDDY Network of Excellence coordinated by CVBF, as further developed in the context of the Category 1 Enpr-EMA member “TEDDY Network of Excellence for Paediatric Clinical Trial”. There will also be relevant links and synergies with the ongoing H2020 project EPTRI European Paediatric Translational Research Infrastructure, coordinated by CVBF, the H2020 project PEDCRIN Paediatric Clinical Research Infrastructure Network coordinated by ECRIN and with the IMI2 C4C project. These are both collaborative projects, in which ad hoc actions for paediatric patients’ empowerment are foreseen, involving also Foundation Sant Joan de Deu (FSJD). The planned activities include short workshops in collaboration with EURORDIS and the eYPAGnet (the European Young Persons' Advisory Group network) for 15 patients’ representatives focusing on the following areas: (i) Genetic /rare disease characteristics and evolution; (ii) Role for paediatric patients and relevance of clinical and translational research (including patients’ engagement in clinical trials, the consent issue, the patient-reported outcomes in the context of paediatric rare diseases); (iii) Orphan Medicinal Products availability and access for paediatric patients on the EU market, pharmacovigilance and off-label use in paediatric setting. The Face to Face ‘paediatric patient experts training course’ will start in year 3 and will be hosted in Italy (TEDDY), Spain (JSJD) and France (EURORDIS). Deliverables: D15.1: Report on ExPRESS (M12 and M60) D15.2: Report on training of patient representatives on scientific innovation and translational research in RD (M24 and M60) D15.3: Report on EURORDIS’ Leadership Programme (M12 and M48) D15.4: Training plan for paediatric patients’ in the EJP (M30) D15.5: Report on paediatric patients’ experts training courses (M60) WP N°16 Online Academic education course Lead FFRD beneficiary Start date M1 End date M 60 Participant UKL-HD (ERN ERKNet) (57) short name & AOUS (LTP -CHU Dijon for RUMC (LTP -Curie Institute NUTH (ERN EURO-NMD) GOSH (LTP-HCL for ERN APHP (MetabERN+ Endo- UMAN (ELIXIR-UK) (76) for ERN GENTURIS) (65) (N°) UCAM (ELIXR-UK) (76) INSERM (Orphanet) (1a) UU (ELIXIR-SE) (76) TransplantCHild) (68) INSERM (AMU) (1d) ERN ITHACA) (63) EURORDIS (77) SERMAS (ERN Epicare) (70) FFRD (12) ERN) (54) (69) P.M 47 3 6 8 1 1,5 1 1,5 1 1,5 1,5 4,5 1, 1,5 5 65 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Participant VUHSK (ERN- short name & (N°) Ithaca) (32) ISCIII (44) EATRIS FGB P.M 3,5 1 4 3,5 Objectives Most of the currently available trainings and courses are either focusing on a group of RD, a specific technology or developed for a national/university audience. The overall objective of this WP is to provide a EU-wide streamlined education programme on RD research to all interested stakeholders via an e-learning established service provider that will combine both certificated courses and MOOC. The modules of the e-learning course will be created and/or adapted from existing/available content together with top-tier RD experts. Education being part of the future activities to be developed by ERNs, this WP will also provide complimentary access to the e-learning platform facilities, as well as visibility to the research training activities and educational material developed by the ERNs and other relevant clinical networks. Educational material developed within the online academic education course is focussed on the transversal aspects across RDs and is non-redundant with that of the ERNs. The specific objectives of this WP are to: ● Ensure a thorough EU-wide benchmark and assessment of RD academic trainings and e-learning courses in order to prevent any duplication of existing content and favour relevant adaptation and inclusion of existing courses in the future EJP-RD online course; ● Develop a comprehensive, high-quality e-learning course, both available to an academic audience but also to a wider public in coordination with a professional service provider; ● Closely monitor the impact of the course in order to implement the relevant modifications throughout the EJP-RD lifetime and ensure its widest impact. Description of work Task 16.1: Assess the needs, target audience, main topics of the academic education course (M1-M6), TL: FFRD; Participants: SERMAS (ERN TransplantChild), RUMC (LTP-Curie Institute for ERN GENTURIS), VUHSK, NUTH (EURO-NMD), EURORDIS, UKL-HD (ERN ERKNet), GOSH (LTP-HCL for ERN EpiCARE), APHP (for MetabERN and Endo-ERN) This task will be performed through a thorough benchmark of existing RD academic courses at EU level by i) building on the outcome of task 17.1 in Pillar 3 regarding ERNs needs and ii) working with other relevant stakeholders (EU Universities, Patients’ Organizations, Learned Societies, EU Infrastructures, Industry stakeholders having developed trainings on RD, etc.). Aside the content, the benchmark will also include targeted audiences of the current available courses as well as experts and lecturers involved in those courses. As far as possible shareable feedbacks from lecturers, students, developers and providers of the courses will be collected. This benchmark will enable to identify gaps and specific needs as well as the main topics to address with the most relevant lecturers to involve. Priority areas of training will be identified in order to implement the course in the most relevant way. Task 16.2: Developing the online course (M6-M48), TL: FFRD, Participants: ISCIII, EURORDIS, VUHSK, AOUS (LTP-CHU Dijon for ERN ITHACA), RUMC (LTP- Curie Institute for ERN GENTURIS), SERMAS (ERN TransplantChild), Inserm (Orph), Inserm (AMU), EATRIS, NUTH (ERN EURO-NMD), UKL-HD (ERN ERKNet), GOSH (LTP-HCL for ERN EpiCARE), APHP (for ERN MetabERN and Endo-ERN), FGB, UU (ELIXIR-SI), FutureLearn (subcontractor) Subtask 16.2.1: Format, technical issues, status, and accreditation STL: FFRD, Participant: FutureLearn (subcontractor) The most suitable format and options/tools for the course will be discussed in close coordination with the e- learning platform provider and the coordinators of the modules. European Credit Transfer System eligibility (ECTS) will be sought, as it will be an incentive to target students more specifically. Based on existing e-learning courses, the envisioned length for each module of the course would be 10 to 15 hours, over two to five weeks. The most-suited number of sessions/year/modules will also be defined, with a minimum of one session/year/module. Based on the success of each module, they could be run as many times a year as relevant with no added-fee. The 66 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. selected e-learning platform is totally scalable and enables to adapt content for different audiences and to provide in parallel free-MOOC open to everyone and programme certification for enrolled students/learners. The partners will rely on a renowned e-learning platform with track record working with EU projects and top-ranked EU Universities together with a strong expertise in Health. The platform will help promote the course and disseminate it, in close coordination with WP5. The platform will be actively involved in managing lecturers of the different modules. Practical issues such as filming, e-tutoring, collaborative learning, virtual classroom will be further defined in collaboration with coordinators of the modules and the lecturers whilst keeping within the service provider contract. Subtask 16.2.2: Identify and work with relevant European universities, learned societies and other institutions to develop the content of the academic course STL: FFRD, Participants: ISCIII, EURORDIS, VUHSK, AOUS (LTP-CHU Dijon for ERN ITHACA), RUMC (LTP- Curie Institute for ERN GENTURIS), SERMAS (ERN TransplantChild), Inserm (Orph), Inserm (AMU), EATRIS, NUTH (for ERN EURO-NMD), UKL-HD (ERN ERKNet), GOSH (LTP-HCL for ERN EpiCARE), APHP (ERN MetabERN andENDO-ERN), FGB, UU (ELIXIR-SI),FutureLearn (subcontractor) Top-tier EU RD experts will be involved in the definition of the course content together with the most relevant lecturers. 10 to 12 modules have been envisioned but will be challenged by task 16.1 outputs. Each module will be built in close collaboration with two co-coordinators (objectives, content, e-learning options, lecturers, detailed programme, evaluation options, etc.). Co-coordinators of the modules are bringing diverse expertise that will enrich the approach: eight ERNs, Universities, Research Institutes (VUHSK, ISCIII, Inserm-AMU, Inserm-ORPHANET), Patients’ Organisations (EURORDIS), EU Infrastructures (EATRIS, ELIXIR, Charities (FFRD, FGB). Modules will be launched progressively: five modules would be implemented by M24, five more by M36 and the rest of them by M48, with the full course running by the end of M48 with several sessions per year per module. The modules to be launched at first will be selected based on task 16.1 outputs. The list of coordinators will also be enriched based on task 16.1 outputs. Modules will encompass a wide variety of subjects taking into consideration a bench-to-bedside approach. Whenever possible and relevant, a three-fold perspective will be followed including patients’ testimonies, clinicians’ perspective and researchers’ expertise. The course will be developed with the ability to link and flag ERN own research e-learning training activities. Access to the e-learning platform facilities to ERNs will also be facilitated. Task 16.3: Follow-up, assessment and monitoring of the e-learning course (M18-M60) TL: UCAM (ELIXIR-UK), UMAN (ELIXIR-UK), Participants: FFRD and FutureLearn ( subcontractor) A close and regular follow-up will be necessary to adapt the online course and ensure its effectiveness. Assessment will encompass both qualitative and quantitative and a strategy for the uptake of suggested improvements to the course itself. Evaluation activities to be performed in this task will be developed in collaboration and shared with transversal WP1 (task 1.3: Monitoring of the EJP RD activities). Objectivity will also be ensured with the task 16.3 leader not being involved in the development of the course’s content. Subtask 16.3.1 Quantitative assessment STL: UCAM (ELIXIR-UK), UMAN (ELIXIR-UK, Participant: FutureLearn (subcontractor) The quantitative follow-up and monitoring will be ensured by the e-learning platform as part of its basic contract (no extra fee). The platform will be capturing, in real time, demographic data (e.g. gender, geographic distribution, age, carrier stage, etc.) as well as students’ performance. De-identified raw data would need further interpretation that will be handled by ELIXIR-UK. Subtask 16.3.2 Follow-up of the assessment, feedback of coordinators/lecturers/attendees STL: UCAM (ELIXIR-UK), UMAN (ELIXIR-UK) Students’ assessment and evaluation will be defined in collaboration with coordinators and lecturers and will allow for a measure of training quality and impact. Metrics and Key Performance Indicators (KPIs) developed by ELIXIR will be used in order to adopt and refine a common benchmark mechanism for the different modules. This will be done in close collaboration with WP1/Task 1.3 and WP5. The application of a common feedback collection approach across all modules’ coordinators and lecturers will guarantee that the same core data will be gathered, allowing for an easy comparison between modules. This will provide not only a benchmarking process for training providers to use but also the ability (through the collection of appropriate metrics and KPIs) to determine the quality and impact of the training being delivered. A combination of short and long-term post-course feedback surveys will be fostered to measure the quality (short term) and impact (long term) of the course. This will be done in close links with WP1 and WP3 of the EJP RD transversal activities. Subtask 16.3.3 Monitoring/adaptation of the course STL: FFRD The modules of the course will be adapted in the subsequent sessions for a given module taken into consideration impact assessment studies. The e-learning platform enabling to run modules separately, improvements could be 67 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. brought module/module and in a very flexible way. The adaptation of the course will be done in close collaboration with the modules co-coordinators and lecturers. Deliverables: D16.1: Draft content of the online academic course (M9) D16.2: Content of the first 5 online modules (M24) D16.3: Content of the full online course (M48) D16.4: Impact assessment of the course (M36 and M60) WP N°17 ERN RD training and support programme Lead beneficiary EKUT Start date M1 End date M 60 Participan EKUT (ERN-RND) UKL-HD (ERKnet) LUMC (EndoERN) RUMC (ERN-Genturis) t short name & (N°) P.M 18 15 15 15 Objectives The overall objective of this WP is to deliver research training programs for the European Reference Networks (ERNs) focusing on cross-cutting and over-arching research themes. The specific objectives of this WP are: ● To map and assess the existing landscape of the training programs in the ERN training networks in terms of needs, target groups, formats, contents, and existing resources regarding cross-cutting and overarching research themes ● To develop and deliver tailored research training activities that will be periodically adjusted to current needs to support RD research in the formed ERN training groups ● To accredit the training activities across Europe. Description of work Methodology In order to implement training programs that provide a cross-ERN added value, the 24 ERNs will be divided into four training groups according to research topics that are shared by the ERNs of each group. The following training groups have been formed: • Group 1 “Neuro” will integrate: ERN-RND (coordination), EURO-NMD, EpiCare, ERN-Eye, ERN-CRANIO, and ERN-ITHACA, • Group 2 “Neoplasm and Malformation” will integrate: GENTURIS, EURACAN, PaedCan, ReCONNECT, EuroBlood Net, ERN RITA, and ERNICA. • Group 3 “Organs” will integrate: ERKNet, Rare-Liver, TransplantChild, Guard-Heart, ERN Lung, and ERN eUrogen, • Group 4 “Systemic” will integrate: Endo-ERN, METABERN, VASCERN, ERN Skin and BOND. These training groups represent the very first integration of ERNs on operational level. The ERN coordinators belonging to the respective groups will jointly introduce a decision-making process to decide on and review funded training activities. Matter of factly, the WP will coordinate its activities with the established ERN CG Working Group on guidelines, education and training. By date, there has not been coordination activities of this group as regards ERN training activities meaning that this WP will act as the main driver. Task 17.1: Mapping to collect information on preferences, needs and resources from the ERNs ecosystem (M1-M3) TL: LUMC, Participants: UKL-HD, EKUT, RUMC The goal of this online survey is for the first time to gather and assess information on cross-cutting and overarching research training interests, activities and themes to feed into the development of research training programs to be delivered in the ERN training groups. Four ERN training groups have been formed based common research topics. Such a mapping has not been done yet and will provide novel data as well as the basis for implementing the ERN 68 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. training groups. Information and data have been collected by some ERNs with a focus on ERN specific content, although not in a coordinated fashion across ERNs. These data might nevertheless serve as a starting point. Research training needs and added value, target groups, formats, contents and existing resources will be taken into account when implementing a structured survey. The survey will contain overarching questions and questions tailored to the respective ERN groups. The results will also inform Pillar 3 Task 16.1 specifically regarding ERN training needs. Task 17.2: Development of training programs for the ERN training networks based on the results of survey, (M4-M6) TL: UKL-HD, Participants: EKUT, LUMC, RUMC; This task will develop bespoke training programs for the ERN groups based on the results of the survey performed in task 1 focusing on identified cross-cutting and overarching research topics. We will use focus group meetings to develop and consent on the training programs. Focus groups will be composed of ERN coordinators, ERN training leads and ePAG representatives. The output of the focus groups that is the consented training program will be delivered through task 17.3. Such training programs present a level of integration not yet achieved on operational level between the existing ERNs. So far ERNs have operationally focused on their respective networks. Task 17.3: Deliver training programs through the ERN training networks, (M7-M60) TL: EKUT, Participants: UKL-HD, RUMC, LUMC Based on the training programs produced in task 17.2, the ERN training groups will be planning, organizing and delivering research training activities. Based on the identified cross-cutting and overarching themes task forces will be formed that are composed of the ERN clinicians and researcher that are experts in the respective theme. Notably, no such cross-cutting ERN task forces on operational level exist yet and will thus bring about a new level of collaboration of the ERNs. The task forces will develop fitting training activities that might comprise formats like fellow exchange, clinical workshops, and further formats to be determined through the mapping exercise. Fellow exchanges might focus on performance of (i) small bilateral research projects linking partners from different ERNs through using cutting-edge methodologies and approaches and/or (ii) training of novel research methodologies that provide added value beyond the single ERN level. Clinical workshops will be directed towards multidisciplinary multi-disciplinary research themes that might have the potential to play a disruptive role in medical practise such as big data based care, tissue engineering and stem cell technologies as well as mind-machine interface. Primary addressees of the training activities are healthcare professionals from ERNs interested or active in research. Task 17.4 Accreditation of training activities, (M7-M60) TL: EKUT, Participants: UKL-HD, LUMC, RUMC The objectives of this task will be to seek the recognition of the training activities to be accredited by respective accreditation organisations such as the European Union of Medical Specialists (UEMS) to allow the participants to get CME accredited training activities recognised in their respective home countries. Deliverables: D17.1: Results of survey on preferences, needs and resources from the ERNs ecosystem (M4) D17.2: EJP RD ERN training programmes (M7) D17.3: Periodic reports on implementation of training programs (M13 and M60) WP N°18 Development and adaptation of training activities Lead VUHSK, beneficiary IPCZD (CMHI), EURORDIS Start date M24 End date M 60 Participan VUHSK (32) IPCZD EURORDIS FFRD ISS (26) EKUT FTELE UU t short (CMHI) (77) (12) (58) (25) *(ELIXIR- name & (40) SI) (76) (N°) P.M 4 2 2 1 1 1 1 0 *Participation in kind Objectives 69 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. The overall objective of this WP is to ensure that capacity building activities within Pillar 3 address the developing education and training needs in RD research of key stakeholders (including clinicians, researchers, patient representatives, but also paramedical sector), across different EU countries. Fostering the constant flow of knowledge and know-how, arising from the activities of Pillars 2 and 4 and reaching out to RD research community as a whole will enhance usage of best practices and standards in RD research. These activities will be done in close collaboration and shared with WP1 Task1.3. These activities will decrease fragmentation of RD research education and training activities across universities, countries, infrastructures, and networks (such as ERNs). The specific objectives of this WP include: ● Adaptation of capacity building activities according to progress of work in Pillar 2 and Pillar 4; ● Adaptation of capacity building activities according to specific needs of EU-13 countries; ● Adaptation of capacity building activities according to specific ERN training and support needs (closely linked to the work of WP17 of Pillar 3 and WP20 of Pillar 4). Description of work Methodology Careful evaluation of different information sources on RD education and training needs will be performed including evaluation of Pillar 3 training users and developers’ experience surveys, self-assessments and reports. Internal (Pillar 1, 2 and 4 leaders, ERNs, EURORDIS) and external sources such as the Association of Medical Schools in Europe and European Union of Medical Specialists, will be consulted for the identification of areas for further development required to address specific emerging needs of the rare disease community (VUHSK, EURORDIS, ISS, FTELE, FFRD, EKUT). In addition, particular attention will be given to the specific adaptation of training activities for EU-13 countries (IPCZD (CHMI), VUHSK, UU (ELIXIR-SI)) with the aims of enhancing EU-13 inclusion into RD communities. Reports of identified gaps and needs will be shared with WP1 Task 1.3 and WP2 Task 2.2 for prioritization and annual planning and with WP5 for dissemination purposes. Task 18.1: Evaluation of developing needs according to progress of work in Pillars 2 and 4 and relevant adaptation of training activities (M24-M60) TL: EURORDIS and FFRD, Participants: EKUT, ISS, VUHSK, FTELE; Task 18.1 will work in synergy with the Operating Group and the Executive Committee (EURORDIS, VUHSK) to review progress, report and identify training areas in need of further development and/or not previously addressed within Pillar 3. For example, close attention will be given to ensure continuous relevance and alignment of training topics and areas of Pillar 3 WP14 (ISS), WP15 (EURORDIS) and WP16 (FFRD) with progress of work in WP10 and WP13 of Pillar 2 (ISS, FTELE, EKUT). Furthermore, it is envisaged that a new training activity will be developed to provide capacity building of the different stakeholders on the use of the common platform to be developed under WP11 of Pillar 2. Task 18.2: Evaluation of strategic priorities and development of existing training activities according to specific needs of EU-13 countries, (M24-M60) TL: IPCZD (CHMI) and VUHSK, Participants: EURORDIS, FFRD, EKUT, ISS, UU (ELIXIR-SI); Currently, EU-13 countries still lag behind in RD research and their wider participation is hindered by challenges such as lack of RD research and training funding and economic constraints for attending international conferences/workshops. Task 18.2 will provide the driving force to make available wider possibilities of education and training to participants from EU-13 (including rotation of courses and fellowships for EU-13 participants), hence contributing to their wider, more active and consistent participation in RD research. Additional efforts to disseminate the free on-line academic courses (WP16) within EU-13 countries will be made to increase visibility and accessibility of these resources. Task 18.2 co-leaders (IPCZD (CHMI) and VUHSK) supported by Pillar 3 leaders and partners (EURORDIS, ISS, FTELE, FFRD, EKUT, Univ of Ljubljana) will carefully evaluate strategic priorities in capacity building needs of EU-13 countries and will transfer their assessment to WP1 Task 1.3 and WP2 Task 2.2 for prioritization and annual planning and to WP5 for dissemination purposes. Task 18.3: Evaluation of developing ERN training and support needs and adaptation of training activities in WP17, (M24-M60) TL: EKUT, Participants: EURORDIS, VUHSK, FFRD Task 18.3 will work in synergy with WP17 of Pillar 3 (EKUT) and WP19, Task 19.2 of Pillar 4 to adapt ERN training and support programmes to the emerging and developing needs of ERNs including but not limited to training in methodologies for clinical trials (WP20 of Pillar 4). The 4 core training networks composed of representatives from all ERNs in WP17 will ensure relevance of the adaptation across rare diseases and facilitate implementation of the new methodologies in the different ERNs. 70 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Deliverables: D18: Final report on evaluation and adaptation of training programmes according to Pillar 2 and 3 progress of work, specific needs of EU-13 countries and developing needs of ERNs (M60) PILLAR 4: ACCELERATING THE TRANSLATION OF HIGH POTENTIAL PROJECTS AND IMPROVING OUTCOMES OF CLINICAL STUDIES IN SMALL POPULATIONS WP N°19 Facilitating partnerships and accelerating Lead EATRIS, FTELE translation for higher patient impact beneficiary Start date M1 End date M 60 Participant HSK (MetabERN) CLB (EURACAN) short name & (HACETTEPE) (N°) Paedcan) (53) EATRIS (75) CCRI (ERN- LUNG) (59) GUF (ERN- FTELE (25) UNEW (52) AFM * (13) CVBF (27) FFRD (12) FGB (24) HUGEN (83) (56) (60) P.M 53 28 7 74 10 12 11 3 5 2 3 2 * Participation in kind Objectives The overall aim of this work package is to provide researchers the mix of competences (drug/diagnostic development, regulatory, methodological, pre-clinical and clinical development, IPR) needed to support rigorous translational research, to secure follow-on funding and find partners for the development of new treatments and diagnostics for rare diseases. To move a research project across all the compulsory steps that lead to market authorization and reimbursement, and remove the well-known difficulties, a multitude of different actions and different sets of competencies are necessary. This WP will support the RD community to more effectively translate high quality research into high impact interventions for the RD patient community, by creating a bridge between basic research and medical innovation, otherwise known as the “bench to bed-side” approach. The specific objectives are: ● Empower researchers to conduct rigorous translational research by providing self-help resources and active project mentoring and technical support; ● Improve the uptake of successful research projects towards clinical implementation with active exploitation and follow-on funding support; ● Improve efficiency and outcomes of translational research, and develop novel funding concept to reduce the ‘valley of death’ funding gap. Description of work Task 19.1: Accelerating translation TL: CVBF, EATRIS, Participants: FTELE, UNEW, GUF (ERN LUNG), CCRI (PAEDCAN) Subtask 19.1.1: Innovation Management Toolbox (M1-M60) In this task, a toolbox will be established as an online virtual library that provides self-help resources that will be openly accessible to the RD research community, and will be utilised by the WP partners and Innovation Managers to implement documents and guidance for projects supported here. This library will be accessible through the virtual platform in Pillar 2. Via electronic surveys of the ERN and basic research community conducted by ERNLUNG, the pressing needs for self-help resources and templates will be ascertained, to drive the population of the library. The toolbox will include technical guidance (such as target validation techniques, use of molecular imaging for drug development, and - drawing upon the work done in other pillars, especially Pillar 2 - patient confidentiality and data handling, animal welfare, biorepositories, plus intellectual property management and contract templates), a project management manual, and regulatory guidance. Many of these materials have already been created in other contexts and will be available after collation. Particular attention to the Paediatric Regulation will be given by CVBF and a handbook will be created by UNEW, to develop an ‘ACT’ (Advisory Committee on 71 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Therapeutics) model for Rare Diseases, based on the successful TACT model17 in the muscular dystrophy field. WP19 will make this library accessible through the Central Helpdesk and Virtual Platform of the EJP RD. It will also provide guidance to Pillar 2 on special requirements for translational/clinical research. Subtask 19.1.2: Assessment of translational research projects (M1-M54) All projects selected for funding through Pillar 1 and ongoing projects from E-Rare-3 will be analyzed to establish the development stage of the project and the likely product classification of the concept. In so doing, the future developmental needs should be confirmed including the regulatory pathway (in collaboration with the regulatory transversal WP4). This analysis will be undertaken by FTELE and EATRIS, and Paediatric projects will be assessed by CVBF, all of which are expert organizations in innovation management and translational research, and comprise experts with basic science, product development, regulatory, commercial and intellectual property expertise. Projects eligible for IM support are: ● Translational research projects funded in Pillar 1; ● Successful RDR Challenge projects from WP8 of Pillar 1; ● Ongoing projects (with 2 years or more still to run at time of application) from E-RARE 3 that request support and are identified as translational. Subtask 19.1.3: Real-time mentoring and technical support for translational research projects (M1-M60) All projects that are translational will be offered the support of a dedicated Innovation Manager (IM) that will utilise the innovation management toolbox (T 19.1) and the extensive networks of the partners in the EJP RD. These networks include those of the ESFRI infrastructures (BBRMI, ECRIN, EATRIS, ELIXIR), the ERNs, global partners in and outside of IRDiRC (especially those with drug, medtech and diagnostics development expertise, such as NIH NCATS, CDRD, LifeArc, AFM Telethon, FTELE), and the paediatric research community through CVBF-EPTRI. Projects will be supported until IM capacity is exhausted and so will be on a first-come-first-serve basis. The assigned Innovation Manager will be the permanent contact point for the supported project, granting access to expertise, facilities and tools. From M1 IM will build a pool of mentors by approaching individuals to request involvement. Consenting experts will be added to a database and will sign a mentoring agreement to establish the rules of engagement. Experts subsequently recruited into support of specific projects will mentor team in a longitudinal, distance format, via regular conference call meetings and occasional face-to-face as needed, and will verify the achievement of milestones, advise on further steps and issue recommendations on technical progress, in order to maximise the project’s potential of success and further development towards the clinic. Finally, on ad hoc basis, the IM and mentors will provide guidance to Pillar 2 on special requirements for translational/clinical research if demanded. Task 19.2: Support in exploitation and follow-on funding (M1-M60) TL:FTELE; Participants: EATRIS, CVBF, FFRD, FGB, HUGEN (HACETTEPE), CLB (ERN-EURACAN), HSK (MetabERN), AFM This task is aimed at providing support and guidance to projects approaching the end of EJP RD funding, in particular on the definition and implementation of a development and exploitation plan. Activities in this task are accessible to principal investigators: ● Funded through the transnational calls of Pillar 1 and that have been indicated as candidates to receive IM support in subtask 19.1.3 ● Originated from the PoC challenges in P1WP8 ● Funded through E-Rare calls upon request and with minimum technology readiness level (TRL) 4. Subtask 19.2.1: Assessing the potential of projects (M1-M54) The aim of this sub-task is to provide Pillar 1 translational projects and those from PoC RDR Challenges approaching their term, the opportunity to discuss envisaged next steps with a panel of experts in drug development, IP and business development, potentially including also relevant experts in the specific disease area (ERNs). Special attention will be paid in selecting the experts for the assessment panel in order to avoid any conflict of interest. The aim of this assessment is to identify the best strategy to bring the projects forward in development depending on the data obtained, TRL reached and expertise required to further development. Subtask 19.2.2: Development and exploitation plan (M3-M60) Based on the assessment conducted in the subtask above, PIs will receive support in the definition of a suitable plan to implement the identified strategy, potentially using a limited part of the remaining funding to cover initial development activities. The plan will encompass: ● Research activities mainly aimed at validating data obtained in the project ● IP strategy 17 http://www.treat-nmd.eu/resources/tact/introduction/ 72 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. ● Definition of the unmet need filled by the project (analysis of the disease field, epidemiology, available treatments/diagnostics, main players) ● Sustainability plan (follow on funding, partnership with industry, company creation). Subtask 19.2.3: Follow-on funding (M5-M60) In order to implement the plan defined above, in the cases where further funding is needed to reach proof of concept, support in identifying suitable funding opportunities (either through public or private funding) and guidance in preparing the application will be provided through the expertise in technology transfer, pre-clinical and clinical development as well as in regulatory affairs. Subtask 19.2.4: Partnering support (M6-M60) This task will support projects that meet the requirements to be uptaken by companies/investors for the achievement of their development plan. FTELE has established over the years a number of partnerships with commercial partners that have allowed to bring one advanced therapy to patients (i.e. Strimvelis, approved by EMA in 2016) and to support clinical trials for 5 genetic diseases. This expertise, combined with that of the other partners in the task, will be made available to PIs to support them in approaching companies. In addition to the identification of the best candidate partners, a guide to the preparation of appropriate project presentations (both confidential and non-confidential) will be provided, including layout models. Task 19.3: Evaluation of Innovation Management and exploitation support tasks (M44-M48) TL: GUF (ERN-LUNG) On the basis of surveys and - if needed - interviews of users of the services provided in T19.1-T19.4, ERN-LUNG will assess the user satisfaction and added value of both services and the library. A report will be created utilizing the Transversal Sustainability matrix provided by WP3, to inform sustainability planning and monitoring Task 1.3. Task 19.4: Roadmap for a European investment platform for RD (M2-M44) TL: FTELE, EATRIS Expanding on specific examples of novel investment platforms in RD and elsewhere, this task will assess feasibility and define a roadmap for the creation of a pan-European funding platform with a focus on RDs, to optimize the path to the patent and sustain the important innovation activities of the EJP RD. The roadmap will feed the sustainability strategy of the EJP RD as a whole performed in WP3. Deliverables: D19.1: Periodic reports on mentoring and technical support for translational research projects (M24, M42, M60) D19.2: Final report on follow-on funding and exploitation (M 60) D19.3: User satisfaction and feasibility report (M48) D19.4: Roadmap for EU investment platform for RDs (M36) WP N°20 Accelerating the validation, use and development Lead beneficiary UKA, APHP, of innovative methodologies tailored for clinical HSK (MetabERN) trials in RDs Start date M1 End date M 60 Participant GOSH (EPICARE) IOR (ERN-BOND) HSK (MetabERN) EURORDIS* (77) short name & SERMAS (ERN- Transplantchild) (N°) (ERKnet) (57) Paedcan) (53) APHP (ERN- EORTC (71)* CCRI (ERN- ECRIN (74) ULIV* (51) SKIN) (54) APHP (54) AFM (13)* UKA (16) UKL-HD (60) (61) (70) (68) P.M 59 64 17 77 6 6 4 10 4 4 0 3 0 2 * Participation in kind Objectives: The overall objective of this WP is to foster the development of innovative methodologies tailored for clinical studies in RDs. The specific objectives are to map the best methodologies for clinical studies in RDs and to validate innovative and promising design and analysis methodologies for therapy evaluation in some specific rare diseases. This WP will support ERNs to use the most adapted methodologies improving clinical trial studies in RDs. Moreover innovative design and analysis methodologies in RD areas should be developed in fields with unmet 73 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. need in order to fill the gaps. Once validated, agreed and accepted by all stakeholders, the innovative methodologies will foster the achievement of IRDiRC goals. Description of work Task 20.1: Task Force Group (M1-M60) TL: UKA, APHP, HSK (Metab-ERN), Participants: UKA, APHP, CCRI (Ped-Can), IOR (ERN-Bond), UKL-HD (ERKnet), GOSH (EPICARE), ECRIN, EURORDIS, ULiv, AFM The main activities within the WP20 will be coordinated and monitored by a Task Force Group (TFG) of experts which will be established during the first month of the EJP RD project (subtask 20.1.1) and represented by the WP leaders with additional scientific, clinical and methodological experts and representative(s) of patients from EURORDIS. The TFG will be responsible for review of the existing state-of-the-art methodologies at European and international levels in specific topics related to clinical trials in rare diseases. Whenever needed the TFG will expand its capacity by including additional experts from ERNs and other external specialists covering different disciplines. The TFG will review the standard of clinical studies methodology usable in RD research and deliver the roadmap of available methodologies promising to gain efficiency for a given RD or a group of RDs. The duties of the TFG will include: (i) coordination of activities within WP20; (ii) identification of promising areas for the demonstration projects and innovative methodology projects; (iii) preparation of detailed internal call (topic) description for internal call for demonstration projects and innovative methodology projects (Tasks 20.3 & 20.4); (iv) writing of the final report summarizing main results of the WP20 including recommendations roadmap. The Group will start the work by a concise knowledge interchange and identification of highly promising areas for validation of recent promising methodologies and areas in need of further innovation. The TFG will be responsible for the monitoring of the progress of the projects and annual progress reports will serve as input to the EJP RD Annual Progress Report. The TFG will also identify the items/findings ready for dissemination to the RD community through Transversal WP5 but also through the clinical trials support office with ECRIN (task 20.2) and through training activities of WPs 15 and 16. The main results of the WP20 of the TFG roadmap will be disseminated via a peer review publications, e.g. summarized in a “Points to Consider” paper by the regulators (EMA, etc.). Task 20.2: Support in design and planning of RD clinical studies (M1-M60) TL: ECRIN, Participants: APHP (ERN-Skin), SERMAS (ERN Child Transplant) To support the RD/ERN clinical investigators in the preparation of clinical studies for the development of new treatments, for drug or device repurposing, or for diagnostic studies a support office will be set up (task 20.2.1). The support office will benefit from the current ECRIN organization reinforced by a dedicated RD clinical manager who will be the permanent contact point for the ERN clinical investigators and partners, collecting information on the projects, organizing and facilitating their access to the specific expertise and ensuring timely delivery of support. The (ECRIN) RD clinical manager will be supported by the (ECRIN) Clinical Operation Manager and medical expert(s). The support will include design and methodological aspects of the study and statistical methodology adapted to the small sample size. The office will offer support to ERN investigators to plan trials testing new treatments or new strategies for the benefit of the patients. Beside ECRIN specialists, it will include two representatives of ERNs, and a methodology expert (from the TFG). Additional experts from the TFG will provide specific input upon request. A “Terms of Reference” document will describe the mission, composition and activities of the support office, and the eligibility of the investigators requesting support (first restricted to members of ERNs, then expanded to the Pillar 1 calls or projects on clinical studies). The support office will meet through teleconferences, inviting the investigators to present and discuss their project proposals. For each project, the office will propose a spectrum of support in the planning of clinical studies on RDs including: (i) the site and country selection; (ii) patient recruitment strategies; (iii) information on regulatory and ethical aspects; (iv) informed consent and insurance requirements on the management of samples and IMP; (v) recommendations on monitoring plan, on data management, sharing and analysis; (vi) support on cost evaluation; (vii) recommendations on consortium and study management and governance; (viii) recommendations on contracting, together with risk assessment and mitigation. Further design aspects will include recommendations on the choice the most efficient study design, the choice of primary endpoint, the comparator, inclusion and exclusion criteria, and on all aspects of the statistical methodology of the study. The requests and nature of support provided will be recorded for evaluation of efficiency (Task 1.3) and incoming needs towards the reinforcement of the capacity of ERNs to initiate and conduct clinical studies, independently of industry sponsors. Task 20.3: Demonstration projects on existing statistical methodologies to improve RD clinical trials (M9- M48) TL: IOR (ERN BOND); GOSH (EPICARE), Participants: APHP, UKA 74 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. By M9 WP20 will organize call for 6 demonstration projects. This will be done with support from Pillar 1 chosen partner to ensure transparent and efficient call implementation and evaluation process. Recent developments suggest that traditional methodologies do not result in cost effective and efficient trials supporting RD research as needed. A major source of innovative methodologies are recently published by IDeAl18, asterix19 and InSPiRe20. However, validation of these new methodologies is still missing. Thus, the overall aim of the 6 small scale demonstration projects will be to validate in practical settings the existing, most recently presented innovative methodologies, in practil settings to provide necessary proofs of their efficacy and thereby raise awareness and usage of these methodologies. The demonstration will be based on existing RD data or running co-funded pilot studies (with industry or private partners) to proof the feasibility for possible use of these methods. The main source for these data will be completed clinical trials data of ERNs. As result, the investigation will show the benefit of these innovative methodologies for therapy evaluation in RD and thereby foster better treatment evaluation with efficient analysis techniques. Taking into account, that the various design aspects, like definition of endpoints, trial layout, randomization techniques and power calculation are related to analysis techniques, the result of this task will be pivotal in influencing design and implementation of clinical trials in RD at large scale. The progress and results of the demonstration projects will be followed and referred to the TFG during the monthly meetings. Finally, these results will be communicated to Pillar 4, Task 20.2, to Pillar 3 WP18 and to the communication manager of the EJP RD. It is expected that with the launch of the call in M9 demonstrators should start in month 15 with 30 months (2.5 years) working period. Thus, the final results of these validation projects will be expected at M45. Task 20.4: Projects on innovative methodologies to improve RD clinical trials in limited populations (M12- M56) TL: CCRI (PAEDCan) & HSK (Metab ERN), Participants: APHP, UKA Recently, the IRDiRC Task Force for ‘Small population Clinical Trials’ tackled the issue of optimization and improvement of commonly adopted approaches to reach agreement between the different stakeholders on appropriate small population studies. Based on the inputs from this Task Force, the TFG together with other relevant experts will identify the most promising areas of research on missing methodologies to close the gaps in clinical studies on limited populations. The internal call will be organized similarly to the one on demonstrators, with the input from the TFG on the detailed call text and factual implementation by partners (from Pillar 1) possessing expertise in launching, implementing and evaluating call for projects. The proposed areas for innovative methodology projects will include: From the clinical perspectives: ● Finding more appropriate endpoints for clinical studies in RDs which allow assessing clinically meaningful responses as PCOMs ● Validation of possible composite end points and surrogates ● Capture in the cohorts of natural history studies efficacy and important safety information through life span. And from statistical methodologies perspectives: ● Level of evidence assessment associated with randomization in limited populations ● Efficient designing and analysis of bridging studies for RD ● Pharmacometric modeling for design and analysis in limited populations The involvement of clinicians, patients and methodologists will be considered as the best configuration to meaningful results to customized methodological development of clinical studies matching the patients need (and not only focusing on testing of a given therapy). The internal call for the innovative methodology projects will be launched in month 12 and will start in month 18 with the 36-month working period. Thus the results are expected by M54. Deliverables: D20.1: “Terms of Reference” for clinical studies support office group (M6) D20.2: Report on the assessment of the support office activity (M36, M48, M60) D20.3: Report on options for long-term sustainability of the support office (M60) D20.4: List of topics for demonstration projects call (M6) D20.5: Final Report of funded Demonstration Projects’ (M50) D20.6: Final Report of funded methodology Projects (M58 D20.7: Summary Report of TFG (M60) 18 www.ideal.rwthaachen.de; Health-FP7-2013-602552 19 www.asterix-fp7.eu ;Health-FP7-2013-603160 20 www.warwick.ac.uk/inspire; Health-FP7-2013-602144 75 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. 3.1c: List of deliverables Del Deliverable title WP Short name of Type1 Dissemination Delivery N° N° lead level2 date3 participant(s) 1.1 Report from the Kick-off WP1 INSERM R PU M2 meeting 1.2 Helpdesk directory of people and WP1 INSERM R CO M3 services 1.3 Report from the face-to-face WP1 INSERM R PU M7, 19, ExCom and Policy Board 31, 43, 55 meeting 1.4 Summary Progress Report and WP1 INSERM R CO M9, 21, Annual Work Plan 33, 45, 57 1.5 Technical and Financial Report WP1 INSERM R CO M15, 27, 39, 51, 63 1.6 Monitoring activities handbook WP1 ULIV/ELIXIR R CO M2 /CVBF 1.7 EJP RD Monitoring Report WP1 CVBF R CO M12, 24, 36, 48, 60 1.8 Initial Data Management Plan WP1 INSERM R PU M6 1.9 Updated Data Management Plan WP1 INSERM R PU M42 2.1 Final list of prioritization criteria WP2 CVBF, FTELE R PU M5 2.2 Prioritization scheme including WP2 CVBF, FTELE R PU M5 decision-making process 2.3 Summary document on mapped WP2 ISCIII, ISS R CO M5, 17, research and innovation needs 29, 41, 53 2.4 Scoping paper WP2 ISCIII, ISS, R PU M7, 19, INSERM 31, 43, 55 2.5 List of refined JTC topics WP2 ISCIII, ANR R CO M7, 19, 31 2.6 List of research and innovation WP2 INSERM R PU M6, 18, needs requiring medium- or 30, 42, 54 long-term approach and related Task Forces 2.7 Analysis of national state of play WP2 ISS, MUW R PU M9, 21, and alignment process with EJP 32, 55 RD 2.7 Report from strategic workshop WP2 ISS, MUW R PU M34, 58 with national policy makers 3.1 Dynamic catalogue of EJP-RD WP3 INSERM R PU M36 sustainable resources including (RaDiCo) Service Roadmap Database 3.2 Study cases of innovative WP3 INSERM D CO M36 sustainability solutions for (RaDiCo) specific EJP RD outcomes 3.3 Analysis of structures, business WP3 ISCIII, EATRIS R CO M42 models and required complementarity from other 76 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. relevant initiatives 3.4 Proposal of structure, governance WP3 ISCIII, EATRIS R CO M46, 54 and financial model and global sustainability roadmap 4.1 First AREB report WP4 FGB R CO M6 4.2 Periodic AREB report WP4 FGB R CO M19, 31, 43, 55 4.3 Set of template agreements for WP4 FTELE R PU M6 EJP RD website 4.4 Periodic IPR report (based on WP4 FTELE R CO M6, 12, ExCom inputs) 18, 24, 30, 36, 42, 48, 54, 60 4.5 IPR support (monitoring) report WP4 FTELE R CO M6, 12, 18, 24, 30, 36, 42, 48, 54, 60 5.1 EJP RD website WP5 INSERM DEC PU M2 5.2 EJP RD Newsletter WP5 INSERM DEC PU M2 5.3 RE(ACT) Congress report WP5 BLACKSWAN R PU M16, 30, 54 6.1 Confidential Call documents: WP6 DLR, ANR, R CO M1, 11, memorandum of understanding, FFRD, ISCIII 23, 35 governance of the call and evaluation document JTC2019- 2022 6.2 Public Call documents JTC2019- WP6 DLR, ANR, R CO M01, 11, 2022: call text, guidelines for FFRD, ISCIII 23, 35 applicants, proposal templates 6.3 Joint selection list of the projects WP6 DLR, ANR, R CO M10, M22, to be funded JTC2019-2022 FFRD, ISCIII M24, M46 7.1 Confidential Call document for WP7 ZonMw R CO M7 Evaluation Committee for Networking scheme including set of criteria for evaluation 7.2 Public Call document for WP7 CSO-MoH, DEM PU M7 Networking scheme ZonMw 7.3 List of funded networks in WP7 ZonMw R PU M21, M54 Networking scheme 7.4 Confidential Observers’ report WP7 ZonMw R CO M12, M30 on the evaluation of sets of applications for the Networking scheme 8.1 Report on multi-stakeholder WP8 EURORDIS R CO M8 workshops 8.2 Call documents for validation WP8 FFRD R PU M13 8.3 List of first phase projects WP8 FFRD R PU M21 financed 8.4 List of second phase projects WP8 FFRD R CO M43 financed 77 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. 9.1 Refined list of indicators for WP9 CSO-MoH R CO M5 monitoring of JTC funded project 9.2 Yearly reports on progress WP9 CSO-MoH, DLR R CO M28, 40, assessment of JTC 2019, 2020 52 and 2021 projects 9.3 Final assessment report of E- WP9 CSO-MoH R CO M35, 47, Rare-3 JTC 2016, JTC 2017, 59 JTC 2018 projects and the EJP RD JTC 2019 projects 9.4 List of indicators for monitoring WP9 CSO-MoH, R CO M7 of Networking grants ZonMw 9.6 Reports on the assessment of WP9 CSO-MoH, R CO M24, 39, results of a 1st, 2nd and 3rd set ZonMw 54, 59 of funded Networking events and a final general report on all funded Networking events 9.7 List of indicators for RD funded WP9 CSO-MoH R CO M21 challenges 9.8 Report on the assessment of 1st WP9 CSO-MoH, FFRD R CO M39 phase results of the challenges 9.9 Report on the assessment of 2nd WP9 CSO-MoH, FFRD R CO M54 phase results of the challenges 10.1 Annual strategic report and WP INSERM R PU M9, Action plan for Pillar 2, 10 (Orphanet) (updated including: Systematic surveys M21, 33, reports, QMS of Pillar 2 45) description, GDPR compliance report and sustainability planning reporting 11.1 Ontological model of resources WP ELIXIR O PU M12, 24, metadata 11 36, 48, 60 11.2 Virtual platform of RD resources WP INSERM DEC PU M12, 24, annotated with EJP ontological 11 (Orphanet) 36, 48, 60 model and updated regularly 11.3 Additional facilities integrated to WP ELIXIR/INSER O PU M12, 24, resources regarding data 11 (RadiCo) 36, 48, 60 deposition and access, including user guidelines and documentation 11.4 Report on processed genome- WP CNAG- R PU M12, 24, phenome datasets and multi- 11 CRG/UCMG 36, 48, 60 omics use cases analysed, including description of new cloud and online analysis functionalities and tools 12.1 Report on core set of unified WP ULEIC R PU M18 FAIR data standards 12 78 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. 12.2 Report on core set of FAIR WP ULEIC R PU M30, M48 software tools and on extended 12 set of unified FAIR data standards, applied in EJP RD 12.3 Report on extended set of FAIR WP ULEIC/LUMC R PU M60 software tools, applied in 12 EJP,including overview of FAIRification guidelines for RD data managers 13.1 Collection of 20 curated WP UM R PU M36 (sub)Portal on WikiPathways 13 13.2 Completed pathway analysis WP UM R PU M48 workflow (data analysis 13 including both types of genetic variant linking and network creation) 13.2 Completed network analysis WP UM R PU M54 workflow (active node detection, 13 lifestyle factor network evaluation and extended network analysis for drugs and toxic compounds) 14.1 Reports of Orphanet WP INSERM R PU M14 and nomenclature training for trainers 14 (Orphanet) M60 and national trainings 14.2 Report on course on WP KULeuven R PU M12 and interpretation of genetic variants 14 M60 and quality standards 14.3 Report on International course on WP ISS R PU M24 and undiagnosed diseases 14 M60 14.4 Report on sample data WP FTELE R PU M12 and management training workshops 14 M60 14.5 Report on International course on WP ISS R PU M12 and Rare Disease Registries and 14 M60 FAIRification of data at source 15.1 Report on ExPRESS WP EURORDIS R PU M12 and 15 M60 15.2 Report on training of patient WP EURORDIS R PU M24 and representatives on scientific 15 M60 innovation and translational research in RD 15.3 Report on EURORDIS’ WP EURORDIS R PU M12 and Leadership Programme 15 M48 79 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. 15.4 Training plan for paediatric WP TEDDY and FSJD R PU M30 patients’ in the EJP 15 15.5 Report on paediatric patients’ WP TEDDY and FSJD R PU M60 experts training courses 15 16.1 Draft content of the online WP FFRD R PU M9 academic course 16 16.2 Content of the first 5 online WP FFRD O PU M24 modules 16 16.3 Content of the full online course WP FFRD O PU M48 16 16.4 Impact assessment of the course WP UCAM (ELIXIR- R RE M36 and 16 UK) M60 17.1 Results of survey on preferences, WP LUMC R PU M4 needs and resources from the 17 ERNs ecosystem 17.2 EJP RD ERN training WP UKL-HD R PU M7 programmes 17 17.3 Annual reports on WP EKUT R PU M13 and implementation of training 17 M60 programs 18.1 Final report on evaluation and WP VUHSK, R PU M60 adaptation of training 18 EURORDIS, programmes according to EJP IPCZD (CHMI) RD progress of work, specific and EKUT needs of EU13 countries and ERN developing needs 19.1 Periodic reports on mentoring WP EATRIS, CVBF R CO M24, 42, and technical support for 19 60 translational research projects 19.2 Final report on follow-on funding WP FTELE, FGB R CO M60 and exploitation 19 19.3 User satisfaction and feasibility WP ERNLUNG R CO M48 report 19 19.4 Roadmap for EU investment WP FTELE, EATRIS R CO M36 platform for RDs 19 20.1 Terms of Reference of clinical WP ECRIN R CO M6 studies support office 20 20.2 Report on the assessment of the WP ECRIN R CO M36, 48, support office activity 20 60 80 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. 20.3 Report on options for long-term WP ECRIN R CO 48, 60 sustainability of the support 20 office 20.4 List of topics for demonstration WP UKA, APHP R CO M6 projects call 20 20.5 Final Report of funded WP UKA, APHP, R PU M50 demonstration projects 20 (IOR) ERN- BOND, GOSH (EPICARE) 20.6 Final Report of funded new WP UKA, APHP, R CO M58 methodology projects 20 CCRI (PAEDCan) & HSK (Metab ERN) 20.7 Summary Report of TFG WP UKA, APHP R PU M60 20 3.2. Management structure, milestones and procedures An initiative such as EJP RD, aiming at developing into an ambitious sustainable structure, needs to establish clear roles and responsibilities in order to meet the objectives, build trust from the wider rare diseases community and mechanisms to solve potential conflicts. The management structure aims at transparent decision-making process with well-defined responsibilities in pillars, WPs and tasks. It will provide efficient and adaptive structure, necessary to capture and deal with emerging strengths and weaknesses. It will manage the strategy planning, annual work (plans) and allocation of resources. It will be responsible for interactions with external (policy and political) stakeholders. It is developed according to the principles of subsidiarity and should stimulate co-decision of each partner and co- creation of knowledge, be it at the EU-level, the national level or at the level of the scientific community. The management structure of the EJP RD will be defined to: ● Plan, organize and monitor the effort to achieve the EJP RD’s objectives within constraints of time schedule and budget. ● Define clearly the decision-making procedures and bodies. ● Run performance control procedures leading to the expected quality of achievements and deliverables described in the work plan. ● Continually inform the partners on the project status and progress. ● Drive the project implementation in accordance with administrative, financial and legal issues defined by the European regulations and national specificities. ● Guarantee that the rights and obligations of the partners are kept compliant with the Grant Agreement signed with the European Commission and the Consortium Agreement. A Consortium Agreement will be signed between the partners to specify the project governance, the internal organization of the consortium, the management of the project and any other critical aspects such as liability and confidentiality. The proposed organizational structure of the consortium is as follows: ● The Governing Board will be the ultimate decision-making body of the EJP RD and will take major decisions with regards to its implementation. General Assembly members will liaise with Policy Board and National Mirror Groups established at national level and outside the framework of this EJP. ● The Coordinator will monitor compliance by the partners with their obligations under the Grant Agreement and will be the intermediary between the European Commission and the consortium. He/she will be responsible for the EJP overall management and coordination as well as the supervision of transversal activities. Given the important size of the EJP RD, the Coordinator will be assisted in these tasks by a Management Office composed of experienced project managers, communication and administrative support. ● Pillar leaders and Work package Leaders will be the operational arms of the EJP. They will be responsible for the EJP proper implementation and the follow up of annual work plans. Together with the chair of ERN coordinators and representative of EURORDIS they will form the Executive Committee (ExCom) that provides assistance to the Coordinator for the monitoring of the programme. 81 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Figure 6. EJP RD governance structure Strategy level: General Assembly: GA will be composed of ALL beneficiaries of the EJP RD. GA will be the ultimate decision making body dealing with extraordinary decision requiring vote of all members like inclusion of new ones or exclusion of a non- performing partner. For other decisions the vote will be centralized and put in hands of Governing Board. Voting procedure: The GA will strive to reach consensus and if consensus cannot be reached, the GA will vote on different options. GA Quorum and voting arrangements will be elaborated on in the Consortium Agreement. Governing Board (GB) GB composition: The Governing Board shall consist of one representative per participating country, one representative of ERNs, one representative of participating EU infrastructures, 1 patient organization representative (EURORDIS), one representative of Orphanet and one representative of other non-profit organizations. Such distribution of representation will reflect and incentivize the need for agreement between stakeholders representing specific country and/or type of beneficiaries (ex. ERNs or infrastructures) on one hand and limit the unbalance that could be provoked by over-representation or a single country or type of beneficiary. It will be up to each participating country/type of beneficiary to decide on the nomination procedure for their representative. In addition, the representatives of EC DG RTD and DG Santé will be invited as “observers”. The GB will elect a chair and set down its rules for procedures (Terms of Reference) as well as Rules for Participation in advance of the official start of the EJP RD. It will be convened by the Coordinator in collaboration with the Executive Committee. The GB will validate the decisions proposed by the Executive Committee such as the annual work plan, the budget, internal calls etc. In particular, the GB will: ● Approve the initial 5-year work plan before submission of the proposal; ● Approve the annual work plans and annual summary reports; ● Monitor and approve the achievement of the most significant milestones; ● Approve ethical, legal and data management frameworks developed; ● Support the Executive Committee in developing a long-term sustainability plan for the EJP RD. 82 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Voting procedure: The GB will strive to reach consensus and if consensus cannot be reached, the GB will vote on different options. GB Quorum and voting arrangements for the GB will be elaborated on in the Consortium Agreement. Meetings: once a year. Coordination level: The Coordinator Role: The Coordinator will be in charge of the day-to-day overall scientific, administrative and financial management of the project and will be the primary contact point for the European Commission. In particular, the Coordinator will: ● Prepare the Consortium Agreement to be signed by the partners, with the support of the Executive Committee; ● Update and maintain the Consortium Agreement and submit amendment requests to Grant Agreement; ● Oversee deadlines and milestones of activities, and quality control of deliverables; ● Report on the implementation of the initiative and challenges encountered to the Executive Committee, the Consortium, General Assembly and the European Commission; ● Chair the Executive Committee and act as the scientific secretariat for their meetings; ● Ensure cooperation across WPs and Pillars; ● Ensure technical and financial reporting to the European Commission and budget management; ● Organize the General Assembly Meeting once a year; ● Ensure transversal activities of the EJP on RDs; ● Supervise the Scientific Secretariat of IRDiRC; ● Represent the EJP on RDs at the EU and international level; ● Together with the Executive Committee manage the project reserve budget. ● The Coordinator will be supported in all these tasks by the Management Office. The Coordination Office The Coordination Office will be under the responsibility of the Coordinator and will be constituted by four project managers, one Communication manager, one financial and administrative manager and one assistant. The project manager will share their time between direct support of EJP RD and of the scientific secretariat of the International Rare Diseases Research Consortium (IRDiRC). Role: The Coordination Office (CO) will be responsible for the day-to-day operational management of the EJP and the Scientific Secretariat of IRDiRC. The financial and administrative officer will provide financial advice support to all partners. Members of the CO will continuously support the Operating Group, Executive Committee and all other partners of the consortium in fulfilling their obligations according to the work plan. Figure 7: Structure of the EJP RD coordination office 83 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Operational level: The Operating Group (OG) The Operating Group will be composed of members of Coordinator, projects managers and eight Pillar leaders. The representation of funders, ERNs, patients and EU infrastructures is currently ensured via the Pillar 1, 2, 3 and 4 leaders respectively. Pillar leaders are nominated for the lifetime of the project. However, in case of change attention will be taken to keep fair representation of respective groups in the Operating Group. The OG will be responsible for close communication and coordination of activities between different pillars and WPs. The OG will reflect on progress and engage in a collective brainstorming on future directions and visions for the EJP RD. Regular (twice a month) conference calls will ensure close follow up of activities, continuous alignment and adequate reactivity in case of urgent situations and risk management. The OG will participate in the preparation of the Executive Committee meetings and will be the driving force for the elaboration of the Annual Work Plans. The Executive Committee (ExCom) The ExCom will consist of the Coordinator, Pillar Leaders and all WP Leaders. It will be chaired by the Coordinator. The ExCom will set down its rules for procedures (Terms of Reference) in advance of the official start of the EJP RD. Role: The ExCom will ensure the implementation of the EJP RD according to the overall 5-year plan of the initiative and the individual annual work plans. It will monitor progress according to the milestones as set out in the 5-year plan and the annual work plan. The ExCom will be responsible for the overall quality control of deliverables and reports. The ExCom will be in charge of adopting solutions to problems encountered during the implementation and can refer to the Governing Board if no agreement can be found or if the solution will imply major deviations from the work plans agreed by the GB. In this case, the Coordinator is in charge of duly informing the European Commission about expected deviations. The ExCom will oversee how resources are spent and propose changes if needed. The ExCom will be the entity preparing the basis for the decisions to be taken in the GB based on input from the Operating Group and WP leaders. The ExCom will also inform the GB about connections established with sister initiatives at national, EU- and international level and can ask for the GB 's assistance to establish contacts if needed. Meetings: every two months, starting month 1 (physical or web conference), adapting the number of meetings to the necessary the following years. Pillar Leaders (PL) Pillar leaders (PL) will support the coordination and interaction of Work Package Leaders (WPL) within their respective Pillars, as well as across the Pillars. The tasks of the PLs are to: ● Ensure the coordination of activities across the WPs in the pillar to deliver a coherent set of results both within the pillar, and with respect to the outputs generated under the other pillars. This will ensure that the overall outcomes of the EJP for RDs are coherent and complementary and together generate a robust and harmonized rare diseases platform and ecosystem; ● Ensure good communication with the coordinator and management office; ● Ensure coordination and collaboration across pillars and promote knowledge transfer within and across pillars (via the Operating Group activities); ● Ensure that tasks are not duplicated and promote complementarity and synergies. The main forum for this process will be the ExCom meetings; ● Organization of regular management meetings (telephone conferences and/or personal meetings) with the respective WP leaders to ensure that work within the WPs is in line with the annual work plans and contributes to the development of annual work plans for upcoming years; ● Collecting training needs from the respective pillar WPs and reporting them to the Pillar 3 leaders; ● Participate in the OG and ExCom meetings and teleconferences; ● Feed into the development of the annual communication plan. Work Package Leaders (WPL) Work Package Leaders (WPL) will be in charge of implementing the tasks of the WPs as agreed in the annual work plans, cross-coordinating with other WPLs, informing the PL about any deviations to the annual work plan and developing contingency plans. The WPL will be supported by a number of Task and Subtask leaders who are responsible for the implementation of a specific task within the work package. The tasks of the WPL therefore are: ● Manage implementation of the WP and tasks, and ensure good communication within the WP in order to ensure efficient flow of information; ● Ensure that work within the WP is in line with the annual work plans; ● Identify any bottlenecks or obstacles, as well as links, synergies and overlaps across WPs, and report them to the Pillar Leaders. 84 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. ● Formal reporting of progress to the Pillar Leaders and the Coordinator for discussion at the Executive Committee meetings, and contributing the sections of the annual report for their WP; ● Draft the WP descriptions for upcoming annual work plans; ● Provide input to training measures; ● Participate in the Pillar and ExCom meetings and teleconferences. Satellite Boards Policy Board The members of the EJP RD are aware of the importance of continuous feedback and dialogue with relevant national, European and international stakeholders. This is necessary to translate efficiently the specific needs and strategy represented by countries or European Commission as well as the outcomes of the EJP RD. The Policy Board will have a major role in ensuring this dialogue and translation through its participation is EJP RD strategy and sustainability development. The Policy Board will be constituted from: ● Representatives of national ministries of research and health; ● Representatives of European Commission Directorates: DG RTD, DG Santé, DG Connect; ● Representative of the pharmaceutical industry and public-private initiatives (e.g. European Federation of Pharmaceutical Industries and Associations, EFPIA; Innovative Medicines Initiative, IMI); ● Representative of regulatory authorities (e.g. European Medicines Agency, EMA, esp. Committee for Orphan Medicinal Products, COMP, EuNetHTA); ● Chair of the European Strategy Forum on Research Infrastructures (ESFRI); ● Chair and vice-chair of the International Rare Diseases Research Consortium (IRDiRC). Meetings: Once a year. National mirror groups (NMG) Participating countries will be strongly advised to constitute NMG, bringing together the national representatives of the EJP RD and other relevant RD stakeholders. The role of the NMGs will be to ensure national coordination, contribute to the objectives of the EJP RD and benefit from it. The creation and composition of a NMG is at the discretion of each participating country. It is expected that NMGs will include representatives of the National plan for RD, national nodes of the European Reference Networks, relevant national authorities and research institutions (whether participating to the EJP RD or not), as well as the relevant national partners of the EJP RD and GB member that will report NMG views and positions during GB meetings. Although not mandatory, it is expected that the establishment of National Mirror Groups will ensure that national activities, strategies and needs are taken into account when taking decisions at the EJP RD level and when designing the annual work plans. Board of funders In order to ensure the independence of joint transnational calls management (Pillar 1), the final decisions on call topics and implementation of calls will be taken autonomously by the Board of Funders (BOF). The composition of Board of Funders will be variable depending on the configuration of funding bodies participating in the joint transnational calls. BOF will be chaired by the Pillar 1 leaders. Meetings: Ad hoc meetings before and after the launch of each joint transnational call for proposals. Ad hoc Advisory Board (AB) The ad hoc Advisory Board(s) will be constituted on demand of BOF or Pillar 2 and 4 leaders in relation to pilot projects foreseen. The AB will consist of international experts and RD stakeholders to include their knowledge and experience and use their input for the definition of the research strategy for joint transnational calls or pilot projects. Table 3.2a: List of milestones MS N° Milestone name WP Due date (in Means of verification month) MS1.1 Coordination & governance structures WP1 M1 Minutes of the 1st Operating Group established conference call MS1.2 Helpdesk entry point set up WP1 M3 Website MS1.3 Policy Board established WP1 M3 List of Policy Board Members MS2.1 Survey on prioritization criteria set up WP2 M3 Survey document and launched 85 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. MS2.2 Prioritization scheme and list of criteria WP2 M6 Minutes of the ExCom and Policy validated by ExCom and Policy Board Board meeting MS2.3 Survey to national mirror groups WP3 M5 Survey document established and launched MS3.1 Suitable structure and sustainability WP3 M42, 54 Proposed model approved by the EJP- model for the EJP RD proposed RD Governance and MS according to decision-making procedures MS3.2 Final proposal for decision on the WP3 M54 Final Business model and sustainability roadmap sustainability plan for adoption MS4.1 AREB set up WP4 M5 List of AREB members MS4.2 Annual AREB meeting held WP4 M6, 18, 30 Meeting minutes 42 MS4.3 Set of template agreements for IPR WP4 M7 Availability on-line (EJP RD website) issues available to the community MS5.1 EJP RD social media pack set up and WP5 M2 Relevant social media accounts running MS5.2 Decision on the organization of the WP5 M4, 18, 42 Minutes of the relevant ExCom RE(ACT) congress conference call MS5.3 Target countries and voluntary helpers WP5 M2 List of target countries and voluntary for translated Newsletter agreed helpers MS 7.1 Implementation of Networking scheme WP7 M7 Public Call document on website and announcement of the first round MS 8.1 Multi-stakeholder workshops to set-up WP8 M8 Report from RDR Challenges RDR Challenges scheme workshops MS 9.1 Adapted monitoring tool implemented WP9 M9 Link to monitoring tool released to for collaborative research projects granted applicants MS 9.2 Adapted monitoring tool implemented WP9 M9 Link to monitoring tool released to for Networking grants granted applicants MS 9.3 Final reports of Rare disease challenge WP9 M54 Final reports projects delivered to monitoring tool MS10.1 Annual retreat of Pillar 2 completed WP10 M6, 18, 30, Annual meeting involving all ERNs, 42, 54 Pillar 2 WPs co-leaders, WP10 partners and Pillar 4 representative organized and achieved, including background documents MS10.2 End-users surveys done WP10 M5, 17, 29, Online surveys developed, sent and 41, 53 results analyzed. MS10.3 Financing models for sustaining and WP10 M18 Matrix and support document listing scaling up FAIRification support the appropriateness of financing services assessed with sustainability models for sustaining and scaling up experts and RD community virtual platform components and stakeholders support services M10.4 Simulations of financing models for WP10 M48 Results of the simulations of financing sustaining and scaling up FAIRification models for FAIRification services listed support services executed and evaluated with sustainability experts and RD community stakeholders MS11.1 Metadata sets of identified and WP11 M9, 21, 33, Prioritized resources having validated prioritized resources 45, 57 metadata sets MS11.2 Common AAI integrated in 3 resources WP11 M24 3 resources integrated with LifeScience/ELIXIR AAI 86 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. MS11.3 PPRL in production for 3 WP11 M36 PPRL available to link data between at projects/resources least 3 projects/ resources MS11.4 Pilot cloud deployed WP11 M24 Pilot cloud computing infrastructure available for deploying workflows at UCMG and BSC(ELIXIR-SI) MS12.1 Core standards teams assembled and WP12 M12 Lists of teams and target standards in working actively place, plus shared document storage MS12.2 Multi-team software collaborations WP12 M18 Lists of teams and target goals and working on agreed goals and standards in place standards MS12.3 Communication established between WP12 M12 List of experts and stakeholders in experts and stakeholder place, plus means of communication representatives involved in practical and shared document storage FAIRification support MS12.4 FAIRification guidelines for RD data WP12 M6, 30, 42, Guidelines document updated by the managers updated 54 latest FAIRification experiences MS13.1 D13.2 workflow used in proof of WP13 M48 Peer reviewed paper or report in concepts study evaluated and BioRXiv. Plus plans on GitHub improved, with project plans for future updates and release scheme. MS13.2 D13.3 workflow used in proof of WP13 M60 Peer reviewed paper or report in concepts study evaluated and BioRXiv. Plus plans on GitHub improved, with project plans for future updates and release scheme MS 14.1 Orphanet training content defined WP14 M10 Report of scientific committee meeting validated and available MS 14.2 Training Roadmap established WP14 M1 Definition of the training schedule MS16.1 Overview/benchmark of online courses WP16 M9 Draft content course for the academic on RD completed online course available MS16.2 Technical platform developed and WP16 M18 Follow-up with the service provider ready for online academic course closely monitored and tracked through deployment regular calls/emails MS16.3 Course accreditations obtained for the WP16 M18 Official feedbacks from relevant RD online academic course organisations MS16.4 First 5 modules of the RD online WP16 M24 5 modules available online and academic course developed accessible to an EU-wide audience MS16.5 Full online course available online WP16 M48 12 modules available online and accessible to an EU-wide audience MS17.1 ERN training groups formed WP17 M1 Consent by respective ERN coordinators MS17.2 Training programs of ERN training WP17 M6 Confirmed research training programs groups consented for ERN groups MS19.1 Innovation Management Toolbox WP19 M8 Toolbox available on website openly accessible MS19.2 User satisfaction survey completed WP19 M46 Internal report on collected survey results MS19.3 Benchmarking of investment platform WP19 M30 Internal report on benchmarking models completed MS20.1 Task Force Group set up WP20 M1 Task Force Appointment list MS20.2 6 demonstration of methodologies WP20 M15 List of demonstration projects projects launched MS20.3 6 innovative methodologies projects WP20 M18 List of innovative projects launched MS20.4 Clinical trials support office established WP20 M3 Report about Kick-off of clinical trials office support group 87 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Table 3.2b: Critical risks for implementation WP N° Description of critical risk Level Proposed mitigation measures (L/M/H) TRANSVERSAL WPs WP1 Incapacity or departure of coordinator L ● High quality of the coordination team with possibility of interim by one of the Pillar leaders ● Strong commitment of the Coordinator WP1 Underestimation of workload to be L ● Close follow up of the work progress (regular meetings, shared by project managers between detailed management plan) Coordination office and IRDiRC SciSec ● Possibility to receive temporary support from IRDiRC members during rush periods WP1 Delay in delivery of Annual Work Plan L ● The plan for 5 years already in place and Annual Progress Report ● Strategy, prioritization and monitoring procedures well organized ● Close follow up of the yearly agenda by Pillar and WP leaders WP1 Misuse of resources L ● Most partners’ institutions are experiences and equipped with internal financial accounting and auditing office ● The Coordination financial officer will advise and partners in preparation of financial documents when necessary WP1 Financial bottleneck due to M ● Detailed business plan prepared before launch of the underestimation of contribution capacity project including 15% risk of budget loss of partner(s) and/or withdrawal of major ● Financial management issues set up in Consortium partner Agreement ● Emergency mitigation procedure set up – possibility to adjust the work plan and align budget WP1 Failure to adapt to events L ● Efficient management strategy put in place, with reactive (opportunities, threats, risks) Operating Group ● Careful monitoring process put in place to be able to react on time and adapt WP2 Difficulty in collection of input from L ● EJP RD partners are highly committed to the Programme stakeholders and will contribute actively to the strategy development ● The analysis that will be provided by Orphanet/UBER Research is a good alternative that demands a limited effort from the stakeholders and shall provide detailed overview of the funded previous and ongoing research and capture the overlaps and trends to be used as recommendations for prioritization WP2 Generalization in the definition of needs L Special attention will be put to differentiate between the needs in EU countries with a higher or lower development of national research plans on RD WP2 Generalization in the prioritization L Special attention will be put to establish a prioritization scheme for actions scheme of actions, taking into account the needs in countries with less developed national research plans on RD WP2 Insufficient coordination of priorities / L • Criteria and process of prioritization agreed at the start unresolved conflicts about strategy of the project and validated by GB • Possibility to call for Policy Board recommendations • Flexibility of Annual Work Plans WP2 Difficulty in the management of the M ● Participation of the RPOs in the prioritization process will Conflict of Interest of EJP RD research be separated from the topic choice that will be reserved performing organizations (RPOs) to funding bodies ● Necessary scientific support for the detailed definition of the topics will be ensure by the ad hoc Advisory Boards called by the funders 88 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. WP2 Problem of the alignment between EJP L IRDiRC SciSec being part of the EJP RD Coo Office will RD proposed TF and IRDiRC TF ensure strong connection with IRDiRC In addition, many EJP RD partners are members of IRDiRC and therefore can help in alignment. Finally, IRDiRC chair and VC will be part of the EJP RD Policy Board to further strengthen the collaboration WP2 Low participation of some countries in M ● Participation of countries will be ensured at multiple collecting state of play information and levels: Policy Board, Governing Board and Mirror Groups in the process for translation of ● The majority of EJP RD countries is represented in the prioritization on national and EU programme by more that one beneficiary and reflects well strategies different type of beneficiaries (RFOs, RPOs, ERN, infrastructures, etc.), which guarantees good potential of translation at national level WP3 Incomplete/poor quality information on M ● Provide guidance and templates to WP leaders for added value of services and resources, sustainability/user demand reporting creates misinformed roadmap ● Perform independent assessment of value of services WP3 Difficult to achieve sustainable M ● Monitor external risk factors related to sustainability collaboration between the service ● Update Sustainability Roadmap as living document providers and the associated ● Give specific attention to other initiatives for agreements communities beyond the project on equitable principles and realistic planning for adoption WP3 Failure to prepare for sustainability M ● WP dedicated to sustainability planned ● Sustainability activities tackled from the start of the project ● Good knowledge of beneficiaries, their capacities and weaknesses ● Important commitment of Member States and direct contact and dialogue ensured via the Policy Board WP4 AREB unable to respond to the needs L AREB will include the necessary expertise to cover the of the consortium different topics of the regulatory and ethical framework. To this aim, members with recognized expertise and the relevant European RIs will join the board. Furthermore, EMA and national competent authorities will be addressed if necessary WP4 Inputs and feedback from pillars to L ● AREB will participate whenever necessary in the OG verify that the projects and activities will conference calls and will be in contact with the CO for be regulatory- and ethically-compliant routine updates not delivered to AREB ● AREB will collaborate closely with Pillar 1 Joint Call Secretariats during the period of call preparation and contractualization of projects WP4 Ethical, regulatory and legal L Awareness raising at meetings, conferences and via documentation collated and made transversal WP5 and Pillar 3 available through the EJP RD is not used by the community WP4 Few/no requests for support from EJP L Ensure awareness and understanding of the support and of RD beneficiaries its value with support from OG and WP leaders WP5 Breach of collaboration with Blackswan L ● Strong commitment of BF and EJP RD to collaborate Foundation and/or impossible to supported by long-lasting collaboration history and organize RE(ACT) congress due to low congress reputation budget or interest ● Possibility to partner with other organizations like ESHG or EURORDIS (ECRD Congress) ● Support from EJP RD Communication Manager to BF team for communication and partnership search PILLAR 1 89 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. WP6 National financial bottlenecks for M ● Earmarking adequate national budgets in line with funding joint transnational research national research capacity and costs projects ● Post-evaluation negotiations on increasing national budget and/or budget negotiations with applicants ● Use of EC co-funding to adjust national budget shortcomings WP6 Lack of contributions and utilization of M Incentives will be set up to facilitate the use of Pillar 2 Pillar 2 components by Pillar 1 research components. Also the projects will be informed regularly projects about the possibilities of use of P2 components. Finally, they will also be encouraged to participate in Pillar 3 WP 14 trainings on data management and quality. WP7 Low number of applications for L After four subsidy rounds an early evaluation of the Networking scheme scheme is foreseen WP8 No challenges are brought up that can L Multi-stakeholder workshops, consisting of be solved up to the stage of proof of representatives of industry, academia and patient concept within the projected time frame organisations will be organised to discuss potential of 18 months with a possible 12-month challenges and the chosen time period for proof of extension concept of solutions WP8 No interest from pharmaceutical L ● Potential access to some 70 companies who are ERTC companies in the project (EURORDIS Round Table of Companies)members confronted with specific hurdles in rare diseases ● Effort also be made to attract industry in Pillar 4 WP8 Approved challenges at risk of not L A face-to-face networking meeting for academia, SMEs finding relevant applicants and industry will be organized to speed up collaboration and increase quality of applications. WP8 Selected projects don’t get expected M A two-stage process makes it possible to put additional results with the risk of challenge not resources at month 18 on the projects which would have being solved been best developed during the first period. Moreover, in case the phase one has taken some delay in starting, a 5-month window is scheduled between the completion of the second phase and the closing of the EJP at year 5. WP9 Missing / incomplete reporting by M Routine procedure of messages and reminders will be coordinators of projects funded within implemented in collaboration with call secretariats and WP6 respective funding agencies. Several funding agencies will only sent the final payment after receiving the final report of their national research group. WP9 Missing / incomplete reporting by L A routine procedure of messages and reminders will be coordinators of Networking scheme implemented in collaboration with the Networking grants scheme Secretariat. The applicants will receive 80% of the grant before the meeting. The final payment of 20% will be sent by ZonMw after receiving the report. PILLAR 2 WP10 ERNs not involved in the Pillar 2 L Maintain constant dialog with the ERNs Research group strategy through Pillar 2 co-leader (ERN coordinator) and incentivisation to bring their use cases and research questions WP10 Poor surveys feedback M Annual retreats and other means of regular contact will be also used to generate user’s feedback WP10 WPs divergent developments L Regular communication (TCs, workshops) will maintain the alignment between both parallel WPs WP11 Failure to deliver metadata model to the L Engage at least 2 partners in the metadata model virtual platform development and extend a metadata model already in place WP11 Failure to deliver single coordinated L Engage at least 2 partners in the query point development query point to resources 90 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. and extend a catalog already in place WP11 Research projects automated database M Replace by manual collection and curation by Orphanet subcontractor failure network teams WP11 Common AAI not deployed in all M Provide support and expertise to encourage resources to resources adopt common AAI to be recommended as deposition platform by the EJP RD WP11 Resources for some of the virtual L Address cases individually and evaluate schemes like platform infrastructures not sufficient to including funding for using infrastructures within Pillar 1 serve high EJP community needs calls WP12 Failure to deliver suitable standards L Engage many partners and external groups, already recommended for software to be based developing and using relevant standards upon WP12 Failure to deliver support software for L Engage at least two 2 software teams per topic, working making data FAIR together and to WP12 standards WP13 Few Multi-omics datasets not available L Funded projects in Pillar 1, Solve-RD and other already for analysis producing multi-omics data: provide analysis to the data producers Pillar 2 Slow adoption of the EJP RD Virtual L All ERNs engaged in driving and testing the VP; WP13 platform (VP) facilities by the providing and promoting re-use by ERNs; strong community communication through WP5 and trainings provided through WP14 achieving a large outreach of the RD community; new trainings proposed through WP18 on the use and value of the VP. PILLAR 3 WP14.1 Problem in recruiting a half time position M If such difficulties are encountered, the position could be training manager considered as full time for 2.5 years in order to develop the training modules and organize the first round of national trainings WP14.2 Availability of experts/teachers for each M Enlarge recruitment base for teachers, link to national of the 3 courses societies via EuroGentest Insufficient number of participants ● Extension of deadline for registration and increased dissemination. Pre-workshop questionnaires sent do potential participants to partly guide workshop content; WP14.4 M Promotion through ERNs, biobanks, etc. ● Increase dissemination in coordination with relevant WP/task leaders in EJP + adjust format and content based on feedbacks received Insufficient number of use cases, A number of use cases to be used for this purpose already WP14.5 L databases for the course available WP14 Incomplete implementation of workshop M ● Post workshop follow-up (3 months, 6 months, etc.) with guidelines by workshop participants all workshop participants to get feedback. once they return to their home ● Common roadblocks should be addressed in future institutions workshops to enable working solutions WP15.1 Decrease of co-funding supporting the L Decrease the number of participants overall participation of patients WP15.2 Decrease or loss of the in-kind support L Alternative on-site venues and on-site visits provided by of Imagine Institute that provides the other EJP RD Partners venue and on-site visits WP16 Course not engaging sufficient number M Increase dissemination in coordination with relevant of students WP/task leaders in EJP + adjust format and content based on feedbacks received WP17 Not all ERNs commit to ERN training L Formation of training groups with committing ERNs Networks WP17 Funding not sufficient to deliver training H Given the size and scope of the ERNs all ERN training 91 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. programs of sufficient scope groups will significantly contribute additional training resources WP18.1 Training needs for Pillar 2 platform M Close monitoring ensured through transversal activities and users not fully defined in time link with Pillar 2 WP18 Funding not sufficient to adapt training M Maximizing resources allocated to training activities in programs of sufficient scope WP14-WP17 to enable adaptation PILLAR 4 WP19 The online resources are not utilized by M Awareness raising at meetings, conferences and via the community transversal WP communication and education of Pillar 3 WP19 Few/no project teams request support of M Ensure awareness and understanding of the support and Innovation Manager (IM) the value of mentoring WP19 Few projects reach stage of need for L ● Support project teams via IM to ensure max chance of exploitation, few/no projects request technical success exploitation support ● Ensure max awareness of support available WP20 Delay of implementation of clinical study L The TFG will implement the support office with another support office member of the ECRIN network WP20 Delay in demonstration or L The TFG will select the next best demonstration project of methodological project start applicant list WP20 Project not finished in due time L A rule will be defined by the TFG that each beneficiary will provide sufficient funding for finishing the project WP20 Deviation from expected research L Tight monitoring of the research progress by the TFG will progress minimize the risk WP20 Deliverable are delayed or cannot be L Tight monitoring of the research progress will minimize achieved the risk of delay. In case of an unachievable deliverable the TFG will develop a solution in agreement with the EJP coordinator taking care of the success of the project 3.3: Consortium as a whole The objectives of the EJP RD, namely improvement of integration, efficacy, production and social impact of research on rare diseases and its translation into clinical applications and uptake in healthcare for the benefit of patients can only be achieved by bringing together key actors and stakeholders thus guaranteeing integrity of the pipeline. The EJP RD consortium is composed of 85 (full) partners from 23 European (AT, BE, CZ, DE, ES, EE, FI, FR, HU, IE, IT, NL, LT, LV, LU, PL, PT, RO, SE, SK, SV, UK), 4 associated (AM, CH, IL, TK) and 1 non-EU country (CA) bringing together expertise necessary to fulfill set aims. The majority of EJP RD’ partners have existing collaborations established through previous projects or are united within existing (infra)structures. Funding: All Pillar 1 members are leading organizations that fund, manage and implement strategically planned focused research programmes in the field of health. They put into action and fund international collaborative research programmes, (e.g. bi-lateral, multi-lateral), and participate into numerous international and European initiatives that match their national strategic issues on research. Most of these funding bodies (20) have previously worked under the ERA-Net E-Rare. At present twenty-nine funding agencies/ministries in Life Science and Health, from twenty-two countries, are part of the EJP RD consortium. The addition of Estonia, Ireland, Luxembourg, Slovakia, Sweden and two Italian regions (Lombardy and Tuscany), enables further European expansion of the programme. Most importantly, the engagement of funders will be translated through strong commitment, that all funding bodies made during the preparation phase of this application, to participate to the two co-funded and subsequent joint calls. Providing financial support to projects is crucial for acceleration of collaborative research on rare diseases and enhancement of knowledge sharing between different national teams. Previous experience of E-Rare has demonstrated that such projects structure the community via long-lasting collaborations and bring direct and meaningful benefit for patients via discovery of new genes, establishment of diagnostic guidelines and development of new treatments. Furthermore, projects financed in Pillar 1 will take advantage of additional tools and support provided within Pillars 2, 3 and 4 creating an optimal ecosystem for accelerated diagnosis and exploitation of results for therapy development. In addition to the well-established joint transnational calls, EJP RD will profit from the know-how of new partners to build novel initiatives needed by the RD community. The proposition of support to Networking scheme stems from numerous demands expressed by the RD research community and (additonal) stakeholders including addressing the need for reinforcement of cooperation and 92 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. knowledge sharing between EU13 and EU15 countries and stronger integration of patients in research. The management of the Networking scheme will be based on the past experience of ZonMw (NL) complemented by knowledge of partners representing different regions (Latvia, Israel, Sweden, Turkey, Canada) and rare disease patients (EURORDIS). EJP RD will also benefit from the extensive experience and management capacities of new partners (FFRD, AFM Telethon & EATRIS) to implement a unique support to the so-called RD Research Challenges to accelerate innovation through public-private partnerships. Moreover, the scheme will be closely connected to Pillar 4 and collaborate with other members of the consortium (EURORDIS, FTELE, IMAGINE, ERNs) to set up effective portfolio of private partners and sponsors interested in challenges. Resources: The development of the virtual platform for rare diseases information and research data, based on existing resources (samples, tools and standards), linked directly with funded research projects to support and accelerate rare diseases research can only be achieved with extensive contribution of research performing organizations and infrastructures. This will be achieved through participation of 20 institutions and 24 ERNs and 5 European research infrastructures (members of ESFRI). Again, EJP RD capitalizes on the previously acquired experience, know-how and, most importantly, standards, resources and tools created by projects and infrastructures including Orphanet, RD-Connect, HPO, RaDiCo, or ERDRI. This will be complemented by strong commitment of several biomedical European Research Infrastructures such as BBMRI, ELIXIR, EATRIS, Infrafrontier and ECRIN, which were developed in the past years through collaborative efforts of Member States. Although not specific for RDs, these infrastructures aim to develop services facilitating access for researchers to resources and knowledge and to enhance data sharing thus avoiding duplication of efforts. Their direct involvement will be key to achieve harmonized user access to biological and medical technologies, samples and services for rare diseases. Even if findable under single virtual platform, the resources can only be efficiently used if they are made accessible and interoperable. That is why EJP RD will be armed with know-how of top-level institutions focusing on the development and implementation of FAIR approaches in Europe. LUMC, UMCG, University of Leicester, CNAG- CRG, AIT and BBMRI will be the driving force to “FAIRification” of key RD resources and enabling FAIR ecosystem at larger scale by assisting the RD community. Furthermore, the capacities of EJP RD research institutions (UM, RUMC, ISCIII, ISS, ACU/ACURARE, INSERM (AMU)) coupled with potential of external projects (Solve-RD, UDNI) as well as European Reference Networks, will extend the platform with workflows that allow holistic research based on rare disease data and biological knowledge, closing the circle between initial data production and its reutilization in explorative studies. The participation of above-mentioned institutions will not be limited to activities foreseen in Pillar 2 but also expanded to, and strongly connected with Pillars 3 and 4. Education and empowerment: In Pillar 3, infrastructures will join leading players to anchor and expand rare diseases education and empowerment programmes. This is where national universities, charities and patient organizations bring their competences, taking advantage of the already established education/trainings and creating a new, coherent landscape for education on rare diseases. The courses on data/resources management and quality initiated by institutions including INSERM (Orph), KULeuven, ISS, FTELE, LUMC and JRC will be enriched by contributions of new partners (EKUT, IPCZD (CMHI), IMAGINE, Charité, LBG (LBI-RUD), HUGEN (HACETTEPE) and more) and also made specifically accessible to EU13 countries in order to enhance capacity and knowledge sharing across Europe. Participation of EURORDIS, TEDDY, FSJD and C4C will be central to further engage and empower rare disease patients into research and provide them with the tools required to apprehend and actively contribute to innovation and therapy development. Furthermore, EJP RD will work with universities, learned societies and ERNs to design first the European rare diseases academic course. Once more, the consortium will take advantage of already existing capacities within national institutions and transform them for the benefit of all. This innovation in education will seek the active participation of the European Reference Networks fostering crosscutting needs of healthcare professionals interested or active in research. Translation: EJP RD can only fully contribute to IRDiRC goals, namely delivery of diagnosis within one year for patients coming to medical attention and development of 1000 new therapies for rare diseases by 2027, by including the participation of the European Reference Networks. All twenty-four ERNs will be part of the consortium. The majority will participate through their coordinating institutions representing the tremendous potential of 900 units from 300 hospitals. ERNs will be the driving wheel of translation of research results into clinical diagnosis and treatment of patients. Accompanied by RPOs, they will be responsible for guidance of Pillar 2 in identification of key resources to be FAIRified and creation of new tools for efficient exploitation and interpretation of data. The know-how of ERNs will command the process of development and validation of methodologies and approaches in clinical research (endpoints, trial layout, randomisation techniques, power calculation, patient centred outcomes, etc.) leading to their dissemination and increased implementation in healthcare systems. Finally, the enhanced uptake of research results and improved innovation potential will be achieved with mentoring and solid support for translational research projects. This link (between Pillar 1 and Pillar 93 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. 4) will be ensured by the group of partners (EATRIS, FTELE, FGB, CVBF, AFM, HUGEN (HACETTEPE) and UNEW) experienced in drug/diagnostic, regulatory, pre-clinical and clinical development. Research projects financed in joint transnational calls will have access to innovation management tools and accompanying of innovation manager allowing maximization of exploitation potential and opening routes to follow-on funding. Other (international) collaborations: Although one of the main goals of the EJP RD is to strengthen European capacity in the field of rare diseases, it does not mean that the ecosystem should be closed to international collaborations. Actually, the linkage with international partners will be ensured at different levels. First of all, through the integration of IRDiRC Scientific Secretariat in the Coordination Office of the EJP RD and joint management of research and innovation strategy (via the participation of IRDiRC Chair and Vice chairs in the EJP RD Policy Board and organization of common Task Forces). Secondly, through the already established collaboration with partners like Australia (Western Australian Department of Health) that expressed interest to participate as so-called Associated Partners contributing to and aligning with research and training activities proposed under Pillars 2, 3 and 4. The status of Associated Partner will be also granted to DECIPHER (Sanger Institute, UK) and ChemBioNet (DE) that could not join EJP RD as full beneficiaries but expressed their willingness to contribute to the EJP RD goals. Finally, EJP RD intends to pursue efforts in expanding the collaboration and integration of other countries willing to join with their knowledge and resources to achieve shared benefits for rare diseases patients. At present, the possibility of cooperation with Japan Agency for Medical Research and Development (AMED) is being discussed. AMED is a key player in rare disease research field, member of IRDiRC since 2015 and would be an invaluable partner for EJP RD bringing the unique opportunity to build the bridges for Japanese-European actions covering research, sharing of resources and acceleration of drug development. Policy Board – the route to exploitation of EJP RD results: Creating an efficient and stable rare diseases research ecosystem will be efficient and productive if it can realistically be translated at the policy-makers level. Therefore, from the very start, EJP RD will be accompanied by the Policy Board composed of representatives of research and health ministries, relevant Commission directorates and other central policy stakeholders. The Board will have the responsibility to consciously contribute in prioritization strategy of the EJP RD by orienting towards the imperatives and at the same time aligning its own activities to support outcomes of the EJP RD. This will be further strengthened by the creation of national Mirror Groups guaranteeing proficient dialogue at national level. The Board will be also primary interlocutor of the EJP RD sustainability work package and recipient of the business plan and sustainability roadmap. 3.4: Resources to be committed The EJP RD consortium members are strongly committed and will support the programme with in cash or in kind contributions. This includes: personnel, resources like data infrastructures, tools, training and education materials, meeting rooms and high level expertise. The initial, earmarked (in cash) budget of EJP RD involved funders is about 37 M€ and further commitments of at least 20 M€ are foreseen (to support non-cofunded joint transnational calls). Due to the large span of proposed activities and related capacity to generate in cash or in kind support, the consortium agreed to apply, rather than fixed 70%, different reimbursement rates and redistribute EC contribution accordingly. The table below details the settled reimbursement percentage per activity and maximum budget per pillar agreed by the consortium: Type of activity Reimbursement rate Max budget per Pillar Central coordination, management and transversal activities (WP1 – 100% 8 929 031 € WP5) Pillar 1 co-funded joint transnational calls (WP6) Variable depending on the 15 983 562 € result of calls (max. 33%) Pillar 1 Networking scheme and RDR Challenge (WP7 – WP8) 100% Pillar 1 all management costs (WP6 – WP9) 100% Pillar 2 all activities (WP10 – WP13) 70% 17 765 609 € Pillar 3 training activities (WP14 – WP18) 80 – 90% 5 934 160 € 94 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Pillar 3 subcontracting of e-learning platform (WP16) 100% Pillar 4 all activities (WP19 – WP20) 70% 6 477 306 € TOTAL EJP RD budget 55 089 667 € In addition, each of the WPs identified activities to be implemented at later stage for which the budget was pre- defined but the allocation to specific partners will take place in subsequent years, based on the agreed Annual Work Plans. It was agreed that the “non-assigned” budget would remain for the time being with the coordination (INSERM): WP Details Reimbursement rate (%) Non-assigned EC contribution (overhead included) WP6 Evaluation meetings 100 % 280 000 € WP8 RDR Challenge scheme 100 % 1 500 000 € WP9 Monitoring meetings 100 % 80 000 € WP10 Workshops & meetings 70 % 49 720 € WP11 FAIRification costs 70 % 100 000 € WP12 FAIRification costs 70 % 900 000 € WP13 Proof of concept projects – data provision by ERNs 70 % 150 000 € WP20 Evaluation of internal calls for demonstration and innovation in 70 % 40 000 € methodologies projects WP20 Demonstration & new methodologies pilot projects 70 % 3 600 000 € TOTAL non-assigned to be kept with coordination (INSERM) 6 699 720 € It is important to note that by reason of different reimbursement rates, the exact redistribution of budget per partner has been defined and will be different from the one presented on the ECAS platform. The real budget redistribution agreed will be part of the Consortium Agreement. Table 3.4a: Summary of staff effort (per participants and per WP) Explanation of allocation of PM: Pillar 1: the number of PM allocated for the majority of the funding bodies correspond to the “basic” participation in funding activities consisting of participation in the process of joint transnational call(s). The number of PMs was calculated based on the solid previous experience (12 years) of running the same activity in ERA-Net E-Rare. Specific case of European Reference Network: the consortium took the decision to involve ALL ERNs from the start of the project even if many of the activities in which ERNs will be fully involved (like WP13 or WP20) will take place at later stage (starting from year 2). However, it is crucial that ERNs are involved from the start via their participation in Annual Retreats of Pillar 2, dedicated Task Forces or meetings of General Assembly, as they are the key actors to guide the work of Pillars 2 and 4, as well as the driving force for the trainings of Pillar 3 WP17. All partners of the EJP RD agreed that any work related to the participation in the meetings will be done as in kind contribution (accountable or not) and thus no PM are allocated to this type of activities for any of the EJP RD partners. This results also in a low number of PM allocated to ERNs. In WP13 and WP20 the distribution of budget will be done at later stage and thus also the distribution of respective PMs. 95 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. PILLAR0 PILLAR1 PILLAR2 PILLAR3 PILLAR4 TOTAL Beneficiary WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 WP10 WP11 WP12 WP13 WP14 WP15 WP16 WP17 WP18 WP19 WP20 1 INSERM 397 10 24 12 66 0 0 0 0 13 431 48 17 28 0 3 0 0 0 0 1049,5 2 FWF 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3,0 3 AIT 0 0 0 0 0 0 0 0 0 0 27 106 0 0 0 0 0 0 0 0 133,3 4 LBI-RUD 0 0 0 0 0 0 0 0 0 0 22 0 1 2 0 0 0 0 0 0 25,0 5 FNRS 0 0 0 0 0 3 0 0 4 0 0 0 0 0 0 0 0 0 0 0 7,0 6 FWO 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3,0 7 KULeuven 0 0 0 0 0 0 0 0 0 0 0 0 0 12 0 0 0 0 0 0 12,0 8 MEYS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 9 MoSAE 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3,0 10 AKA 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3,0 11 ANR 0 2 0 0 0 15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 17,4 12 FFRD 0 0 0 0 0 12 0 17 1 0 0 0 0 0 0 47 0 1 10 0 87,9 13 AFM 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 0 0 0 2 2 8,0 14 IMAGINE 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 2,4 15 DLR 6 1 1 1 1 21 0 2 0 0 0 0 0 0 0 0 0 0 0 0 32,9 16 UKA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 82 82,0 17 CHARITE 0 0 0 0 0 0 0 0 0 0 31 9 0 8 0 0 0 0 0 0 48,4 18 UKLFR 0 0 0 0 0 0 0 0 0 0 17 0 6 0 0 0 0 0 0 0 23,0 19 NKFIH 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3,0 20 HRB 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3,0 21 IT MoH 0 2 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5,0 22 RT (TuscReg) 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3,0 23 FRRB 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3,0 24 FGB 0 0 0 20 0 0 0 0 0 0 0 0 0 0 0 1 0 0 17 0 38,0 25 FTELE 0 1 0 16 0 0 0 0 0 25 10 37 0 27 0 0 0 1 107 0 223,6 26 ISS 0 18 0 0 0 0 0 0 0 6 7 0 12 43 2 0 0 1 0 0 88,6 27 CVBF 16 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 40 0 58,0 28 TEDDY 0 0 0 0 1 0 0 0 0 0 0 0 0 0 22 0 0 0 0 0 23,0 29 MIUR 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3,0 30 VIAA 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1,0 31 LMT (RCL) 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3,0 32 VUHSK 6 1 1 1 1 0 0 0 0 0 5 0 0 1 0 4 0 4 0 0 24,0 33 FNR 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3,0 34 ZON 6 1 1 1 1 3 13 2 0 0 0 0 0 0 0 0 0 0 0 0 27,7 35 UMCG 0 0 0 0 0 0 0 0 0 0 74 162 4 10 0 0 0 0 0 0 250,0 36 UM 0 0 0 0 0 0 0 0 0 1 11 2 88 0 0 0 0 0 0 0 103,0 37 NCBR 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3,0 38 MUW 0 4 0 0 0 0 0 0 0 0 0 12 0 0 0 0 0 0 0 0 15,7 39 MUG 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 0 0 0 0 0 3,0 40 IPCZD 0 0 0 0 0 0 0 0 0 0 10 0 0 4 0 0 0 2 0 0 16,0 41 FCT 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3,0 96 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Beneficiary WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 WP10 WP11 WP12 WP13 WP14 WP15 WP16 WP17 WP18 WP19 WP20 42 INSA 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1,1 43 SAS 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3,0 44 ISCIII 0 16 13 0 0 12 0 0 0 0 10 2 5 6 0 4 0 0 0 0 68,3 45 CNAG-CRG 0 0 0 0 0 0 0 0 0 6 182 11 7 1 0 0 0 0 0 0 206,0 46 UPM 0 0 0 0 0 0 0 0 0 0 11 55 0 0 0 0 0 0 0 0 65,3 47 CIBER 0 0 0 0 0 0 0 0 0 0 15 3 0 0 0 0 0 0 0 0 17,6 48 SRC 0 0 0 0 0 3 1 0 0 0 0 0 0 0 0 0 0 0 0 0 4,0 49 Vinnova 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3,0 50 ULEIC 0 0 0 0 0 0 0 0 0 14 13 194 0 0 0 0 0 0 0 0 220,0 51 ULIV 8 0 3 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 12,0 52 UNEW 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 14 0 14,0 53 CCRI 0 0 0 0 0 0 0 0 0 0 5 0 0 0 0 0 0 0 4 10 19,0 54 APHP 6 1 1 1 1 0 0 0 0 0 0 0 0 0 0 5 0 0 0 93 108,0 55 HUS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 56 CLB 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 3,0 57 UKL-HD 6 1 1 1 1 0 0 0 0 0 3 3 6 0 0 2 15 0 0 6 44,2 58 EKUT 0 0 0 0 0 0 0 0 0 0 0 0 3 7 0 0 18 1 0 0 28,6 59 GUF 0 0 0 0 0 0 0 0 0 0 77 121 0 0 0 0 0 0 7 0 205,2 60 HSK 0 0 0 0 0 0 0 0 0 0 4 0 0 2 0 0 0 0 3 20 28,9 61 IOR 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 9 11,0 62 AOUP 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 63 AOUS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1,0 64 LUMC 0 0 0 0 0 0 0 0 0 5 42 152 64 7 0 0 15 0 0 0 284,7 65 RUMC 0 0 0 0 0 0 0 0 0 0 11 33 55 0 0 2 15 0 0 0 114,9 66 AMC 0 0 0 0 0 0 0 0 0 0 6 94 0 1 0 0 0 0 0 0 101,0 67 Erasmus MC 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 68 SERMAS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 6 7,5 69 NUTH 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 1,5 70 GOSH 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 9 10,5 71 EORTC 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 3 5,0 72 INFRAFRONTIER 0 0 0 0 0 0 0 0 0 0 39 0 0 0 0 0 0 0 0 0 39,0 73 BBMRI 0 0 0 1 0 0 0 0 0 16 44 135 0 5 0 0 0 0 0 0 201,0 74 ECRIN 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 77 78,0 75 EATRIS 6 1 14 2 1 0 0 2 0 0 0 0 0 0 0 4 0 0 76 0 105,0 76 ELIXIR 1 0 3 1 0 0 0 0 0 24 194 26 3 7 0 15 0 0 0 0 273,6 77 EURORDIS 6 1 1 2 2 3 1 4 0 0 0 0 0 3 89 3 0 2 0 0 117,0 78 CSO/MoH 0 0 0 0 0 3 3 0 20 0 0 0 0 0 0 0 0 0 0 0 26,2 79 SNSF 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3,0 80 BLACKSWAN 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 81 TUBITAK 0 0 0 0 0 3 2 0 0 0 0 0 0 0 0 0 0 0 0 0 5,0 82 ACURARE 0 0 0 0 0 0 0 0 0 0 9 3 29 5 2 0 0 0 0 0 47,8 83 HUGEN 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 16 0 17,0 84 CIHR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 85 FRQS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 TOTAL 464,0 61,0 63,0 61,0 76,0 130,6 21,4 29,0 25,0 111,9 1310,7 1208,3 298,0 184,6 117,4 93,0 62,5 12,0 299,0 317,0 4945,2 97 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. Table 3.4b: ‘Other direct cost’ items (travel, equipment, other goods and services, large research infrastructures) Cost (€) Justification WP1 Travel to 5 GA meetings ; WP1 Travels policy board (X5); WP3 travel (6 meetings 6 pax) ; WP4 INSERM Travel 218 910 travel (5 meetings 11 pax) ; WP1 travel to 5 EX Com meetings + Kick off; PL2 Travel costs (Radico, Orphanet+LTP, AMU); WP10 Travel to annual retreat (ORPHANET); WP14 Task 14.1 Travel costs; WP20 PL4 ERN Pilot projects (to be allocated); WP1 General assembly meetings org (X5); WP1 Executive com meetings org (X5); WP1 ERN CHAIR costs to be assigned; WP1 Policy Board+Ethics+ExecCom joint meetings org (X5); WP1 Monitoring meetings org (X5); WP2 IRDiRC Task Forces: Workshops organisation; WP3 meeting org (6 meetings 6 pax) ; WP4 meeting org (5 meetings 11 Other 6 735 027 pax); WP5 EJP website; WP5 Printing/translation/publication/video; WP6 Evaluation meetings (2/year x 4 calls) at average cost 35 000 € (to be allocated); WP9 Meeting costs (to be allocated); WP10 PL2 Annual retreats from year 2 (to be allocated); WP10 PL2 Workshop Orphanet; WP11 Fairification costs (to be allocated); WP12 Fairification costs (to be allocated); WP13 Data provision by ERNs (to be allocated); WP14 Task 14.1 Catering costs; WP20 Organisation of 2 evaluation meetings (to be allocated); TOTAL 6 953 937 FWF Travel 14 850 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs; Other 4 000 CFS Cost TOTAL 18 850 FNRS Travel 14 850 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs TOTAL 14 850 FWO Travel 2 000 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs Other 4 000 CFS Cost TOTAL 6 000 KULeuven Travel 12 730 WP1 Travel to 5 GA meetings ; PL3 Task 14.2 Travel costs ; Other 4 056 PL3 Task 14.2 Catering TOTAL 16 786 MOSAE Travel 14 610 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs TOTAL 14 610 AKA Travel 14 850 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs Other 4 000 CFS Cost TOTAL 18 850 ANR Travel 16 850 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs Other 4 000 CFS Cost TOTAL 20 850 WP1 Travel to 5 GA meetings; WP1 travel to 5 EX Com meetings + Kick off; WP6 Travel costs ; WP8 FFRD Travel 49 510 Travel costs ; WP9 Travel costs ; WP16 Task 16.2 Travel costs; WP16 Task 16.3 Travel costs WP8 1 meeting call development; WP8 2 Evaluation meetings for RD challenge ; WP8 Networking event Other 50 006 for RDR challenge; WP16 Task 16.2 Catering costs; WP16 Task 16.3 Catering costs CFS Cost TOTAL 99 516 AFM Travel 5 900 WP1 Travel to 5 GA meetings TOTAL 5 900 IMAGINE Travel 5 900 WP1 Travel to 5 GA meetings TOTAL 5 900 NKFIH Travel 14 850 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs Other 0 TOTAL 14 850 HRB Travel 14 610 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs Other 4 000 CFS Cost TOTAL 18 610 IT MoH Travel 14 850 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs Other 4 000 CFS Cost TOTAL 18 850 RT (TuscReg) Travel 14 610 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs TOTAL 14 610 FRRB Travel 14 610 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs Other 4 000 CFS Cost TOTAL 18 610 WP1 Travel to 5 GA meetings ; WP2 travel (1 meeting 50 pax); WP1 travel to 5 EX Com meetings + Kick ISS Travel 185 880 off; PL2 travel costs; PL3 Task 14.2 Travel costs; PL3 Task 14.3 Travel costs; PL3 Task 14.5 Travel costs; PL3 Task 15.3 Travel costs WP2 meeting org (1 meeting 50 pax); PL2 annual retreat year 1 (meeting costs); PL3 Task 14.2 Catering Other 136 893 costs; PL3 Task 14.3 Catering costs; PL3 Task 14.5 Catering costs; PL3 Task 15.3 Catering costs ; CFS Cost 98 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. TOTAL 322 773 WP1 Travel to 5 GA meetings ; FSJD (LTP TEDDY) -Task 15.4 Travel costs; TEDDY -Task 15.4 Travel TEDDY Travel 30 440 costs Other 15 404 FSJD (LTP TEDDY) -Task 15.4 Catering costs; TEDDY -Task 15.4 Catering costs TOTAL 45 844 MIUR Travel 14 610 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs TOTAL 14 610 VIAA Travel 6 140 WP1 Travel to 5 GA meetings ; WP9 Travel costs ; TOTAL 6 140 LMT Travel 14 610 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs TOTAL 14 610 WP1 Travel to 5 GA meetings ; WP1 travel to 5 EX Com meetings + Kick off; PL3 Task 14.4 travel costs; VUHSK Travel 44 480 PL3 WP18 travel costs; Other 28 686 PL3 Task 14.4 catering costs; PL3 WP18 catering costs ; TOTAL 73 166 FNR Travel 14 610 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs TOTAL 14 610 NCBR Travel 14 850 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs Other 4 000 CFS Cost TOTAL 18 850 MUW Travel 34 400 WP1 Travel to 5 GA meetings ; WP2 travel (1 meeting 50 pax); PL2 travel costs Other 6 650 WP2 meeting org (1 meeting 50 pax) TOTAL 41 050 MUG Travel 24 840 WP1 Travel to 5 GA meetings ; PL3 Task 14.4 Travel costs; PL3 Task 15.3 Travel costs Other 7 263 PL3 Task 14.4 Catering costs; PL3 Task 15.3 Catering costs ; TOTAL 32 103 IPCZD Travel 15 550 WP1 Travel to 5 GA meetings ; WP1 travel to 5 EX Com meetings + Kick off; PL3 Task 14.2 travel costs Other 4 056 PL3 Task 14.2 catering costs TOTAL 19 606 FCT Travel 14 850 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs TOTAL 14 850 INSA Travel 10 900 WP1 Travel to 5 GA meetings ; PL2 travel costs ; TOTAL 10 900 SAS Travel 14 610 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs TOTAL 14 610 CIBER Travel 10 900 WP1 Travel to 5 GA meetings; PL2 travel costs ; TOTAL 10 900 SRC Travel 14 610 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs Other 4 000 CFS Cost TOTAL 18 610 Vinnova Travel 14 610 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs Other 4 000 CFS Cost TOTAL 18 610 ERN EYE Travel and subsistence for WP20 PL4; WP1 Travel to 5 GA meetings ; ERN EYE PL2 Travel HUS Travel 13 600 costs TOTAL 13 600 EURACAN Travel and subsistence for WP20 PL4; WP1 Travel to 5 GA meetings ; EURACAN PL2 Travel CLB Travel 14 070 costs TOTAL 14 070 ERN KNET Travel and subsistence for WP20 PL4; WP1 Travel to 5 GA meetings (2 teams); ERKnet WP1 UKL-HD Travel 25 560 travel to 5 EX Com meetings + Kick off; ERKnet PL2 Travel costs ; PL3 WP17 Training delivery for 4,5 years; 4 training networks with 6 ERNs each; 90.000 per training Other 409 000 network per year (15k€ per ERN) CFS Cost TOTAL 434 560 ERN RND Travel and subsistence WP20 PL4 ; .WP1 Travel to 5 GA meetings (X2, ERN+nonERN) EKUT Travel 63 460 .WP1 travel to 5 EX Com meetings + Kick off (Holm); ERN RND PL2 Travel costs ; PL3 Task 14.2 travel Costs; PL3 WP17 ERN RD training and support programme travel PL3 Task 14.2 catering; PL3 WP17 ERN RD training and support programme catering; PL3 WP7: Other 422 632 Training delivery for 4,5 years; 4 training networks with 6 ERNs each; 90.000 per training network per year (15k€ per ERN) CFS Cost TOTAL 486 092 ERN Bond Travel and subsistence for WP20 PL4; WP1 Travel to 5 GA meetings ; ERN Bond PL2 Travel IOR Travel 15 840 costs TOTAL 15 840 99 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. ERN Reconnect Travel and subsistence WP20 PL4 ; WP1 Travel to 5 GA meetings ; ERN Reconnet PL2 AOUP Travel 14 070 Travel costs TOTAL 14 070 AOUS Travel 14 070 ERN Ithaca Travel and subsistence WP20 PL4 ; WP1 Travel to 5 GA meetings ; Ithaca PL2 Travel costs TOTAL 14 070 ENDO Ern Travel and subsistence WP20 PL4 ; WP1 Travel to 5 GA meetings (all LUMC teams X2); WP1 LUMC Travel 30 490 travel to 5 EX Com meetings + Kick off (M Roos); Travel costs to PL2 meetings (all LUMC teams X2); PL2 workshop costs (M Roos); WP17 Training delivery for 4,5 years; 4 training networks with 6 ERNs Other 429 000 each; 90.000 per training network per year (15k€ per ERN) ; CFS Cost TOTAL 459 490 ERN Genturis&Eurogen Travel and subsistence WP20 PL4 ; WP1 Travel to 5 GA meetings (X3 RUMC RUMC Travel 39 040 teams); ERN Genturis&Eurogen Travel for PL2 ; Travel for PL2 (non ERN); PL2 workshop costs (non ERN); PL3 WP17 Training delivery for 4,5 years; 4 training networks with 6 Other 426 500 ERNs each; 90.000 per training network per year (15k€ per ERN) ; CFS Cost TOTAL 465 540 ERN Cranio & ERNICA Travel and subsistence WP20 PL4 ; WP1 Travel to 5 GA meetings (X2 ERN); PL2 Erasmus MC Travel 28 140 travel costs (Cranio & ERNICA) TOTAL 28 140 ERN Transplant staff for WP20 PL4; ERN Transplant WP1 Travel to 5 GA meetings ; ERN Transplant PL2 SERMAS Travel 14 070 travel TOTAL 14 070 ERN Rare Liver,Rita, EuroNMD Travel and subsistence WP20 PL4 ; WP1 Travel to 5 GA meetings (X3 NUTH Travel 42 210 ERNs); ERN Rare Liver,Rita, EuroNMD Travel for PL2 TOTAL 42 210 GOSH Travel 15 840 EPICARE travel and subsistence for WP20 PL4; WP1 Travel to 5 GA meetings ; EPICARE travel for PL2 TOTAL 15 840 EORTC Travel 5 900 WP1 Travel to 5 GA meetings TOTAL 5 900 Travel and subsistence for WP20 PL4; WP1 Travel to 5 GA meetings; WP1 Travel to 5 EX Com meetings + Kick off; WP6 Travel costs ; WP8 Travel costs; WP9 Travel costs; EURORDIS Travel 180 850 WP14 Task 14.5 Travel costs; WP15 Task 15.1 Travel costs; WP15 Task 15.2 Travel costs; WP15 Task 15.3 Travel costs WP8 2 Multi-stakeholder workshops for set-up RDR challenge scheme ; WP15 Task 15.1 Catering costs; Other 89 547 WP15 Task 15.2 Catering costs; WP15 Task 15.3 Catering costs ; CFS Cost TOTAL 270 397 SNSF Travel 14 850 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs Other 4 000 CFS Cost TOTAL 18 850 BLACKSWAN Travel 5 900 WP1 Travel to 5 GA meetings Other 150 000 WP5 - REACT congress organisation costs TOTAL 155 900 TUBITAK Travel 14 850 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel costs Other 4 000 CFS Cost TOTAL 18 850 ACURARE Travel 34 550 WP1 Travel to 5 GA meetings ; PL2 travel costs; PL3 Task 14.2 travel costs; PL3 Task 15.3 travel costs; Other 9 243 PL3 Task 14.2 catering; PL3 Task 15.3 catering ; TOTAL 43 793 HUGEN Travel 8 020 WP1 Travel to 5 GA meetings ; PL3 Task 14.4 Travel costs Other 2 076 PL3 Task 14.4 Catering costs TOTAL 10 096 EUROPEAN JOINT PROGRAMME ON RARE DISEASES 100 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 4.1. Participants (applicants) TABLE OF CONTENTS 01-INSERM (a) .................................................................................................................................................... 4 01-INSERM (b) .................................................................................................................................................... 6 01-INSERM (c) .................................................................................................................................................... 8 01-INSERM (d) .................................................................................................................................................. 12 02-FWF ................................................................................................................................................................ 14 03-AIT.................................................................................................................................................................. 15 04-LBG ................................................................................................................................................................ 16 05-FNRS .............................................................................................................................................................. 18 06-FWO ............................................................................................................................................................... 19 07-KU Leuven .................................................................................................................................................... 20 08-MEYS ............................................................................................................................................................. 22 09-MoSAE........................................................................................................................................................... 23 10-AKA ............................................................................................................................................................... 24 11-ANR................................................................................................................................................................ 25 12-FFRD .............................................................................................................................................................. 26 13-AFM ............................................................................................................................................................... 28 14-IMAGINE ...................................................................................................................................................... 30 15-DLR ................................................................................................................................................................ 31 16-UKA ............................................................................................................................................................... 32 17-CHARITE ...................................................................................................................................................... 34 18-UKLFR........................................................................................................................................................... 36 19-NKFIH ........................................................................................................................................................... 38 20-HRB ................................................................................................................................................................ 40 21-IT MoH .......................................................................................................................................................... 40 22-TuscReg ......................................................................................................................................................... 42 23-FRRB .............................................................................................................................................................. 44 24-FGB ................................................................................................................................................................ 46 25-FTELE ............................................................................................................................................................ 48 26-ISS................................................................................................................................................................... 50 27-CVBF ............................................................................................................................................................. 53 28-TEDDY .......................................................................................................................................................... 56 29-MIUR ............................................................................................................................................................. 60 30-VIAA .............................................................................................................................................................. 61 31-LMT................................................................................................................................................................ 62 32-VUHSK .......................................................................................................................................................... 63 33-FNR ................................................................................................................................................................ 64 34-ZonMw ........................................................................................................................................................... 65 35-UMCG ............................................................................................................................................................ 66 1 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 36-UM .................................................................................................................................................................. 69 37-NCBR ............................................................................................................................................................. 71 38-MUW .............................................................................................................................................................. 72 39-MUG............................................................................................................................................................... 74 40-IPCZD ............................................................................................................................................................ 76 41-FCT ................................................................................................................................................................. 78 42-INSA............................................................................................................................................................... 79 43-SAS ................................................................................................................................................................. 81 44-ISCIII .............................................................................................................................................................. 82 45-CNAG-CRG .................................................................................................................................................. 88 46-UPM ............................................................................................................................................................... 89 47-CIBER ............................................................................................................................................................ 91 48-SRC................................................................................................................................................................. 93 49-VINNOVA .................................................................................................................................................... 94 50-ULEIC ............................................................................................................................................................ 94 51-ULIV .............................................................................................................................................................. 96 52-UNEW ............................................................................................................................................................ 98 53-CCRI............................................................................................................................................................. 100 54-APHP (a) ...................................................................................................................................................... 101 54-APHP (b) ..................................................................................................................................................... 103 54-APHP (c) ...................................................................................................................................................... 104 54-APHP (d) ..................................................................................................................................................... 107 54-APHP (e) ...................................................................................................................................................... 109 54-APHP (f) ...................................................................................................................................................... 111 54-APHP (g) ..................................................................................................................................................... 112 55-HUS .............................................................................................................................................................. 114 56-CLB .............................................................................................................................................................. 116 57-UKL-HD ...................................................................................................................................................... 117 58-EKUT ........................................................................................................................................................... 119 59-GUF .............................................................................................................................................................. 120 60-HSK .............................................................................................................................................................. 122 61-IOR ............................................................................................................................................................... 123 62-AOUP ........................................................................................................................................................... 126 63-AOUS ........................................................................................................................................................... 128 64-LUMC .......................................................................................................................................................... 131 65-Raboudumc .................................................................................................................................................. 136 66-AMC ............................................................................................................................................................. 141 67-Erasmus MC ................................................................................................................................................ 144 68-SERMAS ..................................................................................................................................................... 145 69-NUTH ........................................................................................................................................................... 147 70-GOSH ........................................................................................................................................................... 149 2 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 71-EORTC......................................................................................................................................................... 152 72-INFRAFRONTIER .................................................................................................................................... 153 73-BBMRI ......................................................................................................................................................... 155 74-ECRIN/PedCRIN........................................................................................................................................ 157 75-EATRIS........................................................................................................................................................ 159 76-ELIXIR......................................................................................................................................................... 161 77-EURORDIS ................................................................................................................................................. 166 78-CSO-MOH ................................................................................................................................................... 167 79-SNSF ............................................................................................................................................................ 168 80-BLACKSWAN ........................................................................................................................................... 169 81-TUBITAK .................................................................................................................................................... 170 82-ACU/ACURARE........................................................................................................................................ 171 83-HUGEN........................................................................................................................................................ 173 84-CIHR ............................................................................................................................................................ 175 85-FRQS ............................................................................................................................................................ 176 4.2. Third parties involved in the project (including use of third party resources) 177 SECTION 5: Ethics and Security 194 5.1 Ethics 194 5.2 Security 200 LETTERS OF SUPPORT: 201 3 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 01-INSERM (a) INSERM-ITGGB (Institut Thématique Génétique, Génomique et Bioinformatique) Full legal name (Acronym) – Country Institut National de la Santé et de la Recherche Médicale (INSERM) Principal investigator Catherine Nguyen Relevant Network INSERM is the only public research organization in France entirely dedicated to human health. Its objective is to promote the health of all by advancing knowledge about life and disease, treatment innovation, and public health research. Inserm brings together 15,000 researchers, engineers, technicians, and administrative staff around one common goal: to improve the health of all by advancing knowledge of life and disease, innovation in treatment, and public health research. Since its foundation in 1964, Inserm has played a part in many key medical advances, including the first prenatal diagnostic tests, understanding of the HLA system, the first in vitro fertilization, identification of the AIDS virus, radiotherapy for cancer, the first skin graft, deep brain stimulation, and gene therapy. Inserm is the leading European academic biomedical research institution, and with nearly 12,000 publications a year; is second in the world only to the National Institutes of Health (NIH). According to the 2016 ranking by Thomson-Reuters, Inserm is also the world’s 9th most innovative public research organization. Inserm plays a crucial role in the structure of the European Research Area and its international position is strengthened by close collaborations (teams abroad and associated international laboratories). In 2015, the Institute had 22 associated international laboratories at its disposal, 9 mixed international units set up abroad and around thirty international cooperation agreements. With involvement in more than 400 European projects financed by the European Commission within the 7th Research and Development Framework Programme, Inserm has been confirmed as one of the principal European players in the area of research into life sciences and health. Inserm has also been one of the foremost European research institutions in terms of IMI (Innovative Medicines Initiative) financing of public/private research partnerships with a strong presence in the European Research Council. Its mission is supported by the work of 9 theme-based institutes, whose role is to monitor progress and take a lead on research in their respective fields. The Institute of Genetics, Genomics and Bioinformatics (IT GGB) covers genetics and genomics in all living organisms, from viruses, micro-organisms and plants to humans. Scientific projects are focused on organization, evolution, genome variability, gene expression regulation, population genetics as well as genetic and epigenetic determinism of diseases and treatments of genetic diseases. The Institute coordinates discussions and research in the following fields:  Bioinformatics, setup of intermediate platforms to existing national centers relying on mass sequencing platforms,  Genomic diversity, rare diseases, population genomics, metagenomics, evolution,  Molecular genetics, genetic regulation: from transcriptomics to epigenetics,  Genome dynamics, transposable elements, mutations,  Quantitative genetics, multifactorial diseases, rare diseases, complex traits. This Institute liaises with thematic institutes for cross-disciplinary purposes, but particularly with the Cell biology, development and evolution, Molecular and structural bases of living organisms and Cancer. Main tasks in the project per Pillar/WP: Coordination and transversal activities: WP1: Inserm-ITGGB will be responsible for the overall coordination, management and strategy of the EJP RD. It will establish a coordination office composed of: coordinator (Daria Julkowska, PhD), four project managers, communication manager, financial officer and assistant. It will be responsible for the coordination and support within and across all pillars and transversal work packages. Inserm-ITGGB will be also in charge of the Scientific Secretariat of IRDiRC. WP2: Inserm-ITGGB will be involved in Task 2.2 and 2.4 where it contribute to the mapping of research and innovation needs and establishment of short, medium and long-term research and innovation strategy. Inserm-ITGGB will also ensure interaction and common strategy with IRDiRC by organization of joint Task Forces. WP3: Inserm-ITGGB will participate in Task 3.1 and focus on alignment of needs, expectations and engagement of different RD stakeholders in Europe with respect to EJP RD sustainability. WP4: Inserm-ITGGB will support the Advisory Regulatory Ethics Board in management of ethical and regulatory issues of the EJP RD. 4 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases WP5: Inserm-ITGGB will be leading this work package dedicated to communication and dissemination of EJP RD. It will be in charge of the implementation of communication and dissemination strategy as set in the Annex 1. It will develop and provide various communication tools in line with the needs of EJP RD partners. It will liaise and strengthen the integration of EJP RD communication and dissemination strategy with the strategies of involved stakeholders at national and international level. Finally, Inserm-ITGGB will support IRDiRC in its communication and dissemination activities as agreed within the responsibilities of IRDiRC Scientific Secretariat. Previous experience relevant to the Tasks: Inserm-ITGGB is strongly involved in the coordination of national strategic vision and actions of different stakeholders in the field of genetics, genomics and bioinformatics. It represents INSERM in actions related to rare diseases and accompanies the 3rd National Plan for Rare Diseases. It is strongly involved in the implementation of National Plan of Genomic Medicine through the reorganization of French Institute of Bioinformatics to meet specific needs of institutions and organizations involved in biology and health research. It is responsible for animation of scientific community and organization of dedicated events like annual bioinformatics school, advance epigenetics conference or rare diseases and personalized medicine meetings. Short Profile of key Staff Members who will be undertaking the work Dr. Daria Dr. Daria Julkowska has over 15 years of experience in research and management. She is Julkowska responsible for the management of several European and international funding programmes. (Female) Among others, since 2010 she is involved in E-Rare, the ERA-Net for Research programmes on rare diseases, where for the first two years she occupied the position of the project manager to finally (April 2013) take over the coordination of the programme. As the coordinator she developed and put into action a set of collaborations facilitating rare diseases research, including the partnerships with European Research Infrastructures and Patients’ Organizations. She has an extensive knowledge and understanding of European funding schemes and programmes. Since February 2017 she serves as the chair of the Funders Constituent Committee of IRDiRC. Of Polish origin, Dr. Julkowska obtained her international PhD in molecular biology at the University of Paris XI, France and University of Gdansk, Poland in 2005. She pursued her scientific vocation by the post-doctoral experience in cellular biology, at Institut Pasteur, Paris and extensive training in communication and European Union counselling. She also holds MSc in Management of Research from the University of Paris Dauphine (FR). D.Julkowska was also responsible for coordination and preparation of the EJP RD proposal and will be the coordinator of the EJP RD. Dr. Catherine Nguyen Dr.Catherine Nguyen is the director of the INSERM Genomic, Genetic and Bioinformatic (Female) Thematic Institute. She has extensive training in genetics and functional genomics. Between 2002 and 2018 she was leading the Inserm TAGC Transcriptome laboratory in Marseille, France. Her unit dedicated to functional genomics studies (TAGC laboratory) with a transcriptome facility at the Luminy campus, which is nationally recognized as a platform for functional genomics studies within different research organizations in France, focused on bioinformatics analysis of data collected from DNA microarrays and other (bio)informatics fields. Domains of expertise or consultancy: Genomic, transcriptome, immunology and cancer research, DNA chips, splicing, molecular biology. Member (vice chairwoman) authorities of valuation of INSERM (ICSS3 then CT2), of the commission of reflection STIC-INSERM, of the committee of piloting of transcriptome of Marseilles Génopole, of jury of INSERM,-CNRS engineers recruitment. Member of the Committee of Strategic Organization AGENAE INRA. Member of the CHSHS PACA, INSERM. Expert for the authorities of evaluation for the Ministry of research and New Technologies (MRNT), employment and solidarity (PHRC), CNRS (Action DNA chips), Genopoles, the National Association of Technical Research (ANRT), National Network Technologies and Health (RNTS), of IMTSSA Tropical Institute of Medicine dependent of the army office, the French society against myopathies (AFM), the national Research fund (FNR) of Luxembourg, of the French-Indian centre for the promotion of advanced Research (CEFRIPRA), System of Research Grants Council, (CERG) Hong Kong), of the Mission of expertise for the Ministry for French- Korean Research, Edition in Immunology of the Medical Research Council, MRC, UK, of ANR (INCA, PNANO), FRM (bioinfo). Member of HUGO (Human Genome Organisation) since 1995, member of SFI (French Society 5 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases of Immunology) since 1997, coordinator ESF network on technologies for functional genomics, member of scientific comity of the Forum 2000- 2006 (Industrial meeting organization). Patents: 1-N°US 10-007 926 (sight entry): gene expression profiling of primary breast carcinomas using arrays of candidates genes. International Extension PCT/IB01/02811. 2- European Number.EP: 02290949.9 « gene expression profiling of blood tumors using polynucleotides arrays. Grants: since 1999, 35 grants from fundations (ARC, LNCC, AFM, ANRS), from MNRT, from the industry (GALDERMA, IPSOGEN, GENSODI,) and 3 european grant (5th- 7th PCRD); Student training: >30 courses in a frame of National and InterNational university (Pasteur Institut, Paris, Faculty of Sciences St Jérôme, Marseille; ESIL GBMA Marseille, Welcome trust summer schools, UK; European School of Haematology (ESH) Dublin, Irland; University of St Joseph, Lebanon, USTH Vietnam .45 master, 24 PhD student supervision. Publications: 102 research articles in international journals, 31 reviews and 6 book chapters. 43 invited lecturer; more than 100 oral communications in national & international meeting, up to 120 communications in national and international conferences. Personnel to INSERM will recruit four project managers; communication officer, financial officer and assistant be recruited to support the coordinator in management and coordination responsibilities under EJP RD. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Analysis of ERA-NET Cofund actions under Horizon 2020. Final report of the expert group. Niels Gøtke (Chairperson), Effie Amanatidou (Rapporteur), Ioana Ispas, Daria Julkowska, Joaquín Serrano. Directorate- General for Research and Innovation. Publications Office of the European Union, 2016. 2. Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective. Austin CP, Cutillo CM, Lau LPL, Jonker AH, Rath A, Julkowska D, Thomson D, Terry SF, de Montleau B, Ardigò D, Hivert V, Boycott KM, Baynam G, Kaufmann P, Taruscio D, Lochmüller H, Suematsu M, Incerti C, Draghia-Akli R, Norstedt I, Wang L, Dawkins HJS; International Rare Diseases Research Consortium (IRDiRC). ; Clin Transl Sci. 2018 Jan;11(1):21- 27. 3. The importance of international collaboration for rare diseases research: a European perspective. Julkowska D, Austin CP, Cutillo CM, Gancberg D, Hager C, Halftermeyer J, Jonker AH, Lau LPL, Norstedt I, Rath A, Schuster R, Simelyte E, van Weely S. ; Gene Ther. 2017 Sep;24(9):562-571. 4. Improved Diagnosis and Care for Rare Diseases through Implementation of Precision Public Health Framework. Baynam G, Bowman F, Lister K, Walker CE, Pachter N, Goldblatt J, Boycott KM, Gahl WA, Kosaki K, Adachi T, Ishii K, Mahede T, McKenzie F, Townshend S, Slee J, Kiraly-Borri C, Vasudevan A, Hawkins A, Broley S, Schofield L, Verhoef H, Groza T, Zankl A, Robinson PN, Haendel M, Brudno M, Mattick JS, Dinger ME, Roscioli T, Cowley MJ, Olry A, Hanauer M, Alkuraya FS, Taruscio D, Posada de la Paz M, Lochmüller H, Bushby K, Thompson R, Hedley V, Lasko P, Mina K, Beilby J, Tifft C, Davis M, Laing NG, Julkowska D, Le Cam Y, Terry SF, Kaufmann P, Eerola I, Norstedt I, Rath A, Suematsu M, Groft SC, Austin CP, Draghia-Akli R, Weeramanthri TS, Molster C, Dawkins HJS. ; Adv Exp Med Biol. 2017;1031:55-94. List of relevant previous projects or activities, connected to the subject of this proposal E-Rare-1 (2007 – 2011), GA036248 E-Rare-2 (2011 – 2014), GA266608 01-INSERM (b) INSERM-US14 Full legal name (Acronym) – Country Institut National de la Santé et de la Recherche Médicale (INSERM), France Principal investigator Ana Rath Relevant Network Orphanet Network Description of the legal entity/department/laboratory/group: The INSERM-US14 houses Orphanet, the knowledge base of rare diseases and orphan drugs. Its goal is to contribute to improve the diagnosis, management and treatment of rare diseases. For these purposes, the unit produces, compiles and conveys information as well as scientific and medical data with added value, complete, validated and updated for researchers, clinicians, the general public and all the actors in the field of rare diseases 6 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases (researchers, patients, industrialists, decision-makers, professionals in the medico-social sector). INSERM-US14 has been acting as coordinator of the Orphanet network (41 countries in 2018) since the beginning of the European projects in 2001. The INSERM-US14 also acted as coordinator of the Joint Action on RD (RD- ACTION) 2015-2018 and of the HIPBI-RD project. He currently coordinates SUPPORT-IRDiRC (2012-2018) and has acted as the coordinator of the Rare Diseases Task Force (2004-2009) and the European Union Committee of Experts on Rare Diseases (EUCERD)(2010-2013). Main tasks in the project per Pillar/WP: Pillar 2: Dr. Ana Rath will act as Pillar 2 co-leader. WP10: Inserm-Orphanet will co-lead the WP and lead the Task 10.1 Convene yearly retreats leading to Pillar 2 annual strategic plans (in particular being co-responsible for subtask 10.1.2 Annual strategic plan for Pillar 2) WP11: Inserm-Orphanet will co-lead the WP and lead Task 11.2: FAIR-compliant virtual platform for discovery of RD resources (in particular subtasks 11.2.1 and 11.2.2). Orphanet TLP will contribute to subtasks 11.2.1 Collaboratively assemble and curate metadata into the Orphanet catalog, on an ongoing basis, to represent all key databases and resources and 11.2.2. Create a catalog of research projects and clinical trials, on an ongoing basis, to inform funders (IRDiRC Roadmap priority) WP12: Orphanet will contribute to subtasks related to the generation and maintenance of semantic standards and metadata (subtasks 12.1.1, 12.1.5., 12.2.1., 12.3.1.) Pillar 3: WP 14: Training on data management and quality. Inserm-Orphanet will lead the Task 14.1: Developement of a novel training modules for clinicians and scientists involved in various rare disease research fields. After some adaptation to country-specific needs, the Orphanet Network teams will organise trainings in their countries in their national language. Orphanet will contribute also to the Task 14.6. Training on the European RD Registry Infrastructure (ERDRI) and to the Task 14.2 Developing the online course in WP3: Online academic education course Coordination and transversal activities Inserm-Orphanet will contribute to subtasks in the WP1 Coordination and Management, as Pillar 2 co-leader and as Coordinator of the pan-European Orphanet network. Inserm-Orphanet will co-lead the Task 2.1: Mapping and prioritizing the needs in the WP2: Integrative research strategy. Inserm-Orphanet will lead and Orphanet TLP will contribute to the Task 5.2: Integrating EJP RD communiation and dissemination strategies with the strategies of involved stakeholders in the WP5: Communication & dissemination. Previous experience relevant to the Tasks: Orphanet produces the standard nomenclature, classification and ontology for rare diseases including genomic and phenomic data, is a IRDiRC recognized resource and is also recognized as a Human Variome Project recommended system. Orphanet maintains a database of RD-specific expert resources since 1997 by the collection, manual curation and quality control of expert centres (including ERNs), diagnostic tests, patient organisations, infrastructures, registries and databases and RD research projects and clinical trials and orphan drugs in 35 countries of the 41 countries in the Orphanet network. Orphanet has maintained, and contributes to maintain in the frame of RD-Action, the State of the Art of activities related on RD, based on the work of national Orphanet hubs covering all EU countries. Orphanet coordinates RD-Action, the DG Santé Joint action for RD, dealing with data and policies, including codification of RD in health information systems. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Orphanet database owned by Inserm, with its access services and formats : www.orpha.net www.orphadata.org (XML, JSON, OWL) www.orpha.net/sparql/ SPARQL Endpoint 7 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases ORDO http://bioportal.bioontology.org/ontologies/ORDO (OWL, CSV, RDF/XML) HOOM http://www.orphadata.org/cgi-bin/inc/hoom_orphanet.inc.php Orphanet is hosted at CINES (National Computing Center for Higher Education, a French public institution). The Orphanet IT infrastructure is managed both by US14 Inserm unit and by Inserm Department of Information System and has productions, pre-production and development servers organized in several Virtual Machines. Short Profile of key Staff Members who will be undertaking the work Dr. Ana Rath, Ana Rath is a medical doctor with a background in general surgery and a Masters degree in (Female) Philosophy. She oriented her career to medical information in 1997 and joined Orphanet (www.orpha.net) in 2005. She acts as managing editor of the Topic Advisory Group on rare diseases at the World Health Organization. She chairs the Orphanet rare diseases ontology (ORDO:http://bioportal.bioontology.org/ontologies/ORDO). Ana is the current Director of Orphanet and the coordinator of RD-ACTION, the EU Joint Action for rare diseases (2015-2018) and of the HIPBI-RD project. She chairs the Orphanet Rare Disease Ontology (ORDO). Marc Marc Hanauer is an engineer at INSERM and Chief Technology Officer at Orphanet since 2007 Hanauer, and Orphanet Deputy director since 2017. He is also in charge of managing Orphanet's innovation (Male) strategy. Previous to his current position, Marc worked for different internet start-ups from 2000 on-wards. He has an academic background in information and communication sciences." Sylvie Maiella Sylvie Maiella has a PhD in Human Immunology and has been trained to Transversal (Female) management. She oriented her career to scientific project management in 2010 and since 2011 she has been acting as Orphanet international coordinator and project manager of the previous Orphanet- Inserm coordinated Joint actions (OEJA 2011-2014 and RD-ACTION 2015-2018). List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. orphadata.org 2. ORDO (http://www.orphadata.org/cgi-bin/inc/ordo_orphanet.inc.php/) 3. Harmonising phenomics information for a better interoperability in the rare disease field. Maiella S, Olry A, Hanauer M, Lanneau V, Lourghi H, Donadille B, Rodwell C, Köhler S, Seelow D, Jupp S, Parkinson H, Groza T, Brudno M, Robinson PN, Rath A. Eur J Med Genet. 2018 Feb 7. pii: S1769-7212(17)30506- 2. doi: 10.1016/j.ejmg.2018.01.013. [Epub ahead of print] Review. PMID:29425702 4. Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective. Austin CP, Cutillo CM, Lau LPL, Jonker AH, Rath A, et al; International Rare Diseases Research Consortium (IRDiRC). Clin Transl Sci. 2018 Jan;11(1):21-27. doi: 10.1111/cts.12500. Epub 2017 Oct 23. Review. PMID:28796445 5. International Cooperation to Enable the Diagnosis of All Rare Genetic Diseases. Boycott KM, Rath A, et al Am J Hum Genet. 2017 May 4;100(5):695-705. doi: 10.1016/j.ajhg.2017.04.003. List of relevant previous projects or activities, connected to the subject of this proposal Harmonising phenomics information for a better interoperability in the RD field (HIPBI-RD) 2016 – 2019, project financed by ERA-Net E-Rare-3. Promoting implementation of recommendations on policy, information and data for RD Joint action (RD- ACTION); 2015-2018 SUPPORT-IRDiRC; 2012 – 2018, FP7 GA N°: 305207 01-INSERM (c) INSERM-U993/RaDiCo Full legal name (Acronym) – Country Institut National de la Santé et de la Recherche Médicale (INSERM), France Principal investigator Jerome Weinbach Relevant Network Description of the legal entity/department/laboratory/group: The research unit UMR_S933 from INSERM “Pathophysiology of Paediatric Genetic Diseases”, led by Prof. Serge Amselem is subdivided into two distinct components: the Genetic research group and the RaDiCo French national platform on RD cohorts. 8 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases  The genetic research group of the UMRS 933 INSERM/UPMC is devoted to the study of the pathophysiology of several human Mendelian disorders, including auto-inflammatory disorders, primary ciliary dyskinesia, growth disorders of endocrine origin, and disorders of sex development & infertility. It has access to several cohorts of patients with these disorders, which are exceptional, both in their size and their phenotypic characterization. For each pathology investigated, the group develops on the top of the genetic profile (identification of new genetic factors involved the studied diseases), a functional profile with the design of disease- specific studies aimed at:  developing disease-specific cell models,  characterizing the molecular networks to which the proteins involved belong,  evaluating, using different model systems, the consequences of the mutations identified in patients,  and opening up new therapeutic avenues. The research conducted in this team leads to clinical implications with diagnostic, prognostic and therapeutic repercussions (translational research).  The RaDiCo national platform on RD cohorts: RaDiCo (for Rare Disease Cohorts, see www.radico.fr) is a French platform and programme coordinated and administratively managed by the French Institute of Health and Medical Research (Inserm / UMR S 933). Its activities started in November 2013 and are funded within the scope of the ‘Investissements d’Avenir’ (Investments for the Future) programme implemented by the MESR (French Ministry for Higher Education and Research), the Agence Nationale pour la Recherche (ANR, the French National Research Agency). The aim of RaDiCo is to bring in-kind services and large spectrum of expertise to the RD community in France and in Europe to optimizing the design and implementation of high quality multicentric RD cohorts with clearly defined scientific objectives: describing natural history of RDs, establishing genotype- phenotype correlations, assessing the impact of environmental factors, elucidating their physiopathology, identifying new therapeutic approaches and diagnostic / prognostic / theranostic biomarkers, or assessing their medical, economical and societal impacts. To date, RaDiCo is involved in sixteen RD cohort studies, all selected following a national call for proposals by independent experts. Two of them (RaDiCo-ECYSCO and RaDiCo- EURBIO Alport) are already of European. One original cohort (RaDiCo-GenIDA) proposes to the patient community an international social network for data collection on the natural history of rare monogenic forms of intellectual disabilities. Several Public-Private Partnerships with big pharma industries have already been initiated for the use of certain cohort resources through Specific Research Projects. To summarise, the major activities performed by the RaDiCo team are the following: Clinical research eHealth Transversal affairs  Cohort longitudinal Interoperability with pre-  Training courses on regulatory, study design and existing local databases and ethical and standardization issues methodology information sources,  Preparation of legal documents  Design of the case FAIRification  Intellectual property and data report forms and Webservices and e-form access management patient building (eCRF,  Communication questionnaires questionnaires)  Public-private partnerships  Preparation of the Integration of data from agreements regulatory dossiers mobile-health and connected  Dissemination and exploitation  Real time data devices plans / cohort resource access monitoring and Secure-by-design, GDPR- management (data and bio- management compliant electronic collections)  Biostatistical infrastructure / IS resource  European and international expertise and orchestration and collaborations scientific maintenance  Cohort infrastructure as a service: valorisation of the sustainability solutions data/knowledge Main tasks in the project per Pillar/WP: Coordination and transversal activities: WP3: Co-leader of WP3 “Sustainability strategy and business plan”, leader of Task 3.1, joint development of a dynamic catalogue of EJP-RD sustainable resources including Service Roadmap Database and Study cases of innovative sustainability solutions for specific EJP RD outcomes WP4: Participant in WP4 “Ethical, regulatory, legal and IPR framework of the EJP RD” (expertise in ethical and regulatory issues in the MS related to RD patient databases, secure by design information systems and GDPR 9 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases obligations in Europe, expertise in IPR issues and collaborative contractual frameworks (eg Consortium Agreement, Public-Private contracts, involving use and exploitation of data). Pillar 2: WP10: “User-driven strategic planning and transversal activities for Pillar 2 data ecosystem”: Participant in Task 10.3: Coordination of technical GDPR implementation (expert), Task 10.4: Quality oversight (expert), Task 10.5: Sustainability and scaling up (to coordinate with WP3 activities). WP11: “Common virtual platform for discoverable data and resources for RD research”: Participant in notably Task 11.3: Data deposition and access to data infrastructures for RD research (concerning patient cohort data), Task 11.4: Provision of RD analysis and data sharing capabilities through online resources. WP12: “Enabling sustainable FAIRness and Federation at the record level for RD data, patients and samples”: Participant in notably in Task 12.1: Compare and align core interoperability standards of relevance and Task 12.3: Combining expertise for practical FAIRification: experience and PoCs based on RaDiCo cohorts’ databases. Pillar 3: WP14: “Training on data management & quality”: in Task 14.5: Training on rare disease registries and FAIRification of data at the source: trainer in data management and data quality best practices and approaches, next generation registries and database governance models, integration of IoTs, valorisation and exploitation activities. Pillar 4: Involvement in WP20 “Accelerating the validation, use and development of innovative methodologies tailored for clinical trials in RDs” due to strong expertise in clinical trial and study design and implementation at European level within transnational RD patient cohorts. Previous experience relevant to the Tasks: RaDiCo team: 16 fully dedicated employees act within 3 different sub-units: Clinical research, e-Health and Information System. They are bringing complementary expertise and tools since 2014 enabling RD cohorts’ design and implementation. 16 RD cohorts were conceived and are currently managed by the RaDiCo platform at national and European levels, covering more than 40 different rare diseases. The team composition, expertise and organisation has been continuously adapted to cope with the evolution of RaDiCo activities for the supported cohorts. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : The Inserm-RaDiCo platform has selected the free, secured, web-based, and user-friendly electronic data capture (EDC) tool REDCap as its clinical research software suite for electronic data capture and management. All information systems proposed by RaDiCo run in a virtual, redundant and supervised, GDPR- compliant architecture in a certified health data hosting and facilities management centre (HADS in French) in the framework of a service contract with the Inserm. Security audits are performed each year. The equipment is dedicated and isolated. The required operating system is LINUX long term support, Apache, the MySQL database engine and the PhP application scripting language, i.e. the LAMP suite. Short Profile of key Staff Members who will be undertaking the work Prof. Serge Prof. Serge Amselem (Male) - MD (paediatrician), PhD, Professor of human genetics at Université Amselem Pierre et Marie Curie (UPMC) in Paris (France) and director of the U933 Inserm research unit (Male) (UMR_S933 INSERM/UPMC) dedicated to the study of the pathophysiology of several Mendelian disorders. He is the scientific coordinator of the RaDiCo program ~ 150 papers in peer-reviewed journals (first / corresponding author in several international journals, including Nat Genet, New Engl J Med, Am J Hum Genet, J Clin Invest, PNAS, EMBO J, PLoS Genet, Hum Mol Genet). Prof. Paul Landais (Male) - Professor of Public Health, Clinical Epidemiologist and Nephrologist Prof. Paul (MD). Director of the UPRES EA2415 Research Unit, Clinical Research Institute, Montpellier Landais University. Founded the French Renal Epidemiology and Information Network (REIN), the (Male) SCETIDE program with Pr A. Fischer, the CEMARA platform for rare diseases (RD) & past- coordinator of the French national Rare Diseases Data Bank (BNDMR). Co-Coordinator of the national RaDiCo program for RD cohorts. Founder of the Institute for clinical evaluation of medical devices (IDIL). Dr. Jerome Dr. Jerome Weinbach (Male) - Science & Operations Director of the RaDiCo platform at Inserm. Weinbach PhD on adenovirus-based gene therapy of cancer; engineer in microbiology and medical genetics (Male) from the French National Institute of Applied Sciences. Former operation coordinator at the European affairs Dpt of Inserm-Transfert. Jerome prepared and piloted more than 45 European medical research and public health EC funded projects. Awarded French Best Manager of the Year 10 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases (Opteam Trophy), he has been regularly appointed since 2001 as expert evaluator by the European Commission, notably by DG Connect for assessing European projects on e-Science environments (proposals submitted to the INFRASTRUCTURE calls, or for periodic evaluations of European – omics e-infrastructures such as the former DiXa and COSMOS projects). Dr. Laure Dr. Laure Jamot (Female) Head of RaDiCo’s Clinical Research Department. PhD degree in neuro- Jamot genetics from Paris V René Descartes University in Paris. After 5 years of basic research on rare (Female) neurodegenerative diseases (Mount Sinaï hospital, Toronto Canada), moved to the Trophos biotechnology company in 2001, in Marseille to set up the R&D programme on Huntington’s disease. In 2008, joined the Alfact Innovation company, based in Paris, as head of pre-clinical and clinical research programmes. Backed by her team of clinical research project and data-managers, biostatistician and methodologist, she now takes advantage of her 13 year experience in the private sector for dealing with all aspects of translational and clinical research for the benefit of the RaDiCo programme and its cohorts. List of the most relevant publications 1. Data Quality in Rare Diseases Registries. Adv Exp Med Biol. 2017;1031:149-164. Kodra Yllka, Manuel Posada de la Paz, Alessio Coi, Michele Santoro, Fabrizio Bianchi, Faisal Ahmed, Yaffa R. Rubinstein, Jérôme Weinbach, Domenica Taruscio., 2. Manuscript submitted : Recommendations for Improving Quality of Rare Disease Registries. Yllka Kodra, Manuel Posada-de-la-Paz, Virginie Bros-Facer, Lydie Lemonnier, Marieke Van Meel, Daniel Renault, Rainald von Gizycki, Veronica Popa , David van Enckevort, Marco Roos, Ronald Cornet, S. Faisal Ahmed, Alessio Coi, Michele Santoro, Jérôme Weinbach, Paul Landais, Deborah Mascalzoni, Sabina Gainotti, Estrella Lopez, Paola Torreri, Claudio Carta, Fabrizio Bianchi, Heimo Müller, Robert Reis, Yaffa R. Rubinstein, Anna Ambrosini and Domenica Taruscio 3. RSPH3 mutations cause primary ciliary dyskinesia with a near absence of radial spokes and central complex defects. Am J Hum Genet. 2015 Jul 2;97(1):153-62 (*corresponding author), Jeanson L, Bruno Copin B, Papon JF, Dastot-Le Moal F, Duquesnoy P, Montantin G, Cadranel J, Corvol H, Coste A, Désir J, Souayah A, Kott E, Collot N, Tissier S, Louis B, Tamalet A, de Blic J, Clement A, Escudier E, Amselem S*, Legendre M. 4. Kott E, Legendre M, Copin B, Papon JF, Dastot-Le Moal F, Montantin G, Duquesnoy P, Piterboth W, Amram D, Bassinet L, Beucher J, Beydon N, Deneuville E, Houdouin V, Journel H, Just J, Nathan N, Tamalet A, Collot N, Jeanson L, Le Gouez M, Vallette B, Vojtek AM, Epaud R, Coste A, Clement A, Housset B, Louis B, Escudier E, Amselem S. Loss-of-function mutations in RSPH1 cause primary ciliary dyskinesia with central-complex and radial-spoke defects. Am J Hum Genet. 2013 Sep 5;93(3):561-70 4. How should we approach classification of autoinflammatory diseases? Nat Rev Rheumatol. 2013 Oct;9(10):624-9.Grateau G, Hentgen V, Stojanovic KS, Jéru I, Amselem S, 5. Loss-of-function mutations in LRRC6, a gene essential for propoer axonemal assembly of inner and outer dynein arms, cause primary ciliary dyskinesia. Am. J. Hum. Genet., 2012, 91(5):958-64. Steichen OKott E, Duquesnoy P., Copin B, Dastot-Le Moal F, Montantin G, Jeanson L, Tamamlet A, Papon JF, Rives N, Mitchell V, de Blic J, Coste A, Clement A, Escalier D, Touré A, Escudier E, Amselem S. 5. CCDC39 is required for assembly of inner dynein arms and the dynein regulatory complex and for normal ciliary motility in humans and dogs. Nat. Genet., 2011, 43(1):72-79. (*co-first authors and co- supervisors) Merveille A.C.*, Davis E.E.*, Becker-Heck A.*, Legendre M.*, Amirav I., Bataille G., Belmont J., Beydon N., Billen F., Clément A., Clercx C., Coste A., Crosbie R., de Blic J., Deleuze S., Duquesnoy P., Escalier D., Escudier E., Fliegauf M., Horvath J., Hill K., Jorissen M., Just J., Kispert A., Lathrop M., Tomas Loges N., Marthin J.K., Momozawa Y., Montantin G., Nielsen K.G., Olbrich H., Papon J.F., Rayet I., Roger G., Schmidts M., Tenreiro H., Towbin J.A., Zelenika D., Zentgraf H., Georges M., Lequarré A.S.*, Katsanis N.*, Omran H.*, Amselem S.* 6. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1614-9. Jéru I, Duquesnoy P, Fernandes-Alnemri T, Cochet E, Yu JW, Lackmy-Port-Lis M, Grimprel E, Landman-Parker J, Hentgen V, Marlin S, McElreavey K, Sarkisian T, Grateau G, Alnemri ES, Amselem S. List of relevant previous projects or activities, connected to the subject of this proposal MINDDS – a pan- European network for Neurodevelopmental Disorder research - supported as a European COST Action. COST (European Cooperation in Science and Technology) – 26 countries participating. RaDiCo represents France in this project. 11 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 01-INSERM (d) INSERM-AMU Full legal name (Acronym) – Country Institut National de la Santé et de la Recherche Médicale (INSERM), France Principal investigator Christophe Béroud Relevant Network RD-Connect, IRDiRC, ELIXIR Description of the legal entity/department/laboratory/group: The “Marseille Medical Genetics” (MMG, JRU 1251) is a JRU between INSERM and AMU, headed by Pr. Levy. The main areas of research investigated by MMG teams are the genetic and cellular mechanisms involved in rare genetic disorders, and exploration of the phenotypic consequences of these mutations. Our research Center is part of the Timone campus that comprises fundamental research laboratories at the School of Medicine and the Children's Hospital in Marseille – la Timone. Research activities led by the different teams are closely connected to clinical research conducted in the Department of Medical Genetics. MMG occupies 2150 m2 of research space that was designed specifically for its mission. MMG gathers in a fully equipped space over 150 people shared out among 8 research teams. Main tasks in the project per Pillar/WP: Pillar 2: WP11: Inserm-AMU will contribute to the WP: Common virtual platform for discoverable data and resources for RD research (in particular subtasks 11.3 and 11.4). The "Genetics and Bioinformatics" Team (led by Prof. Christophe Béroud) has a strong expertise in the Rare Disease management of data and resources, and is a key partner of the RD-Connect platform that will be central for the EJP platform. WP12: Inserm-AMU will contribute to the WP: Enabling sustainable FAIRness and Federation at the record level for RD data, patients and samples (in particular subtasks 12.2 and 12.3). Inserm-AMU has a strong expertise in software and tool developments for the analysis of genomics and other types of -omics data, and various groups may contribute to this WP. The team led by Prof. C. Béroud has an international recognized expertize in the development of NGS pipelines and tools, expertize in RNA-seq and Chip-seq analyses, NGS data management and analysis, in Locus Specific Databases (GEN2PHEN, TREAT-NMD, NMD-CHIP). Overall, Inserm-AMU will participate to the demonstration that the application of the FAIR principles to various existing resources developed and hosted at AMU, as the TREAT-NMD global registries, is feasible in practice. WP13: Inserm-AMU will contribute to the WP: Enabling multidisciplinary, holistic approaches for rare disease diagnostics and therapeutics. The MMG Network and Systems Biology group (NSBD, led by Dr. Anaïs Baudot) has a strong expertize in modeling, mining and integration of multi-omics data in the disease contexts. The group collaborates closely with the MABIOS team (led by Dr. Elisabeth Remy), from the Marseille Mathematic Institute, composed of mathematicians and computer scientists, to develop algorithms to study biological networks. Pillar 3: AMU, the largest worldwide French speaking University, has all requirements to become a partner in training workpackages. WP 14: Training on data management & quality. Inserm-AMU will contribute to the "Training on-omics" thanks to C. Béroud team, which has long experience in international training sessions (3Gb-test, VEP, ELIXIR, RD- Connect, TREAT-NMD, HGVS). Inserm-AMU will also contribute to the training on undiagnosed once again thanks to "Genetics and Bioinformatics" Team's long experience on this topic. They regularly give international conferences on mutations and their effects on splicing signals. They are also leading the ELIXIR Human-CNV community that is also highly relevant for this task. Moreover, the A Baudot's group, expert in systems biology, is specifically dealing with undiagnosed and multi-omics data analysis. WP16: Online Academic education course. The MMG unit hosts various key teachers involved in general trainings on rare diseases, bioinformatics, databases and registries (DIU "rare diseases", Master 2 "Human pathologies"). Thanks to this recognized expertise, the MMG will be responsible for the "Bioinformatics" part of the "Developing the online course". Previous experience relevant to the Tasks: C. Béroud's team is leading the European RD-Connect WP dedicated to "Clinical Bioinformatics"; international "TREAT-NMD global registries"; national databases BANCCO and RDVD dedicated to the collection of NGS mutations; and various national and international patients' registries and mutations databases. In the context of NGS data analysis, the team developed multiple reference systems including (UMD-Predictor, Human Splicing Finder 12 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases and VarAFT); Internationally recognized Locus Specific Database (LSDB) for various genes. The team has been involved in multiple international projects such as TREAT-NMD, GEN2PHEN, NMD-CHIP, RD-Connect. Complementarily, the NSBD group develops tools and approaches with strong theoretical bases and apply them to biological questions related to human diseases. It will bring its expertise in networks and systems biology that will address complementary aspects of the project. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : C. Beroud team: Leading Elixir human CNV Community, Elixir French node/IFB (French bioinformatics institute) platform, Share memory supercomputer (SGI UV 2000, 256 cores, 1Tb RAM), its HPC cluster node (3 x 64Gb RAM, 16 cores nodes) as well as its storage capacity ( 1Pb). Short Profile of key Staff Members who will be undertaking the work Prof. C. Béroud has over 20 years of experience in research laboratories. He is a Pharmacist, geneticist, Christophe bioinformatician, and professor of Human Genetics at the AMU. He leads the Genetics and Béroud, Bioinformatics" research team at INSERM U1251, which is labeled "Platform of the French (Male) Bioinformatics Institute" and a French node of ELIXIR. His team has become an internationally recognized center for the creation and management of genetic databases and analysis systems. C. Béroud is a member of the scientific committee of the "Human Genome Variation Society" and an expert in the evaluation of research proposals for the French Ministry of Research and various international organizations. Dr. Anaïs A. Baudot is a bioinformatician with more than 14 years of expertize in network biology, both in Baudot biology, cancer and mathematics research centers. She is leading the NSBD group dedicated to (Female) the development of systems and network approaches to better understand human diseases, and rare monogenic diseases in particular. She leads and participates to various national projects. Dr David D. Salgado is a computer scientist with 12 years experience in research laboratories. Since 2012 Salgado, he is a Research Engineer in C. Béroud's research team, and is responsible of the MMG (Male) Bioinformatics platform. He has contributed to the development of multiple bioinformatics systems including pathogenicity prediction system, rare disease patient registries and therapeutic tools, all dedicated to translational research in human rare diseases. Dr Elisabeth After initial training and a PhD in applied mathematics, E. Remy joined the CNRS in 2002. She Remy, has several years of experience in modeling and analysis of logical regulatory networks. She is (Female) now heading the MABIOS group (Mathematics and Algorithms for Systems Biology) in the Marseilles Institute of Mathematics (I2M), working in close collaboration with the NSBD group. She participated in several national/international projects and managed young researcher ANR grant. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements  F.-O. Desmet, D. Hamroun, M. Lalande, G. Collod-Beroud, M. Claustres, and C. Béroud, “Human Splicing Finder: an online bioinformatics tool to predict splicing signals.,” Nucleic Acids Res., vol. 37, no. 9, p. e67, May 2009. (Highly Cited paper: 902 citations Web of Science)  D. Salgado, J.-P. Desvignes, G. Raï, A. Blanchard, M. Miltgen, A. Pinard, N. Lévy, G. Collod-Beroud, and C. Béroud, “UMD-Predictor: a High Throughput Sequencing Compliant System for Pathogenicity Prediction of any Human cDNA Substitution.,” Hum. Mutat., vol. 37, no. 5, pp. 439–446, Feb. 2016.  Didier G, Brun C and Baudot A. Identifying communities from multiplex biological networks. PeerJ 2015. 2015.  Bladen CL, Salgado D,et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat. 2015 Apr;36(4):395-402. doi: 10.1002/humu.22758.  C. Béroud, G. Collod-Beroud, C. Boileau, T. Soussi, and C. Junien, “UMD (Universal mutation database): a generic software to build and analyze locus-specific databases.,” Hum. Mutat., vol. 15, no. 1, pp. 86–94, 2000. List of relevant previous projects or activities, connected to the subject of this proposal EU FP7 (01.02.2008 – 31.01.2013), GEN2PHEN (partner) EU-FP7 (01.12.2009 – 30.11.2012), BIO-NMD (WP leader) EU-FP7 (01.11.2012 – 30.10.2018), RD-CONNECT (WP leader) 13 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 02-FWF Full legal name (Acronym) – Country Fonds zur Förderung der wissenschaftlichen Forschung (FWF), Austria Principal investigator Stephanie Resch Relevant Network Description of the legal entity/department/laboratory/group: The Austrian Science Fund (FWF) is Austria's main funding organisation for basic research. The FWF supports the ongoing development of top-notch Austrian science and basic research based on international standards. In this way, the organisation makes a significant contribution to cultural development, to the advancement of our knowledge-based society, and thus to the creation of added value and prosperity in Austria. One of the FWF's key objectives is to strengthen Austria's international performance and capabilities in science and research as well as the country's attractiveness as a location for high-level research. This is achieved primarily by funding top-quality projects for individuals and teams, and by enhancing the competitiveness of Austria's innovation system and research facilities. Guided by the principle of research-driven education, the FWF also works to develop Austria's human resources for science and research in both qualitative and quantitative terms. In addition, the organisation strives to emphasize and enhance the interaction of science and research with all other areas of society, culture and the economy, and in particular to increase the acceptance of science and research through concerted public relations activities. The FWF's annual funding budget came to EUR 197.8 million in 2016. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will join the transnational calls for collaborative research projects (task 6.1, 6.2, 6.3, 6.4) In WP9, we will contribute to the monitoring activities (task 9.1) Previous experience relevant to the Tasks: One of the key objectives guiding the FWF’s activities at the international level is to enhance Austria’s international visibility as a research location. The FWF’s international programmes include a variety of funding instruments which are essentially designed to support bilateral and multilateral research projects as well as international networking. Since 2003, the FWF has participated in more than 130 bilateral and multilateral international calls, including some 60 ERA-Net calls. The FWF’s funding volume for international programmes amounted to EUR 22.1 million in 2016. The FWF will use its prior experience to make an active contribution to the activities related to the joint calls. The FWF’s Department of Biology and Medical Sciences has participated actively in the following ERA-Nets: E-Rare- 1; E-Rare-2; E-RARE-3; TRANSCAN; TRANSCAN-2; EUROPOLAR; ERA-CAPS; Pathogenomics; Infect-ERA; NEURON I, II and III; BIODIVERSA 1, 2 and 3; ERASynBio; New Indigo; ERA-CVD; ERACoSysMed and ERA PerMed. As a partner in EJP RD, the FWF will be represented on the Network Steering Committee. The FWF will also participate in the COFUND calls as well as other joint calls in the coming years. The personnel involved have vast experience in running joint calls for projects, and in monitoring and strategic activities. Short Profile of key Staff Members who will be undertaking the work Dr. Stephanie Diploma and PhD in microbiology and genetics. Co-founder and R&D manager of a biotech Resch(female) company focusing on vaccine development (Germany and USA). Head of the Department of Biology and Medicine at the FWF since 2005. Participant in various ERA-Nets (e.g. E-RARE, TRANSCAN, ERA-PerMed). List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Funding of 17 Austrian sub-projects with a total budget of 3.6M€ within the framework of E-RARE (sum of all three running periods). List of relevant previous projects or activities, connected to the subject of this proposal :  E-RARE-1; Funder; 2009-2010: promoting transnational funding activities by active participation in the JTC 2009 as well as participation in strategic research funding policy  E-RARE-2; Funder; 2010-2014: promoting transnational funding activities by active participation in the JTC 2011, JTC 2012, JTC 2013, JTC 2014 as well as participation in strategic research funding policy  E-RARE-3; Funder; 2015-2019: promoting transnational funding activities by active participation in the JTC 14 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 2015, JTC 2016, JTC 2018 as well as participation in strategic research funding policy  03-AIT Full legal name (Acronym) – Country AIT Austrian Institute of Technology GmbH (AIT), Austria Principal investigator Günter Schreier Relevant Network Description of the legal entity/department/laboratory/group: AIT Austrian Institute of Technology is Austria’s largest non-university research institute with more than 1.300 employees, structured in 8 centres. AIT’s vision is to bridge the gap between basic research and applied science. Its Digital Health Information Systems (HIS) research team is part of the Center for Health & Bioresources and has comprehensive experience, infrastructure, tools and skills for the design, development and operation of ICT solutions for healthcare and biomedical research – from rapid prototyping through feasibility studies to proof-of- concept and clinical evaluation trials. The interdisciplinary HIS team consists of about 45 scientists and engineers and has been a key partner in numerous EC funded projects and a variety of funding schemes (SIOPEN-R-NET, CARE-MAN, RegIonCo, iStoppFalls, FoSIBLE, ENVIROFI, ENCCA, ExPO-r-Net, CARE, SymbIoTe, …). AIT is currently running various ICT infrastructures for clinical trials and research networks, e.g. in the fields of paediatric oncology, as well as eHealth infrastructures and healthcare IT systems that provide direct links to patients in telehealth settings and to collect so called patient reported outcomes (ePRO). Several large-scale telehealth systems have been developed and operated by AIT, adding up to more than 1.000.000 patient monitoring days so far. More recently, the team has been instrumental in a number of Big Healthcare Data predictive analytics activities, e.g. to predict hospital re-admission, delirium or the need for blood transfusions. The HIS team is supported by AIT’s administrative, financial, legal and marketing units, which provide the ideal project management environment for carrying out also large collaborative research projects. AIT operates the EUropean Patient IDentity management (EUPID) service and will provide this as a basis and key element for pseudonymisation and privacy preserving record linkage in the present project (see also https://eupid.eu). Main tasks in the project per Pillar/WP: Pillar 2: In WP11, we will be leading subtask 11.3.3, with a focus on providing EUPID based registration/pseudonymisation services for the network of EJP partners. In WP12, we will be leading the task 12.2 “Multi-team software development to enable the FAIR ecosystem” and contribute to improving existing software solutions, previously developed in the RD community. Pillar 3: In WP14, we will be contributing to the “Training on the European Rare Diseases Registry Infrastructure (ERDRI)”, in particular regarding patient registration and pseudonymisation with EUPID (task 14.6). Previous experience relevant to the Tasks: In preceding projects, AIT has been leading IT tasks similar to the ones required in the present project in general, both in funding and industrial settings. In particular, the AIT team has already managed EUPID pilot integration projects with partners from the rare disease and paediatric oncology community. AIT has been an IT partner to those communities for many years, and in charge of different kinds of tasks relevant to the present project, including development of IT solution architectures, managing interdisciplinary and cross-institutional system development efforts and providing demonstrations and trainings to end users in face 2 face and virtual sessions. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : AIT operates the EUropean Patient IDentity management (EUPID) services which, in its version 1.0, implements the basic UPID concept descripted below in [4] and mainly consists of a database containing the necessary metadata and functionalities, a RESTful web service (EUPID App Service) providing the EUPID Pseudonymisation Service to clients and the utilisation of an Identity Provider Service allowing to manage users, their authentication and authorisation to use EUPID Services (see https://eupid.eu for up-to-date information). Short Profile of key Staff Members who will be undertaking the work Guenter Günter’s Role in the project will be to manage AIT’s activities in the project. He will provide his Schreier expertise in related ICT / Biomedical Informatics fields, ranging from dataset standardisation, (Male) standards-based interoperability, identity management and data linkage, to security and privacy aspects as well as mHealth and Big Healthcare Data. Günter serves as an advisor to the Austrian Ministry of Health and as a member of the IT advisory board for EC’s European Reference 15 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Networks. He is the founder and president of the annual scientific conference on “Medical Informatics and eHealth” in Vienna (www.eHealth20xx.at). Michael Michael will contribute to the IT system architecture and will be leading AIT’s implementation Nitzlnader, activities. He will coordinate related software developments and operational activities, i.e. (Male) adapting, extending, setting-up and operating the core components of the EUropean Patient Identity management (EUPID) system. He will also be involved in linking the existing sources systems and responsible for the overall security and privacy concept. Michael holds a number of IT certificates highly relevant to the present project and related to IT security, requirements engineering and data protection. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1: Hayn D, Falgenhauer M, Kropf M, Nitzlnader M, Welte S, Ebner H, Ladenstein R, Schleiermacher G, Hero B, Schreier G. IT Infrastructure for Merging Data from Different Clinical Trials and Across Independent Research Networks. Stud Health Technol Inform. 2016;228:287-91. PubMed PMID: 27577389. 2: Hochedlinger N, Nitzlnader M, Falgenhauer M, Welte S, Hayn D, Koumakis L, Potamias G, Tsiknakis M, Saraceno D, Rinaldi E, Ladenstein R, Schreier G. Standardized data sharing in a paediatric oncology research network—a proof-of-concept study. Stud Health Technol Inform. 2015;212:27-34. PubMed PMID: 26063254. 3: Nitzlnader M, Falgenhauer M, Gossy C, Schreier G. Architecture for an advanced biomedical collaboration domain for the European paediatric cancer research community (ABCD-4-E). Stud Health Technol Inform. 2015;212:167-74. PubMed PMID: 26063273. 4: Nitzlnader M, Schreier G. Patient identity management for secondary use of biomedical research data in a distributed computing environment. Stud Health Technol Inform. 2014;198:211-8. PubMed PMID: 24825705. 5: Schreier G, Messmer J, Rauchegger G, Modre-Osprian R, Ladenstein R. A Web-based platform for interdisciplinary biomedical research. Front Biosci (Landmark Ed). 2009 Jan 1;14:2738-46. PubMed PMID: 19273232. List of relevant previous projects or activities, connected to the subject of this proposal (max 5): 1. ENCCA (www.encca.eu) – European Network for Cancer Research in Children and Adolescents – FP7 (2011 – 2015) Network of excellence project to establish a Virtual Institute for cancer research in Europe. AIT served as the IT work package leader and guided the development of the information portal of the Virtual Institute. Some elements developed in ENCCA were the starting point for developments of important ICT infrastructure for data sharing, in particular EUPID. 2. ExPO-r-Net (www.expornet.eu) - European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment - ExPO-r-Net (EC, Health Programme, 2014 – 2017) was the pilot project for the European Reference Network (ERN) for Paediatric Oncology, now established as Paediatric Cancer ERN (PaedCan). AIT was responsibility for the overall IT architecture and the interoperability strategyy and lead the development of a Virtual Tumour Board application. 3. RegIonCo (http://www.regionco.eu) – ERDF project (2008-2012) to foster collaboration between Austria and Hungary regarding the new Ion Therapy facility MedAustron which is currently being established in Austria. AIT’s role has been to design and build a prototype of an interoperable IT infrastructure for cross-border transfer of medical images in order to facilitate continuity of care in accordance with European and international interoperability concepts. 4. SIOPEN-R-NET (www.siopen-r-net.org) –SIOP Europe Neuroblastoma Research Network – FP5 (2002-2006) Thematic Network project to link European Neuroblastoma research – AIT was the IT partner and responsible for design, development and operation of this tailored ICT platform to support research activities on the basic science as well as the clinical level. The resulting SIOPEN-R-NET system is still up and running until today with almost 5000 patients being registered in the system in the course of five different clinical trials. 04-LBG Full legal name (Acronym) – Country Ludwig Boltzmann Gesellschaft (LBG) GmbH, Austria Principal investigators Kaan Boztug, Christoph Bock Relevant Network Orphanet, UDNI (Undiagnosed Diseases Network International), International Human Epigenome Consortium, Human Cell Atlas Description of the legal entity/department/laboratory/group: The Ludwig Boltzmann Society is a research institution, with a strong focus on medicine, hosting 18 research 16 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases institutes of various disciplines in Austria. The Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (LBI-RUD) is Austria’s first and leading research institute dedicated to a broad spectrum of rare and undiagnosed diseases research. LBI-RUD consist of 4 groups focusing on the identification and characterization of inborn errors of the immune and nervous system, the development and improvement of bioinformatics tools for next generation sequencing and safe data exchange, and the ethical and societal implications of rare diseases and rare diseases research. Main tasks in the project per Pillar/WP: Pillar 2: we will make some contributions (limited by budget allocation) to the following specific tasks: - Collaborative integrated analysis of multi-omics data from selected use cases - Provide capabilities for custom analyses through cloud-based solutions - User-driven implementation of new analysis functionalities and tools Pillar 3: we will contribute to training (limited by budget allocation) for clinicians and scientists about the Orphanet database, the Orphanet nomenclature, genetic data prioritization using bioinformatics tools developed in LBI-RUD. We will participate in training activities sharing our expertise in functional dissection of molecular patomechanisms of rare disease patients using a through specific case-studies. Previous experience relevant to the Tasks: LBI-RUD is well-connected in Austria and several Eastern European countries and together with its clinical partners established well-studied patient cohorts of rare and ultra-rare diseases. LBI-RUD has built an effective bioinformatics infrastructure for processing, interpreting, and securely sharing genome/exome/panel sequencing data (e.g. Müller et al. 2017 Nucleic Acids Res). LBI-RUD scientists have a strong track record in the functional dissection of rare disease mechanisms especially in the area of hematopoietic, immune, and neurological disorders (e.g. Dobbs et al. NEJM 2015, Salzer et al. Nat Immunol 2016; Ozen et al. NEJM 2017). LBI-RUD developed and applied advanced multi-omics technology including epigenome mapping (e.g. Farlik et al. Cell Stem Cell 2016, Sheffield et al. Nat Med 2017), proteomics, metabolomics, and single-cell sequencing (e.g. Bock et al. Trends Biotechnol 2016, Mass et al. Science 2016). Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Computational infrastructure. LBI-RUD and CeMM maintain a powerful scientific computing cluster that is upgraded annually to keep pace with steeply increasing data generation (current status: >100 CPUs, >1,000 cores, >10 TB memory, >1,000 TB storage). For even more computation-intensive tasks, CeMM researchers have institutional access to the Vienna Scientific Cluster, a global TOP500 supercomputer operated by a consortium of universities and research institutes in Vienna. Biomedical Sequencing Facility (BSF). The BSF is a large technology platform dedicated to next generation sequencing in biomedicine. It is jointly operated by CeMM and the Medical University of Vienna under the scientific leadership of Christoph Bock. It is equipped with the following machines: (i) three large-scale sequencing machines (1x NovaSeq 6000, 1x HiSeq 4000, 1x HiSeq 3000) for production sequencing; (ii) two medium-scale sequencing machines (1x NextSeq, 1x MiSeq) for technology development; (iii) a PerkinElmer Sciclone NGS (pre- PCR) and Zephyr (post-PCR) supporting 96-well automated library preparation for RNA-seq (PolyA+, RiboZero, and 3’mRNA fingerprinting), RRBS, and ChIP-seq; (iv) a 10x Genomics Single Cell Controller, a Silicon Biosystems DEPArray and a Fluidigm C1 for single-cell sequencing. Short Profile of key Staff Members who will be undertaking the work Dr. Kaan Boztug Kaan Boztug studied Medicine in Düsseldorf, Freiburg and London, followed by his graduate (male) training with Iain Campbell at the Scripps Research Institute (La Jolla, USA), and clinical training and postgraduate research with Christoph Klein at Hannover Medical School (Germany). He joined CeMM in 2011 and holds a dual appointment as Associate Professor at the Department of Paediatrics and Adolescent Medicine at the Medical University of Vienna. Since 2016, Kaan Boztug is director of the LBI-RUD and the CeRUD Vienna Center for Rare and Undiagnosed Diseases and joint director of the Jeffrey Modell Foundation Center for Immunodeficiencies at the Medical University of Vienna and St. Anna Children’s Hospital. Dr. Christoph Christoph Bock is a principal investigator at LBI-RUD and the CeMM Research Center for Bock / male Molecular Medicine of the Austrian Academy of Sciences. His research focuses on disease genomics/epigenomics and on high-throughput technologies for precision medicine. He is also a guest professor at the Medical University of Vienna, scientific coordinator of the Biomedical Sequencing Facility at CeMM, and adjunct group leader for bioinformatics at the Max Planck Institute for Informatics. He has received several research awards, including the Max Planck Society’s Otto Hahn Medal (2009), an ERC Starting Grant (2016-2021), and the 17 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Overton Prize of the International Society of Computational Biology (2017). Dr. David David Medgyesi studied molecular biology and received his PhD in immunology at the Medgyesi / male Eötvös Loránd University Budapest, Hungary. He was a postdoctoral fellow and project leader at Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany. He joined LBI-RUD as a senior research associate in 2017. Dr. Matthias Matthias Haimel studied bioinformatic engineering at Upper Austria University of Applied Haimel / male Sciences at Hagenberg and completed his PhD studies in 2017 at the Department of Medicine, University of Cambridge, UK. He joined LBI-RUD as a bioinformatician in 2018. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Ozen A et al. CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis. (2017) N Eng J Med, 377(1): 52-61. 2. Sheffield NC et al. DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. (2017) Nat Med, 23(3):386-395. 3. Müller H et al. VCF.Filter: Interactive prioritization of disease-linked genetic variants from sequencing data. (2017) Nucleic Acids Res, 45, W567–W572. 4. Salzer E et al. RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics. (2016), Nat Immunol, 17 (12), 1352-60. 5. Dobbs K et al. Inherited DOCK2 deficiency in patients with early-onset invasive infections. (2015) N Eng J Med, 372(25): 2409-22. List of relevant previous projects or activities, connected to the subject of this proposal:  Precise PID; Vienna Science and Technology Fund (WWTF); 2017-2020, leader; using PIDs as model diseases to rationalize patient-specific workflows from gene discovery and pathomechanisms to targeted treatments.  Immuno Core; European Research Council (ERC); 2013-2018, leader; using systems genomics tools to uncover primary deficiencies with a focus on phagocyte deficiencies such as congenital neutropenia syndromes.  Epigenome Programming; European Research Council (ERC); 2013-2018, leader; development methods for targeted (and potentially therapeutic) editing of epigenetic alterations 05-FNRS Full legal name (Acronym) – Country Fond de la Recherche Scientifique-FNRS (F.R.S.-FNRS) – Belgium Principal investigator Florence Quist Relevant Network E-RARE, NEURON, JPIAMR, Description of the legal entity/department/laboratory/group: The Fund for Scientific Research - FNRS (F.R.S.-FNRS) is a research funding agency that promotes and supports basic scientific research in the French-speaking Community of Belgium. Founded in 1928, it mainly receives public subsidies, currently from the French-speaking Community of Belgium, the Walloon Region and the Federal Government of Belgium. The Fund supports individual researchers on the basis of the criterion of excellence by offering temporary or permanent positions; funding to research teams; grants and credits for international collaboration and scientific prizes. F.R.S.-FNRS fosters research in all scientific fields, following a bottom-up approach of investigator-driven research. Further, the Fund supports researchers in an ever growing context of internationalisation through facilitating their mobility, allowing for collaborative transnational projects and supporting a high level international working environment. Since October 2008, Dr. Ir. Véronique Halloin is the Secretary-General of F.R.S.-FNRS. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will participate in the Joint Transnational Calls for collaborative research projects (tasks 6.1, 6.2, 6.3 and 6.4) In WP9, we will participate in the Monitoring of funded projects (tasks 9.1, 9.2 and 9.3) Previous experience relevant to the Tasks: The Fund for Scientific Research - FNRS runs a programme supporting mainly basic research through project- based funding for the French speaking community of Belgium. Research projects are funded through a bottom-up principle following an open competition in a yearly call for research proposals and grants. The F.R.S.-FNRS is currently involved in various European initiatives and bilateral agreements at the 18 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases international level. The Fund is and has been full partner in several FP7 ERA-Nets (CHIST-ERA, ERA-CAPS, FLAG-ERA, GENDER-NET, PASTEUROA, HERA, E-RARE 2) and has participated in numerous ERANET calls (JPND, Neuron, JPI-AMR, ERANET-LAC, Inno Indigo, SEA-EU NET, among others). The F.R.S.-FNRS participated in the E-RARE Joint Transnational Calls in 2011, 2013, 2015 and 2017. Moreover, the F.R.S.-FNRS is also part of practically all the ERANET COFUND initiatives that permit to perform basic science in H2020 (EURONANOMED III, ERA-CVD, M-ERANET 2, NEURON, TRANSCAN, among others) not in the least those that support the Joint Programming Initiatives such as WaterWorks 2014; WaterWorks 2015; WaterWorks 2017; JPCofund; Urban Europe (Smart Cities and Urban Futures); and FACCE Surplus and SusCrop. The F.R.S.-FNRS has been involved in the monitoring of funded projects for E-RARE 2 and is in charge of the whole monitoring work package for E-RARE 3. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Due to its responsibilities in E-RARE 2 and E-RARE 3, the F.R.S.-FNRS has developed an online monitoring tool, which will be adapted to perform the monitoring of the EJP-RD projects. Short Profile of key Staff Members who will be undertaking the work Dr. Florence Dr. Florence Quist, PhD in Chemistry, is a scientific officer at the Unit of International and Quist / Female European Affairs in charge of European cooperation, evaluation and monitoring processes. She has extensive experience in material science through several post-docs and as head of R&D Development in an SME specialized in recycling photovoltaic material. In this capacity, she was also responsible for several projects financed by the Walloon region and the European Commission. Florence complements these experiences with a solid background in management through a complementary Certificate at Solvay Business School. Florence participates in many different ERANETs, including E-RARE III, in which the F.R.S.-FNRS is responsible for project monitoring activities. Mr. Joël Joël Groeneveld, M.A. in Political Science, is a policy officer at the Unit of International and Groeneveld / European Affairs in charge of international cooperation and bilateral agreements. He acquired a Male thorough understanding of project management, monitoring and reporting while working as Finance and Program Officer for the Institute for Historical Justice and Reconciliation. Prior to this experience, he successfully pursued a degree in journalism in The Netherlands and performed extensive editing work as media analyst for Report International in Paris for several years while studying history. Joël has a wide ranged experience in participating in ERANETs, in particular the geographically based FP7 ERANETS, and GENDERNET PLUS and E-RARE III, where FNRS is responsible for monitoring activities. Dr. Arnaud Dr. Arnaud Goolaerts, PhD in Respiratory physiology/Biophysics and MSc in Geochemistry, is a Goolaerts / scientific officer at the Unit of International and European Affairs in charge of European Male cooperation and evaluation and monitoring processes. Prior to coming to the F.R.S.-FNRS, he was a doctoral fellow at the University of California San Francisco and a Marie Curie Fellow at the European Respiratory Society in Paris. Arnaud co- leads the monitoring of projects in E-RARE III and is involved in all biomedical ERANETs. His background in Geochemistry also allows him to work in more climate related topics. He also leads 2 Scientific Commissions in Life Sciences and Natural Sciences in the programmes executed by the F.R.S.-FNRS. List of relevant previous projects or activities, connected to the subject of this proposal  E-RARE III; ERANET; 2014-2019 – WP Leader for Monitoring of funded projects  E-RARE II; ERANET; 2010-2014 – Task Leader for Monitoring of funded projects  Gendernetplus; 2017-2021 – Participant in Monitoring of funded projects 06-FWO Full legal name (Acronym) – Country Fonds Wetenschappelijk Onderzoek - Vlaanderen (FWO) – Belgium (Flanders) Principal investigator Dr. Alain Deleener Relevant Network N/A Description of the legal entity/department/laboratory/group: 19 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases The Research Foundation - Flanders (FWO) is the agency that supports ground-breaking fundamental and strategic research at the universities and research centres of the Flemish Community. The FWO also stimulates cooperation between the Flemish universities and other research institutes. Main tasks in the project per Pillar/WP: The FWO will limit its active participation to Pillar 1, as project funding – similar to the ERA-NET scheme - is the main goal of our participation. The FWO will not take up specific tasks within the consortium. Previous experience relevant to the Tasks: The FWO participated in several ERA-NETs up to now, on a so-called ‘remote’ basis. This implies that we don’t take up any ‘Work Packages’. Our participation is mostly limited to the actual funding of our national/regional research community, besides the administrative basic modalities for participation, e.g.: verifying call docs, eligibility check, acting as national contact point, providing input for deliverables, etc. Additionally, the FWO has the required experience with project funding due to its management of application rounds for projects, fellowships and mobility grants on a yearly basis, and as already mentioned, also the participation in past joint ERA-calls. Short Profile of key Staff Members who will be undertaking the work Dr. Alain Science Policy Advisor Strategic Research Programmes at FWO and responsible - among other Deleener/ things - for the European SBO-projects (Strategic Basic Research) policy and cooperation within male FWO. Dr. Olivier Coordinator Strategy and Policy Cell at FWO and responsible - among other things - for European Boehme/ male joint programming and cooperation within FWO. Toon Advisor Research Affairs at FWO and responsible for the general, daily follow-up of joint Monbaliu/ programming, especially ERA-NET and JPI. male 07-KU Leuven Full legal name (Acronym) – Country Katholieke Universiteit Leuven (KU Leuven) – Belgium Principal investigator Gert Matthijs Relevant Network EuroGentest-ESHG, MetabERN, EURO-CDG(2), IRDiRC, Description of the legal entity/department/laboratory/group: KU Leuven boasts a rich tradition of education and research that dates back six centuries. The university’s basic research orientation has always been and will remain fundamental research From a basis of social responsibility and scientific expertise, KU Leuven provides high-quality, comprehensive health care, including specialised tertiary care, in its University Hospitals. In doing so it strives toward optimum accessibility and respect for all patients. KU Leuven is currently by far the largest university in Belgium in terms of research funding and expenditure (EUR 466.55 million in 2016), and is a charter member of LERU. KU Leuven conducts fundamental and applied research in all academic disciplines with a clear international orientation. In the Times Higher Education ranking KU Leuven is ranked as the 14th European university, while in the Reuters Top 100 of the World’s most innovative institutions, KU Leuven is listed as the first European university. Leuven participates in over 540 highly competitive European research projects (FP7, 2007-2013), ranking sixth in the league of HES institutions participating in FP7. In Horizon 2020, KU Leuven currently has been approved more than 260 projects and is ranked sixth HES institution with regard to number of signed grants. To date, the 107 ERC Grantees (including affiliates with VIB and IMEC) in our midst confirm that KU Leuven is a breeding ground (55 Starting Grants) and attractive destination for the world’s best researchers. In our 229 Actions, of which 111 Initial/European Training Networks, hundreds of young researchers have been trained through research and have acquired the necessary skills to transfer their knowledge into the world outside academia. In Horizon 2020, KU Leuven is ranked first institution of higher education with regard to number of MSCA-ITNs ‘(54) and second for all entities. KU Leuven employs 8,084 researchers on its academic staff (2015). To strengthen international collaboration, KU Leuven has its own international research fellowship programme and supports international scholars in international funding applications. KU Leuven Research & Development (LRD) is the technology transfer office (TTO) of the KU Leuven. Since 1972 a multidisciplinary team of experts guides researchers in their interaction with industry and society, and the valorisation of their research results (110 spin offs, …) . The Center for Human Genetics is the largest genetics department in Belgium. The staff includes clinical 20 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases geneticists, genetic counsellors, psychologists, laboratory geneticists, principal investigators in research, post-docs, PhD students, masters, bio-informaticians and technicians (over 200 co-workers in total). The diagnostic activities focus on rare diseases, with specific interests in intellectual disabilities, multiple congenital anomalies, neurological and neuro-muscular diseases, nephropathies,cardiopathies, immune deficiencies, genodermatoses, metabolic diseases and familial cancer syndromes. The laboratories also offer testing for (rare) cancers. The translation research focusses on the introduction of genomics into medicine. Main tasks in the project per Pillar/WP: Pillar 3 WP14 – task 14.2 Standards and quality of genetics/genomics data in laboratory and clinical research practice ; Leader KU Leuven, Contributor University of Tubingen, ACU RARE, ISS, CMHI, CNAG, INSERM-AMU, UMCG; ‘Next generation sequencing’ (NGS) generates overwhelming amounts of data. Clinical and basic researchers are increasingly confronted with the complexity of genomic data. It is of importance to provide training on the interpretation of genetic variants and quality standards. We will therefore organize residential courses for scientists, bio-informaticians and clinicians with an interest in genomic technologies and applications. The aim is to teach participants about the evaluation of the pathogenic nature and clinical significance of genetic variants, on the criteria that have to be set to the NGS analysis pipelines and on the use of international databases. The course will build on expertise gained by EuroGentest and help in the translation of research tools to diagnostic applications (in line with the IRDiRC objectives). The impact is on the quality and reliability of NGS results, obtained through rare disease research. Over the years, the course content will shift to total genome interpretation, which will entail novel molecular mechanisms for disease and further increase the complexity. Training courses typically host 20-30 participants and last 3-days. It is envisaged to provide the course every year. The courses will travel across Europe: Rome, Warsaw, Istanbul, Tübingen and Leuven. Previous experience relevant to the Tasks: KU Leuven and the Center for Human Genetics have been the coordinator of EuroGentest, a project to harmonize the process of genetic testing, from sampling to counselling, across Europe. It was funded as a Network of Excellence (from 2005 to 2010) and as a Coordination action (2011-2013). The ultimate goal was to ensure that all aspects of genetic testing are of high quality thereby providing accurate and reliable results for the benefit of the patients. A major part of the activities concerned training and the generation of guidelines for good practice. Hence, the courses will build on expertise gained by EuroGentest (www.eurogentest.org. In 2014, EuroGentest has been integrated with the European Society for Human Genetics (ESHG). Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : The Center for Human Genetics has a genetic clinic, and different diagnostic and research facilities, including a Next Generation Sequencing facility (the ‘Genomics Core’ or GC) and bio-informatics support. Researchers have easy access to the animal breeding facilities, microscopy services etc. The laboratories are located on the Health Sciences Campus in Leuven. Short Profile of key Staff Members who will be undertaking the work Gert Pharmacist, PhD in Pharmaceutical Sciences , Laboratory Geneticist. Head of laboratory at the Matthijs Laboratory for Molecular Diagnosis, Center for Human Genetics .Professor at the Faculty of (male) Medicine and Faculty of Pharmacy, University of Leuven;Molecular geneticist, involved in the diagnostics of inherited diseases since 1994. The laboratory offers diagnostic for a large range on rare diseases. His (translational) research activities deal with the development and validation of novel technologies for diagnostic use. Currently, the focus is on the implementation of the newest massive parallel sequencing platforms including whole-genome sequencing for mutation scanning and on the interpretation of genetic variants. His (fundamental) research interest is in Congenital Disorders of Glycosylation, a group of rare inborn errors of metabolism. His group has been focusing on the systematic search for novel types of CDG since 1995. The success is partly due to the fact that the group has committed itself, since 1999, to the coordination of EUROGLYCANET, a network that has been funded by the Commission (FP5, FP6). He was the coordinator of EuroGentest, a network for development, harmonization, validation and standardization of genetic testing in Europe, that was funded by the European Commission from 2005 until 2013. He is a member of the Diagnostic Scientific Committee of IRDiRC (International Rare Disease Research Consortium). He was an alternate member of the Commission Expert Group on Rare Diseases (formally EUCERD). He has been a scientific committee member for INSERM, AERES, INCa, FNRS, ANR and other granting agencies. He was active on the steering committee of the Global Genomic Medicine Collaborative (G2MC), created in 2014. 21 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases At the national level, he has been a thriving force for a revision of the reimbursement system for genetic tests for rare diseases. At the University of Leuven, he has co-coordinated a workgroup on legal, ethical and societal aspects of total genome analysis. In 2013 and 2014, he has published 2 books about genetics and genomics for the public. He is involved in MetabERN, the European Reference Network for Hereditary Metabolic Disorders, wherein the Congenital Disorders of Glycosylation are recognized as one of the disease groups. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Community activity towards the improvement of quality in genetic testing: The EuroGentest ‘Guidelines for Diagnostic NGS’ have been prepared by a multidisciplinary group of experts and stakeholders. Guidelines for diagnostic next-generation sequencing, Gert Matthijs et al.,European Journal of Human Genetics (2016) 24, 2–5 and supplement. 2. Coordination of EuroGentest, a European network for quality in genetic testing, described in EuroGentest NoE, the ESHG, and genetic services, Jean-Jacques Cassiman, European Journal of Human Genetics (2017) 25, S47-S49) 3. Evaluation of the use and treats of patents in genetic testing The European BRCA patent oppositions and appeals: coloring inside the lines, Matthijs G et al., Nature Biotechnology, 31(8):704-10, 2013. 4. Books on genetics, genomics and rare diseases for a specialized and general readerships ‘Mes Gènes, Mon Identité’ (ISBN:9782804702144, Ed. Mardaga 2014). This book was translated from the Flemish boek ‘Wat met genetica’ (ISBN 9789401411462, Ed. Lannoo Campus 2013) was written for medical doctors and other professionals working in the medical field, for interested lay people and for policy makers. The content was compiled from the work of a multidisciplinary ‘think thank’ about ‘Total genome analysis’ at the University of Leuven in 2011-2012. The Human Recipe’ (ISBN 9789462700727, Ed. University Press Leuven), translated from ‘Iedereen GENiaal’ (ISBN 978-94-62101-98-2, Ed. Ballon Media 2014 ), a book really directed towards the public and illustrated by 9 cartoonists, known in Flanders by their cartoons in the newspapers. List of relevant previous projects or activities, connected to the subject of this proposal): Acronyme; Funder; starting year-ending year; role in the project; description  EuroGentest; Eur.Comm.-FP6-7; Coordinator; 2005-2013 Community activity towards the improvement of quality in genetic testing , EuroGentest started in 2005 as an network of excellence (NoE) for development, harmonization, validation and standardization of genetic testing in Europe (www.eurogentest.org). From 2011 to 2013, it was funded as a coordination action (CA).  TECHGENE; Eur.Comm.-FP7; Partner; 2009-2011 High throughput molecular diagnostics in individual patients for genetic diseases with heterogeneous clinical presentation.TECHGENE was a European integrated project (IP) for the introduction of next generation sequencing tools in diagnostics.  EURO-CDG, E-RARE, Coordinator, 2012-2014 A European research network for a systematic approach to CDG and related diseases.  3Gb-TEST; Eur.Comm.-FP7; WP Leader; 2013-2015 Introducing diagnostic applications of ‘3Gb-testing’ in human genetics  EURO-CDG-2, E-RARE, Coordinator, 2016-2018 A European research network directed towards improving diagnosis and treatment of inborn errors of glycosylation. 08-MEYS Full legal name (Acronym) – Country Ministry of Education, Youth and Sports (MEYS), Czech Republic Principal investigator PhDr. Pavel Doleček, Acting Deputy Minister for Higher Education, Science and Research Relevant Network 22 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Description of the legal entity/department/laboratory/group: Ministry of Education, Youth and Sports (MEYS) According to the Act No. 130/2002 Coll. on the Support of Research, Experimental Development and Innovation from Public Funds and on the Amendment to Some Related Acts, MEYS is the central administration authority responsible for R&D, particularly institutional funding for higher education sector, research infrastructures policy and funding and international R&D collaboration. Main tasks in the project per Pillar/WP: MEYS as a member of EJP and a Beneficiary will contribute to the Pillar 1 in WP 6 as a funding agency participating in a Joint Transnational Call. Its role and tasks are clearly defined by the description of tasks 6.1. Joint Transnational Call 2019 – Call co-funded by the EC for three years and 6.2. Joint Transnational Call 2020 – Call co-funded by the EC for two years. The MEYS will actively cooperate as a participants on following subtasks analogous for both calls mentioned above:  Topic selection  Preparation of the call and establishment of the joint call secretariat  Evaluation of the joint call and funding decision  Quality management of call procedures Previous experience relevant to the Tasks: MEYS – Department of Research and Development participates in different initiatives supporting international cooperation in R&D including participation in programme Horizon 2020, ERANets and JPIs (e.g. E-Rare, ERA- Net QuantERA, HERA, JPND, JPICH, JPI AMR, JPI HDHL, JPI Facce). Short Profile of key Staff Members who will be undertaking the work Dr Lukáš Director of the Department of Research and Development in the MEYS. Lukáš Levák was Levák (male) appointed Director of Department for Research and Development in 2014. His current duties and responsibilities comprise particularly formulation and implementation of the strategy for cross- border and international cooperation of the Czech Republic in R&D, mainly within the European Research Area, and defying the research infrastructures policy of the Czech Republic. Renata Hrubá Ing. Renata Hrubá works in the Department of Research and Development in the Unit of the (female) European Research Area in the MEYES. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements : In 2015, Lukáš Levák was the main co-author of “Roadmap of the Czech Republic of Large Infrastructures for Research, Experimental Development and Innovation for the years 2016-2022”. In 2016 he was the main coordinator of preparation of the “ERA Roadmap of the Czech Republic for the years 2016-2020”. Since 2014 he is the leading delegate of the Czech Republic to the ERAC (European Research Area and Innovation Committee). His major current tasks consist mainly in further alignment of the Czech research infrastructures policy with the ESFRI (European Strategy Forum on Research Infrastructures) good practice examples and in updating the Czech national large research infrastructures roadmap (to be accomplished in 2018). Regarding the further integration of the Czech research and innovation system into the European Research Area, the major challenges of Department for Research and Development comprise strengthening the participation of the Czech Republic in Joint Programming process. As for the Czech national R&D policy, the Department of Research and Development will focus on preparation of an overarching national strategy of the Czech Republic for development of human resources and gender equality in R&D. List of relevant previous projects or activities, connected to the subject of this proposal : Department of Research and Development supports and funds the Czech research community in different international initiatives, the most relevant to the EJP are ERANets and JPIs (e.g. E-Rare, JPND, JPI AMR,JPI HDHL,). 09-MoSAE Full legal name (Acronym) – Country Ministry of Social Affairs of Estonia (MOSAE), Estonia Principal investigator Heli Paluste Relevant Network Description of the legal entity/department/laboratory/group: 23 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases The Ministry of Social Affairs (MOSAE) is a government agency. The MOSAE area of government includes the preparation and implementation of national strategies in the field of public health and health care, social security and welfare, employment, the labor market, the working environment, the promotion of equal treatment and the promotion of equality between women and men and the coordination of children's rights and families promotion of quality of life, promotion and support of sporting activities of people with disabilities and drafting of relevant legislation. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will provide in cash contribution to Pillar 1 co-funded calls: earmarked funds for co-funded call 1: 25 000 euros for 2019, 25 000 euros for 2020, 25 000 euros for 2021 (task 6.1) Previous experience relevant to the Tasks: The tasks of the Ministry of Social Affairs of Estonia in the area of research and development are: a) the organization of the research and development activities necessary for its area of government and its financing, taking into account the results of the evaluations and the related assessments and recommendations; b) justification and appointment of funds necessary for the financing of R & D activities within its area of government in the preparation of the budget draft of the government area and approval of budgets of these research and development institutions in the amount of the state budget allocated to the amount allocated to research and development within the area of government. Short Profile of key Staff Members who will be undertaking the work Dr/ Heli Head of Health Care Unit, MD Paluste/F Department of Health System Development MOSAE Ms/ Angela Research Adviser for Health Policy, Ivask/F Analysis and Statistics Department MOSAE List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. National Health Plan 2009–2020 2. Estonian health system research and development and innovation strategy 2015-2020 3. Estonian eHealth Strategic Development Plan 2020 4. Estonian Rare Disease Development Plan 5. Estonian Health Care System Roadmap 2020 List of relevant previous projects or activities, connected to the subject of this proposal 2 hospitals from Estonia are the members of ERN-s. Tartu University Hospital is a member of ERN-ENDO and ERN-BOND. East Tallinn Hospital is a member of ERN-EYE. 10-AKA Full legal name (Acronym) – Country Suomen Akatemia (AKA) - Finland Principal investigator Heikki Vilen Relevant Network Description of the legal entity/department/laboratory/group: The Academy of Finland’s mission is to fund high-quality scientific research, provide expertise in science and science policy, and strengthen the position of science and research. We are an agency within the administrative branch of the Finnish Ministry of Education, Science and Culture. We work to contribute to the renewal, diversification and increasing internationalisation of Finnish research. Our activities cover the full spectrum of scientific disciplines. We support and facilitate researcher training and research careers, internationalisation and the utilisation of research 24 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases results. We are also keen to emphasise the importance of research impact and breakthrough research. We therefore encourage researchers to submit boundary-crossing applications that involve risks but also offer promise and potential for scientifically significant breakthroughs. Each year, our funding contributes to some 2 700 people’s work (FTEs) at universities and research institutes. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will take part in the transnational research funding calls (task 6.1) Previous experience relevant to the Tasks: The Academy of Finland has participated in several ERA-NETs and joint calls. For example, in recent years the Academy of Finland has participated in the calls of JPco-fuND, ERA-NEURON, E-RARE and JPI-AMR. Short Profile of key Staff Members who will be undertaking the work Dr. Heikki Vilen Science Adviser in Health Research Unit of the Academy of Finland, highly experienced in (male) organizing peer-reviewed research panels. Currently, he is the AKA representative in the Call Steering Committee of E-RARE3. List of relevant previous projects or activities, connected to the subject of this proposal : The Academy of Finland has participated / is currently participating in the JTC2017 and JTC2018 calls of the rare diseases research Era-NET E-RARE3 11-ANR Full legal name (Acronym) – Country French National Research Agency (ANR) Principal investigator Dominique Dunon-Bluteau Relevant Network E-Rare Description of the legal entity/department/laboratory/group: The French National Research Agency (ANR) was established by the French government in 2005 to fund research projects, based on competitive schemes giving researchers the best opportunities to carry out their projects and paving the way for ground-breaking new knowledge. The main mission of ANR is to fund the best basic research, but also targeted and applied research in particular through partnerships between companies and public sector laboratories. Its action is thus intended to support French research excellence at both academic and technological levels by means of a rigorous selection process based on evaluation by peer review. Finally, it is also the ANR's mission to strengthen international cooperation by contributing in particular to the funding of international consortia in partnership with other funding agencies in Europe and beyond. ANR funds are available in all scientific fields, for both fundamental and industrial research. Since 2010, ANR has also been the principal operator of the Investments for the Future programme in the field of higher education and research. In this role it ensures the selection, funding and monitoring of projects relating to the centres of excellence, health, biotechnologies, and the transfer of technology and the creation of value from research. Since its inception in 2005, the ANR agency awarded approximately 15,600 grants investing 6,5 billion €. In 2016 for example, 1,257 projects were awarded for an amount of 595,5 M€. Developing European and international collaborations is one of the priorities of the ANR. The ANR has participated/is participating in multiple ERA-NETs, CSAs and JPIs. Currently the Health & Biology Department is contributing to 13 ERA-Nets (JPI-EC-AMR, SEA-EU-NET, ERA-HDHL, HDHL INTIMIC, JPI-JPcofuND, NEURON, FLAG-ERA II, ERA-CVD, ERACoSysMed, ERA PerMed, EuroNanoMedIII and E-Rare-3) and coordinates two of them (E-Rare and ERA-HDHL). ANR also participates in 3 JPIs (JPND, JPAMR, JPI HDHL), as well as other type of collaborative initiatives like IC PerMed or CRCNS (computational neurosciences). In the context of rare diseases, the ANR has funded research projects through the generic programme and thematic programmes not focused on rare diseases, but also thanks to a dedicated yearly thematic call (MRARE, in 2005, 2006 and 2007). Between 2005 and 2017 a total of 496 research projects related to rare diseases have been funded with a budget of 177.6 M€. At the transnational level, the ANR participates in E-Rare since 2007 and coordinates the programme since 2014. In this context, 89 E-Rare projects with French researchers were financed (17,74 M€ of ANR budget + 2,24 M€ other resources [EC and DGOS]). In addition, the ANR is a member of the IRDiRC Executive Committee since its inception. Through its involvement in the EJP RD, ANR will continue its strong involvement and support for rare diseases research. Main tasks in the project per Pillar/WP: Pillar 1: WP6: ANR intends to participate in the two EC co-funded joint transnational calls (2019, 2020) with the budget of 6 M€ (3 M€ per call) and two non-cofunded calls (2021, 2022; budget to be defined). In addition, ANR will act as 25 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases joint transnational call 2020 secretariat, which involves the preparation of the call, the establishment of the joint call secretariat and the implementation of the call. WP9: ANR will support WP and Task leaders in the monitoring activities by providing necessary information on the financed projects with FR components. Coordination and transversal activities WP1 (Coordination): As future member of the EJP RD Consortium, ANR will participate in the prioritization strategy, preparation of the Annual Work Plans and Summary Reports. ANR will be also involved in the activities related to the translation of the EJP RD outcomes and alignment at national level (for example through its participation in National Mirror Group). WP5 (Communication and dissemination): ANR will contribute to the dissemination and communication activities of the EJP RD in order to strengthen the capacity of outreach at national level. Previous experience relevant to the Tasks: As mentioned above ANR (Department of Health & Biology) is currently coordinating E-Rare-3. ANR was also responsible for two JTC secretariats (2011, 2016) and in addition was actively involved in the preparation of all previous E-Rare calls (calls documents’ preparation, selection, monitoring and evaluation of projects). Thus, the experience necessary to overtake the responsibilities foreseen in Pillar 1 is already acquired and available at ANR. In addition, ANR is an active actor in the field of rare diseases at national level by participating in the 2nd Rare Diseases National Plan and as member of the Rare Diseases Mirror Group specifically created by the French Ministry of Research to reflect the needs and align the activities of French stakeholders with EJP RD plans. Short Profile of key Staff Members who will be undertaking the work Prof. Dominique PhD, director of the Biology and Health Department at the ANR, worked for 20 years at the Dunon-Bluteau University Pierre and Marie Curie (UPMC) and CNRS as a group leader in developmental cell (male) biology. In parallel of his scientific activities, he was dean of the Faculty of Biology at UPMC and member of the HCERES (French Agency for evaluation). He became scientific adviser at the French Embassy in Switzerland and then member the Cabinet of Minister of French Higher Education and Research as scientific adviser for Biology and Health. Recently, he was scientific deputy director at Institute of Biology (CNRS) in charge of interdisciplinary research programme implementation. As the head of department, he supervises the involvement of ANR in 3 joint programs (JPI), 10 ERA-NETs and multilateral projects. ANR scientific ANR scientific project manager (yet to be defined). project manager Ms Blandine Ms Castrillo joined the ANR in 2016 as administrative & financial officer for ERA-NETs. She Castrillo graduated in European Project Management from the University of Cergy-Pontoise (UCP) and (female) has been working since then at ANR. She currently assists the ANR’s scientific project managers and coordinators on the administrative and financial management of European projects of the Biology and Health Department and the Digital Technology and Mathematics Department of ANR. She will be the administrative and financial officer for EJP RD at ANR. List of relevant previous projects or activities, connected to the subject of this proposal: E-Rare-1 (2007 – 2011), GA036248 E-Rare-2 (2011 – 2014), GA266608 E-Rare-3 (2014 – 2019), GA643578 Member of IRDiRC, International Rare Diseases Research Consortium. 12-FFRD Full legal name (Acronym) – Country French Foundation for rare diseases (FFRD) Principal investigator Roseline Favresse Relevant Network N.A. Description of the legal entity/department/laboratory/group: FFRD is a unique cooperative framework coordinating research resources and expertise in the RD field. Flagship of the 2nd French National Rare Diseases Plan, with a growing team of 15 people, FFRD acts as a federative hub to fund research and accelerate scientific, clinical and social innovation by stimulating cross-sector cooperation towards effective healthcare to the benefit of RD patients. Its active financial support spans from biomedical sciences to Social Sciences and Humanities. Since its creation in 2012, FFRD has funded 325 projects (out of 994 26 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases submitted) for a cumulated amount of 9,4M€ (30 calls for proposals). With headquarters located in Paris, FFRD also relies on a team of seven regional field coordinators in direct contact with academic and clinical teams all over the national territory to ensure that priorities are driven by grounded needs. FFRD main objectives include: accelerating the translation of research into clinical development; detecting business development opportunities; enhancing access to innovative technologies; facilitating cross-sector partnerships. With its close contacts with academic researchers and clinicians in the field, FFRD is contributing to early identification of proofs of therapeutic concept and making links with other partners in the research value chain, namely SMEs, Pharmas, and TTOs. Main tasks in the project per Pillar/WP: Pillar 1: - In WP6 (Joint Transnational Calls for collaborative research projects) FFRD will be task leader for Task 6.3 Joint Transnational Call 2021 (JTC 2021): call not co-funded by the EC. - In WP8 (Rare Disease Research Challenges), FFRD will coordinate the WP and be involved in task 8.1: Development of the scheme as participant and as task leader for task 8.2: Set-up of challenges; task 8.3: Call for proposals, evaluation and selection of proposed projects for solutions in first phase; task 8.4: Call for proposals, evaluation and selection of proposed projects for solutions in second phase and task 8.5: Management of the funding resources, establishment of contracts and distribution of funding to selected projects. - In WP9 (Monitoring of funded projects), FFRD will participate to task 9.1: Monitoring of Joint Transnational Calls for collaborative research projects and will co-lead task 9.3: Monitoring of Rare Disease Research Challenge Pillar 3: - In WP16 (Online academic education course), FFRD will coordinate the WP (task leader on task 16.1: Assess the needs, target audience, main topics of the academic education course and task 16.2: Developing the online course and task participant in task 16.3: Follow-up, assessment and monitoring of the course). - In WP18 (Development and adaptation of training activities), FFRD will co-lead task 18.1: Evaluation of developing needs according to progress of work in Pillars 2 and 4 and relevant adaptation of training activities and be task participant in task 18.2: Evaluation of strategic priorities and development of existing training activities according to specific needs of EU-13 countries. Pillar 4: In WP19 (Facilitating partnerships and accelerating translation for higher patient impact), FFRD will be involved as task participant in task 19.2: Development and exploitation plan and task 19.3: Follow-on funding. Previous experience relevant to the Tasks: FFRD has developed a French inter-University diploma on RD translational research in 2014-2015 together with 5 French Universities (hence its coordination of WP16/Pillar 3 and participation in WP18/Pillar 3). FFRD coordinates a group of pharmaceutical and biotech companies that have an interest in the early identification and promotion of development projects for candidate medicines, (the “Promotion of Proof of Therapeutic Concepts” Club) (hence its coordination of WP8/Pillar 1 and participation in WP19/Pillar 4). FFRD has successfully handled multiple calls for proposals both in Biomedical Sciences and Social Sciences and Humanities (hence its involvement in Pillar 1 in the management and monitoring of Calls for proposals) Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work: FFRD has a significant background in launching, managing and monitoring calls for proposals (from start to closure). More than 325 grants have been awarded at the French national level for above 9,4M€ in approved funding since the launch of FFRD in February 2012. More than 1000 external experts have been involved in reviewing applications, more than 2500 evaluations have been performed and 50 expert committees organised. FFRD is working with a renowned service provider (eVision) for electronical submission of projects. Short Profile of key Staff Members who will be undertaking the work Ms.Roseline Favresse Roseline Favresse has an academic background in Social Sciences and Humanities in (female) France and Canada (MA in Geopolitics from Sorbonne University and Ecole Normale Supérieure (Paris). She is specialized in the set-up, development and management of international research projects & capacity-building programs in Europe and worldwide. While working for international organizations, NGOs and consulting companies, she has developed a strong knowledge of EU public policies and funding schemes/instruments. For 9 years now, she has been working in the RD field, first as a consultant by setting-up and managing FP6/FP7/H2020 projects (incl. TREAT-NMD) in answer to EC Calls for proposals; then, at FFRD since 2012 where she is coordinating international involvement of FFRD and also acting as a Regional Coordinator helping clinicians and researchers 27 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases speeding up their RD development projects for new medicines. Dr. Christine Fetro Dr Christine Fetro is a Pharm. D. specialized in Clinical Pharmacy, Regulatory Affairs (female) (MSc) and Public Health. She started working at Canadian and French hospitals with involvement in effective medication management and clinical trials. She then worked for 20 years in the pharmaceutical industry holding various positions in the area of public and medical affairs at an international level. As a medical affairs manager (OPI/Eusa) she had the opportunity to focus on RD and orphan drugs challenges and develop a medical and regulatory strategy to register a drug in the Lambert Eaton syndrome. At FFRD, she coordinates the group of pharmal companies with a common interest in RD and early identification of PoC from academic researchers. The main objective is to build successful partnerships between academia and industry. Dr. Ingrid Zwaenepoel Dr Ingrid Zwaenepoel has obtained a PhD in Human Genetics with a Cell and Molecular (female) Biology specialty. She managed research projects at the Pasteur Institute (Paris), the Faculty of Medicine (Geneva) and Curie Institute (Paris). Since 2012, as the FFRD Scientific policy officer, she animates and implements the Scientific Policy, by coordinating in close interaction with the Scientific Advisory Board, calls for proposals in Biomedical Sciences as well as Social Sciences and Humanities and by managing partnerships with technological platforms and providers. Prof. Daniel Scherman Prof Daniel Scherman is a Member of EURASC (European Academy of Sciences) and (male) Head of its Division Medicine and Life Sciences. As FFRD Director, he is in close relationship with the main EU pharmaceutical companies involved in RD, with which common actions are undertaken, such as: co-development of PoC projects, research funding and linking academics with pharma/biotech companies. His academic production is of 490 publications, h index: 62, 16 000 quotations without self-citations. Most of his recent works concern the field of RD, such as Mucopolysaccharidoses of types III-A (Sanfilippo) and VII (Sly), Duchene Muscular Dystrophy, and Leber congenital amaurosis. Prof Scherman has coordinated the FP6 MOLEDA Project (Molecular optimization of laser/electrotransfer DNA administration into muscle and skin for gene therapy) (2005-2008) and the TRANSPOSMART E-Rare2 Project (An innovating platform using transposon and S/MAR for von Willebrand disease gene therapy) (2012- 2015). List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements : 1. French inter-University diploma on RD translational research set up in 2014 with 5 French Universities. 2. FFRD group of pharmaceutical and biotech companies that have an interest in the early identification and promotion of development projects for candidate medicines, (the “Promotion of Proof of Therapeutic Concepts” Club). Launched in April 2017, the club has led to a series of meetings and first partnerships are being concluded between researchers and companies. 3. Five to seven annual calls for proposals for boosting RD research in the fields of NGS, animal model, translational research, HTS and Social Siences and Humanities. List of relevant previous projects or activities, connected to the subject of this proposal:  RD-Connect; H2020, European Commission; 2012-2018; at FFRD, R. Favresse is responsible for inventorying tools developed by RD-Connect in the "–omics" field within the Impact WP.  IRDiRC: FFRD is a member of the IRDiRC Consortium Assembly as a Funding organisation. 13-AFM Full legal name (Acronym) – Country AFM Téléthon (Association Française contre les Myopathies), France Principal investigator Alexandre MEJAT Relevant Network ERN-EuroNMD, Orphanet Description of the legal entity/department/laboratory/group: AFM-Téléthon is a French neuromuscular disease patient association funding research on rare genetic diseases and supporting development of innovative biotherapies such as cell and gene therapies. It also supports and manages 28 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases three Institutes of research: Genethon (Evry, France) dedicated to gene therapy development; I-Stem (Evry, France) dedicated to stem cell therapy and drug screening; and the Institute of Myology (Paris, France) dedicated to clinical research, medical follow-up and clinical trial management for neuromuscular diseases. Main tasks in the project per Pillar/WP: Pillar 1: In WP8 (Rare Disease Research Challenges), we will participate to the workshops implicating industries and stakeholders to identify the specific challenges related to research on rare diseases (Task 8.1) and to the committee approving the Challenges (Task 8.2). Pillar 4: In WP19 (Facilitating Partnerships and accelerating translation for higher patient impact), we will provide our expertise to advise and support projects approaching the end of EC funding (Task 19.2) and participate in the definition of a funding platform dedicated to rare diseases in collaboration with FTELE and EATRIS (Task 19.4). In WP20 (Accelerating the validation, use and development of innovative methodologies tailored for clinical trials), AFM Telethon Medical Affairs department and Institute of Myology (Third party) will provide experts reinforcing the “Task force group on clinical trials” (Task 20.1) and help more particularly in Subtask 20.1.3 “Mapping existing methodologies and prioritize the needs for demonstration or innovative methodologies for clinical studies in rare diseases”. Previous experience relevant to the Tasks: AFM-Téléthon has been creating and developing its own research and development platforms (Genethon and I- Stem) dedicated to research on rare diseases to address unsolved issues in terms of innovative biotherapies development (Pillar 1 – WP 8). It also initiated, in collaboration with the French Bank for Investment (BPI France), its own investment fund investing 50M euros to support 6 start-ups companies dedicated to early stage of research in rare diseases. Moreover, AFM Telethon established research partnerships with several pharmaceutical companies in the field of rare diseases (Pillar 4 – WP 19). AFM-Téléthon and its associated Institute of Myology have developed innovative devices (MyoTools) generating new outcome measures dedicated to the validation of therapeutics approaches implicating mobility limitations (Pillar 4 – WP20). Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : AFM-Téléthon manages and financially supports three Institutes dedicated to the development of innovative biotherapies (Gene therapy in Genethon and Stem cells in I Stem) and to the clinical trials (Institute of Myology) for rare genetic diseases. Short Profile of key Staff Members who will be undertaking the work Dr Alexandre Alexandre MEJAT is a patient and a PhD in molecular and cellular biology by training. He is in MEJAT (Man) charge of the International Scientific Affairs at the scientific department of AFM Telethon. He was a member of the Board of AFM Telethon (2010-2017) and of the I Stem Institute (2004- 2017). Dr Sandrine Sandrine SEGOVIA-KUENY is Director of the Medical Affairs department at AFM-Telethon. SEGOVIA- Medical doctor and PhD in legal affairs by training, Dr Segovia-Kueny has been previously vice- KUENY director of a French Regional Health Agency (ARS). (Woman) List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements (max 5) 1. MyoTools description and use: Upper limb strength and function changes during a one-year follow-up in non- ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial. 29 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Seferian AM, Moraux A, Annoussamy M, Canal A, Decostre V, Diebate O, Le Moing AG, Gidaro T, Deconinck N, Van Parys F, Vereecke W, Wittevrongel S, Mayer M, Maincent K, Desguerre I, Thémar-Noël C, Cuisset JM, Tiffreau V, Denis S, Jousten V, Quijano-Roy S, Voit T, Hogrel JY, Servais L. PLoS One. 2015 (Fév).10(2) : e0113999. 2. Motor Function Measure : http://www.motor-function-measure.org/home.aspx 3. 4. 5. List of relevant previous projects or activities, connected to the subject of this proposal (max 5): ‐ AFM Téléthon has been at the initiative, in collaboration with INSERM, of the Orphanet portal. ‐ AFM Téléthon has been at the initiative of Eurordis creation. 14-IMAGINE Full legal name (Acronym) – Country Institut des Maladies Génétiques Necker Enfants Malades (IMAGINE), France Principal investigator Stanislas Lyonnet Relevant Network EURORDIS Description of the legal entity/department/laboratory/group: Imagine is a research institute dedicated to the study of genetic diseases. Its main objective is to integrate research into clinical practice in order to better understand genetic diseases with unmet medical needs, and to propose and validate diagnostic and therapeutic approaches. The study of genetic diseases is fed by knowledge of fundamental biological mechanisms, and in reverse may uncover novel biological concepts. This vision can be considered according to four core missions: patient-focused research; innovative care; education and training; and technology transfer. The Innovation and Technology Transfer Department of Imagine supports the development of public-private partnership and the valorization of the academic research performed in the institute. Main tasks in the project per Pillar/WP: Pillar 3: In WP14, we will provide a number of cases to ISS for the 3-day training course. We will also be involved in the follow-up phase (task 14.3) In WP15, we will provide in-kind facilities plus on-site visits to genetic labs, bioinformatics, animal facilities and interactive discussions with research teams during the training for patient advocates on scientific innovation and translational research aspects in rare diseases (task 15.2) Previous experience relevant to the Tasks: The institute is focused on genetic diseases and is involved in the organization of several courses dedicated to rare genetic diseases, with academic and private partners. Imagine institute already hosts the Eurordis Winter School. Indeed, Imagine institute for Genetic Disease is perfectly relevant to the topic of this Winter School. The institute provides speakers and in-kind facilities. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work: Imagine institute is located in the middle of Paris and is fully accessible to people with disabilities. The laboratories and facilities are located in the same place and can be visited by all the participants of the training. Short Profile of key Staff Members who will be undertaking the work Pr.Lyonnet Stanislas Director of Imagine Institute (male) Marlange Romain Head of Innovation and Technology Transfer Department (male) List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: ‐ Hosting of the Eurordis Winter School ‐ Organization of a Master Class program on rare diseases with a large pharma company ‐ Participation to the training program EUR-GENE with Descartes University 30 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases ‐ Organization of the Master “Bioentrepreneurs” with Ecole Polytechnique, HEC Paris and Descartes University List of relevant previous projects or activities, connected to the subject of this proposal: ‐ Several research projects focused on rare diseases are coordinated by Imagine, some funded by institutional partners (RHU C’IL-LICO funded by ANR on ciliopathies, others by foundations such as MSD-Avenir on developmental disorders. ‐ Imagine institute is coordinator of a DIM project, funded by the “Ile-de-France” region, which supports a major interest area, the gene therapy, capitalizing on the expertise acquired by academic, hospital, industrial, associative and socio-economic actors of the “Île-de-France” region. ‐ Imagine is partner of the SeqOIA (Sequencing, Omics, Information Analysis) pilot project for very high- throughput health sequencing platforms, of the Plan France Médecine Génomique 2025 which promotes the implementation and prospective over 10 years of the conditions of access to genetic diagnosis in France. 15-DLR Full legal name (Acronym) – Country Deutsches Zentrum für Luft- und Raumfahrt e.V. (DLR), Germany Principal investigator Dr. Ralph Schuster Relevant Network ERA-Net E-Rare Description of the legal entity/department/laboratory/group: DLR is a non-governmental, non-profit German research organisation. Its Project Management Agency DLR-PT is mandated by the Federal Ministry of Education and Research (BMBF) and other ministries with regard to implementation and management of governmental programmes for research funding. Being a trustee for the funding budget, PT-DLR administrates, with a staff of over 1000, more than one billion € of research funding p.a. Fields covered – amongst others – are information technology, education, environment, and life sciences. Within the life sciences, the “health research” department of DLR-PT manages the areas of clinical research and biomedical research for BMBF, administrating a total of more than 200 million € annually in several governmental programmes aiming at fostering all areas of health research, health related research infrastructure as well as internationally competitive research. Main tasks in the project per Pillar/WP: Pillar 1: we will be responsible for co-leading Pillar 1 activities In WP6, we will be responsible for leading the WP and for leading and performing the first Joint Transnational Call (task 6.1) In WP8, we will contribute to planning and implementing the Rare Disease Challenge (tasks 8.1-8.3) In WP9, we will contribute to the monitoring of the Joint Transnational Calls (task 9.1) and the Rare Disease Research Challenge (task 9.3) Pillar 0: Coordination and transversal activities: In WP1, we will contribute to the management as part of the operating group and the executive committee (task 1.2, 1.3, 1.4). In WP2, we will we will contribute to the strategy development as part of the operating group and the executive committee (task 2.2, 2.4)as well as one of the responsible task leaders for one of the Joint Transnational Calls (task 2.3). In WP3, we will contribute to the sustainability development as part of the operating group (task 3.1). In WP4, we will contribute to the ethical, regulatory, legal and IPR framework as part of the operating group and (task 4.2). In WP5, we will contribute to the communication and dissemination as part of the operating group (task 5.1). Previous experience relevant to the Tasks: On behalf of BMBF, the “health research” department of DLR-PT has already participated in E-Rare1-3 and managed 3 of the 10 joint call secretariats for the transnational calls implemented within these three ERA-Nets. Additionally, it is currently acting as coordinator of the ERA-Nets NEURON and ERA-CVD, and has participated / is participating in a number of other health research related ERA-NETs (e.g. TRANSCAN, HIVERA, ERA PerMed) and Joint Programming Initiatives (JPND, HDHL). Other departments of DLR-PT are coordinating or participating in many other ERA-Nets, and there are regular meetings dedicated to discuss the experience with the various ERA-Nets. DLR-PT is also involved as a partner in ERA-LEARN. Also, DLR-PT manages a large and growing number of transnational calls both within and outside of ERA-Nets and JPIs for BMBF, and is serving as call secretariat for many of them. Relevant know-how is pooled, and very experienced personnel available. 31 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : DLR-PT has developed the online proposal submission and evaluation tool PT-Outline which has been and will be used for managing the joint transnational calls. This tool is also available for the management of other research funding schemes in the EJP RD. Short Profile of key Staff Members who will be undertaking the work Dr. Ralph Dr. Ralph Schuster obtained his PhD in biology at the University of Gießen in 2000 with studies Schuster on the molecular biology of the hepatitis B virus. In 2001 he joined the DLR-PT as a scientific (male) officer. Since then, he has been involved in several funding programmes including rehabilitation, genomics and rare disease research. Since 2004, he is the coordinating scientific officer for the national rare disease research funding programme. He participated from the start in setting up the ERA-Net E-Rare and coordinates the German efforts in this network. He has been co-chair of the E-Rare network steering committee since 2013. In addition, he is involved in the national action league for people with rare diseases (NAMSE) which drafted the national plan for people with rare diseases in Germany. He is also member of the IRDiRC consortium on behalf of the BMBF. Dr. Michaela Dr. Michaela Fersch obtained her PhD in biomedicine at the University of Bonn in 2009 working Fersch on immunoregulation in the liver. After a 2-year post-doc she joined the DLR Project (female) Management Agency (DLR-PT) in 2011. Since then she has been involved in several funding programmes including clinical studies, health services research on aging, integrated research and treatment centers as well as rare disease research. Within the programmes of rare disease research she worked on the national funding initiative as well as in the ERA-Net E-Rare. In addition, she is involved in the national action league for people with rare diseases (NAMSE). Dr. Katarzyna Dr. Katarzyna Saedler obtained her PhD in genetics at the University of Cologne in 2015 working Saedler on the genetic mechanism of adipositas and cancer. Completing her PhD work during a short post- (female) doc she joined the DLR Project Management Agency (DLR-PT) in 2017. Since then she has been involved in several funding programmes including clinical studies, child and youth health, integrated research and treatment centers as well as rare disease research. Within the programmes of rare disease research she worked on the national funding initiative as well as in the ERA-Net E- Rare. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Joint call secretariats for E-Rare calls in 2009, 2013, 2015 2. Participation in E-Rare 1-3 3. Participation in IRDiRC consortium 4. Involvement in drafting the national action plan for rare diseases 5. Julkowska D, Austin CP, Cutillo CM, Gancberg D, Hager C, Halftermeyer J, Jonker AH, Lau LPL, Norstedt I, Rath A, Schuster R, Simelyte E, van Weely S. Gene Ther. 2017 Sep;24(9):562-571. The importance of international collaboration for rare diseases research: a European perspective. List of relevant previous projects or activities, connected to the subject of this proposal :  E-Rare; European Commission; 2006-2010, participating in all activities and the 2 joint transnational calls, management of the 2009 Joint Transnational Call  E-Rare-2; European Commission; 2010-2014 participating in all activities and the 4 joint transnational calls, management of the 2013 Joint Transnational Call, co-chair of the Network steering committee since 2013  E-Rare-3 co-fund; European Commission; 2014-2019- participating in all activities and the 4 joint transnational calls, management of the 2015 Joint Transnational Call, co-chair of the Network steering committee 16-UKA Full legal name (Acronym) – Country Universitätsklinikum Aachen (UKA), Germany Principal investigator Prof. Dr. rer. Nat. Ralf-Dieter Hilgers Relevant Network IDeAl The University Hospital Aachen combines consistent patient care, efficient teaching and innovative research. The building of UKA combines the hospital, the Medical Faculty and dentistry and is a place for collaboration of physicians, scientists and engineers. Currently around 2.700 students in medicine and dentistry are studying at the 32 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Medical Faculty of RWTH Aachen University. At the moment 59 professors, 824 scientific assistants and 4.347 non-scientific employees work together in 34 clinical departments and 23 institutes and administration facilities. The Department of Medical Statistics (IMSA) being part of the Medical Faculty of the RWTH Aachen University was founded in 2001. Nowadays the team consists of 1 professor, 1 assistant professor, 3 scientist, 3 non scientific employees, secretary and 10 student workers. Since 2013 the department coordinated the FP7 funded IDeAl project (No. 602552). Main tasks in the project per Pillar/WP: Professor Ralf Dieter Hilgers is co-lead of WP20 in Pillar 4 and recognizes the corresponding responsibilities resulting from the work and results of this work package. He contributes as member of the TFG to task 20..1, and perhaps provides research in projects of task 20.3 and20. 4. He also interacts with ECRIN in task 20.2. Previous experience relevant to the Tasks: Professor Ralf-Dieter Hilgers coordinated the FP7 funded IDeAl project (No. 602552) developing new statistical methodologies in the design and analysis of small population clinical trials. Among other dissemination activities IDeAl results in around 70 peer reviewed publications (www.ideal.rwth- aachen.de). Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Professor Ralf-Dieter Hilgers coordinated the FP7 funded IDeAl project (No. 602552) developing new statistical methodologies in the design and analysis of small population clinical trials. He has IPP rights of the developments. Within his department of medical statistics at UKA, computer resources are available to conduct the proposed activities within the EJP. He will be assisted by Professor Dr. rer. medic Nicole Heussen the co-lead and senior statistican of the IDeAl project. Short Profile of key Staff Members who will be undertaking the work Dr. Ralf Dieter Hilgers Professor who studied mathematics at RWTH Aachen University. He finished his (male) doctoral thesis at the statistical faculty of the University of Dortmund in 1991. In 2000 he received the Venia Legendi for Medical Statistics at the University of Cologne. Since 2001 he is head of the Department of Medical Statistics (IMSA) at the Medical Faculty, RWTH Aachen University. His research interest is in optimal design of experiments, randomizations procedure and clinical trials. Since 1987 he gives biostatistical advice to clinical and experimental trials in all clinical and preclinical areas. Professor Hilgers teaches 300 students in different bio-scientific areas per year and is responsible for the education of investigators in clinical trials. He also acts as reviewer for methodological and clinical journals with main focus on surgical trials. He was coordinator of the IDeAl project funded by the European Community (www.ideal.rwth- aachen.de) form 2013-2017, which established new methodologies for small population group trials. Pr. Nicole Heussen Professor Dr, Nicole Heussen (female) is a biostatistician. She graduated in Statistics at (female) the University of Dortmund and received her PhD in theoretical medicine (2004) and the habilitation with venia legendi for Medical Biometry and Clinical Epidemiology (2012) from the Medical Faculty at RWTH Aachen University. In April 2016, she was appointed to a professorship for Evidence Based Medicine at the Medical School of the Sigmund Freud University in Vienna. Her research interest centres around the design of pre-clinical studies and randomization based inference. She provides statistical input into clinical development plan, project objectivities, experimental design, and data analysis since 1998. Currently she is working as a researcher and teacher for biostatistics and related areas in Aachen and Vienna. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements : 1. Hilgers RD., Bogdan M., Burman CF., Dette H., Karlsson M., König F., Male Ch., Mentré, F., Molenberghs, G., Senn, SJ.: Lessons learned from IDeAl — 33 recommendations from the IDeAl Net about design and analysis of small population clinical trials. Orphanet Journal of Rare Diseases (under review) 2. Hilgers, R.-D., Uschner, D., Rosenberger, W. F., Heussen, N.: ERDO – a framework to select an appropriate randomization procedure for clinical trials. BMC Medical Research Methodology, 4. December 2017. 33 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 3. Hilgers, R.-D., König, F., Molenberghs, G., Senn, S.: Design and analysis of clinical trials for small rare disease populations. Journal of Rare Diseases Research & Treatment. Volume 1. Issue 3. pages 53-60. November 2016. 4. Reetz, K., Dogan, I., Hilgers, R.-D., Giunti, P., Mariotti, C., Durr, A., Boesch, S., Klopstock, T., Rodriguez de Rivera, F., Schöls, S., Klockgether, T., Bürk, K., Rai, M., Pandolfo, M., Schulz, J.: Progression characteristics of the European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study,The Lancet Neurology. Volume 15. pages 1346-1354. December 2016. 5. Hilgers, R. D., Roes, K., and Stallard, N.: Directions for new developments on statistical design and analysis of small population group trials. Orphanet Journal of Rare Diseases. Volume 11. Issue 1. pages 78. June 2016. List of relevant previous projects or activities, connected to the subject of this proposal :  Coordinator and WP1 an 2 lead of the IDeAl, FP7 funded IDeAl project (No. 602552)  Persist a Innovative Training Networks (ITN) within MARIE SKŁODOWSKA CURIE ACTIONS (Call: H2020 MSCA ITN 2018) proposal submit to EC 17th January 2018 17-CHARITE Full legal name (Acronym) – Country Charité Universitätsmedizin Berlin (Charité), Germany Principal investigator Andreas Kurtz, Sebastian Köhler Relevant Network hPSCreg Description of the legal entity/department/laboratory/group: Charité (www.charite.de) is the joint medical faculty of the Humboldt University - and the Free University Berlin. The Charité is one of Europe’s largest university hospitals with over 100 clinical departments and specialized research institutions with 160.000 in-patients and a turnover of about 1 billion EUR per year. Innovative capacity and responsible governance are the central tenets behind Charité research endeavors; with approximately 3,700 researchers developing innovations in the field of medicine. Committed to highest standards of quality and sustainability, they work across 1,000 projects, working groups and collaborative projects. There is a particular focus on the interface between basic and patient-oriented research, which seeks to foster interdisciplinary collaborations with both national and international partners. High priority is given to research areas that offer an interdisciplinary approach and close integration of basic and clinical research. While to ensure that new research findings are quickly translated into clinical practice, training of the next generation of physicians and researchers is equally important. The Berlin-Brandenburg Center for Regenerative Therapies (BCRT – www.b-crt.de) and its associated graduate school is located at one of Charité's 4 campuses and associates more than 15 institutional partners. The BCRT is was established by the German Federal Ministry of Education and Research as a translational center, and is a joint initiative between the Charité and Germany’s largest research organization the Helmholtz-Association. The Laboratory for Stem Cell Research and Knowledge Management at the BCRT coordinates the European human pluripotent stem cell registry (https://hPSCreg.eu), a platform to collect, comprehend and make available data for human stem cells. Main tasks in the project per Pillar/WP: Pillar 2 In WP11, we will be working on the organization and integration into the consortium data framework of cell related data and implement FAIR principles. Task 11.1 : (HPO/Köhler group) Metadata and ontological model definition for cataloging resources for RD research 11.1.2. Define an ontological model compatible with existing key databases and resources Task 11.2 : (hPSCreg/Kurtz group) FAIR-compliant platform for discovery of RD resources 11.2.1. Collaboratively assemble and curate metadata based on the Orphanet catalog, on an ongoing basis, to represent all key databases and resources Task 11.3 : (hPSCreg/Kurtz group) Data deposition and access to data infrastructures for RD research 11.3.3. Adopt a Privacy-Preserving Record Linkage solution to enable data from the same individual to be connected across resources 11.3.4. Provide data deposition guidelines and documentation In WP12, we will Enabling sustainable FAIRness and Federation at the data record, patient and sample level for RD Task 12.1 : (hPSCreg/Kurtz group) Compare and align core interoperability standards of relevance management 34 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 12.1.5. Ontologies & semantics for record-level clinical and preclinical information 12.2.1. Semantic and syntactic harmonisation of data records Task 12.3 : (hPSCreg/Kurtz group) Combining expertise for practical FAIRification support. Subtask 12.3.3 (“FAIR data stewardship service”) entails practical FAIRification activities. Pillar 3: In WP14, we will provide Training on data management & quality Task 14.4: (hPSCreg/Kurtz group) Training for biobanks and researchers/clinicians on sample data Previous experience relevant to the Tasks: The Kurtz group (hPScreg) established and manages several cell focused databases (hPSCreg.eu, CellFinder.org) on the international level and within consortia, and developed relevant tools for their exploitation, association, standardization and improved accessibility (e.g. standard naming tool, ontologie tools, sample classifier). The work involved the management of data of diverse formats, from different sources and multiple levels of standardization, which are highly relevant for the proposed work. The Köhler group has led the development of the Human Phenotype Ontology (HPO) and disease annotations, developed several algorithms for matching of phenotypic profiles (i.e. sets of HPO terms) and provided knowledge integration for phenotype-driven genomics. He personally has 9+ years experience as leader, major developer, and maintainer of the HPO and HPO infrastructure, including maintaining and developing HPO-based tools for clinical diagnostics and variant prioritisation. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : All necessary infrastructure for the proposed tasks, including IT hard and software as well as maintenance, data safety and security implementations and governance structures are available. Also available are relevant training data sets and infrastructure for training as part of the graduate school and the Einstein Center, both associated with BCRT. Short Profile of key Staff Members who will be undertaking the work Prof. Andreas Dr. Kurtz, is managing the EU-hESCreg project (https://hescreg.eu). He is head of the Laboratory Kurtz of Stem Cell Research and Knowledge Management at the BCRT. He established several national Male and international communications-, information technology-, and infrastructure projects in the field of stem cell research and regenerative medicine, including the European Bank of iPSC (EBiSC), Regenerative Medicine Initiative Berlin (RMIB), the Regenerative Medicine Initiative Germany (RMIG), the internet platforms CellFinder.de. He co-established the stem cell core at the BCRT and conducts research in organ modelling for preclinical cell therapy assessment based on iPSC. Prof. Kurtz became in 2006 founding PI of the BCRT and has previously worked as Professor at Georgetown (1995-2000), Harvard (2000-2003) and Seoul National (2009-2016) Universities. Prof. Dr.Köhler recently been appointed as Junior Professor at Charité and before worked at a post-doc Sebastian at NeuroCure in the group of Dr. Dominik Seelow. He is also a PI in the EU-funded project Köhler Solve-RD (http://solve-rd.eu/). He participated in the EU-project HIPBI-RD lead by Orphanet. Male The major focus of Dr. Köhler and his group is the phenotype-driven analysis of patients, genomes, and cohorts using ontologies. He is one of the co-founders of the Human Phenotype Ontology (HPO) and has developed several algorithms and applications of HPO to data from different areas, such as genomics and clinics. Dr. Nancy Dr. Mah is a research scientist at the Berlin-Brandenburg Center for Regenerative Therapies at Mah Charité University Medicine Berlin. As an experienced data wrangler and analyst of transcriptome Female data, she has contributed to a number of publications in the development and stem cell fields, including pluripotent stem cells (PSC) and their PSC-derived cell types. Concurrently, she is developing bioinformatic methods to evaluate the cell identity of PSC-derived cell types compared to their native counterparts. A member of the International Society for Stem Cell Research (ISSCR) and German Stem Cell Network (GSCN), she is also involved in implementing interchangeable data formats for the European Stem Cell Registry (hPSCreg.eu) and actively represents hPSCreg at national and international stem cell conferences. Dr. Stefanie Dr. Seltmann is a bioinformatician and has been implementing stem cell related ontologies and Seltmann databases related to hPSCreg as well as the platform CellFinder. Her main activities are the concept Female and implementation of the database management system (DBMS) behind the public hPSCreg platform and development of long-term storage solutions. She will be responsible for implementing, monitoring, updating the technical concept, database, interface and dissemination. 35 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Kurtz A, Bairoch A, Bittner MS, Bruce K, Capes-Davis A, Clarke L, Crook JM, Daheron L, Dewender J, Faulconbridge A, Fujibuchi W, Gutteridge A, Hei D, Kim YO, Kim JH, Kolb- Kokocinski A, Lekschas F, Lomax G, Loring JF, Ludwig T, Mah N, Matsui T, Müller R, Parkinson H, Seltmann S (*), Sheldon M, Smith K, Stachelscheid H, Stacey G, Streeter I, Veiga A, Xu RH. A standard nomenclature for referencing and authentication of pluripotent stem cells. Stem Cell Reports Stem Cell Reports. 2018 Jan 9;10(1):1-6. 2. Amrani KE, Stachelscheid H, Lekschas F, Kurtz A*, Andrade-Navarro MA. MGFM: a novel tool for detection of tissue and cell specific marker genes from microarray gene expression data. BMC Genomics. 2015 Aug 28;16:645. 3. Seltmann S, Lekschas F, Müller R, Stachelscheid H, Bittner MS, Zhang W, Kidane L, Seriola A, Veiga A, Stacey G, Kurtz A. hPSCreg--the human pluripotent stem cell registry. Nucleic Acids Res. 2016 Jan 4;44(D1):D757-63. 4. Zemojtel*, Köhler*, Mackenroth*, Jager, Hecht, Krawitz, Graul-Neumann, Doelken, Ehmke, Spielmann, Oien, Schweiger, Kruger, Frommer, Fischer, Kornak, Flottmann, Ardeshirdavani, Moreau, Lewis, Haendel, Smedley, Horn, Mundlos and Robinson (2014). "Effective diagnosis of genetic disease by computational phenotype analysis of the disease-associated genome." Sci Transl Med 6: 252ra123.10.1126/scitranslmed.3009262 5. Köhler, Vasilevsky, Engelstad, Foster, McMurry, et al. (2017). "The Human Phenotype Ontology in 2017." Journal/Nucleic Acids Res 45: D865- D876.10.1093/nar/gkw1039 List of relevant previous projects or activities, connected to the subject of this proposal  A. Kurtz is coordinator of hPSCreg, EU-funded since 2007: iPSC registry and data platform  A. Kurtz is responsible for the Information Management System of the EU-Bank of iSC-lines (IMI- EBiSC), since 2015  A. Kurtz implemented the CellFinder database, a human cell atlas funded by German Research Foundation 2010-2013  Dr Köhler is a PI within the Solve-RD project, responsible for phenotype-similarity calculation between solved and unsolved cases.  Dr Köhler was a postdoctoral researcher in the HIPBI-RD project, which aims at harmonising phenomics information for a better interoperability in the rare disease field. 18-UKLFR Full legal name (Acronym) – Country UNIVERSITAETSKLINIKUM FREIBURG (UKLFR) Principal investigator Prof. Janbernd Kirschner Relevant Network TREAT-NMD, EURO-NMD, ECRIN Description of the legal entity/department/laboratory/group: The Medical Faculty is one of the most prestigious research-driven medical schools in Germany and renowned for experimental as well as clinical research. The Medical Center – University of Freiburg is an independent public institution of the University of Freiburg. It is amongst the largest university hospitals in Germany. It collaborates closely with the Medical Faculty, University of Freiburg according to Baden Wuerttemberg state law and engages in research, training and patient care as its core responsibilities, with the goal of offering its patients treatment informed by latest scientific findings. In 2009 UKLFR has established the Freiburg Center for Rare Disease and members of the center are involved in 10 different European Reference Networks for Rare Diseases including the EURO-NMD network for neuromuscular diseases. The Department of Neuropediatrics and Muscle Disorders has a long tradition in clinical research with special focus on rare diseases. UKLFR was founding member of the German muscular dystrophy network MD-NET and the TREAT-NMD network for translational research in neuromuscular disorders. The Department of Neuropediatrics and Muscle Disorders delivers its activities in close close cooperation with the Clinical Trial Unit (CTU) of UKLFR. The CTU is a central facility of UKLFR founded in 1997 which ensures compliance with international quality standards and participates in a number of international joint research projects. The CTU is an ECRIN certified center for data management. Main tasks in the project per Pillar/WP: Pillar 2: 36 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases In WP11, the data of the CTSR will be linked to the EJP platform. In addition, the CTSR will be expanded further or replicated, to include all rare diseases organised along the lines for the ERN Thematic Groupings, extending beyond the original remit in TREAT-NMD. Participation in tasks 11.3.1, 11.3.3, 11.3.4, 11.4.4). Previous experience relevant to the Tasks: The Care and Trial Site registry (CTSR, PubMed 24148153) at Freiburg University – Medical Center is an IRDiRC recognized resource contributing to the European data infrastructure for rare neuromuscular and neurodegenerative disease and exposes highly phenotyped patient cohorts and specialist centres for clinical research (linked to ERNs EURO-NMD and RND). The CTSR currently contains information on the personnel, facilities and patient population of 320 centres in 48 countries, and site-reported data indicates that 60,000 patients are seen in these centres. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work: The Care and Trial Site registry (CTSR, PubMed 24148153) at UKLFR is part of the TREAT-NMD activities and contains information of more than 320 centres for neuromuscular and/or neurodegenerative disease in a single database. The CTSR is also used to collect relevant information for the ERN EURO-NMD from pariticipating centres. The information on patient numbers, investigators, infrastructure has been used in numerous feasibility requests from academic partners and industry to plan and conduct clinical and health care research projects. The Clinical Trial Unit (CTU) of UKLFR has more than 50 employees and provides all services to plan, conduct and evaluate clinical research projects. Together with the Department of Neuropediatrics and Muscle Disorders the CTU has developed specific expertise in the area of rare diseases. CTU has been certified by ECRIN as a European data management centre. Short Profile of key Staff Members who will be undertaking the work Pr.Janbernd Kirschner Acting Medical Director of the Department of Neuropediatrics and Muscle Disorders. As (male) paediatric neurologist his main interest is clinical research in neuromuscular diseases and other rare diseases. Under his leadership UKLFR has developed to one of the leading institutions for clinical research in neuromuscular diseases in Germany. He has been principal investigator for numerous clinical trials for spinal muscular atrophy and Duchenne muscular dystrophy. These include IIT-trials as well as industry sponsored trials. Kirschner was coordinator of the EU-funded project CARE-NMD which explored the care situation of Duchenne patients in 7 EU countries. Kirschner has recently established the SMArtCARE database to collect long-term observational data for patients with spinal muscular atrophy. Kirschner is designated chair of the TREAT-NMD alliance executive committee and member of the ERN EURO-NMD executive committee. Kirschner has authored more than 100 peer-reviewed publications und is section editor of the Orphanet Journal of Rare Diseases. Dr. Hanns Lochmüller Hanns Lochmüller has joined the Department of Neuropediatrics and Muscle Disorders (male ) at the UKLFR in February 2018. Previously, he held the Chair of Experimental Myology at the Institute of Genetic Medicine, Newcastle University, where he is co-led the MRC Centre for Neuromuscular Diseases. Recently, he set up and coordinated the EU funded RD-Connect project, and chaired the Interdisciplinary Scientific Committee of the International Rare Diseases Research Consortium (involving most major Rare Disease funders such as the European Commission and the NIH), which advises this global consortium on issues around data sharing, bioinformatics, registries and biobanks. These roles place him at the heart of efforts to bring together data, analysis methods and clinical bioinformatics tools applicable to rare disease. His research group has successfully established zebrafish as a tool for investigating hereditary muscle disorders and continues to publish basic and translational research in leading journals. Lochmüller has been principal investigator for several natural history and clinical trials for spinal muscular atrophy, Duchenne muscular dystrophy, myotonic dystrophy, and GNE myopathy. He has authored more than 450 peer-reviewed publications and is the editor-in-chief of the J of Neuromuscular Disease. Kirsten König Kirsten König works as an IT specialist at the Clinical Trials Unit of the University of (female) Freiburg – Medical Center. She has programmed registries such as the CTSR, of which she is also curator, as well as other web-based investigational tools. Adrian Tassoni Adrian Tassoni works as IT specialist and is responsible for the IT team at the Clinical 37 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases (male) Trials Unit of the University Freiburg – Medical Center. He works in collaboration with the Department of Neuropediatrics since 2007 and is responsible the technical aspects of the CTSR, the TREAT-NMD Regulatory Affairs Database and the TREAT-NMD TACT Application Form. Within the Clinical Trials Unit he is responsible for a working IT infrastructure including the GCP-compliant development, validation and maintenance of computerized systems like data entry systems, electronic CRFs, and the IT for data-managers, bio-statisticians and pharmaco- vigilance. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements : 1. Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al.; ENDEAR Study Group. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017 Nov 2;377(18):1723-1732. 2. Rodger S, Lochmüller H, Tassoni A, Gramsch K, König K, Bushby K, Straub V, Korinthenberg R, Kirschner J. The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases. Orphanet J Rare Dis. 2013 Oct 23;8:171. 3. Boycott KM, Rath A, Chong JX, Hartley T, …, Lochmüller H. International Cooperation to Enable the Diagnosis of All Rare Genetic Diseases. Am J Hum Genet. 2017 May 4;100(5):695-705. 4. Austin CP, Cutillo CM, Lau LPL, Jonker AH, Rath A, Julkowska D, … Lochmüller H, et al.; International Rare Diseases Research Consortium (IRDiRC). Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective. Clin Transl Sci. 2018 Jan;11(1):21-27 5. Lochmüller H, et al.; RD-Connect consortium; NeurOmics consortium; EURenOmics consortium. RD-Connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases. Eur J Hum Genet. 2018 Feb 27. List of relevant previous projects or activities, connected to the subject of this proposal :  TREAT-NMD: EU-funded period 2007-2013; continuing as TREAT-NMD alliance  MD-NET: German Ministry of Research and Education, 2004-2011, co-lead, coordination of clinical trials  CARE-NMD: EU-funded, DG SANCO, 2010-2013, project lead, Evaluation of Care and Quality of Life of patients with Duchenne muscular dystrophy  CoordinateRare: German Ministry of Research and Education, 2011-2013, project lead, methodological centre for clinical research in rare diseases.  NEUROMICS: EU-funded; 2012-2017, sub investigator, Integrated European Project on Omics Research of Rare Neuromuscular and Neurodegenerative Diseases  ERN EURO-NMD: EU-funded reference network for neuromuscular diseases; since 2017, clinical site and member of the executive committee 19-NKFIH Full legal name (Acronym) – Country Nemzeti Kutatási, Fejlesztési és Innovációs Hivatal (NKFIH) – Hungary Principal investigator Gábor Tóth Relevant Network Description of the legal entity/department/laboratory/group: The National Research, Development and Innovation Office (NKFIH, or NRDI Office) was founded on 1 January 2015 by the Act on scientific research, development and innovation (Act 2014/LXXVI) of the Hungarian Parliament (RDI Act) with the aim to create a stable institutional framework for the governmental coordination of the national research, development and innovation ecosystem, provide predictable funding and implement efficient and transparent use of available resources. It is a national strategic and funding agency for scientific research, development and innovation, the primary source of advice on RDI policy for the Hungarian government, and the primary RDI funding agency. It manages the National Research, Development and Innovation Fund to provide state support for research, development and innovation. Its mission is to develop RDI policy and ensure that Hungary adequately invests in RDI by funding excellent research and supporting innovation to increase competitiveness. Its mandate is to prepare the RDI strategy of the Hungarian government, to handle the National Research, Development and Innovation Fund, and represent the Hungarian government and the Hungarian RDI community in 38 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases international organisations. Is vision is to be a world-class RDI funding agency, create an internationally attractive RDI environment in Hungary, and a stronger link of RDI to the economy and society to increase growth and prosperity. Main tasks in the project per Pillar/WP: Pillar 1 (Funding Collaborative Research on Rare Diseases): In WP6 NKFIH as a funding agency will participate in both co-funded Joint Translational Calls for collaborative research projects. We will be involved in topic selection, call preparation, call secretariat tasks, evaluation and funding decision. Previous experience relevant to the Tasks: With regard to supporting basic research, NKFIH administers open calls for proposals with a bottom-up approach towards research proposals, postdoctoral research proposals, and proposals for international cooperation (often based on bilateral agreements between NKFIH and foreign research funding agencies with the view of Europe and Hungary investing in a knowledge-based society) – without thematic priorities and with a special emphasis on the careers of talented young researchers and on the reintegration of Hungarian researchers returning from postdoctoral trainings or research projects carried out abroad. Competition is intense: in recent years, the average support ratio has been approximately thirty percent of the total number of proposals received. Their evaluation is based on a peer review system where individual expert reviews are collected through an online electronic proposal review system and proposals are further evaluated and ranked by a two-level system of review panels and scientific councils. Previous experience also includes active participation in the call secretariats of the ERA-Chemistry and the M- ERA.NET ERA-NET projects. In the annual program strategy, a specific budget line is dedicated to the support of Hungarian participation in the Horizon 2020 Programme, as well as in related ERA-NET projects such as FLAG-ERA, M-ERA.NET, Quantera, Infect-ERA, E-Rare and ERA PerMed. Furthermore, NKFIH participates in the AAL Joint Programme, in the Joint Programme – Neurodegenerative Disease Research (JPND) as well as in the ECSEL joint technology initiative, in the EUREKA and in the EUROSTARS programmes, and has numerous bilateral international agreements for joint programmes. As a member of the E-Rare-3 ERA-NET consortium NKFIH participated in all joint transnational calls launched by E-Rare-3. Short Profile of key Staff Members who will be undertaking the work Dr. Gábor Tóth Scientific background: bioengineering (MSc degree), molecular genetics (teaching and (male) research experience), bioinformatics (teaching and research experience, PhD degree). PhD in Biology (2001). Recent positions: Head of Department of Life Sciences at the Hungarian Scientific Research Fund, OTKA (2012–2014); Head of Unit of Medical and Biological Sciences at NKFIH (2015); Head of Department of Research and Development at NKFIH (2016–). In the above positions, he has been responsible for the administrative management of national funding programmes in the field of discovery (basic) research, coordinating evaluation of research proposals and monitoring of funded projects. He represents NKFIH in the ERA-NET consortium E-Rare-3. He is the national administrative delegate in the ELIXIR Board. Dr. Előd Nemerkényi PhD in Medieval Latin (2004). (male) Positions: Assistant of International Affairs at the Hungarian Scientific Research Fund, OTKA (2007–2014); Assistant of International Affairs in the Department of Research and Development at NKFIH (2015–). He represents NKFIH in the Working Group of the M-ERA.NET programme. He is also involved in the administrative management of proposal evaluation and project monitoring in national funding programmes. Dr. Klára Horváth She studied Physics and has a PhD degree in Experimental Molecular Biophysics. She (female) has been working with national and EU research programmes at NKFIH (and its legal predecessors) since 2009. Between 2009 and 2012, she took part in the management and monitoring tasks of major Hungarian programmes at the Department of Programme Planning, at present she is working with H2020-related projects and programmes in the field of Health at the Department of International Affairs. She is the national delegate in the Health Programme Committee, in the Innovative Medicines Initiative (IMI) States Representative Group, in the Joint Programme – Neurodegenerative Disease 39 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Research (JPND) Management Board and takes part in the ERA PerMed ERA-NET project. List of relevant previous projects or activities, connected to the subject of this proposal : E-Rare-3; Funder: European Commission; 2014-2019 participant; participation in the launching of joint transnational calls, funding and monitoring of projects. 20-HRB Full legal name (Acronym) – Country Health Research Board (HRB)- Ireland Principal investigator Dr Annalisa Montesanti Relevant Network Description of the legal entity/department/laboratory/group: The Health Research Board (HRB) is a state agency that supports research and provides evidence to prevent illness, improve health and transform patient care. Main tasks in the project per Pillar/WP: Pillar 1: WP6 Funding collaborative research on rare diseases -earmarked funds for co-funded call 1: 370,000 three hundred and seventy thousands euros -earmarked funds for co-funded call 2: 370,000 three hundred and seventy thousands euros Previous experience relevant to the Tasks: We have previous experience with the funding of JPI HDHL DEDIPAC which I managed from start to finish. Also there is plenty of additional expertise in the organisation as we are involved in several JPIs activities. Short Profile of key Staff Members who will be undertaking the work Dr. Annalisa Montesanti Programme Manager managing the Health Research Careers portfolio at the Health (Female) Research Board (HRB). She is responsible for developing and managing a portfolio of training and career development initiatives through a number of mechanisms and at many different levels – ranging from PhD students and mid-career researchers to leaders in health research and other training courses or training initiatives - and generally develop a coordinated approach to building capacity in health research in Ireland. She has previous experience in managing a variety of initiatives, including investigator-led projects, programmatic awards and several career development schemes, including securing funding from European Commission under FP7 MSCA COFUND. At international level she has represented the HRB in the steering committee of funders of the EC Joint Programme Initiative (JPI) Healthy Diet for Healthy Life (HDHL) and in the European Science Foundation (ESF) and Science Europe Research Careers working group. Before joining the HRB in 2005, Annalisa had 13 years’ experience in scientific research in institutions and Universities in Italy, England and Ireland. She has a Bachelor of Science (Molecular Biology) from Palermo University in Italy and a PhD in cancer biology from the Institute of Molecular Medicine in Oxford, UK. She was also awarded a fellowship from the Italian Association for Cancer Research while working in Italy and a Marie Curie Training and Mobility for Researchers fellowship while in Oxford 21-IT MoH Full legal name (Acronym) – Country Ministry of Health – (IT- Moh) - Directorate of Research and Innovation in Healthcare, Italy Principal investigator Giselda Scalera Relevant Network Description of the legal entity/department/laboratory/group: The Ministry of Health represents the central level of the Italian National Health Service and is responsible for overall planning and control and to establish the Italian NHS targets and most important measures to be implemented. The Ministry is the leading body of the national information system on health, which includes data on hospital 40 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases admission and health interventions; the Ministry is also responsible for the overall coordination of Prevention Programmes, including those for elderly and disabled people, in particular correct life-style promotion, surveillance of chronic diseases and c.d. risk factors, promotion and surveillance of secondary prevention. The Ministry is entitled of the resource management of operational Health research, and it is also the Governing body for the legislation on Medical Devices and Health Professionals. The participating Department/Director General has as general task the coordination of Health prevention, Health Research, International and EU Relations and External Communication activities. It also promotes actions and grants in several fields of public health. Main tasks in the project per Pillar/WP: Pillar 1: Task 2.3: Scientific programming of joint transnational calls (M1 – M36) Task 2.5: Translation/impact of prioritization on national and EU strategies (M13 – M60) Previous experience relevant to the Tasks: The Ministry of Health is the main public body funding biomedical research and biomedical innovation in Italy. As a strategic health policy instrument, the Italian the Ministry of Health runs two types of funding programmes in the fields of biomedicine: one on current research and another on targeted research. Current research funding is available to Scientific Institutes of Research, Hospitalisation and Healthcare (IRCCS), the yearly amount is around 170 Mio € and in the evaluation criteria used to allocate this type of research is included the results of the capacity of these Institutions to enter in EU Research Consortium funding in Joint Activities as ERANET and JPIs. Whereas the targeted research funding is open to all researchers of the National HealthSystem. Both programmes constitute priority initiatives for the improvement of the population’s health through the rapid translation of research results into new or improved preventive, diagnostic, and treatment products and processes, and incorporation into health policies and practice.In the period 2011-2012, in line with what was implemented in previous years, efforts were made to ensure transparency and competitive research with a call for proposals for "Targeted Research and Young Researchers 2011-2012". Within the framework of such programme, the Italian Ministry of Health allocated a total funding of about 135 Mio. €. By means of the Ministry of Health research funding vital synergies between public research and private research, including national research and research within and outside Europe are strengthened. At present, the MoH-IT is involved in the following European health research programmes:  E-Rare-3  ERA PerMed  ERA-CVD  EuroNanoMed III  GENDER NET Plus  HBM4EU  ICPerMed Secretariat  JPco-fuND  JPI-EC-AMR  NEURON Cofund  TO-REACH  TRANSCAN-2  ERA-NET for Latin American and Caribbean States II (ERA-NET-LAC II)  Active and Assisted Living - 2 (AAL- 2) The MoH-IT is also committed to support the ESFRI Research Infrastructures in the biomedical science sector, ECRIN, EATRIS and BBMR. Short Profile of key Staff Members who will be undertaking the work Dr.Gaetano Guglielmi Dr. Gaetano Guglielmi (is the Head of the Office of Health Research, DG for Research (male) and Innovation in Healthcare. He represents the Italian Ministry of Health in all EU initiatives in which the DG for Research and Innovation in Healthcare is involved. Dr. Giselda Scalera Head of the Office of Health Research, DG for Research and Innovation in Healthcare; (female) she is involved for the Italian Ministry of Health in following EU initiatives: E-Rare-3; EuroNanoMed III ;GENDER NET Plus ; JPI-EC-AMR ; Active and Assisted Living - 2 (AAL- 2) List of relevant previous projects or activities, connected to the subject of this proposal: ERA-Net for Research Programmes on Rare Diseases E-Rare: Funder.  41 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 22-TuscReg Full legal name (Acronym) Regione Toscana (TuscReg) - Italy – Country Principal investigator Katia Belvedere, Head of Sector for legal advice, research and support for clinical governance bodies, Directorate for Citizenship Rights and Social Cohesion, Tuscany Region Relevant Network These are the ERN where the Centre of Tuscany Region participates: BOND - European Reference Network on Rare Bone Disorders Endo-ERN - European Reference Network on Rare Endocrine Conditions EpiCARE - European Reference Network on Rare and Complex Epilepsies ERKNet - European Rare Kidney Diseases Reference Network ERN-RND - European Reference Network on Rare Neurological Diseases ERNICA - European Reference Network on Rare inherited and congenital anomalies ERN-LUNG - European Reference Network on Rare Respiratory Diseases ERN-Skin - European Reference Network on Rare and Undiagnosed Skin Disorders EURACAN - European Reference Network on Rare Adult Cancers (solid tumors) EuroBloodNet - European Reference Network on Rare Hematological Diseases EURO-NMD - European Reference Network for Rare Neuromuscular Diseases ERN-EYE - European Reference Network on Rare Eye Diseases ITHACA - European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability MetabERN - European Reference Network for Rare Hereditary Metabolic Disorders PaedCan-ERN - European Reference Network for Paediatric Cancer (haemato- oncology) ReCONNET - Rare Connective Tissue and Musculoskeletal Diseases Network VASCern - European Reference Network on Rare Multisystemic Vascular These are the Health care Providers involved in ERN's: University Hospital Careggi University Hospital of Siena University Hospital of Pisa University Hospital Meyer Central Tuscany Local Health Authorities Gabriele Monasterio Tuscany Foundation Description of the legal entity/department/laboratory/group: Tuscany is a region in central Italy with an area of about 23,000 square kilometres and a population of about 3.8 million inhabitants. Regione Toscana (Tuscany Region) is the regional authority and administrative body of the region; it has legislative, administrative, and financial autonomy and is responsible, on a regional level, for issues including education, social issues, healthcare, international cooperation, and the environment. The Tuscan health system includes three Local Health Authorities and four university hospitals: • Central Tuscany: Local Health Authorities (Florence, Prato, Pistoia, Empoli) • Northwest Tuscany: Local Health Authorities (Lucca, Massa e Carrara, Versilia, Pisa and Livorno) • Southeast Tuscany: Local Health Authorities (Siena, Arezzo and Grosseto) • University hospital Careggi (Florence) • University hospital Meyer (Florence) • University hospital of Pisa • University hospital of Siena. The health system is the sector to which the region commits the largest share of its budget and organizational structure, and constitutes an infrastructure of services and activities that can generate positive effects throughout the region. It is, in spite of and even more so in a period of economic crisis, a driving force of development for the entire regional economy, in which economic development is seen not as an end in itself but also includes, in a context of sustainability, measures tied to the social sector and the environment. Regione Toscana is also actively 42 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases involved in the promotion of the Tuscan Life Sciences Cluster for large and small companies operating in the sector. Regione Toscana has a long-standing tradition of activities to promote wellness, including healthy diets and physical activity. The latest version of Regione Toscana’s multi-year health plan includes a major focus on “health in all policies”, i.e. the promotion of healthy lifestyles across all sectors (urban planning, environment, welfare, transportation, commerce, schools, culture, sport, etc.). The project team will include colleagues in other relevant sectors of the regional government as well as the region’s associated health agencies for specific expertise on obesity; expertise in the management of European projects will also be present. Tuscany Region promotes health research and innovation policies to structure an integrated and synergistic research and innovation system in a coordinated context among Tuscan university hospitals and other institutions of the Regional Health Service. Main activities in this field:  calls for funding (using regional, national e structural funds);  creation of UVaR - office for exploitation of research results – that is engaged in assessing, monitoring and exploiting the results of research in terms of applicability and transferability. An activity to support the Tuscan university hospitals and other institutions of the Regional Health Service, universities and public research organizations in order to develop and leverage innovative capacity and technology transfer, also through the creation of collaborative channels with companies and other stakeholders in the Life Sciences sector;  Support to Tuscany Life Sciences Cluster, founded in 2011 by an initiative of the Tuscany Region aimed at creating an integrated Life Sciences system. Its mission is to act as the “glue” between the specialist industrial dimension and the institutional and systemic one, promoting dialogue among companies and the network of excellence present in the field of research and technology transfer in the region. The Rare Diseases Regional Network in Tuscany is the result of a process started in Italy with DM 279/2001 almost 17 years ago when the Regional Coordination group for rare diseases was established to represent highly specialized units, patients no-profit organizations, healthcare institutions. Tuscany region is implementing the National Plan on Rare Diseases with the aim of better organising both the healthcare paths for patients affected by rare diseases, and the regional network activity of the Centres of Expertise. The Centres for rare diseases must ensure continuity with the recommendations through specialized units within the regional network. 6 Health Care Providers in Tuscany are the seat of Centers of expertise on Rare diseases according the Recommendations of the EUCERD committee (2011) on the quality criteria for the selection and the evaluation of the "Centres of expertise" (CEs) for the rare diseases European Reference Networks (ERNs). This HCP partecipates with 28 specialised units in 17 ERN’s and one of them (Reumatology Unit - AOU Pisana) coordinates the ERN ReConnect. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will participate in joint transnational calls of Pillar 1 task 6.1 with support of TLS (Linked Third Party) Previous experience relevant to the Tasks: Competence in the issue of calls for research using regional, national (MoH) e structural funds (ERDF) Short Profile of key Staff Members who will be undertaking the work Mrs Donatella Tanini Dontella Tanini has worked for Tuscany Region - Health Direction since 1990 in the (female) dealing mainly health research and health system. She is responsible of the posizione organizzativa "Health research and cooperation international health". Skills: Organization and coordination of activities related to health research, for the development and funding of research-innovation projects financed by regional, state and community funds. Relations with health research subjects and with regional directorates interested in the research and innovation system. Relations with regional technical structures of the European Union for the promotion and development of the Tuscan health research system. Coordination of administrative activities related to international health cooperation. Mrs Ceclia Berni Middle manager in Tuscany Region, with a Master Diploma in Healthcare Management (female) with honours (Sant’Anna School of Advanced Studies – Pisa) after been graduated with honours in Political Science. She supports the set up of regional policies and procedures for the development of the regional network on rare diseases and on pregnancy and child care. She is involved in the implementation of standards of diagnosis and care and of mechanism for evaluation. She coordinates the work of the Regional group for rare diseases and she is the regional representative in the Nationl working group for rare 43 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases diseases. She is also involved in the Regional Committee on pregnancy and birth and in the National Committee on monitoring induced abortion. Ms Teresa Vieri Master’s Degree in Art, Music and Performing Arts Disciplines, University of Bologna, (female) graduated with honours; First Level Master in “Local human development and International Cooperation: theories, methods and best practices”. She has been Deputy Coordinator of the ART Secretariat for Decentralized Cooperation UNOPS/PNUD in Florence; Area Manager in the Nusa Tengara Timur Province, Indonesia for the ART Programme (Articulating Territorial and Thematic Networks for Human Development) of UNDP (United Nations Development Programme), Public Officer for International Relations and Cooperation in staff of the Mayor of Florence, Municipality of Florence. She is currently Assistant for the Management of National and European Funds, Directorate for Citizenship Rights and Social Cohesion, Tuscany Region. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements : 1. The Rare Disease Regional Network 2.http://toscanaopenresearch.it/ 3.http://www.meetthelifesciences.it/it/ List of relevant previous projects or activities, connected to the subject of this proposal : Projects financed by RT in the field of rare diseases currently in progress:  UNAVIR “Rare Viral Diseases: an innovative strategy to combat them with a single antiviral agent” UNIV. Siena, UNIV. Florence, UNIV. Pisa  GLIOMICS “Proteomic/genomic/metabolomics for biomarker detection and development of an ultra-sensitive detection platform in peripheral body fluids: application to multiform glioblastoma” Scuola Normale Superiore Pisa, Istituto Italiano di Tecnologia IIT, National Research Council CNR  DIAMANTE “Innovative molecular diagnostics for the individual therapeutic choice of pancreatic ductal adenocarcinoma” UNIV Pisa, National Research Council CNR, Scuola Normale Superiore Pisa, IIT NEST. 23-FRRB Full legal name (Acronym) – Country Fondazione Regionale per la ricerca Biomedica (FRRB)- Italy Principal investigator Gianni D’Errico Relevant Network IC-PERMED, ERA-PERMED, TRANSCAN2 Description of the legal entity/department/laboratory/group: The Lombardy Foundation for Biomedical Research (Fondazione Regionale per la Ricerca Biomedica - FRRB) is an entity governed by public law, a non-for-profit organization, established in October 2011 by Regione Lombardia, with the aim of promoting and supporting scientific research in Life Sciences in Lombardy (100 Million € from 2011 have been committed in innovative R&D projects so far). The Foundation represents the main strategic platform for boosting progress, research, development and innovation within the health sector among the regional academic and industrial life science players. Its raison d'être is to serve as support to and for implementing the regional health care research policy, in order to place the Lombardy regional system in a leading position in Europe within this field. In addition, the Foundation aims to distribute local and European resources to innovative basic and translational research projects which enable a positive impact on the local health care eco-system and citizens. Main Activities:  Promote research and innovation in Lombardy by assigning regional funds to basic and translational research projects through public tenders and calls for proposals as to create a financially sustainable and suitable environment for adding value to biomedical projects focused on different pathological conditions including rare diseases.  Through R&D infrastructures, support and coordinate the implementation of scientific research on disease prevention, personalized medicine, medical devices and drug manufacturing and distribution.  Support and promote local and national technological clusters in life sciences, thus enabling a better coordination of research agendas in the biomedical field, as well as a more productive use of the available funds.  Attract European and International research funds to Lombardy by participating to European projects, as 44 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases those in the EU HORIZON 2020 research and innovation funding program, and international partnerships.  Add value to funded projects derived research results through technology transfer activities in order to support and promote the development of new treatments, therapies and devices for the diseases of interest.  Promote the dissemination of scientific knowledge and culture including Responsible Research and Innovation (RRI) principles and promoting a gender balance among Research Funding Organisation (RFOs )and Research Performing Organisations (RPOs). Main tasks in the project per Pillar/WP: Pillar 1: In WP6 - We will participate on all the tasks listed in WP6 (Tasks 6.1 -6.2 -6.3 -6.4) Previous experience relevant to the Tasks: We are building a strong experience in the participation, coordination and management of Transnational Caals for Proposal. Particularly we are already part of the following networks: Main National and International Projects: 1. IC PERMED: FRRB is part of the Executive Committee of IC Permed and participates to the implementation of the roadmap in liaison with the Italian ministry of Health; 2. ERA-NET Transcan 2: FRRB is part of the call steering committee for the Joint Transnational call 2016 and has committed 1 Million € for the call. The support is continuing in the JTC 2017 with 1,25 M€. 3. ERA-PERMED: FRRB is partner and Work package Leader of Era-PerMed Projects and has committed 4 Million € for the joint Transnational Call 2018 Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : As a funding Agency we do not own Research/Innovation Infrastructure, nor technical equipment. We do use all the IT tools for the correct execution of regional and transnational Calls for Proposals Short Profile of key Staff Members who will be undertaking the work Mrs Marina Gerini General Director at FFRB.She obtained her degree cum laude in classic literature in 1981 at (Female) University of Florence. Since 1983 she became a civil servant and started her carrier in the Public Administration. In 1997 she became manager in the Lombardy Government serving at DG Family with responsibility of financial and human resources and between 2004 and 2005 she covered the interim position as responsible of public health interventions. In 2005 she was responsible of the Central DG for external and International Relations till 2009.Between 2009 and 2011 she became General Manager of Directorate General for Social Associations and Volunteering Organisation Associations at the National Ministry of Labour and Social Policy. Between 2011 and 2013 she covered the position of General Secretary of the Lombardy Assembly and was responsible of coordinating the work between the regional activities, the regional and national Government, as well as of realisation of the activities and programmes of the national presidency of the council of ministries. From 2013 to 2014 she was director at Regional agency for transparency and anti-corruption. From 2014 to 2015 she was appointed as Special Manager at Melegnano General hospital.In 2015 she was appointed as Social Director of the at Primary Care Trust (the Italian Azienda Sanitaria Locale) Milano 1 and in 2016 she was appointed as socio medical Director and PCT West Milano. Since February, 2nd 2017 she is General Manager at Lombardy Foundation for Biomedical Research Gianni D’Errico After graduated cum laude at University Federico II in Napoli and obtained my post (Male) graduate master’s degree in project management at SIOI in Rome, I started working in Brussels and then in Maribor, where I got acquainted with R&D programmes and innovative projects in Life Sciences. In Slovenia I cooperated with the University of Maribor, providing lectures to PhD students on IP issues within R&D international projects (competences certificated at University of Bonn). Since September 2015 I have been working at the Regional Foundation for Biomedical Research (a strategic agency specialized in financing highly scientific projects in Life Sciences), where I am in charge of the European strategy, programmes and projects with the aim to create synergies between Lombardy and other European regions’ R&D&I projects/programmes/policy. I am member of the IC-PERMED (International consortium on Personalised Medicine)Executive Committee, main facilitator of the ESTHER (Emerging and Strategic Technologies for Healthcare) Interregional cooperation group, and I have been implementing the participation of the Lombardy Region to TRANSCAN 2, ERA-PerMed (WP4 Leader – Monitoring of Cofunded projects) Dr. Paola Larghi Scopus Author ID: 24740841600 45 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases (Female) ORCID: http://orcid.org/0000-0001-7074-1590 Paola, Since 2017 is Scientific Officer at Fondazione Regionale per la Ricerca Biomedica. She got her degree in Biologic Sciences a University of Milan in 2005 followed by a PhD in experimental Pathology and Neuropathology. She worked as immunologist at European Institute of Oncology (2003-2005), Humanitas Clinical institute (2006-2010 e 2013-2014), and l’Institut Curie in Paris (2010-2013), University of Padova (2015) and at National Institute of Molecular Genetics (INGM) – University of Milan (2015-2017). As researcher she has published different papers on peerrewied international magazines, included Nature Immunology, and a book. (24 Scientific papers – h index 11). List of relevant previous projects or activities, connected to the subject of this proposal :  IC PERMED: FRRB is part of the Executive Committee of IC Permed and participates to the implementation of the roadmap in liaison with the Italian ministry of Health;  ERA-PerMed: we are WP leader of the ERA-PerMed, and we have committed for the JTC 2018 4 Million €  ERA-NET Transcan 2: FRRB is part of the call steering committee for the Joint Transnational call 2016 and has committed 1 Million € for the call. The support will continue in the JTC 2017.  TITTAN (Interreg Europe): Fostering the design, uptake and use of innovative technology based products and solutions for a healthy and active ageing.  TARGET: TAking a Reflexive approach to Gender Equality for institutional Transformation. We are partner of the project whose aim is to contribute to the advancement of gender equality in research and innovation (R&I) by supporting a reflexive gender equality policy in seven Gender Equality Innovating Institutions (GEIIs) in the Mediterranean basin. 24-FGB Full legal name (Acronym) – Country Fondazione per la Ricerca Farmacologica Gianni Benzi onlus (FGB)- Italy Principal investigator Viviana Giannuzzi Relevant Network ENERCA, TEDDY Description of the legal entity/department/laboratory/group: Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus (FGB) is a registered not-for-profit scientific research organisation promoting research in biological, medical and pharmaceutical areas, with particular reference to patients affected by rare diseases and other populations with specific therapeutic needs. FGB aims are inspired to the work of Professor Gianmartino Benzi, a scientist who dedicated a large part of his life to promoting the translation of the emerging biological and pharmacological discoveries into new products for humans, as expert and member of the EMA Management Board and COMP. FGB main effort in the rare diseases field is EuOrphan, a database collecting regulatory and scientific information on drugs having orphan designation and/or approval for rare diseases in the EU and US. Analyses of developmental status, research results, marketing success and availability for patients are regularly produced. Originated by an eTen grant (510774 2003/C 118/19), it is voluntarily managed by FGB since 2008. FGB activities are mainly focused on the regulatory, ethical and methodological support to research. In the context of national and international collaborative projects, FGB contributes to the plan and conduct of clinical studies and project management. Besides research, FGB activities are addressed to training activities consolidating the existing knowledge in regulatory sciences, including the annual ‘Foresight Training Courses’. More recently, FGB has hosted an IT & Research laboratory applied to clinical and pharmaceutical research formally acknowledged as Research Organisation/Laboratory in the list of Living Labs organisations (Apulia Region). The laboratory is also working on the design and implementation of patient registries. Main tasks in the project per Pillar/WP: FGB will co-lead WP4 of transversal activities and will lead Tasks 4.1 and 4.2, coordinating regulatory and ethical activities. Pillar 3: In WP16, we will co-coordinate the e-learning module on social sciences and humanities applied to RD (task 16.2). Pillar 4: In WP19, we will support the identification of suitable funding opportunities (task 19.2). Previous experience relevant to the Tasks: With regards to regulatory and ethics, FGB 1) has acted as a partner of the following projects to deal with the 46 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases compliance with the relevant requirements in interventional and non-interventional clinical studies, consent and assent process, data collection and analysis, secondary use: ARPEC (2009 11 01, Health Programme), CloSed, DEEP, EPIICAL (Viiv Healthcare grant), GAPP (FP7-HEALTH-2013-INNOVATION-1-602962), GRiP (FP7- HEALTH–2010-261060), InNerMeD, SMART (H2020-TWINN-2015-692327), High-Technology District “Health and Biotechnology” (H-BIO Puglia); 2) has organised training activities at national and international level: ten annual ‘Foresight Training Courses’ devoted to create a critical mass of experts in the field of the regulatory sciences and two international e-learning courses on registrative procedures and regulatory novelties; 3) has participated in public consultations on European policies and regulations. FGB will support and guide the identification of funding for projects as foreseen in Pillar 4 (WP1), thanks to the consolidated experience in not-for-profit research networking, funds scouting and applications. Finally, FGB participates in the c4c project, as responsible of WP5 dealing with research performance and quality, utility, reusability, and uniformity of data gathered from the studies performed by c4c. Overall, the robust expertise in the regulatory and ethical field as well as in the standardised collection of data on rare diseases represents a key element to provide EJP with a well-addressed coordination of these activities spanning from the conduction of clinical and non-clinical studies and regulatory validation procedures to the collection of health data, guidance for researchers and protection of patient rights. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : FGB hosts an IT & Research laboratory that develops platforms, databases and other tools (e.g., surveys and e- learning environment) to support research activities. FGB manages two databases in the rare diseases field: 1) EuOrphan, developed on Windows Server 2008 operating system and using SQL Express 2008 for data storage. Queries are designed for the advanced research by active substance, therapeutic area, sponsor, trade name, type of disease; 2) HTA-THAL, a patients’ registry based on electronic case report forms, one for adults and one for minors, written in HTML language using scripts in PHP and JAVA language. Data are stored on MySQL database. It is hosted on servers with RAID 5 disks with HDSL connection and daily backup. A user authentication system controls the access for data entry and standard security measures have been adopted. According to the relevant rules, patient data are anonymised and securely stored in each centre. Forms to obtain the patient's consent have been developed. In the framework of InNerMeD project, FGB issued the IT platform containing regulatory, genetic, clinical and therapeutic information, as collected through advanced crowling and data mining services from pre-selected public databases after a validation process carried out by the network. Short Profile of key Staff Members who will be undertaking the work Dr Viviana Giannuzzi PharmD, PhD, post-graduate Degree Master in Clinical Research of Medicines, (female) PDCO alternate member representing patients affected by rare haemoglobinopathies. Researcher, ethical and regulatory expert, project manager of EuOrphan, scientific director of Foresight Training Courses at FGB. She was the Scientific Secretary of the Ethics Committee in Lecce (IT). Eng Fedele Bonifazi Biomedical Engineer, post-graduate Master in HTA and Management, member (male) of HTA working group in the Apulia Region Health Agency, expert for the Health Dept of Basilicata Region. FGB Vice President. Project Manager of many projects (GRiP, TEDDY, InNerMeD, HTA-Thal). Mrs Annalisa Landi PharmD and student of the second level postgraduate Master in Regulatory (female) Sciences “G.Benzi”. Research Assistant at FGB, where she is involved in scientific and regulatory activities related to data protection and confidentiality, patient registries and medicine databases management. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements : 1. Giannuzzi V, Landi A, Bosone E, et al. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs. BMJ Open. 2017;7(9):e017358. 2. Giannuzzi V, Conte R, Landi A, et al. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen. Orphanet J Rare Dis. 2017;12(1):64. 3. Giannuzzi V, Devlieger H, Margari L, et al. The ethical framework for performing research with rare inherited neurometabolic disease patients. Eur J Pediatr. 2017;176(3):395-405. 4. Ruggieri L, Giannuzzi V, Baiardi P, et al. Successful private-public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines. Eur J Pediatr. 2015;174(4):481-91. 47 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 5. Bonifazi F, Conte R, Baiardi P, et al. on behalf of HTA-THAL Multiregional Registry. Pattern of complications and burden of disease in patients affected by beta thalassemia major. Curr Med Res Opin. 2017; 33(8):1525-33. List of relevant previous projects or activities, connected to the subject of this proposal: 1. InNerMeD-I-network; 2nd Health Programme 2008-2013 – G.A. n. 2012 12 12; 01/04/2013 - 31/05/2016. It was aimed to create a network of information on diagnosis and treatment of inherited neurometabolic diseases, based on the collection and exchange of information. FGB was in charge of developing the IT platform, preparing ethical and methodological recommendations and supported the project management. 2. DEEP; FP7-HEALTH-2010 G.A. n. 261483; 01/01/2011 - 31/08/2016. Is aimed to study the efficacy and safety of deferiprone in children affected by rare transfusion-dependent haemoglobinopathies. FGB was involved in regulatory and ethical issues and pharmacoeconomic analyses. 3. c4c; H2020-JTI-IMI2-2016-10-04; proposal number 777389-2; 01/05/2018 (foreseen start date). It aims to generate a sustainable infrastructure on paediatric trials. FGB co-leads WP5 “Data coordinating centre and data quality standards” to contribute to implementing performance metrics, quality improvement plan of expert groups, training materials, and awareness and dissemination campaign. 4. PEPPER; DETERMINAZIONE 22-12-2017, n. 162 “POR Puglia FESR-FSE 2014-2020 - “Innolabs”; 01/04/2018 - 01/09/2019 (foreseen). It is aimed to set up and validate methodologies and tools to evaluate research performance and quality in all the different phases (trials, prototyping, basic research). The system will suggest corrective/improvement measures for performance optimization. 5. CloSed; FP7-HEALTH-2013-INNOVATION-1 G.A. n. 602453; 01/12/2013 – ongoing. It is aimed to perform a multinational paediatric trial on clonidine for sedation in the intensive care. FGB is involved in regulatory, ethical and dissemination activities, and supports the project management. 25-FTELE Full legal name (Acronym) – Country Fondazione Telethon (FTELE) - Italy Principal investigator Lucia Faccio Relevant Network UDNI, EuroBioBank, IRDiRC, NORD, Rete delle Associazioni Amiche di Fondazione Telethon, ENMC, Alliance Regenerative Medicine Description of the legal entity/department/laboratory/group: Fondazione Telethon is an Italian charity founded in 1990 at the behest of a group of patients to support research on rare genetic diseases. Research is the central activity that FTELE pursues to fulfil its mission. This is done through both intramural research in three Telethon institutes (all focusing on rare genetic diseases) directly managed by FTELE and research performed in extramural laboratories funded through competitive calls. FTELE invests in the whole pipeline of research, from basic laboratory research up to clinical studies, as well as in the support of infrastructures for research, such as the Telethon Network of Genetic Biobanks. As a charity, FTELE has also built a strong expertise in drug development, including patenting, negotiation and management of industrial alliances and regulatory affairs. Moreover, FTELE, being a reference for RD patients, works in partnership with almost 200 Italian patient organizations. Main tasks in the project per Pillar/WP: Pillar 0: In WP2 FTELE co-leads Task 2.1: Prioritization scheme for EJP-RD actions. FTELE is involved in Task 2.5: Translation/impact of prioritization on national and EU strategies. FTELE also co-leads WP4 and is responsible of Task 4.3: Managing legal and IPR issues Pillar 2: FTELE participates in a number of tasks related with the development, monitoring and management of RD Biobanks data and related networking activities (WP10, WP11, WP12). Below listed 3rd parties will contribute use cases. Pillar 3: In WP14, FTELE contributes to Task 14.3 and leads Task 14.4: Training for biobanks and researchers/clinicians on sample data management. FTELE participates in activities of WP18 on Development and adaptation of training activities. Pillar 4: FTELE co-leads WP19, participates in Task 19.1 and is responsible of Task 19.2: Support in exploitation and follow-on funding and co-responsible of Task 19.4: Roadmap for a European investment platform for RD. Previous experience relevant to the Tasks: 48 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases IP and Research Exploitation: FTELE currently has a portfolio of 36 active patent families and is involved in 5 alliances with industrial partners for the development of therapies for 14 rare/genetic disorders. Moreover in 2017 FTELE in partnership with Sofinnova designed a technology transfer fund dedicated to RD in Italy that was approved by the European Investment Fund Board of Directors in November of the same year. Biobanking: FTELE has been supporting EuroBioBank since 2012, in the role of administrative coordinator and more recently as general coordinator. EuroBioBank has become the biobank network of RD-Connect, whose biobanking work-package is led by FTELE. Within RD-Connect, FTELE has continued to work towards alignment of data models and FAIR principles, interoperability and quality protocols of EuroBioBank biobanks with new- generation tools. Patients’ empowerment: FTELE has set an informal network of 200 Patient Organizations called Telethon Friends with the aim of sharing information on research. Since 2009 FTELE trained more than 1.000 patients through annual meetings focusing on the mechanism of research and its tools (Clinical Trials, biobanks, registries, etc.). Short Profile of key Staff Members who will be undertaking the work Lucia Faccio, Lucia is the Director of Research & Development at FTELE. She directs a team of 18 PhD, Female professionals in charge of the peer reviewed research evaluation process, monitoring of research results, strategic analyses of performance and translational potential of the funded research, technology transfer, intellectual property protection, regulatory affairs, negotiation and management of alliances with partnering organizations. Lucia has more than 17 years of technology transfer and business development experience in the life science field. Lucia obtained a PhD in Biotechnology in association with the Harvard Medical School. Simona Simona is the IP Manager at FTELE and has over 12 years of experience as a patent professional Varani, in the life science field. Previously Simona was a partner of Zebra Ventures, a consultancy firm Female dedicated to providing business development, licensing and IP support to life-science companies and academic institutions. She also served as head of IP for Allozyne Inc, a US Biotech company based in Seattle, and BioXell SpA, an Italian biopharmaceutical Company. Simona has a degree in pharmaceutical chemistry obtained from the University of Milan. Chiuhui Mary Mary has been working in the field of RD biobanking since 2014 and is managing the biobank Wang, PhD, activities in RD-Connect and EuroBioBank. Mary is experienced in organising international Female biobank training workshops and webinars. At Telethon she also oversees the program support for the Telethon Network of Genetic Biobanks. Mary received her PhD in Cell Biology from University College London, UK. After the completion of her PhD she worked as postdoctoral researcher in the UK and Italy. Lucia Lucia is the Head of Research Impact and Strategic Analysis of FTELE and was Telethon’s Chief Monaco, PhD, Scientific Officer between 2008 and 2017. She is leading the biobanking WP of RD-Connect and Female is the EuroBioBank coordinator. She represents FTELE in IRDiRC and is a member of the Horizon 2020 Advisory Group for Societal Challenge 1 – Health, demographic change and well- being. Alessia Alessia is the manager of relations with Patient Organizations and coordinator of the Telethon Daturi, helpline for RD. She has been working at FTELE since 2006 taking care of patients’ advocacy Female and empowerment. She graduated in Philosophy at the Università Cattolica del Sacro Cuore of Milan and specialized in Business and Social Communication for non profit organizations. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements : 1. L. Monaco, L. Faccio, Patient-driven search for rare disease therapies: the Fondazione Telethon success story and the strategy leading to Strimvelis, EMBO Molecular Medicine, 2017 2. S. Gainotti, et.al., The RD-Connect Registry & Biobank Finder: a tool for sharing aggregated data and metadata among rare disease researchers. Eur J Hum Genet. 2018 3. C. Baldo et.al., The alliance between genetic biobanks and patient organisations: the experience of the telethon network of genetic biobanks. Orphanet J Rare Dis. 2016 4. M. Mora et.al., EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases. Eur J Hum Genet. 2015 5. Willmann R., et. Al., 227th ENMC International Workshop:: Finalizing a plan to guarantee quality in translational research for neuromuscular diseases Heemskerk, Netherlands, 10-11 February 2017, Neuromuscul Disord. 2018 List of relevant previous projects or activities, connected to the subject of this proposal: 1. RD-Connect; European Commission – FP7; 2012-2018, leader of the WP on biobanks. 49 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 2. Determinazione Rara; Ministero del Lavoro e delle Politiche Sociali; 2013-2014, FTELE has provided contents and speakers for the experience-based training for Patient Organisations on clinical trials, registries and biobabanks. 3. T2B – Translation to Business; Regione Lombardia, 2017-2018, coordinator of the feasibility study for a PoC- like call at Regional level in the biomedical sector. 4. Sofinnova Telethon SCA; European Investment Fund, 2018-2030, Technology transfer fund focused on early stage life sciences investments, primarily supporting the development of therapies and drugs for rare genetic diseases, in Italy. 26-ISS Full legal name (Acronym) – Country Istituto Superiore di Sanità (ISS), Italy Principal investigator Domenica Taruscio Relevant Network ECRIN, EATRIS, UDNI Description of the legal entity/department/laboratory/group: The Istituto Superiore di Sanità (ISS), Rome, Italy, is the scientific advisory body of the National Health System in Italy, namely of the Ministry of Health, the Regions and the Local Health Unit. The National Health Fund allocates to the ISS resources for research and action according to the objectives of the National Health Plan. The ISS undertakes research funding, management and training functions in relation to public health in Italy. The ISS: a) collaborates with the Minister of Health in preparing and implementing scientific and health planning; b) promotes programmes in line with the objectives of the National Health Plan, and c) promotes programmes of research on the relationship between environment and health, as well as programmes and clinical trials of national interest. With regard to rare diseases, the ISS, through the National Centre for Rare Diseases, acts as a coordinator of rare disease research, surveillance and public health actions at the national and international levels. Actually, the ISS is one of the key bodies targeting health-related aspects of rare diseases in Italy; in particular, the ISS coordinates the Italian Network on Rare Diseases; it is responsible for the organization and implementation of the National Registry of Rare Diseases. Main tasks in the project per Pillar/WP: Pillar 0: COORDINATION & TRANSVERSAL ACTIVITIES ISS will be co-leader in - WP2 Integrative research and innovation strategy - Task 2.2 Mapping the research and innovation needs - Task 2.5: Translation/impact of prioritization on national and EU strategies of WP2 ISS will be Partner in - Task 2.1: Prioritization scheme for EJP RD actions - Task 2.4: Management of the medium, longer-term research strategy questions and dedicated linkage with Task Forces of IRDiRC Pillar 2: INNOVATIVE COORDINATED ACCESS TO DATA AND SERVICES FOR A TRANSFORMATIVE RARE DISEASE RESEARCH ISS will be leader of - Subtask 13.1.8. Environmental toxicology of Task 13.1: Fill a number of pre identified gaps to allow integrative systems biology approaches for rare diseases ISS will be co-leader in - Subtask 10.1.1 (“Whole-RD-community annual retreat”) of the Task 10.1 (“Convene yearly retreats leading to Pillar 2 annual strategic plans”) ISS will be partner - Task 10.5: Sustainability and scaling up - Task 11.3: Data deposition and access to data infrastructures for RD research - Task 11.4: Provision of RD analysis and data sharing capabilities through online resources ISS will participate in kind in the activities of WP12: Enabling sustainable FAIRness and Federation at the record level for RD data, patients and samples Pillar 3 CAPACITY BUILDING & EMPOWERMENT ISS will be leader of - WP 14: Training on data management & quality 50 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases - Task 14.3: Training on strategies to foster solutions of undiagnosed rare disease cases - Task 14.5: Training on rare disease registries and FAIRification of data at the source ISS will be partner of: - Task 14.2: Standards and quality of genetics/genomics data in laboratory and clinical research practice - Task 15.3: Training for patient representatives and advocates on leadership and communication skills - Task 18.1: Evaluation of developing needs according to progress of work in Pillars 2 and 4 and relevant adaptation of training activities - Task 18.2: Evaluation of strategic priorities and development of existing training activities according to specific needs of EU-13 countries Previous experience relevant to the Tasks: National Centre for Rare Diseases (CNMR) employs a wide range of scientific and technical expertise from various fields (medicine, genetics, molecular biology, epidemiology, public health, psychology, sociology etc.) and holds a network of national and international collaborations, which allow the development of a sound and integrated approach to RDs. The history of the CNMR dates back to the institution of the National Registry for Rare Diseases in 2001, which was the first nucleus of the Centre and now there are also specific rare disease registries maintained by the CNMR. A number of national, European and international projects on RDs are undertaken yearly by the Centre. The CNMR holds a portal on RDs which provides topics of interest to RD patients, to the scientific community and to anyone interested in RDs . Every year, the CNMR organises a number of education and training activities on RD directed to various stakeholders (patients and their families, patient organisations, physicians, nurse practitioners, paediatricians, residents of professional schools, etc.) Since 2013 the Center has organised and held a specific course on Rare Disease and Orphan drug registries for health professionals, researchers, clinicians and representatives of patient associations engaged in rare disease patient registries. The Center is actively involved in undiagnosed rare diseases research at National and International level. Since 2016, at National level the Center, is coordinator of a project (namely "Undiagnosed Rare Diseases: a joint Italy - USA project" funded by Ministry of Foreign Affairs and International Cooperation) aimed at developing a national strategy to foster undiagnosed rare diseases. At International level the Center is co-founder of the "undiagnosed diseases network international" network established in 2014 across several countries to improve the rate of definite diagnosis for persons living with undiagnosed conditions. Short Profile of key Staff Members who will be undertaking the work Dr. Domenica Degree in Medicine and Surgery. Post graduate Specialist in Histopathology. Post-doctoral fellow Taruscio/F in Human Genetics (Yale University, USA) and Ethics. Director of the Italian National Centre for Rare Diseases (Istituto Superiore di Sanità). Responsible of the Italian National Registry for Rare diseases. Coordinator of the following EU projects: NEPHIRD, EUROPLAN, EPIRARE, RARE- BestPractices. WP Leader: ADVANCE HTA, EUROCAT JA, E-RARE, RD-Connect. WP co- Leader: Endo-ERN, EuRRECa. Member of: EU Task Force on Rare Diseases, Expert EU Commission Group on Rare Diseases, EMQN Management Board. Coordinator of the Italy-USA bilateral project “Undiagnosed Rare Diseases”. Advisory Member of SOLVE-RD. Co-Founder of Undiagnosed Diseases Network International (UDNI, www.udni.org). Past President and Board Member of ICORD (www.icord.se). Vice Chair of ISC IRDiRC (www.irdirc.org). Coauthor of more the 150 peer reviewed publications (https://www.ncbi.nlm.nih.gov/pubmed/?term=taruscio+d) Prof. Degree in Medicine and Surgery-Postgraduate Specialist in Hygiene and Preventive Medicine Gualtiero President of Istituto Superiore di Sanità (ISS) from September 2015 . Expert Panel Member on the (Walter) Effective Ways of Investing in Health (EXPH) European Commission,DG SANTE. Coordinator Ricciardi/M of TO-REACH consortium (producing research evidence supporting health care services and systems to become more resilient, effective, equitable, accessible, sustainable and comprehensive (in Europe, and abroad). Dr Claudio Claudio has a PhD in Biomedical and Cytomorphological Sciences. His previous research was Carta/M focused on the molecular basis of RASopathies caused by mutations affecting genes involved in the RAS-MAPK pathway. Since October 2012, he has been working as a researcher at the National Center for Rare Diseases, Istituto Superiore di Sanità. His current work focuses on data management for rare disease registries and particularly on how to make registries Findable Accessible Interoperable and Reusable (FAIR) for humans and computers with other registries, biobanks and bioinformatics data 51 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Dr Marco Researcher in Molecular Genetics at the National Center Rare Diseases, Istituto Superiore di Salvatore/M Sanità. His research is focused on rare diseases and on undiagnosed rare diseases; in particular he studied i) the role of specific microRNAs in the biology of rare diseases (i.e. Hepatolastoma, Hailey-Hailey disease; osteocondromas); ii) the role of specific genetic markers for diagnosis and prognosis of rare tumours. He is member of the coordination Team of National program for External Quality Assessment of genetic test and for Sweat choloride test for cystic fibrosis. He attended at the Management Board of the European Molecular Quality Network (EMQN) (2008-14, on behalf of Italian member). He is member of Undiagnosed Diseases Network International (UDNI) and is member of the coordination team of the Italian Project for Undiagnosed Rare Diseases (Italy-USA bilateral framework). From 2016 he is member of the Scientific Committee of the Italian Cystic Fibrosis (CF) Patient Registry. Dr Alberto AM (DVM, MSc) is a senior scientist with a long-standing expertise in toxicology and Mantovani/M toxicological risk assessment, mainly on endocrine disruptors,but encompassing also trace elements, nanomaterials and pesticides . AM is a toxicology expert in EFSA Panels since 2003; in particular he has been member of the PPR Panel (pesticides, 2012-5) where he has contributed to the opinion on the use of AOP to elucidate the potential links between pesticide exposure and human diseases (Parkinson's disease, childhood leukemia) (2017). He is principal investigator for ISS in the H2020 project Eu-ToxRisk (wwww.eu-toxrisk.eu) pivoting on AOP development Dr. Paola Graduated in Chemistry and Pharmaceutical Technologies, Researcher at the National Center for Torreri /F Rare Diseases, Management of E-rare project: ERA-Net for Research Programmes on Rare Diseases; collaboration on RD-Connect project especially for the activities of WP2 on rare disease registries. Management of the Italian National Rare Disease Registry Dr. MD, specialised in Epidemiology and Public Health and PhD in Public Health. She is a researcher Yllka Kodra/F at the National Centre for Rare Diseases. Her key qualifications are: expertise in epidemiology and public health, design/implementation of rare disease and congenital malformations registry, biostatistical analysis, disease classification system, Patient-reported outcomes (PROs) studies, design/implementation of neonatal screening programme De Santis She’s researcher at the National Centre for Rare Diseases, where she’s the coordinator of the Marta/F National Helpline for Rare Diseases and of the network of institutional helpline “R.I.C.A.Ma.Re”. She's responsible for liaising with the Patient Associations; she participates as a speaker/teacher in conferences and courses and promotes training&information initiatives for the general public and specifically to the patients (e.g. Educational programs for patients on several issues on RD as orphan drugs and expanded newborn Screening; Open Days on Rare Diseases, Parent training courses to family members of people with rare disease, ecc). She's deputy representative of Dr. Taruscio on the Italian Scientific Board of the EUPATI project ("European Patients' Academy on Therapeutic Innovation"). Currently a member of the Coordinating Team of Task 2.5 "Sustainable Health Systems for Rare Diseases" in Work package 2 - Joint Action "RD-ACTION. Data and policies for rare diseases "(2015-2018). Angela She’s a psychologist and works at the National Centre for Rare Diseases-Istituto Superiore di Ruocco/F Sanità. She’s a counselor of the National Helpline for Rare Diseases and is a member of the coordinating team of the network of institutional helpline “R.I.C.A.Ma.Re”. She collaborates in open days on rare diseases and several training/informative initiatives aimed at patient associations. She’s member of the organizational staff of “Volo di Pegaso”, artistic, literary and musical contest on rare diseases. She's in the staff of an association that deals with the rights of the weakest part of the population end leads self-help groups. She participates as speaker in conferences and courses on social inclusion. Federica Researcher at National Centre of Rare Diseases; Degree in Biology; specialist medical training in Censi/F medical genetics. I have a broad background in human genetic, with specific expertise in Genetic testing. She carried out the Organization of the Italian External Quality Assessment for nine schemes of genetic testing included Oncology genetic, Cytogenetics and Molecular Genetics Fabrizio Tosto Researcher at National Centre of Rare Diseases; Degree in Biology. He has a broad background in /M genetic testing, with long experience in External Quality Assessment in Genetic Testing Organization. He carried out the Organization of the Italian External Quality Assessment for nine schemes of genetic testing included in the area of Oncology genetic, Cytogenetics and Molecular Genetics. List of the most relevant publications and/or products, services (including widely-used datasets or software), 52 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases or other achievements : 1.The RD-Connect Registry & Biobank Finder: a tool for sharing aggregated data and metadata among rare disease researchers. Eur J Hum Genet. 2018 Feb 2. 2. Data Quality in Rare Diseases Registries. Adv Exp Med Biol. 2017; Adv Exp Med Biol. 2017;1031:149-164. 3. Undiagnosed Diseases: Italy-US Collaboration and International Efforts to Tackle Rare and Common Diseases Lacking a Diagnosis. Adv Exp Med Biol. 2017;1031:25-38. doi: 10.1007/978-3-319-67144-4_2. 4. Adverse outcome pathways: opportunities, limitations and open questions. Arch Toxicol. 2017 Nov;91(11):3477-3505 5. Linked Registries: Connecting Rare Diseases Patient Registries through a Semantic Web Layer. Biomed Res Int. 2017;2017:8327980. List of relevant previous projects or activities, connected to the subject of this proposal : . EPIRARE (European Platform for Rare Disease Registries); 2011-2013; is a three-year project co-funded by the European Commission within the EU Program of Community Action in the field of Public Health. ISS was the coordinator. The general objective of the EPIRARE project is to build consensus and synergies to address legal, ethical and technical issues associated with the registration of RD patients and to elaborate a proposal for a EU web-based multi-disease platform which, by sharing information and resources, can increase the sustainability of registries, promotes the use of standards and of registry quality procedures and provides an effective way of dissemination of the results. . RD Connect; FP7; 2012-2018, ISS is WP leader " Databases/patient registries" in the European RD-Connect project, and developed the online searchable catalogue that is meant to offer detailed information on the content of the databases included . E-rare3: "ERA-NET rare disease research implementing IRDiRC objectives", Horizon 2020, 2015-2020-ISS is WP leader “Strengthening research collaboration and enhancing knowledge translation” . RD-Action; EU Health Programme-2015-2018, promoting implementation of recommendations on policy, information and data for RD; the ISS is co-leader, with EURORDIS, of Workpackage 2, focused on "Communication and dissemination", and Leader of Task 2.5 (WP2) “Sustainable Health Systems for Rare Diseases”. This Task aims to support national authorities to quantify the burden of RDs and available resources for sustainable and resilient health systems, taking into account principles of equity, quality and efficiency, and involving stakeholders, policy makers, and civil servants in charge of national strategies on RDs. . TO-REACH is a coordination and support action (CSA) to prepare a joint European research programme aimed at producing research evidence supporting health care services and systems to become more resilient, effective, equitable, accessible, sustainable and comprehensive (in Europe, and abroad). ISS is the coordinator. 27-CVBF Full legal name (Acronym) – Country Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) - Italy Principal investigator Giovanni Migliaccio Relevant Network EPTRI, TEDDY, C4C, INCiPiT, Enpr-EMA, EUCROF, AICRO Description of the legal entity/department/laboratory/group: Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) is a non-profit organization whose mission is to perform research and education in the pharmaceutical field integrating regulatory, methodological, ethical, clinical, epidemiological, economical and statistical expertise. CVBF has a longlasting experience in performing paediatric clinical trials where CVBF a) acts as sponsor and project coordinator of independent trials; b) provides specific services related to clinical trial management, data collection and storage, clinical operations, drug management, monitoring and quality assurance, clinical study reports and statistics, c) is registered in EudraVigilance to perform pharmacovigilance activities. CVBF has also developed a European Paediatric Medicines Database (EPMD) including information on medicines approved for children by EMA (indication, dosages, by age populations, studies and trials, etc). CVBF has significant expertise in the project coordination, conducting research activities mainly in the context of 53 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases national and EU funded projects and being Coordinator of two FP7 projects (DEEP, GAPP) and Partner in many other projects funded by the European Commission (DG-Research and DG-SANCO). CVBF will participate to the conect4children (C4C) pan-European Paediatric Clinical Trial Network funded under the IMI2 call 10. CVBF is the Coordinator of EPTRI (European Paediatric Translational Research Infrastructure), funded as a Horizon 2020 project, a new complementary Research Infrastructure (RI) in the context of the existing RIs intended to putting together and networking all the available competences and technologies useful to enhance paediatric research in paediatric medicines from drug discovery and early development phases to be translated into clinical phases and medicines uses. To harness efficiency in delivery of paediatric research activities and services, EPTRI will act as a ‘Paediatric Common Service’ in the ESFRI (European Strategy Forum on Research Infrastructures) scenario and will cover all the different scientific domains grouped in the following five thematic platforms: 1. Pediatric Medicines Discovery and Preclinical Studies; 2. Biomarkers; 3. Paediatric Pharmacology, 4. Formulation Science, 5. Underpinning Paediatric Studies. EPTRI involves 26 partners from 19 EU and non-EU countries including consolidated research infrastructures, top- level universities, research centers of excellence in Europe. Main tasks in the project per Pillar/WP: Pillar 0 WP1 Coordination and Management CVBF will lead task 1.3 (Monitoring of the EJP RD activities and achievements), aimed to evaluate the quality of the EJP RD activities and the achievement of the expected project goals. The task is further divided into:  subtask 1.3.1 (Identification of key performance indicators), leaded by ULIV  subtask 1.3.2 (Implementation of the monitoring process), leaded by CVBF. WP2 Integrative research and innovation strategy CVBF will co-lead task 2.1 (Prioritization scheme for EJP RD actions). Pillar 4 WP19 Facilitating partnerships and accelerating translation for higher patient impact CVBF will co-lead task 19.1 (Accelerating translation). In particular, will lead subtask 19.1.1 (Innovation Management Toolbox) contributing to structure and empower translational research in EU by providing key paediatric competences into operational Platforms for enhancing and optimizing the use of key technologies to be included in the rare diseases medicines developmental process, and will participate in the following subtasks:  subtask 19.1.2 Assessment of translational research projects  subtask 19.1.3 Real-time mentoring and technical support for translational research projects CVBF will also participate in task 19.2 (Support in exploitation and follow-on funding). Previous experience relevant to the Tasks: CVBF is the Coordinator of EPTRI that is aimed to overcome fragmentation, leading to efficacious use of data and resources and a faster scientific progress. Through EPTRI many dispersed and disaggregated paediatric research expertise will be linked and integrated, increasing collaboration and sharing of facilities, resources and related services. EPTRI will act as a “one-stop-shop” for advice in order to bridge the existing gaps in paediatric medicines research and development and contribute to EJP RD by providing data from its operational Platforms, including information on target drugs, new molecules, biomarkers, clinical and non-clinical innovative study results, databases and repositories of research data. In this way, CVBF and EPTRI will contribute in accelerating discovery by rapidly validating hypothesis that can give rise to further research and in producing interoperable re-usable data for researchers. CVBF has developed many surveys to increase the knowledge about different paediatric issues and currently is developing within EPTRI a large inventory of existing paediatric research resources allowing to bridge dispersed resources in a common interoperable infrastructure, including: 1) centers involved in new discovery and target identification for paediatric untreated diseases (mainly Rare diseases); 2) available resources (including data and samples repositories/databases) related to paediatric disease and pharmacological characteristics including neonates and placental research (paediatric PKPD population data and/or modelling/simulation/extrapolation application, biobanks and databases collecting data and sample from children affected by many rare pathologies including RPME data): the goal of this collection is to identify clinical, demographic and genetic biomarkers possibly linked to clinical diagnostic and therapeutic data; 3) all available good methodological guidelines usable in each sector for new therapies identification, diagnosis and treatment monitoring. Description of any significant infrastructure and/or major items of technical equipment, relevant to the 54 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases proposed work : CVBF manages several databases and registries such as the Inventory of the Ethical and Regulatory procedures for paediatric clinical trial (CT) approval and conduction in EU and non-EU countries and the EPMD database related to drugs for children authorised by the EMA under the centralised procedure. CVBF has managed the certification process and the interoperability of a network of human biobanks in the project RIMedRI (Integrated clinical and biological Network for Rigenerative Medicine). CVBF has also created an e-learning platform to provide courses on medicines, regulatory issues and clinical research. In particular, it is recognised provider of ICH-Good Clinical Practice (GCP) Training by TransCelerate BioPharma with the e-learning “ICH-Good Clinical Practice (GCP) Training Course”. The course is based on the international E6 ICH Good Clinical Practice (R2), revised in 2016, and is aimed at providing a guide for all individuals that are involved in clinical research and clinical. It meets the Minimum Criteria for ICH GCP Investigator Site Personnel Training identified by TransCelerate BioPharma, as necessary to enable mutual recognition of GCP training among trial sponsors. Short Profile of key Staff Members who will be undertaking the work Donato Bonifazi/Mecon CVBF Chief Executive Officer, economist. Project manager and trial manager in FP7 (male) projects/clinical trials (DEEP – DEferiprone Evaluation in Paediatrics, GA n. 261483; GAPP – GAbapentin in Paediatric Pain, GA n. 602962). PedCRIN (Paediatric Clinical Research Infrastructure Network, GA n. 731046) work package leader. ID-EPTRI (European Paediatric Translational Research Infrastructure, GA n. 777544) Coordinator. Pr.Ornella Pastoris President of CVBF, Master Degree in Biological Sciences, Associate Professor of (female) Pharmacology at the University of Pavia, Department of Molecular Physiological Pharmacology. Pr.Lucia Margari Member of the Boards of Director at CVBF. Degree in Medicine and Surgery. (female) Specialist in Neurology. Full Professor and Director of Specialization School in Child and Adolescent Neuropsychiatry at University of Bari. PhD Mariagrazia Felisi Coordinator of the Clinical Research Unit, responsible for the Quality Management (female) System at CVBF. Master Degree in Pharmacovigilance, she is Qualified Person (certified as QPPV in EudraVigilance). Giovanni Migliaccio Senior Advisor at CVBF. He has been EATRIS Scientific Director from 2011 to end of (male) 2017. He was the Italian National Delegate to the Committee for Advanced Therapies at EMA from 2009 to 2011. He is currently the sitting member for Advanced Therapies Medicinal Products in the committees delegated to the authorisation of clinical trials in Italy. Pr. Oscar della Pasqua Senior Advisor at CVBF. He holds the Chair of Clinical Pharmacology & Therapeutics (male) at University College of London and is also affiliated with GlaxoSmithKline. He has authored over 100 scientific peer-reviewed articles, an H-index of 17 and has a key interest in drug development and personalised medicine. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Capone, F., Lombardini, L., Pupella, S., Grazzini, G., Costa, A. N., and Migliaccio, G. (2011) Cord blood stem cell banking: a snapshot of the Italian situation. Transfusion 51, 1985-1994 2. Rubinstein, P., Dobrila, L., Rosenfield, R.E., Adamson, J.W., Migliaccio, G., Migliaccio, A.R., Taylor, P.E. and Stevens, C.E. (1995) Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proceedings of the National Academy of Sciences of the United States of America, 92, 10119-10122 3. Cella M, Danhof M, Della Pasqua O. Bridging strategies for drug combinations in pediatric indications. Clin Pharmacol Ther. 2012; 91(4):726-33. 4. Ruggieri L, Giannuzzi V, Baiardi P, Bonifazi F, Davies EH, Giaquinto C, Bonifazi D, Felisi M, Chiron C, Pressler R, Rabe H, Whitaker MJ, Neubert A, Jacqz-Aigrain E, Eichler I, Turner MA, Ceci A; on behalf of the GRiP Consortium. Successful private-public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines. Eur J Pediatr. 2015 174(4):481-91. 5. Bellanti F, Del Vecchio GC, Putti MC, Maggio A, Filosa A, Cosmi C, Mangiarini L, Spino M, Connelly J, Ceci A, Della Pasqua O; Consortium DEferiprone Evaluation in Paediatrics (DEEP). Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years. Br J Clin Pharmacol. 2017 Mar;83(3):593-602. doi: 10.1111/bcp.13134. Epub 2016 Nov 6. List of relevant previous projects or activities, connected to the subject of this proposal :  DEEP (DEferiprone Evaluation in Paediatrics); European Commission, Grant Agreement n°261483 - FP7- 55 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases HEALTH-F4-2010; 2011-2016; CVBF is the project Coordinator and provides the overall scientific strategy and coordination of the project. It is responsible for the project management activities, the planning, designing, implementation and analysis of the Efficacy/Safety Clinical Trial as well as the dissemination activities. DEEP is a project involving EU and non-EU countries to study deferiprone, in children affected by congenital anaemias requiring chronic transfusion therapy and iron chelation, such as the β-thalassaemia major and the Sickle Cell Disease (SCD) and develop a new formulation suitable for children. To this aim, the project has conducted three multi-national paediatric studies. Results from paediatric clinical studies will be used for a PUMA (Paediatric Use Marketing Authorisation) application. In the context of DEEP, for the first time the cardiac MRI T2* is evaluated as primary endpoint and will be validated as biomarker.  GAPP (GAbapentin in Paediatric Pain); European Commission, Grant Agreement n° 602962 - FP7 HEALTH 2013 INNOVATION 1; 2013-2017, CVBF is the project Coordinator, responsible of the Project Management activities, guaranteeing that the project plan is completed in due time with the contribution of all the participating Beneficiaries and with the highest quality standards) and of the regulatory activities. GAPP is aimed to develop, test and made available a new formulation of gabapentin for the treatment of neuropathic chronic pain in the paediatric population. Results from paediatric clinical studies will be used for a PUMA application. Genomic biomarkers are evaluated in the context of GAPP clinical trials.  GRiP (Global Research in Paediatrics), European Commission, Grant Agreement n°261060 - FP7-HEALTH-F5- 2010; 2011-2017. CVBF was partner in the project and was responsible for the development of innovative methodologies to facilitate the implementation of paediatric clinical trials and for developing contents of two of the ten modules of the International Master of Science in “Paediatric Medicines Development and Evaluation”. GRiP is a 5-year EU-funded Network of Excellence aimed at stimulating and facilitating the development and safe use of medicines in children. An International Master in Paediatric Clinical Pharmacology has been realised and proposed at global level (Europe, USA, Canada, Japan, China, etc.).  ID-EPTRI (Infradev –European Paediatric Translational Research Infrastructure); European Commission, Grant Agreement n° 777554 – H2020 - INFRADEV-2017-1; 2018-2019; CVBF is coordinator of the project; ID- EPTRI is aimed to create the framework for a new Research Infrastructure (RI) intended to enhance technology- driven paediatric research in discovery and early development phases to be translated into clinical research and paediatric use of medicines  PedCRIN (Paediatric Clinical Research Infrastructure Network); European Commission, Grant Agreement n°731046 - H2020-INFRADEV-2016-1; 2017-2020; CVBF is partner in the project and is responsible for the development of tools and databases specific for paediatric and neonatal clinical trials. PedCRIN is a four-year project funded by the European Union’s Horizon 2020 programme, aimed to bring together the European Clinical Research Infrastructure Network (ECRIN) and the founding partners of the European Paediatric Clinical Trial Research Infrastructure (EPCT-RI) to develop capacity for the management of multinational paediatric clinical trials. PedCRIN will effectively bridge paediatricians and other partners across Europe (and internationally) to combine resources and expertise to conduct and manage robust studies, while minimising risk and protecting the child participants  SMART (Small Medicines Advanced Research Training), European Commission, Grant Agreement n°692327 - H2020-TWINN-2015, 2016-2018. CVBF is partner in the project and acts as internationally-leading research institutions providing specific expertise in paediatric clinical trial government and developing, M&S and Extrapolation applications, new formulation generation. SMART is aimed at raising the Instytut Pomnik Centrum Zdrowia Dziecka (IPCZD – Poland) staff’s research profile and increase capacity in providing innovative paediatric research methods. A specific training programme is foreseen. 28-TEDDY Full legal name (Acronym) – Country European Network of Excellence for Paediatric Clinical Research (TEDDY) - Italy Principal investigator Annagrazia Altavilla Relevant Network Enpr-EMA, ENCePP, EPTRI, C4C, INCiPiT, RECLIP Description of the legal entity/department/laboratory/group: TEDDY European Network of Excellence for Paediatric Clinical Research is a scientific organisation arisen from the Task-force in Europe for Drug Development for the Young, a consortium funded in 2005 as TEDDY project (LSHB-CT-2005-005216) within the Sixth Framework Programme of the European Commission with the aim to favour the integration of the paediatric pharmacological research activities, the implementation of adequate health policies and a social awareness on the importance of the paediatric medicines across Europe covering different 56 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases specialty areas (haematology, oncology, infectious diseases, respiratory diseases, intensive care, pain, endocrinology, rare diseases, neonatology). At the end of the 5-years funding period, the consortium was further renewed and now TEDDY is operating as an independent multidisciplinary, multinational network including 50 members in 20 EU and non- EU countries. In June 2017 TEDDY has acquired an autonomous legal status allowing the Network to be fully represented and consolidated in the paediatric research community framework. The main objective of TEDDY network is to promote research on medicinal products in children providing methodological expertise and implementing good practices, Standard Operating Procedures (SOPs) and tools to plan, design and perform clinical studies at national and international level. TEDDY is a category 1 network member of Enpr-EMA, the European Network of Paediatric Research at the European Medicines Agency and registered at ENCePP (the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance), an initiative coordinated by the EMA with the aim of strengthening post-authorisation research, pharmacoepidemiological research and risk-benefit monitoring of medicines. TEDDY can count on the expertise and collaboration of researchers, scientists, health experts and paediatric clinical research centers working together to identify the most appropriate research tools and procedures that reflect the specificity of the paediatric patient population and collaborates with existing paediatric networks and research organisations with the goal to promote and foster scientific and technological excellence in paediatric research. Thanks to the international recognition and the wide geographical representativeness, TEDDY is able to provide the paediatric community of: easy dissemination of relevant information; consultation on paediatric drug development issues; involvement in paediatric studies; documents and recommendations in the sector of paediatric study methodology. Moreover, TEDDY has developed many surveys to increase the knowledge about different paediatric issues (Expert Groups and research priorities in 2007-8, Ethic and Regulatory in 2009 and 2011, Off-label use in 2010) and currently is managing a Survey on the assessment of paediatric sites’ services and capacities. TEDDY is particularly committed to setting up and implementing appropriate methodologies to conduct clinical research, with reference to innovative and traditional studies including population PK study, Modeling & Simulation, extrapolation. To this aim, TEDDY is both involved in the scientific discussion to prepare and disseminate recommendations and publication on this issue and in the practical development and conduction of paediatric national or multinational clinical trials using innovative methodologies. TEDDY is also particularly engaged in favouring awareness on the topics of paediatric research, to spread information on the rational use of paediatric medicines and to identify unmet medical needs in paediatrics. Moreover, by developing ad hoc informative and educational tools, TEDDY aims to increase awareness on the topics of paediatric research and to encourage the participation of children in all the relevant experimental procedures. Regarding the patients empowerment and the involvement in the paediatric clinical research, TEDDY has promoted the creation the first Italian (in Bari) and Albanian (in Tirana) Young Persons Advisory Group (YPAG). Main tasks in the project per Pillar/WP: Pillar 3: In WP15, we will lead the task related to “Educational materials and activities for paediatric patients” (task 15.4) dedicated to the development and organization of educational materials and activities for paediatric patients. Several tools such as videos, cartoon and serious game for children and adolescents will be developed and disseminated and a yearly face to face “paediatric patients experts training course’ will be organized. Pillar 0: Transversal WP5 “Communication & Dissemination”: We will be involved in Task 5.2: Integrating EJP-RD communication and dissemination strategies with the strategies of involved stakeholders. We will be in charge of communication, dissemination and networking activities, establishing a live mechanism of interactions and providing a link between the parties involved in the project and the European scientific community. Previous experience relevant to the Tasks: Experience of the team relevant to the tasks in the proposal: - Patients Advocacy on research: TEDDY provides support, education and information to patients and families regarding their participation in clinical trials. Currently, we have designed different educational resources with different format, e.g. serious games, comics, videos on the development of clinical trials. - KIDS Bari and Albania: Regarding the patients empowerment and the involvement in the paediatric clinical research, TEDDY has promoted the creation the first Italian (in Bari) and Albanian (in Tirana) Young Persons Advisory Group (YPAG) named respectively KIDS Bari (in collaboration with Consorzio per Valutazioni Biologiche e Farmacologiche and the paediatric University Hospital Azienda Ospedaliero-Universitaria 57 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Consorziale Policlinico di Bari – Ospedale Pediatrico “Giovanni XXIII”) and KIDS Albania (in collaboration with the Albanian Branch Office of CVBF and the University Hospital Center Tirana “Mother Teresa”, Service of Paediatrics) in order to provide the youths to be able to help researchers in trials design, prioritizing future researches, improving communication with the target population and increase awareness on clinical research through the different means of communication. - Communication and dissemination on clinical research: TEDDY is leading different projects on this field developing different kind of activities: webinars, social media education, specific website about clinical trials for patients and families, conferences, etc. TEDDY has developed age-appropriate informative materials (age-tailored information booklets, assent forms and videos) to duly inform children and families involved in clinical study, prepared in the framework of the DEEP and GAPP projects, two EC-FP7 funded project. All the materials have been developed with a language and a wording appropriate to age, psychological and intellectual maturity, taking into account the cultural and linguistic differences, in a collaborative effort among pharmacologists, paediatricians, child psychologists and illustrators. - Training: TEDDY has created an e-learning platform to provide courses on medicines, regulatory issues and clinical research, realised in the context of the TEDDY FP6 project (http://www.teddylearning.org/). Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : To conduct the networking and dissemination activities, TEDDY is able to provide communication and dissemination activities such as websites and newsletter, in order to deliver relevant publications or guidelines which were believed to be of interest for the Network and useful to stimulate scientific debate. TEDDY Network pays particular attention to the theme of the empowerment of paediatric patients in the healthcare field and is involved in several activities such as: - Videos (a spoonful of info helps the medicine go down) and training material, specifically addressed to children explaining some main concepts on drugs and their use. - Development of age-appropriate informative material to duly inform children and families involved in clinical studies (e.g. DEEP project informative material) - Quality evaluation of informative materials addressed to paediatric patients involved in clinical trials - Advisory group setup in the international paediatric project GAPP - Analysis of existing Young Person Advisory Groups and improvement of strategies to involve paediatric patients in the healthcare decisions (GRiP project activity) - Participation to public consultations and roundtables on this topic. Finally, TEDDY is always proactive to ensure a collaborative and continuous action involving paediatricians and healthcare professionals, psychologists, families, children. An e-learning Platform has been created by TEDDY aimed to distribute to different stakeholders updated Information on Medicines for children with particular reference to their better use, valuable effects and possible risks. Short Profile of key Staff Members who will be undertaking the work Mariangela Lupo/ M. Lupo has a Master’s Degree in Political Science, International Relations. Bachelor’s Communication and Degree in Foreign Languages - Linguistic Mediation in the European Union. She is Patient Advocacy responsible for Communication and Development at TEDDY and involved in the Manager/ female communication and dissemination activities in several European projects (e.g. GAPP and DEEP). She is responsible for the activities dedicated to patient’s advocacy and coordinates the KIDS Bari and KIDS Albania, the first Young Persons Advisory Group in Italy and in Albania. Annagrazia Altavilla/ A. Altavilla Professor (PAST) at Aix-Marseille University – EEM (Bioethics Research Lawyer and Ethicist/ Centre) and lawyer specialised in Health Law and Bioethics (LL.M. in Health Law and female PhD Sciences –Ethics). Former member of the European Medicine Agency (EMA) Paediatric Committee (2008/2011) and of the “Third countries clinical trials” EMA Working Group; rapporteur on ethical and legal aspects of the “Reflection paper on ethical and GCP aspects of clinical trials of medicinal products for human use conducted in third countries and submitted to marketing Authorisation to EMA” (2009/2012). Author of a book and about 40 publications in national and international journals. Joana Claverol/ CTO Paediatric Clinical trials Unit Manager at FSJD, where she manages and oversees Coordinator of more than 100 clinical trials in all paediatric specialities. She is paediatric clinical research Clinical Trial Office consultant for pharmaceutical companies and lecturer of different masters of the University at HSJD/female of Barcelona, ESAME business school and Moebio. She has over 13 years of medical and clinical research experience in the pharmaceutical and biotechnology industry, particularly 58 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases in Drug Development, Clinical Operations, Commercial, Marketing, Regulatory, and Medical Affairs functions. Together with Ms Begoña Nafria, she coordinates the Young Patient’s Advisory Group KIDS Barcelona and the European network of YPAG (eYPAGnet). Begonya Nafría/ Experience in coordinating and managing projects in clinical research on rare diseases. Patient Advocacy Coordinator of YPAG-KIDS Barcelona and RareCommons platform. Fellow of the Manager on Research EUPATI IMI2 project (first cohort), member of the Course Committee and member of the at FSJD/ female Spanish National Platform and Course Committee of Eupati. Chair of the Educational Committee of ICan. Before her professional relationship with FSJD, she worked during two years as a research technician of CIBERER (Biomedical Center for the Research on Rare Diseases Networks) and during three years in a research project about the involvement on clinical research and health education for patients’ associations in agreement with the Open University of Catalonia (APTIC Project) and the Hospital Sant Joan de Déu. Antonella Minervini/ She is responsible for the organization of meetings and training activities within TEDDY Administrative and organizational Manager/ female List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Veal GJ, Malik S, Lupo M, MacFarlane S, Lepola P, Costello M, Ceci A, Boué C, Lecour C, Otto A, Rastegari M, Berry P. Investigating the roles and training of paediatric research nurses working across Europe: a questionnaire-based survey. BMJ Paediatrics Open. 2017 August 11 2. Giannuzzi V, Altavilla A, Ruggieri L, Ceci A. Clinical Trial Application in Europe: What will change with the new Regulation? Sci Eng Ethics. 2016 Apr;22(2):451-66. doi: 10.1007/s11948-015-9662-0. Epub 2015 Jun 3. 3. Baiardi P, Giaquinto C, Girotto S, Manfredi C, Ceci A; TEDDY Network of Excellence. Innovative study design for paediatric clinical trials. Eur J Clin Pharmacol. 2011 May; 67 Suppl 1:109-15. 4. Altavilla A, Manfredi C, Baiardi P, Dehlinger-Kremer M, Galletti P, Pozuelo AA, Chaplin J, Ceci A. Impact of the new European paediatric regulatory framework on ethics committees: overview and perspectives. Acta Paediatr. 2012 Jan;101(1):27-32. 5. Armayones, M., Camino-León, R., Cantarín, V., De la Fuente, J., Families Lowe Syndrome, S., Gómez, B., Maldonado, E., Nafría, B., Ojea, T., Pascual, S., Pérez, B., Pousada, M., Serrano & M., Vidal- Valls, J. (2013). Results of a families-researchers collaborative project in Lowe Syndrome: ten patients with a wide neurological phenotype. Journal of Inherited Metabolic Disease, (2), 330. doi: 10.1007/s10545-013- 9635-x. List of relevant previous projects or activities, connected to the subject of this proposal :  ID-EPTRI (Infradev –European Paediatric Translational Research Infrastructure); European Commission, Grant Agreement n° 777554 – H2020 - INFRADEV-2017-1; 2018-2019; TEDDY is Third party of CVBF in the project and is involved in the communication , networking and patients engagement; ID-EPTRI is aimed to create the framework for a new Research Infrastructure (RI) intended to enhance technology- driven paediatric research in discovery and early development phases to be translated into clinical research and paediatric use of medicines  GAPP (GAbapentin in Paediatric Pain); European Commission, Grant Agreement n° 602962 - FP7 HEALTH 2013 INNOVATION 1; 2013-2017, TEDDY was involved in the preparation of age- appropriate informative materials aimed to duly inform children and families involved in the clinical studies conducted within the project: GAPP was aimed at designing paediatric studies with gabapentin for the treatment of chronic pain of neuropathic origin in children.  PedCRIN (Paediatric Clinical Research Infrastructure Network); European Commission, Grant Agreement n°731046 - H2020-INFRADEV-2016-1; 2017-2020; TEDDY is involved in the project in developing or adapting tools to be used for multinational paediatric and neonatal clinical trials. PedCRIN is aimed to enrich the current ECRIN (European Clinical Research Infrastructure Network) tools and actions with paediatric components in order to better address the real needs and the gaps of the paediatric research community.  GRiP (Global Research in Paediatrics), European Commission, Grant Agreement n°261060 - FP7- HEALTH-F5-2010; 2011-2017. TEDDY was involved in the project for the development of innovative methodologies to facilitate the implementation of paediatric clinical trials and for developing contents of two of the ten modules of the International Master of Science in “Paediatric Medicines Development and 59 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Evaluation”. GRiP is a 5-year EU-funded Network of Excellence aimed at stimulating and facilitating the development and safe use of medicines in children. An International Master in Paediatric Clinical Pharmacology has been realised and proposed at global level (Europe, USA, Canada, Japan, China, etc.).  RESPECT (Relating Expectations and Needs to the Participation and Empowerment of Children in Clinical Trials - 201938 - FP7- HEALTH-2007-4.1-4), a project aimed to identify the needs and motivations of children and their families participating in clinical trials in Europe. The project makes available recommendations for researchers about how to empower children, respect their interests and motivate their participation in future clinical trials. CVBF has provided an extensive knowledge on the ethical procedures with the current European and national provision (guidance and control), on-line questionnaires (elaboration and validation), statistical support. 29-MIUR Full legal name (Acronym) – Country Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR) - Italy Main contact / Principal investigator Gianluigi Consoli Relevant Network NA Description of the legal entity/department/laboratory/group: The Italian Ministry for Education, University and Research (MIUR) is the key RTD policy actor and funding agency in Italy at state level. MIUR is in charge to prepare and to submit the National Research Programme (PNR – Piano Nazionale della Ricerca) proposal to the Government and to directly manage it. Besides, the Ministry, in charge of definition of strategic priorities in Research and higher education, has the following responsibilities: • coordination, assessment and evaluation of the national university system and advanced training schools; • supporting and fostering basic research in university and research institutions, programming intervention in public research institutions; • coordination, regulation and funding of national research institutions; • coordination of the research activities promoted by other Ministries; • monitoring and supporting the integration between the research system and industries; • integration between public research and applied research; • promoting and supporting research in the industry system; • funding research programmes for southern regions; • promoting initiatives such as the Funds for the diffusion of scientific culture; • enforcement of EU and international rules on university education and research. The Ministry also has key responsibilities for international co-operation. It concludes bi- and multilateral agreements on research and technology collaboration and is in charge of co-ordinating Italy’s participation in the European Union’s Framework Programme. Main tasks in the project per Pillar/WP: Pillar 1: WP 6: Joint Transnational Calls for collaborative research projects. Previous experience relevant to the Tasks: MIUR has a large experience in joining Calls for proposals. MIUR has participated in 7 FP6 ERANETs, 11 FP7 ERANET and 3 FP7 ERANET PLUS. MIUR is participating also in more than 20 ERANET Cofund of which: CoBioTech, CORE Organic, EMEurope, ENSUF, ERA4CS, ERA-HDHL, ERA-MIN 2, EURONANOMED III, FACCE Surplus, FLAG-ERA II, GEOTHERMICA, HDHL INTIMIC, JPco-fuND, M-ERA.NET2, MANUNET III, MarTERA, QuantERA, SUSFOOD2, TRANSCAN2, WaterWorks 2014, WaterWorks2015, WaterWorks2017. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : NA Short Profile of key Staff Members who will be undertaking the work Dr Gianluigi Consoli Dr Gianluigi Consoli is in charge as a Head of Planning and promotion of international (male) scientific research and coordination of aerospace research Office within MIUR. He is also the Italian representative in several EU initiatives and he is the person in charge of the administrative, legal and financial aspects in all the ERANET and ERANET+ projects in which MIUR participates. Dr Aldo Covello Dr Aldo Covello is a senior scientific advisor for MIUR and represents the ministry in 60 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases (male) several European initiatives and committees: JTI ECSEL, JPIs, ERANETs and ERANET+. Dr Valeria Cardia Dr Valeria Cardia is a Project Officer at MIUR. She is involved in the administrative and (female) financial management of several European initiatives: JPIs, CSAs, ERANETs, ERANET+ and ERANET Cofund. 30-VIAA Full legal name (Acronym) – Country VALSTS IZGLITIBAS ATTISTIBAS AGENTURA (VIAA), LATVIA Principal investigator Dr. Janis Ancans Relevant Network E-Rare-3, other subject related ERA NET/ EJP partnership Description of the legal entity/department/laboratory/group: VIAA ensures evaluation, administration and supervision of international cooperation programme projects in the field of science and technology development in the Republic of Latvia. Main tasks in the project per Pillar/WP: Pillar 1: In WP7 «Networking to share knowledge on rare diseases», Task 7.2. Evaluation of applications. VIAA will participate in the Evaluation Committee that will evaluate the applications for network meetings, workshops or conferences to share knowledge on rare diseases based on specific criteria and on a competitive basis. This will be performed according to confidentiality and conflict of interest issues rules. In WP9 Task «Monitoring of granted projects», Task 9.2. Monitoring of networking to share knowledge on rare diseases (WP2).VIAA will participate in the follow-up, monitoring and assessment of results of the networking grants funded by the Evaluation Committee under WP7, as the result of Task 7.2 activity. Previous experience relevant to the Tasks: VIAA responsibilities include Erasmus+ programme; joint programmes and joint technology initiatives stipulated in Article 185 and 187 of the Treaty on the Functioning of the European Union as well as EU COST, EJP, JPI, ERA-NET un ERA-NET+ projects; Euroguidance and Eurydice networks in accordance with the aims and tasks set out in EU guidelines; administration of the European Economic Area financial instruments, Norway and Swiss financial instrument programmes and projects; and other international and bilateral programmes. VIAA is involved in nationwide management of the EU Structural Funds in education and science sector. The Agency ensures implementation of EU policy initiatives in Latvia in the field of education and science policy. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Human resources with professional expertise relevant to abovementioned Pillar 1 tasks. Short Profile of key Staff Members who will be undertaking the work Dr. Janis Ancans Senior expert at VIAA Horizon 2020 National Contact point, responsible for Health, (male) Demographic Change and Wellbeing since 2017. Previously served as Head of Laboratory at University of Latvia, 2005-2017. Delegate from Latvia to the Committee for Advanced Therapies at European Medicines Agency (EMA) 2009 - 2014; European expert at EMA WPs. External expert at the national medicines agency for medical biotechnology and biopharmaceutical products. Expert for medical biotechnology and pharmaceutical project evaluation at Lithuanian Business Support Agency (LBSA) 2013 - 2016. Personal expertise includes consulting for experimental medicinal, bioanalytical, biotech R&D services biotechnology service and product development. TBC (involvement VIAA personal or experts will be involved as required by specific Pillar 1 tasks, including as required by networking project evaluation stage, and provide expertise on project management, financial tasks) issues, monitoring and assessment, and related competencies. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: In Horizon 2020, VIAA has participated in 22 projects as ERA-NET/EJP/JU partner and funding agency. List of relevant previous projects or activities, connected to the subject of this proposal : VIAA is partner in the following projects: E-Rare/ E-Rare-3. ERA-NET for research programmes on rare diseases which has been extended under Horizon 2020 to the third phase, implementing IRDiRC objectives 01.12.2014. - 30.11.2019. 61 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases TRANSCAN-2. ERA-NET aligning national/regional translational cancer research programmes and activities. 01.01.2015. - 31.12.2019. NEURON. ERA NET in the area of brain-related diseases and disorders of the nervous system. 01.01.2016. - 31.12.2020. HBM4EU. COFUND-EJP European Human Biomonitoring Initiative. 01.01.2017. - 31.12.2021. ERA PerMed. ERA NET in Personalised Medicine. 01.12.2017. - 31.11.2022. 31-LMT Full legal name (Acronym) – Country Lietuvos mokslo taryba (LMT), Lithuania Principal investigator Dr. Aistė Vilkanauskytė, Head of International Programmes Unit (head of Department which is responsible for the implementation of international programmes at LMT (Research Council of Lithuania)) Relevant Network Description of the legal entity/department/laboratory/group: The Council is a counsellor of the Lithuanian Parliament and the Government on research and researchers training issues, implements programme based competitive funding of research, administers most important Lithuanian science development programmes, evaluates research performance and represents Lithuanian science in various European institutions and other international organisations. The Council is the principal national institution providing competitive R&D funding in Lithuania, focusing on financing high-level research projects. The Council regularly holds competitions for R&D in every area, taking responsibilities of conducting (administrative) verification, evaluation by experts, selection of winning projects and administrative management during implementation. Main tasks in the project per Pillar/WP: Pillar 1: WP6: participation in joint transnational calls for collaborative research projects. Previous experience relevant to the Tasks: Every year the Council publishes more than 30 calls for research proposals. The funding portfolio includes top- down schemes with pre-define research topics, such as National Research Programmes, national Lithuanian studies, as well as bottom-up schemes. The list of the programmes comprises in average 40 national and international programmes and the EU funds' schemes designed to provide funding for different research, career, mobility and dissemination activities. The Council, as an institution implementing the national research programmes, is engaged in the international initiatives of coordination of the national research programmes: the European research area networks developed under the FP7 (such as ERA-NET), and the networks for cofunding European research (ERA-NET COFUND), joint programming and the initiatives under Article 185 of the Treaty establishing the European Community. The Council participates in seven ERA-NET/ERA-NET COFUND projects, engaged in the activities of Joint Programming Initiatives (JPI) also organises the participation of Lithuanian researchers in the activities of the COST programme. Short Profile of key Staff Members who will be undertaking the work Dr. Saulius Marcinkonis Chief officer at the international programmes unit of the Council in charge of (male) international cooperation and bilateral agreements. He is programme manager for the Lithuanian–Ukrainian Cooperation Programme in the Fields of Research and Technologies, M-ERA.NET programme (ERA-NET COFUND project) and national support scheme for preparation of Horizon 2020 proposals, also acting as national contact point (NCP) for Health, demographic change and well-being (SC1) and ERC under Horizon 2020. Dr. Marcinkonis has extensive former researcher experience (over 20-years) also worked as a strategist in leading institution of Lithuanian UAS sector. List of relevant previous projects or activities, connected to the subject of this proposal:  Research Council of Lithuania is the participant of 11 ongoing H2020 projects (JHEP2, FLAG-ERA II, CHIST-ERA III, EuroNanoMed III, HERA JRP UP, BiodivScen, HERA-JRP-PS, DIAL, BiodivERsA3, ENSUF and M-ERA.NET 2. 62 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases  32-VUHSK Full legal name (Acronym) – Country Vilnius University Hospital Santaros Klinikos (VUH SK) – Lithuania Principal investigator Birute Tumiene Relevant Network ITHACA ERN Description of the legal entity/department/laboratory/group: Vilnius University Hospital Santaros Klinikos (VUH SK) is one of the largest University hospitals in Lithuania and Eastern Europe encompassing all main medical specialties. VUH SK is founded by Vilnius University and Lithuanian Ministry of Health with three key assignments of highly specialized healthcare, research and education/training. Considerable part of VUHSK human resources is active in research and education including > 320 PhD and 43 professors. All rare disease activities in VUH SK are coordinated by Joint Center for Competences and Biomedical Research (JCCBR) that serves as a clinical and biomedical research hub providing IT infrastructures, managerial, administrative and coordination services for 36 Competence centres for rare and complex diseases. The volumes of JCCBR include approx. 7,000 rare disease patients/year and at least 90-100 clinical research studies for investigational medical products and devices at a time. VUH SK is a designated national coordinator of Orphanet Lithuania, a hub of Human Biological Resource Center – a national biobanking system integrated with BBMRI-ERIC, a true Member of 8 European Reference Networks (ERN; ITHACA ERN, EuroBloodNet, MetabERN, ERN RND, ERKNet, eUROGEN, TransplantChild, PaedCanERN). Main tasks in the project per Pillar/WP: Pillar 0: Coordination and transversal activities: In WP1, we will carry out the overall management of EJP RD including HelpDesk activities as one of Pillar 3 leaders (Task 1.1; Task 1.2; Task 1.3) In WP5, we will develop and implement EJP RD communication and dissemination strategy as one of Pillar 3 leaders (Task 5.1) Pillar 2: In WP11 VUSHK will represent ERN-ITHACA participate in Task 11.2 FAIR-compliant virtual platform for discovery of RD resources Pillar 3: In WP14, we will perform national training on Orphanet nomenclature and RD ontologies as a LTP of Orphanet (Task 14.1); training for biobanks and researchers/clinicians on sample data management as a LTP of FTELE (Task 14.4). In WP16, we will participate in the development of on-line academic education course modules (Task 16.2) In WP18, we will adapt Pillar 3 training activities according to the developing EJP RD needs (Task 18.1; Task 18.2; Task 18.3) Previous experience relevant to the Tasks: In collaboration with Vilnius University, Faculty of Medicine, VUH SK is the main provider of rare disease education/training and research activities in Lithuania. From 2004, it is a national coordinator of Orphanet Lithuania. Besides, it participates in multiple other international RD-related activities including RD-Action, JARC, EORTC, BBMRI and ERNs, among others. Short Profile of key Staff Members who will be undertaking the work Pr. Birute Tumiene Clinical geneticist and Coordinator for Competence Centers at VUH SK, lecturer and (female) researcher at Vilnius University, Faculty of Medicine, with special interests in clinical genetics/rare diseases, epilepsy genetics and inborn errors of metabolism; Orphanet Lithuania National Coordinator and a member of Orphanet Operating Committee responsible for Northern Eastern European countries (LT, LV, EE, SK, SI, PL); RD- Action WP6 (Policy Development for Rare Diseases and Integration), WP5 (Steering, maintaining and promoting the adoption of Orphacodes across MS), WP4 (Orphanet, the European database for Rare Diseases) partner; ERN Board of Member States Lithuanian representative. Pr. Algirdas Utkus Clinical geneticist, the Head of Medical Genetics Centre at VUH SK, the Dean of Faculty (male) of Medicine, Vilnius University, the Chair of Lithuanian Society of Human Genetics. Association of Medical Schools in Europe Board Member. Special interests: clinical 63 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases genetics, syndromology, dysmorphology. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Tumienė B, Maver A, Writzl K, et al. Diagnostic exome sequencing of syndromic epilepsy patients in clinical practice. Clin Genet. 2017 Dec 29. doi: 10.1111/cge.13203. [Epub ahead of print] 2. http://kimg.eu/en/tools/epigene-database 3. Savickienė J, Matuzevičius D, Baronaitė S, et al. Histone Modifications Pattern Associated With a State of Mesenchymal Stem Cell Cultures Derived From Amniotic Fluid of Normal and Fetus-Affected Gestations. J Cell Biochem. 2017;118(11):3744-3755. 4. Inashkina I, Jankevics E, Stavusis J, et al. Robust genotyping tool for autosomal recessive type of limb-girdle muscular dystrophies. BMC Musculoskelet Disord. 2016;17:200. 5. Stavusis J, Inashkina I, Jankevics E, et al. CAV3 gene sequence variations: National Genome Database and clinics. Acta Neurol Scand. 2015;132(3):185-90. List of relevant previous projects or activities, connected to the subject of this proposal:  Joint Action RD-Action; European Union’s Health Programme (2014-2020), 677024; 2015-2018; WP5 (Steering, maintaining and promoting the adoption of Orphacodes across MS), WP4 (Orphanet, the European database for Rare Diseases) partner  Orphanet; supported by grants from EC; 2004-current; National Coordinator, Orphanet Lithuania  COST EUCID Action; FP7/2007–2013, BM12082013-2017, partner  UNIGENE; Lithuanian –Swiss cooperation programme; 2014-2016, partner. 33-FNR Full legal name (Acronym) – Country Fonds National de la Recherche (FNR) - Luxembourg Principal investigator Sean Sapcariu Relevant Network Description of the legal entity/department/laboratory/group: The National Research Fund (FNR) was set up by the Law of 31 May 1999. Through the FNR, an additional impetus was given to Luxembourg research, with the aim to create and strengthen competences and knowledge and to develop national and international synergies in order to increase the attractiveness of Luxembourg as a scientific and economic site of excellence.Since 2000, several multi-annual research programmes have been launched in specific fields of interest to Luxembourg. Calls are addressed to public institutions, Luxembourg administrations and public establishments authorised to undertake R&D activities or technology transfer in their respective fields of activity.As an outcome of the 2007 Foresight Exercise and the subsequent choice of national research priorities by the Government, the new thematic research programme CORE was launched in 2008 with the prime objective fostering scientific quality in selected areas of Luxembourg public research. The FNR also regularly launches calls in the three structural programmes: ATTRACT (Attract Researchers to Luxembourg), the PEARL (Excellence Award for Research in Luxembourg) and the INTER (Promoting International collaboration. The FNR is also in charge of the Luxembourg research grants for PhDs and post-docs. Furthermore, the FNR subsidises accompanying measures, addressed to a larger public and aiming to strengthen the general framework of scientific research in Luxembourg. The FNR also wishes to strengthen the links between science and society and the general public to feel concerned with science. Activities for promoting scientific culture are mostly targeted to young people.FNR funds running research projects within the biomedical field through its CORE programme, which has an annual budget of approximately 4 Mio € and covers the following areas: Regenerative Medicine in Age-related, Translational Biomedical Research and Public Health research. Main tasks in the project per Pillar/WP: Pillar 1: In WP 6, we intend to participate in two co-funded and two non-cofunded joint transnational calls. In WP 9, we will FNR will support the WP leaders in the monitoring of funded research projects. FNR will participate in the co-funded call. It will contribute to the overall implementation of the co-funded call by commenting on the proposed call text and other call documents, publication and promotion of the call, eligibility check of candidates applying for FNR support and participation in funding decision. In addition, FNR will participate in additional funding activities by contribution to the workshops in which the topics of the additional activities will be determined Previous experience relevant to the Tasks: 64 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases At an international level, the FNR currently participates to the following initiatives: - ERA-Nets: TRANSCAN, NEURON I and II, ERA-SysAp, MATERA, MNT, ERA-SysBio, ERA-Age, HERA, CHIST-ERA, CORE Organic. - Coordinated Actions: CoA-SysMed, CoA-PerMed; - JPND: Joint programming in neurodegenerative diseases; - Agreements with 11 funding agencies in Europe to fund bilateral research projects. By participating to these initiatives, the main objective of the FNR is foster cooperation and coordination of research activities carried out across Europe, and to increase visibility of Luxembourg research in selected domains. Short Profile of key Staff Members who will be undertaking the work Sean Sapcariu Sean Sapcariu, Ph. D. is a Programme Manager of the biomedical sciences research programme (male) (CORE BM) at the FNR. He has over 6 years of experience in the Luxembourgish research ecosystem, involved in biomedical research, university administration and strategy, and facilitation of funding agency programs. 34-ZonMw Full legal name (Acronym) – Country ZORGONDERZOEK NEDERLAND ZON (ZonMw), The Netherlands Principal investigator Sonja van Weely Relevant Network E-Rare, IRDiRC Description of the legal entity/department/laboratory/group: ZonMw, The Netherlands Organisation for Health Research and Development, funds health research and stimulates use of the knowledge developed to help improve health and health care. Research on rare diseases is funded in several clusters within ZonMw. Main tasks in the project per Pillar/WP: Pillar 1: - Coleader of Pillar 1 “Funding Collaborative Research on Rare Diseases” P1WP6 - Participant in WP6: “Joint Transnational Calls for collaborative research projects” P1WP7 - Leader of WP7: “Networking to share knowledge on rare diseases” - Co-taskleader WP7 task 7.1: “Development of the networking scheme” - Taskleader WP7, task 7.2: “Implementation of networking scheme” - Taskleader WP7, task 7.3: “Evaluation of applications” P1WP8 - Participant in WP8, task 8.1: “Development of the scheme” - Participant in WP8, task 8.2: “Set-up of challenges” - Participant in WP8, task 8.3: “Call for proposals, evaluation and selection of proposed projects for solutions in first phase” - Participant in WP8, task 8.4: “Call for proposals, evaluation and selection of proposed projects for solutions in second phase” P1WP9 - Co-taskleader WP9, task 9.2: “Monitoring of networking to share knowledge on rare diseases” Pillar 0: Coordination and Transversal activities As Coleader of Pillar 1 involved in ‐ WP1 “Coordination and management” ‐ WP2 “Integrative research strategy” ‐ WP3 “Sustainability strategy and business plan” ‐ WP4 “Legal, ethical and regulatory framework of the EJP RD” ‐ WP5 “Communication and Dissemination” Previous experience relevant to the Tasks: ZonMw is a co-creating party in European research programming and is involved in four Joint Programming Initiatives and many ERA-Nets related to health, and in four Research Infrastructures (BBMRI, BBMRI, 65 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases EATRIS, ELIXIR and EuroBioImaging). From 2006 ZonMw is involved in the ERA-Net E-Rare and was leader of several work packages and/or tasks. In the current programme E-Rare 3, ZonMw is co-chair of the Network Steering Committee, leader of the work package “Strategy” and Call Secretariat for E-Rare Joint Transnational Call JTC 2018. ZonMw has executed several national network subsidy programmes, including a specific network subsidy programme for rare diseases research. ZonMw is member of the Consortium Assembly of the International Rare Disease Research Consortium (IRDiRC) from 2011. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : ZonMw has its own online project portal (ProjectNet), which could be used for the submission of applications for the networking scheme, for which ZonMw will be WP leader. Short Profile of key Staff Members who will be undertaking the work Dr. Sonja Van Weely The professional career of Sonja van Weely is dedicated to rare diseases. After working for (female) more than 10 years as scientist in the field of biochemistry of rare diseases, she became scientific officer of the multidisciplinary Dutch Steering Committee on Orphan Drugs that was installed by the Minister of Health (2001-2011). Subsequently, she was appointed as senior programme officer dedicated to research and network programmes on rare diseases and orphan drugs at ZonMw (2011-now). As representative of ZonMw she is involved in E-Rare from 2006. In the current programme E-Rare 3 she is co-chair of the Network Steering Committee, leader of the work package Strategy and takes part in the Call Secretariat JTC 2018. She is also representative of ZonMw in the Consortium Assembly of the International Rare Disease Research Consortium (IRDiRC) from 2011. Sonja is involved in the preparation of the EJP RD from the beginning and will act as one of the two coleaders on funding of rare disease research. Dr. Harald Moonen Dr. Moonen was originally trained as a chemical engineer at the Eindhoven University of (male) Technology. He then shifted his focus of interest towards biomedical research and obtained his PhD at the University of Maastricht, after investigating the relationship between dietary habits, the formation of endogenous formation of carcinogenic compounds and colorectal cancer risk. Subsequently he worked for almost 4 years as a postdoctoral researcher on the relationship between dietary factors and modulation of chronic oxidative stress. In 2007 he continued his career in research management and –policy. Since 2009 he has been working as senior programme officer at ZonMw on several programmes including research and network programmes on rare diseases, both in a national and international context (E-Rare). List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Julkowska D, Austin CP, Cutillo CM, Gancberg D, Hager C, Halftermeyer J, Jonker AH, Lau LPL, Norstedt I, Rath A, Schuster R, Simelyte E, van Weely S. Gene Ther. 2017 Sep;24(9):562-571. The importance of international collaboration for rare diseases research: a European perspective. 2. Results of Networking Subsidy scheme in ZonMw programme Priority Medicines Rare Diseases and Orphan Drugs, page 131-132; https://www.zonmw.nl/fileadmin/documenten/Corporate/ZonMw_jaarverslag_2015.pdf 3. Report on E-Rare Strategic Workshop “Strategic Research Agenda of E-Rare in relation to other initiatives on rare diseases”, organised by ZonMw on March 7, 2016 in Barcelona (Spain), http://www.erare.eu/sites/default/ files/Report%20E-Rare%20Strategic%20Workshop%20March%207%202016%20VFF.pdf 35-UMCG Full legal name (Acronym) – Country Academisch Ziekenhuis Groningen (UMCG) - The Netherlands Principal investigator Prof.Dr. Morris Swertz Relevant Network BBMRI, ELIXIR Description of the legal entity/department/laboratory/group: The UMCG (Academisch Ziekenhuis Groningen) is the second largest academic hospital in the Netherlands with a staff of 10,000 people in patient care, education & training and research, with a focus on ‘Healthy Ageing’. The work is planned at the Genomics Coordination Center (GCC) a multi-discipliniary 25fte streong bioinformatics core facility and big data stewardship hotel of the UMCG and University of Groningen on a mission to unlock big data for personalized genomics using smart informatics software, methods and tools. GCC is part of the 66 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Department of Genetics, having Prof. dr. Richard Sinke (male) - head of diagnostics and power user from diagnostic perspective, Prof. dr. Nine Knoers (female) – head of department, Prof. dr. Cisca Wijmenga (female) – head of BBMRI-NL 2.0, immune/complex disease, Mw Prof. dr. Irene van Langen MD (female) – head of clinic, ELSI, power user from clinical perspective, Prof. dr. Lude Franke – head of research and leading in multi-omics data integration, Prof. dr. Rolf Sijmons MD (male) – daily power user, national ontology expert, consultant to the project. Main tasks in the project per Pillar/WP: In Pillar 2: WP11 UMCG will participate in tasks on Metadata and ontological model definition for cataloging resources for RD research (Task 11.1), FAIR-compliant virtual platform for discovery of RD resources (Task 11.2), Data deposition and access to data infrastructures for RD research (Task 11.3), and Provision of analysis and data sharing capabilities to the RD community through online resources (Task 11.4). /WP12 UMCG will participate in tasks to Compare and align core interoperability standards of relevance (Task 12.1), Multi-team software development to enable the FAIR ecosystem (Task 12.2), and Combining expertise for practical FAIRification support (Task 12.3). WP12 UMCG will participate in tasks to Fill a number of pre identified gaps to allow integrative systems biology approaches for rare diseases (Task 13.1) In Pillar 3: WP14 UMCG will participate in tasks on Standards and quality of genetics/genomics data in laboratory and clinical research practice (Task 14.2), Training on strategies to foster solutions of undiagnosed rare disease cases (Task 14.3), Training for biobanks and researchers/clinicians on sample data management (Task 14.4) and Training on rare disease registries and FAIRification of data at the source (Task 14.5) Previous experience relevant to the Tasks: The GCC is and has been part of several national and EU Rare Disease and Infrastructure grants in which we have developed tools to make biobank and registries data and samples findable and accessible and link it with sample/data request workflows. We developed the MOLGENIS software that we used to build the BBMRI-ERIC (Biobank) Directory and the RD-Connect Sample Catalogue. MOLGENIS is also used for Rare Disease patient registries, e.g. CHARGE database (chd7.org) DEB central (www.deb-central.org) AIP (aip.fipapatients.org), MVID (mvid-central.org). In particularly relevant the GCC develops and operates the UMCG facilities for large scale DNA and RNA data processing for research and genome diagnostic health care. In addition, GCC is lead of the BBMRI-NL Dutch national IT infrastructure for biobanking, the BBMRI-ERIC Directory (catalogue), BBMRI-NL Dutch data and sample catalogue, LifeCycle large scale harmonization and federated analysis of EU child cohort data; RD-connect sample catalogue, Solve-RD bioinformatics team, and task lead in EU CORBEL access to sensitive project and RD-connect linked data project. All software is available as open source as part of the MOLGENIS software platform for scientific data at http://www.molgenis.org. UMCG is ISO 9001 and ISO 27001 certified. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : GCC has a multi-discplinary team of 25 biologists, statisticians and computer scientist providing research, support, large scale analysis and data management. Next to open source software MOLGENIS, GCC hosts a database cloud consisting of 4 servers, 100 database servers and a computer cluster consisting of 20+ servers hosting >1500 Terabyte of NGS data, >1000 CPU cores and >5Terabyte of RAM. GCC is also host of the UMCG research IT infrastructure, in particular big data. In addition, UMCG is partner in University of Groningen Center for Information Technology, the second largest academic compute center in the Netherlands and part of SURF and Excelerate, with ample of capacity to host big data compute projects. Short Profile of key Staff Members who will be undertaking the work Pr. Morris Swertz Adj. Prof. dr. Swertz coordinates large scale bioinformatics research and support to the Dept. (male) of Genetics, other UMCG departments, and several (inter)national consortia. His research lines focus on: (1) methods for DNA, RNA and phenotype data analysis, and (2) user-friendly systems for large scale data management, analysis, interpretation and sharing. Swertz developed a novel data framework (Bioinformatics 2012) and computational framework (Molgenis/Compute) to enable large genome analyses, e.g. used in Genome of the Netherlands (EJHG 2013, Nature Genetics 2014), discovery of novel human gene-disease associations based on eQTL studies (NAR 2014), inconsistencies in the metabolic pathway knowledge (BMC Systems Biology 2013), and to inform genetic variant interpretation in various diseases (Human Mutation 2011-2015). Swertz also developed analysis methods to call genotypes from RNA-sequencing that enables identification of (rare) variants affecting 67 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases gene- expression levels (Genome Med 2015) and a framework to estimate RD variant pathogenicity classification for clinical application (Human Mutation 2015, Genome Biology 2017). Finally, Swertz is Co-Lead of BBMRI-NL 2.0 'IT', genetics datasharing in VKGL & VKGN, Co-lead of UMCG Personalized Genomics Medicine programme Lead of UMCG Research IT program, focus on big data. David Van Before making the switch to bioinformatics in 2010 David van Enckevort has worked in Enckevort different roles at commercial ICT providers in the Netherlands. From 2010 - 2013 he was a (male) Senior Software Integration Engineer and Technical project lead (TPL) for the biobanking task force at the Netherlands Bioinformatics Center (NBIC). As TPL he was responsible for the day-to-day management of the development of BBMRI-NL catalogue and the day to day management of the GoNL Imputation Working Group. In 2013 he joined the department of Genetics at the UMCG as a project manager and he is responsible for the day to day management of the BBMRI-ERIC CS-IT WP1 (development of the BBMRI-ERIC Directory), BBMRI-NL catalogue, RD-Connect Sample Catalogue and the RD-Connect Data Linkage plan (co-Lead by Marco Roos, LUMC) and the harmonisation effort as Dutch representative in the MIABIS working group. He is a member of GA4GH and was a key participant in the GA4GH/IRDiRC joint Privacy Preserving Record linkage working group and he is co-Chair of the ISBER Resource Locator Working Group. Dr. K. Joeri van K. Joeri van der Velde graduated as BSc Bioinformatics on pathway visualizations of kinase der Velde activity at the Groningen Bioinformatics Centre in collaboration with the UMCG dept. of Cell (male) Biology and then continued to work on MOLGENIS software infrastructure for multi-omics research in Arabidopsis, mice and C. elegans at the Groningen Bioinformatics Centre. In 2018 he obtained his PhD at the UMCG dept. of Genetics, working on new methods for downstream clinical analysis of next-generation sequencing data in the group of Prof. Swertz. Now, as a postdoc amongst a unique crowd of clinicians, software developers, geneticists, parallel computing experts, wet-lab technicians and statisticians, he aims to discover new ways to revolutionarize the speed, yield and applications of genome interpretation for medical genetics, powered by NL and EU collaborations (e.g. Solve-RD) and a wealth of untapped resources available in the public domain. Dr. Salome Salome Scholtens (PhD) is a programme manager and epidemiologist at the University Scholtens (female) Medical Center Groningen in the Netherlands. She is expert on data management training and the set-up of research data infrastructure. Patrick Deelen Patrick Deelen completed his BASc bioinformatics at the Hanze University Groningen in (male) 2010 and his MSc of bioinformatics at the VU University Amsterdam in 2012 with honors. He is currently working on his PhD thesis at the genetics department of the UMCG. He mostly works on DNA and RNA data of population’s cohorts. He worked on the Genome of The Netherlands, Lifelines, and the BIOS cohort. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Holub, Swertz, Reihs, van Enckevort, Muller and Litton (2016). "BBMRI-ERIC Directory: 515 Biobanks with Over 60 Million Biological Samples." Journal/Biopreserv Biobank 14: 559-562. DOI: https://doi.org/10.1089/bio.2016.0088 2. Pang, Hendriksen, Dijkstra, van der Velde, Kuiper, Hillege and Swertz (2015). "BiobankConnect: software to rapidly connect data elements for pooled analysis across biobanks using ontological and lexical indexing." Journal/J Am Med Inform Assoc 22: 65-75. DOI: https://doi.org/10.1136/amiajnl-2013-002577 3. Van Diemen, et al, van der Velde, et al, Swertz, Sinke, van Langen, Wijmenga (2017) Rapid Targeted Genomics in Critically Ill Newborns. Peadiatrics 140(4). DOI: https://doi.org/10.1542/peds.2016-2854 4. K. Joeri van der Velde, et al, Morris A. Swertz. “GAVIN: Gene-Aware Variant INterpretation for medical sequencing.” Genome Biology, 201718:6. DOI: https://doi.org/10.1186/s13059-016-1141-7 5. Patrick Deelen, et al, Morris A Swertz and Lude Franke "Calling genotypes from public RNA-sequencing data enables identification of genetic variants that affect gene-expression levels" Genome Medicine2015 7:30, DOI: https://doi.org/10.1186/s13073-015-0152-4 List of relevant previous projects or activities, connected to the subject of this proposal : 1. RD-Connect; European Union; 2012-2018; lead development of the RD-Connect Sample catalogue and integrated it with the Registry and Biobanks finder; co-Lead of the RD-Connect data linkage plan to link data from different sources; Data harmonisation and improving findability according to the FAIR principles. 68 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 2. Solve-RD; European Union; 2018-2022; Development of the Solve-RD Sandbox environment for development and piloting of innovative diagnostic tools; Data harmonisation and improving findability according to the FAIR principles. 3. ADOPT; European Union; 2015-2018; As part of ADOPT and the BBMRI-ERIC Common Services for IT we developed the BBMRI-ERIC biobank Directory and integrated the Directory with the BBMRI-ERIC Negotiator tool. 4. SAID, E-RARE; European Union/ZonMW; 2016-2020; lead large scale data sharing, annotation and integration for DNA variants, *omics and phenotypes from patients suffering from systemic autoinflammatory diseases 5. CORBEL; European Union; 2016-2020; We focussed in particular on interoperability (e.g. BiobankConnect) and systems to access sensitive human data. 36-UM Full legal name (Acronym) – Country Maastricht University (UM), The Netherlands Principal investigator Prof. Chris Evelo Relevant Network ELIXIR Description of the legal entity/department: Maastricht University (UM), the most international university in the Netherlands, stands out for its innovative approach to learning and international outlook. With almost 16,000 students and 4,000 staff, UM offers a wide choice of academic programs, all of which are designed to bring out the best in its students. The Department of Bioinformatics – BiGCaT uses bioinformatics and integrative systems biology approaches to answer questions in biology. Technologies and algorithms are continuously explored to make biological knowledge and data more Findable, Accessible, Interoperable, and Reuseable (FAIR) and then actually reuse them for multi- omics data integration to answer new questions. Pathway and network biology form the heart of the in silico approaches used to explain health and disease issues with including the role of nutrients, the interaction of (nano)materials with biological matter, and the role of metabolism and other small compounds in human health. The unit comprises 6 FTE senior researchers and 8 PhD candidates, all doing research around biological data integration and analysis. Main tasks in the project per Pillar/WP: Contribution in Pillar 2: In WP10, we will contribute to the annual strategic plans for WP2&3 and to the bi-monthly progress reports and strategy discussions with WP11 and 12 leaders . In WP11 we will contribute to define ontological and metadata models for new relevant sources, to adapt the ELIXIR’s bio.tools for the RD community, to enhance the catalogue platform for query capabilities and collaboratively analysis multi-omics data from the selected use cases. In WP 12, we will contribute to develop and improve metadata (and other data) models, and the federation architecture, networks and registries In WP13, we will act as WP leader; we will co-lead the gap filling task to help facilitate holistic approaches using omics and genetics data in rare diseases ; we will participate in the proof principle studies to show and improve the usability of the work flows from task 13.1; we will make a connection with pillar 3 to provide training in the usage of the workflows developed in the WP. Previous experience relevant to the Tasks: Our work focuses on integrative (FAIR) data approaches in systems biology. This WP tries to make that approach work for rare diseases and is thus exactly in line with our expertise and available skills and resources. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Servers to run WikiPathways and related tool and data collections Short Profile of key Staff Members who will be undertaking the work Pr. Chris Evelo Prof. Evelo is the founder and head of the department of Bioinformatics - BiGCaT and is a PI in (male) the Maastricht Center for Systems Biology (MaCSBio). His research focus is on bioinformatics for integrative systems biology; aiming at a better interpretation of experimental data through integration in data models that build on structuring existing knowledge. Integrative approaches are multi-faceted, and as a generalist he is involved in many projects related to capturing and processing, integrating and understanding experimental data. This 69 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases includes the interoperability approaches underlying such efforts: standards, ontologies, mapping tools and documentation of the origin of the data and methods used (the provenance). He is a co- lead of the interoperability platform of ELIXIR which he represents in the rare disease use case. WikiPathways and the accompanying mapping, analysis and network biology tools form his core project. WikiPathways is a resource for community curation of biological pathways and originates from collaboration with Alex Pico’s group at UCSF. He is a board member of the Open PHACTS foundation for large-scale semantic web based knowledge structuring of relations between chemicals, gene-products and diseases. Chris is scientific advisor for the IMI project for translational quantitative systems biology (TransQST) and for two SME’s (Edgeleap and Micelio). He is a.o. governing council member of the nutrigenomics organization NuGO, a member of the micronutrient genomics organization for which he lead the IRSES project Microgennet, involved in H2020 projects OpenRiskNet and EUToxRisk and a workpackage leader in the COST CHARME for harmonization of standards in biology and a member of the JPI ENPADASI that works on the development of a phenotype database that he helped conceptualize and develop. Dr. Friederike Dr. Friederike Ehrhart is currently post-doc researcher at the Department of Bioinformatics (head Ehrhart of department: Prof. Dr. Chris Evelo) and the Dutch Rett Expertise Centre-GKC (director: Prof. (female) Dr. Leopold Curfs). Educated and trained as cell and molecular biologist, working on tissue engineering of neurological, pancreatic and liver tissue, and high throughput and omics data approaches. Joining the Department of Bioinformatics at Maastricht University in 2015 she works on systems biology and bioinformatics methods to analyze (single or multi) omics data, especially within pathway and network analysis. Together with the Dutch Rett Expertise Centre in Maastricht she is working since 2016 on the systems biology of Rett syndrome, a rare neurological disorder with a genetic cause. Friederike has coordinated and co-coordinated 7 public and 3 industry funded projects and published 23 papers. Within ELIXIR (EU bioinformatics infrastructure project) she coordinated an implementation study which analyses and improves molecular data interoperability of rare diseases. She is a member of the SSBP (Society for the Study of Behavioral Phenotypes) to investigate (rare) genetic syndromes and their phenotypic outcome including fetal alcohol syndrome, Prader-Willi and Angelman syndrome. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. WikiPathways and PathVisio biological pathway collections and related analytical tools including network biology connections including BridgeDb database identifier mapping services and mappings for gene products and gene variants. 2. WikiPathways: capturing the full diversity of pathway knowledge. 2015. M Kutmon et al. NAR 44 (D1), D488. 3. The FAIR Guiding Principles for scientific data management and stewardship. 2016. MD Wilkinson et al., Scientific data 3 4. Open PHACTS: semantic interoperability for drug discovery. 2012. AJ Williams et al., Drug discovery today 17 (21-22), 1188. 5. Rett syndrome–biological pathways leading from MECP2 to disorder phenotypes. 2016. F Ehrhart et al. Orphanet journal of rare diseases 11 (1), 158. List of relevant previous projects or activities, connected to the subject of this proposal:  ELIXIR EXCELERATE; H2020; 2015-19; helps ELIXIR coordinate and extend national and international data resources to ensure the delivery of world-leading life-science data services: co-leading the interoperability platform and linking this to the rare disease use case.  Open PHACTS; IMI; 2011-16; Open Pharmacological Concepts Triple Store for drug discovery: central tech team, providing RDF formatted pathways, identifier mapping services & mappings, driver question resolution.  OpenRiskNet; H2020; 2016-19; Open e-Infrastructure to support risk assessment: API & ontology development.  EUToxRisk; H2020; 2016-21; ‘Flagship’ program driving mechanism-based toxicity testing and risk assessment: Adverse Outcome Pathway development and use in analysis, link to Open PHACTS  MICROGENNET; FP7/H2020; 2012-15; collaborations for a community-driven knowledge base for micronutrient genomics, coordinator. 70 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 37-NCBR Full legal name (Acronym) – Country The National Centre for Research and Development (NCBR), Poland Principal investigator Marcin Chmielewski Relevant Network E-Rare-3 / EJP RD Description of the legal entity/department/laboratory/group: The National Centre for Research and Development is the implementing agency of the Minister of Science and Higher Education. It was appointed in the summer 2007 as an entity in charge of the performance of the tasks within the area of national science, science and technology and innovation policies. When if was founded, it was the first entity of this type, created as the platform of an effective dialogue between the scientific and business communities. The main task of the National Centre for Research and Development is management and execution of strategic research and development programs, which lead directly to the development of innovativeness. Among the tasks of the National Centre for Research and Development, are the support of commercialization and other forms of transfer of scientific research results, the management of applied research programs and the performance of national security and defense projects. The Centre also attempts to provide young scientists with training and development opportunities i.a. by implementing international scientific mobility programs. Special attention is paid to the participation of young scientists in research programs. The Centre enables young researchers to expand their business and intellectual property management skills and to learn how to commercialize research results. At the same time, via implemented initiatives, it draws attention to the necessity of rasing the R&D staff’s awareness of the importance of industrial property protection to the commercialization of modern solutions and international patent protection opportunities for research units. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will participate in JTCs for proposals as a programme partner (WP6.1, 6.2, 6.3 and 6.4). Previous experience relevant to the Tasks: NCBR is the most important research funding agency in Poland. Currently, it operates under the Act on National Centre for Research and Development dated 30 April 2010 (Journal of Laws from 2010, No. 96 item 616). The science reform adopted in the autumn 2010 gave the Centre more freedom to manage its financial assets, within the scope of a strategic research programme. In addition, the National Centre for Research and Development extended its activity with new initiatives and possibilities on 1 September 2011. Assigned by the Ministry of Science and Higher Education the function of the Mediation Institution in three operational programmes: Human Capital, Innovative Economy and Infrastructure and Environment, the Centre became one of the greatest innovation centres in Poland. The activity of the Centre is funded by the national treasury and the European Union. NCBR participates in more than 30 different international initiatives (ERA-NETs, JPIs, bilateral cooperation programmes). Short Profile of key Staff Members who will be undertaking the work Dr Marcin Marcin Chmielewski, Chief expert in Programmes Management Department, studied Chmielewski Biology at the University of Warsaw, specialisation - Parasitology. He got his PhD from the /Male Warsaw Medical University on the thesis “Apoptosis during the course of infection with hepatitis C virus (HCV) and human immunodeficiency virus (HIV).” Former lecturer at Warsaw Medical University. Since summer 2011 employed in National Centre for Research and Development (NCBR) as a Scientific officer. Currently responsible for coordination of international programs in the field of medicine. Main task is to take care of the projects during the whole funding period. It includes administrative and formal issues, but also scientific reviews. Matylda Matylda Marczak, Senior Expert in Financial Department of NCBR. Main responsibilities Marczak/Female are: financial control of the projects financed from national and international programs. 71 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 38-MUW Full legal name (Acronym) – Country Medical University of Warsaw (MUW) Poland Principal investigator Associate Professor Maciej Kosieradzki Relevant Network Description of the legal entity/department/laboratory/group: Department of General and Transplantation Surgery, Medical University of Warsaw is a clinical department that has a great experience with organ’s transplantation and it is an active member of European Transplantation Society. Our experience is based on transplantation liver, kidney and pancreas/ islet cells including patients with rare disease. The Department has clinical facilities and laboratory space dedicated just for departments’’ needs, diagnostic facilities are also included and High-class specialists with international experience. Main tasks in the project per Pillar/WP: Pillar 0: WP2 Task 2.5: Translation/impact of prioritization on national and EU strategies-co-leader Task 2.2 Mapping the research and innovation needs - Verification of integrated and coordinated set of commitments and actions designed to exploit core competencies on national level. - Sharing the good practice. - Grouping, verifying of specific therapeutic needs. - Identification of tasks during ongoing program, which were not included in the program. - Monitoring and controlling of the ongoing activities. - Analysis of risks and problems and adjusting the tools to solve them. Pillar 2: Task 12.1: Compare and align core interoperability standards of relevance Task 12.2 : Multi-team software development to enable the FAIR ecosystem We will 1) Identify diagnosis and standardization of procedures for international and interdisciplinary system which will classify diseases based on geno-diagnosis. 2) Improve the diagnostic and therapeutical standards. 3) Verification of caring out the preclinical and clinical research within Rare Disease 4) Monitor of oncological patients with RD 5) Develop infrastructure of R&D based on research of ATMPs indicated to RD, Oncology and Personalized Medicine. 6) Assessment of pharmacotherapy including safety and efficacy of medicinal products and analysis of benefit-risk ratio We will try to develop IT program together with centres, which have already existing data to harmonize diagnosis, symptoms, clinical treatment and monitoring follow-up in patients with RD. Development of clinical protocol to introduce as international standards for clinical study phase 1,2 and 3 including primary and secondary points to evaluate the benefit/risk ratio. Pillar 3: Task 14.1: Training on the Orphanet nomenclature and RD ontologies for RD research We will take a part in scientific committee for training on the Orphanet nomenclature and RD ontologies for RD research. Previous experience relevant to the Tasks: 1) develop diagnosis and standardization of procedures for international and interdisciplinary system 2) set the diagnostic and therapeutical standards. 3) Monitor of oncological patients with RD We have profound experience in transplantations of patients with RD proceeded from 2000: PSC – 48, Wilson – 24, HEHE – 2, Frantz tumor – 2, FAP – 2 Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work (if applicable): We have full equipment and laboratory with specialization of ATMP research adequate to European standards for developing research and clinical trails for advanced therapy medicinal products in patients with rare disease and/or personalized medicine in oncology. Short Profile of key Staff Members who will be undertaking the work 72 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Associate Professor Maciej Head of the Department of General and Transplantation Surgery, Medical Kosieradzki, University of Warsaw. High class specialist with international experiance, from Male 2011 has been certified a European Board of Surgery Qualification in Transplantation Surgery. Research intern in the Division of Transplantation, Department of Surgery of the University of Wisconsin, Madison. President of an NGO, Polish Union for Transplantation Medicine. He was involved in EC project “Coordinationg a European Initiative among National Organizations for Organ Transplantation”. He manages a department that treats 24 patients with Wilson disease, nearly 50 patients with primary sclerotising cholangitis and some rare liver tumors. He authored 51 articles indexed in Medline. Professor Piotr Fiedor Prof. Piotr Fiedor, since 2010 up to 2017 held position of polish member of Male Committee for Medicinal Products for Human Use (CHMP) in European Medicine Agency (EMA). Prof. Fiedor is an clinicial professor hired by Medical University of Warsaw and was Chief of Executive Officer at National Medicines Institute in Warsaw, Poland. 2010-2013 – alternate member of Biological Working Party, European Medicines Agency. Additionally, he is an active expert in Scientific Advisory Group EMA. Professor Fiedor is clinical professor with long-term clinical experience (surgery, oncology, transplantology, immunology). He was a member of Orphan Diseases Group by the Ministry of Health and member of Medicinal Product Commission by the President of The Office for Registration of Medicinal Products, Medical Devices and Biocides. Prof. Fiedor is a international Expert in assessment and review of research programs and scientific collaboration by The Ministry of Science and Higher Education. He published over 140 scientific papers. Associate Professor Marek High class specialist, transplantologist with international experiance, involved in Pacholczyk The European Society of Organ Transplantation, The Polish Hepatology Society, Male Male The Polish Surgery Society. Currently he is working in the Department of General and Transplantation Surgery, Medical University of Warsaw. Asc. Profesor with long-term clinical experience. He authored 62 articles indexed in Medline. PhD Karolina Maria PhD, currently MBA student at ESG University of Quebec at Montreal (ESG Nowak UQAM) and Warsaw School of Economics, Internship in Stanford Biomaterials and Female Advanced Drug Delivery Laboratory, School of Medicine, she finished with honors Postgraduate Management Studies, Leadership 2.0 at the Warsaw School of Economics. Participation in Science Management and Commercialization Program, Stanford Centre for Professional Development, Stanford University. Previous experience as a acting head of R&D office in National Medicine Institute. Eight years of experience in research and development in Pharmaceutics. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Immune biomarkers and long-term graft survival: a prospective follow-up of 457 kidney transplant recipients. Ciszek M, Mucha K, Foroncewicz B, Żochowska D, Kosieradzki M, Grochowiecki T, Durlik M, Górski A, Pączek L. Pol Arch Intern Med. 2017 Feb 15;127(3):178-183. doi: 10.20452/pamw.3937. 2. Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature Review Tronina. O, Ślubowska K, Mikołajczyk-Korniak N, Komuda-Leszek E, Wieczorek-Godlewska R, Łągiewska B, Pacholczyk M Lisik W, Kosieradzki M, Durlik M. Transplant Proc. 2017 Jul - Aug;49(6):1409-1418. doi:10.1016/j.transproceed.2017.01.077. 3. The effects of in vitro hemodilution and fibrinogen concentrate substitution on thromboelastometry analysis in patients qualified for liver transplantation - Preliminary results. Nicińska B, Pluta J, Kosieradzki M, Lągiewska B, Wasiak D, Lazowski T, Chmura A, Trzebicki J. Transplant Proc. 2014 Oct;46(8):2758-61. doi: 10.1016/j.transproceed.2014.09.048. 4. Regulatory evaluation of Glybera in Europe - two committees, one mission. Melchiorri D, Pani L, Gasparini P, Cossu G, Ancans J, Borg JJ, Drai C, Fiedor P, Flory E, Hudson I, Leufkens HG, Müller-Berghaus J, Narayanan G, Neugebauer B, Pokrotnieks J, Robert JL, Salmonson T, Schneider CK.Nat Rev Drug Discov. 2013 Sep;12(9):719. doi: 10.1038/nrd3835-c1. 5. Liver transplantation for nonresectable metastatic solid pseudopapillary pancreatic cancer. Annals of Transplantation 2013; 18: 651-3. 73 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases List of relevant previous projects or activities, connected to the subject of this proposal :  BIOOPA (Epidermolisis bullosa), NCBR; 2016- is pending – Coordinator of project, This project is the world's first research project based on the use of allogeneic human skin matrix ADM seeded with allogeneic stem cells and on a dressing of autologous cells taken from the areas of revertant mosaicism in the epidermolysis bullosa treatment.  International cooperation to develop new research for medicinal product in RD (preclinical study)  Isolation/immunomodyfication of hepatocytes and pancreatic islets National transplantation program-Polgraft, steam cells. 39-MUG Full legal name (Acronym) – Country Medical University Gdansk (MUG),Gdanski Uniwersytet Medyczny (GUMed), Poland Principal investigator Aleksandra Zurowska Relevant Network MUG members of ERKNet, PaedCan,eUROGEN, BBMRI.pl Description of the legal entity/department/laboratory/group: Medical University Gdansk teaches nearly 3000 students( including >800 international students) at its teaching hospital which is the largest in Northern Poland (1300 beds) with all specialities represented and full diagnostic and research facilities on site. Its Centre for Rare Diseases incorporates research, teaching activities of the departments which are members of several European Reference Networks. Department of Pediatrics, Nephrology & Hypertension and Department of Nephrology, Transplantation & Internal Medicine are members of ERKNet involved in the care of rare kidney diseases. Department Surgery & Urology for Children and Adolescents , a member of PaedCan ERN, eUROGEN ERN Department Pediatrics, Oncology & Hematology includes Infant Ward dedicated to rare diseases, member of PaedCan ERN Department Clinical Analytics- Central Bank Frozen Tissues and Genetic Specimens – member of BBMRI.pl Main tasks in the project per Pillar/WP: Pillar 3: WP 14. Capacity Building and Empowerment. We will be one of task leaders for Training for biobanks and researchers/clinicians on sample data management hosting 1 of annual workshops in Gdansk, Poland (Task 14.4) WP 15. Capacity building and training of patients and researchers in Rare Disease research and processes. We will be one of task leaders for Training for patient representatives and advocates on leadership and communication skills supporting the development of the annual face-to-face 2 days training programme for 30 participants and organising 1 of the rotating location courses in Gdansk, Poland (Task 15.3) Previous experience relevant to the Tasks: We have helped in the establishment of several patients organisations for rare diseases e.g Tuberous Sclerosis Complex (TSC), Hemolytic Uremic Syndrome (aHUS), Alport Syndrome. We have been long term cooperation with non-governmental organizations from all over Poland, including: Cornelia de Lange Association, Parent Project ( DMD) , Williams Syndrome Association , Fra X Family, Prader Willi Association, TSC, aHUS etc. We have organized a series of nationwide conferences on rare diseases with the participation of representatives of patient organizations and two international conferences for Duchenne Disease Families (Sobieszewo 2013 and 2015) as well as three conferences for Down Syndrome patients and families from Pomeranian district for Phenyloketonuria and LCHADD. We participate in annual conferences for Cornelia de Lange and William Syndrome Families and TSC Association. The CBTFT&GS functions as an IT node biobank for the Polish biobanking network as well as for the Biobanking and Biomolecular Resources Research Instructure (BBMRI) - European Research Instructure (ERIC). The CBTFT&GS is a gating biobank of BBMRI.PL for retrieving data from health- and public-related country databases (National Health Fund, Central Statistical Office, National Cancer Registry) as well as with the biobanks databases of BBMRI.EU. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : we have well equipped lecture halls with multimedia support and simultaneous translation capabilities and modern Biobank facilities (Fully automated and robotized repository, Omics labs, Cell biology unit , histochemical unit with fully automated system for tissue staining procedures, IT scanning and telemetric transfer system of images, TMA equipment, Unit for preclinical studies with modalities for in vivo imaging). Short Profile of key Staff Members who will be undertaking the work 74 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Prof Aleksandra Zurowska, professor in pediatric nephrology, head Department Paediatrics, Aleksandra Nephrology & Hypertension, the President of The Polish Pediatric Nephrology Association, Zurowska former council member of ESPN and IPNA. Organiser of Polish Registry for Renal femle Replacement Therapy in Children closely collaborating with International Registries – ESPN ERA/EDTA Registry and IPDN involving other ERKNet Centres . Poland’s national representative in the ESPN/ERA-EDTA Registry, member of the European Pediatric Dialysis Working Group which issues guidelines on the management of children with Chronic Kidney Disease. Endorses multicentre activities like PolTube, Polish HUS Registry. Disseminates knowledge and guidelines organising working groups for National Guidelines for both specialists and the general practitioner. Organiser of national multicentre projects in rare diseases initiating the Polish PODONET, Nephrosis Online, paediatric ADPKD Registry and Alport Registry. International collaboration > 15years in the ESCAPE Clinical Research Network IPDN, PodoNet and ESPN Registries. Author of > 200 publications ( 40 joint international publications). Prof Ass Professor Jolanta Wierzba Pediatrician, Clinical Genetist, specialist of pediatric Jolanta metabolism , Head of Department of Infant Pathology, Consultant of the Outpatients Genetic Wierzba Department. Member of the World Scientific Advisory Council Cornelia de Lange syndrome. female Member of board of Polish Society of Human Genetics .Author of > 200 publications mostly related to genetically determined diseases. Prof Alicja Slizien Debska, professor of nephrology. Head of the Department of Nephrology, Alicja Debska Transplantology and Internal Medicine. Coordinator of Transplantation programme for Northern Slizien Poland, organiser of Reference centre for Tuberous Sclerosis Complex, involved in setting female national guidelines for ADPKD and kidney management in TSC. Author of nearly 500 publications. Prof Piotr Czauderna, professor paediatric surgery. Head Department Surgery and Urology for Piotr Children and Adolescents and President of European Pediatric Surgeon's Office of European Czauderna Union of Medical Specialists (UEMS).Former member of Scientific Committee of the male International Society for Pediatric Oncology (SIOP), chairman of International Liver Tumors Strategy Group in Children – SIOPEL, former president of the Polish Society of Pediatric Surgeons. Involved in several European projects on rare paediatric cancers (ENCA,EXPORNET). Author of >180 publications. Prof Head of Department of Clinical Analytics at Faculty of Pharmacy and co-organiser of Central Leszek Bank of Frozen Tissues and Genetic Specimens in MUG. Co-organiser and vice-national Kalinowski coordinator of BBMRI.pl a partner of BBMRI-ERIC and a member of BBMRI.EU clinical male biobank working group. Author of > 100 scientific publications in clinical analytics. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1.Members of 3 ERN’s: ERKNet, eUrogenERN, PedCanERN since 1st March 2017 2.Datasets : National Registries for: Renal Replacement Therapy in Children , Alport Syndrome, ADPKD, PolishPODONET (steroidresistant nephrotic syndrome- modern diagnostic genetic programme ), Hemolytic-Uremic Syndrome. Close collaboration with International Registries – ESPN ERA/EDTA Registry and IPDN which includes 16 other ERKNet centres 3.International research activities and clinical trials ( ESCAPE, PREDICT, PODONET, Levamisol Trial in SDNS) and national multicentre activities;. 10 year record of organising national workshops for promoting national multicentre studies and dissemination of specialized guidelines in nephrology. National Reference Centre for Tuberous Sclerosis Complex, Cornelia di Lange Syndrome and Williams Syndrome, National node for Pediatric Liver Tumours affiliated with the SIOPEL [International Childhood Liver Tumors Strategy Group], internartional projects on rare tumours ENCA,EXPORNET. 4. Publications : Kidney Versus Combined Kidney and Liver Transplantation in Young People With ARPKD: Data From the ESPN/ERA/EDTARegistry. Mekahli D, van Stralen KJ, ..Zurowska A, et al Am J Kidney Dis. 2016 Nov;68(5):782-788. European Reference Networks: Share, Care, and Cure-Future or Dream? Wijnen R, Anzelewicz SM, Petersen C, Czauderna P. Eur J Pediatr Surg. 2017 Oct;27(5):388-394. Organization of BBMRI.pl: The Polish Biobanking Network. Witoń M, Strapagiel D, .., Kalinowski L, et al. Biopreserv Biobank. 2017 Jun;15(3):264-269. List of relevant previous projects or activities, connected to the subject of this proposal : 1.ERKNet Registry for Rare Kidney Diseases [ERK-REG] grant [PARTNER} and ERN-PAEDCAN: Paediatric 75 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Rare Tumours Network - European Registry grant [PARTNER]: CHAFEA Health programme grants 1/1/2018-30/12/2020 2. Introduction of reimbursed Eculizumab drug programme for atypical Hemolytic Uremic in Poland in cooperation with aHUS patient organisation on 1st Jan 2018 3. International 2 day conferences for Duchenne Disease Families ( Poland, Sobieszewo 2013 and 2015) 3. National 2 day Conference “ Rare disorders”,Dec.2016,Gdansk,Poland:participation 15 patient organisations 5. co-organizer of BBMRI.pl partner with BBMRI-ERIC 40-IPCZD Full legal name (Acronym) – Country “Instytut Pomnik- Centrum Zdrowia Dziecka” (IPCZD), Poland Principal investigator Prof. Krystyna Chrzanowska Relevant Network Orphanet Description of the legal entity/department/laboratory/group: The Children's Memorial Health Institute is a research institute, and also one of the largest specialized pediatric hospitals in Poland acting for the benefit of modern pediatrics. The aim of the Institute is to conduct research and development activities and to provide medical services focused on the health needs of children, adolescents and young adults. The Institute also undertakes teaching responsibilities aimed at adapting the results of research and development into practice. The CMHI has been awarded category A+ by the Polish Ministry of Science and Higher Education, a category granted only to research institutes with the highest quality R&D. The CMHI’s scientific and clinical achievements are the result of nearly 40 years of work of its medical staff. The CMHI is one of the main Polish reference centers for rare diseases- it leads two ERNs (transplantation and epilepsy). The Department of Medical Genetics of the CMHI is focused on both diagnostics of a wide spectrum of rare genetic diseases/syndromes to provide complete genetic counseling for families at risk, and on translational research aimed at unravelling physiologic and disordered molecular mechanisms leading to a disease, with the ultimate aim of improving patient care. Dysmorphic syndromes, inherited errors of metabolism (including mitochondrial disorders), imprinting disorders, and chromosomal instability syndromes are of particular interest. Various genetic techniques are used: cytogenetic, molecular (including NGS, i.e. targeted diagnostic panels, WES, WGS), methylation analysis). In the period 1980-2017, over 110 research projects were realized, and over 215 peer-reviewed papers were published (IF=985.517). Main tasks in the project per Pillar/WP: Pillar 2: Orphanet LTP and Network will contribute to subtask 2.2.2. Create a catalog of research projects and clinical trials, on an ongoing basis, to inform funders (IRDiRC Roadmap priority). Pillar 3: In WP14(Training on data management & quality):  Task 14.1: Developement of a novel training modules for clinicians and scientists involved in various rare disease research fields: After some adaptation to country-specific needs, the Orphanet Network teams will organise trainings in their countries in their national language.  CMHI (KCH) is a contributor of the Task 14.2: Standards and quality of genetics and genomics data in laboratory and clinical research practice. One of the courses will be organised by CMHI in Poland.  CMHI (KCH/PS) is a contributor of the Task 14.3: Training on strategies to foster solutions of undiagnosed rare disease cases. CMHI will contribute in presenting one or two selected cases. In WP18 (Development and adaptation of training activities):  CMHI (KCH) is a Co-Leader of the Task 18.2 together with VUHSK: Evaluation of strategic priorities and development of existing training activities according to specific needs of EU-13 countries. Short Profile of key Staff Members who will be undertaking the work Prof. Krystyna Chrzanowska Krystyna Chrzanowska MD, PhD: Paediatrician and Consultant in Clinical 76 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases (female) Genetics, Full Professor and Head of the Department of Medical Genetics and Genetic Counseling Unit, CMHI, Warsaw, Poland. Special interest in clinical and molecular aspects of dysmorphic syndromes, chromosomal instability syndromes and imprinting disorders. Principal investigator (10) and investigator (16) in national projects sponsored by government institutions, contributed in 7 EU projects (PERFECT, EURO-PID-NAS, DYSCERNE, ORPHANET EUROPE, RD ACTION, EUCID, EuroCID). Over 155 peer reviewed publications (125 indexed in PubMed, IF >540, h-index 29, citations >3200); also review articles and book contributions. Member of the Orphanet Poland since 2011. Prof. Piotr Socha Professor of Pediatrics & Gastroenterology in the Department of (male) Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics in CMHI and the Director Deputy for Research. His research and clinical work were mainly devoted to cholestatic liver disease, non-alcoholic fatty liver disease,rare metabolic liver diseases (eg. Wilson disease, newly described PGM-1), nutrition in hepatology and gastroenterology (eg. LCPUFA deficiency), obesity prevention and therapy, feeding disorders, protracted diarrhoea of infancy and early childhood. Piotr Socha was the chair of the Hepatology Committee of ESPGHAN (2010-2013) and he was appointed Scientific Secretary of ESPGHAN in 2015. Piotr Socha contributs/contributed to 7 EU projects (CHOP, EUROWILSON, EARNEST, PERFECT, NUTRIMENTHE, TOYBOX, EARLY NUTRITION). He was the president of the Polish Society for Pediatric Gastroenterology, Hepatology and Nutrition. He published over 400 peer reviewed papers (160 indexed in pubmed) and contributed to 40 book chapters. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Krystyna Chrzanowska actively participated in EUCID (COST Action project BM 1280), and in writing recommendations by 36 international Silver-Russell syndrome specialists: Diagnosis and management of Silver-Russell syndrome: first international consensus statement. Wakeling EL, Brioude F, Lokulo-Sodipe O, O'Connell SM, Salem J, Bliek J, Canton AP, Chrzanowska KH, et al. Nat Rev Endocrinol. 2017;13(2):105- 124. Krystyna Chrzanowska initiated Nijmegen breakage syndrome registry in Poland (a world largest group of patients with NBS), and continued international collaboration contributing in EURO-PIDNAS and EuroCID grants, which resulted many publications, e.g.: Nijmegen Breakage Syndrome: clinical and immunological features, long- term outcome and treatment options - a retrospective analysis. Wolska-Kusnierz B., Gregorek H., Chrzanowska K., et al. on behalf of the Inborn Errors Working Party of the Society, for European Blood and Marrow Transplantation, the European Society for Immune Deficiencies. J Clin Immunol. 2015;35(6);538-549 Piotr Socha- led the Polish group of experts in the EU EUROWILSON project, which was devoted to construction of a European database for Wilson disease 3. Wilson's Disease in Children: A Position Paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Socha P, Janczyk W, Dhawan A, Baumann U, D'Antiga L, Tanner S, Iorio R, Vajro P, Houwen R, Fischler B, Dezsofi A, Hadzic N, Hierro L, Jahnel J, McLin V, Nobili V, Smets F, Verkade HJ, Debray D. J Pediatr Gastroenterol Nutr. 2018 Feb;66(2):334-344. 5. A heterozygous mutation in GOT1 is associated with familial macro-aspartate aminotransferase. Kulecka M, Wierzbicka A, Paziewska A, Mikula M, Habior A, Janczyk W, Dabrowska M, Karczmarski J, Lazniewski M, Ginalski K, Czlonkowska A, Socha P (corresponding author), Ostrowski J (corresponding author). J Hepatol. 2017 Nov;67(5):1026-1030. List of relevant previous projects or activities, connected to the subject of this proposal : Prof. Krystyna Chrzanowska:  PERFECT; EC FP5; 2002-2005, leader WP4  EURO-PID-NAS; 2003-2004; investigator  DYSCERNE, 2007-2010; investigator  ORPHANET EUROPE; EC 2nd Health Programme; 2011-2014; partner, Co-Coordinator in Poland  RD ACTION; EC 3rd Health Programme EU; 2015-2018; partner, member of the Polish team  EUCID; COST ACTION BM 1208; 2013-2016, member of the management board 77 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases  EuroCID, ERA-NET e-Rare; 2016-2019; investigator Prof. Piotr Socha:  CHOP; EC FP5, 2002-2006, investigator  EUROWILSON; EC FP6, 2004-2008, principal investigator  PERFECT; EC FP5, 2003-2005, investigator  EARNEST; EC FP6, 2005-2010, investigator  NUTRIMENTHE; EC FP7, 2008-2013, investigator  Toybox; EC FP7, 2010-2014, principal investigator  41-FCT Full legal name (Acronym) – Country Fundação para a Ciência e a Tecnologia (FCT), Portugal Principal investigator Anabela Isidro Relevant Network E-Rare-2, NEURON II, Infect-ERA, FLAG-ERA, BESTF Plus Description of the legal entity/department/laboratory/group: Fundação para a Ciência e a Tecnologia is the national funding agency that supports science, technology and innovation, in all scientific domains, under responsibility of the Ministry for Science, Technology and Higher Education, in Portugal. FCT started its activity in August 1997, succeeding the Junta Nacional de Investigação Científica e Tecnológica (JNICT). Since March 2012 FCT has coordinated public policies for the Information and Knowledge Society in Portugal, after the integration of the Knowledge Society Agency-UMIC. In October 2013, FCT took over the attributions and responsibilities of the Fundação para a Computação Científica Nacional (FCCN), [Foundation for National Scientific Computation]. FCT’s mission is to continuously promote the advancement of knowledge in science and technology in Portugal, attain the highest international standards in quality and competitiveness, in all scientific and technological domains, and encourage its dissemination and active role in society and in economic growth. FCT pursues its mission by funding fellowships, studentships and research contracts for scientists, research projects, internationally competitive research centres and state-of-the-art infrastructures, via competitive calls with international peer-review. FCT ensures Portugal’s participation in international scientific organisations, fosters the participation of the scientific community in international projects and promotes knowledge transfer between R&D centres and industry. Working closely with international organisations, FCT coordinates public policy for the Information and Knowledge Society in Portugal and ensures the development of national scientific computing resources. The results of FCT accomplishments are, in essence, the outcome of the work carried out by the individual scientists, research groups and institutions that are funded by FCT. Main tasks in the project per Pillar/WP: Pillar 1: In WP9, we will participate, as contributors, in the monitoring exercise of the Joint Transnational Calls for collaborative research projects (task 9.1), led by CSO-MOH (Israel) and co-led by DLR (Germany). Previous experience relevant to the Tasks: Over the last years, FCT team has been involved in the monitoring processes of the Joint Transnational Calls in several ERA instruments and initiatives, from all scientific domains (Social Sciences and Humanities, Exact Sciences and Engineering, Natural and Environmental Sciences, and Life and Health Sciences). During the last years, FCT was involved in the monitoring of the funded projects of the E-Rare ERA-NET. Short Profile of key Staff Members who will be undertaking the work Dr. Anabela Isidro PhD in Molecular Biology in 2002 at the Institute for Chemical and Biological (female) Technology, New University of Lisbon (PT). From 2002 to 2004 she got Postdoctoral training period at the Centre National de la Recherche Scientifique (CNRS). From 2005 to 2009 she was a Post-doc at the Institute for Biological Chemistry, New University of Lisbon (PT) and later got a principal investigator position at the Faculty for Veterinary Medicine till 2010. Her current scientific officer position at the Department of International Relations, FCT, involves the management of ERA-NETs in the field of 78 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Medical and Life Sciences, and Engineering (e.g., E-Rare-2, NEURON II, Infect-ERA, FLAG-ERA and BESTF Plus). Dr Carlos Almeida PhD in Bioethics / Philosophy of Science, with a Master’s degree in Management of Pereira Science, Technology & Innovation, a Specialization Course in Anthropology and Health, (male) and a Post-Graduation Course in Neurosciences. Science Officer at the Department for International Relations, FCT, since February 2013, taking various tasks and roles in transnational funding programmes: JPIs (JPND; JPI CH); ERA-NETs (HERA; Neuron; NORFACE, EuroNanoMed III; E-Rare); CSAs (JHEP2, ProSafe). Co-coordinator of the Programme for Responsible Research of FCT. FCT’s representative in the European Network of Research Integrity Offices (ENRIO). FCT’s representative in the National Commission for the Protection of Animals Used for Scientific Purposes. Head of the Thematic Group «Social Sciences and Humanities» (for the transnational cooperation). List of relevant previous projects or activities, connected to the subject of this proposal:  Neuron; funder: EC/national and regional partners; 2003-…; role in the project: partner  E-Rare; funder: EC/national and regional partners; 2006-2019; role in the project: partner  EuroNanoMed; funder: EC/national and regional partners; 2008-…; role in the project: partner  Infect-ERA; funder: EC/national and regional partners; 2013-2016; role in the project: partner  JPND; funder: EC/national and regional partners; 2011-…; role in the project: partner 42-INSA Full legal name (Acronym) – Country Instituto Nacional de Saúde Dr. Ricardo Jorge (INSA)- Portugal Principal investigator Sandra Alves Relevant Network Description of the legal entity/department/laboratory/group: INSA develops its activity as the Portuguese State Laboratory, National Reference Laboratory and National Observatory of the health sector. INSA’s Human Genetics Department has contributed for more than three decades now to the diagnosis and research of a large set of rare diseases (RD), such as thalassemias, cystic fibrosis, hemophilias, mitochondrial and lysosomal storage disorders among others, being the major Portuguese centre in the diagnosis of RD (including the Portuguese Newborn Screening Program). A great effort has also been put in fostering the research activities involving all aspects of these pathologies: molecular and biochemical characterization of the patients, establishment of genotype-phenotype correlations, study of the patophysiological mechanisms, cell biology studies, development of novel therapies and monitoring of the efficacy of the already available ones. As a consequence INSA’s team includes experts that have accumulated a large and very significant experience on RD. Main tasks in the project per Pillar/WP: Pillar 2: In WP10, we will participate as contributors in the task 10.2. 2 (Survey and structured interview approaches on technical and scientific matters, to monitor progress and inform strategic decisions) led by FTELE (Italy). Previous experience relevant to the Tasks: Relevant experience for Pillar 2: INSA Human Genetics Department research groups have widely contributed to the identification of the molecular basis of many rare genetic diseases leading to an improvement in the functional annotation of the human genome and in diagnosis precision and personalized medicine approaches. Participation in the Joint Action N° 20112201 under EU Health Programme 2008-2013, EUCERD Joint Action: working for rare diseases; INSA was responsible for the Evaluation Work package. Participation in international networks and COST actions related to Rare Diseases. (e.g. E-HOD European Network and Register and Cost action BM1207-Networking towards application of antisense-mediated exon skipping). Relevant experience for Pillar 3: Partner of the Portuguese Rare disease integrated strategy: interministerial, intersectorial and interinstitutional cooperation towards the complementary usage of medical, social, educational and scientific resources for the benefit of rare disease affected people and their caregivers. Contribution to increased public awareness in health science through the regular reception of visitor groups from schools and high schools, participation in public events such as the European Researchers' Night and summer 79 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases hands-on lab training initiatives. Furthermore a 10-minute educational video was produced for students at age 10 to 15 to explain basic genetics concepts. Special attention was given to the interaction with patient organizations for rare or chronic diseases as well as the distribution of informative health guide leaflets on to promote health literacy of patients, families and communities . Related Outreach activities also included: training and networking initiatives such as “One day with the Newborn Screening Programme”. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work: Next Generation Core facility Short Profile of key Staff Members who will be undertaking the work PhD. Sandra Alves PhD in Molecular Biology in 2002 at Faculty of Sciences of the University of Porto (PT). (female) From 2002 to 2004 she had a PostDoctoral training period in the Institute of Molecular Pathology and Immunology of the University of Porto. In 2004 she became Auxiliary Researcher in the Department of Human Genetics in the Instituto Nacional de Saúde Dr. Ricardo Jorge (INSA), Porto and Head of the Lysosomal Storage Diseases Research Group in 2009. Since 2013, she is the INSA’s representative in the Portuguese Commission for the Treatment of Lysosomal Storage Diseases.. As principal investigator she conducted 8 R&D projects and has the authorship in more than 30 peer reviewed scientific publications. Focused on biochemical and molecular aspects of inherited metabolic diseases she has the domain of specialization in lysosomal storage diseases. Dr. Glória Isidro Expert in Molecular Biology and Genetics. Coordinator of the Human Genetics (female) Department (Instituto Nacional de Saúde Doutor Ricardo Jorge – INSA). She was responsible for the Evaluation WP of the EUCERD Joint Action: Working for Rare Diseases. PhD.Laura Vilarinho PhD in Biomedical Sciences in 2000. She has over 130 articles published in peer (female) reviewed journals and more than 150 lectures in scientific meetings. Responsible for the Unit of Newborn Screening and Diagnosis of Inherited Metabolic Diseases (Department of Human Genetics, Instituto Nacional de Saúde Dr. Ricardo Jorge - INSA). Coordinator of the Executive Committee of the Portuguese Newborn Screening Program. PhD. Olg Amaral PhD in Biomedical Sciences (Faculty of Sciences, University of Porto-UP) in 2001. (female) Specialization domain: Human Molecular Genetics and Lysosomal Storage Disorders (LSD). She has worked in research and diagnosis in the field of rare metabolic disorders, having participated in several research projects, as well as being responsible for the set up, coordination and supervision of molecular diagnosis of sphingolipidoses and mucopolysaccharidoses at U.Enzimologia of IGMJM and Unilipe at IBMC-UP (1989- 2005). At INSA she´s a member of the Unit of Research & Development in the LSDs Group (DGH). She’s been principal investigator of projects with competitive financing, with 30 peer reviewed papers and over 80 peer reviewed presentations List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements (: 1.Vilarinho L1, Rocha H, Sousa C, Marcão A, Fonseca H, Bogas M, Osório RV. Four years of expanded newborn screening in Portugal with tandem mass spectrometry J Inherit Metab Dis. 2010;33 Suppl 3:S133-8. 2. Matos L, Canals I, Dridi L, Choi Y, Prata MJ, Jordan P, Desviat LR, Pérez B, Pshezhetsky AV, Grinberg D, Alves S, Vilageliu L. Therapeutic strategies based on modified U1 snRNAs and chaperones for Sanfilippo C splicing mutations. Orphanet J Rare Dis. 2014; 9:180. 3. Matos L, Gonçalves V, Pinto E, Laranjeira F, Prata MJ, Jordan P, Desviat LR, Pérez B, Alves S. Functional analysis of splicing mutations in the IDS gene and the use of antisense oligonucleotides to exploit an alternative therapy for MPS II. Biochim Biophys Acta. 2015;1852:2712-21. 4. Cruz S, Taipa R, Nogueira C, Pereira C, Almeida LS, Neiva R, Geraldes T, Guimarães A, Melo-Pires M, Vilarinho L. Clinical, biochemical, molecular, and histological features of 65 Portuguese patients with mitochondrial disorders. Muscle Nerve. 2017;56(5):868-872. 5. Huemer M, Diodato D, Schwahn B, Schiff M, Bandeira A, Benoist JF, Burlina A, Cerone R, Couce ML, Garcia- Cazorla A, la Marca G, Pasquini E, Vilarinho L, Weisfeld-Adams JD, Kožich V, Blom H, Baumgartner MR, Dionisi-Vici C. Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis. 2017;40(1):21-48. List of relevant previous projects or activities, connected to the subject of this proposal :Desvendar. NORTE- 80 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 2020. (2016-2018). Proponent. This project focuses the application of innovative methods of molecular biology for the study of rare diseases. The main objective is the implementation of a Next Generation Core facility in INSA Human Genetics Department in Porto.  Joint Action N° 20112201 under EU Health Programme EUCERD Joint Action: working for rare diseases. (2008-2013). General objectives: The EUCERD was mandated to assist the EC in formulating & implementing the Community's activities in the RD field, to foster exchanges of relevant experience, policies & practices between the MS & stakeholders. Specifically, the JA addressed the following: a) Enhanced visibility and recognition of RD; b) Contributed to the development and dissemination of knowledge on RD; c) Contributed to improvements in access to quality services and care, from diagnosis, through to care and social support and innovative therapies. INSA was responsible for the Evaluation WP.  Splicether. FCT (Fundação para a Ciência e a Tecnologia). (2016-2019). Proponent. This research project is in the rare diseases disease field and makes the bridge between patient diagnosis and characterization of the mutations found and the development of alternative therapeutic approaches (mutation-specific).  CeMoLy. FCT (Fundação para a Ciência e a Tecnologia). (2016-2019). Proponent. This research project aims at establishing cellular models for the investigation of rare diseases, through the use of iPSCs, in order to provide alternative means for pathophysiology and therapeutic studies.  Genetic Defects of Mitochondrial Diseases: a Next Generation Sequencing Approach. FCT (Fundação para a Ciência e a Tecnologia). (2016-2018). Proponent. The overall aim of this project is the development of a Next Generation Sequencing strategy to identify genetic defects in patients with a presumptive diagnosis of Mitochondrial Disease. 43-SAS Full legal name (Acronym) – Country Slovak Academy of Sciences (SAS) - Slovakia Principal investigator Ján Barančik, PhD. Relevant Network www.sav.sk Description of the legal entity/department/laboratory/group: The Slovak Academy of Sciences (SAS) a governmental research organization, is the recognized leading research and scientific institution aimed at excellent basic, strategic and applied research in Slovakia. The SAS as a funding body supports those scientific disciplines which have attained international level and which are deemed necessary for the advancement of Slovakia. It consists of 70 organizations and publishes 54 scientific and professional journals and 8 yearbooks. There are 49 scientific and scholarly associations, societies and unions affiliated with the SAS. The Assembly, the Scientific Council, and the Presidium are the Academy’s self-governing bodies. The SAS governs the total budget of more than 60 Mio. Euro. Significant part of this amount is distributed on the competitive principle via annual project calls. The scientific policy of SAS supports interdisciplinary research and collaboration with research teams at Universities and with the industry.The SAS together with the Slovak universities operates the Scientific Grant Agency (VEGA – Vedecka grantova agentura) to which the project proposals in different research fields including the Rare Diseases research can be submitted in the frame of the “ Research in the field of biological, medical and farmaceutical sciences”. A part of the budget is reserved for international research cooperation within the schemes such as FP EU, ERA-Net, Horizon 2020 COST, ESA etc. The funding supports multidisciplinarity and synergy effects stemming from international cooperation with the emphasis on incorporation of post docs and young researchers. The duration of funding is based on the individual project needs (as a rule, several years). SAS has an expertise concerning ERA.NET (Cofund) scheme in the various fields of science. The participation of SAS in the ERA-Nets projects have been based on the official mandate of the Ministry of Education of the Slovak Republic for the SAS to act as RD programme owner and manager. Selection procedures for the applications have been established and approved by the SAS Presidium. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will participate in task 1.1 – Joint Transnational Call 2019 In WP6, we will participate in task 1.2 – Joint Transnational Call 2020 81 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases SAS will actively participate in the project as committed partner in several tasks. Previous experience relevant to the Tasks: Participation of SAS in the “EJP Rare Diseases” project as committed partner will result from participation and experience in many ERA.NETs (cofund) including the field of medicine e. i. TRANSCAN, NEURON, ERACoSysMed, ERA-CVD, EuroNanoMed, etc. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work (if applicable): Short Profile of key Staff Members who will be undertaking the work Jan Barancik, PhD. Coordinating person responsible for the overall timely management of the “EJP Rare Diseases project, comprising the content of the work plan, the finances and the administration. He is the head of International Cooperation Dpt. at SAS. He has a teorethical and working experience as a coordinator and project manager of many European networks (ERA.NETs) and international projects not only in the field of medicine e.g. TRANSCAN, NEURON II, EuroNanoMed II, ERACoSysMed,, ERA-CVD but also in other scientific fields e.g. , M-ERA.NET, INCOMERA, ANIHWA,CONCERT Japan, ERA.NET RUS Plus QuantERA, FLAG-ERA, ICT-CHIST ERA III etc. Katarina Bibova Project Manager responsible for the day-to-day operational management of administrative and organizational aspects in this project. He is engaged in several european and international projects at SAS i.e NEURON, ERACoSysMed, EuroNanoMed and in the SAS bilateral JRP Programmes related to the field of medicine and environment (Japan, Korea, Russia) Tbc Senior scientist. He/She will act as Scientific Manager responsible for scientific aspects in this project. List of relevant previous projects or activities, connected to the subject of this proposal (max 5): SAS as a financing member of several consortia in the scheme of ERA-NETs (cofund) in the field of biological, medical and farmaceutical sciences, as mentioned above.  44-ISCIII Full legal name (Acronym) – Country Instituto de Salud Carlos III (ISCIII)  Spain Principal investigator Eva Bermejo-Sánchez, PhD Relevant Network Description of the legal entity: The Instituto de Salud Carlos III (National Institute of Health Carlos III, ISCIII) is the main Public Research Entity funding, managing and carrying out biomedical research in Spain. The Institute has been conducting research and providing key services in the life and health sciences for over 25 years. Its mission focuses on basic, translational and applied research as well as health technologies. ISCIII performs intramural activities and has a regulatory role as far as accreditation of research centres is concerned. It is also the body responsible for managing Spain's Health Research and Development Strategy within the framework of the National R+D+I Plan. Reports directly to the Ministry of Economy, Industry and Competitiveness (Royal Decree 345/2012) and in operational terms to both this Ministry and to the Ministry of Health, Social Services and Equality (Royal Decree 200/2012), has as its main mission to support the development of scientific knowledge in the health sciences and to contribute to innovation in treatment, healthcare and the prevention of disease. Putting patients and the public at the heart of all its activities and objectives, the Institute promotes and coordinates biomedical research and provides scientific and technical services of the highest quality in partnership with all the organizations forming part of the Spanish System of Science, Technology and Innovation. In terms of budget, the Institute is publicly funded (more than 270 M€ year 2016) and allocates funds to extramural research, including competitive annual calls. Since its inception, through a rigorous selection process based on peer 82 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases review evaluation, ISCIII has awarded grants for research projects, networks, equipment, fellowships, technical manpower and research contracts. Moreover, under the Horizon 2020 umbrella, the Institute has been actively involved in the promotion of Spanish research excellence via its participation in key European transnational initiatives such as: ERA-Net cofund, ERA-Nets, ERICs, ESFRI project preparatory phases, Art. 185 TFEU initiatives, and Joint Programming Initiatives. The Institute also participates in other international research consortia (e.g. IRDiRC, ICGC and the Personalized Medicine Coalition). Departments involved in this EJP: The principal investigator from ISCIII for this EJP is Eva Bermejo-Sánchez, Head of department of the IIER (Institute of Rare Diseases Research), under the Sub-Directorate General for Applied Services, Training And Research (SGSAFI). Manuel Posada, Director of the IIER and member of the Executive Committee of the IRDiRC will be also deeply involved. Both are included in “Team b” below. There will be 2 main departments of ISCIII involved in this EJP: ‐ Team a: from the Sub-Directorate General for International Research Programmes and Institutional Relations (SGPIIRI). ‐ Team b: from the Sub-Directorate General for Applied Services, Training and Research (SGSAFI). There will be mainly researchers from IIER, but also from other two units, as it will be detailed in a separate table, as indicated in the instructions. Team a: The specific team of the SGPIIRI involved in this EJP leads the follow-up of the international research activities and programs, mainly the European ones. It has also leaded other like the Spanish participation in multilateral and international organizations like IARC (International Agency for Research on Cancer), TDR (Special Programme for Research and Training in Tropical Disease), IANPHI (International Association of National Public Health Institutes), EuSANH (European Science Advisory Network for Health) and RIMAIS (Red Interministerial de Aprendizaje e Investigación en Salud). Moreover,it has collaborated with European research infrastructures in the development of the ESFRI roadmap (e.g. ECRIN, EATRIS, ELIXIR and ERINHA) and it has also been involved in the reinforcement of cross-border cooperation of research programmes through Joint Programme Initiatives: JPND, JP HDHL, JPAMR, JP MYBL; Article 185 TFEU (AAL and EDCTP); ERA-Net cofund (ERACoSysMed, E-RARE-3, TRANSCAN 2, JPco-fuND); ERA-Nets (E-RARE, NEURON, TRANSCAN, EuroNanoMed, Infect-ERA), JPIs to Co-Work and EULAC Health. Within the context of these initiatives, the Institute has adopted a number of roles: Coordinator, National Contract Point and Joint Call Secretariat. [Details on “Team b” can be found in a separate table, as indicated in the instructions] Main tasks in the project per Pillar/WP: TEAM A will participate in: Coordination & Transversal Activities: In WP3: Co-leader, together with INSERM and EATRIS. ‐ Task Co-leader for tasks 3.1, 3.3 and 3.4 ‐ Task 3.2: Participant. Pillar 1: In WP6: Participant, and ‐ Task 6.4: Leader, for the 4th Joint Transnational Call (JTC 2022) not co-funded by the EC In WP9: Participant in Task 9.1 (Subtasks 9.1.1, 9.1.3 and 9.1.4), and Task 9.2. Previous experience relevant to the Tasks: ERA-Net Infect-ERA is an initiative in which ISCIII contributed to the development of Work Package 7. The latter dealt with the design of a long-term collaboration framework, the set-up of the external scientific committee and the generation of a network with similar initiatives. ERA-Net Cofund ERACoSysMed aimed to enhance the implementation of Systems Medicine approaches in both clinical research and medical practice throughout Europe and beyond. ISCIII was WP leader of the WP devoted to the evaluation of the cofounded call and will be in charge on an additional call as Joint Call Secretariat. ERA-Net Neuron II seeked to coordinate national and regional research programmes in neuroscience. ISCIII was responsible for Neuron II’s Work Package 7, which dealt with the development of a long-term collaboration framework. Additionally, ISCIII participated in the execution of Work Package 2, which dealt with the creation of the strategic agenda; Work Package 5, intended to provide support to young researchers; and the monitorization of the consortia’s communication activities. 83 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases ERA-Net EuroNanoMed III seeked to foster the competitiveness of European research centres engaged in Nanomedicine. ISCIII was responsible of the Work Package that dealt with the development of the Research Strategic Agenda, the drafting of joint call documents and the design of the long-term collaboration framework. ERA-NET Cofund E-Rare-3, ISCIII was responsible of the management of the call secretariat of the third JTC. In two occasions (2012 and 2014) ISCIII has been in charge of running the Joint Call Secretariat (ERA-Net E-Rare- 2). The tasks executed during both Calls included: drafting of call documents, design and coordination of the assessment process, management of the IT platform, selection of reviewers and the organization of the evaluation panels −among other things. Joint Call 2012 was focused on Young Investigators. EU Joint Programme – Neurodegenerative Disease Research (JPND) ISCIII participated in kind in the JUMPAHEAD project that supported the implementation of JPI to combat neurodegenerative diseases. It is a three year project funded by an FP7 2 million euro grant GA no. 260774, in which ISCIII actively contributed with the execution of organizational tasks. In ERA-Net cofund JPco-fuND ISCIII mainly participated in the WP for additional activities and is co-leader in the alignment of national research plans task. J-AGE is a Coordination Action for the implementation of the JPI "More Years, Better Lives - the Challenges and Opportunities of Demographic Change". ISCIII was responsible of the management of the call secretariat of the second and third JTC. ISCIII participated in the drafting of a non-comprehensive list of possible instruments that could be used for the implementation of the Strategic Research Agenda (SRA) and the compilation of results of a Workshop held in Madrid on 22/03/2013. Short Profile of key Staff Members who will be undertaking the work Mr./ Ignacio Project Officer managing and coordinating European transnational research collaborations at the Baanante- EU and Internationalization Dept of SGPIIRI at ISCIII. In 2010 and 2012 he worked at the Balastegui/ European Office of the Spanish Ministry of Science and Innovation, based in Brussels, where he Male participated in the evaluation and monitoring of scientific policies at National, European and International level, and contributed to drafting analytical documents (i.e. Impact Assessment). In 2008 he was involved and provided support in other initiatives [PRIOMEDCHILD, Art. 185 TFEU (AAL), ERA-Nets (TRANSCAN, INFECT-ERA), and JPI More Years Better Life and its CSA (J-AGE), as well as in training activities in the biomedical field. Undertook several Joint Call Secretariats (ERA-Net E-Rare, EuroNanoMed). He will be in charge of call-4 secretariat and Pillar 1 activities of ISCIII, and will provide support for the ones in transversal WP3, in this EJP. Mrs./ María Project Officer at the Deputy Director’s Office for International Research Programmes and Druet- Institutional Relations (SGPIIRI) at the National Institute of Health Carlos III. Ms Druet is Ampuero/ actively involved in the coordination, management and follow-up of European transnational Female collaborations European network of transnational collaborative RTD such as: EURONAOMED, TRANSCAN, NEURON, and E-RARE. Ms Druet plays an instrumental role in the management and coordination of E-RARE, TRANSCAN, NEURON and EURONANOMED Joint Call Secretariat’s administrative and financial activities. A total of 21 funding agencies cooperate within the novel EURONAOMED III where the Institute of Health Carlos III is the coordinator.Previously, during 2011-2013, she worked in the European project office like the Project Manager of the CSA Joint Programming Initiatives a process of mutual learning Toward a Common adoption of framework Conditions, (VIIPM). She will support the call-4 secretariat and Pillar 1 activities of ISCIII, as well as of the ones in transversal WP3 in this EJP. Dr./ Carlos Carlos Segovia-Pérez has been involved in several European and international health research Segovia- initiatives since 2007. He has been structural trainee at DG Research (EC) and National Focal Pérez/ Male Point for the EC Health programme. He is the current chair of the Joint Programming Initiative on Antimicrobial Resistance. He was Deputy Director of International Research Programmes (2009- 13) at ISCIII, and as such, Spain’s representative at IARC, TDR, IVI, RIMAIS, IANPHI, Coordinator of FP7 ‘EU-LAC Health’ and ‘JPIs to Co-Work’, and President of EuSANH. Technical Advisor of International Research Programmes (2006-2009) at ISCIII and National Focal Point for EC-SANCO Health Programme. Technical Advisor at the Social and Health Care Coordination Unit, at the Regional Department of Health Castilla y Leon. Carlos Segovia is primary care physician and master of public health from Harvard University. Before joining ISCIII, Carlos has been coordinator of a primary care centre for two years, deputy director for primary care quality and research of a province for ten years, and expert for social and health care coordination at a Regional Department of Health for two years. 84 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases He will be in charge of WP3, which is co-leaded by ISCIII. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements See above the cell on Previous Experience, that includes some achievements from a set of relevant activities of similar nature to the one of this proposal. List of relevant previous projects or activities, connected to the subject of this proposal See above the cell on Previous Experience, that includes a set of relevant activities of similar nature to the one of this proposal. Full legal name (Acronym) – Country Instituto de Salud Carlos III (ISCIII)  Spain Principal investigator Eva Bermejo-Sánchez, PhD Relevant Network Description of the legal entity: The description of the Instituto de Salud Carlos III (National Institute of Health Carlos III, ISCIII) is included in a separate table, where the description of ISCIII’s “Team a”, also involved in this EJP, is described. Departments involved in this EJP: The principal investigator from ISCIII for this EJP is Eva Bermejo-Sánchez, Head of department of the IIER (Institute of Rare Diseases Research), under the Sub-Directorate General for Applied Services, Training And Research (SGSAFI). Manuel Posada, Director of the IIER and member of the Executive Committee of the IRDiRC will be also deeply involved. Both are included in “Team b” below. There will be 2 main departments of ISCIII involved in this EJP: ‐ Team a: from the Sub-Directorate General for International Research Programmes and Institutional Relations (SGPIIRI). [Details on “Team b” can be found in a separate table, as indicated in the instructions] ‐ Team b: from the Sub-Directorate General for Applied Services, Training and Research (SGSAFI). There will be mainly researchers from IIER, but also from UITeS (Telemedicine and eHealth Unit) and BU-ISCIII (Bioinformatics Unit). These are the details on them: The Institute of Rare Diseases Research (IIER) is a national center belonging to the ISCIII. It has two different areas of work: Rare Diseases Epidemiology, and Human Genetics. The IIER was officially designed as a WHO Collaborating Center for the epidemiology of diseases of unknown origin, between 1996 and 2011. It was also responsible for the coordination of the Spanish Network for Epidemiological Research on Rare Diseases (REpiER) and the Spanish National Rare Diseases Registry (SpainRDR). Currently, IIER is leading the National Rare Diseases Biobank, being a founder of EuroBioBank network. On behalf of ISCIII, it assists the Ministry of Health, Social Services and Equity in the development of its Strategy regarding Rare Diseases. Some members of the IIER form part also as a research group of the Centre for Biomedical Research on Rare Diseases as a Network (CIBERER). The IIER has also contributed to projects as RD-Connect, RIBERMOV, RareBestPractices, EUROPLAN and EPIRARE, among others. It also takes part in the International Conference on Orphan Drugs and Rare Diseases (ICORD) and the Undiagnosed RD Cases Network International (UDNI). Since 1981, IIER has been responsible for the old Spanish cohort with more than 20,000 people involved and followed by more than 37 years due to their affection by a rare disease, and at the same time IIER has contributed to the creation of some patient RD registries or cohorts of patients. UITeS (Telemedicine and eHealth Unit): Its mission is to promote and develop research, development and innovation work in the field of ICT applied to health. Its work follows the priorities of the National R&D&I Programme, the EU Framework Programme in ICT for health, public health and environmental health. Its main areas of interest are: telemedicine; e-health; mobile systems, network service platforms, biomedical instrumentation; wireless networks, electromagnetic security and compatibility, plus applications to support assistance for people with chronic conditions and help to prevent dependence. Its work covers scientific and technological research and the promotion of innovation in the National Health System by carrying out pilot projects, demonstrations and clinical trials jointly with other research groups, healthcare institutions and relevant industrial concerns. BU-ISCIII (Bioinformatics Unit): It is a transversal unit at ISCIII that gives support to other of its units. Therefore, BU-ISCIII will act supporting “Team b” of ISCIII for this EJP in what refers to the general analysis of data, genomic data and big data of any nature, linked to research on rare diseases, as it has been doing since its inception at ISCIII. Main tasks in the project per Pillar/WP: (See details on ISCIII’s “Team a” in a separate table, according to the 85 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases instructions) TEAM B will participate in: Coordination & Transversal Activities: In WP2: Co-leader, together with ISS. ‐ Task Co-leader for tasks 2.2 and 2.3 ‐ Participant for Tasks 2.1, 2.4 and 2.5. Pillar 2: (Costs of the in-kind contribution of ISCIII to Pillar 2 will be of at least 39,000.00 €, including indirect costs) ‐ WP11: Participant for Tasks 11.1, 11.3, and 11.4 ‐ WP12: Participant for Task 12.1 ‐ WP13: Participant for Task 13.1 Pillar 3: (Costs of the in-kind contribution of ISCIII to Pillar 3 will be of at least 18,000.00 €, including indirect costs) ‐ WP14: Participant for Tasks 14.3, 14.4 and 14.5 ‐ WP16: Participant for Task 16.2 (Subtask 16.2.2) Previous experience relevant to the Tasks: More than 30 years working in the field of Rare Diseases (RD), in their research, development and coordination of networks, creation of: the platform of the Spanish National Registry of RDs and the work for its FAIRification, the Spanish National biobank for RD, a program for undiagnosed cases of RD, worldwide contribution to the match-maker exchange approach to RD patients, leading and participation in numerous research projects (either in Spain and at the international level –Europe and worldwide). Working on biospecimen and patient registries, diagnosis, genomic studies, therapies development, orphan drugs, clinical studies, and e-health. Hundreds of scientific papers. Contributing to the Spanish National Policy on RD. Very close contact to the Spanish Federation of patients with Rare Diseases and their families (FEDER), and specific patients’ associations. Member of the Steering Committee for the MOOC Course at Coursera “Preparing for an Ageing Population” (Univ. of Melbourne). Chair of the Intl. Medical Informatics Association´s WG on Exposome Informatics. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : - Platform: Spanish Rare Diseases Research Registries Network (SpainRDR) - Platform: Spanish National Biobank for Rare Diseases (BioNER) - On-line course on rare diseases for health professionals, developed by IIER at ISCIII. - Computational infrastructure, High Performance Computing and Data storage, required for achieving the aims of this project. Short Profile of key Staff Members who will be undertaking the work Dr. (MD, Director of IIER, member of the Executive Committee of the IRDiRC, President of the PhD)/ Manuel International Conference on Orphan Drugs and Rare Diseases (ICORD), and Member of the past Posada-de-la- European Commission’s Experts Group of RD (CEGRD) by designation. Director of BioNER Paz/ Male (National Biobank on Rare Diseases). Chief of Research Group U-758 at CIBERER (Centre for Biomedical Research as a Network). Director of the WHO Collaborating Centre in the Epidemiology of Environment-Related Illnesses (1996-2011), Director of the Research Center CISATER, International General Coordinator of the Research Programme on the Spanish Toxic Oil Syndrome (WHO-Health Research Fund). Principal investigator for the Spanish Network for Epidemiological Research on Rare Diseases (REpiER) and the Spanish Rare Diseases Research Registries Network (SpainRDR). Leading one IRDIRC project and numerous projects funded by the EU and main Spanish agencies, with hundreds of papers published. Dr.(MSc, Tenured Scientist, Chief of Area of the Institute of Rare Diseases Research (IIER), ISCIII. Past PhD)/ Eva President of the Executive Committee of ICBDSR, Chief of Research Group U-724 at CIBERER. Bermejo- Scientific Coordinator of the Spanish Collaborative Study of Congenital Malformations Sánchez/ (ECEMC), its registry, and its clinical network. Scientific Director of the National Biobank of the Female Institute of Health Carlos III. Accredited in Human Genetics. Working in the field of epidemiology, clinical genetics and clinical teratology, for congenital anomalies, and in the Spanish Undiagnosed Rare Diseases Program of IIER (SpainUDP). 130 peer-reviewed papers published (h-index: 24) and Principal Investigator of several research projects on congenital anomalies and other rare diseases. Long participation in EUROCAT and JRC. Dr. (PhD, Research Professor in Biomedical Informatics and Digital Health at ISCIII. Full Professor at the FACHI, Division of Health Informatics at Weill Cornell Medicine and participated in the US Precision FACMI, Medicine Initiative (2015-17). Former Chair of Health Informatics at the Melbourne Medical 86 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases CHIA, School and foundational Director of the Health and Biomedical Informatics Centre (HaBIC) at the MIAHSI)/ University of Melbourne. PhDs in Informatics and Medicine; MSc in Knowledge Engineering Fernando and BSc in Biochemistry and Molecular Biology. Served as Vice-President of the International Martín- Medical Informatics Association and Chair of the Scientific Program Committee for the XV Sánchez/ Male World Conference in Health and Biomedical Informatics, MEDINFO 2015. More than 180 peer- reviewed publications (h-index: 25). 40 grants from the EC and main agencies from Spain, Australia and the USA. Dr.(MSc, Tenured Scientist at the Institute of Rare Diseases Research (IIER), of ISCIII. She is also part of PhD)/ the Centre for Biomedical Network Research on Rare Diseases. Involved in different European Verónica and national projects in Spain, her research is focused on Rare Diseases: morbidity and mortality Alonso- studies, geographical analysis, population-base and patient registries, biobanking and Ferreira/ interoperability, among other topics. Female Dr. (PhD)/ Researcher. PhD in Pharmacy. Skills in Pharmacy, Biochemistry, Microbiology, Environmental Estrella Health and Rare Diseases research. Current postdoctoral position in IIER of ISCIII, participating López-Martín/ in several tasks related to the Spanish Undiagnosed Rare Diseases Program SpainUDP. Also Female involved in activities derived from the European projects RD-Connect and Solve-RD, focused on infrastructures and research on RD. Expertise within the rare diseases field: interoperability strategies at international level, undiagnosed diseases programs, phenotype ontologies and research projects. Dr.(PhD)/ Leader of the Computational Biology Unit of the UFIEC in the Institute of Health Carlos III. She Victoria has a Master of Biotechnology from the University of Madison Wisconsin (USA) and a PhD in López- Biochemistry and Molecular Biology from the University of Valencia. Wide experience in Alonso/ bioinformatics and system biology data analysis. She has participated in several research projects Female related to new technologies at the intersection of biology and computer science. Mrs.(PhD)/ Scientist and Bioinformatics Unit leader at ISCIII (BU-ISCIII). Master degree in Bioinformatics Isabel Cuesta- and Computational Biology. Taught by Complutense University in partnership with National Plaza/ Female Center of Biotechnology and ISCIII. Additional training visiting leading groups in Principe Felipe Research Center Bioinformatic service (CIPF), European Bioinformatic Institute (EMBL-EBI). She directs final master degree projects, organises and participates in courses on data mining and high throughput sequencing data analysis at ISCIII. BUISCIII is involved in national and EU- funded projects, among others, and is partner of Spanish Undiagnosed Rare Diseases Program (SpainUDP), project leaded by IIER and integrated in RD-Connect European project, focusing on the diagnosis of RD based on WES data analysis and sharing. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Spanish National Registry of Rare Diseases (SpainRDR): https://registroraras.isciii.es/ 2. Spanish National Biobank for Rare Diseases (BioNER): http://bioner.isciii.es/ 3. Spanish Program for Undiagnosed Rare Diseases (SpainUDP): http://portal-spainudp.isciii.es 4. Book: “Rare disease Epidemiology Book: Update and Overview” [2017] http://www.springer.com/la/book/9783319671420 5. Martin-Sanchez FJ, Lopez-Campos GH. The New Role of Biomedical Informatics in the Age of Digital Medicine. Methods Inf Med. 2016 Oct 17;55(5):392-402. List of relevant previous projects or activities, connected to the subject of this proposal REpIER (Spanish Network for Epi Research on RDs); Funder: ISCIII-Call for Networks of Thematic Cooperative Research; 2002-05. Project Leader (MPP). Development of a program for epidemiological research on RDs in Spain, for better orientation of social and health policies.  SpainRDR; Funder: IRDiRC; 2012-14; Project Leader (MPP). Creation of the National Rare Diseases Registry in Spain based on the input of two different strategies: patient registries addressed to patient outcome research and population-based registries aimed at epidemiologic research and health-social planning.  BioNER (Natl. Biobank on Rare Diseases); Funder: ISCIII; 2013-present. Creation and Manager (MPP). Spanish National Biobank for RDS.  NYC-PMI (New York City Precision Medicine Initiative); Funder: NIH. 2015-17. Co-investigator (FMS);  BiomarkerCard; Funder: NICTA (National Information and Communications Technology Australia); 2013-14. Principal investigator (FMS); Knowledge representation systems to assess the clinical relevance of biomarkers. 87 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 45-CNAG-CRG Full legal name (Acronym) – Country Fundació Centre de Regulació Genòmica (CNAG-CRG), Spain Principal investigator Ivo Gut Relevant Network ELIXIR Description of the legal entity/department/laboratory/group: The CRG is as a multidisciplinary research centre focusing on biomedicine. It is a first-class multidisciplinary research center that hosts a total of 30 group leaders, of which ~half hold an ERC grant. The «Centro Nacional de Análisis Genómico» (CNAG-CRG) is a non-profit organization founded in 2009 and integrated with the CRG. CNAG-CRG is funded by the Spanish Ministry of Economy and Competitiveness and the Catalan Government. CNAG-CRG’s mission is to carry out projects in DNA sequence analysis for the improvement of quality of life in collaboration with the European and International Research Community. It has a staff of 79. CNAG-CRG’s director, Dr. Ivo Gut, leads the Biomedical Genomics group. Its main line of research is mining, analysis and re-analysis of genomic data from biomedical studies focussing on projects in rare disease (RD), common diseases and cancer. Dr. Sergi Beltran leads the Bioinformatics Unit at CNAG-CRG, composed by 21 people and devoted to the development and operation of tools and pipelines for the analysis and interpretation of sequencing data. In 2017, the group analysed more than 250 projects in genomics, including germline variant identification, somatic variant identification and differential gene expression analysis. Dr. Beltran leads the development of the RD-Connect Genome-Phenome Analysis Platform (GPAP). Since 2013, the CRG is co- managing the European Genome-phenome Archive (EGA) in partnership with the EBI. The CRG EGA group is led by Jordi Rambla, and has expertise in different areas, especially software development and database design. The EGA is hosting many studies and datasets from RD. Main tasks in the project per Pillar/WP: Pillar 2: In WP10, we will participate in Coordinating Pillar 2 Work Packages and aligning to RD community needs (Task 10.1), Convene yearly retreats leading to Pillar 2 annual strategic plans (Task 10.2), Coordination of technical GDPR implementation (Task 10.3), Quality oversight (Task 10.4) and Developing sustainable models (Task 10.5). In WP11, we will co-lead WP11 and lead Provision of analysis and data sharing capabilities to the RD community through online resources (Task 11.4). We will also participate in tasks, FAIR-compliant platform for discovery of RD resources (Task 11.2) and Data deposition and access to data infrastructures for RD research (Task 11.3). In WP12, we will participate in Multi-site teams for software and tool development with respect to WP12 (Task 12.2) and Practical FAIRification support (Task 12.3). In WP13 we will participate in Fill pre-identified gaps (Task 4.1). Pillar 3: In WP14, we will participate in Standards and quality of genetics/genomics data in laboratory and clinical research practice (Task 14.2) and Training on strategies to foster solutions of undiagnosed RD cases (Task 14.3) Previous experience relevant to the Tasks: PILLAR 2: The CNAG-CRG has been collaborating in sequencing and analysing RD patients since its foundation. In 2014 the CNAG-CRG opened a call to sequence 300 exomes for RD research within Spain. In 2016, the CNAG- CRG launched a call to sequence 900 exomes for RD research within the framework of the EU-FP7 project BBMRI-LPC. Currently, the center is leading the sequencing and analysis of 1,000 RD whole genomes within the NAGEN-1000 project (http://www.navarrabiomed.es). Dr Sergi Beltran team has led the development of the RD-Connect platform (platform.rd-connect.eu) which, among other, enables the standardised analysis and interpretation of genomic data linked to the corresponding clinical information collected with controlled vocabularies and the Human Phenotype Ontology (HPO). PILLAR 3: The CNAG-CRG provides training at several levels to researchers, clinicians, patients and students, through dedicated hands-on workshops and courses on genome analysis and bioinformatics. Specifically for RD- Connect, the CNAG-CRG has already led 14 hands-on workshops since 2015 in nine EU countries The CNAG- CRG also generates online training materials and collaborates closely with the ELIXIR training platform through Task 8.3 from ELIXIR-EXCELERATE and RD-Connect. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : To analyse the data the CNAG-CRG operates a 3,500 core supercomputer, with nodes carrying from 48 GB to 2 TB of RAM. CNAG-CRG uses CPUs, GPUs and FPGAs and has compute capacity in excess of 200 Tflops. The computer has 7.6 PB of disk and tape storage. An internal 10 Gb/s network and multiple 10 Gb/s physical connections to the Barcelona Supercomputing Center (BSC, www.bsc.es) which has over 50,000 compute cores and provides backup.The RD-Connect cluster is hosted at the CNAG-CRG's Data Processing Center (DPC). The cluster includes 19 nodes with a total of 304 cores, 4.8 TB of RAM, 336TB HDD and 19TB SDD. 88 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases The operation of CNAG-CRG is certified ISO9001 and accredited ISO17025. Short Profile of key Staff Members who will be undertaking the work PhD. Ivo Gut Ivo Gut is Director of the CNAG-CRG. He has more than 20 years’ experience in high- (male) throughput nucleic analysis (genotyping and sequencing DNA, RNA and DNA methylation), technology development in nucleic acid and protein analysis. He was Head of Technology Development and Associate Director at the Centre National de Génotypage (CNG) – CEA (1999-2009), where he established the highest throughput genotyping platform in Europe, executed many genome-wide association studies, initiated and was the coordinator of the EU-funded Project READNA. He is currently participating as principal investigator in five FP7/ H2020 projects: BCAST, RD-CONNECT, ELIXIR- EXCELERATE, SINGEK and SPIDIAP4P. He is author of more than 350 research papers, 11 reviews and 12 book chapters, cited over 34,000 times (H-Index = 82, Google Scholar), inventor of 25 patents or patent applications, founder of 4 biotech start-ups, and serves on numerous international advisory boards. PhD.Sergi Beltran Sergi Beltran has over 15 years of experience with genomics and bioinformatics and has (male) participated in over 45 international publications. He leads the development of the RD- Connect platform (platform.rd-connect.eu). His group participates in the IRDiRC/GA4GH MatchMaker Exchange (MME) and GA4GH Beacon projects through RD-Connect and is co-leading the development of the new MME API, which will enable more complex queries while maintaining the same privacy standards. Within ELIXIR-EXCELERATE, Dr. Beltran participates in the RD use case co-led from the CNAG-CRG and in benchmarking activities. Jordi Rambla(male) Jordi Rambla is project manager for the EGA since 2013. He has 30 years of experience in developing complex IT projects involving data integration, data cleansing, database architecture and data warehousing exploitation. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements : 1. RD-Connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases. Lochmuller, H, et al. including Gut, I and the RD-Connect consortium. Eur J Hum Genet. 2018 Feb 27. 2. From Wet-lab to Variations: Concordance and Speed of Bioinformatics Pipelines for Whole Genome and Whole Exome Sequencing. Laurie S, et al. including Gut I and Beltran S. (last author). Hum Mutat. 2016 Sep 8. 3. A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Alioto TS et al. including Beltran S and Gut I (last author). Nat Commun. 2015 Dec 9;6:10001. 4. The Matchmaker Exchange: A Platform for Rare Disease Gene Discovery. Philippakis AA, Azzariti DR, Beltran S et al. Hum Mutat. 2015 Oct;36(10):915-21. doi: 10.1002/humu.22858. 5. Genomic characterization of mutant laboratory mouse strains by exome sequencing and annotation lift-over. Derdak S et al., including Beltran S. (last author). BMC Genomics. 2015 May 6;16:351. List of relevant previous projects or activities, connected to the subject of this proposal: 1. RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research (Coordinator: Hanns Lochmüller). CNAG-CRG PI: Ivo Gut; CNAG-CRG budget: 1,997,994 €; timeline: nov12-oct18; Call: FP7-HEALTH.2012.2.1.1-1-C 2. SOLVE-RD: Solving the unsolved rare diseases (Coordinator: Olaf Riess). CNAG-CRG PI: Sergi Beltran; CNAG-CRG budget: 1,505,132 €; timeline: jan18-dec22; Call H2020-SC1-2016-2017 3. ELIXIR-EXCELERATE: Fast-track ELIXIR implementation and drive early user exploitation across the life- sciences. (Coordinator: Niklas Blomberg). CNAG-CRG PI: Ivo Gut; CNAG-CRG budget: 200,000 €; timeline: sep15-ago19; Call: H2020-INFRADEV-1-2015-1. 4. BBMRI-LPC: BBMRI – Large Prospective Cohorts (Coordinator: Markus Perola). CNAG-CRG PI: Ivo Gut; CNAG-CRG budget: 535,660 €; timeline: feb13-ene17; Call: FP7-INFRA-2012-1.1.9. More than 900 exomes from RD patients and their relatives sequenced and analysed through a transnational access call.. 5. MatchMaker Exchange (www.matchmakerexchange.org, MME, IRDiRC and GA4GH) and Beacon project (http://ga4gh.org/#/beacon, GA4GH) participants. Co-leaders of new MME API. 46-UPM Full legal name (Acronym) – Country Universidad Politecnica de Madrid (UPM), Spain Principal investigator Mark Wilkinson Relevant Network none 89 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Description of the legal entity/department/laboratory/group: The Technical University of Madrid is the largest Spanish technological university as well as a renowned European institution being twice recognized as a Campus of International Excellence. It boasts 114 Departments, more than 36,600 undergraduate students, more than 1,600 Masters’ Degree students and over 2,700 PhD Degree and Postgraduate students, all under the supervision of nearly 3,300 teachers. UPM’s annual budget is 370 million Euros. UPM heads the Spanish participation in the 7th Framework Program of the European Union for research and technological development. More than 2,400 researchers carry out their activity at the UPM, which is committed to technology transfer and startups, with a dedicated “incubator” facility, and staff dedicated to commercialization of intellectual property. CBGP has four primary objectives (i) generation of knowledge on the genomics and biotechnology of plants and plant-interacting organisms; (ii) development of new technologies and tools for functional analyses (iii) development of new products and processes relevant to the productive sectors; and (iv) transmission of information and implementation of educational programmes for scientists and technicians. In the last few years, knowledge on plant biology has progressed at an unprecedented pace. A major cause for this progress is the development of innovative technologies that allow efficient and global analyses of genome structure, information and expression. The new technologies are rooted in advances in the sequencing of DNA and proteins, in the use of microchips, in the automation of many laboratory procedures, and in the possibility of handling large amounts of information through bioinformatic tools. UPM is a leading center in Spain for pursuing both pure research and product development, using these cutting-edge technologies. Main tasks in the project per Pillar/WP: Pillar 2  We will contribute our expertise in FAIR data modelling in the BBMRI/ELIXIR RD Connect project to guide the selection, design, and extension of data and metadata models. (Task 11.1.1, 11.1.3)  We will apply our expertise in the domain of ontology building and use to define ontological models for the project (Task 11.1.2)  We will create FAIR Accessors and smartAPI meta-descriptors to help with accessing the ELIXIR BioTools database (Task 11.2.3)  We will use our expertise, as the inventors of the FAIR Discovery model (FAIR Accessors/Projectors) to better enable dynamic discovery of appropriate catalogues to query, and facilitate metadata extraction from these Accessor metadata documents (Task 11.2.4).  We will align our data and metadata models with other biomedical initiatives globally (Task 12.1.1).  We will implement our existing federation architecture (the FAIR Data Point) into the project infrastructure to enable federated query and discovery (Task 12.1.2).  We will implement the prototype of our semantic consent/privacy negotiation infrastructure, and evaluate its utility; we will assist in the task of anonymising data outputs Task (12.1.3).  We will ensure that all components are compliant with existing data and representation standards v.v. federated query and data exchange, including the use of static and dynamic FAIR data sources. (Task 12.1.4)  We will apply our expertise in clinical ontologies to the representation of clinical and pre-clinical information  We will oversee the harmonization between participating sites by harmonizing data models (Task 12.2.1)  We will utilize our FAIR Accessor platform to enable metadata and sample-level discovery (Task 12.2.3)  We will apply our FAIR Projector technology as a self-directed FAIRification service. (Task 12.3.3) Previous experience relevant to the Tasks: Our laboratory were lead authors on the FAIR Principles, and inventors and lead-authors on the first fully FAIR platform that spanned from metadata to individual cells in an underlying spreadsheet. The laboratory head, Mark Wilkinson, has spent more than a decade in clinical ontology creation, dynamic and automated discovery, integration, and analysis clinical data, and the design of biomedical data systems that can support automated workflow construction. Our flagship technologies – SADI and SHARE – were the first to use the global standard SPARQL to drive the discovery, synthesis, and execution of analytical workflows that represented the solutions to conceptual questions asked by biomedical researchers, and won the prize for best demonstration of semantic technologies for their ability to support multi-lingual queries. Short Profile of key Staff Members who will be undertaking the work 90 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Dr. Mark For the past 15 years, my laboratory has focused on designing biomedical data/tool Wilkinson, representation, discovery, and automated reuse infrastructures - what would now be called FBBVA Chair in "FAIR". I am the EU technical lead of the FAIR "Skunkworks" initiative, charged with rapidly Biotechnology prototyping cutting-edge FAIR infrastructures. I participate in the emergent GO FAIR initiative, and Isaac Peral including being founding members of the FAIR Metrics working group, tasked with defining Distinguished the precise, measurable behaviors that FAIR resources should exhibit. Beyond data Researcher. integration, we have extensive machine-learning experience over a diverse range of data types including longitudinal microbiome data, and were the first to identify shifting “states” in microbiomes that could be attributed to specific interventions, opening-up approaches to microbiome engineering. Senior TBA Technician List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Wilkinson MD; Dumontier M; Aalbersberg IjJ; et al. "The FAIR Guiding Principles for scientific data management and stewardship". Sci. Data 3:160018. 2016. 2. Wilkinson MD; Verborgh R; Bonino da Silva Santos LO; et al. "Interoperability and FAIRness through a novel combination of Web technologies". PeerJ Comput. Sci. 3:e110. 2017. 3. Egaña Aranguren M; Wilkinson MD. “Enhanced reproducibility of SADI web service workflows with Galaxy and Docker”, GigaScience 4(1), p59, 2015. 4. Wilkinson M, Vandervalk B, McCarthy L. “The Semantic Automated Discovery and Integration (SADI) Web service Design-Pattern, API and Reference Implementation”. Journal of Biomedical Semantics, 2:8, 2011. 5. Samadian S; McManus B; Wilkinson MD. Extending and encoding existing biological terminologies and datasets for use in the reasoned semantic web. Journal of Biomedical Semantics, 3:6, 2012. List of relevant previous projects or activities, connected to the subject of this proposal 1. Founding Member. FAIR Metrics Group. 2017-date. A group of 6 stakeholders representing researchers, technologists, public databases, and journal editors, assembled to create quantifiable metrics to evaluate the FAIRness of a resource. 2. Co-Chair, Common Repository Interfaces, Force11 Data Citation Implementation Group, 2012-2014. 3. European Lead, Data FAIRport Working Group 3 - “Skunkworks”, 2015-date. 4. Invited Expert – Semantics in Health Care and Life Sciences (HCLS) Working Group, World Wide Web Consortium: May 2009 – 2015. 5. Board of Trustees, Identifiers.org Project: 2012 – date. 47-CIBER Full legal name (Acronym) – Country Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER) - Spain Principal investigator Pablo Lapunzina Relevant Network Description of the legal entity/department/laboratory/group: CIBER is a Public Research Consortium created in 2006 under the leadership of the Carlos III Health Institute (ISCIII, the main Public Research Entity responsible of funding, managing and carrying out biomedical research in Spain), to promote research excellence and build a critical mass of researchers in the field of Biomedicine and Health Sciences. Organized in 11 research areas including Cardiovascular Diseases (CIBERCV), Bioengineering, Biomaterials and Nanomedicine (CIBERBBN), Mental Health (CIBERSAM), Hepatic Diseases (CIBEREHD), Diabetes and Metabolic Diseases (CIBERDEM), Rare Diseases (CIBERER), Respiratory Diseases (CIBERES), Public Health and Epidemiology (CIBERESP), Obesity and Metabolic Diseases (CIBEROBN), Cancer (CIBERONC), Fragility and Healthy Ageing (CIBERFES), CIBER is the largest Research Network in Spain. CIBER counts with more than 800 dedicated employees and 6,000 associated researchers integrated in more than 400 leading-edge research groups. Thanks to its network structure, CIBER is capable of bringing together more than 100 different associated institutions including Hospitals, Research Centers, Technology Centers, Private Institutions and Universities selected to join CIBER consortium on the basis of their excellence.Within this consortia CIBERER is the area of CIBER designed for the development and implementation of cooperative 91 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases research in the field of rare diseases (RD), to the study of Rare Diseases, integrating 61 research groups and 20 associated clinical groups, furthering scientific and technical research, stressing the aspects of genetic molecular, biochemical and cellular research, with the aim of improving the understanding of causes and pathogenic mechanisms of these disorders as a fundamental item for developing and implementing new diagnostic techniques and therapeutic strategies. The following are specific aims of CIBERER: Contributing to research in the field of RDs; Helping to solve healthcare problems connected with RD; Reinforcing the participation of research groups in scientific-technical activities on an international scale; Promoting the transfer of research results to society and in particular to the National Health System and to the pharmaceutical and biotechnological production sector; and Supporting dissemination and participation in educational activities connected with RD. Main tasks in the project per Pillar/WP: In Pillar 2 we will contribute to: ‐ WP11: Common platform for discoverable data and resources for RD research Task 11.1: Metadata and ontological model definition for cataloging resources for RD research Task 11.2: FAIR-compliant platform for discovery of RD resources Task 11.3: Data deposition and access to data infrastructures for RD research Task 11.4: Provision of analysis and data sharing capabilities to the RD community through online resources ‐ WP12. Enabling sustainable FAIRness and Federation at the data record, patient and sample level for RD Task 12.1: Compare and align core interoperability standards with respect to WP3 ‐ WP13. Enabling multidisciplinary, holistic approaches for rare disease diagnostics and therapeutics Previous experience relevant to the Tasks: CIBERER research groups expertise range from basic genetic research to its clinical application in a day to day context, so the whole chain from basic knowledge to bedside is tackled by our diverse groups. Such diversity encompasses expertise in NGS data generation and interpretation, together with complementary physiological and biochemical data, all applied in a clinical context to provide high quality diagnostic on rare diseases. As a result, we act as catalysts between basic research and clinical practice (Both highly represented in our network), and cooperate with industry to transforming the latest -omics technologies into useful tools for the clinical routine. In their daily exercise many CIBERER groups face the challenges arising for the NGS and omics application to the diagnosis of rare diseases, many of them as responsible of genetic testing services in the main hospitals of Spain. Also involved in the definition of Good Clinical Practice guidelines form the technical, procedural and ethical points of view. CIBERER groups have diagnostic activity on a wide range of rare diseases, most of them genetic through genetic testing. Up to 48 CIBERER research groups have activity on this field, as part of their research and/or in a clinical context, with more than 20 providing genetic clinical diagnostics and some being responsible of Genetic Diagnostic Services of the main Spanish hospitals. CIBERER is seriously involved in the new challenges associated with cross-border genetic testing for RD. With a wide range of our staff (physicians, researchers, technicians, bioinformatics…) working to carry out large scale projects in DNA sequencing and analysis in collaboration with researchers around the world, in order to ensure the best implementation of this new technology in our hospitals genetics services. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : 1. - CIBERER BIOBANK (CBK) is a public and non-profit-making biological sample repository which centralices the reception of samples connected with rare diseases. It is a CIBERER initiative and it is located at the Centro Superior de Investigación en Salud Pública (CSISP) in Valencia, Spain. 2- Bioinformatics Platform for Rare Diseases (BIER) (http://www.ciberer.es/BIER/?q=node/1), is a transversal work group whose main task is to cooperate with the experimental groups working with genomic data, by giving them I.T. and scientific support for the analysis and interpretation of this information. 3- CIBERER Exome Server (http://bioinfo.cipf.es/apps-beta/exome-server/beta/), a public, free online tool, launched in 2014, designed to improve the filtering of potentially pathogenic genetic variants found in Spanish individuals. As local variations could be significant, this server contributes to other international available exome servers. Any researcher using CIBERER Exome Server will be able to obtain information about all variants detected in the Spanish population. CIBERER aims to set up a repository of variant data contributed by all investigators (academic, clinical or industrial) having sequenced exomes from Spanish individuals. Short Profile of key Staff Members who will be undertaking the work PhD. Pablo Lapunzina Specialist in pediatrics and medical genetics. Head of Department and Director of the (male) Instituto de Genética Médica y Molecular (INGEMM), Hospital La Paz (Madrid, Spain). Scientific director of CIBER on Rare Diseases (CIBERER). Beatriz Gómez BSc in Nursing and BA in Journalism. CIBERER’s, WP7 EJA and RD-ACTION 92 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases (female) Manager. Ingrid Mendes BSc in Biology. CIBERER’s Scientific Manager. Asst. to CIBERER´s Scientific (female) Director. Dr. Juan Luque PhD in Biology. CIBERER´s Scientific and Transfer Manager. (male) Dr. Andrés Medrano PhD in Biology. CIBERER´s Scientific and Training Manager. (male) Dr. Beatriz Morte PhD in Pharmacist CIBERER´s Scientific Manager of the Undiagnosed RD Programme. (female) List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Technical and Institutional Committees. Rare Diseases Strategy of the National Health System. Spanish Ministry of Health and Social Services. Madrid, 2009. NIPO: 840-09-0752-X. 2. “Report on the State of the Art of Rare Disease Activities in Europe”, 2011-2016. 3. Villanueva A, Woolley R, Corrochano V, Gómez B, Molas J, Barberá JD, Palau F. EUCERD Joint Action - WP7: “Quality of Care and Centres of Expertise”. ECRD. Berlin, Germany, 8-10th May 2014. 4. EUCERD Joint Action Workshop. From Centers of Expertise to European Reference Networks. Ministry of Health, Social Services and Equality. Madrid, Spain 28-29 October, 2015. 5. RD Registries Workshop, Organized by CIBERER and financed by CHAFEA. Madrid, Spain, 21-22 March 2017. List of relevant previous projects or activities, connected to the subject of this proposal: ‐ Programme for “Genes in non-diagnosed Rare Diseases”. Through this project, CIBERER has promoted and enabled the application of the exome sequencing technique to discover new genes and variants involved in pathologies such as metabolism disorders, neuromuscular pathologies, mitochondrial diseases, polymalformation syndromes, birth defects or primary immunodeficiencies. ‐ Partner of EUCERD Joint Action: Working on Rare Diseases.2012-2015. ‐ Partner of RD-ACTION: Promoting Implementation of Recommendations on Policy, Information and Data for RD. 2016-2018. ‐ Others describe in Orphanet-Spain description partner template. 48-SRC Full legal name (Acronym) – Country Swedish Research Council (SRC), Stockholm, Sweden Principal investigator Malin Eklund Relevant Network Funder Description of the legal entity/department/laboratory/group: In 2001, the Swedish parliament enacted legislation to set up the Research Council “in order to support basic research of the highest academic quality within all areas of knowledge", hence merging five councils into one. The Swedish Research Council (SRC) has a leading role in developing Swedish research of the highest scientific quality, thereby contributing to the development of society. The SRC is also responsible for coordinating participation and funding of national and international research infrastructures. The SRC is working to stimulate Swedish participation in European and international research cooperation. The aim is a greater exchange of experience and collaboration. The SRC has a specific responsibility for research cooperation within the EU, as well as a large commitment in Science Europe. The Swedish Research Council tasks include also research policy analysis and research policy advice, as well as communication about research and public understanding of science. The annual budget was around SEK 6 billion for 2017. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will participate as funder in task 6.1 WP7 Previous experience relevant to the Tasks: SRC, together with the Ministry of Education, has responsibility for programme committee work in seven areas of the EU's current framework programme mainly within the excellence pillar but also within the Societal Challenge pillar. SRC is also hosting the National Contact Point within these areas. SRC is taking part in three joint 93 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases programming initiatives JPI Climate, JPND and JPIAMR and is the coordinator of the latter. SRC participates in a number of ERA-Net cofund such as ERA-PerMed, Gender-net Plus, Quant-ERA, Flag-ERA. Short Profile of key Staff Members who will be undertaking the work Dr Malin Eklund Senior Research Officer within the field of medicine and health. PhD in Biotechnology from KTH, Stockholm. 10 years of experience as a researcher and project manager in the pharmaceutical industry before joining SRC in 2014. SRC representative in IC PerMed and ERA PerMed. Previously Policy Officer based in Brussels between 2015-2017. 49-VINNOVA Full legal name (Acronym) – Country Vinnova - Sweden Principal investigator Frida Lundmark Relevant Network Description of the legal entity/department/laboratory/group: Vinnova is Sweden's government agency for innovation. Our mission is to contribute to sustainable growth by improving the conditions for innovation. We do this mainly by funding innovation projects and the research needed to develop new solutions. We also invest long term in strong research and innovation environments. We stimulate collaborations between companies, universities and other higher education institutions, public services, civil society and other actors. Our activities also focus on strengthening international cooperation. Each year, Vinnova invests around SEK 3 billion in fostering innovation. Most of these funds are allocated via calls for proposals in which companies, public sector actors and other organisations apply for funding. All investments are continuously monitored and evaluated and we regularly analyse the impacts of our investments. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will participate as a funder (task 6.1) Previous experience relevant to the Tasks: Vinnova participate in several international initiatives and consortia such as “International consortia for personalised medicine” (ICPerMed), “JPI More years better lives”, “Nordic call on personalised medicine” (NordicPerMed), “Innovative medicines initiative” (IMI). Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Not relevant Short Profile of key Staff Members who will be undertaking the work Frida Lundmark Doctoral degree in neurogenetics from Karolinska institute, Sweden. More than 12 years of (female) experience from pharma industry focusing on translational science and precision medicine. Before joining Vinnova several years of experience from public health sector focusing on strategies for clinical research for Karolinska university hospital as well as national strategies for biobanking in Sweden. 50-ULEIC Full legal name (Acronym) – Country University of Leicester (ULEIC) Principal investigator Anthony J Brookes Relevant Network Solve-RD Description of the legal entity/department/laboratory/group: The University of Leicester (ULEIC) is a publicly funded university based in Leicester, UK. It is a research- intensive university and was ranked in the top quartile of universities in the 2014 REF assessment of UK university research. ULEIC contributions in this project will be led by the Department of Genetics and Genome Biology, within the College of Medicine, Biological Sciences and Psychology - which is the largest and best-funded of the University’s four Colleges, attracting substantial funding from the European Community. Notable discoveries made in the Department of Genetics include the discovery and development of DNA fingerprinting (profiling) and, more recently, the DNA-based identification of the remains of King Richard III. This Department also leads various University wide initiatives, under the Directorship of lead applicant Anthony Brookes, namely: a) the 'NUCLEUS' 94 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases service group which provides a full spectrum of advanced genomics technology services to university researchers; and b) the regional 'BINERI' network of health data science researchers and professionals, which brings together and facilitates multi-disciplinary projects between mathematicians/statisticians, data analysts, bioinformaticians, ethics/governance experts, healthcare providers, IT services, computer scientists and physicists. Main tasks in the project per Pillar/WP: ULEIC will contribute to many tasks in EJPRD, but has specific responsibility for leading or coleading the following: Pillar 2: In WP10, we will co-lead the whole WP. Additionally we will coordinate all parties involved in drafting the Annual Strategic Plan (SubTask 10.1.1) based on input from surveys, the user community, the VP developers, and the outcomes of the Pillar 2 Annual Retreat. This will be enabled by our role as lead of Task 10.2, which will drive and summarise regular TC discussions between Pillar 2 WP leaders, and in parallel undertake survey and structured interview approaches on technical and scientific matters. In WP11, we will make supportive contributions in Tasks 11.1, 11.2 and (mainly) 11.3. In WP12, we will co-lead the whole WP. We will also lead Task 12.1 to compare and align core interoperability standards relevant to the Pillar 2 mission. This will entail coordinating 5 subtask teams, of which we will lead two concerning machine-readable access (Subtask 12.1.3) and query languages plus data exchange formats (Subtask 12.1.4). This will require us to find and engage relevant experts within and beyond EJPRD, and facilitate them to work together to identify and align relevant standards needed by the VP and support their adoption by the project's software developers. We will also lead Subtask 12.2.3, which is building software tools and modules for data discovery. This must be done as a multi-team effort, ensuring different technologies can interoperate. So as well as developing our own contributions to this area we will be responsible for getting all the different development teams to collaborate effectively. Additionally, within Task 12.3 we will lead Subtask 12.3.2. Thereby we and others will enable people to make their data and samples and subjects safely and appropriately discoverable if they cannot do that within their own data systems, and we will achieve this by providing a brokered hosting service with concomitant data harmonisation support. Previous experience relevant to the Tasks: ULEIC researchers contributing to this project have wide-ranging expertise in areas including Human/Medical Genetics and Informatics, relevant to the proposal, including: (1) Leading a multi-disciplinary ‘Bio-Informatics Network for Education, Research and Industry (BINERI)’ across the UK Midlands to ensure data synergies, discoverability, and appropriate sharing across the regional biomedical research and healthcare sectors by activities that entail interacting, not least, with Genomics England Ltd for which we head up the national data analysis clinical interpretations partnership. (2) Playing a central role in several major international initiatives for data standards development, not least the GA4GH/IRDiRC Beacon, MatchMaker Exchange, and ADA-M Task Teams. The latter is a metadata standard for the digitisation of conditions of use and consent, essential for future: (i) unambiguous communication of conditions of use; (ii) inclusion of conditions of use considerations in resource discovery settings; and (iii) automation of controlled access decision making. (3) Creating Café Variome, a flexible data discovery platform with the ability to handle large, diverse and complex datasets. It is agnostic regarding the types of entity it enables to be discovered, and it can be deployed as a central through to a highly federated architecture. A core Oath2-based authorisation and authentication server, compatible with the AAI from ELIXIR, enables fine-grained control of user permissions. (4) Running large-scale databasing and data management projects, not least providing the world's largest public domain GWAS database (GWAS Central), leading IT aspects of biomedical EU projects (GEN2PHEN, BioShare, GCOF, Solve-RD), contributing 'discovery science' aspects of IMI projects (EMIF, eTOX, EPAD), and direct translational medicine data management in large consortia (COPD-MAP (UK MRC), REQUITE (EU)). Short Profile of key Staff Members who will be undertaking the work Professor Director BINERI, Director HDR-UK Leicester, Research Group leader. Anthony J Qualifications in preclinical Medicine (Honors) and Medical Biochemistry (1st Class), creator of Brookes / various technology patents, Founder of two biodata related companies, 30 year's experience as Male academic researcher in leading institutions. Published >180 peer reviewed articles and reviews, served two 3-year terms on the HUGO Council, co-founded the Human Variome Project and the Human Genome Variation Society (now Vice-President) Dr Colin Veal Senior bioinformatician and Brookes Research Group co-lead. / Male Biology degree plus 20 years experience as academic researcher conducting biomedical informatics, human genomic technology innovation, and genetic disease studies. Additional degree qualifications in mathematics and statistics 95 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Dr Tim Beck / Current position: Independent 'Future Leaders' Research Fellow, associated with HDR-UK Male Profile description: Biology degree plus 15 years experience as academic researcher in biomedical informatics, spanning human and animal model investigations, operational lead on GWAS Central, and with special expertise in semantics and ontologies. Professor Professor in genetics Raymond Support and guidance role as independent PI running several LSDBs, plus contribution and Dalgleish / further development of the 'Variant Validator' platform for management of mutation nomenclature Male List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. World’s largest public-domain GWAS database (http://www.gwascentral.org/) 2. Café Variome platform for federated data discovery (www.cafevariome.org) 3. Nature Reviews Genetics (2015) 16, 702-715. Human Genotype-Phenotype Databases: Aims, Challenges And Opportunities. A.J.Brookes and P.N.Robinson. 4. Human Mutation (2012) 33, 867-873. Observ-OM and Observ-TAB: Universal Syntax Solutions for the Integration, Search and Exchange of Phenotype And Genotype Information. . T.Adamusiak, H.Parkinson, J.Muilu, E.Roos, 5. Nature Reviews Genetics (2009) 10, 9-18. Genotype-Phenotype Databases: Challenges and Solutions For The Post-Genomic Era. G.A.Thorisson, J.Muilu and A.J.Brookes List of relevant previous projects or activities, connected to the subject of this proposal : 1. GEN2PHEN (RTD): Genotype-To-Phenotype Databases: A Holistic Solution (HEALTH-F4-2007-20075): To June 2013. 2. BioShaRE (RTD): Biobank Standardisation and Harmonisation for Research Excellence in the European Union (261433): To November 2015. 3. GCOF: Stepping stone approach towards the Genetics Clinic of the Future (H2020-HCO-2014-643439): To June 2017. 4. EMIF: A European Medical Information Framework of patient-level data to support a wide range of medical research (115372-2): Ends June 2018. 5. Solve-RD: Solving the unsolved Rare Diseases (779257). To December 2022 51-ULIV Full legal name (Acronym) – Country University of Liverpool (ULIV), United Kingdom Principal investigator Mark Turner Relevant Network EPTRI, PedCRIN (after 01 May conect4children) Description of the legal entity/department/laboratory/group: The University of Liverpool (ULIV) is one of the great centres of research, knowledge and innovation and one of the UK’s leading research institutions with an annual turnover of £400 million, including £140 million for research. The university’s pioneering reputation attracts students, experts and partners from around the world. Through research, teaching and collaborations ULIV seeks to be life changing and world shaping. The University is globally recognised for its research in health and life sciences, science and engineering, and humanities and social sciences. ULIV is 75th in Europe according to the Times Higher Education rankings, is 61 – 100 in medicine according to the global QS rankings and is the 78th most international university in the world. The Department of Women’s and Children’s Health is internationally renowned for its research and has specialist groups covering obstetrics, gynaecology, neonatology and medical and surgical paediatrics. The department’s main research facilities are integrated with two of the largest specialist Women’s and Children’ hospitals in Europe – Centre for Women’s Health research within the Liverpool Women’s Hospital and Institute in the Park within the Alder Hey Hospital. Main tasks in the project per Pillar/WP: Pillar 0 WP1: Coordination SubTask 1.1.2: Central Helpdesk; Task 1.3: Monitoring of the EJP RD activities and achievements; Leader of Subtask 1.3.1: Identification of key performance indicators SubTask 1.3.2: Implementation of the monitoring process 96 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Task 3.1: Service roadmap: alignement of needs, expectations and engagement of the different RD research stakeholders in Europe with repsect to EJP RD sustainability; Task 3.2: Preparation of sustainable EJP RD service calalogue; Task 3.3: Preparation of the EJP RD sustainability plan with business plan; Task 3.4: Sustaainability roadmap; Task 5.2: Integrating EJP RD communication and dissemination strategies with the strategies of involved stakeholders; WP20: Task 20.1: Task Force Group (100% in kind contribution) Previous experience relevant to the Tasks: Mark Turner’s expertise is about developing new and improved medicines for children. This includes leadership of clinical studies in neonates: Phase 0 microdosing; Phase 1 first-in-human; Phase 2 PK and PD, particularly for antibiotics; excipient kinetics; Phase 3 studies. Other work includes mixed methods assessment of: adverse drug reactions in children by professionals and parents; manipulations of drugs used by children; management of stillbirth; induction of labour. Turner has extensive experience bridging between research communities. He has chaired the UK NIHR AMR Neonatal Clinical Studies Group (2007 – present); chaired the European Network for Paediatric Research at the European Medicines Agency (2013 – present); been European Co-Director of the International Neonatal Consortium (2014 – present). This includes developing relationships between all stakeholders in drug development (families, regulators, industry, investigators) and at all stages of drug development (basic science, formulations, clinical studies etc.). He developed the European Paediatric Clinical Trials Research Infrastructure which was recognised as a complementary research infrastructure in the 2016 ESFRI Roadmap. He is the Scientific Coordinator of the Conect4Children consortium that has applied to IMI2 Call 10 Topic 4 “European Paediatric Clinical Trials Network”. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Mark Turner developed the European Paediatric Clinical Trials Research Infrastructure which was recognised as a complementary research infrastructure in the 2016 ESFRI Roadmap. He is the Scientific Coordinator of the Conect4Children consortium that will receive the award for the IMI2 Call 10 Topic 4 “European Paediatric Clinical Trials Network”. Collaborative Network for European Clinical Trials for Children (conect4children) will begin 01 May 2018. Short Profile of key Staff Members who will be undertaking the work Dr. Mark Turner Mark Turner BSc, MBChB, PhD, DRCOG, MRCP, MRCPCH, FFPM(Hon) is a (male) Neonatologist at Liverpool Women’s Hospital and the University of Liverpool. He aims to improve the access of newborn babies and children to high quality medicines. He has studied the dosing, safety and efficacy of 12 medicines in neonates with rare conditions in the past 5 years. In older children his group is currently working on manipulations of medicines, the avoidability of adverse drug reactions and the pharmacoeconomics of age-appropriate formulations. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. A systematic review of the use of dosage form manipulation to obtain required doses to inform use of manipulation in paediatric practice. Richey RH, Hughes C, Nunn AJ, Turner MA Int J Pharm. 2017 25:155-166 2. The International Neonatal Consortium: collaborating to advance regulatory science for neonates. Turner MA, Davis JM, McCune S, Bax R, Portman RJ, Hudson LD. Pediatr Res. 2016 80:462-4 3. Essential medicines containing ethanol elevate blood acetaldehyde concentrations in neonates. Pandya HC, Mulla H, Nunn AJ, Turner MA. Eur J Pediatr. 2016 175:841-7 4. Observational infant exploratory [(14) C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis. Garner CR, Park KB, Maruszak W, Turner MA. Br J Clin Pharmacol. 2015 80:157-67 5. Potentially harmful excipients in neonatal medicines: a pan-European observational study. Nellis G, Metsvaht T,Turner MA, Lutsar I. Arch Dis Child. 2015 100:694-9. List of relevant previous projects or activities, connected to the subject of this proposal 1. EPRTI WP 9 Lead funded by the European Commission H2020 INFRADEV programme from Jan 2018 – Dec 2019 2. PedCRIN WP 2 Lead funded by European Commission H2020 from Jan 2017 – Dec 2019 97 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 3. Global Research in Paediatrics (GRIP): Scientific Coordinator of this FP7 Network of Excellence; funded European Commission FP7 from Jan 2015-Jun 2017 4. European Study of Neonatal Excipient Exposure (ESNEE): Chief Investigator of this project, funded by ERA-NET PRIOMEDCHILD from Jan 2011 – Mar 2014 5. Treat Infection in Neonates (TINN): Work Package Lead and Clinical Chief Investigator; European Commission FP7 funded from Nov 2008 – Oct 2015 6. NeoVanc: Work Package 2 and 5 European Commission FP7Lead European Commission FP7 funded from Feb 2014 – Jan 2019 52-UNEW Full legal name (Acronym) – Country University of Newcastle upon Tyne (UNEW) - UK Principal investigator Volker Straub Relevant Network TREAT-NMD Description of the legal entity/department/laboratory/group: The team at UNEW performing this work is based in the John Walton Muscular Dystrophy Research Centre (JWMDRC), Institute of Genetic Medicine, Newcastle University. Newcastle University is one of the top research- intensive universities in the UK: in the recent Research Excellence Framework (REF) evaluation, Newcastle University was ranked 16th (out of 154) in the UK for research power. The university also ranks in the top 5 for both hospital and laboratory based clinical subjects. Within the University, the JWMDRC is a clinical and research reference centre led by Prof. Volker Straub, providing a depth of clinical expertise in Muscular Dystrophies unparalleled elsewhere in the UK. Clinical management and drug development for Neuromuscular diseases (NMDs) are core activities of the Centre, with national and international clinical trials funded via Wyeth, Sarepta, GSK, Prosensa, BioMarin, Trophos, Roche, Ultragenyx, NIH, BHF, EU, NIHR and MRC. In addition, Newcastle houses the MRC Translational Research Centre for Neuromuscular Diseases and Biobank, jointly established with UCL (London). Over the least decade, the team in the JWMDRC has increasingly built a reputation for rare disease expertise per se, from a disease-agnostic policy and infrastructure perspective (consolidated through leadership positions in the EUCERD Joint Action for Rare Diseases, RD-Connect, and RD-ACTION (the Policy stream of which is led from the JWMDRC)). Main tasks in the project per Pillar/WP: Pillar 4: UNEW is a partner in P4 WP19 Facilitating partnerships and accelerating translation for higher patient impact. Task19.1. The team will participate to the creation of an Innovation Management Tool Kit, by elaborating and tailoring a ‘handbook’ for disease areas wishing to develop an ‘ACT’ (Advisory Committee on Therapeutics), based upon the successful TACT model in the neuromuscular field. Most of the PM activity will be spent on liaising with ERN communities (in greater detail where that ERN is able to dedicate person time, in-kind or funded externally) to set-up an ACT in disease areas outside of the NMD field, based upon ERN thematic groupings/subdomains. A workshop will be organised to support this broad ERN engagement. Previous experience relevant to the Tasks: TREAT-NMD has now been successfully operating for 10 years and has generated a number of tools and strategies to support the development of therapies for rare neuromuscular diseases. Amongst these – and led from UNEW, at present by V. Straub and C. Turner)- is the TREAT-NMD Advisory Committee for Therapeutics (TACT) model. TACT is a model to convene a unique multidisciplinary international group of well recognized academic and industry drug development experts, patient representatives and institutional governmental scientific research centres, who meet twice a year to review development plans from academic groups and industry and provide guidance on the translation and development path of therapeutics programs in rare neuromuscular diseases with large unmet need. By suggesting improvements or changes to pre-clinical research or trial design TACT can help academics and industry to avoid potential pitfalls in the therapeutic development pipeline and facilitate the faster development of therapies. ● Since its launch, TACT has formally reviewed 46 programme applications from both Industry (29) and Academics (17) 21 of these reviews have been for novel compounds, 25 for repurposed drugs. ● The added-value is the approach is clear – in fact, some funders now request that a TACT review has been completed before (co)-funding clinical trials ● The strength of the model lies in the assembly of bespoke panels for each application. Thus, the UNEW team is ideally-placed to explore the expansion of this model to other disease areas, through elaboration and deployment of a ‘Tool-Kit’ or handbook to support communities in embedding a model along these 98 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases lines. The ERNs are a logical ‘target’ for such discussions (and, as far as resources allow, more practical action) and in this respect too, the UNEW team possesses the relevant experience and expertise to forge such synergies. UNEW led a EU Joint Action dedicated to Rare Diseases (the EUCERD JA), and continues to lead the Policy Strand of the current Joint Action, RD-ACTION – these initiatives have played a key role in supporting the conceptualisation and implementation of ERNs, and as such the team currently led by V.Hedley developed robust working relationships with many of the ERN coordinators and their teams, and understands the opportunities and challenges for expansion of an ACT model into these communities. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : N/A Short Profile of key Staff Members who will be undertaking the work Pr. Volker Straub Current Director of the John Walton Centre, founding joint co-ordinator of TREAT-NMD (male) (www.treat-nmd.eu), executive board member of the World Muscle Society and R&D Director of the North Tees and Hartlepool NHS Foundation Trust. Trained as a paediatric neurologist, Volker has a longstanding interest in the pathogenesis of muscular dystrophies and is engaged in research using zebrafish and mouse models. He has a special interest in the use of MRI in muscular dystrophies. Catherine Turner Duchenne Liaison and TACT Coordinator. She oversees the running of TACT, solicits (female) applications, works with expert panel members to facilitate the review process and ensures funding and sustainability. She also provides the link between TACT and multiple stakeholders including the patient community, industry and regulators. Victoria Hedley Policy Manager (previously Thematic Coordinator) for RD-ACTION, the EU Joint Action for (female) rare diseases. She leads on the RD-ACTION provision of policy support to ERNs, and is in charge of generating the Resource on the State of the Art of Rare Disease Activities in Europe. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Leary R, Oyewole AO, Bushby K, Aartsma-Rus A. ‘Translational Research in Europe for the Assessment and Treatment for Neuromuscular Disorders (TREAT-NMD)’. Neuropediatrics 2017 Aug;48(4):211-220. doi: 10.1055/s-0037-1604110. Epub 2017 Jul 6. 2. Heslop E. et. al. ‘The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development’, Orphanet J Rare Dis. 2015 Apr 23;10:49. doi: 10.1186/s13023-015- 0258-1. 3. Evangelista T, Hedley V, Atalaia A, Johnson M, Lynn S, Le Cam Y, Bushby K, ‘The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference Networks’, Orphanet J Rare Dis 2016 (11) 10.1186/s13023-016-0398-y 4. Numerous outputs related to Policy support for ERNs (http://www.rd-action.eu/european-reference-networks- erns/) Including Hedley et.al. Recommended Practices for Standardising Data in the Framework of the Operation of ERNs (2017) 5. TGDOC – TREAT-NMD has established a global network of patient registries, with an agreed core data set. This allows academia and industry to conduct feasibility and recruitment enquiries through the registries to accelerate clinical trials. List of relevant previous projects or activities, connected to the subject of this proposal : TREAT-NMD: FP6, 2007-2011, Acted as coordinator. EU funded ‘network of excellence’ with the remit of ‘reshaping the research environment’ in the neuromuscular field. RD-ACTION : 3rd Public Health Programme, EC, 2015-2018, WP lead (WP6,Policy and Integration). Leading on support for the implementation and (policy-oriented) development of ERNs, and on the generation of the State of the Art resource. EURO-NMD: 3rd Public Health Programme, EC, 2017-2021, Current coordinator. EURO-NMD is the ERN for neuromuscular diseases. EUCERD-JA: 2nd Public Health Programme, 2012-2015, Coordinator. Led the Joint Action to support EC and the MS in formulating and implementing policies pertaining to rare diseases 99 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 53-CCRI Full legal name (Acronym) – Country St. Anna Kinderkrebsforschung (CCRI) - Austria Principal investigator Ruth Ladenstein Relevant Network ERN-PaedCan Description of the legal entity/department/laboratory/group: The CCRI is owned by the private charity-based association St. Anna Kinderkrebsforschung, with the overall aim to improve treatment options for children suffering from cancer through basic, translational and clinical research. The CCRI is closely affiliated with the St. Anna Children’s Hospital, the largest clinical haemato-oncological centre for the treatment of childhood cancer in Austria. The CCRI and the St. Anna Children´s Hospital have formed a comprehensive cancer centre in order to address patient-relevant scientific questions to better understand the disease and effective therapies through bidirectional knowledge exchange from research to clinical applications and diagnostics. The CCRI hosts 12 research groups in the areas of molecular and cellular biology, molecular genetics, genomics and epigenomics, immunology, cellular therapies and clinical research with a focus on bone and soft tissue sarcomas, neuroblastoma and acute leukaemias. The CCRI is devoted to bench to bedside research translational activities. The Unit for Clinical Trails and Statistics of the CCRI (S2IR: Studies and Statistics for integrated Research Projects) under the leadership of Prof Dr Ruth Ladenstein serves as the national trial centre for almost all childhood cancer trials and registries in Austria, but also is a recognised international trial unit running several world-wide international phase 3 trials in the area of neuroblastoma, Langerhans Cell Histiocytosis and Stem Cell transplantation as international academic sponsor. The unit has major experience in setting up and running academic trials and has initiated and then supported a drug development in partnership with industry achieving EMA approval in 2017 which made a new immunotherapy for neuroblastoma accessible across Europe. Main tasks in the project per Pillar/WP: Pillar 2 - Coordinated access to data and services: WP 11 Common virtual platform for discoverable data and resources for RD research Pillar 3 - Capacity building and empowerment: WP 14 Training on data management & quality WP 16 Online Academic education course WP 18 Development and adaptation of training activities Pillar 4 - Accelerating research translation & therapy development: Accelerating the validation, use and development of innovative methodologies tailored for clinical: .participation to Task force .demonstration calls organization and FU (methodologists/Erns) .new methodologies development calls (methodologists/ERNs/regulatory) Previous experience relevant to the Tasks: With Prof Dr Ruth Ladenstein acting as coordinator, the CCRI has acquired extensive experience in the management of strategic EU-funded projects, namely large pan-European paediatric cancer networks such as: SIOPEN-R-NET (QLRI-CT-2002-01768) - the SIOP European Neuroblastoma Research Network; ENCCA (261474) - the European network for cancer research in children and adolescents; ExPO-r-Net (20131207) - the pilot network European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment; and of particular relevance for this project, ERN-PAEDCAN - the European Reference Network for Paediatric Oncology . The CCRI has also played a leading role and coordinated other EU-funded projects such as MODICELL (285875) - a Marie Curie Industry-Academia Partnerships and Pathways network aiming to improve the understanding of the complexity of immune cell responses by studying cells designed for therapies in the settings of cancer or transplantation; and FUNGITECT (602125) - an innovation project aiming at optimising diagnostics for improved treatment stratification in invasive fungal diseases. In addition, the CCRI has also been the initiator and key partner of other EU-funded projects, including AutoFLOW (610872) - a Marie Curie Industry-Academia Partnerships and Pathways network aiming at developing innovative IT-based automation tools for flow cytometric assessment of pediatric leukaemia; ASSET (259348) - an HEALTH project aimed at tackling human diseases through systems biology approaches; and currently, the CCRI is also a partner in the strategic IMI-2 consortium ITCC-P4 (116064), which will develop a large-scale platform comprising 400 novel research tools based on cells and tissues from patients covering 10 common childhood cancers, including neuroblastoma, high grade glioma, and osteosarcoma. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : The Research Support Office of the CCRI (RSO) provides active assistance and expertise in the implementation of 100 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases national and international actions. A team of project managers, which also integrates the ERN-PAEDCAN network manager, is involved in the day-to-day management of projects, monitoring the status of milestones and deliverables, timely technical and financial reporting, and with the dissemination of results. Short Profile of key Staff Members who will be undertaking the work Professor/Ruth Head of the Studies and Statistics Department at the CCRI and a senior consultant in the St. Ladenstein Anna Children’s Hospital. Chief investigator of the high risk neuroblastoma trial (HR-NBL- (MD, MBA, 1/SIOPEN) with over 3000 patients enrolled. Past president of SIOPEN (SIOP Europe cPM)/Female Neuroblastoma Group; 2007- 2011) and past president of SIOPE (2009- 2012) and Head of the Austrian Paediatric Oncology Group (AGPHO) and Chair of OKIDS (Austrian medicines for children network). She has 144 full publications in peer-reviewed journals and 20 published book chapters. She coordinated the ERN Pilot project ExPO-r-Net (European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment, 2014 – 2017) and is now the Coordinator of the ERN PaedCan (European Reference Network for Paediatric Cancer). Nuno Andrade, Head of the Research Support Office at the CCRI. Manages and supervises the management of (PhD, numerous international grants, including of the ERN PaedCan. He is experienced in the MBA)/Male establishment of project management and procedures and has contributed in numerous initiatives to acquire projects funded at the national and international levels. Karoline ERN PaedCan Project Manager. She is responsible for the management and implementation of Noworyta ERN´s non-clinical activities. She has experience with EU funded projects, coordination of (B.Sc., communication and dissemination activities for European projects as well as advocacy and event MPH)/Female organization. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Ladenstein R, et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):292-305 2. Ladenstein R, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017 Apr;18(4):500-514 3. Park JR, et al. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017 Aug 1;35(22):2580-2587 4. Ranft A, et al. Quality of Survivorship in a Rare Disease: Clinicofunctional Outcome and Physical Activity in an Observational Cohort Study of 618 Long-Term Survivors of Ewing Sarcoma. J Clin Oncol. 2017 May 20;35(15):1704-1712 5. Abbasi MR, et al. Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone. Clin Cancer Res. 2017 Aug 1;23(15):4224-4232 List of relevant previous projects or activities, connected to the subject of this proposal : SIOPEN-R-NET (QLRI-CT-2002-01768) – funded under FP5, from 2002-11-01 to 2006-04-30 – Project Coordinator of the SIOP European Neuroblastoma Research Network. ENCCA (261474) – funded under FP7, from 2011-01-01 to 2015-12-31 – Project Coordinator of the European network for cancer research in children and adolescents. ExPO-r-Net (20131207) – funded under 2HP, from 2014-03-01 to 2017-08-31 – Project Coordinator of the pilot network European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment. 54-APHP (a) Full legal name (Acronym) – Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France Principal investigator Rima Nabbout (Hôpital Necker) Relevant Network Reference centre for rare epilepsies (as ERN EPICARE member) Description of the legal entity/department/laboratory/group: The group is composed by the team of the reference centre for rare epilepsies leaded by Pr Rima Nabbout. Necker enfants Malades, AP-HP, Imagine Institute, Paris Descartes, Paris, France Main tasks in the project per Pillar/WP: Rima nabbout is a member of the steering group and leader of the Pillar 4 (WP19-20) together with A Ussi (Eatris) Pillar 0: 101 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Rima Nabbout will participate to all transversal activities as part of the operating group Pillar 4: Rima Nabbout is the leader of Pillar 4. She is leading also the task force group (WP20, task 1 and will participate to task 20.1.1, task 20.1.2, 20.1.3 as well as tasks 20.3 and 20.4). Her role will be to coordinate the work of the pillar, to chair the task force for mapping, dissemination, validation and innovation in clinical studies dedicated to rare diseases. Previous experience relevant to the Tasks: PI in many orphan drugs development in rare epilepsies. Rima Nabbout is the coordinator of the French centre for rare epilepsies and member of the steering committee of EPICARE (European network of rare and complex epilepsies) where she is in charge for laboratory diagnosis and clinical trials. She is involved in clinical trials since over 10 years and is PI in CT in rare epilepsies with new orphan drugs designation and proposed recently a work on composite end points for a better evaluation in CTs. She is a member of the regulatory task force for drugs in epilepsy in the International league against epilepsy. Her expertise in genetics and phenotyping adds to the actual search for mechanisms for drugs and her close work with patient groups help in a better understanding of patients centered outcome. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Short Profile of key Staff Members who will be undertaking the work MD, PhD Pr. Rima Nabbout as supervision of the work Pr. Rima Nabbout Pr. Rima Nabbout is Professor of Paediatric Neurology at Paris Descartes University as Female well as Director of the Centre for Rare Epilepsies at Necker Enfants Malades Hospital, Imagine Institute, Paris, France. She is a member of the steering committee of EPICARE (European reference network on rare epilepsies) and of scientific committees of patients associations on rare epilepsies. Pr. Nabbout areas of research include electro clinical delineation of rare childhood epilepsies, genetics of epileptic encephalopathies, clinical trials in rare epilepsies and transition from childhood into adulthood. She has authored or co-authored more than 150 peer-reviewed papers, and is presently leading a research group at Imagine in the group of Dr. Kabashi Translational Research for Neurological Diseases, Institut des Maladies Génétiques Imagine, Research Unit UMR1163 Inserm / Université Paris Descartes. To be recruited Post doc to be assigned for the work under the supervision of Pr. Nabbout with an expertise in trials and in research and bibliography. Mrs Wenzel Coordination part time to help in the coordination of Pillar 4 and to organise the Task force Female and the different groups meeting (face to face or webex…) and to do the secretary of the group. A person fluent in English, French and German is already previewed. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1) Gaspard N, Hirsch LJ, Sculier C, Loddenkemper T, van Baalen A, Lancrenon J, Emmery M, Specchio N, Farias-Moeller R, Wong N, Nabbout R. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives. Epilepsia. 2018 Apr;59(4):745-752. doi: 10.1111/epi.14022. Epub 2018 Feb 24. Review. PubMed PMID: 29476535. 2) Nabbout R, Auvin S, Chiron C, Irwin J, Mistry A, Bonner N, Williamson N, Bennett B. Development and content validation of a preliminary core set of patient- and caregiver-relevant outcomes for inclusion in a potential composite endpoint for Dravet Syndrome. Epilepsy Behav. 2018 Jan;78:232-242. doi: 10.1016/j.yebeh.2017.08.029. Epub 2017 Nov 4. PubMed PMID: 29108913. 3) Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S; Cannabidiol in Dravet Syndrome Study Group. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017 May 25;376(21):2011-2020. doi: 10.1056/NEJMoa1611618. PubMed PMID: 28538134. 4) French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de 102 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Vries PJ, Dlugos DJ, Berkowitz N, Voi M, Peyrard S, Pelov D, Franz DN. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016 Oct 29;388(10056):2153-2163. doi: 10.1016/S0140-6736(16)31419-2. Epub 2016 Sep 6. PubMed PMID: 27613521 List of relevant previous projects or activities, connected to the subject of this proposal  EPISTP FP7 Health project: 2013-2018  DESIRE FP7 project 2013-2018  Coordinator of the reference centre for rare epilepsies 2010-2022  WP leader at EPICARE 2017-2022 54-APHP (b) Full legal name (Acronym) – Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France Principal investigator Guillaume Jondeau (Hôpital Bichat) Relevant Network VASCERN (as ERN coordinator) Description of the legal entity/department/laboratory/group: The National Center de Reference located in the Bichat Hospital, 75018 Paris is the place where the patients are seen. The hospital includes 1000 beds, and all the medical specialists are presents, including reanimation, heart and lung transplantation. The radiological department possesses MRI, CT scanner, and all last imaging techniques. In the same hospital, the research center, which is composed of more than 100 researchers, includes 5 teams. Team 2 is leaded by Guillaume Jondeau, and is dedicated to genetics in rare diseases (INSERM U1148 / Team 2). Lastly, this HCP is coordinating VASCERN, the European Rare Disease Network devoted to vascular diseases, which is present in 11 countries and includes 30 other HCPs. [Other VASCERN team is involved in the project under the coordination of AP-HP: Radboudumc, Prof Leo Schultze Kool - see Beneficiary Radboudumc description.] Main tasks in the project per Pillar/WP: Pilar 3 In WP17 ERN RD training and support programme AP-HP/VASCERN, as contributor of “systemic” training Previous experience relevant to the Tasks: A long history of research in both the fundamental and clinical areas, with strong interaction between the 2: from bedside to bench and back from bench to bedside, allowing discovery of new diseases, proposition of new therapies. Interaction with numerous HCPs and research teams within Europe through VASCERN. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Structuration of the clinical and research entities with strong interactions between the 2: Centre de Référence pour le Syndrome de Marfan et appârentés (www.marfan.fr) and LVTS INSERM U 1148 (https://lvts.fr/). Short Profile of key Staff Members who will be undertaking the work Pr Guillaume Professor Jondeau has been a Professor of Cardiology since 1999, in Université Paris V, and has Jondeau moved to Université Paris VII - Denis Diderot, since 2007. He is also leading a research team (team 2 LVTS, INSERM U1148) focusing on aortic aneurysm, and has authored more than 200 publications in peer-reviewed international journals. Professor Jondeau’s research interests are in the field of aortic aneurysms and heart failure. He is leading the centre de reference for the Marfan syndrome (www.marfan.fr) and related disorders, which is seeing more than 1000 patients every year, following >1200 patients with FBN1 mutations, and is responsible for the organization of the care of these patients throughout the country. Research units on genetics (co-leaded by Catherine Boileau) and pathophysiology (leaded by JB Michel) in INSERM U1148 are closely linked to this centre de reference. He is a funding member of the nucleus of the new ESC working group on Aorta and peripheral vascular diseases. He is leading the “Filière de Santé maladies rares” on rares vascular diseases, which is taking care of patients with thoracic aortic aneurysms, aneurysms of systemic arteries, and HHT and lymphatic pathologies throughout France, networking 3 reference centers, more than 30 103 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases competence centers, 5 diagnostic laboratories, 3 research units (www.favamulti.fr). He is leading the European Rare Disease Network VASCERN (www.vascern.eu), gathering 31 centers from 11 European countries. He is involved in studies in acute heart failure and chronic heart failure. He is a former president of the Heart Failure Working Group of the French Society of Cardiology and has been a member of the board of the Heart Failure Association of the European Society of Cardiology. He is a fellow of the European Society of Cardiology, American College of Cardiology, and American College of Chest Physicians and is a member of the board of the French Society of Cardiology. Professor Jondeau participated in the steering or executive committees of international trials, and was the principal investigator of investigator-driven and industry-sponsored clinical trials. He was end-point committee’s member. Dr Jondeau has authored more than 200 articles in peer-reviewed international journals. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1) Jondeau G, Boileau C, Milleron O. Marfan Syndrome: Always Evolving. Circ Cardiovasc Genet. 2017 Jun;10(3). pii: e001785. doi: 10.1161/CIRCGENETICS.117.001785. PubMed PMID: 28600389. 2) Milleron O, Arnoult F, Ropers J, Aegerter P, Detaint D, Delorme G, Attias D, Tubach F, Dupuis-Girod S, Plauchu H, Barthelet M, Sassolas F, Pangaud N, Naudion S, Thomas-Chabaneix J, Dulac Y, Edouard T, Wolf JE, Faivre L, Odent S, Basquin A, Habib G, Collignon P, Boileau C, Jondeau G. Marfan Sartan: a randomized, double- blind, placebo-controlled trial. Eur Heart J. 2015 Aug 21;36(32):2160-6. doi: 10.1093/eurheartj/ehv151. Epub 2015 May 2. PubMed PMID: 25935877. 3) Aubart M, Gross MS, Hanna N, Zabot MT, Sznajder M, Detaint D, Gouya L, Jondeau G, Boileau C, Stheneur C. he clinical presentation of Marfan syndrome is modulated by expression of wild-type FBN1 allele. Hum Mol Genet. 2015 May 15;24(10):2764-70. doi: 10.1093/hmg/ddv037. Epub 2015 Feb 4. PubMed PMID: 25652400. 4) Barbier M, Gross MS, Aubart M, Hanna N, Kessler K, Guo DC, Tosolini L, Ho-Tin-Noe B, Regalado E, Varret M, Abifadel M, Milleron O, Odent S, Dupuis-Girod S, Faivre L, Edouard T, Dulac Y, Busa T, Gouya L, Milewicz DM, Jondeau G, Boileau C. MFAP5 loss-of-function mutations underscore the involvement of matrix alteration in the pathogenesis of familial thoracic aortic aneurysms and dissections. Am J Hum Genet. 2014 Dec 4;95(6):736-43. doi: 10.1016/j.ajhg.2014.10.018. Epub 2014 Nov 26. PubMed PMID: 25434006; PubMed Central PMCID: PMC4259978. 5) Boileau C, Guo DC, Hanna N, Regalado ES, Detaint D, Gong L, Varret M, Prakash SK, Li AH, d'Indy H, Braverman AC, Grandchamp B, Kwartler CS, Gouya L, Santos-Cortez RL, Abifadel M, Leal SM, Muti C, Shendure J, Gross MS, Rieder MJ, Vahanian A, Nickerson DA, Michel JB; National Heart, Lung, and Blood Institute (NHLBI) Go Exome Sequencing Project, Jondeau G, Milewicz DM. TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat Genet. 2012 Jul 8;44(8):916-21. doi: 10.1038/ng.2348. PubMed PMID: 22772371; PubMed Central PMCID: PMC4033668. List of relevant previous projects or activities, connected to the subject of this proposal 1) ANR-05-PCOD-014 : « diversité génétique et monotonie phénotypique des anévrysmes artériels non athéromateux » avec l’U 698 (Bichat), l’U 383 (Necker), l’U 36 (HEGP) 2) ANR-14-CE15-0012 (porteur de projet) : 420243 € 3) CRC 10 043 : Apport de la PET pour le suivi des patients présentant une dissection de l’aorte descendante (porteur de projet) : 100 000 € 54-APHP (c) Full legal name (Acronym) – Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France Principal investigator Pierre Fenaux (Hôpital Saint Louis) Relevant Network ERN EuroBloodNet (as ERN coordinator) Description of the legal entity/department/laboratory/group: Prof Pierre Fenaux moved in 2013 to Hôpital St Louis/Paris 7 university to create a new clinical hematology section for myeloid disorders in the elderly which he is currently chairing. He is involved in clinical and laboratory research in the field of myelodysplastic syndromes (MDS) and acute myeloid leukemia (especially promyelocytic leukemia). He is a founding member and chairman of the French speaking MDS group (Groupe Francophone des Myélodysplasies) and of the French APL group (GT-LAP), and currently part of INSERM unit 1131 in Paris for his research 104 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases [Other EuroBlooNet teams are involved in the project under the coordination of AP-HP: AOUFIIN with Prof. Achille Iolascon, CING with Prof. Marina Kleanthous, CHUM with Prof. Patricia Aguilar Martinez and IRCCSCG with Dr. Paola Bianchi] AP-HP remains coordinator but Pr. Achille Iolascon from AOUFIIN will be more involved in this EJP. Since 1983 Prof. Iolascon Research group is currently an international reference group for genetics of rare hemolytic anemias, either due to hyporegenerative defects and RBCs membrane defects. Achille Iolascon is a full Professor of Medical Genetics at University of Naples “Federico II” and PI of a group composed by: 2 researchers, 2 post-doctoral fellows, 4 PhD students, 9 post graduate students in residency school of medical genetics at Ceinge - Biotecnologie Avanzate, Naples, Italy. Main tasks in the project per Pillar/WP: Pillar 2 Contribution to WP10 annual retreats to guide the priorities for Virtual Pltaform development and FAIRification of resources. Previous experience relevant to the Tasks: The ERN EuroBloodNet coordinator Pierre Fenaux, AP-HP has contributed in RESEARCH ACTIVITIES mainly concern acute myeloid leukemias (AML) and myelodysplastic syndromes (MDS). 1° clinical research - Coordinator of European clinical trials in Acute Promyelocytic Leukemia since 1990 - Founding member of the French MDS group (groupe francophone des myélodysplasies –GFM-in 1992), Président (1992-1995, and since 1999) Vice- Président (1996-1998). The GFM is sponsor of about 10 clinical trials in the field of myelodysplastic syndromes 2° biological research P Fenaux part of INSERM Unit 1131, Hôpital St Louis, Paris, where the main subject of our research is: translational research in MDS and APL For what concerns ERN-EuroBloodNet LTPs, some relevant experience: LTP CING - PKDeep 2017-2018. Funded by the FUNDACIÓ INSTITUT RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS - H2020-INFRADEV-01-2017 – ID-EPTRI project European Paediatric Translation Research Infrastructure (777554-ID-EPTRI) 2018-2020. LTP AOUFIIN - 2014-2017: PRIN research grant “Study of the molecular mechanisms of erythropoiesis for the identification of therapeutic targets” LTP CHUM The principal investigator of CHUM has acted as a workpackage leader in the field of education and training in 3 European projects. We have developed several e-learning platforms and many of us are university professors/teachers having participated to numerous educational programmes The principal investigator of CHUM and her team are specialists in molecular biology applied to rare diseases, including sequencing and next generation sequencing tools. LTP IRCCSCG -2016-present BBMRI-LPC Whole Exome Sequencing Call: “Sequencing the exome of 500 rare disease samples in collaboration with EuroBioBank” (PI) - 2013-2016 e-Health workplan for the European reference network on rare anaemias (e-ENERCA), EU Executive Agency for Health and Consumers. (Italian Partner) Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : 105 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases - The Cyprus Institute of Neurology and Genetics (CING) is a non-profit research organization, with the vision of operating as a Regional Centre of Excellence, in the areas of Neurology, Genetics and Biomedical Sciences. With a particular focus on rare diseases, the activities of the CING include delivery of state-of-the-art diagnostic and clinical services, execution of innovative research programmes and participation in postgraduate education. - The CHU of Montpellier is fully equipped with a platform of next generation sequencing (NGS) and all genetics and genomics facilities which are shared by the different laboratories. Short Profile of key Staff Members who will be undertaking the work Prof. Pierre Pierre Fenaux, after training at the University Hospital of Lille, France, where he became Fenaux Professor in Hematology in 1993, created and was head of the clinical hematology section at Hôpital Avicenne/Paris 13 university (belonging to Assistance Publique- Hôpitaux de Paris) from 2002 to 2013. He moved in 2013 to Hôpital St Louis/Paris 7 university to create a new clinical hematology section for myeloid disorders in the elderly which he is currently chairing. He is involved in clinical and laboratory research in the field of myelodysplastic syndromes (MDS) and acute myeloid leukemia (especially promyelocytic leukemia ). He is a founding member and chairman of the French speaking MDS group (Groupe Francophone des Myélodysplasies) and of the French APL group (GT-LAP), and currently part of INSERM unit 1131 in Paris for his research. Prof. Since 1983 Prof. Iolascon works in the field of rare anemias and he gradually gained international Achille recognition in this field. Using continuously renewed methods in molecular biology and in Iolascon medical genetics, he characterized a large number of previously unknown genes and mutations: SPTA1, ANK1, AE1, SEC23B, ABCB6, KCNN4 and PIEZO1. Prof. Iolascon Research group is currently an international reference group for genetics of rare hemolytic anemias, either due to hyporegenerative defects and RBCs membrane defects. Achille Iolascon is a full Professor of Medical Genetics at University of Naples “Federico II” and PI of a group composed by: 2 researchers, 2 post-doctoral fellows, 4 PhD students, 9 post graduate students in residency school of medical genetics at Ceinge - Biotecnologie Avanzate, Naples, Italy. Dr. Paola Since 1993 she is involved in diagnosis and translational research on hemolytic anemias, both Bianchi congenital (red cell membrane defects, erythroenzymopathies, congenital dyserythopoietic anemias) and acquired (paroxysmal nocturnal hemoglobinuria), contributing to the identification and characterization of more than 200 erythroenzymopathies, 50 CDAII and 30 PNH and some peculiar cases of red cell membrane defects (HS, HE and HSt). As Head Biologist responsible of the molecular biology of “Pathophysiology of Anemia UOS”, she shared National and International projects on moleculear characterization and genotype-phenotype correlation (by mutagenesis and in vitro expression of recombinant mutants), and studied the epigenetic factors that might influence clinical phenotype in these disorders. By NGS (whole exome sequencing, targeted NGS platforms and genomic–proteomic approach she identified new genes responsible for rare forms of hemolytic anemia (SEC23B, KCNN4, PARP4). She is involved in molecular diagnonsis of mieloprolopherative disorders (qualitative /quantitatative evaluation of JAK2V617 allele burden, JAK2, MPL sequencing) and rare forms of congenital erythrocytosis, participating to the JakNet Italian Network. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1) Russo R, Andolfo I, Manna F, Gambale A, Marra R, Rosato BE, Caforio P, Pinto V, Pignataro P, Radhakrishnan K, Unal S, Tomaiuolo G, Forni GL, Iolascon A. Multi-gene panel testing improves diagnosis and management of patients with hereditary anemias. Am J Hematol. 2018 Feb 3. (LTP AOUFIIN) 2) De Franceschi L, Iolascon A, Taher A, Cappellini MD. Clinical management of iron deficiency anemia in adults: Systemic review on advances in diagnosis and treatment. Eur J Intern Med. 2017 Jul;42:16-23. (LTP AOUFIIN) 3) Charitou G, Petousis V, Tsertos C, Parpottas Y, Kleanthous M, Phylactides M, Christou S. First study on iron complexes in blood and organ samples from thalassaemic and normal laboratory mice using Mössbauer spectroscopy. Eur Biophys J. 2017 Jul 10. doi: 10.1007/s00249-017-1234-6 (LTP CING) 4) Reorganisation of the WHO Human Genetics programme (HGN) website, during a mission at WHO headquarter, Geneva (LTP CHUM) 5) *Grace RF, Bianchi P, van Beers E, Eber EW, Glader B, Ya ish HM, et al. The clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate kinase deficiency Natural History Study March 2018 Blood, DOI10.1182/blood-2017-10-810796 (LTP IRCCSCG) List of relevant previous projects or activities, connected to the subject of this proposal : 106 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 1) Non Invasive Prenatal Diagnosis of β-thalassaemia based on the detection of paternally inherited alleles using Targeted Next Generation Sequencing2015-2018. Funded by Telethon grant. (LTP CING) 2) eENERCA; DG SANCO; 2009-2013-WP leader, WP: “Education and training”: organisation of European Courses,(LTP CHUM) 3) 2011-2013: AIRC research grant “Targeting neuroblastoma tumours through the hypoxia-induced dedifferentiation in cellular systems” (LTP AOUFIIN) 4) 2009-2012: European Network for Rare and Congenital Anaemias (LTP IRCCSCG) 5) 2009-2012: Telethon research grant “Congenital Dyserythropoietic Anemia Type II: genotype-phenotype correlation, molecular mechanisms, animal model New insights in erythropoiesis and iron overload”(LTP AOUFIIN) 54-APHP (d) Full legal name (Acronym) Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France Principal investigator Christine Bodemer (Hôpital Necker) Relevant Network ERN-Skin (as ERN coordinator) Description of the legal entity/department/laboratory/group: Necker-Enfants Malades Hospital activity concerns more particularly patients with rare and chronic diseases and its excellence is certified in the field of health care and research. The Dermatology department is a referral dermatology department and prioritizes seeing patients with rare skin diseases. We are recognized as National Referral Centre (MAGEC centre) for many rare and complex skin diseases. The expansion of the research activities in the department has led to close partnership with in house, national and international research laboratory HCPs and benefits of the environment of 36 other national referral centres in its institution, covering other specialities, with strong interaction. Prof C Bodemer, MD, PhD is in charge of the Dermatology Department and lastly is coordinating ERN-Skin, the European Rare Disease Network devoted to dermatological rare diseases, which is present in 18 countries and includes 56 HCPs. She is also the coordinator of the French network for rare skin diseases [Other ERN-Skin teams are involved in the project as LTP under the coordination of AP-HP: EBHS, Pr. Johann Bauer and IRCCS, Pr. Maya El Hachem] AP-HP remains coordinator but Pr. Johann Bauer from EBHS will be more involved in this EJP. The EB House Austria which opened in November, 2005 is located as part of the hospital complex of the General Hospital Salzburg and is closely aligned to the Paracelsus Medical University (PMU), Department of Dermatology. It is the single point of contact for people who are suffering from Epidermolysis bullosa (EB). It consists of 3 units: EB Outpatient Unit, EB Research Unit and the EB Academy. Main tasks in the project per Pillar/WP: ERN-Skin's (AP-HP/Christine Bodemer/Necker Hospital-Paris) main tasks in the project per Pillar/WP are : Pillar 2: In WP1, Johann Bauer from EBHS (LTP : EBHS / ERN-Skin) will take part to the management of the next- generation data ecosystem strategic plan, by : - optimizing and aligning WP1 and WP2 activities with real-world community needs, and taking part to 3-day strategy meetings (annual retreat) (task 1.1.1). - working on continuous monitoring and coordination of the usefulness of WP1 and WP2 activities, moreover on survey and structured interview approaches on technical and scientific matters, to monitor progress and inform strategic decisions (incl. Definition of indicators) (task 1.2.2). - and by working on quality management system, on the design and deployment of the QMS processes, documentation, internal tools and procedures, continuous improvement system, dysfunction tracing (task 1.3.1). Christine Bodemer (Necker Hospital / ERN-Skin) and Johann Bauer will participate to the ERN task force in Pillar2, Pillar 3: Maya El-Hachem from IRCCS (LTP : IRCCS / ERN-Skin) and Christine Bodemer will participate to the ERN task force. Pillar4 : 107 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases in WP 20, Christine Bodemer will take part to Task 20.2: for “support in design and planning of RD clinical trials” (M3 – M60)”. Previous experience relevant to the Tasks: Prof. C. Bodemer has participated to numerous Congress in the domain of rare diseases in Dermatology, and to many selection committees, advisory boards, scientific committee for Grants in the same field, such as ESPD congress, WCD congress, scientific board meeting of the Fondation René Touraine. Dr J. Bauer was studying medicine from 1981-1988 at the Leopold Franzens University of Innsbruck, Austria. After several post-doc years in Innsbruck, Atlanta and Philadelphia he joined faculty of the Department of Dermatology, Paracelsus Medical University Salzburg. In 2014 he was appointed Chairman of the Department of Dermatology of the SALK, the University Hospital of the Paracelsus Medical University Salzburg. Concurrently he is medical director of the EB House Austria, the accredited national center for patients with Genodermatoses. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Short Profile of key Staff Members who will be undertaking the work Professor Professor Christine Bodemer (MD, PhD) is the head of the Department of Dermatology at the Christine Necker Enfants- Malades Hospital, Paris, France. Bodemer, She received her PhD on Cutaneous Biology in 1997, a qualification to direct Research in 2000, MD,PhD and she is Professor in Dermatology at the Paris Descartes-Sorbonne Paris Cité University since 2001. She is regularly invited to give lecture in international congresses and is more particularly specialized in Pediatric dermatology. Pr Bodemer has published more than 300 articles in international Journals, and taken part in the main textbook of Pediatric dermatology as author. She received regular grants to lead research programs. One of this main field of interest concerns rare skin disorders in children and she coordinates a national certified centre for rare pediatric skin diseases (mostly Genodermatoses) (MAGEC) the French national network (FIMARAD) and European network (ERN-SKIN) for rare skin diseases. She is a member of many scientific societies, associated editor of different journal, as the British Journal of Dermatology, and she is actually the president of the French Society of Pediatric Dermatology and in the board of the European Society of Pediatric Dermatology. She took part in the organization of the World Congress of Pediatric Dermatology in Paris and organized recently the 13th congress of Pediatric Dermatology (Paris, 2016). She developed regular international training supported by European Grants. Professor Prof. Bauer was studying medicine from 1981-1988 at the Leopold Franzens University of Johann Innsbruck, Austria. After several post-doc years in Innsbruck, Atlanta and Philadelphia he joined Bauer, faculty of the Department of Dermatology, Paracelsus Medical University Salzburg. In 2014 he MD was appointed Chairman of the Department of Dermatology of the SALK, the University Hospital of the Paracelsus Medical University Salzburg. Concurrently he is medical director of the EB House Austria, the accredited national center for patients with Genodermatoses and Co- coordinator of ERN-Skin. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements Christine Bodemer : 1) Eosinophilic esophagitis and colonic mucosal eosinophilia in Netherton syndrome. Paluel-Marmont C, Bellon N, Barbet P, Leclerc-Mercier S, Hadj-Rabia S, Dupont C, Bodemer C. J Allergy Clin Immunol. 2017 Jun;139(6):2003-2005.e1. 2) Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa.El Hachem M, Zambruno G, Bourdon-Lanoy E, Ciasulli A, Buisson C, Hadj-Rabia S, Diociaiuti A, Gouveia CF, Hernández- Martín A, de Lucas Laguna R, Dolenc-Volj M, Tadini G, Salvatori G, De Ranieri C, Leclerc-Mercier S, Bodemer C. Orphanet J Rare Dis. 2014 May 20;9(1):76 3) Live rubella virus vaccine long-term persistence as an antigenic trigger of cutaneous granulomas in patients with primary immunodeficiency. Bodemer C, Sauvage V, Mahlaoui N, Cheval J, Couderc T, Leclerc-Mercier S, Debré M, Pellier I, Gagnieur L, Fraitag S, Fischer A, Blanche S, Lecuit M, Eloit M. Clin Microbiol Infect. 2014; 20):O656-63 4) Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from 108 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases a French national survey. Chandesris MO, Melki I, Natividad A, Puel A, Fieschi C, Yun L, Thumerelle C, Oksenhendler E, Boutboul D, Thomas C, Hoarau C, Lebranchu Y, Stephan JL, Cazorla C, Aladjidi N, Micheau M, Tron F, Baruchel A, Barlogis V, Palenzuela G, Mathey C, Dominique S, Body G, Munzer M, Fouyssac F, Jaussaud R, Bader- Meunier B, Mahlaoui N, Blanche S, Debré M, Le Bourgeois M, Gandemer V, Lambert N, Grandin V, Ndaga S, Jacques C, Harre C, Forveille M, Alyanakian MA, Durandy A, Bodemer C, Suarez F, Hermine O, Lortholary O, Casanova JL, Fischer A, Picard C. Medicine (Baltimore). 2012 91:e1-19. 5) Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. Bodemer C, Hermine O, Palmérini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS, Hadj-Rabia S, Nasca L, Georgin-Lavialle S, Cohen-Akenine A, Launay JM, Barete S, Feger F, Arock M, Catteau B, Sans B, Stalder JF, Skowron F, Thomas L, Lorette G, Plantin P, Bordigoni P, Lortholary O, de Prost Y, Moussy A, Sobol H, Dubreuil P. J Invest Dermatol. 2010;130: 804-15. Johann Bauer : 1) Wally V, Lettner T, Peckl-Schmid D, Klausegger A, Murauer EM, Hintner H and Bauer JW. The pathogenetic role of interleukin-1 beta in severe epidermolysis bullosa simplex. J Invest Dermatol 2013. 133(7):1901-3 2) Gruber C, Koller U, Murauer EM, Hainzl S, Hüttner C, Kocher T, South AP, Hintner H, Bauer JW. The design and optimization of RNA trans-splicing molecules for skin cancer therapy. Mol Oncol 2013 Dec;7(6):1056-68 3) Bauer JW, Brandl C, Haubenreisser O, Wimmer B, Karl T, Klausegger A, Breitenbach M, Hintner H, von der Haar T, Tuite M, Breitenbach-Koller H. Personalized ribosomes: a customized tool for selective mRNA translation. PLOS one 2013 10.1371/journal.pone.0067609 4) Bauer JW, Koller J, Murauer EM, De Rosa L, Enzo E, Carulli S, Bondanza ,S, Recchia A, Muss W, Diem A, Mayr E, Schlager P, Gratz IK, Pellegrini G and De Luca M. Closure of a large chronic wound through transplantation of gene-corrected epidermal stem cells. J Invest Dermatol 2016 Nov 10. pii: S0022- 202X(16)32636-7. doi: 10.1016/j.jid.2016.10.038 5) Hirsch T*, Rothoeft T*, Teig N*, Bauer JW*, Pellegrini G*, De Rosa L*, Scaglione D, Reichelt J, Klausegger A, Kneisz D, Romano O, Secone Seconetti A, Contin R, Enzo E, Jurman I, Carulli S, Jacobsen F, Luecke T, Lehnhardt M, Fischer M, Kueckelhaus M, Quaglino D, Morgante M, Bicciato S, Bondanza S, De Luca M. Regeneration of the entire human epidermis using transgenic stem cells. Nature 2017 Nov 16;551(7680):327- 332. doi: 10.1038/nature24487. Epub 2017 Nov 8. PMID: 29144448 *shared first authors List of relevant previous projects or activities, connected to the subject of this proposal Christine Bodemer : Examples of recent research programs supported b grants 1) Phase II clinical trial using Humira in Nztherton syndrome (anti TNF-SN) 2) A replacement protein administrated to male infants with X-Linked hypohydrotic Ectodermal Dysplaisa (Phase II) 3) A Multi-Centre, Open Label, Single Arm, Phase IB/IIA, Trial of Taselisib (GDC0032) in PIK3CA-Related Overgrowth 4) Treatment of superficial voluminous complicated slow-flow vascular malformations with sirolimus: a phase 2 trial in children observational-phase designed Johann Bauer : 1) GENESKIN Website; European Commission (contract LSHM-CT-2005-512117) between 2005 and 2008. In 2011 the EDF (European Dermatology Foundation) has taken over responsibility to manage the website. Co- ordinator 2) EB House Austria; DEBRA Austria; 2006-ongoing; Medical director 54-APHP (e) Full legal name (Acronym) – Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France Principal investigator Dr. Belmatoug (Hôpital Beaujon) Relevant Network ERN MetabERN (participation as ERN member) Description of the legal entity/department/laboratory/group: 109 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Assistance Publique-Hôpitaux de Paris (AP-HP) is the legal entity where all research projects including clinical trials are administered. The Referral Centre for Lysosomal Diseases (RCLD) certified by the health ministry since 2004, is located at AP-HP, University Hospital, Paris-Nord Val de Seine, Department of internal medicine, Beaujon Hospital. The characteristics of the centre are: multidisciplinarity, collaborative approach, coordination, symptomatic and specific care for disabled patients, epidemiology and registries, reactivity to give expertise, transition programme from childhood to adulthood, enzyme replacement therapy for outpatients, home therapy, clinical trials, research. Various platforms are present. High-level specialized performances with multidisciplinary meetings locally and with external consultants in structured national organizations that exist since 2000 : CETL (Treatment Evaluation multidisciplinary Committee for Lysosomal Diseases). Our HCP contributes to the continuous training for lysosomal diseases for nurses, dietitians, residents, interns, fellows and medical students etc. Teaching courses in LD are organized by HCP locally and in many university hospitals. Beaujon hospital has a 3 research departments called DHU organizing teaching courses for trainees (medical and research : http://hupnvs.aphp.fr/dhu/. Clinical research department in Beaujon Hospital give methodological assistance for clinical trials, monitoring and coordinating data management (http://hupnvs.aphp.fr/liste-des- specialites/epidemiologie-recherche-clinique-beaujon/). The centre is included in the French Inherited Metabolic Diseases (IMDs) network “G2M” that integrates 19 rare diseases centres and was certified in 2013. 9 HCP of “G2M” are members of MetabERN. MetabERN is being coordinated by Prof Maurizio Scarpa. MetabERN represents 69 nationally certified healthcare providers from 18 European countries, 44 patients organisations and is endorsed by the Society for the Inborn Errors of Metabolism (SSIEM). The centre has numerous academic national registries: The French Gaucher registry, RaDiCo (MPS), Niemann Pick. Bio-banks are affiliated to registries Main tasks in the project per Pillar/WP: Pillar 3 In WP16 : Online academic education course Task 16.1 : Access the needs, target audience, main topics of the academic education course Task 16.2 : Developing the online courses Our main contribution will be based on our experience and model and find new concepts to give courses in the field of rare diseases. Education of health care professionals outside the field of rare diseases is also crucial. Previous experience relevant to the Tasks: ‐ Leader of work package : Education, Training and Capacity Building for MetabERN ‐ Organisation and participation of courses for rare diseases : inter-universitary diploma on lysosomal diseases and metabolic diseases with Pascal de Lonlay (AP-HP Necker Hospital) ‐ Organisation and participation of education programmes for the patients and families in patient associations. ‐ Lessons for medical students at University Paris Diderot ‐ Responsible of rare diseases websites : For Lysosomal Diseases : www.cetl.net For the European working group on Gaucher: www.ewggd.com For MetabERN website : the section on education and training : metabern-edu.eu Since 2004, our HCP is interested in developing new tools to create original programmes and curriculum for education and training in the field of rare diseases. The creation of a pilot programmes that integrates a multidisciplinary approach with physicians, researchers, scientists, biologists, nurses, etc.), “around “patients and families stories with the participation of patient associations is already set up and need evaluation. Different perspectives on rare diseases must be offered and developed for the students. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Two members of the referral centre for lysosomal diseases and of MetabERN with an expertise in the field will be dedicated to the tasks. Short Profile of key Staff Members who will be undertaking the work MD, MD, Rheumatologist-Internist, master of infectiology, 123 publications. Knight of the Order of Belmatoug the Legion d’Honneur in 2010 given by the health ministry. Head of the outpatient unit in the Nadia Female department of internal medicine. Involved in rare diseases since 1992. Coordinator of the Referral Centre for Lysosomal Diseases since 2004. Coordinator of the French National Gaucher disease Registry (600 patients) certified by Inserm. Head of the multidisciplinary committee CETL : 110 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Comité d’Evaluation du Traitement des maladies Lysosomales, for the french filère « G2M”. Investigator for clinical trials on enzyme replacement therapy and Substrate Reduction Treatment. Clinical research on lysosomal diseases, collaboration with research units : laboratory of excellence GR-Ex : Inserm U1149, Inserm U1134; university of Orsay (LETIAM) for basic research on pathophysiology of Gaucher. Member of the scientific committee of the patient association : Vaincre les Maladies Lysosomales. Member of the European Gaucher Alliance. Member of Maladies Rares Info-services. Coordinator of TENALYS programme (Transition from childhood to adulthood for Lysosomal Diseases). Expert at the social security for reimbursement of care and approval of treatment for metabolic diseases since 1996. Expert and copilote at the French Health Ministry for the second and third rare disease plans. PhD Beaujon University Hospital Khemiri Head of mission for the French « filière G2M » in charge of research and clinical trials Azza Female Education and training in MetabERN List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Regenboog M, van Dussen L, Verheij J, Weinreb NJ, Santosa D, Vom Dahl S, Häussinger D, Müller MN, Canbay A, Rigoldi M, Piperno A, Dinur T, Zimran A, Mistry PK, Salah KY, Belmatoug N, Kuter DJ, Hollak CEM. Hepatocellular carcinoma in Gaucher disease: an international case series. J Inherit Metab Dis. 2018 Feb 8. 2. Bremova-Ertl T, Schiffmann R, Patterson MC, Belmatoug N, Billette de Villemeur T, Bardins S, Frenzel C Malinová V, Naumann S, Arndt J, Mengel E, Reinke J, Strobl R, Strupp M. Oculomotor and Vestibular Findings in Gaucher Disease Type 3 and Their Correlation with Neurological Findings.Front Neurol. 2018 Jan 15;8:711. 3. Lefebvre T, Reihani N, Daher R, de Villemeur TB, Belmatoug N, Rose C, Colin-Aronovicz Y, Puy H, Le Van Kim C, Franco M, Karim Z. Involvement of hepcidin in iron metabolism dysregulation in Gaucher disease. Haematologica. 2018 Apr;103(4):587-596. 4. Mehta A, Belmatoug N, Bembi B, Deegan P, Elstein D, Göker-Alpan Ö, Lukina E, Mengel E, Nakamura K, Pastores GM, Pérez-López J, Schwartz I, Serratrice C, Szer J, Zimran A, Di Rocco M, Panahloo Z, Kuter DJ, Hughes D. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Mol Genet Metab. 2017 Nov;122(3):122-129. 5. Belmatoug N, Di Rocco M, Fraga C, Giraldo P, Hughes D, Lukina E, Maison-Blanche P, Merkel M, Niederau C, Plӧckinger U, Richter J, Stulnig TM, Vom Dahl S, Cox TM. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. Eur J Intern Med. 2017 Jan;37:25-32. List of relevant previous projects or activities, connected to the subject of this proposal : EUROPLAN National conferences 2010 EUCERD Joint Action April 2014 : Workshop on Centres of Expertise for Rare Diseases RaDiCo MPS 2017 MetabERN : Leader of WP 7 : Education, training, Capacity building, 2017-2022. French Health Ministry : Leader of the workpackage “Research and Treatment” for the construction of the 3 rd French rare disease plan, 2017-2018 54-APHP (f) Full legal name (Acronym) – Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France Principal investigator Jérôme Bertherat (Hôpital Cochin) Relevant Network ERN Endo (participation as ERN member) Description of the legal entity/department/laboratory/group: Assistance Publique - Hôpitaux de Paris (AP-HP) is the Legal entity where all research projects including clinical trials are administered in the field of endocrine diseases within the ERN Endo. AP-HP hosts the French Reference Centre for Rare Adrenal Disease and the French Network for Rare Endocrine Diseases, Service d’Endocrinologie, Hôpital Cochin, HUPC. [ERN Endo is under the coordination of LUMC: PI Prof Alberto Pereira – See Beneficiary LUMC description] Main tasks in the project per Pillar/WP: Pillar 3: 111 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases We will contribute to assess the needs, target audience and main topics of the academic education course. (task 16.1) We will co-coordinate the development of on-line course module: choice of the lecturers/speakers, the harmonization and general design of the module's content (task 16.2) We will participate in the follow-up, evaluation and monitoring of the course. Previous experience relevant to the Tasks: Professor of endocrinology, responsible for various post-graduate course dedicated to are endocrine diseases at Paris 5 University, coordinator of the French reference center for rare adrenal disease and the French national network for rare endocrine disease, Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Short Profile of key Staff Members who will be undertaking the work Pr Jérôme MD, PhD, Head of the Endocrinology dept of Cochin hospital Bertherat, M Pr Lionel MD, PhD, Professor of endocrinology, Paris Descartes University, coordinator of the national Groussin diploma on endocrine tumors List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. On line course on endocrine tumors (Paris Descartes University) 2. Web site of the French network for rare endocrine diseases (www.firendo.fr) 3. Assié G, Libé R, Espiard S, … Groussin L, Bertagna X, Stratakis CA, Ragazzon B, Bertherat J. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med. 2013 Nov 28;369(22):2105-14. List of relevant previous projects or activities, connected to the subject of this proposal : 1) Coordinator Work Package geneomics of adrenal tumors ENSAT-CANCER (FP7) : FP7-HEALTH-2010; 259735 (2011-2016) 2) Coordinator E-RARE Genomics and signalisation of cAMP in adrenal Cushing, (RARE 0008-01) (2014-2017) 3) Coordinator Work-Package 2, H2020 633983, ENSAT-HT (2015-2020) 54-APHP (g) Full legal name (Acronym) – Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France Principal investigator Marc Humbert (Hôpital Bicêtre) Relevant Network ERN-LUNG (participation as ERN member) Description of the legal entity/department/laboratory/group: Assistance Publique - Hôpitaux de Paris (AP-HP) is the Legal entity where all research projects including clinical trials are administered in the field of pulmonary hypertension within the ERN LUNG. AP-HP hosts the French Reference Centre for Pulmonary Hypertension, Service de Pneumologie, Hôpital Bicêtre, France. ERN-LUNG is being coordinated by Prof. Dr. TOF Wagner, head of the FRZSE, the clinical Rare Disease Unit of Universitätsklinikum Frankfurt (UKF). ERN-LUNG is a project of building a clinical care network for all rare diseases of the respiratory system. ERN-LUNG has been evaluated by the European Commission and on 15 December 2016 the European Reference Network Board of Member States approved ERN-LUNG. ERN-LUNG is a network of European healthcare providers dedicated to ensuring and promoting excellence in care and research for the benefit of patients affected by rare respiratory diseases. [ERN-LUNG is under the coordination of GUF : PI Prof TOF Wagner – See Beneficiary UKF description] Main tasks in the project per Pillar/WP: Pillar 2: WP11 Task 11.1.1. Define metadata model compatible with existing key databases and resources – contributing experience with metadata registries and minimum data sets (e.g. ERDRI) WP11 Task 11.2.4. Enhance the catalogue platform to optimise and federate query capabilities, and to automate metadata collection/curation– contributing experience and work done on federate search and inter-operability WP12 Task 12.2.1. Semantic and syntactic harmonisation of data records – contributing experience and work done on federate search data and inter-operability 112 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Pillar 4: WP19 Task 19.1. Survey to understand the ERN community needs and evaluation of services provided– perform a survey to understand the ERN community needs in terms of educational resources for translational research (to inform the population of our virtual library), and then later to perform an evaluation of the translational and partnering services provided in the WP. WP 19 Task 19.3. Evaluation of Innovation Management and exploitation support tasks Other activities: Several contributions to other Tasks in its role as one of the ERNs, and in close collaboration with JRC, Ispra, Italy (ERDRI). Previous experience relevant to the Tasks: AP-HP, represented by M. Humbert, and O. Sitbon has many years of experience in registry work by running registries and registry infrastructure. The group has developed the national French Pulmonary Hypertension Registry. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Short Profile of key Staff Members who will be undertaking the work Pr. Marc Marc Humbert, MD, PhD, is Professor of Respiratory Medicine at the South Paris University Humbert (Université Paris-Saclay) in Le Kremlin-Bicêtre, France. In addition to his academic responsibilities, he is the Director of the French Reference Centre for Pulmonary Hypertension, Department of Respiratory and Intensive Care Medicine, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, France. Along with membership to several scientific councils and institutes, Marc Humbert is the current Director of the INSERM Unit "Pulmonary Hypertension: Pathophysiology and Innovative Therapies" and of the “Thorax Innovation” University Hospital Department. He has been the Chief Editor of the European Respiratory Journal from 2013 to 2017. Pr. Olivier Sitbon, MD, PhD, is Professor of Respiratory Medicine at the South Paris University Olivier (Université Paris-Saclay) in Le Kremlin-Bicêtre, France. In addition to his academic responsibilities, Sitbon he is in charge of the French Pulmonary Registry, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, France. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1) Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 903-75. 2) Montani D, Girerd B, Jaïs X, Levy M, Amar D, Savale L, Dorfmüller P, Seferian A, Lau EM, Eyries M, Le Pavec J, Parent F, Bonnet D, Soubrier F, Fadel E, Sitbon O, Simonneau G, Humbert M. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respir Med 2017; 5:125-34. 3) Ghofrani HA, Grimminger F, Grünig E, Huang Y, Jansa P, Jing ZC, Kilpatrick D, Langleben D, Rosenkranz S, Menezes F, Fritsch A, Nikkho S, Humbert M. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med 2016; 4:361–71. 4) Humbert M, Lau EM, Montani D, Jaïs X, Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 2014; 130 :2189-208. 5) Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, Chelghoum N, Coulet F, Bonnet D, Dorfmüller P, Fadel E, Sitbon O, Simonneau G, Tregouet DA, Humbert M, Soubrier F. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014; 46:65-9. List of relevant previous projects or activities, connected to the subject of this proposal 1)EFORT; Funder; PHRC (French MoH); 2011-2017: Biomarkers of outcomes in PAH 2)VIGIAPATH; ANSM (French EMA); 2013-2018: Pharmacovigilance of drugs inducing PAH 3)SNOOPY-2; (Inserm, Univ. Paris-Sud, Technion, AP-HP) 2015-2018: Associated International Laboratory Technion – Univ. Paris-Sud - Inserm on the development on an electronic nose to detect pulmonary hypertension 4)ERN-LUNG; EC DG SANTE; 2017-2022-TOF Wagner Coordinator, ERN for rare diseases of the respiratory system 5)RD REGWAREHOUSE; EC DG SANTE; 2018-2021-TOF Wagner Ccoordinator, three level registry infrastructure for ERN-LUNG 113 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 55-HUS Full legal name (Acronym) – Country Hôpitaux Universitaires de Strasbourg (HUS) - France Principal investigator Hélène Dollfus Relevant Network ERN-EYE Description of the legal entity/department/laboratory/group: Ranked among the top French university hospitals, the University Hospital of Strasbourg (HUS) is renowned for the quality of the care provided, the excellence of its level of clinical research, innovation expertise, and its leadership in the primary or life-time training of the healthcare professionals in the Alsace region and beyond. The HUS as a university hospital (CHU) providing primary, secondary, tertiary care, teaching and research works in close in connection with the University of Strasbourg (IDEX label) . For the last 20 years, the HUS has developed expertise for diagnosis, care, clinical research and scientific research in the field of Rare Eye Diseases (RED) and since 2004 is a national centre for rare diseases (CARGO). Since then >6000 files have been opened and >1750 consultations for secondary and tertiary referral of pediatric and adult RED are done yearly. CARGO has established a highly specialized multidisciplinary network for care of syndromic eye diseases (with pediatrics, neurology, nephrology, dermatology…). CARGO has low vision aid expertise for poorly sighted or blind patients of all ages with a regional and national network for specialized careers. CARGO is one of the 3 French centres authorized to perform patient selection and rehabilitation for artificial retinal implantation. CARGO is highly specialized in genetic counselling for RED in close collaboration with the HUS Medical genetics department. CARGO deals with preimplanatory diagnosis (PID) as well as prenatal diagnosis (PND) for various RED in close contact with the HUS pluridisciplinary centre for prenatal diagnosis. The Molecular Genetics Unit of is constantly developing various NGS panels for retinitis pigmentosa and for ciliopathies. CARGO is embedded in the stimulating environment of the IGMA (Institut de Génétique Médicale d’Alsace) that brings together biologists, clinicians, ophthalmologists and bio informaticians. CARGO leads or participates in clinical research protocols (R= regional or N=national; PHRC) as principal investigator: Bardet-Bield syndrome I and II, Alström syndrome, NGS panel for retinitis pigmentosa (R); or as associated investigator: Leber’s congenital amaurosis (N), retinitis pigmentosa autosomal recessive and dominant (N). CARGO is tightly linked to fundamental research laboratories especially the INSERM UMRS_S1112 and other human genetics laboratories in Strasbourg and many others worldwide. Since 2014, CARGO is the chair of the national network for rare sensory diseases in France (SENSGENE) providing medical coordination of RED care for France including: mapping social care, child to adult transition, education, national molecular network. The HUS coordinates the European Reference Network dedicated to RED, ERN-EYE constituted by 29 Healthcare providers through 13 European Member States. Main tasks in the project per Pillar/WP: ERN-EYE members carry research with highly heterogeneous (phenotype and genotype) non-syndromic rare eye diseases (ie: eye developmental anomalies, retinal degenerations, corneal dystrophies, optic neuropathies, ...) as well as syndromic conditions (i.e.: ciliopathies, ultra rare syndromes, mitochondrial disorders etc. …) overlapping with other ERN’s fields prompting for ERNs close interactions. 43 research entities are collaborating with ERN-EYE members of which 25 are working in the close vicinity of the ERN HCPs; a premise to an excellent setting for holistic approaches to be developed. Genomics research for rare eye diseases is tackled by ERN-EYE members with a continuous effort for solving the unsolved leading to multiple novel gene identifications and with regular novel pathway & biomarker discovery . ERN-EYE will share this holistic systemic biology approach strategy in this project and will solicit our network members & their research partners for this purpose. Most importantly, therapies are being elaborated in preclinical terms by many groups of ERN-EYE (often based on system biology approaches) and tackles the very high degree of phenotypic variability and as well as the high number of genes involved to date putting multi-omics and holistic research at the forefront of our priorities in the next years. We will fulfil the here under described tasks in PILLAR 2: WP 10. User-driven strategic planning and transversal activities for Pillar 2 data ecosystem Task 10.1: Pillar 2 annual strategic plans (M1-M60) including participation to prioritization, elaboration of WP11 and 12 of the proof of concept demonstrators, active participation to the annual retreat (we will propose use case, use testers , …) Task 10.2: Coordinating Pillar 2 Work Packages outputs and aligning to RD community needs (M1-M60) where will be involved in advising, designing and responding to the activities. Task 10.4: Quality oversight (M1-M60). We will offer regular participation to the process. 114 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases WP 13. Enabling multidisciplinary, holistic approaches for rare disease diagnostics and therapeutics Task 13.1: Fill a number of pre identified gaps to allow integrative systems biology approaches for rare diseases (M1-M60). We can contribute to most subtasks due to the ERN-EYE ongoing collaboration with platforms and institutes focusing on a holistic approach to diagnosis, biomarker identification and design of novel therapies. Task 13.2: Organize proof of principle studies to identify efficacy of the work done and identify remaining (including new) gaps (M1-M60) Previous experience relevant to the Tasks: We are highly interested in next generation data infrastructure and can contribute with our expertise in the field of RED. WP10 is of concern for members of ERN-EYE involved in genomics research in RED , especially in solving the unsolved and having access to common validated datasets would be a tremendous resource. Many collaborators (i.e: Germany, France, UK, the Netherlands) are leading world experts in the field of gene identification and genotype-phenotype studies in the field of retinal dystrophies. Therapies are also at the fore front of RED (i.e: gene therapy getting into market, retinal implants also on the market and pharmacological therapies on the way) with many preclinical studies as well as ongoing clinical trials. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : These are the one from each institute member of ERN-EYE, for the coordinating HCP we lean on INSERM and the university of Strasbourg facilities (i.e.: for bioinformatics for instance). Short Profile of key Staff Members who will be undertaking the work Pr. Hélène Dollfus Hélène Dollfus, MD, PhD is specialized in Medical Genetics and Ophthalmology. She is (female) the head of the Medical Genetics Department of the Strasbourg University Hospitals (HUS) since 2003, Coordinator of the Rare Diseases in Ophthalmic Genetics Reference Center (CARGO) since 2004, as well as the national rare diseases network SENSGENE since 2014, Director of the Medical Genetics Laboratory Inserm UMRS_S 1112 since 2002, Instigator of the future Institute of Medical Genetics of Alsace (IGMA), President of the scientific council of Retina France and Coordinator of the European Reference Network ERN-EYE since 2017. Dr. Jean Muller Jean Muller, PhD is specialized in Human Genetics testing and Bioinformatics. Member of (male) the diagnostic laboratory of the HUS since 2009, he is responsible of the post and prenatal diagnosis of rare sensory diseases. He is coordinator of the French network “NGS- Diagnostic” since 2014. Member of the Medical Genetics Laboratory INSERM UMRS_S 1112 since 2015 is coordinating research around bioinformatics and rare ophthalmologic diseases including ciliopathies as well as development of WES and WEGS in novel gene identification and novel path way discoveries. Dr. Dorothée Leroux Dorothée Leroux (PharmD, PhD) is the project Manager of ERN-EYE since its creation. (female) She manages ERN-EYE operatatiosn with important interactions with patients and patient groups. She is particularly involved in the ontology work organized last year and in the development of a training program for ERN-EYE. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. A mutation in VPS15 (PIK3R4) causes a ciliopathy and affects IFT20 release from the cis-Golgi.Stoetzel C, Bär S, De Craene JO, Scheidecker S, Etard C, Chicher J, Reck JR, Perrault I, Geoffroy V, Chennen K, Strähle U, Hammann P, Friant S, Dollfus H.Nat Commun. 2016 Nov 24;7:13586 2. Mutations in TUBGCP4 alter microtubule organization via the γ-tubulin ring complex in autosomal- recessive microcephaly with chorioretinopathy.Scheidecker S, Etard C, Haren L, Stoetzel C, Hull S, Arno G, Plagnol V, Drunat S, Passemard S, Toutain A, Obringer C, Koob M, Geoffroy V, Marion V, Strähle U, Ostergaard P, Verloes A, Merdes A, Moore AT, Dollfus H.Am J Hum Genet. 2015 Apr 2;96(4):666-74. 3. [Bardet-Biedl syndrome: cilia and obesity - from genes to integrative approaches].Chennen K, Scerbo MJ, Dollfus H, Poch O, Marion V.Med Sci (Paris). 2014 Nov;30(11):1034-9 4. Insights into Ciliary Genes and Evolution from Multi-Level Phylogenetic Profiling.Nevers Y, Prasad MK, Poidevin L, Chennen K, Allot A, Kress A, Ripp R, Thompson JD, Dollfus H, Poch O, Lecompte O.Mol Biol Evol. 2017 Aug 1;34(8):2016-2034. 5. Comparing the Bbs10 complete knockout phenotype with a specific renal epithelial knockout one highlights the link between renal defects and systemic inactivation in mice.Cognard N, Scerbo MJ, Obringer C, Yu X, Costa F, Haser E, Le D, Stoetzel C, Roux MJ, Moulin B, Dollfus H, Marion V.Cilia. 2015 Aug 13;4:10. 115 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases List of relevant previous projects or activities, connected to the subject of this proposal ‐ RADICO Cohort COBBALT (Cohort for Bardet-Biedl and Alström syndrome); start 2016 first inclusion 2018 for next 7 years ‐ OCUTher project, Call H2020 –MSCA-ITN-2016 Maria SKLODOWSKA-CURIE Action ITN innovative training Educational network in ocular drug delivery and therapeutics (PI: Pr Arto URTi University of Eastern Finland (UEF).Ongoing, until 2020 ‐ Identification of novel genes in ultra rare sensorial diseases, PI, various sources of funding, Hospital calls, Fondation Maladies Rares, Retina France, on going since 2004 ‐ ALSM1, PHRC national, for the study of Alström syndrome patients, PI, ends 2018 ‐ PHRI retinopathies pigmentaires, PI, Panel sequencing for retinal dystrophies, 2016 ends 2018 56-CLB Full legal name (Acronym) – Country Centre Leon Berard (CLB),FRANCE Principal investigator Jean-Yves BLAY Relevant Network ERN EURACAN Description of the legal entity/department/laboratory/group: The legal entity is the Centre Leon Berard, the comprehensive cancer center in Lyon France The Participating department is the Department of Medicine within the Centre Leon Berard Main tasks in the project per Pillar/WP: Pillar 2: In WP10, we will contribute to the definition of the needs of the rare cancer community to the RD analysis and sharing capabilities Pillar 4: EURACAN will participate in Task 19.2: Support in exploitation and follow-up funding Previous experience relevant to the Tasks: Development of shared facilities in the SIRIC program of the French NCI (INCA). Contribution to the creation of training courses in rare cancers with ESO and ESMO Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Molecular platformes and bioinformatics, participation to rare cancer networks, national and international level, in house department for education and training courses, links with the University of Lyon. Short Profile of key Staff Members who will be undertaking the work Prof Isabelle Professor of medical oncology, head of the subdomain rare ovarian cancer in the EURACAN Ray-Coquard ERN female Prof Sylvie Professor of pathology, head of the translational pathology department in the CLBN Lantuejoul female Dr Pierre MD, PhD, Head of the platform for molecular characterization of Cancer in the CLB Saintigny Male List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 11: Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marréaud S, van der Graaf WT, Zalcberg JR, Litière S, Blay JY. Time to Definitive Failure to the 116 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol. 2015 Dec 20;33(36):4276-83. doi: 10.1200/JCO.2015.62.4304. Epub 2015 Nov 16. PubMed PMID: 26573069. 2: Gelderblom H, Cropet C, Chevreau C, Boyle R, Tattersall M, Stacchiotti S, Italiano A, Piperno-Neumann S, Le Cesne A, Ferraresi V, Penel N, Duffaud F, Cassier P, Toulmonde M, Casali P, Taieb S, Guillemaut S, Metzger S, Pérol D, Blay JY. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2018 Mar 20. pii: S1470-2045(18)30143-8. doi: 10.1016/S1470-2045(18)30143-8. [Epub ahead of print] PubMed PMID: 29571946. 3: Blay JY, Soibinet P, Penel N, Bompas E, Duffaud F, Stoeckle E, Mir O, Adam J, Chevreau C, Bonvalot S, Rios M, Kerbrat P, Cupissol D, Anract P, Gouin F, Kurtz JE, Lebbe C, Isambert N, Bertucci F, Toumonde M, Thyss A, Piperno-Neumann S, Dubray-Longeras P, Meeus P, Ducimetière F, Giraud A, Coindre JM, Ray-Coquard I, Italiano A, Le Cesne A; NETSARC/RREPS and French Sarcoma Group–Groupe d’Etude des Tumeurs Osseuses (GSF-GETO) networks. Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol. 2017 Nov 1;28(11):2852-2859. doi: 10.1093/annonc/mdx484. PubMed PMID: 29117335; PubMed Central PMCID: PMC5834019. 4: Blay JY, Coindre JM, Ducimetière F, Ray-Coquard I. The value of research collaborations and consortia in rare cancers. Lancet Oncol. 2016 Feb;17(2):e62-e69. doi: 10.1016/S1470-2045(15)00388-5. Review. PubMed PMID: 26868355. 5: Blay JY, Brahmi M, Ray-Coquard I. European Journal of Cancer's Biennial report on soft tissue and visceral sarcomas or the rapid evolution of treatment concepts in sarcomas. Eur J Cancer. 2017 Jan;70:83-86. doi: 10.1016/j.ejca.2016.07.028. Epub 2016 Nov 24. Review. PubMed PMID: 27889671. List of relevant previous projects or activities, connected to the subject of this proposal:  NETSARC ; INCA; 2009-ongoing, head/PI, national network for sarcoma management in France  LYRIC/LYRICAN ; INCA; 20011-ongoing, head/PI, site of excellencenetwork for translational research development  EUROSARC : FP7; 2011-17, head/PI, Acadelic clinical trials in sarcoma EURACAN ERN ; FEur Commission; 2017-22r-Director, ERN of rare adult cancers AURAGEN: DGOS/INSERM, France Medecine Genomic 2025 platform in Lyon, scientific director 57-UKL-HD Full legal name (Acronym) – Country Universitätsklinikum Heidelberg (UKL-HD) - Germany Principal investigator Prof. Dr. Franz Schaefer Relevant Network ERN ERKNet Heidelberg University is ranked #42 globally, #13 in Europe and #1 in Germany in the field of life science and medicine (World University Rankings 2017). Heidelberg University Center for Paediatrics and Adolescent Medicine has a strong focus on clinical and translational research in rare diseases, in particular hereditary kidney and metabolic disorders. The Pediatric Nephrology division, headed by Prof. Franz Schaefer, has an international reputation in clinical, genetic and experimental research in pediatric kidney diseases. The unit has recently been awarded the status of a European Reference Center for Rare Kidney Diseases. Main tasks in the project per Pillar/WP: 117 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Pillar 0: In WP1, we will serve in the Operationg Group. In this function, we will be part of the Operating Group and Central Helpdesk (Subtask 1.1.2), provide coordination and support within and across the pillars (Task 1.2), participate in the writing of the Annual Progress Reports and Annual Work Plans (Subtask 1.2.1), contribute to the development of key performance indicators (Subtask 1.3.1), and help updating the Data Management Plan (Task 1.4). In WP2, we will participate in the mapping of the research and innovation needs of the RD community from the ERN perspective (Task 2.2). Pillar 2: In WP10, we will participate in the annual retreats (task 10.1). In WP11, we will participate in data FAIRification and in PPRL development (task 11.2). In WP12, we will participate in the development of Federation architectures subserving the interoperabilty of ERN patient registries Task 12.1). In WP13, we will help organizing proof of concept studies by identifying and making available suitable data sets from ERN partners (Task 13.2). Pillar 3: In WP16, we will be instrumental in assessing the needs of the ERNs and developing the contents of the academic education course (Tasks 16.1, 16.2). In WP17, we will lead the sub-network “Organs” within the ERN Training Network and will lead Task 17.2 “Development of training programs for the ERN training networks”. Pillar 4: In WP20, we will participate in the Task Force directing the topic selection for demonstrator projects regarding rare disease clinical research methodologies and trial designs (task 20.1) Previous experience relevant to the Tasks: Prof. Schaefer’s unit has ample experience in organizing clinical and translational collaborative research projects. Also we have created several international registries and cohort studies and have performed clinical trials in children with rare diseases and cohort studies, and have carried out multi-level omics studies in rare kidney diseases. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : The unit is home to the Central Office of the European Rare Kidney Disease Network (ERKNet) and hosts several large rare kidney disease registries (see below) with a team of project managers, IT experts, data managers and biostatisticians. The unit runs a fully equipped laboratory for translational, genetic and clinical research with a central biorepository containing more than 180,000 serum, plasma, urine and DNA aliquots from patients with rare kidney diseases. Short Profile of key Staff Members who will be undertaking the work Dr. Franz Schaefer Professor of Pediatrics and Chief of the Pediatric Nephrology Division at Heidelberg (male) University Hospital. His research interests include the genetic basis of hereditary kidney diseases, the physiopathology and prevention of kidney disease progression, the cardiovascular, metabolic and endocrine consequences of kidney disease in children, and the mangement of end-stage kidney disease by renal replacement therapy. Prof. Schaefer has a special interest in rare disease research. He established the PodoNet Project for Research in Steroid Resistant Nephrotic Syndrome and coordinates the EURenOmics Consortium for High-Throughput Research in Rare Kidney Diseases. He is a member the Scientific Advisory Board of the Global aHUS Registry. Recently he founded and currently coordinates the European Rare Kidney Disease Reference Network (ERKNet). Furthermore, he conducted numerous collaborative clinical trials and established several international research consortia including the European Study Group for Progressive Chronic Kidney Disease in Children (ESCAPE), the International Pediatric Dialysis Network (IPDN), coordinated the European registry for pediatric dialysis and transplantation for six years and is the current chair of the Global IPNA Registry for pediatric renal replacement therapy. Dr. Schaefer has published more than 500 scientific articles and book chapters, is co-editor of the standard textbooks ‘Pediatric Kidney Disease’ and ‘Pediatric Dialysis’ and is Associate Editor of two leading nephrology journals. 118 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements  Chesnaye NC, Schaefer F, Bonthuis M, et al. Mortality risk disparities in children receiving chronic renal replacement therapy for the treatment of end-stage renal disease across Europe. Lancet 2017; 389:2128-2137  Devuyst O, Knoers NVA, Remuzzi G, Schaefer F. Rare inherited kidney diseases: Challenges, opportunities and perspectives. Lancet 2014; 383:1844-59  Lemaire M, Frémeaux-Bacchi V, Schaefer F, .... Recessive mutations in DGKE cause atypical hemolytic- uremic syndrome. Nat Genet 2013; 45:531-6.  Lapeyraque AL, Malina M, Fremeaux-Bacchi V, ..., Schaefer F. Eculizumab in severe Shiga-toxin-associated HUS. New Engl J Med 2011; 364: 2561-3.  Wühl E, Trivelli A, Matteucci MC, ..., Schaefer F. Strict blood pressure control and progression of renal failure in children. N Engl J Med 2009; 361: 1639-50. List of relevant previous projects or activities, connected to the subject of this proposal  EURenOmics; EU FP7; 2012-2017; Coordinator  ERK-REG; EU/Chafea; Coordinator; 2018-2020  RenalTract; Marie-Curie-ETN; 2016-2018; project leader  NeoCyst; BMBF (German Reseach Ministry); 2016-2018; WP leader  PodoNet; eRare; 2009-2011; Coordinator 58-EKUT Full legal name (Acronym) – Country Eberhard Karls Universität Tübingen (EKUT), Germany Principal investigator Holm Graessner Relevant Network ERN-RND, Solve-RD Description of the legal entity/department/laboratory/group: EKUT is the coordinator and leading center of the ERN-RND (European Reference Network on Rare Neurological Diseases). This ERN establishes a large patient-centred network to address the needs of patients with RND of all age groups, with or without a definite diagnosis, by implementing an infrastructure for diagnosis, evidence-based management, treatment and collection of patient data. It represents a large-scale network of expert centres dedicated to rare neurological diseases (RND) and exploits all well-established international rare disease infrastructures such as Orphanet, EURORDIS and RD-Connect. This ERN will provide a rich expertise network and infrastructure resource for EJP-RD. Additionally, EKUT is a world-leading cluster of expert institutions focussing on next-generation genomics of rare neurological diseases, bringing together the expertise and methodologies from the Centre for Rare Diseases, Clinical Department of Neurodegeneration, the Hertie-Institute for Clinical Brain Research (HIH), the German Center for Neurodegenerative Diseases (DZNE), and the Institute of Medical Genetics and Applied Genomics. This renowned infrastructure provides the resources that allows EKUT to coordinate Solve-RD a H2020 diagnostic RD research project that will interconnect and interlink with EJP-RD. Furthermore, EKUT has been leading many prominent European consortia on rare diseases such as Solve-RD, NeurOmics, MultiSyn, EUROSCA. Main tasks in the project per Pillar/WP: Pillar 2: In WP10, we will provide important contribution to the management of the next-generation data ecosystem strategic plan. In WP13, we will provide important contribution to • Task 13.1: Identification of areas in which a holistic, systemic biology approach is needed to overcome the diagnostic and therapeutic challenges of RD Pillar 3: In WP17, we will lead the WP and provide important contribution throughout. In WP14, we will provide important contribution • Task 14.2: Standards and quality of genetics/genomics data in laboratory and clinical research practice • Task 14.3: Training on strategies to foster solutions of undiagnosed rare disease cases In WP18, we will provide important contribution to the assessment and adaptation of the Pillar 3. Furthermore, ERN-RND will be participating (as applicants) in the calls as issued by Pillars 1,2 and 4. Previous experience relevant to the Tasks: EKUT is coordinator of ERN-RND and Solve-RD, two main networks that will contribute to EJP-RD. 119 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Furthermore with regards to training activities and besides the activities being pursued in ERN-RND and Solve- RD as well as the seven EU Initial Training Networks that we have been coordinating in our group over the last years, we have set up the German Academy for Rare Neurological Diseases (www.dasne.de) and the Academy for Further Medical Education for rare diseases (www.fakse.info) Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : 1. Centre for Rare Diseases Tübingen (www.zse-tuebingen.de) 2. Recognised German NGS centre 3. Neurobiobank with biomaterials from >22.000 patients with neurodegenerative diseases, in particular FTD, ataxias, HSP, rare movement disorders 4. Coordinator of the international EOA registry (>350 patients included) and HSP registry (> 1400 patients included) Short Profile of key Staff Members who will be undertaking the work Dr. Holm Graessner PhD, MBA, is coordinator of ERN-RND, managing director of the Rare Disease Centre (male) Tübingen and head of the research management unit of the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. He has profound experience in rare disease research and care. He has been coordinating/been responsible for the project management of collaborative projects such as the FP6, FP7 and H2020 EU projects EUROSCA, MEFOPA, RATstream, SENSE-PARK, TreatPolyQ, MultISyn, NeurOmics and Solve-RD. Dr. Carola Reinhard PhD, is project manager of ERN-RND. She has previously been managing EU FP7 and (female) H2020 projects like Moving-beyond, Keep-Control and TreatPolyQ. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. RD-Connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases. Lochmüller H, Badowska DM, Thompson R, Knoers NV, Aartsma-Rus A, Gut I, Wood L, Harmuth T, Durudas A, Graessner H, Schaefer F, Riess O; RD-Connect consortium; NeurOmics consortium; EURenOmics consortium. Eur J Hum Genet. 2018 Feb 27. doi: 10.1038/s41431-018-0115-5. [Epub ahead of print] PMID: 29487416 2. European Reference Networks : Consequences for healthcare in Germany. Graessner H, Schäfer F, Scarpa M, Wagner TOF. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 May;60(5):537- 541. doi: 10.1007/s00103-017-2533-x. German. 3. Participatory design in Parkinson's research with focus on the symptomatic domains to be measured. Serrano JA, Larsen F, Isaacs T, Matthews H, Duffen J, Riggare S, Capitanio F, Ferreira JJ, Domingos J, Maetzler W, Graessner H; SENSE-PARK Consortium. J Parkinsons Dis. 2015;5(1):187-96. doi: 10.3233/JPD-140472. PMID: 25588357 4. German Academy for Rare Neurological Diseases (www.dasne.de) 5. Academy for Further Medical Education for Rare Diseases (www.fakse.info) List of relevant previous projects or activities, connected to the subject of this proposal  ERN-RND; EU; 2017-2022; coordinator; the European Network of rare neurological diseases is a network of care providers set up to share and enhance the knowledge and resources used for treating rare neurological diseases.  Solve-RD; EU-H2020; 2018-2022; coordinator; Solve-RD will work directly with four ERNs to improve the diagnosis of RD. The main ambitions are to solve large numbers of RD for which a molecular cause is not known yet by combined omics approaches, and to improve diagnostics of RD patients through a “genetic knowledge web”.  NeurOmics; EU-FP7; 2012-2017; coordinator; NeurOmics is a European –omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases.  EUROSCA; EU-FP6; 2004-2009; coordinator; EUROSCA is a European project on spinocerebellar ataxias. 59-GUF Full legal name (Acronym) – Country Johann Wolfgang Goethe-Universität Frankfurt am Main (GUF) Principal investigator Thomas WAGNER Relevant Network ERN-LUNG 120 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Description of the legal entity/department/laboratory/group: Universitätsklinikum Frankfurt (UKF) is the legal entity coordinating ERN-LUNG. Goethe University Frankfurt (GUF) is the Legal entity where all research projects including clinical trials run at UKF are administered. There is a clear legal link between both legal entities. All activities within EJP will be organized by GUF with UKF being a linked third party, coordinated by TOF Wagner. ERN-LUNG is being coordinated by Prof. Dr. TOF Wagner, head of the FRZSE, the clinical Rare Disease Unit of UKF. Professors holding lead positions at the UKF are Professors of GUF. ERN-LUNG is a project of building a clinical care network for all rare diseases of the respiratory system. ERN-LUNG has been evaluated by the European Commission and on 15 December 2016 the European Referece Network Board of Member States approved ERN-LUNG as one of the 23 ERNs for rare diseases. ERN-LUNG is a network of European healthcare providers dedicated to ensuring and promoting excellence in care and research for the benefit of patients affected by rare respiratory diseases. [Other ERN-LUNG teams involved in the project under the coordination of GUF: APHP, PI Prof Humbert – See Beneficiary APHP description] Main tasks in the project per Pillar/WP: Pillar 2: WP11 Task 11.1.1. Define metadata model compatible with existing key databases and resources (Co-Task Leader) – contributing experience with metadata registries and minimum data sets (e.g. ERDRI) WP11 Task 11.2.4. Enhance the catalogue platform to optimise and federate query capabilities, and to automate metadata collection/curation (Task Leader) – contributing experience and work done on federate search and inter- operability WP12 Task 12.2.1. Semantic and syntactic harmonisation of data records (Co-Task Leader) – contributing experience and work done on federate search data and inter-operability Pillar 4: WP19 Task 19.1. Survey to understand the ERN community needs and evaluation of services provided (Sub-Task leader) – In WP 19 we will perform a survey to understand the ERN community needs in terms of educational resources for translational research (to inform the population of our virtual library), and then later to perform an evaluation of the translational and partnering services provided in the WP. Other activities: Several contributions to other Tasks in its role as one of the ERNs, and in close collaboration with JRC, Ispra, Italy (ERDRI). Previous experience relevant to the Tasks: The Frankfurt group, represented by TOF Wagner, Holger Storf, and Gernot Rohde has many years of experience in registry work by running registries and establishing registry software and registry infrastructure. The group has developed the national RD registry platform (OSSE) containing cutting edge open source modules for registry development, registry of registry, meta data repository and pseudonymization. These modules have been used to build the European Rare Disease Registry Infrastructure (ERDRI) which is being built at JRC, Ispra, Italy. All structures developed and run respect the highest possible standards of data safety and data ownership and sovereignty. Another module built is the ‘bridgehead’ which allows interoperability of existing registries with the European registry platform. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : https://www.osse-register.de/de/ Short Profile of key Staff Members who will be undertaking the work Pr. TOF Wagner Head of the Dept. for Rare Diseases of the Universitätsklinikum Frankfurt (UKF), pulmonary (male) medicine, Cystic Fibrosis and Lung transplantation. Coordinator of ERN-LUNG; PI of the ERN-LUNG RD registry data warehouse project Dr. H. Storf Head of the Medical Informatics Group of the Universitätsklinikum Frankfurt (UKF) and (male) project coordinator of OSSE and ERDRI and partner in ERN-LUNG RD registry data warehouse project Pr. G. Rohde Head of the Dept. of Pulmonary Medicine of the Universitätsklinikum Frankfurt. Leads the (male) section on Rare Respiratory diseases of the Universitätsklinikum Frankfurt as well as the Christiane Herzog Zentrum for Cystic Fibrosis in Children, Adolescents and Adults. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1: Storf H, Schaaf J, Kadioglu D, Göbel J, Wagner TOF, Ückert F. [Registries for rare diseases : OSSE - An open- source framework for technical implementation]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 May;60(5):523-531. 2: Pauer F, Göbel J, Storf H, Litzkendorf S, Babac A, Frank M, Lührs V, SchauerF, Schmidtke J, Biehl L, Wagner 121 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases TO, Ückert F, Graf von der Schulenburg JM, Hartz T. Adopting Quality Criteria for Websites Providing Medical Information AboutRare Diseases. Interact J Med Res. 2016 Aug 25;5(3):e24. doi: 10.2196/ijmr.5822. 3: Storf H, Hartz T, Tegtbauer N, Pfeiffer W, Schmidtke J, Graessner H, Wagner T, Uckert F. Vision and challenges of a cartographic representation of expert medical centres for rare diseases. Stud Health Technol Inform. 2014;205:677-81. 4: Hirche TO, Knoop C, Hebestreit H, Shimmin D, Solé A, Elborn JS, Ellemunter H, Aurora P, Hogardt M, Wagner TO; ECORN-CF Study Group. Practical guidelines: lung transplantation in patients with cystic fibrosis. Pulm Med. 2014;2014:621342. 5: Hirche TO, Bradley J, d'Alquen D, De Boeck K, Dembski B, Elborn JS, Gleiber W,Lais C, Malfroot A, Wagner TO; European Centres of Reference Network for Cystic Fibrosis (ECORN-CF) Study Group. Travelling with cystic fibrosis: recommendations for patients and care team members. J Cyst Fibros. 2010 Dec;9(6):385-99. List of relevant previous projects or activities, connected to the subject of this proposal :  ECORN-CF; EC DR SANTE; 2012-2016-TOF Wagner Coordinator, Cross border online Expert advice for RD  ENCE-CF-LAM-LTX; EC DG Research; starting year-ending year-TOF Wagner Coordinator, blueprint for ERNs  ERN-LUNG; EC DG SANTE; 2017-2022-TOF Wagner Coordinator, ERN for rare diseases of the respiratory system  RD REGWAREHOUSE; EC DG SANTE; 2018-2021-TOF Wagner Ccoordinator, three level registry infrastructure for ERN-LUNG 60-HSK Full legal name (Acronym) – Country Helios Dr. Horst Schmidt Kliniken (HSK), Wiesbaden DE Principal investigator MetabERN Relevant Network MetabERN Description of the legal entity/department/laboratory/group: The HELIOS Dr. Horst Schmidt Kliniken in Wiesbaden is a highly qualified multidisciplinary center aimed at the treatment of patients with rare diseases as a maximum care facility involving 22 specialized departments and 4 institutes. The team at the Center for Rare Diseases coordinates a multidisciplinary care aimed to satisfy patients´ need. As Health Care Provider HSK is coordinating the MetabERN, the first European Reference Network for Hereditary Metabolic Diseases connecting 69 Center of excellence in rare diseases, in 18 EU countries and following 43000 RD Patients. The MetabERN is running the U-IMD, project, the first EU funded project to create registry for all metabolic diseasesin Europe Main tasks in the project per Pillar/WP: WP 11, task 11.3 to serve the needs for depositing, integrating and storing quality controlled (meta)data produced by the EJP and the overall RD community building on existing resources including registries, in particular HSK will be involved in evaluating strategies to integrate registries from patients in charge of the MetabERN. In WP14 task 14.5, we will participate in course for the FAIRification of rare diseasae registries In WP19, task 19.2 we will participate together with other ERNs to support and guidance to projects approaching the end of EC funding, in particular for the definition and implementation of a development and exploitation plan. In WP 20, task 20.1 we will participate actively to the Task Force on clinical trial to joint discussion to identify the areas of action to improve RD research on clinical trials, design and methodology on evaluation for safety and efficacy of new treatments Previous experience relevant to the Tasks: The team is involved in the management of registries for rare disease since over 15 years, following at clinical level 400 patients affected by rare disease. Furthermore the Team is coordinating the European Reference Network for Metabolic Diseases at European level. Maurizio Scarpa and Christina Lampe are experienced with the running of phase I-III clinical trials for lysosomal diseases. Short Profile of key Staff Members who will be undertaking the work Dr. Maurizio Prof. Dr. Maurizio Scarpa is the Director of the Institute for Rare Diseases at the Scarpa Department of Pediatrics of the Helios Dr. Horst Schmidt Klinik. He is the Coordinator of MetabERN. He will collaborate in the Coordination and the dissemination of the project inside MetabERN. He will participate in all the tasks. Dr. Christina Dr. Christina Lampe, MD is the ViceDirector of the Institute for Rare Diseases at the 122 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Lampe Department of Pediatrics of the Helios Dr. Horst Schmidt Klinik. She is actively participating in registries for lysosomal disease, she will participate to task 11.3 and 14.5 Dr. Cinzia Dr. Cinzia Bellettato PhD is the MetabERN Project Manager will coordinate the Bellettato involvement of the MetabERN in the project List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Inborn Errors of Metabolism Involving Complex Molecules: Lysosomal and Peroxisomal Storage Diseases. Bellettato CM, Hubert L, Scarpa M, Wangler MF. Pediatr Clin North Am. 2018 Apr;65(2):353-373 2. Treatment of brain disease in the mucopolysaccharidoses. Scarpa M, Orchard PJ, Schulz A, Dickson PI, Haskins ME, Escolar ML, Giugliani R. Mol Genet Metab. 2017 Dec;122S:25-34. 3. A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. Burton BK, Balwani M, Feillet F, Barić I, Burrow TA, Camarena Grande C, Coker M, Consuelo-Sánchez A, Deegan P, Di Rocco M, Enns GM, Erbe R, Ezgu F, Ficicioglu C, Furuya KN, Kane J, Laukaitis C, Mengel E, Neilan EG, Nightingale S, Peters H, Scarpa M, Schwab KO, Smolka V, Valayannopoulos V, Wood M, Goodman Z, Yang Y, Eckert S, Rojas-Caro S, Quinn AG. N Engl J Med. 2015 Sep 10;373(11):1010-20. 4. Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series. Lampe C, Bosserhoff AK, Burton BK, Giugliani R, de Souza CF, Bittar C, Muschol N, Olson R, Mendelsohn NJ.J Inherit Metab Dis. 2014 Sep;37(5):823-9 5. Enzyme Replacement Therapy in Mucopolysaccharidosis II Patients Under 1 Year of Age. Lampe C, Atherton A, Burton BK, Descartes M, Giugliani R, Horovitz DD, Kyosen SO, Magalhães TS, Martins AM, Mendelsohn NJ, Muenzer J, Smith LD. JIMD Rep. 2014;14:99-113. List of relevant previous projects or activities, connected to the subject of this proposal: MetabERN: DGSANTE contract 769046 starting 2017-running U-IMD: DGSANTE contract 777259 starting 2018-running InnerMEd: DGSANTE contract 20121212, starting 2012- ending 2015 61-IOR Full legal name (Acronym) – Country ISTITUTO ORTOPEDICO RIZZOLI – IRCCS (IOR), Italy Principal investigator Dr. Luca Sangiorgi Relevant Network ERN BOND Description of the legal entity/department/laboratory/group: The Rizzoli Orthopaedic Institute (Bologna) is the main Italian institute for orthopedics and traumatology. Since 1981, the Italian Ministry of Health recognized to Rizzoli Institute the status of a “Scientific Research Hospital” due to its close integration between healthcare (about 150,000 patients examined and over 20,000 orthopaedic operations every year) and scientific research, which is carried out in nine different laboratories employing physicians, biologists, engineers, physicists, statisticians and technicians. High expertise, organization aimed at integration between research and treatment, high quality healthcare and innovative technologies in continuous evolution – are the ingredients for Rizzoli’s success in Italy and worldwide. With reference to its specializations, the following shall be mentioned: treatment of degenerative pathologies of the hip, knee and ankle joints; spine pathologies; pathologies of the foot and upper limbs; sports related pathologies; tumours of the musculoskeletal system; paediatric orthopaedic pathologies; diagnosis and treatment of rare skeletal diseases. Rizzoli also houses the specialization school of Orthopedics and Traumatology and the specialization school of Physical Therapy and Rehabilitation of University of Bologna; indeed, there is a special cooperation agreement between Rizzoli Orthopedic Institute and the University. Furthermore, the Institute participates in the Emilia-Romagna Regional High Technology Network (Tecnopolo) with additional six research laboratories oriented toward translational research; their activities is characterized by strong relations with industrial partners of the area operating in the following fields: regenerative medicine, biomedicine, biomedical device, pharmaceutics, biomechanics and clinical IT. The Department of Medical Genetics and Rare Orthopaedic Diseases directed by Dr. Luca Sangiorgi, is accredited from the Emilia-Romagna region as centre of coordination for the Regional Hub and Spoke Network of Rare Skeletal Diseases. The Department is composed of a) the Molecular Laboratory that performs diagnosis and 123 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases research on RDs, b) the Medical Genetics Outpatient Clinic, welcoming patients with suspected familiar syndromes and offering counselling and c) the Biobank of Genetic Samples (BIOGEN) created in order to collect high quality biological materials of patients affected by skeletal dysplasias and other rare diseases. The samples collected, more than 6500 different biospecimens, cover many fields of genetic and genomic research applications; in fact, the biobank includes human blood, blood components and derivates, DNA, RNA, urine, serum, tissues. Most of the samples are collected for diagnostic purpose, but patients are asked to use the blood/buccal scraping for research scopes, after reading and signing informed consent agreement. Other samples are collected only for research finality, like tissues, urine and serum. The Department works also in concert with the Clinical Bioinformatics Lab - CLIBI - (always under the direction of Dr. Sangiorgi) and performs activities of research, development and consultancy in the field of Clinical Bioinformatics. Being part of the Regional Network of RareSkeletal Diseases, mentioned above, means that the Dept. and BIOGEN are in a net which involves 11 hospitals/institutions in Emilia- Romagna region. Furthermore, the Rizzoli Institute is the Coordinator of European Reference Network on BONe rare Diseases (ERN BOND) that involves 38 health care providers, from 10 EU countries. The main ambition of the ERN BOND is to implement measures that facilitate multidisciplinary, holistic, continuous, patient-centred and participative care provision to people living with rare bone diseases (RBD), supporting them in the full realisation of their fundamental human rights. In particular, BOND ERN aims to ensure that people living with a RBD are afforded the same standards of care and support as the ones available to other citizens with similar requirements. To meet this goal, BOND ERN gathers European professionals highly specialized in the field of RBD for both scientific research and multidisciplinary care to increase knowledge on RDs, to improve healthcare quality and patient safety, to increase access to ultra specialized medical expertise and accessible information beyond national borders, in accordance with Directive 2011/24/EU. Main tasks in the project per Pillar/WP: Comtribution to the following pillars Pillar 2: Development of ontologies to facilitate implementation of clinical trials and research activity. Pillar 3: Improvement of timely diagnosis and care. Pillar 4: Implementation of a help desk to support implementation of clinical trials. PILLAR 2. In WP10 we will participate in annual retreats and in definition of priorities for Virtual Pltaform and FAIRification. ERN BOND Research Working Group (WG2) is promoting good quality and safe care for those with rare bone diseases, and clinical research in this field. The WG is mapping the ongoing clinical and research activity, to understand where this research activity is complimentary and where there are areas of weakness, in order to facilitate the development of new research programs and collaboration between different partners. PILLAR 3. In WP 14 we will contribute to Task 14.2 Standards and quality of genetics/genomics data in laboratory and clinical research practice. ERN BOND Training and Education Working Group (WG8) is increasing awareness and knowledge about Rare Bone Diseases in order to prevent unacceptable diagnostic delays and their associated burden of potentially disabling complications, and allow timely use of the best available therapeutic options. PILLAR 4. In WP 20 we will contribute to Task 20.1 Task Force Group and lead the Task 20.3 Demonstration projects on existing statistical methodologies to improve RD clinical trials ERN BOND Clinical Trials Working Group (WG4) is engaging relevant ERN members and relevant professional groups (eg ESPE, ECTS, ICCBH) and regulators (EMA) in order to ensure patient benefit, inclusion and collaboration in clinical trials to liaise with patient groups to identify and prioritise the clinical trials needed in relation to unmet need, To developing a robust process for interaction with industry. Previous experience relevant to the Tasks: The scientific area of interest covers the diagnosis and the genetic and genomic research on hereditary skeletal diseases furthermore we collect also clinical and genetic data of our patients (disease registries), we integrate clinical data and molecular results in a genotype phenotype correlation. To date 4 disease registries are active at MGD (Osteogenesis Imperfecta, Multiple Exostoses, Ehlers-Danlos Syndrome & Ollier Maffucci). Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Facilities: Biobank of Genetic Samples (BIOGEN): The samples collected are more than 6500 different biospecimens, cover many fields of genetic and genomic research applications; in fact, the biobank includes human blood, blood components and derivates, DNA, RNA, urine, serum, tissues. Most of the samples are collected for diagnostic purpose, but patients are asked to use the blood/buccal scraping for research scopes, after 124 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases reading and signing informed consent agreement. Other samples are collected only for research finality, like tissues, urine and serum. Networks: EATRIS (European infrastructure for translational medicine), BBMRI-ERIC (Biobanking and BioMolecular Resources Research Infrastructure – ERIC), TNGB (Telethon Network of Genetic Biobank). Short Profile of key Staff Members who will be undertaking the work Phd. Luca Sangiorgi Head of the Department of Medical Genetics, Rizzoli Orthopaedic Institute, Bologna, (male) Italy and Head of the Clinical Bioinformatics Lab and Rare Disease. He is also the coordinator of the Rizzoli Rare Disease Centre and responsible of 4 National Registers of Rare Diseases (REM: Multiple Hereditary Exostoses, ROI: Osteogenesis Imperfecta and RED: Ehlers-Danlos Syndrome, ROM: Ollier-Maffucci diseases). He was nominated in December 2014 as Italian representatives to the expert group on the "Committee for Advanced Therapies" of EMA (European Medicines Agency) by the Italian Minister of Health. He is also a Member of the National Coordination Team for Clinical Genetics Department and manages the National and Regional Hub and Spoke Network on Skeletal Dysplasia. Luca Sangiorgi is a Member of HL7 interest group for bioinformatics. Contributor of more than 50 articles published in peer-reviewed journals such as American Journal of Human Genetics, Journal of Clinical Oncology, Human Mutation and International Journal of Cancer, he is an active Member of several international medical associations, serving on the Executive Committee of the CTOS as President. Since 2013 he has been appointed as Italian government representative for the Assembly of the Member States for BBMRI Italy in Europe and he is Member of the National Node Coordination Office and coordinator of the Rare Disease Interest Group. He is also Member of the BBMRI-ERIC Steering Committee and Vice Chair of the Financial Committee. Expert Reviewer for the European Union Commission for the Framework Projects 6 (FP6) and Framework Projects 7 (FP7) grants and Horizon 2020, he is the coordinator of a European Project within the ERA NET on Translational Cancer Research (TRANSCAN) on the Identification of molecular therapeutic targets and diagnostic/prognostic biomarkers for malignant transformation of osteochondromas. He has been an invited speaker in several national and international conferences and workshops. Dr. Sangiorgi research interests are on clinical and molecular genetics and correlation between genotype and phenotype in musculoskeletal genetic disorders and bone sarcomas. He is also interested in bioinformatics applications that correlate genomic alteration and occurrence of diseases. Phd. Marina Mordenti Senior Research Scientist at MGD & CLIBI Lab (IOR) and she is, at present, Registry (female) Manager of four disease registries of rare skeletal disorder (REM, ROI, RED and ROM) and curator of data management and protection of BIOGEN, the Biobank of Genetic Sample (at MGD, IOR). Her main domains of interest include the design of biomedical platforms for disease registries, for genotype-phenotype correlation, for sample management, imaging as well as software for quality and risk management procedures. She acquired good knowledge of international standards in the biomedical field and databases on-line related to the world of scientific research and a good command of quality control processes and risk management and good preparation on the protection of privacy and security. She has been involving in several European projects, such as ADOPT-BBMRI and CORBEL and she is author of peer-reviewed articles. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements - Bonafe L, Cormier-Daire V, Hall C, Lachman R, Mortier G, Mundlos S, Nishimura G, Sangiorgi L, Savarirayan R, Sillence D, Spranger J, Superti-Furga A, Warman M, Unger S Nosology and classification of genetic skeletal disorders: 2015 revision American Journal of Medical Genetics, Part A (167), 2869- 2892 (2015) 10.1002/ajmg.a.37365 - Baldo C, Casareto L, Renieri A, Merla G, Garavaglia B, Goldwurm S, Pegoraro E, Moggio M, Mora M, Politano L, Sangiorgi L, Mazzotti R, Viotti V, Meloni I, Pellico MT, Barzaghi C, Wang C, Monaco L, Filocamo M. The alliance between genetic biobanks and patient organisations: the experience of the telethon network of genetic biobanks. Orphanet J Rare Dis (11(1)), 142 (2016) - Mordenti M, Ferrari E, Pedrini E, Fabbri N, Campanacci L, Muselli M, Sangiorgi L. Validation of a new multiple osteochondromas classification through Switching Neural Networks Am J Med Genet A. (161A(3)), 556-60 (2013) 125 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases - Gentile FV, Zuntini M, Parra A, Battistelli L, Pandolfi M, Pals G, Sangiorgi L. Validation of a quantitative PCR-high-resolution melting protocol for simultaneous screening of COL1A1 and COL1A2 point mutations and large rearrangements: application for diagnosis of osteogenesis imperfecta. Hum Mutat. (33(12)), 1697-707 (2012) - D'Eufemia P, Palombaro M, Lodato V, Zambrano A, Celli M, Persiani P, De Bari MP, Sangiorgi L. Child abuse and osteogenesis imperfecta: how can they be still misdiagnosed? A case report. Clin Cases Miner Bone Metab. (9(3)), 195-7 (2012) List of relevant previous projects or activities, connected to the subject of this proposal : 1. “Ma.Tr.OC - Identification of molecular therapeutic targets and diagnostic/prognostic biormarkers for malignant transformation of osteochondromas” - ERA-Net Transcan-2 JCT 2012 – Italian Ministry of Health – Coordinator – 2014-2018 2. “ADOPT BBMRI-ERIC: implementAtion anD OPeration of the gateway for healTh into BBMRI-ERIC" - Grant agreement n. 676550 - Horizon 2020- European Commission - beneficiary, WP Leader – 2015-2018; 3. "CORBEL: Coordinated Research Infrastructures Building Enduring Life-science services”– Grant Agreement n.654248 – Horizon 2020 – European Commission - Linked third party – 2015-2019; 4. ERN BOND: European Reference Network on BONe rare Diseases – Framework Partnership Agreement n. 739539 - 3rd Health Programme – European Commission – Coordinator – 2017-2022; 5. “MCDS-Therapy - Repurposing of carbamazepine for treatment of skeletal dysplasia” - Grant Agreement n.754825 – Horizon 2020 – European Commission – beneficiary – 2018-2022. 62-AOUP Full legal name (Acronym) – Country Azienda Ospedaliero Universitaria Pisana (AOUP), Italy Principal investigator Prof. Marta Mosca Relevant Network ERN ReCONNET Description of the legal entity/department/laboratory/group: The Rheumatology Unit is part of the University Department of Clinical and Experimental Medicine of University of Pisa (Italy); patients care, clinical research and education are the three main objectives of the Unit. The Unit is the coordinating Clinical Centre of the ERN-RECONNET, the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases approved by the European Commission in 15th December 2016. The clinical activity of the Unit is focused on inflammatory rheumatic diseases and it is the Tuscany referral center for systemic autoimmune diseases including SLE, undifferentiated connective tissue disease, antiphospholipid syndrome, Systemic Vasculitides, Inflammatory myopathies and Systemic Sclerosis. The clinical activity of the Unit is structured in three levels of patient care: outpatients visits, day-hospital for daily drug infusions and inpatients ward. The outpatients clinic provides 16 daily visits for first rheumatologic assessment and disease-specific second-level clinics for SLE (Lupus clinic), Systemic sclerosis (Scleroderma clinic), Sjogren’s Syndrome (Sjogren Clinic), rheumatoid arthritis, Inflammatory myopathies, systemic vasculitis and fibromyalgia. All these dedicated clinics share common characteristics including the multidisciplinary approach to the patients as several health professionals other than rheumatologists are involved in the clinics: nurses, physical therapists, obstetrics and gynaecologists, nephrologists, ophthalmologists, psychiatrist, cardiologists and orthopaedics. Moreover, all these clinics are characterized by a strong effort toward quality of care and a patient-centered approach. Overall, 400 SLE, 350 UCTD, 350 SSc, 600 SS, 200 SAPL, 2000 RA, 250 vasculitis and 650 fibromyalgia patients are regularly followed at the dedicated clinics of the Rheumatology Unit. The research activity of the Unit is focused on epidemiological studies and prognostic factors of systemic autoimmune diseases; quality of care, imaging studies, outcomes measures are other topics of the research activity of the Rheumatology Unit. The research activity is documented in more than 500 published scientific articles over 40 years of activity, several participations to national and international congresses and a worldwide esteem of the research activity. The Rheumatology Unit takes part and leads of several collaborative research studies with Italian and European centers. The educational mission of the Rheumatology Unit is achieved by several initiatives addresses to medical students, internal and external rheumatologists in training, rheumatologists, nurses, general practitioners. Among these initiatives, a particular mention goes to the bi-annual EULAR scientifically endorsed course on SLE successfully arrived at its VIII edition and entirely organized by Prof. Marta Mosca and her staff. The Course is aimed at 70 young rheumatologists (aged less than 40 years of age) coming from all over the world; the course is aimed at providing a comprehensive and intensive training on various aspects of systemic lupus erythematosus (SLE). Main tasks in the project per Pillar/WP: 126 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Pillar 2: In WP10, we will contribute in 5x pan-RD-community, 3-day strategy meetings (annual retreat)(task 10.1.1), and in carrying out survey and structured interview approaches on technical and scientific matters, to monitor progress and inform strategic decisions - incl. Definition of indicators (task 10.2.2) Pillar 3: In WP17, we will contribute in the assessment of the needs and development of training activities for ERNs as members of Group 2 Neoplasm and Malformation”. Previous experience relevant to the Tasks: Recently Prof. Marta Mosca has coordinated the development of “EULAR Recommendations for monitoring SLE patients in clinical practice and observational studies”, of quality measures in SLE and of a core set of measures to be used in clinical practice to standardize patients care. In addition, she is part of the Steering Committee for the development of the "Treat to Target Recommendations in SLE" and for the definition of Remission in SLE. She is also participating to a SLICC/ACR project aiming at defining flares in SLE. She is coordinating and has coordinated entire projects and/or Research Units on SLE and other Musculoskeletal Disorders at a national and international level. Since 2011, she is part of the medical panel of the European Lupus Patients Association LUPUS EUROPE. Since 2013, she is member of the Ethical Committee of the district area of Western Tuscany (including the Pisa University Hospital and other 15 hospitals). Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : The Rheumatology Unit (the day hospital section) includes 12 seats and 2 beds for daily intravenous drug-infusion; two rheumatologists and three nurses are assigned to this section of the Unit. The inpatients ward consists of 18 beds addressed to severely ill patients with rheumatology conditions; two experienced rheumatologists and four rheumatologists in training are assigned to the inpatients care with two daily nurses and a team of 12 shift worker nurses. Short Profile of key Staff Members who will be undertaking the work Pr. Marta Mosca Associate Professor of Rheumatology at the Department of Clinical and Experimental (female) Medicine of the University of Pisa, Italy and chief of the Rheumatology Unit of the Azienda Ospedaliero Universitaria Pisana. She graduated from the Medical School of the University of Pisa in 1992 and in the same year she has started her fellowship in Rheumatology. In 1999 she has obtained a PhD in Immunology of Organ Transplantation. Her research interests are represented by connective tissue diseases, with special interest in systemic lupus erythematosus (SLE) and undifferentiated connective tissue diseases (UCTD), with particular interest to clinimetrics. She is the Network Coordinator of ERN-RECONNET, the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases approved by the European Commission in 15th December 2016. Her clinical activity includes the follow up of patients with connective tissue diseases followed at the Rheumatology Unit, where she runs the Lupus Clinic and the Pregnancy Clinic.Prof. Marta Mosca has co-authored 176 papers published in peer reviewed journals (at March 16th, 2018), with an H index of 40 (SCOPUS, March 16th, 2018), and 6684 citations. Dr. Rosaria Talarico Rosaria Talarico, MD, PhD. Rheumatologist at the Rheumatology Unit of AOUP (Since (female) March 2017). Employed under independent contract in the INFORMaR project, University of Pisa, Italy. (from October 2013 to March2017) and from September 2011 to September 2013 she was employed under independent contract in the Rheumatology Division, University of Pisa, Italy, within the Rare Diseases Regional Project. Member of the Coordinating Centre for Rare Diseases at the “Azienda Ospedaliera Universitaria Pisana (AOUP)”, University of Pisa, Italy, as epidemiological expert. Experience in research. 2007-2009: Participation as Fellow for the research of the literature for the EULAR project “Development of recommendations for monitoring systemic lupus erythematosus (SLE) patients in clinical practice and in observational studies”. 2012: Participation as Fellow for the research of the literature for the project “Systematic review of 2008-2012 literature and update of recommendations for the use of methotrexate in rheumatic diseases, with a focus on rheumatoid arthritis”; 2012-ongoing: Participation as Methodological coordinator for the research of the literature for the FIRMA project “Development of recommendations for the clinical application of autoantibodies determination in systemic autoimmune diseases”. Rosaria Talarico has co-authored 150 papers published in peer reviewed journals (at March 127 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 21th, 2018), with an H index of 18 (SCOPUS, March 21th, 2018), and 943 citations. Dr. Chiara Baldini MD, PhD. Associated Professor in Rheumatology (MED/16), Rheumatology Unit, (female) University of Pisa, Italy. Her clinical research activity and interests are in the field of clinical Research on connective tissue diseases and vasculitis. Lab Research identification and validation of novel non-invasive diagnostic, prognostic and therapeutic proteomic biomarkers for primary Sjogren’s syndrome and other systemic autoimmune disorders which might eventually improve the diagnostic processes and the assessment of patients affected by systemic autoimmune disorders. Principal investigator and co-investigator in several phase III and IV clinical trials carried out in systemic autoimmune disorders; has co- authored 150 papers published in peer reviewed journals (at March 21th, 2018), with an H index of 26 (SCOPUS, March 21th, 2018), and 1541 citations. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Tani C, Vagelli R, Stagnaro C, Carli L, Mosca M. Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort. Lupus Sci Med. 2018 Feb 27;5(1):e000234. 2. van Vollenhoven R, Voskuyl A, Bertsias G, Aranow C, Aringer M, Arnaud L, Askanase A, Balážová P, Bonfa E, Bootsma H, Boumpas D, Bruce I, Cervera R, Clarke A, Coney C, Costedoat-Chalumeau N, Czirják L, Derksen R, Doria A, Dörner T, Fischer-Betz R, Fritsch-Stork R, Gordon C, Graninger W, Györi N, Houssiau F, Isenberg D, Jacobsen S, Jayne D, Kuhn A, Le Guern V, Lerstrøm K, Levy R, Machado-Ribeiro F, Mariette X, Missaykeh J, Morand E, Mosca M, Inanc M, Navarra S, Neumann I, Olesinska M, Petri M, Rahman A, Rekvig OP, Rovensky J, Shoenfeld Y, Smolen J, Tincani A, Urowitz M, van Leeuw B, Vasconcelos C, Voss A, Werth VP, Zakharova H, Zoma A, Schneider M, Ward M. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017 Mar;76(3):554- 561. 3. Barsotti S, Zampa V, Talarico R, Minichilli F, Ortori S, Iacopetti V, D'ascanio A, Tavoni AG, Bombardieri S, Mosca M, Neri R. Thigh magnetic resonance imaging for the evaluation of disease activity in patients with idiopathic inflammatory myopathies followed in a single center. Muscle Nerve. 2016 Oct;54(4):666-72. 4. Luciano N, Baldini C, Tarantini G, Ferro F, Sernissi F, Varanini V, Donati V, Martini D, Mosca M, Caramella D, Bombardieri S. Ultrasonography of major salivary glands: a highly specific tool for distinguishing primary Sjögren's syndrome from undifferentiated connective tissue diseases. Rheumatology (Oxford). 2015 Dec;54(12):2198-204. 5. Ruffatti A, Salvan E, Del Ross T, Gerosa M, Andreoli L, Maina A, Alijotas-Reig J, De Carolis S, Mekinian A, Bertero MT, Canti V, Brucato A, Bremme K, Ramoni V, Mosca M, Di Poi E, Caramaschi P, Galeazzi M, Tincani A, Trespidi L. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb Haemost. 2014 Oct;112(4):727-35. doi: 10.1160/TH14-03-0191. Epub 2014 Jul 10. List of relevant previous projects or activities, connected to the subject of this proposal : ERN RECONNET; Funder: European Commission (CHAFEA); 2017-2021; PI-Network Coordinator. 63-AOUS Full legal name (Acronym) – Country Azienda Ospedaliera Universitaria Senene (AOUS), Siena, Italy Principal investigator Alessandra Renieri Relevant Network ITHACA Description of the legal entity/department/laboratory/group: The mission of AOUS is to provide clinical care, training and research. AOUS delivers inpatients and outpatient specialist services, emergency and urgency services and pursues the development of high medical specialization. The Hospital operates within the Regional Health Service that guarantees to all users treatment and rehabilitation in accordance with the principles of equality, fairness and compassionate care, free of charge or with a contribution according to the National Health Service regulations. The main objective of AOUS is to achieve a high level of response to the health demand, meant as recovery and preservation of physical, mental and social health. Medical Genetics Unit provides genetic counselling, genetic tests, information and support to people who have, or may be at risk for, genetic disorders and, in particular, for pediatric and adult patients with intellectual disability and their families. During a consultation, a medical geneticist meets with an individual or family to discuss genetic risks or to diagnose, confirm, or rule out a genetic condition and to evaluate the possibility to perform a prenatal 128 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases diagnosis. The AOUS offers molecular tests for a large number of genetic conditions characterized by intellectual disability: Rett, Coffin Siris, Nicolaides Baraitser, Cohen, Angelman, Prader Willi, and Lesch Nyhan Syndromes and others. Furthermore, it provides array-CGH analysis for Rare Chromosomal Disorders. All patients with other rare intellectual disability syndromes and rare undiagnosed malformation syndromes hospitalized are evaluated by several healthcare professionals, namely Geneticists, Child Neuropsychiatrists, Neuroradiologists, Neurophysiopatologist, Cardiologists, Odontologists, Gastroenterologists, Physical Therapists and Pediatricians in order to obtain a complete examination, to ameliorate health conditions and to obtain a defined diagnosis. Weekly multidisciplinary discussions regarding specific cases are in place. The majority of these diseases do not have a specific cure. However, providing specific diagnosis may help in patient daily care and rehabilitation therapy including physiotherapy and speech therapy. Whenever the syndrome includes epileptic involvement, treatment with specific antiepileptic drugs (even multidrug teraphy) in both pediatric and adult patients is administered. The clinical service is complemented by a wide range of research activities, which include genetic and experimental research in a dedicated laboratory as well as the coordination of national and international clinical research consortia. Medical Genetics Unit is certified through a National Assessment Program concerning specifically the ISO 9001:2008 certification released by ACCREDIA. Site visits are annually planned. It certifies that the Management System of the Unit has been audited and found to be in accordance with the requirements of the management system standard. Supplies services are Clinical Genetics, Genetics Biobank, Scientific research in Medical Genetics and Laboratory of Medical Genetics including Molecular Genetics, Cytogenetics, Forensic Genetics and Preimplantation Genetic Diagnosis. Furthermore, every year the Italian Society of Human Genetics (SIGU) certifies that the above organisation has been audited and found to be in accordance with SIGU. Main tasks in the project per Pillar/WP: Pillar 2: In WP11, we will contribute to facilitate data generated from RD research to be deposited in existing repositories by improving their capacity, interoperability, privacy protection and security compliance through the development of a specific informatic tool, named “IVANA/FastPG”. The searching algorithm, based on a machine-learning approach, will combine data from several sources (i.e. bibliometric databases, and specialized biological databanks) using data-mining techniques. Pillar 3: In WP16, we will contribute in Online Academic education course. A streamlined education programme could be made available to all stakeholders via an established e-learning service provider. The e-learning modules will be created or adapted with the help of interested universities. Since Education is also part of the future activities to be developed by the European Rare Disease Networks (ERNs), the EJP on RD will provide support, complimentary access to the e-learning platform, and visibility to the research training activities and educational material developed by the ERNs. The EJP will also develop its own educational material which should be complementary to the ERN resources rather than overlapping. Specifically, we will contribute to assess the needs, target audience, main topics of the academic education course (task 3.1 - VUH SK). This task will be performed through a thorough benchmark of existing RD academic courses at EU level and through survey and audits of potential target audiences and experts involved in those courses (not restricted to students) and the main topics to address, the most relevant lecturers. The e-learning programme will be based on already existing initiatives such as the French inter- university diploma. The contribution will be also related to task 3.2 (CHU DIJON) in developing the online course. E-learning approaches could combine different components: e-learning content, e-tutoring, collaborative learning, virtual classroom. Activities can be synchronous or asynchronous. One key component to be addressed in this task will be the status of this academic course (free-access or based on tuition fees from each partnered organisation; European Credit Transfer System eligibility (ECTS); the most relevant length of the course; etc.). The identification of an established e-learning service platform will be also performed (on going discussions with FutureLearn). The platform will develop and implement the e-learning scholar content received from lecturers. Pillar 4: In WP20, we intend to contribute to Task 20.2 Support in design and planning of RD clinical studies . We will also contribute to Task 20.4 Projects on innovative methodologies to improve RD clinical trials in limited populations Previous experience relevant to the Tasks: Universities of beneficiary and LTP have developed specific academic courses for RD. There is a great need to share this knowledge and make it available to the broader public including students, medical doctors, healthcare providers or patients at the European level. The beneficiary directs the Genetic Biobank of Siena (GBS, http://www.biobank.unisi.it), one of the few in Italy certified SIGU-CERT and ISO9001, and funded by Telethon since 2002. GBS is the Italian Partner of BBMRI 129 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases (Biobanking and Biomolecular Resources Research Infrastructure), member of EuroBioBank and RD-Connect. Since 2009, she coordinates the international Rett database network (http://www.rettdatabasenetwork.org). The Medical Genetics of AOUS also coordinates the Italian Registry of Alport disease, an Italian network for Alport disease. The beneficiary is leading for ERN ITHACA the Registry Work Package. The beneficiary already experienced preclinical trials on gene therapy within four different genetic diseases. Thus, we can contribute to develop a system devoted to assess if a disease can be treated more or less effectively with gene therapy. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Beneficiary and LTP are equipped with the all major equipment relevant to the proposed work. Short Profile of key Staff Members who will be undertaking the work Pr.Francesca Mari Prof. Mari F. is currently Associate Professor of Medical Genetics at University of Siena (female) and Medical Geneticist of AOUS. She contributed to the development of the genetic counselling activity in the Medical Genetics Unit in Siena performing and supervising thousands of genetic counselling clinics. Her main research interests are focused on understanding the genetic bases of rare disorders mainly Intellectual disability, including Rett syndrome, Alport syndrome, and rare cancers. Dr.Simone Furini Dr. Furini S. is currently a Researcher / Assistant Professor at the Department of Medical (male) Biotechnologies of the University of Siena. His main area of expertise is Systems Biology, with a particular interest on how deterministic and stochastic models can be used to predict the outcome of gene networks. Dr.Elisa Frullanti Dr. Frullanti E. is currently a Researcher / Assistant Professor of Medical Genetics at (female) University of Siena. Her main research interests were aimed to dissect the molecular and genetic bases of lung cancer in never smoker young patients as well as genetic bases of rare disorders following an innovative “omics” approach that will integrate genomic (Whole- Exome/Genome Sequencing) and transcriptomic (RNA sequencing) data. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Ivanovski I, Djuric O, Caraffi SG, Santodirocco D, Pollazzon M, Rosato S, Cordelli DM, Abdalla E, Accorsi P, Adam MP, Ajmone PF, Badura-Stronka M, Baldo C, Baldi M, Bayat A, Bigoni S, Bonvicini F, Breckpot J, Callewaert B, Cocchi G, Cuturilo G, De Brasi D, Devriendt K, Dinulos MB, Hjortshøj TD, Epifanio R, Faravelli F, Fiumara A, Formisano D, Giordano L, Grasso M, Grønborg S, Iodice A, Iughetti L, Kuburovic V, Kutkowska- Kazmierczak A, Lacombe D, Lo Rizzo C, Luchetti A, Malbora B, Mammi I, Mari F, Montorsi G, Moutton S, Møller RS, Muschke P, Nielsen JEK, Obersztyn E, Pantaleoni C, Pellicciari A, Pisanti MA, Prpic I, Poch-Olive ML, Raviglione F, Renieri A, Ricci E, Rivieri F, Santen GW, Savasta S, Scarano G, Schanze I, Selicorni A, Silengo M, Smigiel R, Spaccini L, Sorge G, Szczaluba K, Tarani L, Tone LG, Toutain A, Trimouille A, Valera ET, Vergano SS, Zanotta N, Zenker M, Conidi A, Zollino M, Rauch A, Zweier C, Garavelli L. Phenotype and genotype of 87 patients with Mowat-Wilson syndrome and recommendations for care. Genet Med. 2018 Jan 4. doi: 10.1038/gim.2017.221. 2. Mari F, Marozza A, Mencarelli MA, Lo Rizzo C, Fallerini C, Dosa L, Di Marco C, Carignani G, Baldassarri M, Cianci P, Vivarelli R, Vascotto M, Grosso S, Rubegni P, Caffarelli C, Pretegiani E, Fimiani M, Garavelli L, Cristofoli F, Vermeesch JR, Nuti R, Dotti MT, Balestri P, Hayek J, Selicorni A, Renieri A. Coffin-Siris and Nicolaides-Baraitser syndromes are a common well recognizable cause of intellectual disability. Brain Dev. 2014 Sep 20. pii: S0387-7604(14)00212-5. 3. Grillo E, Villard L, Clarke A, Ben Zeev B, Pineda M, Bahi-Buisson N, Hryniewiecka-Jaworska A, Bienvenu T, Armstrong J, Martinez AR, Mari F, Veneselli E, Russo S, Vignoli A, Pini G, Djuric M, Bisgaard AM, Mejaški Bošnjak V, PolgárN, Cogliati F, Ravn K, Pintaudi M, Melegh B, Craiu D, Djukic A, Renieri A. Rett networked database: an integrated clinical and genetic network of Rett syndromedatabases. Hum Mutat. 2012 Jul;33(7):1031- 6. 4. Ariani F, Hayek G, Rondinella D, Artuso R, Mencarelli MA, Spanhol-Rosseto A, Pollazzon M, Buoni S, Spiga O, Ricciardi S, Meloni I, Longo I, Mari F, Broccoli V, Zappella M, Renieri A. FOXG1 is responsible for the congenital variant of Rett syndrome. Am J Hum Genet. 2008 Jul;83(1):89-93. 5. Renieri A, Mari F, Mencarelli MA, Scala E, Ariani F, Longo I, Meloni I, Cevenini G, Pini G, Hayek G, Zappella M. Diagnostic criteria for the Zappella variant of Rett syndrome (the preserved speech variant). Brain Dev. 2009 Mar;31(3):208-16. List of relevant previous projects or activities, connected to the subject of this proposal  “FoxG1 gene therapy using CRISPR/Cas9 technology and AAV9 iPSCs-derived neurons”; Blackswan 130 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Foundation; 2017-2018 - PI: Renieri A. Building on the possibility of obtained and characterized iPSCs from skin biopsy of Rett patients, we propose a combination of CRiSPR/Cas9 technology with AAV9 system to delete the FOXG1 mutated gene and replace it with the “healthy”/wild type gene in FOXG1 mutated iPSCs. We plan to apply this strategy on an ex-vivo model, to prove efficacy and safety of the method.  “Development of an innovative strategy of personalized medicine for the diagnosis and therapy of kidney diseases in children”; Tuscany Region; 2016-2018 - PI: Renieri A. We propose an innovative diagnostic strategy, potentially extending to all pediatric nephropathies, for the diagnosis and therapy of kidney diseases in children.  “Telethon Network of Genetic Biobanks”; Telethon; 2013-2017 – Unit PI: Renieri A. The goal is to realize the first national, standardized biospecimen/genetic data Resource, creating a nationally coordinated network of pathological biospecimens and related data collection as well as normal controls, and developing a centralized bioinformatics system of rare diseases for improving links between the existing Telethon biobanks as well as for facilitating Network presentation world−wide and external access to the collections. 64-LUMC Full legal name (Acronym) – Country Academisch Ziekenhuis Leiden, also acting under the name Leiden University Medical Centre (LUMC), The Netherlands, (Team A): Human Genetics department / Biosemantics group Principal investigator Dr. Marco Roos, team A Relevant Network Description of the legal entity/department/laboratory/group: The LUMC is a university medical centre for research, education and patient care with a high-quality profile and a strong scientific orientation and ranks as the 6th best medical research institute in Europe (Shanghai 2015/2014). It has a unique research practice, ranging from pure fundamental medical research to applied clinical research. This enables LUMC to offer patient care and education that is in line with the latest international insights and standards – and helps it to improve medicine and healthcare both internally and externally. The LUMC participates in the League of European Research Universities (LERU), a strong international network of 21 renowned research universities based in 10 European countries (www.leru.org). LUMC’s well-structured and productive research and training environment annually produces ~115 PhD theses and ~1750 scientific publications. Each year, LUMC welcomes many visiting scientists and foreign MSc/PhD students, who will also be enrolled in the LUMC Graduate School (now > 900 PhD-students). Currently, LUMC is active in 54 granted Horizon2020 projects (17 as coordinator). Thus, LUMC has ample experience with the legal and financial implementation of these projects. Website: https://www.lumc.nl/research/. The department of Human Genetics (team A) is a broadly oriented research department with focus on the (epi)genomic contribution to inherited and acquired diseases. HG has research focus on genome technology, functional genomics, novel diagnostics, model systems and bioinformatics of human diseases. The department provided leadership for the human genome project, BBMRI, and Orphanet-NL (professor emeritus dr. GJB van Ommen, Dr. Petra van Overveld) to which it contributed information for the Netherlands. The BioSemantics group (PIs Dr. M. Roos, Prof. Dr. B. Mons) focuses on the development and application of the FAIR data principles for translational research, particularly in the domain of rare diseases, and the automated discovery of new biological knowledge from FAIR data. Main tasks in the project per Pillar/WP: Team A Pillar 0: In WP1, we will contribute to data management planning of the EJP RD (task 1.4) as per our responsibility as co- lead of WP12 in Pillar 2. For WP3, we will contribute to the communication between WP10 Task 1.5 (sustainability and scaling up of the VP) and WP3. Pillar 2 In WP10, we will contribute to: - Coordination of Pillar 2 Work Packages and aligning to RD community needs (task 10.1) - Convening yearly retreats leading to Pillar 2 annual strategic plans (task 10.2) - Coordination of technical GDPR implementation (task 10.3) - Quality oversight (task 10.4) 131 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases - Developing sustainable models (task 10.5) In WP11, we will contribute to the following tasks: - Metadata and ontological model definition for cataloguing resources for RD research (task 11.1) - FAIR-compliant platform for discovery of RD resources (task 11.2) - Provision of analysis and data sharing capabilities to the RD community through online resources (task 11.4) In WP12, we will contribute to: - Comparing and aligning core interoperability standards with respect to WP12 [in conjunction with other standards bodies, & spanning RD patient data, biobanks, registries] (task 12.1) - Multi-site teams for software and tool development with respect to WP3 (task 12.2) - leading practical FAIRification support (task 12.3) LUMC, team A, co-leads WP3. In WP13 we will contribute to: - Filling a number of pre-identified gaps to allow integrative systems biology approaches for rare diseases (task 13.1) - Organising proof of principle studies (task 13.2) Pillar 3 In WP14, we will contribute to training on rare disease registries and FAIRification of data at the source (task 14.5) In WP15, we will contribute to the ExPRESS Expert Patients and Researchers EURORDIS Summer School (task 2.1) Previous experience relevant to the Tasks: LUMC team A will contribute significantly to the implementation and exploitation of FAIR data principles as core elements of the Virtual Platform for the RD community via protocols, tools, training, and practical FAIRification support. LUMC team A is one of the founders of the FAIR data principles and has extensive experience with developing and applying technologies related to FAIR. It organised the meeting where the principles were first conceived (Lorentz workshop, Leiden, 2014). It has a track record in activating communities towards better data and knowledge management (PMID:18507872; PMID:21445068). It previously developed the nanopublication model as a means to share research findings in a machine-readable format (PMID:26464783; nanopub.org), and contributed to the development of the research object model to improve reproducibility of analysis (PMID: 25276335; researchobject.org). In recent years LUMC team A software engineers formed the core of the DTL-P led FAIR engineering team that developed FAIRification protocols and a suite of FAIR data tools to create, publish, index and annotate FAIR data sources (https://github.com/DTL-FAIRData). LUMC team A was one of the initiators of OpenPHACTS, an IMI project that served as a milestone project on enabling queries over distributed linkable data. Over the past 2 years, the Biosemantics group has (co)organized 10+ Bring Your Own Data workshops: a combination of hackathon and training event to introduce techniques for making data linkable and FAIR at the source. BYODs and hackathons in the rare disease domain, co-organised between DTL-P, ISS and LUMC, have contributed significantly to the FAIR guiding principles (PMID:26978244). LUMC team A successfully submitted the application for these guidelines as an IRDiRC recognized resource with several RD community representatives also involved with this EJP proposal. Together with UMCG, LUMC team A is leading the so-called ‘Rare Disease Data Linkage Plan’ that provides a starting point for WP3 in Pillar 2, and some tasks in WP2 and WP4. The plan helps stakeholders make a rare disease registry or biobank FAIR ‘at the source’ by temporarily providing FAIR data stewardship expertise to a group that manages RD data and would like to make those more FAIR. The plan has been supported by RD-Connect, ELIXIR, ELIXIR-EXCELERATE, BBMRI-NL, and stakeholders (currently it is running pilots with VASCERN, BOND-ERN, and DMD resources). LUMC team A has a leading role in European-wide efforts to harmonize data and establish FAIR-compliant infrastructure, particularly for rare diseases. PI Mons was co-lead of the interoperability platform in ELIXIR, was chair of the high-level expert group for developing the European Open Science Cloud, and is leading the organisation that supports starting Global Open FAIR implementation networks. PI Roos is co-leading the Rare Disease Work package within ELIXIR-EXCELERATE. Together with leaders from the RD-Connect community, such as V. Bros-Facer from EURORDIS, A. Rath from Orphanet, Y. Rubinstein from NIH, PI Roos initiated the creation of a rare disease GO FAIR implementation network to foster FAIR in the rare disease community. In addition, LUMC team A has extensive experience in extracting and structuring knowledge from literature, and developed algorithms that use structured knowledge for the purpose of finding novel genotype - phenotype relationships, drug targets and drug repurposing, and multi-omics analysis, for rare and genetic diseases (PMID:26919047, PMID:27524956, PMID:23356878, PMID:29441734, PMID:27476530). Finally, LUMC team A is also responsible for the Leiden Open Variation Database software (IRDiRC recognized resources) and Mutalyzer. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : 132 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases  Resource of gene-disease associations predicted from the literature: https://datadryad.org//resource/doi:10.5061/dryad.gn219  FAIR service suite: https://github.com/DTL-FAIRData  Leiden Open Variation Database: http://www.lovd.nl/  Mutalyzer sequence variant nomenclature checker: https://mutalyzer.nl/, https://github.com/mutalyzer/mutalyzer Short Profile of key Staff Members who will be undertaking the work Dr. Marc Roos Dr. Marco Roos is group leader of the Biosemantics group of Prof. dr. Barend Mons. His (male) background is in molecular biological research and computer science. He has expertise in enhancing biomedical research by interdisciplinary collaboration and methods emerging from computer science (e-Science), particularly Semantic Web, ontologies, and computational workflows. He is currently interested in FAIR data stewardship and FAIR data analytics to enhance translational research in the domain of rare diseases. He co-leads the rare disease use case in ELIXIR-EXCELERATE, and (together with UMCG) he co- leads the rare disease data linkage plan to make rare disease registries and biobanks interoperable, and he chairs the Rare Disease Linked Data and Ontology task force that originated from RD-Connect. He has initiated a Rare Disease GO FAIR implementation network towards the implementation of FAIR principles in the rare disease community Dr.Kristina Hettne Kristina is a senior research scientist in the Biosemantics group at the Human Genetics (female) department of LUMC. She obtained her PhD in bioinformatics of toxicogenomics from the University of Maastricht in 2012. She has developed resources and methods for in-silico knowledge discovery in the biomedical domain and integrated prior knowledge from literature with statistical pathway analysis methods to analyze and integrate -omics data. She has contributed to setting standards for providing resources and methods to the research community in a Findable, Accessible, Interoperable and Re-useable (FAIR) way through the development and application of Research Objects (standard format for describing an in- silico experiment), Nanopublications (standard format for stating an assertion), and scientific research pipelines (workflows), within the EU FP7 project Workflow forever. Since 2017, she leads the working group on integrating transcriptomics data with proteomics and metabolomics data in the RD-Connect project. Dr.Mark Thompson Mark Thompson is a senior research scientist in the Biosemantics group at the Human (male) Genetics department of LUMC. He obtained a PhD in Computer Science from the University of Amsterdam in 2012. He has expertise in hardware and software architecture (co-)design, data management, data modeling, FAIR data infrastructure and computational aspects of knowledge discovery. He serves as a Linked Data expert and trainer at Bring Your Own Data (BYOD) events and FAIR Data hackathons. Currently he is developing a FAIR data stewardship program for the LUMC. He leads local and international pilots towards the adoption of FAIR principles in a translational research environment. MSc.Annika Annika Jacobsen studied systems biology engineering at the Technical University of Jacobsen Denmark. She did her PhD research computational modeling of biological networks at the (female) Vrije Universiteit Amsterdam in an interdisciplinary setting (planned graduation in 2018). Apart from technical skills, she has developed her organisational and communicative skills as active member of the Dutch and international ISCB student council. She is currently the FAIR data steward for the Rare Disease Data Linkage plan, where she has the central role in the FAIRification process between registry managers and FAIR data software engineers and ontology experts. MSc.Rajaram Rajaram Kaliyaperumal studied biomedical engineering in India and Linköping University Kaliyaperumal in Sweden. Over the last four years he has worked as scientific software engineer at the (male) LUMC as part of the FAIR software engineering team, contributing to prototyping and stabilizing FAIR software services, and recently also as software project lead. Prof.Barend Mons Barend Mons is Professor in Biosemantics at the Human Genetics department of Leiden (male) University Medical Center, and leads the international GO FAIR office in the Netherlands. He is a molecular biologist by training (PhD Leiden University 1986) and spent over 15 years in malaria research. After that he gained experience in computer-assisted knowledge discovery. Barend has worked as head-of-node of ELIXIR-NL, Integrator Life Sciences at the Netherlands eScience Center, board member of the Leiden Centre of Data Science, and director of DTL Projects. In 2014, Barend initiated the FAIR data initiative and in 2015, 133 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Barend Mons was appointed Chair of the European Commission's High Level Expert Group for the “European Open Science Cloud”, DG Research and Innovation. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Wilkinson MD., Dumontier M., Aalbersberg IjJ., Appleton G., Axton M., Baak A., Blomberg N., Boiten J- W., Da Silva Santos LB., Bourne PE., Bouwman J., Brookes AJ., Clark T., Crosas M., Dillo I., Dumon O., Edmunds S.,Evelo CT., Finkers R., Gonzalez-Beltran A., Gray AJG., Groth P., Goble C., Grethe JS., Heringa J., ’t Hoen PA.,Hooft R., Kuhn T., Kok R., Kok J., Lusher SJ., Martone ME., Mons A., Packer AL., Persson B., Rocca-Serra P.,Roos M., van Schaik R., Sansone S-A., Schultes E., Sengstag T., Slater T., Strawn G., Swertz MA., Thompson M.,Van der Lei J., van Mulligen E., Velterop J., Waagmeester A., Wittenburg P., Wolstencroft K., Zhao J., Mons B. 2016. The FAIR Guiding Principles for scientific data management and stewardship. Scientific Data 3:160018. DOI: 10.1038/sdata.2016.18. (IRDiRC recognized resource) 2. Mark Thompson, Luiz Bonino, Mark D Wilkinson, Rajaram Kaliyaperumal, Kees Burger, Shamanou van Leeuwen, Annika Jacobsen, Claudio Carta, Erik Schultes, David van Enckevort, Richard Finkers, Mascha Jansen, Barend Mons, and Marco Roos Overview of a suite of middle-ware services for implementing FAIR data principles, Proceedings of the 2017 edition of SWAT4HCLS, Rome, December 4-7, 2017 (http://CEUR-WS.org/Vol-2042) http://www.swat4ls.org/wp-content/uploads/2017/12/paper_23.pdf 3. B. Mons, H. Van Haagen, C. Chichester, P.-B. ’t Hoen, J. T. Den Dunnen, G. Van Ommen, E. M. Van Mulligen, B. Singh, R. Hooft, M. Roos, J. Hammond, B. Kiesel, B. Giardine, J. Velterop, P. Groth, E. Schultes, and J. T. Den Dunnen, The value of data., Nat. Genet., vol. 43, no. 4, pp. 281–283, 2011. 4. Hettne KM, Thompson M, van Haagen HH, van der Horst E, Kaliyaperumal R, Mina E, Tatum Z, Laros JF, van Mulligen EM, Schuemie M, Aten E, Li TS, Bruskiewich R, Good BM, Su AI, Kors JA, den Dunnen J, van Ommen GJ, Roos M, 't Hoen PA, Mons B, Schultes EA. The Implicitome: A Resource for Rationalizing Gene-Disease Associations. PLoS One. 2016 Feb 26;11(2):e0149621. PMID: 26919047 5. Mastrokolias A, Pool R, Mina E, Hettne KM, van Duijn E, van der Mast RC, van Ommen G, 't Hoen PA, Prehn C, Adamski J, van Roon-Mom W. Integration of targeted metabolomics and transcriptomics identifies deregulation of phosphatidylcholinemetabolism in Huntington's disease peripheral blood samples. Metabolomics.2016;12:137. PMID: 27524956 List of relevant previous projects or activities, connected to the subject of this proposal ELIXIR-EXCELERATE, H2020-INFRADEV-1-2015-12, 2015-2019, co-lead work package rare disease use case, contributor to work package interoperability, contributor to ELIXIR Bring Your Own Data workshops, EXCELERATE helps ELIXIR coordinate and extend national and international data resources to ensure the delivery of world-leading life-science data services. It supports a pan-European training programme, anchored in national infrastructures, to increase bioinformatics capacity and competency. It provides efficiencies in management and operation throughout the infrastructure, which is distributed amongst 17 countries. Open Data Exchange for all, Data Science program NWO/e-Science Center. Project coordinator and contributor to core FAIR service software development. The ODEX4all project focuses on the challenges associated with the ever-growing amount of research data in the life sciences. In Next Generation Sequencing alone the data doubles every 6-8 months and high-throughput datasets contain up to millions of new associations. Traditional ways of publishing, retrieving and using these massive data sources are inadequate to provide researchers and computers access to information in a manner needed for the scientific reasoning process. ODEX4all sets out to generate the infrastructure for the comprehensive exploitation of available data sets in a continuous machine-mind interaction. RD-Connect, FP7-HEALTH-2012-INNOVATION-1: contributor to bioinformatics services, registry interoperability, and rare disease data linkage plan. RD-Connect develops an integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research. The Open Pharmacological Concepts Triple Store, Open PHACTS, grant agreement n° 115191, FP7/2007-2013 and EFPIA, contributor to nanopublication model and interoperability services. The Open PHACTS Discovery Platform has been developed to reduce barriers to drug discovery in industry, academia and for small businesses. The integrated pharmacological data can be accessed via the Open PHACTS API, the Open PHACTS Explorer and explorer apps. BBMRI-NL2.0, Netherlands Organisation for Scientific Research (NWO) National Roadmap Large Research Facilities program, contribution to development of FAIR and interoperability for biobanks and catalogues. BBMRI-NL2.0 produces a collaborative hub between biobanks in the Netherlands. 134 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Full legal name (Acronym) – Country Academisch Ziekenhuis Leiden, also acting under the name Leiden University Medical Centre (LUMC), The Netherlands, (team b): Coordinating Endo-ERN Principal investigator Prof.dr. Alberto Pereira Arias Relevant Network Endo-ERN Description of the legal entity/department/laboratory/group: See description in the Partner Description Form of team a. Main tasks in the project per Pillar/WP: Pillar 2 In WP10, we will contribute in optimising and aligning WP10 and WP11 activities with real-world community needs (task 10.1), in utilisation of the EuRRECa platform to monitor the utility of these activities amongst the Endo-ERN members (task 10.2), and in designing and deployment of the QMS (task 10.3). In WP2, we will provide details to be used to serve the registry needs and to ensure that compatibility of ontological models can be compared between ERN based registries and this project (task 11.1). We will utilise the EuRRECa platform to provide metadata and create a catalogue of research projects (task 11.2) and ensure the EuRRECa platform acts as an effective data deposition facility for core endocrine data including exploration of linkages to other datasets (task 11.3). We will contribute to the improvement of RD phenomics-genomics and multi-omics analysis capabilities (task 11.4). In WP12, we will be instrumental in providing the EuRRECa platform as a model of a RD registry which can be operated within a harmonised environment for registries to ensure maximum interoperability (task 12.1) and will ensure that our platform will achieve semantic and syntactic harmonisation of other parallel activities (task 12.2). We will contribute to the practical FAIRification support process (task 12.3). Pillar 3 In WP 14 we will participate and teach a course on International Registry Summer School (task 14.5) and provide training on the European Rare Disease Registry Infrastructure (ERDRI) (task 14.6) through the experience of the EuRRECa platform and the I-DSD and I-CAH Registries. In WP17, we will lead task 17.1 (development of online survey) and contribute (task 17.2, 17.3 and 17.4) to the develop and deliver research training programs including accreditation for the European Reference Networks (ERNs). Pillar 4 In WP19, Endo-ERN will be surveyed enabling the development of an openly accessible Library of self-help resources and materials for good RD translational research practice. In WP20, Endo-ERN is ready to be included by providing specific additional scientific, clinical and methodological experts for the Task Force Group (TFG) of experts . In Tasks 20.3 and 20.4, Endo-ERN will participate in the preparation of innovative methodology projects calls. Previous experience relevant to the Tasks: Endo-ERN is the largest European Reference Network for Rare Diseases, encompassing the broadest range of rare endocrine conditions from birth to senescence. Endocrine RDs are highly heterogeneous conditions of variable origin, but with severe impact on development, well-being and life expectancy, and specific age-related phenotypic and biochemical profiles. Several endocrine rare conditions have an unknown origin and/or lack therapeutic options. Endo-ERN is founded on several EU networks and projects that have already in the past contributed to data infrastructure, -omics strategies, model systems, and innovative therapies. In specific, we will contribute to all proposed tasks, such as FAIRification processes, the operational management of the NGS-platform (linked to the overarching registry. Endo-ERN is one of the few ERNs which was successful in securing a CHAFEA grant for the development of a core registry for rare endocrine conditions (EuRRECa). Furthermore, Endo-ERN is officially supported by ESE and ESPE, the main pan-European professional and scientific societies which, between them, cover people of all ages for all the conditions covered within Endo-ERN. Finally, Endo-ERN prioritizes the inclusion of ePAGs, training and capacity building of professionals, patients and support groups. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Short Profile of key Staff Members who will be undertaking the work: Pr.Alberto Pereira Alberto M. Pereira is professor of medicine, and head of the division of Endocrinology at the Arias (male) Leiden University Medical Center, the Netherlands. In addition, he is coordinator of the European Reference Network on Rare Endocrine Conditions (2017-2022), and president of the European Neuroendocrine Association (2016-2018). His research focusses on the long- 135 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases term effects of pituitary tumours and of its treatment, and in specific on the effects of stress hormones on the central nervous system. He (co)authored more than 250 papers and book chapters, and supervised 15 PhD students. Pr. O. Hiort Professor Hiort specialised in Paediatrics and the subspecialities Neonatology, Paediatric (male) Endocrinology and Diabetes, as well as in Laboratory Medicine. He was appointed as Professor of Paediatrics in 2001 at the University of Lübeck. He is heading the Division of Paediatric Endocrinology and Diabetes at the University Hospital of Schleswig-Holstein in Lübeck. His scientific interest is with the natural history and pathophysiology of complex rare conditions, namely with disorders of sex development and calcium and phosphate metabolism. Pr.F.Ahmed Professor Faisal Ahmed was appointed in 2000 as a consultant at the Royal Hospital for Sick (male) Children, Yorkhill, Glasgow. In 2012 he was appointed to the Samson Gemmell Chair of Child Health at the University of Glasgow where he leads the Developmental Endocrinology Research Group and has published over 230 scientific communications, with a focus on rare conditions. In addition, he coordinates the long-standing International DSD (I-DSD) Registry and a new EU CHAFEA project, the European Registries for Rare Endocrine Conditions (EuRRECa). Professor Ahmed currently serves as the Chair of the Science Committee of the European Society for Paediatric Endocrinology (ESPE) and leads the e-Health & ICT Working Group within the European Reference Network for Rare Endocrine Conditions (Endo-ERN). List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Cox K, Bryce J, Jiang J, RodieM, Sinnott R, Alkhawari M, Arlt W, Audi L, Balsamo A, Bertelloni S, Cools M, Darendeliler F, Drop S, Ellaithi M, Guran T, Hiort O, Holterhus P-M, Hughes I, Krone N, Lisa L, Morel Y, Soder O, Wieacker P, Ahmed SF. Novel associations in disorders of sex development: findings from the I-DSD Registry. J Clin Endocrinol Metab. 2014;99:e348-355. 2. Lucas-Herald A, Bertelloni S, Juul A, Bryce J, Jiang J, Rodie M1, Sinnott R, Boroujerdi M, Lindhardt-Johansen M, Hiort O, Holterhus PM, Cools M, Guaragna-Filho G, Guerra-Junior G, Weintrob N, Hannema S, Drop S, Guran T, Darendeliler F, Nordenstrom A, Hughes IA, Acerini C, Tadokoro-Cuccaro R, Ahmed SF. The long term outcome of boys with partial androgen insensitivity syndrome and androgen receptor gene mutations. J Clin Endocrinol Metab. 2016 Nov;101(11):3959-3967. 3. Doehnert U, Bertelloni S, Werner R, Dati E, Hiort O. Characteristic features of reproductive hormone profiles in late adolescent and adult females with complete androgen insensitivity syndrome. Sex Dev. 2015;9(2):69-74. doi: 10.1159/000371464. Epub 2015 Jan 20. 4. Bas-Hoogendam JM, Andela CD, van der Werff SJA, Pannekoek JN, van Steenbergen H, Meijer OC, van Buchem MA, Rombouts SA, van Mast RC, Biermasz NR, van der Wee NJ, Pereira AM. Altered neural processing of emotional faces in remitted Cushing's disease. Psychoneuroendocrinology 2015;59:134-46 5. Andela CD, Repping-Wuts H, Stikkelbroeck NMML, Pronk MC, Tiemensma J, Hermus AR, Kaptein AA, Pereira AM, Kamminga NGA, Biermasz NR. Enhanced self-efficacy after a self-management programme in pituitary disease: a randomized controlled trial. Eur J Endocrinol. 2017 Jul;177(1):59-72. doi: 10.1530/EJE-16- 1015. List of relevant previous projects or activities, connected to the subject of this proposal  Endo-ERN; EU/CHAFEA, 2017-2022, Coordinator (LUMC), European Reference Network on Rare Endocrine Conditions, grant agreement nr. 739527 / 769031  CEF Telecom: EU/INEA, 2018-2019, Coordinator (LUMC), Operational Helpdesk for Endo-ERN to ensure structured and tailored Use of Collaborative Platform and CPMS  EuRRECa: EU/CHAFEA, 2018-2021, Coordinator (UoG), European Registries For Rare Endocrine Conditions, grant agreement nr. 777215  DSDnet: EU-H2020, COST Action, Coordinator (UzL/USKH), Systematic elucidation of Differences of Sex Development 65-Raboudumc Full legal name (Acronym) – Country Stichting Katholieke Universiteit (Radboudumc), The Netherlands Principal investigator Nicoline Hoogerbrugge 136 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Relevant Network ERN GENTURIS Description of the legal entity/department/laboratory/group: Radboud University Medical Center (Radboudumc) is a leading academic center with expertise in medical science and healthcare. Expertise plays an essential part in our organization and connects research, education and patient care. Our more than 8,500 staff and 3,000 students are committed and ambitious, helping to shape the future of healthcare and medical science. Team (a): The department of Human Genetics is one of its largest departments, employing 300+ staff (including clinicians, diagnosticians, and scientific researchers), treating over 5,000 patients annually. The department of Human Genetics is nationally and internationally acknowledged for the implementation of genomic medicine, at the levels of patient care, genetic diagnostics and research, using expert knowledge and innovation to reach this goal. With this mission, the department of Human Genetics is recognized as one of the centers of expertise for rare Diseases in the Netherlands and Europe. Main tasks in the project per Pillar/WP: Pillar 2: In WP10 we will participate in Task 10.1: regular retreats with ERNs Pillar 3: In WP16 (Online Education Course), we will participate in: Task 16.1.: Assess the needs, target audience, main topics of the academic education course (Inst. Curie) Task 16.2.2.: Developing the online course Diagnostic of rare diseases (Inst. Curie). In WP17, we will contribute to: Task 17.1.: Mapping to collect information on preferences, needs and resources from the ERNs ecosystem Task 17.2.: Development of training programs for the ERN training networks based on the results of survey Task 17.3.: Deliver training programs through the ERN training networks Task 17.4.: Accreditation by universities (Radboudumc, KI, CMFT) Previous experience relevant to the Tasks: N. Hoogerbrugge is coordinator of ERN GENTURIS and initiator and chair of national and international teaching programs, such as the Dutch Up-to-date in hereditary cancer thematic days (http://www.vkgn.org/files/190/2017Up-to-date%20LYnch%20syndroom.pdf) and the Spring Course in Hereditary Cancer Genetics in Bertinoro, Italy (http://www.ceub.it/default.asp?id_c=772&id=436#.WqlNY6- ouHs). Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : The Radboud Health Academy is specifically equipped to develop and organise training programs. Short Profile of key Staff Members who will be undertaking the work Prof.dr. Nicoline Hoogerbrugge (female) is currently full professor hereditary cancer and head of the multidisciplinary expert center in hereditary cancer RadboudUMC. She has initiated and conducted many research projects on innovation of care and on genetic predisposition of cancer. She has published more than 250 peer- reviewed manuscripts. She is coordinator of the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS). Full legal name (Acronym) – Country Stichting Katholieke Universiteit (Radboudumc), The Netherlands Principal investigator Wout Feitz Relevant Network ERN eUROGEN Description of the legal entity/department/laboratory/group: Team (b) Department of Urology 137 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Main tasks in the project per Pillar/WP: Pillar 2: In WP10 we will participate inTask 10.1: regular retreats with ERNs Previous experience relevant to the Tasks: Prof. Wout Feiz is the coordinator of ERN eUROGEN for rare and complex urogenital diseases and conditions. eUROGEN aims to improve diagnosis, create more equitable access to high-quality treatment and care for patients with rare urogenital diseases and complex conditions needing highly specialised surgery. Short Profile of key Staff Members who will be undertaking the work Prof.dr. Wout Feitz (male) works as a pediatric urologist at Radboudumc (including Amalia children’s Hospital) which is one of the 8 University Hospitals in The Netherlands and has been involved in more than 200 scientific publication and mentored students, PHD’s, post docs and Fellows for paediatric urology. Radboudumc Pediatric urology care and research has been recognized by the ministry of Health as an expertise center for congenital urogenital anomalies. He participates in the Radboudumc Urology Research Laboratory (Heads Prof. J. Schalken and Dr. E. Oosterwijk) which is one of the leading urological research laboratories in Europe and is the coordinator for the Radboudumc Research Theme Reconstructive and Regenerative Medicine (13 departments). He has coordinated FP6 Integrated project EuroSTEC with 15 European partners including 5 SME’s, a Marie Curie program and EU funded regional urology directed research collaborations (7 partners including 5 SME). He is a member of the EUMS/JCPU Board for the fellowship programs in paediatric urology and a member of the EAU Scientific Congress Office for Paediatric Urology. He is the director of the EUMS/JCPU fellowship program for Pediatric Urology, coordinator for the EBU-EAU Host Center for Pediatric Urology, Radboudumc health care representative in the Strategic Board of the ERN eUROGEN (11 EU countries with 29 HCP partners), Member of the operational board of eUROGEN, Workstream 1 coordinator for the disease areas for rare congenital uro-recto- genital anomalies (23 HCP partners). Full legal name (Acronym) – Country Stichting Katholieke Universiteit (Radboudumc), The Netherlands Principal investigator Leo Schultze Kool Relevant Network ERN VASCERN Description of the legal entity/department/laboratory/group: Team (c) Department of Radiology and Nuclear Medicine: The group of Schultze Kool at the Radboudumc is a mutlidisciplinairy team composed of 12 different disciplines focussed on the treatment of vasculair malformations in adults and children. On a yearly basis approx 5000 patients are seen and treated. The HCP is part of the ERN vascern which covers mulitsystemic vasculair diseases like rendu osler weber, lymfatic diseases HTAD and MSA. The group has a close collaboration with the patient organizations for the development of patient centered and patient controlled health systems. In collaboration with the biosemantic group in Leiden a FAIR based patient signal bank has recently been developed. A pilot for a FAIR based registry among the vasculair malformations centers in europe is in progress. The group is closely related to the DTL and the bioinformatics group of the Radboudumc with focus on interoperability and federated data management Main tasks in the project per Pillar/WP: Pillar 2: In WP10, we will participate in: Task 10.1.1: 5 x pan-RD community, 3 days strategy meetings Task 10.1: regular retreats with ERNs Task 10.2.2: Survey and structured interview approaches on technical and scientific matters In WP11, we will participate in: Task 11.1.1: Defíne metadata model compatible with existing key databases and resources Task 11.2.1: Collaboratively assemble and curate metadata based on the Orphanet catalog, on an ongoing basis, to represent all key databases and resources 138 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases In WP12, we will participate in: Task 12.3.3: FAlRification service for data from Pillar 1 studies, from Pillar 2-WP10 activities, and prioritized EU data sources Radboud umc will actively participate in the above mentioned WP with our partners in the Radboudumc (‘t Hoen) and the biosementics (Roos) group in Leiden. The work will be building on already existing partnerships. Joint datastewards will ensure that an optimal collaboration effort is obtained. Previous experience relevant to the Tasks: Schultze Kool is part of the FAIR group of the Radboud umc, chair of the registry WG of VASCERN and co chair of the vasculair malformations WG. He developed several new innovative treatments (2 patents), was co director of the digital research group of the university of leiden (1986-1993) and is the chair of the Biodatabank congenital anomalies. He has recently been proposed as a boardmember of the steering committee Research data management of the Radboud University. Short Profile of key Staff Members who will be undertaking the work Prof.dr. Leo J Schultze Kool (male) is a full professor of Interventional Radiology of the Radboud University Medical Center. Before he was head of the radiology department of the Dutch Cancer Institute in Amsterdam. His main topic is the further development of main innovative treatments for patients with vasculair malformations and further development of personalized care for these groups. Interests are the development of FAIR based registries, linking with FAIR based biodatabanks and EHR to allow datamining. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements A FAIR compliant registry for the vascular malformation centres within the European Reference Networks. How it was done. Author(s): Leo Schultze Kool, Alan IRVINE, Päivi Salminen, Nader Ghaffarpour, Andrea Diociaiuti, Jochen Rössler, C.T. van den Bosch, Eulalia Baselga, Anne Dompmartin, Laurence Boon, Miikka Vikkula, Luiz Bonino, Mark Thompson, Annika Jacobsen, David van Enckevort and Marco Roos. ISSVA meeting 2018 Enrichment of rare disease patient registries by FAIRification. Authors: Annika Jacobsen, Mark Thompson, Erik A. Schultes, Ronald Cornet, Mark Wilkinson, Rachel Thompson, Marina Mordenti, Luca Sangiorgi, Claudio Carta, Karlijn Groenen, Martijn Kersloot, Leo Schultze Kool, David van Enckevort, Marco Roos. ECRD meeting 2018 Full legal name (Acronym) – Country Stichting Katholieke Universiteit (Radboudumc), The Netherlands Principal investigator Peter-Bram ‘t Hoen Relevant Network DTL / ELIXIR / Solve-RD / RD-Connect / EATRIS / EURO- NMD Description of the legal entity/department/laboratory/group: Team (d) Centre for Molecular and Biomolecular Informatics: The group of ‘t Hoen focuses on the identification of diagnostic, prognostic and therapeutic biomarkers from multi-omics profiles through innovative data integration methods. They are implementing and further developing FAIR data stewardship approaches to increase reusability of data and tools. Radboudumc is a member of the Dutch Techcentre for the Life Sciences (DTL, the Dutch ELIXIR node) and actively contributes to DTL services on FAIR data infrastructures, stewardship and training. Main tasks in the project per Pillar/WP: Pillar 2: In WP10, we will participate in: Task 1.1.: regular retreats with ERNs In WP11 we will participate in: Task 11.4.1.: Provide RD phenotype-genotype analysis and data sharing capabilities through the RD-Connect 139 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases platform for molecular diagnostics and gene discovery Task 11.4.4.: User-driven implementation of new analysis functionalities and tools We will be collecting and modeling experimental metadata for RD studies and contribute to method development for knowledge discovery through integration of FAIR data resources relevant to the RD field. In WP12, we will participate in: Task 12.2.4.: Consent and data use management, plus automated access control Task 12.3.3.: FAIRification service for data from Pillar 1 studies, from Pillar 2-WP1 activities, and prioritized EU data sources. We will co-develop federated architectures and systems recording patient consent and enabling the use of patient- related data in a privacy-protective manner. In WP13, we will contribute to the development of integrative systems biology approaches for rare diseases, we fill a number of pre-identified gaps, allowing linkage of external FAIR data sources, and discovering environmental factors influencing disease (task 13.1), and lead task 13.2 to organize proof-of-concept studies around these gaps. Previous experience relevant to the Tasks: Developing new methods for interpreting -omics information in the context of health and disease is the core activity of the group. In the context of RD-Connect, we have developed workflows for mapping and integration of multi-level -omics data and applied these to the study of rare neuromuscular, neurodevelopmental disorders and thalassemias. I emphasise data interoperability to facilitate data integration and professional software engineering, as to make my research and data optimally useful for the community, and are actively contributing to the principles and metrics for FAIR data management. I am actively contributing to the Personal Health Train, an infrastructure that facilitates health data exchange, is fully based on FAIR data architecture and empowers patients / citizens to be in control of their data. In the context of the Personal Health Train and a BBMRI-funded project, we developed a prototype for a machine readable consent systems that is based on FAIR data architecture and is a way for patients to provide dynamic consent to the use of their data by researchers and/or health care providers. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Digital Research Environment, FAIR data infrastructure, Personal Health Train Short Profile of key Staff Members who will be undertaking the work Prof.dr. Peter-Bram ’t Hoen (male) started in February 2018 as full professor in bioinformatics at Radboudumc (Centre for Molecular and Biomolecular Informatics). Before that, he was postdoc, assistant and associate professor in the Human Genetics department at Leiden University Medical Center. His group studied the aetiology of rare muscular dystrophies using state-of-the-art molecular technologies. He was among the first researchers in the Netherlands to implement microarray and (novel) RNA-sequencing technologies, and organized many (inter)national courses on these topics. With these new technologies, he identified major players and mechanisms in the transcriptional and post-transcriptional regulation of gene expression in health and disease. His main drive is to optimally analyze and interpret large -omics data sets to facilitate diagnosis, patient stratification and personalized medicine approaches.. In their interpretation, he typically goes beyond standard (pathway) analysis methods and develops and employs automated knowledge discovery approaches and new statistical routines. This resulted in the prediction and validation of novel biomarkers, novel protein:protein interactions, and new candidate drugs. ‘t Hoen is member of the International Rare Diseases Research Consortium (IRDiRC ) taskforce on data mining and drug repurposing, board member of the research working group European Reference Network on neuromuscular diseases (EURO-NMD) and management team member of the Personal Health Train consortium, developing a data infrastructure to advance healthcare and biomedical science through interoperable and federated data management. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Daria V. Zhernakova, Patrick Deelen, Martijn Vermaat, Maarten van Iterson, Michiel van Galen, Wibowo Arindrarto, Peter van 't Hof, Hailiang Mei, Freerk van Dijk, Harm-Jan Westra, Marc Jan Bonder, Jeroen van Rooij, Marijn Verkerk, P. Mila Jhamai, Matthijs Moed, Szymon M. Kielbasa, Jan Bot, Irene Nooren, René Pool, Jenny van Dongen, Jouke J. Hottenga, Coen D.A. Stehouwer, Carla J.H. van der Kallen, Casper G. Schalkwijk, Alexandra Zhernakova, Yang Li, Ettje F. Tigchelaar, Niek de Klein, Marian Beekman, Joris Deelen, Diana van Heemst, Leonard H. van den Berg, Albert Hofman, André G. Uitterlinden, Marleen M.J. van Greevenbroek, Jan H. Veldink, 140 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Dorret I. Boomsma, Cornelia M. van Duijn, Cisca Wijmenga, P. Eline Slagboom, Morris A. Swertz, Aaron Isaacs, Joyce B.J. van Meurs, Rick Jansen, Bastiaan T. Heijmans*, Peter A.C. ’t Hoen*, Lude Franke*. * shared last author. Identification of context-dependent expression quantitative trait loci in whole blood. Nature Genetics 49:139-145 (2017) IF:31.6 2. Kristina M. Hettne, Mark Thompson , Herman H. H. B. M. van Haagen,Eelke van der Horst,Rajaram Kaliyaperumal, Eleni Mina, Zuotian Tatum, Jeroen F. J. Laros, Erik M. van Mulligen, Martijn Schuemie, Emmelien Aten, Tong Shu Li, Richard Bruskiewich,Benjamin M. Good, Andrew I. Su, Jan A. Kors, Johan den Dunnen, Gert-Jan B. van Ommen, Marco Roos, Peter A.C. ‘t Hoen, Barend Mons, Erik A. Schultes The Implicitome: A Resource for Rationalizing Gene-Disease Associations PLoS One 11:e0149621 (2016) IF: 3.057 3. F. Cynthia Martin, Monika Hiller, Pietro Spitali, Stijn Oonk, Hans Dalebout, Magnus Palmblad, Amina Chaouch, Michela Guglieri, Volker Straub, Hanns Lochmüller, Erik H. Niks, Jan J.G.M.Verschuuren, Annemieke Aartsma-Rus, André M. Deelder, Yuri E.M. van der Burgt, Peter A.C. ’t Hoen Fibronectin is a serum biomarker for Duchenne muscular dystrophy Proteomics 8:269-78 (2013) IF: 4.079 4. Harish Dharuri, Peter Henneman, Ayse Demirkan, Jan Bert van Klinken, Dennis Owen Mook-Kanamori, Rui Wang-Sattler, Christian Gieger, Jerzy Adamski, Kristina Hettne, Marco Roos, Karsten Suhre, Cornelia M. Van Duijn, EUROSPAN consortia, Ko Willems van Dijk, Peter A.C. ’t Hoen Automated workflow-based exploitation of pathway databases provides new insights into genetic associations of metabolite profiles. BMC Genomics 14:865 (2013) IF: 3.867 5. Peter A.C. ’t Hoen, Marc R. Friedländer, Jonas Almlöf, Michael Sammeth, Irina Pulyakhina, Seyed Yahya Anvar, Jeroen F.J. Laros, Henk P.J. Buermans, Olof Karlberg, Mathias Brännvall, The GEUVADIS Consortium, Johan T. den Dunnen, Gert-Jan B. van Ommen, Ivo G. Gut, Roderic Guigó, Xavier Estivill, Ann-Christine Syvänen, Emmanouil T. Dermitzakis, Tuuli Lappalainen. Reproducible mRNA and small RNA sequencing across laboratories. Nature Biotechnol 31:1015-22 (2013) IF 32.4 List of relevant previous projects or activities, connected to the subject of this proposal :  RD-Connect, EU-FP7, 2012-2018,  BIO-NMD, EU-FP7, 2013-2015, identification of biomarkers for neuromuscular disorders, workpackage leader 66-AMC Full legal name (Acronym) – Country Academic Medical Center (AMC) – The Netherlands (Team a) Principal investigator Arthur A.M. Wilde Relevant Network ERN GUARD-Heart Description of the legal entity/department/laboratory/group: In 1996, the Cardiogenetics team of the AMC was one of the first worldwide to start a specialized cardiogenetic outpatient clinic where cardiologists, clinical genetic counsellors, and molecular geneticists act synergistically. Our Cardiogenetics team aims to identify the diagnosis and to provide timely often presymptomatic treatment to the carriers of pathogenic mutations. These carriers are, for the greater part, followed, supported, and treated in our outpatient clinic, according to state-of-the-art methods. At the same time, specific molecular-genetic expertise has been deployed to determine whether gene variants thus found can be regarded as the disease-causing gene defects. This knowledge and expertise is extremely important in the light of the great technological advances in DNA testing in recent years. With the advent of NGS techniques (e.g., whole-exome sequencing), the number of DNA variants to be found, both disease-causing mutations and rare variants of unknown significance in known and unknown genes, increased drastically. We anticipate, that with the enormous amount of molecular-genetic data, intensive collaboration between cardiologists, genetic counsellors, and (molecular) geneticists who combine research and patient care in specialized cardiogenetics centres and share their knowledge in international databases will become even more important. In addition, the Cardiogenetics team of the AMC has a strong national and international position in clinical research. A biobank has been implemented. Since 2004, patients with a familial 141 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases heart disease are included in a national (GENCOR) database. Main tasks in the project per Pillar/WP: Pillar 2: In WP11, we will participate in the process of optimising and align the activities of EJP with real-world community needs by taking active part in annual strategy meetings with other stakeholders in the rare disease community and discuss the management of the next-generation data ecosystem strategic plan) and the setup of a common platform for discoverable data and resources for rare diseases research (Pillar 2 WP11)). In WP10, we will also provide experts to assist in monitoring and coordination of the progress and the usefulness of the activities of Pillar 2 WP10. Previous experience relevant to the Tasks: The Cardiogenetics team of the AMC consists of a dedicated group of cardiologists, clinical geneticists, counsellors, a psycho-social worker and molecular geneticists with expertise in the management of patients with rare and low prevalence diseases of the heart. Since 1996, members of our Cardiogenetics team work together to diagnose and treat patients with familial electrical diseases and familial cardiomyopathies. This design has allowed us to adopt a candidate-gene approach to find the familial-disease gene variant, often driven by specific knowledge about familial electrical diseases and familial cardiomyopathies. The yearly number of counselees increased to reach ~1100 in the last few years. In addition, our team has established a strong position in basic, clinical and translational research and has participated in many national and international research projects, databases and patient registries. In addition, since March 2017, AMC coordinates the activities of the European Reference Network for rare diseases of the heart (ERN GUARD-Heart). It is for these reasons that our Cardiogenetics team is an ideal partner for the EJP to optimise and align Pillar WP 1 and WP2 activities with real-world community needs (which are very well identified by our team members), and to assist in monitoring and the usefulness of WP1 and WP2 activities, according to the needs and the requirements of the rare disease community. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : The Cardiogenetics team of the AMC consists of 7 (paediatric) cardiologists, 6 clinical geneticists / genetic counsellors, a psycho-social worker and 3 molecular geneticists, all of them being specialized in the management of patients with rare and genetic heart diseases. The team members work together in multidisciplinary teams according to a strategic work plan, in which the tasks and responsibilities of each team member are well described. The care is provided according to national and international guidelines and patient pathways with the use of specialised and state-of-the-art equipment, infrastructure, and information technology. The team discusses patients who suffer from high complex rare conditions within the ERN GUARD-Heart using the Clinical Patient Management System (CPMS). Short Profile of key Staff Members who will be undertaking the work Prof. Dr. Arthur A.M. Wilde is a cardiologist-electrophysiologist and head of the Department of Clinical Arthur A.M. and Experimental Cardiology at the AMC, Amsterdam, the Netherlands. He is the Coordinator of Wilde, MD, the European Reference Network for rare and complex diseases of the heart (ERN GUARD- PhD, Male Heart). He is a member of the Dutch Academy of Science. His research interest includes the genetic basis of cardiac arrhythmias, ranging from the monogenetic diseases to more broader healthcare problems as sudden cardiac death in the setting of ischemic heart disease. Recent studies centre on genotype-phenotype relationships in these disorders and the role of clinical and genetic modifiers in establishing the phenotype. Dr. Ahmad S. Ahmad Amin is a cardiologist at AMC, Amsterdam, the Netherlands. He is project manager of the Amin, MD, ERN GUARD-Heart. His research interest includes the genetic basis of familial electrical diseases PhD, Male and familial cardiomyopathies. In his recent studies, he investigates the role of genetic and clinical modifies on the phenotype in order to explain phenotypic variability in patients with these orders (even in families affected with the same pathogenic ‘familial’ mutation). List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Priori SG,* Wilde AA,* et al. Heart Rhythm. 2013;10:1932-63. 2. Ackerman MJ, …, Wilde AA, et al. Heart Rhythm. 2011;8:1308-1339. 3. Postema PG, Wolpert C, Amin AS, …, Wilde AA. Heart Rhythm. 2009;61335-1341. 4. Hofman N, …, Wilde AA. Circulation. 2013;128:1513-1521. 5. Amin AS, …, Wilde AA, et al. European Heart Journal. 2012;33:714-723. List of relevant previous projects or activities, connected to the subject of this proposal . ERN GUARD-Heart; European Union; 2017-2022 - Network coordinator (Wilde), European Reference Network for rare and complex diseases of the heart. . Improve CPVT; European Union (ERA-Net E-Rare); 2016-2020 - Project Coordinator (Wilde), improving 142 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia: integrating clinical and basic science. . PREDICT; Dutch Heart Foundation; 2013-2018 - Principal Investigator (Wilde), predicting sudden cardiac death. . Netherlands Organisation for health Research and Development; 2012-2016 - Principal Investigator (Wilde), preventing arrhythmias & sudden cardiac death in LQTS3 through pharmacological late sodium current inhibition. . Dutch Heart Foundation; 2014-2017- Principal Investigator (Amin), variants in the 3'UTR modify disease severity in inherited cardiac diseases by altering microRNA binding. Full legal name (Acronym) – Country Academic Medical Center (AMC) – The Netherlands (Team b) Principal investigator Ronald Cornet Relevant Network Description of the legal entity/department/laboratory/group: The Department of Medical Informatics at the Academic Medical Centre (AMC) in Amsterdam is one of the leading Medical Informatics departments in the Netherlands and Europe. It is one of the few groups that provides Medical Informatics training and research at BSc, MSc and PhD level, as well as MSc-level Health Informatics training for healthcare professionals. These training programs deliver a continuous stream of young academics and provide a fertile ground for collaboration with clinical partners. The department has a strong track record in research on standardization of healthcare information, combining a demand-driven perspective with strong theoretical foundation. Research encompasses application of description logic, semantic modelling using information models and ontologies, structured data capture, and use of structured data. The department is based in the AMC, one of the major health and care research institutions in the Netherlands, and one of its largest hospitals. Over 7,000 people work here to provide integrated patient care, fundamental and clinical scientific research, and teaching. Main tasks in the project per Pillar/WP: Pillar 2: In WP11, we will contribute to the metadata and ontological model definition for cataloguing resources for RD research. Our focus in this will be on the clinical resources. In WP12, we will lead subtasks on FAIRification of data. These tasks consist of a) development and application of methods for semantic and syntactic harmonisation of data records, and b) a coordinated effort to define strategies to move towards generating data that is FAIR from the start, rather than post-hoc FAIRification. These tasks will be led using the experience gained in the subtasks in which interoperability standards are compared and aligned. Pillar 3: In WP14, we will contribute to the training on rare disease registries and FAIRification of data at the source. In the last years, we have successfully contributed to this course, which has consisted of a summer school and a hands-on tutorial. Previous experience relevant to the Tasks: The department of Medical Informatics of the AMC has previously been involved in standardization and harmonization efforts in various domains, including intensive care, nephrology, anaesthesiology, oncology, and HIV/AIDS-care. The department has been involved in various national efforts towards standardized and structured data capture, predominantly the introduction of SNOMED CT in the Netherlands, and raising awareness of the importance of point-of-care clinical data capture. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : The department has a variety of semantic resources in place, as well as knowledge, skills and permission to access even more resources. Furthermore, the department has a broad network, via active or past involvement in national, international and global data harmonisation efforts. Short Profile of key Staff Members who will be undertaking the work Dr. Ronald Ronald Cornet holds a position as associate professor at the department of Medical Informatics in Cornet, PhD, the Amsterdam Public Health research institute, Academic Medical Center - University of Male Amsterdam. His research focuses on semantic interoperability, both from a technical perspective and from a users' point of view, including natural language processing. This research has resulted in over 40 journal publications and over 70 peer-reviewed conference proceedings. Ronald is involved in the Modelling Advisory Group of SNOMED International, the organisation that is responsible for maintenance and further development of SNOMED CT. He chairs the IMIA working group on Language and Meaning in Biomedicine. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 143 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 1. Zini EM, Lanzola G, Quaglini S, Cornet R. Standardization of immunotherapy adverse events in patient information leaflets and development of an interface terminology for outpatients' monitoring. J BIOMED INFORM 2018;77:133-144 2. Burger G, Abu-Hanna A, de Keizer N, Cornet R. Natural language processing in pathology: a scoping review. J CLIN PATHOL 2016;69 (11):949-955 3. Dentler K, Cornet R. Intra-axiom redundancies in SNOMED CT. ARTIF INTELL MED 2015;65 (1):29-34 4. Lee D, de Keizer N, Lau F, Cornet R. Literature review of SNOMED CT use. J AM MED INFORM ASSN 2014;21 (E1):E11-E19 5. Geller J, Perl Y, Halper M, Cornet R. Special issue on auditing of terminologies. J BIOMED INFORM 2009;42 (3):407-411 List of relevant previous projects or activities, connected to the subject of this proposal  International Summer School on Rare Disease and Orphan Drug Registries, organized by the Italian National Centre for Rare Diseases (CNMR) in collaboration with Services and Centre for International Affairs (ISS), RD-Connect, Elixir, RD-Action, EURORDIS and endorsed by ICORD; 2016-2017 - faculty  ASSESS-CT - Assessing SNOMED CT for Large Scale eHealth Deployments in the EU; European Union; 2015-2016; participant.  SemanticHealthNet; European Union; 2013-2014; Advisory board member.  NephroQUEST Initiative; European Union; 2007-2010; Workpackage leader 67-Erasmus MC Full legal name (Acronym) – Country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), The Netherlands (Team a) Principal investigator Prof. dr. I.M.J. Mathijssen Relevant Network ERN CRANIO Description of the legal entity/department/laboratory/group: Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) Department of Plastic and Reconstructive Surgery Main tasks in the project per Pillar/WP: Pillar 2: In WP10, we will work on 5x pan-RD-community, 3-day strategy meetings (annual retreat) (task 10.1.1) In WP10, we will work on Survey and structured interview approaches on technical and scientific matters, to monitor progress and inform strategic decisions (incl. Definition of indicators) (task 10.2.2) Previous experience relevant to the Tasks: I am leading the craniofacial team of the Erasmus MC and involved in care, research and training regarding craniofacial anomalies. As secretary-treasurer of the International Society of Craniofacial Surgery I have a large network within the field. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : We have all the medical specialties and all relevant equipment for this project, ranging from a electronic patient file, data bases for research, multidisciplinary teams for providing care, educational programs for all care providers, close interaction with the patient society, training programs for fellows from all over the world. Short Profile of key Staff Members who will be undertaking the work Pr. Irene M.J. MBA-Health,Head of department of Plastic and Reconstructive Surgery, and Hand Surgery Mathijssen Erasmus MC, Rotterdam (female) List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Cornelissen MJ, Softeland M, Apon I, Ladfors L, Mathijssen IMJ, Cohen-Overbeek TE, Bonsel GJ, Kolby L Perinatal complications in patients with unisutural craniosynostosis: An international multicentre retrospective cohort study. J Craniomaxilofac Surg 45: 1809-14, 2017 2. . Van Veelen MLC, Kamst N, Touw C, Mauff K, Versnel S, Dammers R, De Jong THR, Prasad V, Mathijssen IM. Minimally invasive, spring-assisted correction of sagittal suture synostosis. Technique, outcome and complications in 83 cases. Plast Reconstr Surg 141: 423-33, 2018 3. Miller KA, Twigg SR, McGowan SJ, Phipps JM, Fenwick AL, Johnson D, Wall SA, Noons P, Rees KE, Tidey 144 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases EA, Craft J, Taylor J, Taylor JC, Goos JA, Swagemakers SM, Mathijssen IM, van der Spek PJ, Lord H, Lester T, Abid N, Cilliers D, Hurst JA, Morton JE, Sweeney E, Weber A, Wilson LC, Wilkie AO. Diagnostic value of exome and whole genome sequencing in craniosynostosis. J Med Genet. 54: 260-8, 2017. 4. Spruijt B, Mathijssen IM, Bredeo-Boelhouwer HH, Cherian PJ, Corel LJ, Van Veelen ML, Hayward RD, Tasker RC, Joosten KF. Sleep architecture linked to airway obstruction and intracranial hypertension in children with syndromic craniosynostosis. Plast Reconstr Surg 138: 1019e-1029e, 2016. 5. Mathijssen IM. Guideline for care of patients with the diagnoses of craniosynostosis: Working group on craniosynostosis. J Craniofac Surg 26: 1735-1807, 2015. List of relevant previous projects or activities, connected to the subject of this proposal: OCT; Stichting Lijf en Leven; 2017-2020, the use of OCT for detection of raised intracranial pressure in craniosynostosis CRISPR-CAS; Dalijn Stichting; 2014-2017, repair of craniosynostosis genetic defects BRAIN; JANIVO stichting; 2016-2019, study into brain anomalies in congenital craniofacial defects Ultra; Nuts Ohra Foundation; 2013-2017, prenatal and perinatal findings in craniosynostosis 68-SERMAS Full legal name (Acronym) – Country SERVICIO MADRILEÑO DE SALUD-HOSPITAL UNIVERSITARIO LA PAZ (SERMAS) - Spain Principal investigator Eduardo López Granados Relevant Network ERN TransplantChild Description of the legal entity/department/laboratory/group: TransplantChild is the only ERN focused on a highly complex procedure: Pediatric Transplantation, both solid organ (SOT) and hematopoietic stem cell transplantation (HSCT). Transplantation is yet the only curative option for many paediatric rare diseases that compromise organ anatomy and function, or hematopoietic and immunological capacity and control. Transplanted patients overcome their severe primary disease, but acquire a life-long medical condition, that yet fulfills many characteristics of RD as low prevalence, and favors the appearance of transplant-related rare diseases (e.g. graft versus host disease) and complications (e.g. rejection, opportunistic infections). Many of these complications share a common pathogenic root, the immunosuppressed status of the transplanted individual, appear in all type of transplants, or even aggravate when several organs or SOT and HSCT are accomplished. Immune-mediated conditions present challenges because of their complexity and variety; however, they also provide research opportunities as biomarker discovery and novel therapeutics. Current transplantation outcomes in children, in terms of quality of life, morbidity and mortality can be improved. This requires better clinical management of associated complications by implementation of prognostic and diagnostic tools, for a precise and patient-centered monitoring of the transplantation process based on novel -omics and the development of innovative preventive and therapeutic procedures at all stages of transplant. The identification of patients likely to respond to novel procedures, as operational tolerance induction, would be important both in terms of health, and in terms of cost effectiveness. Innovative efforts are particularly challenging in paediatric transplantation, and requires dedicated coordinated efforts across pediatric-experienced institutions to overcome major challenges that are shared with others areas of research in RD: 1) existing fragmentation of efforts, data and resources in single organ-oriented efforts; 2) difficulties to re-use results of funded research; 3) the need for optimization of tools and resources that already exists and that can be adapted from their original design for primary disease diagnosis to the transplantation-related complications. Main tasks in the project per Pillar/WP: Pillar 0: WP1: Coordination and management Support of the ERN TransplantChild in the tasks. Pillar 2: WP 10: User-driven strategic planning and transversal activities Attending, participating and making decisions on the strategy at the annual retreats. Also depending on the strategic decisions, TransplantChild may be connected to the virtual platform and also may conduct POCs in WP13 depending on the POCs prioritised. Pillar 3: WP 16: On line education course: 145 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Task 16.1 "Assess the needs, target audience, main topics of the academic education course”. This task will be performed through a thorough benchmark of existing RD academic courses at EU level and through survey and audits of potential target audiences and experts involved in those courses (not restricted to students) and the main topics to address, the most relevant lecturers. Task 16.2 Developing the online course as Co-coordinators of development of training. E-learning approaches could combine different components: e-learning content, e-tutoring, collaborative learning, virtual classroom. The platform will develop and implement the e-learning scholar content received from lecturers. Pillar 4: WP20: Accelerating the validation, use and development of new methodologies tailored for clinical studies in RDs. As coordinators of the ERN TransplantChild and representing it, will participate in all the tasks related to the objectives of the WG. Previous experience relevant to the Tasks: TransplantChild would provide coordinated access to a comprehensive, accessible and interoperable suite of tools. We collaborate with FAIR clinical and standardized routine analytical data (collected in a pan-trasplant dedicated registry following recommendations of the DG Joint Research Centre (JRC), with identified relevant cohorts). With the aim to create a critical mass of collected biological samples, based on recommended and harmonized quality based banking procedures in each ERN HCP to increase and accelerate research opportunities. Stimulating a collaborative bridging of existing advanced data analytics services for generation and exploitation of –omics data, seeking the integration with existing European platforms, for the precise monitoring of the transplant procedure for children with rare diseases. TransplantChild provides effective interaction between patients, healthcare professionals, academics and researchers to support training activities to bridge the gap between patient needs, clinical practice and new treatment strategies at European, national and regional levels. We´ve created a best expertise knowledge platform (online) and Training Programs, based on e-learning modules, specific sessions in online courses. Collaboration with other ERNs focused on disease groups that require transplantation will be favored. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Biobank facility at Hospital premises, dedicated registry for all types of pediatric transplant procedure), integrative platform for collection and exploitation of clinical, routine lab and research data. Clinical simulation platform oriented to learn and train in the approach of the patient in critical clinical situations with the highest standards and equipment. Clinical Research Unit of Clinical Trials (UCICEC) with staff specialized in the management and development of clinical investigation and clinical trials including Phase I unit accredited. Short Profile of key Staff Members who will be undertaking the work Eduardo López Consultant Clinical Immunologist and PhD with 20 years’ experience in the diagnosis, genetic Granados and immunological characterization of Primary Immunodeficiencies (PIDs), a large group of (male) RD. Previous clinical and Research positions at NIAID/NIH and Human Immunology Unit at MRC Weatherall Institute of Molecular Medicine, Univ. of Oxford. Head of La Paz University Clinical Immunology Department. From the experience of PIDs, we are introducing cellular and molecular biomarkers for better definition of the secondary immunodeficiency and immune dysregulation generated by transplant procedures, for better clinical management of complications. TRANSPLANTChild Research Working Group Coordinator Antonio Pérez Paediatric Hemato-Oncologist with experience in hematopoietic stem cell Transplantation and Martínez Associated Professor of Paediatric at La Paz University Hospital (HULP), and Faculty of (male) Medicine of the Autonoma University, respectively, in Madrid, Spain. ERN TRANSPLANTChild Education and training Working Group Coordinator. Juan M.Torres MD, specialist in Clinical Immunology. Medical Supervisor of ERN-TRANSPLANTChild, Canizales participating in the organizational management and orientation of Research and Education and (male) Training, together with the rest of the network working groups. List of the most relevant publications and/or products, services or other achievements 1.Scientific communications about the ERN vision and orientation at: Third IRDiRC Conference on February 8-9, 2017 in Paris 2.Communication at European Conference on Rare Diseases & Orphan Products 2018 3. Oral presentation at the 5th National Congress of the Spanish Society of Transplantation 30 June 1 July 2018. 4. Continuous training course in paediatric transplantation focused on physicians, emphasizing a transversal and 146 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases holistic approach. The model used is a mixed platform: through face-to-face training combined with multimedia and audio-visual materials available on the e-learning platform. 5. We promoted the short-term secondees program for medical specialists and specialist trainee who are currently dedicated to paediatric transplantation in any of any of the members for best practices sharing. List of relevant previous projects or activities, connected to the subject of this proposal - TRANSMIT: European TRAining Network on perSonalised Medicine for Tolerance in PaedIatric Transplantation; Innovative Training Networks (ITN) Call: H2020-MSCA-ITN-2018 (Submitted, on evaluation); Through multidisciplinary and multicentric approach strengthened by European-level cooperation and coordination, TRANSMIT will exploit immunological signatures in tolerance, alloreactivity and immunosuppression related biomarkers, allowing to centres of expertise and professionals in different countries to share knowledge of personalised medicine in PT recipient patients. - PRICISION: European Network on Paediatric transplantation Risk stratification by Immunological biomarkers-driven Clinical ImmunoSuppressIon decisiONs; COST Action OC-2017-1 (Submitted, on evaluation); The Aim of this Action is to establish a European-led multidisciplinary network of researchers collaborating in the validation and standardization of immune biomarkers for personalized immunosuppressive therapy in paediatric transplantation. - PETER: PaEdiatric Transplantation European Registry; HP-PJ-06-2016; The overall objective of the project is to create a new rational, efficient, interoperable, open, accessible and predictive paediatric transplant registry; the first that includes jointly solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). 69-NUTH Full legal name (Acronym) – Country Newcastle-Upon-Tyne Hospitals NHS Foundation Trust (NUTH) Principal investigator Kate Bushby (as coordinator EURO-NMD) and Teresinha Evangelista David Jones (as coordinator RARE-LIVER) Andrew Cant (as Coordinator ERN RITA) Relevant Network ERN-EURO-NMD , ERN-Rare-Liver ,ERN-RITA Description of the legal entity/department/laboratory/group: NUTH has been providing patient-centred healthcare to communities in the North East of England and beyond for over 250 years. NUTH is one of the largest NHS trusts in the UK, offering a wider range of specialist services than any other. NUTH has a great deal of expertise in rare disease research and is the coordinator of three European Reference Networks (ERN):  ERN-EURO-NMD, the ERN for rare and complex neuromuscular diseases;  ERN-Rare-Liver for rare and complex hepatological diseases  ERN-RITA for Rare Immunodeficiency, auto inflammatory and autoimmune diseases. ERN-EURO-NMD is part of the Institute of Genetic Medicine (IGM). It is coordinated by Katie Bushby who is an honorary consultant at the world leading John Walton Muscular Dystrophy Research Centre. Her team based at the Institute of Genetic Medicine, Newcastle University and its associated hospitals work together towards the development and application of genomic and translational medicine to improve the health outcomes of people living with neuromuscular diseases. ERN-Rare-Liver (coordinated by Prof. Andrew Cant) and ERN-RITA (coordinated by Prof. David Jones) are part of the Institute of Cellular Medicine (ICM). Main tasks in the project per Pillar/WP: IGM PILLAR 2: WP10-Strategy. EURO-NMD and RITA will put themselves forward to join the monthly stakeholder board and annual meetings. The decision on exactly which ERNs will be represented on the board will be made at the up- coming ERN coordinators meeting. PILLAR 3 WP16 – Online Education course EURO-NMD has been approached by the WP lead (FFRD) and agreed to be involved in the development of an 147 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases academic course this will include contributing to task 16.1-Assess the needs, target audience and main topics of the academic training course. We will also contribute to task 16.2.2 – Identify and work with relevant European Universities, learned societies and other institutions to develop the content of the academic course. WP17 – ERN RD Training and support Programme. Under this WP the ERN’s have been organized into four thematic diseases groupings. EURO-NMD will participate in Group 1 “Neuro”. ERN-RITA will participate in Group 2 ‘Neoplasm and Malformation”. ERN-Rare-Liver will participate in Group 3 “Organs”. Previous experience relevant to the Tasks: Within the IGM the team coordinates a number of relevant rare disease projects. Katie Bushby was a co- coordinator for TREAT-NMD and the coordinator of the EUCERD joint action on Rare diseases. The centre has the expertise and over 12 years of experience in the management and participation in EU funded initiatives. From 2006 to 2009, Andrew Cant was President of the European Society for Paediatric Infectious Diseases (ESPID). He is also a member of the Medical Advisory Board of the International Patient Organisation for Primary Immunodeficiencies (IPOPI). He has thus contributed strongly to the success of the ESID registry. He also has access (through ERN-RITA) to specific expertise in database interoperability. Short Profile of key Staff Members who will be undertaking the work - across all three departments Prof. David ICM, Coordinator of ERN-RARE-LIVER Jones David Jones is a NIHR Dean for Faculty Trainees and an active researcher in the area of Professor of Autoimmune Liver Disease, with a particular focus on the impact of the diseases on patients and Liver how we can improve outcomes through the development and evaluation of new treatment Immunology approaches. He co-wrote the European treatment guidelines for autoimmune liver disease upon which all current therapy is based. I lead the UK PBC Consortium which brings together all Male centres in the UK with the goal of improving therapy for everybody with autoimmune liver disease. David Jones is the coordinator of ERN-Rare Liver Prof. Andrew ICM, Coordinator of ERN-RITA Cant As Consultant in Newcastle for 24 years, he set up one of two national referral centres for the Hon Clin Prof treatment of children with severe immunological disorders and I am a world leader in the field of Paediatric childhood infection, immune disorders, and bone marrow transplantation, also holding clinics in Immunology Leeds, Scotland and Ireland he is a past President of the European Society for Paediatric Infectious Diseases and President Elect of the European Society for Immunodeficiencies. Male Professor Cant is a leading researcher and teacher of international repute, and in the last 28 years he has been awarded grants of over £7 million to support research into childhood tuberculosis, meningococcal disease, the epidemiology and pathology of primary immune deficiencies, defining the role of bone marrow transplantation as a treatment for primary immune deficiencies, viral infection in the immunocompromised host, polysaccharide antibody responses following solid organ transplantation and vaccine responses in preterm infants; leading to over 200 peer reviewed papers, his most recent leading work on the delineation of Activated Protein Kinase Delta syndrome. Dr. Teresinha IGM, Acting Coordinator of ERN-EURO-NMD Evangelista. Dr Teresinha Evangelista has over 20 years’ experience working as a Neurologist. Dr Teresinha Acting Evangelista played an important role in the development of a diagnostic network for EURO-NMD Neuromuscular Diseases during the years working in Portugal and was appointed as President of coordinator the Portuguese Society for The Study of Neuromuscular Diseases in 2009 in recognition of status as a leading reference for Neuromuscular Diseases in Portugal. Female Her work currently focuses on clinical and research work on hereditary muscle diseases, FSHD and Congenital Myasthenic Syndromes. Simultaneously as a member of the Joint Actions for rare diseases (EUCERD Joint Action and RD-Action), developed a particular interest on Rare Diseases policies. As a result of the policy work become responsible for the concept and setting 148 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases up of the neuromuscular ERN (EURO-NMD) that integrates 61 healthcare providers from across Europe. Thus far, she has published over 70 peer-reviewed papers and 5 book chapters. She has given many invited lectures at meetings, symposiums and workshops as well as patient/parent organizations meetings. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1.Translational Summer School and wider NMD training programme 2. Neuropediatrics. 2017 Aug;48(4):211-220. doi: 10.1055/s-0037-1604110. Epub 2017 Jul 6. Translational Research in Europe for the Assessment and Treatment for Neuromuscular Disorders (TREAT-NMD). Leary R, Oyewole AO, Bushby K, Aartsma-Rus A. 3. Muscle Nerve. 2018 Mar;57(3):380-387. doi: 10.1002/mus.25991. Epub 2017 Nov 7. Chronic pain has a strong impact on quality of life in facioscapulohumeral muscular dystrophy. Morís G, Wood L, FernáNdez-Torrón R González Coraspe JA, Turner C, Hilton-Jones D, Norwood F, Willis T, Parton M, Rogers M, Hammans S, Roberts M, Househam E, Williams M Lochmüller H, Evangelista T. 4. Non-PTLD Malignancy post HSCT in patients with Primary Immunodeficiency: UK experience. Unni MNM, Elfeky R, Rao K, Nademi Z, Chiesa R, Amrolia P, Skinner R, Slater O, Worth A, Flood T, Abinun M, Hambleton S, Qasim W, Gaspar HB, Cant AJ, Gennery AR, Veys P, Slatter MA. J Allergy Clin Immunol. 2018 Mar 7. pii: S0091-6749(18)30391-9. doi: 10.1016/j.jaci.2018.02.038. 5. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study. Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, Goodlad JR, Farmer G, Steele CL, Leahy TR, Doffinger R, Baxendale H, Bernatoniene J, Edgar JD, Longhurst HJ, Ehl S, Speckmann C, Grimbacher B, Sediva A, Milota T, Faust SN, Williams AP, Hayman G, Kucuk ZY, Hague R, French P, Brooker R, Forsyth P, Herriot R, Cancrini C, Palma P, Ariganello P, Conlon N, Feighery C, Gavin PJ, Jones A, Imai K, Ibrahim MA, Markelj G, Abinun M, Rieux-Laucat F, Latour S, Pellier I, Fischer A, Touzot F, Casanova JL, Durandy A, Burns SO, Savic S, Kumararatne DS, Moshous D, Kracker S, Vanhaesebroeck B, Okkenhaug K, Picard C, Nejentsev S, Condliffe AM, Cant AJ. J Allergy Clin Immunol. 2017 Feb;139(2):597-606.e4. doi: 10.1016/j.jaci.2016.06.021. Epub 2016 Jul 16. List of relevant previous projects or activities, connected to the subject of this proposal : TREAT-NMD: FP6, European commission, 2007-2011, Acted as coordinator. EU funded ‘network of excellence’ with the remit of ‘reshaping the research environment’ in the neuromuscular field. EURO-NMD: Third Health Programme, EC, 2017-2021, Current coordinator of the Network. EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. EURO-NMD facilitates discussion on complex or rare neuromuscular diseases and conditions that require highly specialised treatment, and concentrated knowledge and resources. ERN-Rare Liver and ERN-RITA: Third Health Programme, EC, 2017-2021, Current coordinators of the Network. EURO-NMD and ERN RITA are two of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. 70-GOSH Full legal name (Acronym) – Country Great Ormond Street Hospital for Children NHS Trust (GOSH) Principal investigator Professor J Helen Cross Relevant Network EpiCARE Description of the legal entity/department/laboratory/group: Great Ormond Street Hospital (GOSH) is a large children’s hospital providing tertiary and quaternary services to children from across the UK and overseas. We provide the widest range of specialist paediatric health services on one site found in the UK. Together with our research partner, UCL Great Ormond Street Institute of Child Health we form the UKs only academic Biomedical Research Centre specialising in paediatrics Main tasks in the project per Pillar/WP: Pillar 2: In WP 10.2 & 10.4 (MEYER) Professor Renzo Guerrini, will to the annual retreats and guidance on priorities for 149 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Virtual Platform and FAIRification In WP11 (MEYER) we will contribute through Professor Renzo Guerrini with his knowledge and development of existing genetic epilepsy expertise, specifically his involvement in existing genetic epilepsy platform) Pillar 3 WP16.1 (GHE-HCL) Through Professor Alexis Arzimanoglou, assess the needs, target audience, main topics of the academic education course" as well as task 16.2.2. "Identify and work with relevant European Universities, learned societies and other institutions to develop the content of the academic course" Professor Arzimanoglou will also contribute, together with EATRIS, to Module 8 on Regulatory affairs. In the domain of the epilepsies there has been a regular collaboration between International League Against Epilepsy representatives and the EMA/FDA. Pillar 4 Task 20.1: Task Force Group WP 20 (GOSH) as a participant and contributor, and contributory to C4C, with regard to the set up and methodologies for clinical studies Previous experience relevant to the Tasks: Great Ormond Street Hospital (GOSH) is a major referral centre for rare and complex epilepsies in the UK, and coordinates the European Reference Network EpiCARE. With its partner organisation UCL-GOSH Institute of Child Health, it is part of the clinical trial network C4C and has participated in several European Funded research projects. Professor Renzo Guerrini has extensive experience in coordination of global epilepsy genetics projects including Epi4K, EuroEPINOMICS, Epi25 and as leader of the FP7 funded project DESIRE (Development and Epilepsy: Strategies for Innovative Research to improve diagnosis, prevention and treatment in children with difficult to treat Epilepsy) Professor Alexis Arzimanoglou leads the educational workpackage of EPiCARE. He is editor of the International League Against Epilepsy Educational journal Epileptic Disorders and leads on several course initiatives in rare and complex epilepsies. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : All participants are centres within the European Reference Network for Rare and Complex Epilepsies EPiCARE. Short Profile of key Staff Members who will be undertaking the work Pr.Helen Cross Professor Helen Cross is The Prince of Wales’s Chair of Childhood Epilepsy and Head of the (female) Developmental Neuroscience Programme at UCL-Great Ormond Street Institute of Child Health, Honorary Consultant in Paediatric Neurology Great Ormond Street Hospital for Children NHS Foundation Trust, London and Young Epilepsy, Lingfield, UK. Her research has been targeted at improving outcomes in early onset epilepsy, specifically in assessing the role of surgery and ketogenic diet She leads the European Reference Network for Rare and Complex Epilepsies, EpiCARE Pr.Renzo Guerrini Renzo Guerrini is Medical Doctor; Neurologist; Child Neurologist and Psychiatrist; Clinical (male) Neurophysiologist. Current position: Professor of Child Neurology and Psychiatry, Director of Pediatric Neurology Unit and Laboratories, Children's Hospital A. Meyer-University of Florence. He was previously appointed Clinical Professor at Department of Neurology, GKT Medical, London, King’s College Hospital (1999-2001): Professor Pediatric Neurology, Institute of Child Health, University College London and Great Ormond Street Hospital (2001-2003). Pr.Alexis Alexis Arzimanoglou is currently consultant and Coordinator of the Epilepsy Program of the Arzimanoglou Epilepsy Unit at SJD Barcelona Children's Hospital and Director of the Epilepsy, Sleep and (male) Pediatric Neurophysiology Department at the University Hospitals of Lyon, France. He is also member of the DYCOG research team at the Centre de Recherche en Neurosciences de Lyon (France). His clinical and research activities are focused on: the pharmacological and surgical management of childhood epilepsies, the cognitive development and emotional regulation disorders in children with focal epilepsies List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. https://epi-care.eu/ 2. Blumcke I, Spreafico R, Haaker G, Coras R, Kobow K, Bien CG, Pfäfflin M, Elger C, Widman G, Schramm J, 150 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Becker A, Braun KP, Leijten F, Baayen JC, Aronica E, Chassoux F, Hamer H, Stefan H, Rössler K, Thom M, Walker MC, Sisodiya SM, Duncan JS, McEvoy AW, Pieper T, Holthausen H, Kudernatsch M, Meencke HJ, Kahane P, Schulze-Bonhage A, Zentner J, Heiland DH, Urbach H, Steinhoff BJ, Bast T, Tassi L, Lo Russo G, Özkara C, Oz B, Krsek P, Vogelgesang S, Runge U, Lerche H, Weber Y, Honavar M, Pimentel J, Arzimanoglou A, Ulate-Campos A, Noachtar S, Hartl E, Schijns O, Guerrini R, Barba C, Jacques TS, Cross JH, Feucht M, Mühlebner A, Grunwald T, Trinka E, Winkler PA, Gil-Nagel A, Toledano Delgado R, Mayer T, Lutz M, Zountsas B, Garganis K, Rosenow F, Hermsen A, von Oertzen TJ, Diepgen TL, Avanzini G; EEBB Consortium.Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery. N Engl J Med. 2017 Oct 26;377(17):1648-1656. 3. Whelan CD, Altmann A, Botía JA, Jahanshad N, Hibar DP, Absil J, Alhusaini S, Alvim MKM, Auvinen P, Bartolini E, Bergo FPG, Bernardes T, Blackmon K, Braga B, Caligiuri ME, Calvo A, Carr SJ, Chen J, Chen S, Cherubini A, David P, Domin M, Foley S, França W, Haaker G, Isaev D, Keller SS, Kotikalapudi R, Kowalczyk MA, Kuzniecky R, Langner S, Lenge M, Leyden KM, Liu M, Loi RQ, Martin P, Mascalchi M, Morita ME, Pariente JC, Rodríguez-Cruces R, Rummel C, Saavalainen T, Semmelroch MK, Severino M, Thomas RH, Tondelli M, Tortora D, Vaudano AE, Vivash L, von Podewils F, Wagner J, Weber B, Yao Y, Yasuda CL, Zhang G, Bargalló N, Bender B, Bernasconi N, Bernasconi A, Bernhardt BC, Blümcke I, Carlson C, Cavalleri GL, Cendes F, Concha L, Delanty N, Depondt C, Devinsky O, Doherty CP, Focke NK, Gambardella A, Guerrini R, Hamandi K, Jackson GD, Kälviäinen R, Kochunov P, Kwan P, Labate A, McDonald CR, Meletti S, O'Brien TJ, Ourselin S, Richardson MP, Striano P, Thesen T, Wiest R, Zhang J, Vezzani A, Ryten M, Thompson PM, Sisodiya SM. Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study. Brain. 2018 Feb 1;141(2):391-408. 4. http://epilepsydesireproject.eu/ 5. http://www.jle.com/en/revues/epd/revue.phtml List of relevant previous projects or activities, connected to the subject of this proposal ERN EpiCARE; coordination funded through Chafea grant 769051 — EpiCARE 151 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 71-EORTC Full legal name (Acronym) – Country European Organisation for Research and Treatment of Cancer (EORTC)- BE Principal investigator Sandrine Marreaud, Saskia litière, Stéphane Lejeune Relevant Network EORTC, ERN EURACAN, IRCI, IRDIRC Description of the legal entity/department/laboratory/group: The EORTC is a non-profit international research organization created under Belgian law in 1962. Since its creation, the EORTC has contributed to improve the survival rates for several types of cancer through translational and clinical research. Over 50 EORTC sponsored clinical trials are open to patient recruitment at any given time. Both multinational and multidisciplinary, the EORTC Network comprises more than 4,000 collaborators from all disciplines involved in cancer treatment and research in more than 700 university hospitals in over 30 countries. The EORTC provides the know-how and the capacities to develop, perform, analysis and publish clinical research projects including clinical trial protocol development, trial design, trial coordination, medical review, translational research, pharmacovigilance, regulatory affairs management, contracts and insurances, Quality of Life/ PRO investigation, imaging platform, radiotherapy QA, CDISC compliant database development and data management, biostatistics, monitoring, QA/QC, etc.. The scientific activities of EORTC are strictly peer-reviewed and subject to quality assurance/quality control programs. The EORTC operates on an independent basis, and in this capacity is able to work in partnership with the pharmaceutical industry in evaluating innovative molecules. EORTC has contributed to several success stories in terms of new anti-cancer drug development including registrations by the FDA and the EMA. The EORTC has a proven track record in establishing new clinical standards, e.g. Response Evaluation Criteria In Solid Tumours (RECIST), quality of life of cancer patients, etc. The EORTC is running the SPECTA program to enable efficient access to molecular screening platforms for efficient biomarkers-driven clinical trials access in lung, colorectal, melanoma, brain, and rare cancers. EORTC works in partnership with various clinical research groups from Europe, America, Asia and Australia. Main tasks in the project per Pillar/WP: Pillar 2 – WP11 Multi-omics pipelines and reference maps for rare diseases research: pilot project in rare cancers if funded. Pillar 4 – WP20 Support office for clinical study: EORTC will provide advice and guidance to EURACAN selected clinical studies in rare cancers. Previous experience relevant to the Tasks: The EORTC holds a strong track record in the field of rare diseases. The EORTC has performed 62 international clinical trials over the past 15 years accruing a total of more than 20,123 patients in various rare disease entities such lymphomas, melanoma, leukemia, sarcoma, brain, lung, urogenital, head and neck, male breast, cutaneous T cell lymphoma, mesothelioma, thymoma, and anal cancers. These clinical trials are multidisciplinary and involve various treatment modalities (chemotherapy, radiotherapy, surgery, hormonotherapy, targeted agent) alone or in combination. Recognizing the challenge of the complex diagnosis of rare cancers, mandatory central pathology review is enforced by EORTC and supported by international network of pathologists. Thanks to database centralization, consistent data collection, and strict quality control procedure, the EORTC has accumulated unique repositories of fully documented patient data and biological samples accessible for future research. Since 2011, the US National Cancer Institute, the UK National Clinical Research Network, Cancer Research UK and the EORTC decided to join force within the International Rare Cancers Initiative to perform new international clinical trials in rare cancers otherwise lacking infrastructural support. EORTC is member of IRDIRC. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Located in Brussels, the EORTC Headquarters with its 220 professionals is a unique facility in Europe. It provides scientific, legal, logistic, and administrative support to EORTC clinical and translational research activities with strong track record in the field of rare diseases. SPECTA is a standardized, quality-assured pan-European infrastructure collecting clinically annotated human biological material (HBM) and characterizing tumors for the purpose of biomarker discovery and ultimately integrating these newly discovered biomarkers into clinical trials. SPECTA is built on existing EORTC resources and expertise in clinical research. Amongst common cancer types, SPECTA is targeting rare cancers i.e., cancers with an incidence of less than 6/100,000 in the adult and teenager/young adult populations. Rare anal, biliary tract, neuroendocrine, endometrium, cervical, vulvar, lung, mesothelioma, thyroid, brain and sarcoma cancers will be considered in priority. The range of targeted cancer types is adapted according to the medical needs, the progress of science and the requirements from downstream research 152 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases projects using SPECTA. Longitudinal patient follow-up with both clinical/pathological data and HBM collection take place for all consented SPECTA patients until death or loss to follow-up, irrespective of the patients' treatment as part of routine clinical care or participation in clinical trials within or outside the SPECTA structure (downstream clinical trial or any other clinical trial). Long-term patient follow-up (annually) enables continued acquisition of clinical data after all lines of treatment as part of routine clinical care or participation in a clinical trial. A systematic histopathological central assessment of the patient tissue sample is performed to confirm the rare cancer diagnosis and also to confirm that the quality of the material is adequate for further molecular testing(s). All analyses are centrally performed by high-quality laboratories selected according to the needs. Short Profile of key Staff Members who will be undertaking the work Msc Sandrine Head of the EORTC Medical Dept. She is a medical doctor specialized in pharmaceutical medicine Marreaud research with extensive experience in various types of cancers. She is supervising the Clinical (female) Research Physicians who coordinate and provide clinical and methodological support to EORTC clinical trials. PhD Saskia Biostatistician and associated head of the EORTC statistics Dept. Saskia has in depth expertise in Litière the design and analysis of clinical trials in various types of rare cancers. She is also a member of (female) the Response Criteria In Solid Tumors (RECIST) Working Group and is involved in the ongoing update of RECIST. MSc Head of European Program. Stephane is responsible for coordinating EORTC participation in EU Stephane funded projects. He will be the liaison person. He is experienced in various aspects of clinical Lejeune research operations. Stephane contributes to contract preparation with research group, and (male) laboratory. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Van den Bent M et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open- label intergroup study. Lancet. 2017 Oct 7;390(10103):1645-1653. 2 Schöffski P et al. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: EORTC phase II trial 90101 ‘CREATE’. Annals of Oncology, Volume 28, Issue 12, 1 December 2017, Pages 3000–3008, 3. Perry J, et al. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med 2017 Mar 16;376(11):1027-1037. 4. Baumert BG et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016 Nov;17(11):1521-1532 5. BOGAERTS J et al. Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer 2014; 51 (3):271-281. List of relevant previous projects or activities, connected to the subject of this proposal - FP7 EUROSARC (European Clinical trials in Rare Sarcomas within an integrated translational trial network). EORTC is performing clinical trial. - FP7 EEC (EURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma). EORTC is performing clinical trials. - H2020 MOTRICOLOR (Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer). EORTC is performing clinical trials. - Associated partner to the ERN EURACAN in rare adult solid cancers, EORTC is the research infrastructure. - Collaborating partner to the Joint Action in rare cancers. EORTC is providing its expertise. 72-INFRAFRONTIER Full legal name (Acronym) – Country INFRAFRONTIER GmbH, Germany Principal investigator Martin Hrabe de Angelis Relevant Network INFRAFRONTIER Description of the legal entity/department/laboratory/group: INFRAFRONTIER is the European research infrastructure for the development, phenotyping, archiving and distribution of mammalian models. It is a distributed research infrastructure with partners in 15 European countries. The core services of INFRAFRONTIER comprise the development and systemic phenotyping of mammalian disease models, and the archiving and distribution of mouse mutant lines by the European Mouse Mutant Archive (EMMA). All INFRAFRONTIER resources and services can be accessed at www.infrafrontier.eu. The 153 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases INFRAFRONTIER GmbH was established in April 2013 as management and coordination unit of the INFRAFRONTIER Research Infrastructure. It is based in Germany at the Helmholtz Zentrum München. The INFRAFRONTIER GmbH is responsible for developing the INFRAFRONTIER GmbH resources and services, for providing transnational access and for operating the INFRAFRONTIER IT infrastructure. It is also the contact point for all stakeholders of the INFRAFRONTIER Research Infrastructure and coordinates the networking and outreach activities. Main tasks in the project per Pillar/WP: Pillar 2: WP11: Common platform for discoverable data and resources for RD research; contribution of metadata and ontological models related to INFRAFRONTIER mouse mutant resources (task 2.1) to a FAIR compliant platform for discovery of RD resources (tasks 2.2 and 2.3) Previous experience relevant to the Tasks: INFRAFRONTIER operates the EMMA database and actively compiles Rare Disease relevant mouse mutant resources, which will be contributed to the common EJP RD platform for discoverable data and resources for RD research. Furthermore, INFRAFRONTIER has considerable expertise in running EU funded Trans-national Access service calls, which will inform the set-up of the EJP RD brokerage system e.g. regarding service contributors, proposal evaluation and service call administration. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : INFRAFRONTIER GmbH operates the EMMA database and hosts the INFRAFRONTIER web portal at www.infrafrontier.eu. Short Profile of key Staff Members who will be undertaking the work Pr. Martin Hrabé Full professor and chair at the Technical University in Munich and holds the chair of De Angelis Experimental Genetics. At the same time he serves as director of the European Mouse (male) Mutant Archive (EMMA). His research focus is on large-scale mutagenesis, functional genomics, stem cell biology and metabolic research. He founded the German Mouse Clinic (GMC) for systemic analysis of human diseases. He is member of the Project Committee of the German National Genome Network (NGFN) for which he served as spokesman from 2006 to 2009. Prof. Dr. Hrabé de Angelis coordinated the INFRAFRONTIER preparatory phase project and other national and international research consortia funded by the German government and the European Commission (FP6/7). He is member of the Executive Steering Committee of the International Mouse Phenotyping Consortium (IMPC) and founding member and member of the Board of the German Center for Diabetes Research (DZD). Since April 2014 he serves as Scientific Director of the INFRAFRONTIER GmbH. Prof. Dr. Dr. h.c. Martin Hrabè de Angelis received numerous awards and honours. Dr. Michael Räß, Trained biologist and research manager. He did his PhD thesis in behavioral physiology in (male) 2006. After working for two years as a postdoc in this field, he changed in 2008 to the Helmholtz Zentrum München as lead project manager for the INFRAFRONTIER Preparatory Phase and head of the INFRAFRONTIER Project Office. In 2010 he received a MSc degree in „Science Communications and Marketing“. Since 2014 he is Head of General Management of the INFRAFRONTIER GmbH. Michael Raess is the Leader of the CORBEL Work Package 5 (Common Solutions for User Access). Dr Sabine Fessele Dr. Sabine Fessele studied Technical Biology at the University of Stuttgart. After doing her (female) PhD in cellular and molecular immunology at LMU Munich, she worked as project manager for NascaCell GmbH in the department of Functional Biology. In another biotech start-up company, EPIDAUROS Biotechnologie AG, she held the position of Data Manager. She started to work as project manager for the Helmholtz Zentrum München in 2006 and coordinated several areas of the European Mouse Mutant Archive (EMMA). Since 2013 Sabine Fessele is a PMI-certified Project Management Professional (PMP®) and since 2015 she is the Head of Unit - Operations and IT of the INFRAFRONTIER GmbH. Philipp Gormanns Philipp Gormanns studied bioinformatics at the universities LMU and TUM in Munich. He (male) worked as a bioinformatics scientist in the Max-Planck Institute of Psychiatry in the field of biomarker discovery for depression and anxiety from 2007 to 2011. From 2012 to 2015 he was working at the Helmholtz Zentrum München as an IT scientist for the German Mouse Clinic and technical project lead for BioMedBridges. Since 2016 he is Senior Developer at the INFRAFRONTIER GmbH. 154 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Meehan TF, et al. 2017. Disease model discovery from 3,328 gene knockouts by The International Mouse Phenotyping Consortium. Nature genetics, 2017-06-26 2. Meehan TF, et al. 2015. INFRAFRONTIER – providing mutant mouse resources as research tools for the international scientific community. Nucleic Acids Research 43, D1171-1175 3. Hrabě de Angelis M, et al. 2015. Analysis of mammalian gene function through broad-based phenotypic screens across a consortium of mouse clinics. Nature Genet 47(9), 969-978 4. INFRAFRONTIER portal providing access to EMMA mouse mutant resources www.infrafrontier.eu 5. IMPC portal providing access to IMPC phenotyping data www.mousephenotype.org List of relevant previous projects or activities, connected to the subject of this proposal  INFRAFRONTIER2020, Horizon2020, 2017-2020 - Towards enduring mouse resources and services advancing research into human health and disease  CORBEL, Horizon2020, 2015-2019 - Coordinated Research Infrastructures Building Enduring Life-science Services  IPAD-MD, Horizon2020, 2015-2019 - Research Infrastructures for Phenotyping, Archiving, and Distribution of Mouse Disease Models - Promoting International Cooperation and User Engagement to Enhance Biomedical Innovation  RItrain, Horizon2020, 2015-2019 - Research Infrastructures Training Program  INFRAFRONTIER-I3, FP7, 2013-2016 - Development of mouse mutant resources for functional analyses of human diseases - Enhancing the translation of research into innovation 73-BBMRI Full legal name (Acronym) – Country Biobanking and BioMolecular resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC), AT Principal investigator Erik Steinfelder Relevant Network BBMRI-ERIC Description of the legal entity/department/laboratory/group: The pan-European Biobanking and BioMolecular resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC) improves the accessibility and interoperability of the existing comprehensive collections, either population-based or clinical-oriented, of biological samples from different (sub)populations of Europe. These collections include the attached data on factors such as health status, nutrition, lifestyle, and environmental exposure of the study subjects. Combined with the expertise of the clinicians, pathologists, bio-informaticians, and molecular biologists involved, a globally unmatched, Europe-wide platform for translational medical research is envisaged with the aim to develop personalized medicine and disease prevention for the benefit of European citizens. To reach this goal, also biotech and pharmaceutical industry must have a possibility to collaborate with academic researchers in order to fully realize the enormous potential of European biobanking. In addition to clinical, ethical and legal experts, patient communities are involved to achieve standards and guidelines that properly balance individual values, such as protection of privacy and informed consent, with shared values of facilitated access to progress in health care and disease prevention. On 3 December 2013, BBMRI was officially awarded the Community legal framework for a European Research Infrastructure Consortium (ERIC). This specific legal form is designed to facilitate the joint establishment and operation of research infrastructures of European interest. The ERIC status allows pulling together biobanks and biomolecular resources into a pan-European facility and providing access to collections of partner biobanks and biomolecular resources, their expertise and services on a non-economic basis. BBMRI-ERIC shall establish, operate and develop a pan-European distributed research infrastructure of biobanks and biomolecular resources in order to facilitate the access to resources as well as facilities and to support high quality biomolecular and medical research. BBMRI-ERIC operates on a non-economic basis. BBMRI-ERIC is set up as a distributed research infrastructure in most, if not all European Member States. BBMRI- ERIC consists of 19 Member States and one International Organisation, making it one of the largest research infrastructures for health research in Europe. 155 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Members: Austria, Belgium, Czech Republic, Estonia, Finland, France, Germany, Greece, Italy, Latvia, Malta, the Netherlands, Norway, Poland, Sweden, and the United Kingdom. Observer Countries: Cyprus, Switzerland, Turkey, IARC/WHO Main tasks in the project per Pillar/WP: Pillar 2 Petr Holub BBMRI-ERIC will lead tasks on technical GDPR implementation (Task 10.3) and Quality oversigth (Task 10.4), and it will contribute to federated searches architectures (Tasks 11.2 and 12.1), machine readable access (Task 12.1), integration of existing services into Orphanet catalog (Task 11.1), and brokering hosting services for FAIR data provisioning (Task 12.3). Pillar 3 Michaela Th. Mayrhofer Within Pillar 3, BBMRI-ERIC will contribute with its expertise in ethical, legal and societal matters related to rare diseases. In particular, it will share its experience in operating the custom based ELSI Helpdesk and self-service Knowledge Base. Additionally, BBMRI-ERIC commits to host a 3-day training workshop in Graz ensuring awareness raising and appropriate knowledge transfer (Task 14.4). Previous experience relevant to the Tasks: BBMRI-ERIC designs, implements and operates its IT services via its Common Service IT (CS IT), with particular attention to biobanks dealing with human biological material and data. It delivers both centralized and distributed findability (Directory and Locator services), accessibility (Negotiator), interoperability (MIABIS data model), and reusability (common inteoperable provenance model developed within ISO TC276 WG5). Together with BBMRI- ERIC Rare Diseases Working Group it delivers services specific to RD community, such as RD section of BBMRI- ERIC Directory and Helpdesk for Rare Diseases. BBMRI-ERIC has also commitment to sustainably operate selected outcomes of RD-Connect, namely Registry & Biobank Finder (aka ID-cards) and Sample Catalogue. BBMRI-ERIC Negotiator is also being extended by the RD-Connect to implement the access pipeline for rare disease resources within RD-Connect. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : BBMRI-ERIC Common Services form a key element for the research infrastructure as they provide the biobanking community and biobank users with expertise, services and tools specific to biobanking. The Common Services are established under BBMRI-ERIC and under the responsibility of its Director General. The ELSI Helpdesk is a personalised support service assisting researchers who have ethical, legal and societal questions in the context of a research project. We offer assistance on topics that are crucial in biobanking, such as informed consent and data protection amongst others, in order to promote compliance with regulatory requirements and best practice principles Short Profile of key Staff Members who will be undertaking the work Dr Petr Holub Associate Professor of computer science at Masaryk University, the second largest (male) university in the Czech Republic. He has background both in sciences (MSc with specialization on computational quantum chemistry in 2001) and computer science (PhD in 2005, specializing on computer networks, self-organizing systems and multimedia processing). He was head of the Division of Communication Technologies at Institute of Computers Science, Masaryk University, as well as architect of advanced multimedia and collaborative systems of the Czech national e-infrastructure developed and operated by CESNET. His research in computer networks and multimedia processing has lead to more than 40 research papers in established computer science journals and ranked conferences, as well as to practical software systems and patents. Since 2011, he has been responsible for design and development of IT infrastructure of the Czech BBMRI, as well as its subsequent operation using national research cloud e-infrastructure CERIT-SC. He is also responsible for the IT and data management infrastructure of the ongoing EU THALAMOSS project, focusing on data collection and processing for stratification of patients suffering from thalassaemia. He has been a contributor to a number of international and national projects linking computer science and biomedicine. He joined BBMRI-ERIC as its IT/Data Protection Manager in January 2015. Dr. Michaela Political scientist and historian by training. She was educated in Vienna, Louvain-la-Neuve, Mayhofer Essex and Paris. In 2010, she has earned her PhD from both the Ecole des Hautes Etudes en (male) Sciences Sociales and the University of Vienna, which was shortlisted by the Austrian Society for Political Science for 'best thesis 2010'. Prior to her involvement in BBMRI- ERIC, she was investigator in several national and international research projects focusing on the politics of biotechnology and the life sciences, especially the governance of biobanks. 156 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Her academic career led to various positions at the Centre de Recherche Médecine, Sciences, Santé et Société, the University of Vienna, the Institute of Science, Technology and Society Studies at Alpen-Adria-Universität Klagenfurt/ Vienna/Graz, the Technical University of Vienna and the Medical University of Graz. Today, she serves as the Chief Policy and Coordination Officer of BBMRI-ERIC and leads the Code of Conduct for Health Research Initiative. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Michaela Th. Mayrhofer (2013): About the New Significance and the Contingent Meaning of Biological Material and Data in Biobanks. IN: Hist. Phil. Life Sci 35, 449 467. 2. Michaela Mayrhofer (2008): Patient Organisations as the (Un)Usual Suspects in Biomedical Research, IN H. Gottweis & A. Petersen (Ed.): Biobanks: Governance in Comparative Perspective, Routledge, p. 71 87. 3. Mayrhofer MT, Holub P, Wutte A, Litton JE (2016): BBMRI-ERIC: the novel gateway to biobanks. From humans to humans. IN: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Mar;59(3):379-84. doi: 10.1007/s00103-015-2301-8. 4. Holub, P., Mayrhofer MT, Wutte, A et.al. (2018): Enhancing Reuse of Data and Biological Material in Medical Research: From FAIR to FAIR-Health. IN: Biopreservation and Biobanking, see https://doi.org/10.1089/bio.2017.0110 List of relevant previous projects or activities, connected to the subject of this proposal  1. BioSHaRE: https://www.bioshare.eu/  2. BBMRI-LPC: http://www.bbmri-lpc.org/  3. SPIDIA4P: http://www.bbmri-eric.eu/scientific-collaboration/spidia4p/  4. BioMedBridges: http://www.biomedbridges.eu/  5. CORBEL: http://www.corbel-project.eu/home.html 74-ECRIN/PedCRIN Full legal name (Acronym) – Country European Clinical Research Infrastructure Network (ECRIN)- France Principal investigator Jacques Demotes Relevant Network ECRIN, PEDCRIN project Description of the legal entity/department/laboratory/group: The European Clinical Research Infrastructure Network (ECRIN, www.ecrin.org) is a sustainable, not-for-profit, distributed infrastructure with the legal status of a European Research Infrastructure Consortium (ERIC). ECRIN provides support for the planning and implementation of multinational clinical research projects in Europe. ECRIN currently has eight Member Countries (France, Germany, Spain, Italy, Portugal, Hungary, Czech Republic and Norway) and one Observer Country (Switzerland). Additional countries are about to join. ECRIN provides services for the management of multinational -investigators initiated and SME sponsored- trials; central services (data management through ECRIN certified data centres, central vigilance) and distributed services provided by the ECRIN partner in each country involved (regulatory and ethical submissions and follow-up, monitoring, local vigilance, project management etc.). As part of its trial support activities, ECRIN develops and maintains freely accessible tools such as databases on regulatory and ethical issues, outcome measures, and risk-based monitoring. ECRIN contributes to capacity building projects aiming to establish shared services in biomedical areas, and to foster international cooperation in non-commercial trials. ECRIN organisation: ECRIN’s ‘distributed infrastructure’ includes a Core Team based in Paris, France (headquarters) and European Correspondents (EuCos) working in each Member and Observer Country and hosted by the national scientific partners (networks of academic clinical trial units (CTUs) and/or clinical research centres (CRCs)). ECRIN scientific partners (a total of 80 CTUs and CRCs) are the final service providers for ECRIN-supported clinical trials; they provide services and expertise under the coordination of ECRIN. ECRIN has also partners in other countries in Europe and internationally with which it collaborates. Main tasks in the project per Pillar/WP: 157 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases In WP 20, ECRIN will be in charge of the clinical trial helpdesk (tasks 20.1 and 20.2). ECRIN will also provide its regulatory and ethical expertise in the WP4 task 4.2. Previous experience relevant to the Tasks: -Development of tools and operational services for multinational clinical trials in Europe and in particular for rare diseases through the ECRIN-IA project -Leader of the Medical Infrastructure work package in the CORBEL cluster project -Co-secretariat (with US NIH) of the CRIGH (clinical research initiative for global health) promoting international cooperation in clinical trials. Short Profile of key Staff Members who will be undertaking the work Jacques Director General of ECRIN. Professor of cell biology, clinical neurologist. Dr Demotes was Demotes, MD, the coordinator of ECRIN’s four FP6- and FP7-funded projects, which supported the PhD, MBA (male) sustainable development of ECRIN as a pan-European infrastructure with “ERIC” status (awarded in 2013). He has participated in more than 50 FP6, FP7, H2020 and IMI-funded projects. Christine Operations Director of ECRIN. She holds a PhD from University Paris XI in pharmaceutical Kubiak, PharmD, sciences. She has more than 20 years’ experience in the planning, setup, and management of PhD (female) multinational clinical trials and in the coordination of clinical programmes in the pharmaceutical industry. At ECRIN since 2006, she played a key role in ECRIN’s FP6 and FP7 funded projects. She currently oversees projects development and implementation, and contributes to strategy and business development. Sabine Kläger, ECRIN Clinical Operations Manager since October 2017. She has over 30 years of experience PhD, MSc (Biol.), in biomedical research, initially in the field of tropical diseases, including drug development MSC programmes from P1 to P3, and the use of new medicines in mass treatment programmes (Epidemiology), across endemic areas (Africa, South America), and later in the planning, setup, and DLSHTM management of multi-national clinical trials in various therapeutic areas in the UK and (female) Europe. Since 2003 she was working for academic Sponsors, ensuring the implementation of necessary regulatory requirements to comply with the EU Directives on Clinical Trials, including the set-up and operational and strategic management of a CTU for Cambridge University-Hospital partnership. Currently, she is also chairing the DMECs for 3 drug trials, running across several Sub-Saharan countries Salma Malik, PEDCRIN project manager. Holds a PhD in paediatric clinical endocrinology and has PhD (female) experience in the development and conduct of paediatric clinical trials and paediatric research projects. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1.European Clinical Research Infrastructures Network: promoting harmonisation and quality in European clinical research. Demotes-Mainard J, Ohmann C. Lancet. 2005 Jan 8-14;365(9454):107-8 2.Cloud computing' and clinical trials: report from an ECRIN workshop. Ohmann C et al. Trials. 2015 Jul 29;16:318. doi: 10.1186/s13063-015-0835-6. 3 A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome? Ana Rath et al. Trials. 2017 Nov 22;18(1):556. doi: 10.1186/s13063-017-2287-7. 4.Global health: Boost multinational clinical research. Demotes-Mainard J et al. Nature 545:289 (2017) doi:10.1038/545289b 5.Sharing and reuse of individual participant data from clinical trials: principles and recommendations. Christian Ohmann et al. BMJ Open. 2017 Dec 14;7(12):e018647. doi: 10.1136/bmjopen-2017-018647 List of relevant previous projects or activities, connected to the subject of this proposal : -ECRIN-IA: European Clinical Research Infrastructures Network - Integrating Activity, including a competitive call to support multinational trials (FP7 Infrastructure 2011; grant number 284395) (ECRIN coordinator) -PedCRIN: Paediatric Clinical Research Infrastructure Network (H2020-INFRADEV-2016-2017; grant number 158 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 731046) (ECRIN coordinator) -CORBEL: Coordinated Research Infrastructures Building Enduring Life-science Services (H2020 INFRADEV-4- 2014/2015; grant number 654248) -CRIGH: Clinical Research Initiative for Global Health (Collaboration Agreement between international partners in order to promote and develop international collaboration) -TRANSVAC: European Vaccines Research and Development Infrastructure (H2020 INFRAIA-2016-1- grant number 730964) 75-EATRIS Full legal name (Acronym) – Country EATRIS-ERIC (EATRIS)- The Netherlands Principal investigator Toni Andreu (MD, PhD) Relevant Network EPTRI, CORBEL Description of the legal entity: EATRIS, the European Infrastructure for Translational Research offers a new collaboration model for fostering innovation. The infrastructure plays a fundamental role in the advancement of knowledge and technology in translational research and drug development. With over 90 leading institutes, across 12 EU Member States, EATRIS provides access to the entire pipeline of academic translational infrastructure and expertise, and optimises the route from discovery to proof-of-concept in medicines development. It provides a new development pathway, open to academic researchers and companies in need of support for advancing biomedical innovations. The EATRIS ‘Coordination & Support’ office employs 14 people, with expertise ranging from project management, marketing, and technology transfer to translational product development. EATRIS is a European Research Infrastructure Consortium (ERIC) since 2013, a legal entity established by the European Commission to facilitate the operation of international research infrastructures. Main tasks in the project per Pillar/WP: Pillar 0 - Coordination and Transversal activities In WP1, we will support the coordinator with the overall management of the project by being part of the operating group (tasks 1.1; 1.2; 1.3) In WP2, we will be involved in the development of EJP RD research and innovation strategy by contributing to the mapping exercise (tasks 2.2; 2.4) In WP3, we will co-lead WP activities, contribute to the design of a service roadmap and catalogue and lead the task aiming at preparing the EJP-RD sustainability plan with business plan (tasks 3.1; 3.2; 3.3) In WP4, we will provide advice on regulatory procedures (task 4.2) In WP5, we will contribute to the implementation of the communication and dissemination strategy of the project (task 5.1) Pillar 1 In WP8, we will co-develop the rare disease research challenges (tasks 8.1; 8.2; 8.3; 8.4) Pillar 3 In WP16, we will contribute to the development of online courses (task 16.2) Pillar 4 In WP19, we will act as co-WP leader and will be involved in all tasks to provide researchers with the right support to conduct translational research (tasks 19.1; 19.2; 19.3; 19.4) Previous experience relevant to the Tasks: Examples of services provided by the Coordination Office of EATRIS since 2013: EATRIS Matchmaking: EATRIS matches clients’ needs to the specific capabilities and expertise of the institutions, relying on a sophisticated and detailed database outlining EATRIS institutional capabilities. The EATRIS operational model in which a large consortium operates under harmonized conditions and a framework agreement, offers user the same reach of a consortium, but with the safety and effectiveness of a bilateral relationship. This service lies at the heart of EATRIS operations, has been offered to an increasing number of users since 2013, ranging from biotech companies to academia and pharmaceutical industry. EATRIS Inside: EATRIS has worked together with funders and charities to bring the European-wide EATRIS expertise and infrastructure ‘inside’ their funding procedure. Principal Investigators, shortlisted by the funder, are invited by the funding agency or the charity to contact EATRIS for translational optimisation of their proposal. EATRIS then performs a preliminary assessment of the translational feasibility of the project based on the elements available: unmet medical need and clear end-product definition; preliminary analysis of the intellectual property status; technical feasibility and regulatory pathway. Based on this potential assessment, the PI completes 159 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases their full proposal for subsequent review by the funder. EATRIS has already piloted successful collaboration with several funders and charities (for instance, ZonmW - The Netherlands Organisation for Health Research and Development- and Rheumafonds). Innovation Management: EATRIS has been responsible for the facilitation of multiple public-private collaboration, involving SME’s and also large pharma. Additionally, since 2015, it has been leading the WP dedicated to Accelerating Innovation of CORBEL (see below), and set up an Innovation Helpdesk, providing partnering, legal, IP support to other biological and medical research infrastructures. Business planning: EATRIS has been in charge of drafting the sustainability plan of TRANSVAC-2 (see below), as well as the business plan of EPTRI (see below). Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : N/A Short Profile of key Staff Members who will be undertaking the work Anton Ussi Operations & Finance Director for EATRIS C&S. Anton Ussi has a background in engineering (male) and SME administration. He is a specialist in the establishment and execution of strategic public- private and public- public collaborations based on the deployment of high value translational research infrastructure for medicine. Anton has been co-responsible for the development of several ongoing public private partnerships and spin-out companies, among which the €130 million VU University Medical Imaging Center Amsterdam, and the Dutch Imaging Hub, a public-private translational initiative with Roche-Genentech and three Dutch university medical centers. Tim Moser EATRIS industry partnering specialist, educated in biology, later combining an MBA in Supply (male) Chain Management. His work experience includes scientific research, evolving into operational and site management in life sciences companies. Since 2010 he works in technology transfer and specializes in industry partnering. As former business developer for Industry Alliance Office of Neuroscience Campus Amsterdam, Tim has developed and negotiated collaboration agreements with many different companies ranging from biotech to international big pharma. He specializes in identifying the frontier areas in academic translational medicine that spark interest for industry and pursuing ideal routes toward partnership. Rosan Vegter After graduating and working as an emergency vet for several years, she has worked in (female) pharmaceutical industry where she completed a PhD on the Challenges in the Clinical Development of Orphan drugs. At EATRIS, she is in charge of the coordination and implementation of training activities. One of her main activities has been developing curricula for PhDs and Postdocs involved in translational medicine for the Erasmus+ funded C-COMEND project. Furthermore, she is part of the communication team as content writer. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. G.A.M.S. van Dongen, et al. EATRIS, a European initiative to boost translational biomedical research. Am J Nucl Med Mol Imaging. 3, 166-174 (2013). 2. CT. Gilliland, et al. Putting translational science on to a global stage. Nat. Rev. Drug Discov. 15, 217–8 (2016). 3. A.E. Ussi, et al. In Search of System-Wide Productivity Gains - The Role of Global Collaborations in Preclinical Translation. Clin. Transl. Sci. 10, 423–425 (2017). 4. A.J. Van Gool, et al. Bridging the translational innovation gap through good biomarker practice. Nat Rev Drug Discov, (2017). List of relevant previous projects or activities, connected to the subject of this proposal 1. CORBEL (H2020, 654248) (2015-2019): Coordinated Research Infrastructures Building Enduring Life- science Services project of thirteen biological and medical research infrastructures (BMS RIs), creating a platform for harmonised user access to biological and medical technologies, biological samples and data services required by cutting-edge biomedical research. EATRIS is leading the Innovation WP, which provides support for RI on public-private collaboration and industry partnering. 2. C-COMEND (Erasmus Plus, 2015-1-NL01-KA203-008986) (2015-2017): Project coordinated by EATRIS along with academic and SME partners to develop a competency profile, e-learning and face-to-face courses on medicines development for PhD students and PostDocs. 3. ID-EPTRI (H2020, 777554) (2018-2020): the project aims at designing the business and governance model for an infrastructure for pediatrics translational research. EATRIS leads the WP dedicated to Governance and is responsible for delivering the business and governance models. 160 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 76-ELIXIR Full legal name (Acronym) – Country European Molecular Biology Laboratory (EMBL) (ELIXIR, EMBL-EBI) Principal investigator Niklas Blomberg Relevant Network ELIXIR Description of the legal entity/department/laboratory/group: The European Molecular Biology Laboratory (EMBL; http://www.embl.org/ ) was established in 1974 and is supported by over twenty countries. EMBL is a centre of excellence for research in molecular biology. EMBL is a centre of excellence for research in molecular biology. It is a distributed international research organization (24 member states) with its main laboratory in Heidelberg. Research at EMBL emphasizes experimental analysis at multiple levels of biological organisation, from the molecule to the organism. One of EMBL’s five core missions is to develop and make available new technologies for the Life Sciences. Accordingly, EMBL has an extensive success record in developing new biology-driven technologies and providing service- oriented user infrastructures including the Advanced Light Microscopy Facility (ALMF) offering external user access, a high-throughput light microscopy screening facility, the Centre for Bioimage Analysis, the Electron Microscopy Core Facility (EMCF) and the EMBL-EBI data resources. Another core mission of EMBL is to provide advanced training to researchers, which is organized by the EMBL International Centre for Advanced Training (EICAT) and encompasses the EMBL International PhD Programme (EIPP), the EMBL Postdoctoral Programme and the Visitors Programme as well as a large number of workshops, courses and conferences. EMBL maintains strong interactive relationships to the major life science research institutions in Europe and has more than 40 years of experience in integrating European research. In addition to EMBL in Heidelberg, the European Bioinformatics Institute (EMBL-EBI) in Hinxton is involved in Euro-BioImaging and will host the general data services of EuBI ERIC. Established in 1996, EMBL-EBI (http://www.ebi.ac.uk/ ) is an outstation of the EMBL and has a long-standing mission to collect, organise and make available databases for biomolecular science. EMBL-EBI makes available a collection of databases along with tools to search, download and analyse their content. These databases include nucleotide sequences (European Nucleotide Archive), protein sequences (UniProt), structures (PDBe), genome annotation (Ensembl), gene expression information (ArrayExpress), molecular interactions (Intact) and pathways (Reactome). Connected to these are linking and descriptive data resources such as protein motifs (InterPro), ontologies and many others. In many of these efforts the EMBL-EBI is a European node in global data-sharing agreements. ELIXIR (https://www.elixir-europe.org/) is an inter-governmental organisation, which builds on existing life sciences data resources and services within Europe to orchestrate the collection, quality control and archiving of large amounts of biological data. It follows a hub-and-nodes model, with a single Hub located at EMBL-EBI in Hinxton, Cambridge, UK (with EMBL providing the legal entity) and a growing number of Nodes located at centres of excellence throughout Europe. ELIXIR is an ESFRI Research Infrastructure in permanent operations phase since 2013. The ELIXIR Consortium Agreement established ELIXIR as an independently governed entity within the legal framework of EMBL. To date, 21 countries plus EMBL have signed the consortium agreement: Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Ireland, Italy, Israel, Luxembourg, the Netherlands, Norway, Portugal, Slovenia, Spain, Sweden, Switzerland, UK and Greece. In May 2014 ELIXIR was one of only three priority projects identified by ESFRI as mature enough to support for implementation in 2015-2016. Governments and ministries of ELIXIR Member States are responsible for contributing funding for the ELIXIR Hub and coordinating the scientific community in their country into a national Node that provides services to the ELIXIR community, including data resources, tools, Compute provision, Standards development, Training and support to Industry. Main tasks in the project per Pillar/WP, Description of Beneficiaries and Third Parties involvement. Pillar 0 Transversal activities: In WP1: Coordination and management ● ELIXIR Hub will be co-leading Task 1.3 Monitoring of the EJP RD activities and achievements KPI definition and Subtask 1.3.1 Identification of key performance indicators In WP2: Integrative research and innovation strategy ● DTL-Projects(ELIXIR-NL) will contribute to Task 2.1 Prioritization scheme for EJP RD actions and Task 2.2 Mapping the research and innovation needs 161 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases In WP4: Ethical, regulatory, legal and IPR framework of the EJP RD ● ELIXIR Hub will be contribute to Task 4.2 Managing ethical and regulatory issues Pillar 2: In WP10: User-driven strategic planning and transversal activities for Pillar 2 data ecosystem ● ELIXIR Hub will be co-leading Task 10.3 Coordination of technical implementation of General Data Protection Regulations (GDPR) task. ● ELIXIR Hub will be co-leading Task 10.4 Quality oversight task ● DTL-Projects (ELIXIR-NL) will be leading Task 10.5 Developing sustainable models. ELIXIR Hub will be contributing to this task also. In WP 11: Common virtual platform for discoverable data and resources for RD research ● EMBL-EBI will be leading Task 11.1 Metadata and ontological model definition for cataloging resources for RD research task. SIB(ELIXIR-CH) will also be contributing in this task, to define an ontological model compatible with existing key databases and resources. ● DTU(ELIXIR-DK) and BSC(ELIXIR-ES) will be contributing to the Subtask 11.2.3 To make relevant RD analysis tools and methods discoverable, the ELIXIR's bio.tools catalogue will continue its adaptation for the RD community initiated in EXCELERATE ● EMBL-EBI will be leading Task 11.3 Data deposition and access to data infrastructures for RD research. CSC(ELIXIR-FI) and MU-CERIT-SC (ELIXIR-CZ) will be contributing to Subtask 11.3.2 Implement a unified authentication and authorisation mechanism, based on ELIXIR’s AAI. EMBL-EBI, ELIXIR Hub, CSC(ELIXIR-FI), BSC(ELIXIR-ES) and UU(ELIXIR-SE) will be contributing to Subtask 11.3.4 develop data deposition guidelines and documentation. ● BSC(ELIXIR-ES) and SIB(ELIXIR-CH) will be contributing to Task 11.4 Provision of analysis and data sharing capabilities to the RD community through online resources to Provide RD phenotype- genotype analysis and data sharing capabilities through the RD-Connect platform for molecular diagnostics and gene discovery. EMBL-EBI, CSC(ELIXIR-FI), BSC(ELIXIR-ES), UU(ELIXIR-SE) and SIB(ELIXIR-CH) will contribute to Subtask 11.4.2 collaborative integrated analysis of multi-omics data from selected use cases. BSC(ELIXIR-ES) will contribute to Subtask 11.4.3 provide capabilities for custom analyses through cloud-based solutions. EMBL-EBI, BSC(ELIXIR-ES) and UU(ELIXIR-SE) will contribute to Subtask 11.4.4 user-driven implementation of new analysis functionalities and tools task. In WP12: Enabling sustainable FAIRness and Federation at the record level for RD data, patients and samples ● EMBL-EBI will contribute to Subtask 12.1.2 federation architectures, and networks registers. CSC(ELIXIR-FI) will also contribute to Subtask 12.1.3 implement machine readable access (e.g., consent & use conditions, governance, identifiers, security, anonymization). EMBL-EBI will contribute to Subtask 12.1.4 Query languages and Subtask 12.1.5 data exchange formats and ontologies & semantics for record- level clinical and preclinical information. ● EMBL-EBI will contribute to Subtask 12.3.2 Brokered hosting service for FAIR data provision, discovery and matchmaking. SIB(ELIXIR-CH) will contribute to Subtask 12.3.3 FAIRification service for data from Pillar 1 studies, from Pillar 2-WP1 activities, and prioritized EU data sources. In WP13: Enabling multidisciplinary, holistic approaches for rare disease diagnostics and therapeutics EMBL-EBI and SIB(ELIXIR-CH) will contribute to Subtask 13.1.3 the Mapping (combinations) of variants to protein function task. Pillar 3: In WP14: Training on data management & quality ● CNR (ELIXIR-IT) and DTL-Projects(ELIXIR-NL) will contribute to Task 14.5 training on rare disease registries and FAIRification of data at the source. In WP16: Online Academic education course ● UL(ELIXIR-SI) will be co-leading the Biotechnologies & bioinformatics: databases, NGS and -omics interpretation tools module of the online academic course. ● UCAM(ELIXIR-UK) will be leading Task 16.3 Follow-up, evaluation and monitoring, UNIMAN(ELIXIR-UK) will be also contributing to this task Previous experience relevant to the Tasks: The utility of the EMBL-EBI to the scientific community today is evidenced by massive use of its services. EMBL- EBI’s web portals receive over 27 million requests per day from 5 million unique IP addresses, 12 million compute jobs per month are executed on EMBL’s cores.The community served ranges from basic academic researchers 162 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases through to applied research in diverse areas including pharmaceuticals, agriculture and nutrition. Alongside the core service activities, the EMBL-EBI is a basic research institute, with bioinformaticians regularly publishing the biological findings of computational investigations of biomolecular information. The constituency of the EMBL- EBI most emphatically includes the commercial sector as well as academic research. It has a flourishing Industry Programme and SME engagement activities for European companies involved in bioinformatics. EMBL-EBI also provides a substantial proportion of EMBL's external training. ELIXIR is an inter-governmental organisation, which builds on existing life sciences data resources and services within Europe. It currently works across 21 member states and the EMBL-EBI, collectively reaching nearly 200 institutes involved in Bioinformatics research or service provision. ELIXIR’s core role is to orchestrate the collection, quality control and archiving of large amounts of biological data, with a strong focus on ensuring that these data are made as FAIR (Findable, Accessible, Interoperable and Reusable) as possible. During the past 4 years, ELIXIR has sought to be guided by the scientific community through the establishment of Use Cases, which have included Human Data, Rare Diseases, Plant Sciences and Marine Metagenomics. Through these efforts ELIXIR has ensured that the key Bioinformatic services and resources are increasingly accessible to and embedded across LIfe Science Research in the EU. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work: EMBL-EBI manages large-scale biological databases, which are available to clients via web services 24/7/365. The demand for rapid access to all publicly available biological databases is constantly growing, as is the volume of biological information held within the databases. To support these needs, EMBL-EBI manages an infrastructure of extensive, high-performance compute infrastructure along with large data-storage farms. EMBL-EBI's state-of- the-art technical architecture is secure and robust, and is distributed in four discrete, Tier 3+ security data centres in different geographical locations to assure long-term security. This gives our data very high protection through redundancy, and provides sufficient capacity and reserve to ensure our management of the rising influx of data and compute requests. In August 2013 our main compute farm has ~17,000 cores and the installed disk based storage capacity is above 30 Petabytes. Part of EMBL-EBI’s core mission is to maintain large life science archives hosting critical reference data for research. This includes ENSEMBL and genome archives; the EGA for human genomes and UniProt. The ELIXIR Hub is charged with coordination activities, whilst the Nodes provide the service delivery of the key bioinformatics resources. The largest ELIXIR Node is EMBL-EBI and delivers some of Europe’s key bioinformatics services, which are described above. Further information can be found at: www.ebi.ac.uk Short Profile of key Staff Members who will be undertaking the work Dr. Niklas ELIXIR Director, Project Coordinator. Dr. Blomberg joined ELIXIR as Director in 2013 Blomberg following 14 years in the pharmaceutical industry with AstraZeneca. He led the global (M) cheminformatic function from 2006-2011 with responsibility for global delivery of novel computational approaches and external partnerships in screening, and in 2011-2013 led the build of new computational biology / computational chemistry unit for the AZ inflammatory research area. He has also previously been the Chairman of the board for Bioinformatics for Life Science in Sweden (BILS), Chair of the advisory board for the Swedish e-Science for Cancer prevention and cure project, Advisory board member for the Swedish eScience center and the IMI eTRIKS project. He was co-chair for IMI OpenPHACTS, a project with 24 industrial and academic partners to develop standards and infrastructure for effective data-interoperability across chemistry and biology for drug-discovery research Dr. Helen EMBL-EBI, Team Leader: Head of Molecular Archives comprising three teams and 85 people Parkinson (F) delivering core databases, data coordination activities, semantic data integration tools. Her team deliver the BioSamples database, the Ontology Lookup Service, the Knockout Mouse Project 2 informatics, PDX resources and the Human Cell Atlas Data Coordination. She is a also partner in Infrafrontier. Dr Johanna EMBL-EBI, Team Leader: Literature services. Dr. McEntyre has been Team Leader for McEntyre (F) Literature Services at EMBL-EBI since 2009. She is the PI for Europe PMC - the database of abstracts and full-text articles for the life sciences. Prior to joining EMBL-EBI, Jo was a staff scientist at the NCBI, National Library of Medicine, NIH, USA, and was the Editor at Trends in Biochemical Sciences (TiBS), Elsevier. Jo is active in the Force 11 Data Citation Implementation Group, and is interested in text mining as a means to improve the integration of literature with 163 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases public data resources. Dr Steven EMBL-EBI, Head of Technical Services. Dr Newhouse leads 5 teams comprising over 85 people Newhouse supporting EMBL-EBI’s various IT functions. This includes the teams delivering the 200+PB of (M) storage and over 30,000 cores of cloud, HTC and HPC analysis platforms, the database, desktop and cloud support functions, hosting of public web services and tools, development of web sites and more general open-source software development and operations which include the EBI Cloud Portal and GA4GH compatible task-based analysis platforms. Dr Thomas EMBL-EBI, Team Leader: European Genome Phenome Archive (EGA), the European Variation Keane (M) Archive (EVA), as well as the Archival Infrastructure for the European Nucleotide Archive (ENA) at EMBL-EBI. He is responsible for strategic planning for EGA, ENA (AI) and EVA, is a member of the Global Alliance for Genomics and Health (GA4GH) steering committee and leads the Large Scale Genomics workstream. He is the scientific lead for the Mouse Genomes Project, a collaboration with the Wellcome Sanger Institute. Sandra EMBL-EBI, Team Leader: Protein Function Content team. Responsible for the curation of Orchard (F) UniProt at EMBL-EBI, and annotation of the Gene Ontology, carrying out manual annotation and producing the rules for automated annotation. The team also create and maintain value-added interfaces for exploring protein data, for example the Enzyme Portal and Complex Portal. Sandra additionally works on standards development in protein data capture and annotation and is Co- Chair of the HUPO Proteomics Standards Initiative Claire EMBL-EBI, Head of Metabolomics. Provides the biomedical community with information on O'Donovan metabolism: small molecules and their interplay with biological systems. Responsible for (F) MetaboLights, a resource for data from metabolomics experiments and derived information. The database is cross-species, cross-technique and covers metabolite structures and their reference spectra as well as their biological roles, locations and concentrations, and experimental data from metabolic experiments. Also responsible for PhenoMeNal, a comprehensive and standardised e- infrastructure that supports the data processing and analysis pipelines for molecular phenotype data generated by metabolomics applications. Dr Fiona EMBL-EBI, Team Leader: Variation Annotation team. Fiona is part of the senior management for Cunningham Ensembl (www.ensembl.org), a genome information system. Her team developed Ensembl's (F) Variant Effect predictor (VEP), the software tool for annotating variation data, and led the creation of the variation and phenotype data in Ensembl. Fiona works very closely with the GENCODE project to improve transcript annotation for clinically relevant genes. Her team deliver robust and reliable reference resources for consistent variant annotation in any species. She is also a co-PI on the NHGRI-EBI GWAS Catalog project. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Postmitotic nuclear pore assembly proceeds by radial dilation of small ER membrane openings. Otsuka S, Steyer AM, Schorb M, Heriche JK, Hossain MJ, Sethi S, Schwab Y, Beck M, Ellenberg J. Nat Struct Mol. Biol. 2018 Jan; 25(1):21-8. Epub 2017 Nov 27. 2. Sister chromatid resolution is an intrinsic part of chromosome organization in prophase. Nagasaka K, Hossain MJ, Roberti MJ, Ellenberg J, Hirota T. Nat Cell Biol. 2016 Jun;18(6):692-9. doi: 10.1038/ncb3353. Epub 2016 May 2. 3. Inverted light-sheet microscope for imaging mouse pre-implantation development. Strnad P, Gunther S, Reichmann J, Krzic U, Balazs B, de Medeiros G, Norlin N, Hiiragi T, Hufnagel L, Ellenberg J. Nature Methods. 2016 Feb;13(2):139-42. Epub 2015 Dec 14. 4. High-throughput fluorescence correlation spectroscopy enables analysis of proteome dynamics in living cells. Wachsmuth M, Conrad C, Bulkescher J, Koch B, Mahen R, Isokane M, Pepperkok R, Ellenberg J. Nat Biotechnol. 2015 Apr;33(4):384-9. Epub 2015 Mar 16. 5. Nuclear Pore Scaffold Structure Analyzed by Super-Resolution Microscopy and Particle Averaging Szymborska A, de Marco A, Daigle N, Cordes VC, Briggs JAG, Ellenberg J. Science. 2013 Aug 9;341(6146):655-8. Epub 2013 Jul 11. 6. van Gool, A. J., Bietrix, F., Caldenhoven, E., Zatloukal, K., Scherer, A., Litton, J.-E., et al. (2017). Bridging the translational innovation gap through good biomarker practice. Nature Reviews Drug Discovery, 16(9), 587–588. http://doi.org/10.1038/nrd.2017.72 7. Durinx, C., McEntyre, J., Appel, R., Apweiler, R., Barlow, M., Blomberg, N., et al. (2016). Identifying ELIXIR Core Data Resources. F1000Research, 5, 2422. http://doi.org/10.12688/f1000research.9656.1 8. Auffray, C., Balling, R., Barroso, I., Bencze, L., Benson, M., Bergeron, J., et al. (2016). Making sense of 164 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases big data in health research: Towards an EU action plan. Genome Medicine, 8(1), 860. http://doi.org/10.1186/s13073-016-0323-y 9. Wilkinson, M. D., Dumontier, M., Aalbersberg, I. J., Appleton, G., Axton, M., Baak, A., et al. (2016). The FAIR Guiding Principles for scientific data management and stewardship. Scientific Data, 3, 160018. http://doi.org/10.1038/sdata.2016.18 10. Budd, A., Corpas, M., Brazas, M. D., Fuller, J. C., Goecks, J., Mulder, N. J., et al. (2015). A quick guide for building a successful bioinformatics community. PLoS Computational Biology, 11(2), e1003972. http://doi.org/10.1371/journal.pcbi.1003972 11. CE Cook, MT Bergman, G Cochrane, R Apweiler, E Birney. 2018. The European Bioinformatics Institute in 2017: data coordination and integration. Nucleic acids research 46 (D1), D21-D29 DOI: 10.1093/nar/gkx1154 List of relevant previous projects or activities, connected to the subject of this proposal: . Project coordinator of ELIXIR-EXCELERATE (2015-2019): an H2020 project (H2020-INFRADEV- 1-2015-1) Fast-track ELIXIR implementation and drive early user exploitation across the life sciences, Grant number: 676559, 2015-2019 . Project Coordinator of CORBEL (2015-2019): an H2020-funded cluster project of the thirteen ESFRI biological and medical research infrastructures (BMS RIs), which together have created a platform for harmonised user access to biological and medical technologies, biological samples and data services required by cutting-edge biomedical research. EMBL is co-leading the WP4 on the open call for users to common service pipelines commonly offered by the ESFRI BMS RIs. . Project Coordinator of BioMedBridges (2011-2015): a joint effort of twelve biomedical sciences research infrastructures on the ESFRI roadmap to develop the shared e-infrastructure—the technical bridges—to allow data integration in the biological, medical, translational and clinical domains. . Project Coordinator of Euro-BioImaging Preparatory Phase I: an ESFRI infrastructure project that will provide open user access to state-of-the-art imaging technologies in biological, molecular and medical imaging for life scientists in Europe and beyond, including advanced light microscopy and electron microscopy technologies. EMBL-HD (ALMF) participated in Euro-BioImaging Proof-of-Concept studies in 2012 during which it hosted external Euro-BioImaging users. . Partner in iNEXT consortium (infrastructure for NMR, EM and X-rays for Translational research), providing access to Advanced light microscopy and Electron microscopy techniques. . Project Coordinator of Euro-BioImaging Preparatory Phase II: EuBI PPII project aims not only at submitting the ERIC application to the European Commission but also at enabling the rapid finalization of the legal, financial, managerial and technical documents, tools and procedures to start the operation of the EuBI ERIC on the day of the signature of the ERIC statutes by all its member states. . Project Coordinator of Global BioImaging: Funded by the European Commission’s Horizon 2020 Programme it has received 1.78M €, to achieve multi-lateral international cooperation between Euro- BioImaging and its infrastructure counterparts in six countries (Argentina, Australia, India, Japan, South Africa, the USA) in the field of life sciences - including biological sciences, marine biology, biodiversity, medical sciences and agricultural sciences. GBI enables Euro-BioImaging to exchange best practice with its international infrastructure partners on open user access to their various services, and in the long term to pursue international agreements on the reciprocal use of these services Third parties involvement: 1. BSC (ELIXIR-ES) 2. CSC (ELIXIR-FI) 3. CNR (ELIXIR-IT) 4. DTU (ELIXIR-DK) 5. MU-CERIT-SC (ELIXIR-CZ) 6. SIB (ELIXIR-CH) 7. UCAM (ELIXIR-UK) 8. UU (ELIXIR-SE) 9. UNIMAN (ELIXIR-UK) 10. DTL-Projects (ELIXIR-NL) 11. UL (ELIXIR-SI) 165 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 77-EURORDIS Full legal name (Acronym) – Country EURORDIS-Rare Diseases Europe (EURORDIS) Principal investigator Virginie Bros-Facer Relevant Network EURORDIS Description of the legal entity/department/laboratory/group: EURORDIS-Rare Diseases Europe is a non-governmental patient-driven alliance of patient organisations representing 792 rare disease patient organisations in 69 countries and is the voice of the estimated 30 million patients affected by rare diseases throughout Europe. EURORDIS’ vision is to enable better lives and cures for people living with a rare disease and its mission is to work across borders and diseases to improve the lives of people living with a rare disease. Since its creation in 1997, EURORDIS has gained significant and well-recognised experience in networking and capacity building for patient organisations, in information sharing as well as in policy development, regulatory affairs, medicines development and patient engagement in RD research and research infrastructure projects. EURORDIS promotes, supports and coordinates the patient engagement with most of the stakeholders involved during the lifetime of a medicinal product. Main tasks in the project per Pillar/WP: Pillar 1: In WP8 (RD Research challenges), EURORDIS will be the co-leader (leader FFRD) of this WP, responsible for the development of the scheme (leader of task 8.1) and participant in task 8.2 and 8.3 to set up the challenges and support the evaluation of funded projects. Pillar 3: EURORDIS is co-leader of Pillar 3 with VUHSK In WP15, we will lead task 15.1 “ExPRESS Expert Patients and Researchers EURORDIS Summer School” In WP15, we will lead task 15.2 “Training for patient advocates on scientific innovation and translational research” In WP15, we will lead task 15.3 “training for patient advocates and representatives on leadership and communication skills”. In WP15, we are also participant in task 15.4 co-lead by TEDDY and FSJD to develop education materials and activities for paediatric patients. In WP18, we are co-leader with CHMI, supporting VUH as leader of this WP and we lead task 18.1 with FFRD on “Evaluation of developing needs according to progress of work in Pillars 2 and 4 and relevant adaptation of training activities”. Coordination & Transversal activities: As Pillar 3 leader, EURORDIS is a member of the Operating Group and is involved as a participant in Pillar 0 WP1, WP2, WP3, WP4 and WP5. Previous experience relevant to the Tasks: Virginie Bros-Facer (VBF) previously worked for the NC3Rs in the UK, the organisation who pioneered the CRACK IT challenges which is the funding model to be used to develop the RD Research challenge in Pillar 1 WP3 and therefore has a deep and detailed understanding of the mechanisms used in this innovative funding scheme. Furthermore, as Scientific Director, VBF represent EURORDIS is RD research and research infrastructure projects (see below) as well as other relevant European and international initiatives (IRDiRC, UDNI, SWAN Europe, Go FAIR RD Network, BBMRI-ERIC Stakeholders forum), bringing the RD patient voice & perspectives and developing specific capacity building programmes to engage and support RD patient representatives in these projects and initiatives. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : N/A Short Profile of key Staff Members who will be undertaking the work Dr. Virginie Bros- Virginie Bros-Facer is Scientific Director at EURORDIS-Rare Diseases Europe. Her Facer responsibilities include monitoring the European landscape on rare disease research from a (female) strategy, policy and action perspectives, overseeing and managing all activities related to rare disease research, diagnostics, infrastructures and technologies as well as related ethical issues. Prior to joining EURORDIS, she worked for several research funding organisations in the UK, including as Director of Medical Research for Sparks, a children's medical research charity based in London and as Research Funding Programme Manager for the NIHR and the National Centre for Replacement, Reduction and Refinement of Animals in Research (NC3Rs under the MRC umbrella). Virginie holds an MSc and a PhD in Neuroscience from King's College London and also worked for 7 years at the UCL Institute of Neurology in London on several research projects aiming to develop new therapeutic strategies for motor neuron disease and other neuromuscular disorders. 166 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Nancy Hamilton Nancy Hamilton is part of the EURORDIS Operations team, her work is centred around (female) empowering patients’ advocates. She coordinates the organisation of the capacity-building EURORDIS Summer School, Winter School and the EURORDIS e-learning tools. She is the contact person at EURORDIS for the EUPATI and ECRIN projects respectively to develop a European Patients Academy and to set up a European Clinical Research Infrastructure Network. Her previous experience includes working as Education Resource Coordinator at the European Haematology Association in Rotterdam where she played a key role in the development of the European Haematology CME system. Nancy has a passion for human rights and volunteers at Amnesty International France and is currently completing a legal diploma (Capacité en Droit) at the Faculté de Droit of the University of Paris Sorbonne Panthéon. Nancy has a B.A. in medical sociology and an M.A in French literature. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1.The voice of 12.000 patientshttp://www.eurordis.org/IMG/pdf/voice_12000_patients/EURORDISCARE_FULLBOOKr.pdf 2. Position paper of EURORDIS on Rare Diseases Research (2012) http://www.eurordis.org/sites/default/files/EURORDIS_Rapport_Research_2012.pdf 3. International Joint Recommendations to address specific needs of Undiagnosed Rare Disease Patients (2016) https://www.eurordis.org/publication/international-joint-recommendations-address-specific-needs-undiagnosed-rare- disease-patients 4. Rare disease patients’ participation in research: a report on the results of the Rare Barometer survey on rare disease patients' participation in research (2018). https://www.eurordis.org/publication/rare-disease-patients-participation- research List of relevant previous projects or activities, connected to the subject of this proposal  IRDiRC; Virginie Hivert (EURORDIS Therapeutic Development Director) is co-chair of the Therapeutic Scientific Committee and Virginie Bros-Facer (EURORDIS Scientific Director) is a member of the Patient Advocacy Constituent Committee  RD-Connect; FP7; 2013-2018- EURORDIS is WP8 leader (patient engagement), member of the Executive Management Committee and chair the Patient Advisory Council comprised of 16 rare disease patient representatives representing 15 rare diseases and European countries supporting their active involvement in the different WPs of the project (Biobanks, registries, bioinformatics tools, communication and the phenome-exome analysis platform). RD- Connect’ s resources are represented throughout the EJP in Pillar 2 and Pillar 3.  Solve-RD; H2020; 2018-2022- EURORDIS is a partner in several WPs and is responsible for the creation and animation of the Community Engagement Task Force aiming at supporting the interaction and the engagement with the different initiatives and networks currently existing in the field of diagnosis at the European and International levels. EURORDIS will also develop the first 2 editions of the Winter School (Patient Capacity Building Programme on Scientific Innovation and Translational Research in 2018 and 2019, to be developed further in Pilar 3, WP2.2 from 2020).  European Reference Networks; EC; 2017-2021-EURORDIS is responsible for the creation of all 24 European Patient Advocacy Groups (ePAGs) involved in the different ERNs. EURORDIS actively supports the activities of the 24 ePAGs communities in all ERNs and provides capacity building for these RD patient representatives within the different networks (link with future training activities in Pillar 3, WP2.3).  Connect for Children (C4C); IMI2; 2018-2023- EURORDIS is a partner involved in 6 work packages and will work together with the Sant Juan de Deu Foundation (co-leader of WP2.4 with Teddy in Pillar 3) to specifically engage young rare disease patients in the development of the pan-European paediatric clinical trials network and infrastructure. 78-CSO-MOH Full legal name (Acronym) – Country Chief Scientist Office, Ministry of Health (CSO-MOH), Israel Principal investigator Irit Allon Relevant Network https://www.health.gov.il/English/Pages/HomePage.aspx Description of the legal entity/department/laboratory/group: If the Beneficiary is composed of several teams (a, b, c) and you decide to replicate this table several times, there is no need to repeat the “legal entity” description in each of the tables. 167 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will participate in the Joint Transnational Calls In WP7, we will lead Task 7.1 Public Call document for networking scheme In WP9, we will lead the WP on Monitoring of the funded projects and be the leaders of Tasks 9.1, 9.2, 9.3 Previous experience relevant to the Tasks: In the last 14 years, CSO-MOH has been actively involved in several health- related Era-Nets and JPIs. In particular, CSO-MOH has been responsible for science to society issues, communication and dissemination and young scientists. In the last year CSO-MOH has added another field of interest, monitoring, which is currently done in the framework of E-RARE-3 and ERA-Net Per-Med. In the EJP, it will be the first time that CSO-MOH leads the entire WP and responsible for all the tasks within it. Short Profile of key Staff Members who will be undertaking the work Pr. Abraham Prof. Avi Israeli, MD, is the Chief Scientist at the Ministry of health. He is a specialist in internal Israeli medicine and the current head of the Department of Health Policy, Health Care Management and (male) Health Economics at the Hebrew University – Hadassah Faculty of Medicine. Prior to this he was the Director General of the Israel Ministry of Health (2003-2009) and the Director – General of Hadassah Medical Organization (1998 -2001).Prof. Israeli is an NSC member in several ERA- Nets, CSAs and JPIs. Dr. Irit Allon Dr. Irit Allon, DMD, Ph.D is the director of the medical research department.She is the previous (female) national coordinator of several ERA-Nets and JPIs in the CSO-MOH. She is a specialist in Oral pathology and since 2005 has gained experience in managing ERA-Nets and leading the Science to Society and Communication & Dissemination activities. She is the former national coordinator of ERA-NET PathoGenoMics, ERA-Age1 and 2, FUTURAGE and the current liaison of E- RARE, Infect-ERA, EuroNanoMed2, and JPIAMR at the CSO-MOH. Dr. Nava Dr. Nava Levine, PhD, is the national coordinator of several ERA-Nets in the CSO-MOH. She is Levin the projects manager in the Israeli association for cardiovascular research and has coordinated (female) ERA-Nets in the CSO-MOH during 2006-2013 mainly focused on the Science to Society and Communication & Dissemination activities. Ms. Elina Ms. Elina Kushnir is the- ICT director in CSO-MOH, supporting the technical and financial Kushnir aspects of ERA-NET activities. (female) 79-SNSF Full legal name (Acronym) – Country Swiss National Science Foundation (SNSF), Switzerland Principal investigator None Relevant Network ERANET E-RARE Description of the legal entity/department/laboratory/group: Mandated by the federal government, the Swiss National Science Foundation (SNSF) supports basic science in all academic disciplines, from history to medicine and the engineering sciences. The SNSF is Switzerland’s foremost research funding organisation. The SNSF was established as a private foundation in 1952. Main tasks in the project per Pillar/WP: The tasks of the SNSF is to participate in the implementation and execution of four Joint Transnational Calls for collaborative research projects. Pillar 1: In WP6, we will participate in: Task 6.1 Joint Transnational Call 2019 (JTC 2019): Call co-funded by the EC for three years Task 6.2 Joint Transnational Call 2020 (JTC 2020): Call co-funded by the EC for two years Task 6.3 Joint Transnational Call 2021 (JTC 2021): call not co-funded by the EC Task 6.4 Joint Transnational Call 2022 (JTC 2022): call not co-funded by the EC Previous experience relevant to the Tasks: The SNSF is a longstanding funding partner in the ERANET E-RARE and member of the E-RARE Steering Committee. Short Profile of key Staff Members who will be undertaking the work Dr. Christoph Meier Head of Section Clinical, Social and Preventive Medicine SNSF 168 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases (male) Dr. Ayşim Yilmaz Head of Department Biology and Medicine SNSF (male) List of relevant previous projects or activities, connected to the subject of this proposal  The SNSF has participated in ERANET E-RARE Joint Transnational Calls since 2013. 80-BLACKSWAN Full legal name (Acronym) – Country BLACKSWAN Foundation, Switzerland Principal investigator Olivier Menzel Relevant Network E-Rare, Eurordis, NIH, RDI, UDNI, IRDiRC, ProRaris Description of the legal entity/department/laboratory/group: The BLACKSWAN Foundation was established in Switzerland in 2010 to contribute to the development of research on rare and orphan diseases worldwide. The Foundation supports research on all different types of rare and orphan disease, which makes its vision unique and helps in finding new solutions that can assist a large variety of projects. Besides its funding research mission, the Foundation organizes every two years the RE(ACT) Congress, which became an international reference point for rare disease experts. In 2014, the BLACKSWAN Foundation launched the RE(ACT) Community a crowdfunding and a knowledge sharing digital platform that connects researchers, patients and other rare disease stakeholders. Since 2015, BLACKSWAN Foundation has also started an international advocacy and awareness campaign called #RAREvolution to ensure rare diseases are recognized as an international public health and research priority. Main tasks in the project per Pillar/WP: Pillar 0: Transversal WP (WP5 external communication & dissemination of results) Our main task will be the organization of the RE(ACT) Congress – International Congress of Research on Rare and Orphan Diseases, a human platform to scale up scientific cooperation on rare and orphan diseases. The Congress intend to promote RD research and provide stimulating environment for its stakeholders. Previous experience relevant to the Tasks: The RE(ACT) Congress – International Congress on Research of Rare and Orphan Diseases was initiated in 2012 by the BLACKSWAN Foundation to create a human platform to scale up scientific cooperation on rare and orphan diseases. Since its inception the congress was supported by ERA-Net E-Rare and co-organized by the two institutions since 2016. In its four editions, the RE(ACT) Congress brought together almost 1,000 world leaders and young scientist from a variety of breaking through scientific field to present cutting edge research, discuss results and exchange ideas. Many patients and patient organizations committed to research were present to share their experience. The Congress was also the place of joint targeted workshops fostering promotion and collaboration with EMA, UDNI, ERNs or private investors. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : The BLACKSWAN put a part-time dedicated person in the organization of each edition of the RE(ACT) Congress. The RE(ACT) Congress website (react-congress.org) beside giving all the information on the next editions is a source of scientific information by displaying the speakers’ slides and videos of the previous editions. The RE(ACT) Community (the crowdfunding and a knowledge sharing digital platform) will use its social media channels to promote scientific communications. Short Profile of key Staff Members who will be undertaking the work Dr. Olivier Menzel Doctor of Science (UNIL, EPFL) from the Swiss Institute for Experimental Research (male) Against Cancer in 2006, he led the Pediatric Surgery Laboratory of the University Hospitals of Geneva for seven years and worked for two years in the Management Team of the Swiss Medical Network, second largest group of private clinics in Switzerland. He also holds an Executive MBA in Health Management (HEC Lausanne). Olivier Menzel created the BLACKSWAN Foundation in 2010, to respond to the lack of interest and resources devoted to rare and orphan diseases. Mrs Chiara Ciriminna Chiara Ciriminna Swan has been working for the Foundation since 2012. She is a lawyer (female) by training. She studied law and international affairs in Italy before joining the United Nations Peacekeeping Operations in Côte d’Ivoire (ONUCI). From 2007 to 2012, she has 169 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases been Project Manager for the Foundation Saint-Camille de Lellis, a Swiss organization dedicated to support public health and mental health in West Africa. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Create and maintain a scientific community 2. Scientific communication 3. Knowledge sharing 4. Crowdfunding 5. Scientific awareness and advocacy 81-TUBITAK Full legal name (Acronym) – Country The Scientific and Technological Research Council of Turkey (TUBITAK),Turkey Principal investigator Orkun Hasekioglu Relevant Network E-Rare Description of the legal entity/department/laboratory/group: The Scientific and Technological Research Council of Turkey (TUBITAK) is the leading agency for management, funding and conduct of research in Turkey. It was established in 1963 with a mission to advance science and technology, conduct research and support Turkish researchers. The Council is an autonomous institution and is governed by a Scientific Board whose members are selected from prominent scholars from universities, industry and research institutions. TUBITAK is responsible for promoting, developing, organizing, conducting and coordinating research and development in line with national targets and priorities. TUBITAK funds research projects carried out in universities and other public and private organizations, conducts research on strategic areas, develops support programs for public and private sectors, publishes scientific journals, popular science magazines and books, organizes science and society activities and supports undergraduate and graduate students through scholarships.TÜBİTAK acts as an advisory agency to the Turkish Government on science and research issues, and is the secretariat of the Supreme Council for Science and Technology (SCST), the highest S&T policy making body in Turkey. More than 4000 scientific and administrative staff work in 15 different research institutes and headquarters of TUBITAK where contract research as well as targeted, nation-wide research is conducted. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we intend to join the first two cofunded Joint Transnational Calls 2019 and 2020 with a budget of 2 M€ and two non-cofunded calls (2021, 2022; budget to be defined) In WP7, we will contribute to Development of the Networking scheme (task7.1), Application and evaluation of proposals for the Networking Scheme (task 7.2) and Early assessment of the Networking scheme (task 7.3) In WP9, we will contribute to Monitoring of networking grants to share knowledge on rare diseases (task 9.2) Previous experience relevant to the Tasks: TUBITAK is the main public funding agency in Turkey and an active partner of the ERA-NET projects in EU Framework Programmes. For instance, during the course of FP7 TUBITAK was a member of 4 ERA NET Plus consortia as well as 27 ERA NET and 29 INCO/INCO-NET projects. Moreover, in Horizon 2020 Programme, TUBITAK has been involved in 33 ERA NET Cofund projects. Since 2006, TUBITAK is a member of E-Rare consortia and up to date, supported 20 research team from Turkey with an amount of 5,5 M TL. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : N/A Short Profile of key Staff Members who will be undertaking the work Dr. Orkun PhD, Executive Vice President at TUBITAK, Turkish Scientific and Technological Hasekioglu Research Foundation and President, responsible from research institutions and (male) international relations. He is a member of the Board of Governors of TUBİTAK and European Commission Joint Research Centers (JRC), member of the Governing Council of the United Nations Technology Bank and other international scientific organizations. Dr. Orkun Hasekioglu has BS, MS (Caltech), PhD (RPI) degrees in Electronics, Computer and Systems Engineering, with a specialization in signal processing, communications 170 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases systems and networks. Prior to joining Turkish Technic, after engaging in academia at Caltech and RPI, Dr. Hasekioglu, has served in General Electric R&D Center, Schenectady, NY, as a research engineer, Moren Communications as Chief Technology Officer, CHEMI Inc. as Vice President. He is European Commission Horizon 2020 National Coordinator and supervises the involvement of TUBITAK in Horizon 2020 Programme, 1 joint program (JPI), 5 ERA NETs and bilateral and multilateral calls. Ms Jale Sahin Ms Jale Sahin received her PhD (Molecular Biology and Neurochemistry) in 2010 from (female) Leibniz Institute for Neurobiology, Magdeburg, Germany. After that she worked as a postdoctoral fellow in the Department of Brain and Cognitive Sciences in Seoul National University. In 2011 she returned to Turkey and started to work at The Scientific and Technological Research Council of Turkey (TUBITAK), National Metrology Institute as a senior scientist. Since 2015 she is working at the Directorate for International Cooperation Bilateral and Multilateral Relations Department as a scientific programmes senior expert. She is the national contact point for ERA NET Cofund E-Rare-3, and FP7 SEA-EU-NET2 project (2012-2017) - Joint Funding Scheme 2017, and international organisations EMBO, EMBL, ICGEB, EURAMET (EMPIR programme) in TUBITAK. She will be national contact point as well as administrative and financial officer of the project. List of relevant previous projects or activities, connected to the subject of this proposal E-Rare-1 (2007 – 2011), GA036248 E-Rare-2 (2011 – 2014), GA266608 E-Rare-3 (2014 – 2019), GA643578 82-ACU/ACURARE Full legal name (Acronym) – Country ACIBADEM UNIVERSITY, ACURARE-Rare Disease and Orphan Drugs Application and Research Center, ACU/ACURARE, Turkey Principal investigator Ugur SEZERMAN, Ugur OZBEK Relevant Network Orphanet, BBMRI Description of the legal entity/department/laboratory/group: ACURARE is a multidisciplinary Center in the University. The Center’s mission is to integrate academic knowledge and practice in the field of RD and OD research and policy development in Turkey Main tasks in the project per Pillar/WP: Pillar 2: In WP11, Metadata and ontological model definition for cataloging resources for RD research (task 11.1) Provision of analysis and data sharing capabilities to the RD community through online resources ( task 11.4) In WP12 Compare and align core interoperability standards (task 12.1) In WP13 Fill pre identified gaps ( task 13.1) Organise proof of principle studies ( task 13.2) Pillar 3: In WP14, Training of Data Management and Quality we will contribute with in kind personnel to support the training course on “Omics Data”. (task 14.2) We will contribute with in kind personnel to support the training course on “Training on strategies to foster solutions of undiagnosed rare disease case”. (task 1.3) In WP15, Capacity Building and Training of Patients. We will contribute with in kind personnel to support the training course on “Training of patient representatives and advocates on leadership and communication skills”. (task 15.3) Previous experience relevant to the Tasks: ACU-RARE, Acibadem University Rare Disease (RD) and Orphan Drug (OD) Research and Application Center, has been established by corporate support of ACU Center for Health Policies, School of Medicine and Faculty of Pharmacy in 2016. The Center’s mission is to integrate academic knowledge and practice in the field of RD and OD for research and policy development in Turkey. The Center has existing national and International relationships with experts and institutions to achieve this mission. First of its kind in Turkey, as a multi-departmental center, ACU-RARE gathers researchers, academics, patient organizations and policy makers under its umbrella. The hub 171 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases like structure of ACU-RARE gives capacity to facilitate networking, training, demonstration and dissemination activities and services. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : ACU-RARE is also a part of BBMRI-ERIC through Turkish BBMRI node, actively participating in Rare Disease Biobank, Quality and Education work packages of the Consortium. Currently, ACU has established a research Biobank facility for rare disease and undiagnosed patients. Combined structure of our Center’s participation as research organization and higher education establishment will contribute to networking, training, demonstration and dissemination needs of this project. Short Profile of key Staff Members who will be undertaking the work Pr.Ugur Ozbek ACU-RARE director Prof.Dr. Ugur Ozbek, MD, PhD is the head of Medical Genetics (male) Department of ACUSoM and director of ACU Institute of Health Sciences. He is currently the National Coordinator for Orphanet in Turkey since 2008. He has been organized several dissemination activities such as Easter European Rare Disease Conference (2011), National RD OD Symposiums (2011-2017), working actively with several Turkish RD patient associations. He was a advisory board member of FP7-Rare Best Practices project and he is collaborating partner to ongoing DG-SANCO RD-ACTION Project. He is partner to ongoing FP7-ADOPT Project (Rare Disease Biobank Work Package) which is led by BBRMI-ERIC members. His research interests include delineation of the genetics and molecular biological mechanisms underlying the disorders of childhood and adolescence leukemia, familial epilepsy syndromes, hereditary cancers and rare disorders. Pr.Ugur Sezerman Prof. Dr. Ugur Sezerman, PhD. is the head of Biostatistics and Medical Informatics (male) Department of ACUSoM. He is specialized in analysis of omics data in a pathway related context to study etiology of diseased individuals. He has applied his methods to several complex diseases and identified personalized disease development mechanism. This approach was also used for analysis of several Rare Disease cases and gave very promising results. As ACU-RARE we can also contribute to the multiple omics data and its integration to identify disease related alteration in cellular functions. We are developing several tools to this end. The tools that we developed are widely used by the scientific community He is also the IT Coordinator of Turkey BBMRI-ERIC project. We are developing standardized and structured databases that will be incorporated to BBMRI-ERIC. The data is easily queriable and accessible by our partners. These are the ways we will contribute to Pilar2. Pr Yasemin Alanay Prof. Yasemin Alanay, MD, PhD is the Dean of ACUSoM. Her team is one of the most (female) experienced groups specialized in research and clinical management of Rare Diseases in Turkey. Throughout her carrier as a pediatric geneticist and researcher, she has participated in many multi-center studies in the field of genetic diseases of skeleton and craniofacial malformations. She was the primary investigator in identification of new genes leading to recessive OI (FKBP10) as a postdoc at Cedars Sinai Medical Center under mentorships of Prof David Rimoin and Prof Deborah Krakow and recessive facial clefting (ALX1) as a team member in CRANI-RARE. In 2017, Dr Alanay as PI represents Turkey in the multinational, multicenter clinical trial on Achondroplasia treatment (BMN-301). She has served as a ESHG Board Member (2012-2017) and is a now a member of ESHG SPC (scientific programme committee). She is on the Editorial Board of American Journal of Medical Genetics and Clinical Dysmorphology. She also serves as an Executive Board Member of Down Turkey, one of the largest patient organizations in Turkey. Finally, as the current Dean of ACUSoM, she encourages translation of genetic knowledge into medical education in the genomics era. She will have pivotal role in translation of the findings of EJP on Rare disease into clinical practice List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Holub P., Kohlmayer F., Prasser F., Mayrhofer M.T., Schlünder I., Martin Gillian M., Casati S., Koumakis L., Wutte A., Kozera Ł., Strapagiel D., Anton G., Zanetti G., Sezerman O.U., Mendy M., Valík D., Lavitrano M., Dagher G., Zatloukal K., van Ommen GertJan B., Litton J.E. (2018) Enhancing Reuse of Data and Biological Material in Medical Research: From FAIR to FAIR-Health. Biopreservation and Biobanking. 2. Bakir-Gungor B., Egemen E., Sezerman O.U. (2014) PANOGA: a web-server for identification of SNP targeted pathways from genome-wide association study data. Bioinformatics, 30(9), pp. 1287-1289. 172 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases List of relevant previous projects or activities, connected to the subject of this proposal  LEGEND; COST Action; CA16223_LEukaemia GENe Discovery by data sharing, mining and collaboration. 2017-2021  CHARME; Cost Action CA15110;Harmonising standardisation strategies to increase efficiency and competitiveness of European life-science research  BEAT-PCD; Cost Action BM1407;Translational research in primary ciliary dyskinesia - bench, bedside, and population perspectives 83-HUGEN Full legal name (Acronym) – Country Hacettepe University Center for Genomics and Rare Diseases/Biobank for Rare Diseases (HUGEN), Turkey Principal investigator Meral Ozguc Relevant Network University Description of the legal entity/department/laboratory/group: Hacettepe University Founded in 1967, Hacettepe University is a public university. It has 11 faculties, 14 vocational schools and 13 institutes. There are about 26000 students enrolled in undergraduate and graduate programs. The number of teaching staff is about 4000. The University is located in two campuses, namely Beytepe and Sihhiye. Beytepe campus accommodates engineering and basic sciences faculties, as well as Hacettepe Technology Development Centre (Technopolis) where health related SMEs are active in innovation. Sihhiye Campus (Health Sciences Campus) houses Faculties of Medicine, Health Sciences, Dentistry, Pharmacy and the University Hospitals. Being a member of EUA (European University Association), Hacettepe University has finalised an Institutional Evaluation Program in 2008. School of Medicine School of Medicine has 1953 students. It has two teaching programs; The Turkish language program has 1087 students and the English teaching program has 845 students. The faculty is divided between 3 Divisions: Basic Sciences (149), Surgical Sciences (406) and Medical Sciences (607). Medical Centre The Medical Centre hospital complex consists of Children’s Hospital (241 beds, 163.835 3utpatients/year, 4.694 inpatients/year), Adult Hospital (808 beds, 435.438 outpatients/year, and 23.465 inpatients/year), and Oncology Hospital (180 beds, 30.000 outpatients/year). Since 2007 adult hospital is accredited by JCI (Joint Commission International). This high in/out patients capacity and being situated in Central Anatolia makes Hacettepe Medical Centre a large reference centre for patients from Eastern, S. Eastern, Northern and Southern Anatolia serving a population of about 30 million, that is almost half of the total population of Turkey. Serving such a large population, from different parts of Turkey, has been instrumental in establishing large patient registries and a bio-repository for genetic disorders which created unique opportunities for genomics research. Main tasks in the project per Pillar/WP: Pillar 3: HUGEN WP14: Training on data management & quality Task 14.4: Training for biobanks and researchers/clinicians on sample data management and interoperability with rare disease tools and databases (M1-M60) The goals of this task are to train (subtask 14.4.1) researchers/clinicians on how to use biobanks to support their projects for biological sample management, and (subtask 14.4.2) to train biobank staff how to share and link individual RD samples and associate data, using platforms and standards developed by EJPRD (Pillar 2). Two workshops, rotating in different locations including EU-13 countries, will be organised every year. Training modules will cover how samples should be annotated, how to share meta- and provenance data, how to engage patient organisations and up-to-date ELSI including privacy requirements. Trainees will be encouraged to bring their case studies for discussion. Reviewing training program for especially local audiences. Pillar 4 : Hacettepe Technopolis Technology Transfer Center (HT-TTM) WP 19: facilitating partnerships (PPP and PP2P) to complete the therapy development path (HT-TTM) Task 19.1: Assessment of the translational potential of projects (throughout the project, in coordination with WP1) (HT-TTM) 173 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Task 19.3: support researchers in approaching companies/investors (HT-TTM) Task 19.4: Partnering events (HT-TTM) Previous experience relevant to the Tasks: 1. The Biobank is experienced in training courses for QA and ethical aspects of biological sample storage aimed at technical staff. 2. The Biobank is a member of EuroBioBank network and activities. 3. HUGEN is a partner to BBMRI-ADOPT project local team (Turkey is a observer country). 4. Awareness raising activities for biobanks in collaboration with Hacettepe University Center for Bioethics. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Hacettepe Rare Diseases Biobank is a non-commercial hospital integrated facility that was established in 1994 by Technology Development Fund of Turkey. It was supported by The Scientific and Technological Research Council of Turkey (TUBITAK) until 2007 when the whole infrastructure was turned over to Hacettepe University. It constitutes a major infrastructure of the Hacettepe University Center for Genomics and Rare Diseases. The total capacity of the cryopreservation unit is: -20°C, 15,000; -80°C, 200,000 and -196°C, 15,000 samples. By 2018, the biological registry holds a total number of DNA samples (39.000) from 5950 families and 1200 cells/tissues (lymphoblastoid cell lines, fibroblast, muscle, brain and other biopsy specimens). The main contributions to the DNA registry are neurological (46%), metabolic (19%), nephrological (15%), gastroenterological (9%), immunological/haematological (5%), chest diseases (3%) and dermatological disorders (3%). The medical and personal data from the families are maintained via the Inhouse Database Server System. Besides the cryopreservation unit, the Biobank infrastructure has cell culture, molecular biology/genetics facilities. The Biobank became a member of EuroBioBank Network in 2014. Short Profile of key Staff Members who will be undertaking the work Pr. Meral Meral Ozguc is currently Professor of Medical Biology at the Faculty of Medicine, Hacettepe Ozguc University, Ankara, Turkey, where she received her PhD. in Medical Biology in 1985. She (female) completed her undergraduate studies at Fairleigh Dickinson University in chemistry and recieved masters degree in biochemistry from Columbia University in the USA. Immediately afterwards, she worked for 3 years as Research Associate in the Department of Research Hematology, Childrens Hospital of Philadelphia, before joining the Hacettepe Faculty in 1980. She served as Assistant Dean of the Faculty of Medicine (2006-2009), and currently she is the Director of the Hacettepe University Center for Genomics and Rare Diseases/Biobank for Rare Diseases. Her work, which is supported by State Planning Agency, Scientific and Technical Research Council of Turkey (TÜBİTAK) and through international grants, is focused on a genomic medicine approach for the study of rare disesaes. She is actively involved in the formulation of national policies to create an awareness of and to promote genomics in public health. Her scientific publications concentrate in the area of identification of new disease genes and genomic variants and devolopment of diagnostic tests. She is also involved in networking activities, governance and bioethical aspects of sample acquisition and data management of biobanks. She is member of European, Middle Eastern and African Society for Biopreservation and Biobanking. She has worked as a member of various international committees involved in genomics and health such as OECD - Working Party on Biotechnology and Human Health Related Biotechnologies, ESF – Integrated Approaches to Functional Genomics, EC-FP6 Genomics and Biotechnology for Health (National Contact Point), and UNESCO-International Bioethics Committee. Currently she is the chair of the Bioethics Committee of the Turkish National Commission for UNESCO. She serves as a member of National EPMA Board in the section for Neonatal Diagnostics and Population Screening. She has been selected in 2017 as a member of Scientific Committee of National Genome Project – National Health Institutes of Turkey. PhD Ayşe Ayse Yuzbasioglu is a graduate of Ankara University, Faculty of Sciences, and Department of Yuzbasioglu Biology in 1998. She has received her Masters degree in 2008 and completed her doctorate (female) studies at Ankara University Biotechnology Institute in 2012. Currently she is the manager of the Rare Diseases Biobank. PhD Ece Ece Akhan Guzelcan is a graduate of Bilkent University, Department of molecular Biology and Akhan Genetics. She has received her PhD at the same Instute in 2015. She is responsible for Güzelcan management of the quality assurance process of the cryopreservation of biological samples, (female) coordination of tissue acquisition from surgery platforms, and management of the data base linked to the biological samples. 174 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements Precision Medicine Tools and Quantitative Approaches, Editors: Hans-Peter Deigner Matthias Kohl eBook ISBN: 9780128054338, Elsevier, 2018. Chapter 4 : Biobanks as Basis of Individualized Medicine: Challenges Toward Harmonization, Ayşe Yüzbaşıoğlu, Burcu Kesikli, Meral Özgüç Rare Diseases – Integrative PPPM Approach as the Medicine of the Future, Editor: Meral Özgüç ISBN: 978- 94017-9213-4, Springer, 2015 Gülbakan B, Özgül RK, Yüzbaşıoğlu A, Kohl M, Deigner HP, Özgüç M. Discovery of biomarkers in rare diseases: innovative approaches by predictive and personalized medicine. EPMA J. 2016 Dec 8;7:24. Review. Yüzbaşıoğlu A, Özgüç M. Biobanking: sample acquisition and quality assurance for ‘omics’ research. N Biotechnol. 2013 Mar 25;30(3):339-42. List of relevant previous projects or activities, connected to the subject of this proposal Rare Diseases Biobank has been the Principle Investigator of the following projects for development of infrastructure, sample acquition, networking activities in rare diseases biobanking. 1998 – 1999 Genethon Human Genome Resource Center, France. Genetic mapping in inbred families with Ichtiosis and Psoriasis. 2001 – 2002 Genethon Human Genome Resource Center, France . Collection of families and genetic mapping in rare disorders. 2006 - 2008 BIYONET – National Networking for Biobanking Activities, MoDevelopment 2016-2018 INFBIO – Strengthening the Infrastructure of Rare Diseases Biobank, Hacettepe Research Fund 2018 - NatBioRARE – Creating a National Focal Point for Rare Diseases Biobanking, MoDevelopment 84-CIHR Full legal name (Acronym) – Country Canadian Institutes of Health Research (CIHR) Principal investigator Étienne Richer Relevant Network E-Rare, IRDiRC, Orphanet, IC PerMed, ERA PerMed Description of the legal entity/department/laboratory/group: As Canada’s health research investment agency, CIHR collaborate with partners and researchers to support the discoveries and innovations that improve health and strengthen health care systems. CIHR is part of the Health Portfolio which supports the Minister of Health in maintaining and improving the health of Cabelans. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, CIHR will participate in all relevant aspects of the joint transnational call. Pillar 2 and 3: CIHR will liaise with other Canadian resources that could contribute to pillar 2 and pillar 3. Previous experience relevant to the Tasks: CIHR launched and managed multiple rare diseases and personalized medicine call for applications since 2010, including 6 in the context of the E-Rare consortium that we joined in 2012. We are also actively involved in multiple international consortium in addition to E-Rare, including IRDiRC and IC PerMed, among others. Finally, we are working closely with the rare diseases research community and the patients’ organizations in order to maximize that value of our investments in the rare diseases area. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : National funding platform, college of reviewers. Short Profile of key Staff Members who will be undertaking the work Dr. Étienne Richer Dr. Étienne Richer first joined McGill University as a postdoctoral scientist in genetics of (male) infectious diseases. Dr. Richer then joined BioMedCom Consultants where he was involved in projects covering a broad range of healthcare issues from biologics therapies to reimbursement policies. Dr. Richer returned to McGill in 2011 as the Associate Director for the CIHR Institute of Genetics. Dr. Richer has been involved in the strategic orientation of the institute, the development of its team and the delivery of its activities. While establishing tight links with the national research community, an international focus is also infused in these three sectors. Personalized medicine and rare diseases constitute two area of focus of his work as he has been involved since 2012 in CIHR’s Personalized Medicine Initiative and 175 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Personalized Health Initiative, was a member of the CSA PerMed, is member of IC PerMed and E-Rare and is involved in the development of ERA PerMed. Danièle St-Jean Danièle St-Jean is the Advisor of International Relations, Partnerships and Business (female) Development at CIHR. She is also the Canadian National Contact Point for Health, demographic change and wellbeing for Horizon 2020. In this role, Danièle is responsible for managing CIHR’s international health research partnerships with the Europe Commission and all matters pertaining to foreign relations. Danièle holds a Bachelor in Science, specialisation in Human Kinetics, a Master’s in Business Development (MBA) at the University of Ottawa and her Bachelor in Education at the University of Laurentian. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Syme R, Carleton B, Layens L, Richer E. Integrating Personalized Medicine in the Canadian Environment: Efforts Facilitating Oncology Clinical Research. Public Health Genomics, 2015;18(6) : 372-380 2. Leyens L, Hackenitz E, Horgan D, Richer E, Brand A, Bußhoff U, Ballensiefen W. CSA PerMed: Europe’s Commitment to Personalised Medicine. Eurohealth, 2014;20(3) 3. Leyens L, Richer É, Melien Ø, Ballensiefen W, Brand A. lable Tools to Facilitate Early Patient Access to Medicines in the EU and the USA: Analysis of Conditional Approvals and the Implications for Personalized Medicine. Public Health Genomics. 2015;18(5):249-59. List of relevant previous projects or activities, connected to the subject of this proposal :  E-Rare ERA-Net, EC, 2012-…, contribution to joint transnational calls, organisation of the E-Rare Data Workshop  CSA PerMEd, EC; 2012-2014, production of the CSA PerMed Strategic Research and Innovation Agenda  ERA PerMed; EC; 2017-…, Contribution to the development of the application to the EC, contribution to the first joint transnational call, work on the Patients’ engagement aspects of ERA PerMEd 85-FRQS Full legal name (Acronym) – Country Fonds de recherche du Québec – Santé (FRQS) // Canada (Québec) Principal investigator Anne-Cécile Desfaits Relevant Network Description of the legal entity/department/laboratory/group: Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will be contributors for Tasks 1.1 & 1.2 In WP7, we will be contributors Previous experience relevant to the Tasks: Previous experience with ERA-NET NEURON Cofund Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : NONE Short Profile of key Staff Members who will be undertaking the work Dr Anne-Cecile Director of Programs and Partnerships since April 2012 Desfaits, Female M. Maxime Program Manager, international collaborations since September 2017 Beaudoin, male List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1.FRQS Annual Report 2016-2017 - http://www.frqs.gouv.qc.ca/documents/11314/489770/RAG_SA_2016- 2017.pdf/88d0c583-4dd6-47b1-93f4-42a64f4ce586 176 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 4.2. Third parties involved in the project (including use of third party resources) I - Participants planning to subcontract certain tasks 1.INSERM (b) Pillar 2, WP10 (160 000€) In order to provide the funders with analytical tools to inform the strategic research strategy, and to facilitate the collection and curation of research projects in participating countries and IRDiRC members, and in the frame of the continuation of Support-IRDiRC activities into the EJP RD, a global research projects database and analysis tools for funders license will be purchased. 1.INSERM (c) Pillar 0, WP3 (150 000€) For WP3 “Sustainability”, tasks to be subcontracted to lawyers / senior business developers for writing legal documents / drafting in legal terms key sections of the EJP-RD sustainability roadmap, translating documents 12. FFRD Pillar 3, WP16 (150 000€) As WP16/Pillar 3 Coordinator, FFRD will subcontract to an e-learning service provider in order to develop the technical platform for e-learning. The subcontractor will be chosen based on: its experience in working with large EU programmes/top EU-Universities, its international audience covering 100+ countries and 3,6M learners in EU, its experience in the Health sector. The subcontracting fees will include a basic contract that will start on year 2 and will run until year 5 and will be based on an annual fee (25k€/year). The annual fee will open to a set of services: assignment of a Partnership Manager for initial training & guidance to create an online course; access to the repository of guidelines, templates and best practices; follow up with the Partnership Manager through regular calls/contacts (providing feedback on course planning and design, setting deadlines for course delivery, carrying out quality assurance, sending emails to learners of the courses, providing reports and data after a course finishes); etc. Aside the annual contract, some specific services will be provided by the platform. Those services will be further defined in coordination with the modules’ coordinators over the first year. An envelope of 50K€ for the 10-12 modules has been secured for anticipated needs such as video scripting, filming on location or in studio, graphics and animation, subtitling, copywriting, sub-editing and proofing, graphic, storyboarding, etc. Needs expressed by coordinators and lecturers will be assessed against feasibility and within the budget limit of 50K€. The platform is totally scalable. Several models (certificate courses and MOOCs) can coexist and can be launched successively or at the same time. Public and private accesses to the modules are also compatible. The e-learning platform will also realize part of the follow- up/monitoring (raw data generated and accessible in real time on courses’ statistics and performance). The subcontractor also offers the possibility to develop as many courses as requested and the content remains the EJP RD ownership and can be implemented to another platform or solution at the end of the EJP RD period. 25. FTELE Pillar 4, WP19 (15 000€) Lawyer and VC specialists to support the definition of the roadmap for a European investment platform for RD 177 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 28.TEDDY Pillar 3, WP15 (55 000€) TEDDY intends to engage service providers for the development of the following educational materials and tools foreseen within task 15.4: 1 video, 1 cartoon, 1 serious game. The subcontractors will be chosen and selected on the basis of the TEDDY internal procedures and ensuring the best value for money or the lowest price, and avoiding conflict of interest. 54. AP-HP Pillar 4, WP20 (11 250€) Costs of external experts who will take part to the Task Force meeting: - 3 expert from USA joining 3 meetings each at € 750,00 per expert per meeting - 3 expert from EU joining 3 meetings each at € 500 per expert per meeting 58.Ekut Pillar 3, WP17 (50 000€) Accreditation of training activities of pillar 3 WP4. We will seek the recognition of the training activities to be accredited by respective accreditation organisations such as the European Union of Medical Specialists (UEMS) to allow the participants to get CME accredited training activities recognised in their respective home countries II- Participants envisaging that part of its work is performed by linked third parties 1.INSERM (b) The TLP are part of Orphanet network and have signed a Network Agreement. Tasks that will be carried out are described in Section 4.1 (Inserm b description): List of TLP: 1 Center of Medical Genetics and primary Health care, Armenia 2 Medizinische Universitat Wien, Austria 3 Institut Scientifique De Sante Publique, Belgium 4 Bulgarian association for Promotion and Education and Science, Bulgaria 5 Klinika za djecje bolesti Zagreb, Croatia 6 University Hospital in Motol, Czech Republic 7 Charles University, 2nd Faculty of Medicine, Czech Republic 8 University of Tartu, Estonia 9 Rinnekoti Foundation, Finland 10 Medizinische Hochschule Hannover, Germany 11 Georgian Foundation for Genetic and Rare Diseases, Georgia 12 Health Service Executive, Ireland 13 Sheba Fund for Health Services and Research (R.A.), Israel 14 Bambino Gesù Children's Hospital, IRCSS-The Bambino Gesù Paediatric Hospital, Italy 15 Children’s Clinical University Hospital, Latvia 16 Ministry of Health, Malta 17 Universitatea De Medicina Si Farmacie “Grigore T. Popa” Iasi, Romania 18 Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Serbia 19 University Medical Centre Ljubljana, Slovenia 20 Karolinska University Hospital, Clinical Genetics, Centre for Rare Diseases, Sweden 21 Geneva University Hospital, Switzerland 22 Public Health Institute, United Kingdom 178 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 1.INSERM (c) University of Montpellier, official Third Party of the Inserm RaDiCo platform, as it is the employing institution of Prof. Paul Landais 1.INSERM (d) Aix Marseille Université (AMU) will participate as linked third party of INSERM (UMR 1251). Personnel involved in EJP RD: Christophe Beroud, Anaïs Baudot, David Salgado, Elisabeth Rémy 21. IT MoH APRE, , Agency for the Promotion of European Research, is a non-profit research organization; will participate as Linked Third Parties of the MOH-IT supporting it in the implementation of project tasks and activities. Contribution: - Support to Ministry of health - Italy for participation in EJP Rare - Seconded personnel 28.TEDDY Fundació Sant Joan de Déu (FSJD) is a private non-profit research organization founded in 2002. Its mission is to contribute to the improvement of the health and wellbeing of people by fostering, supporting and managing the research and innovation activities of the Maternity-Children’s Hospital Sant Joan de Déu (HSJD) and Parc Sanitari Sant Joan de Déu (PSSJD). FSJD currently has 8 consolidated research groups that are primarily active in the fields of maternal and child health and mental health, conducting research in Paediatric neuroscience, Paediatric Cancer, Adult-age disorders originating in the foetal period or in the early years of life, Infectious diseases and systemic inflammatory response in paediatrics, Foetal/Paediatric Diseases and environment, among others. Moreover, FSJD offers specialized services and support to the Hospital’s Investigators and their research activities. FSJD’s structure includes a Clinical Trial Unit, Research Support Office, Administration and Human Resources Department, Clinical Research Ethics Committee, Management of Knowledge and Communication, among other facilities and services. FSJD has a prior agreement with HSJD and PSSJD by means of which it is in charge of handling the financial and administrative aspects of the research activities conducted. FSJD has managed 29 EC-funded projects both coordinated (one H2020, one ERASMUS+ and one ERA-NET) and partnered (5 FP7, 3 SANCO, 3 DG Justice, 1 COST, 2 EIP, 3 ERASMUS+, 2 ERA-NET, 2 EIT Health, 4 H2020 and 1 IMI2), including the recent H2020-funded PEDCRIN and IMI2-ITCC-P4. Clinical Trials Unit of FSJD: The Clinical Trials Office (CTO) of Maternity- Children’s Hospital Sant Joan de Déu (HSJD) offers a research support to assist sponsors and researchers to perform clinical studies and is operated by FSJD. The CTO provides the scientific tools and facilities to execute, coordinate and/or facilitate paediatric clinical research studies, in a "one-stop/full service" model, facilitating this single contact point for external and internal sponsors, supporting the performance of commercial and non-commercial clinical trials (from recruitment of cohorts, clinical assessments or sample and data collection). The CTO understands sponsors’ needs and is committed to conducting clinical studies with the objective of streamline administrative procedures (negotiation of economic study budget and contracts), to reduce the set-up timelines and to ensure the recruitment committed with the sponsor. Quality assurance is also part of the process, ensuring the implementation of clinical trials in compliance with ethical requirements, current legislation and GCP. The CTO works with own Standard 179 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Operating Procedures (SOPs) consistent with regulatory requirements. On site Ethics Committee (http://www.fsjd.org) to evaluate and supervise the paediatric clinical trials with medicines. HSJD is the National leading centre on clinical research. Currently, more than 100 paediatric Clinical Trials, 55 Observational Studies and 12 Clinical Research Projects are being conducted and managed by the CTO. The CTO actively contribute and partners with regional, national (RECLIP, SAMID) and International paediatric research networks, such as Printo, Penta, ITCC, Teddy. FSJD is also an active member of EnprEMA activities. Hospital Sant Joan de Déu (HSJD) is one of the leading medical centers in Europe for childhood and adolescence and offers a comprehensive and multidisciplinary approach to health care from birth through 18 years of age. HSJD is a private not- for-profit center, working mainly for the National Health System offering the public contracted services. HSJD combines basic general paediatrics with specialized care for all tertiary-level paediatric pathologies, in particular neuroscience, cardiology, endocrinology, infectious diseases, neonatology, oncology, and orthopedic surgery, covering a paediatric population of 200,000 children. Annually it attends more than 3.200 births, 25,470 in-patient admissions and 120,835 emergencies (representing 17% of paediatric population of Catalonia), with 306 beds, 134 outpatient rooms and 13 Operating rooms. The CTO has established a scientific council of young advisors: The Young Persons’ Advisory Group (YPAG) KIDS Barcelona. KIDS Barcelona works together with Innovation Department and the CTO of HSJD to provide a voice for children and families in health, medicine, research, and innovation through synergy, communication and collaboration. HSJD is the only paediatric hospital in Spain that has an YPAG. With the collaboration of YPAG, HSJD created the guidelines for the format and content of the informed consent for clinical trials, materials to educate paediatric patients and has offered different scientific advice in the design of clinical trials. KIDS Barcelona belongs to the International Children’s Advisory Network (ICAN), and has organised the annual global meeting in Barcelona. The Clinical Trials Office (CTO) of FSJD is leading the European YPAG network (eYPAGnet) that currently is composed by 9 YPAGs around Europe. The network has two important aims: 1) - To support and coach Hospitals and other organisations (research centres, patients’ associations, etc.) for the creation of new European YPAG; 2- To establish a framework for the involvement of young expert patients during drug lifecycle. FSJD is member of TEDDY and will support it in the development of the training contents, in the organisation of the meetings and courses (logistics and organisation) and in the design, development and dissemination of the educational materials, taking particularly care of the organization of one of the training course in Spain. 54.APHP (d) The following entities will participate as LTP within the framework of an ERN Network agreement: ERN SKIN : -EB House Austria, Salzburg, Austria (EBHS) -Ospedale Pediatrico Bambino Gesù, Rome, Italy (IRCCS) ERN EUROBLOODNET: -Università Federico II di Napoli, Italy (AOUFIIN) -The Cyprus Fondation for muscular Distrophy Research, Cyprus (CING) 180 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases -Montpellier University hospital , Montpellier France (CHUM) -Foundation IRCCS Ca` GraNda Ospedale Maggiore Policlinico Milano, Italy, (IRCCSCG) 58. EKUT University Hospital Tübingen, legal link through federal state law. 59.GUF Universitätsklinikum Frankfurt (UKF), represented by Prof. Dr. Jürgen Graf, is committed to participate as linked third party of Johann Wolfgang Goethe- Universität Frankfurt am Main (GUF). UKF is the legal entity coordinating ERN- LUNG. Goethe University Frankfurt (GUF) is the Legal entity where all research projects including clinical trials run at UKF are administered. There is a clear legal link between both legal entities. All activities within EJP will be organized by GUF with UKF being a linked third party, coordinated by TOF Wagner. 63. AOUS The third parties below are linked to the participant via the ERN ITHACA network agreement (ERN on Rare Congenital Malformations and Rare Intellectual Disability): Manchester University Hospital, MFT NHS TRUST Centre Hospitalier Reg Universitaire Dijon, CHU DIJON 64. LUMC The third parties below are linked to the participant via the ENDO-ERN network agreement: Universitätsklinikum Schleswig-Holstein (UKSH, O. Hiort): Endo-ERN Deputy Coordinator, Endo-ERN Paediatric Chair, Endo-ERN Steering Committee Member (Chair main thematic group ‘Sexual Development & Maturation), DSDNet Principal Investigator/Coordinator Pillar 2 – WP6: task 6.1, 6.2, 6.3 – WP7: Task 7.3, 7.4 – WP8: task 8.2, 8.3 University of Glasgow (UoG – F. Ahmed): Endo-ERN Steering Committee Member (Chair Work Package E-health & ICT), EuRREca Principal Investigator/Coordinator. Pillar 2 – WP10: task 10.1, 10.2 – WP11: Task 11.1, 11.2, 11.3, 11.4 – WP12: task 12.1, 12.2 Pillar 3 – WP14: task 14.5, 14.6 65.RUMC The third parties below are linked to the participant via the ERN GENTURIS network agreement. Third party Institute Curie is involved in Pillar 3, WP3: Task 3.1: Assess the needs, target audience, main topics of the academic education course Task 3.2.2: Developing the online course Diagnostic of rare diseases. Third parties KI and CMFT are involved in Pillar 3, WP4: Task 4.1: Mapping to collect information on preferences, needs and resources from the ERNs ecosystem 181 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Task 4.2: Development of training programs for the ERN training networks based on the results of survey Task 4.3: Deliver training programs through the ERN training networks Task 4.4: Accreditation by universities 70. GOSH GHE-HCL, and MEYER are centres linked through participation in EpiCARE, the ERN for rare and complex epilepsies as coordinated by GOSH GHE-HCL: Pillar 3 WP16.1 (GHE-HCL) Through Professor Alexis Arzimanoglou, assess the needs, target audience, main topics of the academic education course" as well as task 16.2.2. "Identify and work with relevant European Universities, learned societies and other institutions to develop the content of the academic course" Professor Arzimanoglou will also contribute, together with EATRIS, to Module 8 on Regulatory affairs. In the domain of the epilepsies there has been a regular collaboration between International League Against Epilepsy representatives and the EMA/FDA. MEYER: Pillar 2: WP10 (MEYER) Contribution to strategy through Professor Renzo Guerrini as an experienced lead in major European funded research projects WP11 (MEYER) (Virtual Platform of data and resources) 73.BBMRI The European Research Infrastructure Consortium (BBMRI-ERIC) has the following framework agreements : - BBMRI-MUG (Heimo Müller) Medical University Graz (MUG) has developed RD-Connect Registry and Biobank Finder (known also as ID-cards) and developed extensions to BBMRI- ERIC Negotiator in order to implement access pipeline for the rare diseases biobanks in RD-Connect as well as rare disease biobanks in BBMRI-ERIC. Based on these experiences the team will contribute to tasks on growing deposition and access capabilities of existing RD-Related databases (Task 11.3), implementation of authentication in these services using LifeScience AAI (Task 11.3), and to developing metadata/data/sample-level findability (Task 12.3, in collaboration with CRS4). - BBMRI-ErlangenUni (Hans-Ulrich Prokosch) University of Erlangen is implementing metadata registry service, ontology mapping and metadata/data harmonization services within BBMRI-ERIC Common Service IT, which are used by other centralized/distributed Findability and Accessiblity services. The team has extensive experiences with medical 182 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases ontologies and their mapping and clinical data harmonization, thus enabling Interoperability for other services. Based on these experiences the team will contribute to ontologies, semantics and data harmonization for clinical and preclinical information (Tasks 12.1 and 12.2). - BBMRI-Terveyden (Kaisa Silander) THL leads development of common data models within BBMRI-ERIC and coordinates development of additional modules for MIABIS 2.0 community community standard. Recent achievement is a common metadata model on samples and donors to enable Findability of samples. The team will contribute to development of common data and metadata models in EJP RD (Tasks 11.1 and 12.1). - BBMRI-MunichTechnicalUni (Fabian Praßer) Institute of Medical Statistics and Epidemiology at Technical University Munich is one of European leaders in anonymization and privacy protection for medical information, developing also practical tools such as open-source ARX toolbox. In BBMRI-ERIC they are contributing to security policies and privacy protection policies. In the project they will focus on deidentification, anonymization, and privacy control (Task 12.2). - BBMRI-CRS4 (Gianluigi Zanetti) CRS4 is a leading Italian institute in sequencing , operating substantial infrastructure of integration of multi-modal and multi-omics data and big data analysis for medical research. CRS4 also contributes to development of electronic health record standards and machine readable provenance information standards to improve reproducibility of medical research, thus also improving Reusability of shared data. CRS4 will work on collaborative analysis of multi-omics data (Task 11.4), data exchange formats (Task 12.1), and to developing metadata/data/sample-level findability (Task 12.3, in collaboration with MUG). For ELIXIR-MU-CERIT-SC (Ludek Matyska), which is the same group as BBMRI-MasarykUni, BBMRI proposes the following text: Institute of Computer Science, Masaryk University, also develops and operated BBMRI-ERIC Authentication and Authorization Infrastructure (AAI) and works on its incorporation into the upcoming LifeScience AAI. The team also supports integration of services provided by BBMRI-ERIC with the AAI. As a part of EJP RD, BBMRI-ERIC services delivered within the project, will be interated with AAIs. 75.Eatris EATRIS, the European Infrastructure for Translational Research has the following framework agreements: University of Oslo (UiO), Norway Member institution of EATRIS and the representative of the Norwegian node of the infrastructure, signatory of the EATRIS Framework agreement defining long- term collaboration. UiO coordinates the Norwegian node of EATRIS, which has 8 partnering institutions, the four Norwegian Universities with a Medical School (UiO, Universities of Bergen and Tromsø and Norwegian University of Science and Technology) and the four Regional Health Authorities for South Eastern, Western, Middle and Northern Norway (incorporated public health care system that owns all hospitals in Norway). The UiO coordination of EATRIS goes through the Centre for Molecular Medicine Norway (NCMM), which is a national centre that focuses on translational research in molecular medicine with cancer and immune 183 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases diseases among the primary targets. The NCMM local environment constitutes 9 research groups and some 100 staff of which more than 50% is international (from some 30 nations (see www.ncmm.uio.no). The breadth of expertise is supported by close links with EMBL and centres in Sweden and Finland under the Nordic EMBL Partnership. NCMM and UiO offers proteomics, interactomics, chemical biology screening, imaging and flow cytometry facilities and gene targeting, bioinformatics/modelling, signal network analyses immune function studies, as well as molecular and live imaging. High-throughput DNA sequencing (Norwegian Sequencing Centre, UiO), disease models, transgenic facility and translational research infrastructure are also available at UiO. NCMM, by its Director Kjetil Taskén, has represented Norway in EATRIS since the start of the preparatory phase project in 2008. Vall D’Hebron (VHIR), Spain VHIR is a member institution of EATRIS and the representative of the Spanish node of the infrastructure, signatory of the EATRIS Framework agreement defining long-term collaboration. The Vall d’Hebron Research Institute (VHIR) is a public-sector institution that promotes and develops the biomedical research, innovation and teaching at Vall d'Hebron University Hospital (HUVH), the hospital of Barcelona and the largest of Catalan Institute of Health (ICS). VHIR’s task is not only basic or translational, but also as a leader in clinical research. It has created its own model of innovation to transfer research results to society while it operates as a development economy agent. VHIR is the scientific coordinator of all the accredited biomedicine research institutes in Spain (EATRIS.es), together with the Institute of Health Carlos III (ISCIII), its political coordinator. Since November 2014, EATRIS.es is a full member of EATRIS ERIC. Vall d'Hebron, has 17 clinical services working on Rare Diseases and, during the last 5 years, more than 360 Rare Diseases have been treated and researched upon and 218 clinical trials on Rare Diseases have been carried out. During the period of 2013-2017, Vall d'Hebron published more than 300 peer reviewed papers on rare diseases. Both UiO and VHIR will be involved in Pillar 4 – WP19 activities. 184 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 76.ELIXIR 1.BSC (ELIXIR-ES) Organisation Barcelona Supercomputing Center (BSC) (www.bsc.es/) was established in 2005 and serves as the Spanish national supercomputing facility. The Center hosts MareNostrum 4, one of the most powerful supercomputers in Europe and its mission is to research, develop and manage information technologies in order to facilitate scientific progress. BSC is recognised as a first-class research center in supercomputing and in scientific fields that demand it, such as Life and Earth Sciences and Engineering. BSC has over 500 staff from more than 40 countries engaged in multidisciplinary scientific collaboration and innovation. BSC is a hosting member of the PRACE distributed supercomputing infrastructure and an active participant in HiPEAC, the ETP4HPC and other international forums such as BDEC and BDVA. The centre develops technologies for Exascale within the BSC-led Mont-Blanc project, in the DEEP and DEEP-ER projects and the Human Brain Flagship project. BSC has also established joint research centers on Exascale with Intel and IBM. The Life Sciences Department integrates the independent research of senior scientists that work on various aspects of computational biology, ranging from bioinformatics for genomics to computational biochemistry and text mining. This department is the coordinator of the National Spanish Bioinformatics Institute (INB) and, consequently, the Spanish representative of the European Bioinformatics Infrastructure ELIXIR. 2.CSC (ELIXIR-FI) CSC – IT Center for Science Ltd (http://www.csc.fi), is the Finnish national HPC center providing high-performance and cloud computing, networking and data services to academia, research institutes, public sector and industry. CSC is a non- profit limited company whose shares are fully owned by Finnish Government and Finnish universities. Established in 1971, it currently has over 300 employees, and supports a European-wide customer base of thousands of researchers in disciplines such as biosciences, environmental science, linguistics, chemistry and mathematical modelling. CSC provides Finland's widest selection of scientific software and databases, training and expert support, storage and data services, and Finland's most powerful supercomputing environment, and operates the Finnish national research and education network Funet. CSC is the Finnish ELIXIR node, initiator and coordinator of the collaborative data infrastructure EUDAT and a committed actor in the development of the European Open Science Cloud through leading roles in EOSCpilot and EOSC-hub. As responsible for national e- Infrastructures, CSC is also member of PRACE and EGI.Three major national organisations (CSC, Institute for Molecular Medicine FIMM and National Institute for Health and Welfare THL) involved in the biomedical ESFRIs have a consortium agreement since 2012 to build and operate and seek funding for integrated national infrastructure for biomedical science - Biomedinfra.fi comprising ELIXIR, BBMRI and EATRIS. Within this consortium Infrastructure components for biomedical service providers delivered via private network solutions that can be used to host tools and build topical data services and software environments needed for personalised medicine. Biomedinfra.fi builds upon existing strengths and track record of Finnish research and enables molecular level genetic diagnostics of, for example, heart diseases, cancer and obesity to improve health of aging population, one of the European grand challenges. 185 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 3.CNR (ELIXIR-IT) Consiglio Nazionale delle Ricerche (National Research Council, CNR; establ. in 1923), with more than 8000 employees, is the largest multidisciplinary public research institution of Italy. its duty is to carry out, promote, spread, transfer and improve research activities in the main sectors of knowledge growth and of its applications for the scientific, technological, economic and social development of the Country. CNR is distributed all over Italy through a network of 102 institutes aiming at promoting a wide diffusion of its competences throughout the national territory and at facilitating contacts and cooperation with local firms and organizations. The project includes the participation of two research Institutes with expertise in different areas of the interest in the proposal Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies The Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies (IBIOM) of the Italian National Council of Researches (CNR) is in charge of the management of the Italian node of ELIXIR, leaded by CNR and involving other 16 Institution under a Joint Research Unit agreement. The Italian ELIXIR Node offers a vast portfolio of high quality bioinformatics services, tools and data resources for the life science community. Publicly available bioinformatics services are often complemented with downloadable, stand alone tools used in structural bioinformatics, genomics and proteomics. The node hosts several flagship data resources and databases. Computational resources, under form of HPC and cloud computing services, are operational and available to international users. Bioinformatics services are complemented with extensive training activities (courses, workshops) oriented to the international life science user community. 4.DTU (ELIXIR-DK) For almost two centuries DTU, Technical University of Denmark, has been dedicated to fulfilling the vision of H.C. Ørsted – the father of electromagnetism – who founded the university in 1829 to develop and create value using the natural sciences and the technical sciences to benefit society. Today, DTU is ranked as one of the foremost technical universities in Europe with a profile that increasingly includes the life sciences. At this point the university has over 45% life science activities and operates in close collaboration with the Danish pharma and biotech industries in addition to many international collaborators in this space. The National Life-Sciences Supercomputing Center in Denmark called “Computerome” is national collaborative computing platform built for processing of very large data sets especially sensitive data from Healthcare. Computerome center serves as the Danish national infrastructure provider for health care and life sciences as well as representing as the Danish infrastructure in Elixir and Nordforsk since 2014. Computerome center’s infrastructure is tailored specifically towards big data processing with High Throughput Computing (HTC).The center’s main infrastructure is an HPDA (High-Performance Data Analytics) platform and the center provides services such as developing, maintaining, optimising (if needed re-design) and scaling HPC application codes Computerome hosts computing for both non-sensitive and sensitive research projects. The offering for non-sensitive data is Computerome’s HPC system, with configuration aimed for data-driven research. The systems also offers secure cloud computing platform both as PaaS and SaaS variants, with several security profiles including extremely high-security setups for the most sensitive data. Within the cloud platform researchers will be free to create their own “supercomputers on demand”, comprising of hundreds of nodes (thousands of CPU cores) and petabyte-scale storage while maintaining complete freedom to define any environment they require, such as commercial analytical platforms, NGS analysis pipelines, user management schemes, queuing systems etc. The environment is 186 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases built with certified, high performance and high security components designed for processing of sensitive data. 5.MU-CERIT-SC(ELIXIR-CZ) Masaryk University, established in 1919, is the second largest Czech university with around 36,000 students and 4,500 staff in 9 faculties and 2 university Institutes. Masaryk University is involved in several biomedical research infrastructures, as a partner or as a national leading institution. Institute of Computer Science, one of the university Institutes, with its staff of around 140 persons, is a leading national institute in the area of e-infrastructures and cybersecurity. It hosts national research infrastructure CERIT-SC (CERIT Scientific Cloud) and the Czech Cybercrime Centre of Excellence (C4E) and recently is taking national leadership and coordination in the GDPR implementation for the university/academic environment in the Czech Republic. CERIT-SC is a founding partner of the Czech ELIXIR CZ node, together with CESNET responsible for its e-infrastructure needs. CERIT-SC and CESNET are co-developing Perun, the core of advanced ELIXIR AAI, and used also as part of the EGI AAI. Recently, CERIT-SC is leads a capacity building program for ELIXIR CZ, coordinating a project funded through the national structural funds program. CERIT-SC, together with CSC FI, is responsible for the ELIXIR AAI development and management, primary within the ELIXIR EXCELERATE project and supported also by ELIXIR Implementation studies. CERIT-SC has been developing national IT infrastructure for BBMRI.cz since 2011, which dealt with findability and accessibility of biological material from the Czech biobanks. This infrastructure has become an early concept of what has become an access pipeline for the European BBMRI-ERIC in 2016-2017. CERIT- SC has also worked with Masaryk Memorial Cancer Institute (hosting node of BBMRI.cz) on implementing scalable proteomics workflows as a part of EGI- Engage project. CERIT-SC provides BBMRI-ERIC Authentication and Authorization Infrastructure since second half of 2016. CERIT-SC has been also involved in number of medical informatics and bioinformatics projects, such as building data management platform for THALAMOSS project focused on developing new treatments for rare disease of beta-thalassaemia. It is leading an e-infrastructure dedicated workpackage in the West-life project, with a strong emphasis on the AAI and cloud delivery for the structural biology environments. Similarly, CERIT-SC is a partner of the just started EDIREX project that builds the distributed infrastructure for research on patient-derived cancer xenografts, again with the responsibility for the e- infrastructure and also for the data analytics. 6.SIB(ELIXIR-CH) The SIB Swiss Institute of Bioinformatics ( www.sib.swiss ) is an academic not- for-profit organization whose mission is to lead and coordinate the field of bioinformatics in Switzerland. Its data science experts join forces to advance biological and medical research and enhance health. SIB (i) provides the national and international life science community with a state-of-the-art bioinformatics infrastructure, including services, resources, expertise; and (ii) federates world- class researchers and delivers training in bioinformatics. The institute includes some 70 world-class research and service groups including 800 scientists in the fields of genomics, proteomics, evolution and phylogeny, systems biology, structural biology, text mining and machine learning and personalized health. 187 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases 7.UCAM(ELIXIR-UK) The University of Cambridge is one of the most renowned Research/Higher Education Institute and is frequently ranked amongst the top 5 in international academic rankings such as ARWU and Shanghai Ranking. It has a long-standing history of academic and scientific excellence backed up with rich culture, learning, research and creativity. Many affiliates of University of Cambridge have won Nobel Prizes for their significant advances. University of Cambridge is also a major participant in European projects and is one of the top recipients of FP7 funding. The Bioinformatics Training Programme of the University of Cambridge offers a wide-ranging portfolio of training courses in bioinformatics and data science, at both undergraduate and post-graduate level. In 2017, it comprised 102 postgraduate training events and hosted 83 undergraduate training sessions; 2,600 postgraduates and 760 undergraduates are trained on average each year. 8.UU(ELIXIR-SE) Uppsala University is the legal entity for the national bioinformatics infrastructure NBIS (National Bioinformaitics Infrastructure Sweden), which is coordinating the Swedish ELIXIR node. NBIS is a distributed national research infrastructure to provide support for life science researchers in Sweden. The organisational structure allows for changes in services over time as new techniques are developed and utilised. NBIS also matches international efforts, such as the European infrastructure for biological information, ELIXIR, where NBIS is the Swedish node and coordinates the Swedish contributions to the ELIXIR infrastructure. NBIS constitutes the SciLifeLab Bioinformatics Platform and provides project support, infrastructure and tools development, and advanced training. In this project, our main contributions will be within the area of infrastructure development and integrative analyses. Uppsala University is the oldest university in Sweden, founded in 1477, with 6,949 employees and 41,470 students. World-class research and high quality education pursued here benefit society and business on a global level. The University is characterised by diversity and breadth, with international frontline research at nine faculties and limitless educational offerings at Bachelor’s and Master’s levels. Annual turnover of SEK 6.5 billion (€688 million). UU has 2,437 doctoral students (48% women). 9.UNIMAN(ELIXIR-UK) The University of Manchester is one of the UK's top research-led universities, laying claim to 25 Nobel Prize winners amongst its current and former staff/students, including 4 current Nobel laureates on staff. The University of Manchester was rated in the top four in the UK in the 2017 Jiao Tong rankings. In REF 2014, the School of Computer Science ranked 4th in UK by GPA, 1st in overall research environment, with 94% of research classified as world-leading or internationally excellent. The school plays important roles in the two EU FET flagship projects, Graphene and Human Brain Project and two of the BMS EU Research Infrastructures: ISBE (Systems Biology) and ELIXIR (Life Science Data). In this proposal, UNIMAN is represented by the School of Computer Science. The Information Management Group, co-led by Goble, is large (50+). Goble’s e- Science sub group focus on the application of semantic and distributed computing technologies to accelerating computational science, scientific reproducibility and FAIR results management and scholarship, producing software and data platforms 188 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases that are production quality and widely used. Innovations address resource- interoperability through workflows, web-based resource sharing, and semantic- driven infrastructures. Developed core components of EU Research Infrastructures: (i) ELIXIR, the TeSS training portal and; (ii) ISBE, the FAIRDOM-SEEK platform for managing data, models, SOPS and workflows for collaborative projects and data management bridging local, national and European infrastructures. 10.DTL-Projects (ELIXIR-NL) The DTL Projects Foundation (‘Stichting DTL Projects’, hereafter: ‘DTL Projects’) is an independent project organisation that supports collaborative projects that fit the scope of the collaborative DTL, the Dutch Techcentre for Lifesciences (www.dtls.nl): Data, Technologies and Learning in the broader life sciences domain. DTL Projects offers a formalised structure to establish collaborative multi-party projects that foster advancement in dealing with data in research and innovation. DTL Projects is the formal host of ELIXIR-NL, the Dutch Node in the pan-European research infrastructure ELIXIR. DTL Projects runs projects facilitating community building, coordination in technology and infrastructure development, standardisation as well as capacity building through training and education. 11.UL (ELIXIR-SI) The University of Ljubljana (http://www.uni-lj.si/eng/; PIC UL: 999923240) is a public autonomous educational, research and artistic higher education institution with a very rich tradition. It was established in 1919 and it encompasses 23 faculties and 3 art academies. It is the largest and the oldest university in Slovenia, with more than 40,000 undergraduate and graduate students attending over 300 different study programmes. In 2016 UL had 286 research groups with over 3,000 registered researchers (548 PhD students) and creates almost half of the research results of Slovenia. From 2008 the UL is committed to respect the principles of the European Charter for Researchers and the Code of Conduct for Recruitment of Researchers. In 2013 the UL was awarded the 'HR Excellence in Research' logo. UL is very active in national research and educational programmes. In 2016 the UL cooperated in 174 national research programmes, 480 basic and 650 applied research projects, 26 post-doc projects, 39 targeted research projects (CRP) and 7 technological platforms. UL is also very active in international and EU R&D programmes: in the period 2007-2016 it was involved in more than 750 European projects, among them 160 FP7/H2020 and 1 ERC grant. Within FP7/H2020 projects the UL cooperated in 20 Marie Curie actions (13 ITN, 2 IAPP, 3 IRSES, 1CIG, 1 ERG). Currently UL cooperates in 317 EU projects out of which 83 FP7 (12 Marie Curie) and 233 other European projects. Overview of the budget of linked-third Parties (Personnel and Other Direct Cost Only) Linked 3rd Party Activity 189 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases Subtask 11.2.3 Adapt biotools catalogue, 11.3.4 deposition guidelines and documentation. Task 11.4 Provision of analysis and data sharing capabilities, Subtask 11.4.2 analysis of multi-omics data BSC (ELIXIR-ES) Subtask 11.4.3 provide capabilities for custom analyses through cloud-based solutions and Subtask 11.4.4 user-driven implementation of new analysis functionalities and tools Subtask 11.3.2 AAI, 11.3.4 deposition CSC (ELIXIR-FI) guidelines and documentation and 11.4.2 analysis of multi-omics data Task 14.5 training on rare disease registries CNR (ELIXIR-IT) and FAIRification of data at the source. DTU (ELIXIR-DK) Subtask 11.2.3 Adapt biotools catalogue MU-CERIT-SC (ELIXIR-CZ) Subtask 11.3.2 AAI. Subtask 13.1.3 the Mapping (combinations) SIB (ELIXIR-CH) of variants to protein function. Task 16.3 Follow-up, evaluation and UCAM (ELIXIR-UK) monitoring Task 11.4 Provision of analysis and data sharing capabilities, Subtask 11.4.2 collaborative integrated analysis of multi- omics data, Subtask 12.3.3 FAIRification UU (ELIXIR-SE) service and Subtask 11.3.4 develop data deposition guidelines and documentation. Subtask 11.4.2 collaborative integrated analysis of multi-omics data Task 16.3 Follow-up, evaluation and UNIMAN (ELIXIR-UK) monitoring Task 2.1 Prioritization scheme for EJP RD actions, Task 2.2 Mapping the research and innovation needs, Task 10.5 Developing sustainable models, Task 14.5 training on DTL-Projects (ELIXIR-NL) rare disease registries and FAIRification of data at the source, Task 14.5 training on rare disease registries and FAIRification of data at the source. UL(ELIXIR-SI) Task 16.2 Developing the online course 83.HUGEN Affiliate: 190 This proposal version was submitted by Dahlia TSAKIROPOULOS on 18/04/2018 16:23:22 Brussels Local Time. Issued by the Participant Portal Submission Service. European Joint Programme on Rare Diseases HT-TTM is the Technology Transfer Office of Hacettepe University formally. It is a private company working at Hacettepe Technopolis and coordinating University Industry Colloboration, IP protection and applications, applying funds/grands, coordinating enterpreneurship activities of Hacettepe University. HT-TTM will organise the activities, meetings and these meetings, activities will be performed at HT-TTM infrastructure. III-Participant envisaging the use of contributions in kind provided by third parties (Articles 11 and 12 of the General Model Grant Agreement) 1.Inserm (d) Protisvalor Méditerranée SAS In-kind contributions provided by its third party, Protisvalor Méditerranée SAS (PVM), as defined in the Article 12 of the H2020 Model Grant Agreement. The EU grant department of PVM through its international and interdisciplinary team of 9 people with extensive experience of European Research Projects Management and the ability to speak fluently in six different languages, has been involved in more than 100 FP7 projects and until now in 54 H2020 projects. PVM, being in charge of the financial handling of the EJP RD contribution dedicated to AMU, will handle some means and expenses necessary for the fulfilment of AMU tasks described in this document. These include amongst others the following tasks: hiring the non-permanent personnel, buying the necessary consumables and/or equipment to execute the project, reimbursing the travel and accommodation costs for the researchers involved in the project, or any other expenses necessary for its execution. 4. LBIRUD Research Center for Molecular Medicine (CeMM) Our partner and host institute the Research Center for Molecular Medicine (CeMM) provides lab space and research infrastructure. 22. RT Toscana Life Sciences (TLS) Tuscany Region envisages the use of in-kind contributions by Toscana Life Sciences (TLS), especially through seconded personnel that will be appointed for the execution of Task 8.5.The (TLS) Foundation is a non-profit organization that has been active in the regional panorama since 2005 with the objective of supporting research activities in the Life Sciences and, in particular, of sustaining the development of projects from basic research to industrial
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel